U.S. patent application number 16/482473 was filed with the patent office on 2019-11-21 for immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides.
The applicant listed for this patent is ModernaTX, Inc.. Invention is credited to Eric Yi-Chun HUANG, Jared IACOVELLI, Kristine MCKINNEY, Sze-Wah TSE, Nicholas VALIANTE.
Application Number | 20190351039 16/482473 |
Document ID | / |
Family ID | 61244714 |
Filed Date | 2019-11-21 |
View All Diagrams
United States Patent
Application |
20190351039 |
Kind Code |
A1 |
HUANG; Eric Yi-Chun ; et
al. |
November 21, 2019 |
IMMUNOMODULATORY THERAPEUTIC MRNA COMPOSITIONS ENCODING ACTIVATING
ONCOGENE MUTATION PEPTIDES
Abstract
The disclosure features immunomodulatory therapeutic
compositions of an mRNA encoding an activating oncogene mutation
peptide and an mRNA encoding a polypeptide that enhances immune
responses to the activating oncogene mutation peptide, for example
an mRNA encoding an immune potentiator. The disclosure also
features methods of using the same, for example, to stimulate
anti-cancer immune responses.
Inventors: |
HUANG; Eric Yi-Chun;
(Boston, MA) ; TSE; Sze-Wah; (Cambridge, MA)
; IACOVELLI; Jared; (Waltham, MA) ; MCKINNEY;
Kristine; (Cambridge, MA) ; VALIANTE; Nicholas;
(Cambridge, MA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
ModernaTX, Inc. |
Cambridge |
MA |
US |
|
|
Family ID: |
61244714 |
Appl. No.: |
16/482473 |
Filed: |
February 1, 2018 |
PCT Filed: |
February 1, 2018 |
PCT NO: |
PCT/US2018/016510 |
371 Date: |
July 31, 2019 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
62541571 |
Aug 4, 2017 |
|
|
|
62490523 |
Apr 26, 2017 |
|
|
|
62467063 |
Mar 3, 2017 |
|
|
|
62453465 |
Feb 1, 2017 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61K 9/5123 20130101;
A61K 2039/53 20130101; C07K 14/7051 20130101; A61P 35/00 20180101;
A61K 9/0019 20130101; A61K 39/39 20130101; A61K 2039/572 20130101;
A61K 39/001164 20180801; A61K 2039/575 20130101; A61K 2039/55561
20130101; A61K 39/0011 20130101; A61K 9/5015 20130101 |
International
Class: |
A61K 39/00 20060101
A61K039/00; A61K 9/50 20060101 A61K009/50; A61K 39/39 20060101
A61K039/39; A61K 9/51 20060101 A61K009/51; A61K 9/00 20060101
A61K009/00 |
Claims
1. An immunomodulatory therapeutic composition, comprising: an mRNA
comprising an open reading frame encoding a concatemer of two or
more activating oncogene mutation peptides.
2. (canceled)
3. The immunomodulatory therapeutic composition of claim 1, wherein
at least one of the activating oncogene mutation peptides is a KRAS
mutation peptide, optionally wherein the KRAS mutation peptide
comprises a G12 mutation and/or a G13 mutation, optionally wherein
the G12 KRAS mutation is selected from (i) G12D, G12V, G12S, G12C,
G12A, and G12R KRAS mutations; or (ii) G12D, G12V, and G12C KRAS
mutations, optionally wherein the G13 KRAS mutation is a G13D KRAS
mutation.
4-10. (canceled)
11. The immunomodulatory therapeutic composition of claim 3,
wherein the concatemer comprises 3, 4, 5, 6, 7, 8, 9, or 10
activating oncogene mutation peptides, optionally wherein the
concatemer comprises 4 activating oncogene mutation peptides.
12. (canceled)
13. The immunomodulatory therapeutic composition of claim 11,
wherein the concatemer comprises activating oncogene mutation
peptides comprising, individually, G12D, G12V, G12C, and G13D KRAS
mutations.
14-16. (canceled)
17. The immunomodulatory therapeutic composition of claim 3,
wherein the activating oncogene mutation peptides comprise,
individually, 10-30, 15-25, or 20-25 amino acids in length, or
wherein the activating oncogene mutation peptides comprise,
individually, 20, 21, 22, 23, 24, or 25 amino acids in length.
18-53. (canceled)
54. The immunomodulatory therapeutic composition of claim 3,
wherein the concatemer comprises an amino acid sequence selected
from the group consisting of SEQ ID NOs: 42-47, 73 and 137, or
wherein the mRNA encoding the concatemer comprises a nucleotide
sequence selected from the group consisting of SEQ ID NOs: 129-131,
133, 138 and 169.
55. (canceled)
56. The immunomodulatory therapeutic composition of claim 54,
wherein the mRNA includes at least one chemical modification,
optionally wherein the chemical modification is selected from the
group consisting of pseudouridine, N1-methylpseudouridine,
2-thiouridine, 4'-thiouridine, 5-methylcytosine,
2-thio-1-methyl-1-deaza-pseudouridine,
2-thio-1-methyl-pseudouridine, 2-thio-5-aza-uridine,
2-thio-dihydropseudouridine, 2-thio-dihydrouridine,
2-thio-pseudouridine, 4-methoxy-2-thio-pseudouridine,
4-methoxy-pseudouridine, 4-thio-1-methyl-pseudouridine,
4-thio-pseudouridine, 5-aza-uridine, dihydropseudouridine,
5-methyluridine, 5-methyluridine, 5-methoxyuridine, and 2'-O-methyl
uridine, or wherein the chemical modification is selected from the
group consisting of pseudouridine or a pseudouridine analog, or
wherein the chemical modification is N1-methylpseudouridine.
57-69. (canceled)
70. A lipid nanoparticle comprising the immunomodulatory
therapeutic composition of claim 1, optionally wherein the lipid
nanoparticle comprises a molar ratio of about 20-60% ionizable
amino lipid:5-25% phospholipid:25-55% sterol, and 0.5-15%
PEG-modified lipid, optionally wherein the ionizable amino lipid is
a compound of Formula (I), optionally wherein the compound of
Formula (I) is Compound 25.
71-106. (canceled)
107. The lipid nanoparticle of claim 70, wherein the lipid
nanoparticle comprises a molar ratio of about 50% Compound 25:about
10% DSPC:about 38.5% cholesterol; and about 1.5% PEG-DMG.
108-119. (canceled)
120. A pharmaceutical composition comprising the immunomodulatory
therapeutic composition of claim 1, and a pharmaceutically
acceptable carrier, optionally wherein the pharmaceutically
acceptable carrier comprises a buffer solution.
121. A pharmaceutical composition comprising the lipid nanoparticle
of claim 70, and a pharmaceutically acceptable carrier, optionally,
wherein the pharmaceutically acceptable carrier comprises a buffer
solution.
122. The pharmaceutical composition of claim 120, which is
formulated for intramuscular delivery.
123-124. (canceled)
125. A kit comprising a container comprising the immunomodulatory
therapeutic composition of claim 1, and an optional
pharmaceutically acceptable carrier, and a package insert
comprising instructions for administration of the immunomodulatory
therapeutic composition, the lipid nanoparticle or pharmaceutical
composition, for treating or delaying progression of cancer in an
individual.
126. The kit of claim 125, wherein the package insert further
comprises instructions for administration of the immunomodulatory
therapeutic composition in combination with a composition
comprising a checkpoint inhibitor polypeptide, and an optional
pharmaceutically acceptable carrier, for treating or delaying
progression of cancer in an individual.
127-134. (canceled)
135. A method of reducing or decreasing a size of a tumor,
inhibiting a tumor growth, or inducing an anti-tumor response in a
subject in need thereof, comprising administering to the subject
the immunomodulatory therapeutic composition of claim 1.
136. The method of claim 135, wherein the immunomodulatory
therapeutic composition is administered in combination with a
cancer therapeutic agent, or wherein the immunomodulatory
therapeutic composition is administered in combination with an
inhibitory checkpoint polypeptide or polynucleotide encoding the
same, optionally wherein the inhibitory checkpoint polypeptide is
an antibody or an antigen-binding fragment thereof that
specifically binds to a molecule selected from the group consisting
of PD-1, PD-L1, TIM-3, VISTA, A2AR, B7-H3, B7-H4, BTLA, CTLA-4,
IDO, KIR and LAG3.
137-138. (canceled)
139. The method of claim 135, wherein the cancer is selected from a
cancer of the pancreas, peritoneum, large intestine, small
intestine, biliary tract, lung, endometrium, ovary, genital tract,
gastrointestinal tract, cervix, stomach, urinary tract, colon,
rectum, and hematopoietic and lymphoid tissues.
140-189. (canceled)
190. The pharmaceutical composition of claim 121, which is
formulated for intramuscular delivery.
191. The immunomodulatory therapeutic composition of claim 1,
wherein the concatemer comprises the amino acid sequence of SEQ ID
NO: 137.
192. The immunomodulatory therapeutic composition of claim 1,
wherein the ORF comprises the nucleotide sequence of SEQ ID NO:
169.
193. The immunomodulatory therapeutic composition of claim 1,
wherein the mRNA comprises the nucleotide sequence of SEQ ID NO:
167.
194. The immunomodulatory therapeutic composition of claim 193,
wherein the mRNA comprises at least one chemical modification that
is N1-methylpseudouridine.
Description
RELATED APPLICATIONS
[0001] This application claims the benefit of U.S. Provisional
Application Ser. No. 62/453,465, filed on Feb. 1, 2017; U.S.
Provisional Application Ser. No. 62/467,063, filed on Mar. 3, 2017;
U.S. Provisional Application Ser. No. 62/490,523, filed on Apr. 26,
2017; and U.S. Provisional Application Ser. No. 62/541,571, filed
on Aug. 4, 2017. The entire contents of the above-referenced
applications are incorporated herein by this reference.
BACKGROUND OF THE DISCLOSURE
[0002] The ability to modulate an immune response is beneficial in
a variety of clinical situations, including the treatment of cancer
and pathogenic infections, as well as in potentiating vaccine
responses to provide protective immunity. A number of therapeutic
tools exist for modulating the function of biological pathways
and/or molecules that are involved in diseases such as cancer and
pathogenic infections. These tools include, for example, small
molecule inhibitors, cytokines and therapeutic antibodies. Some of
these tools function through modulating immune responses in a
subject, such as cytokines that modulate the activity of cells
within the immune system or immune checkpoint inhibitor antibodies,
such as anti-CTLA-4 or anti-PD-L1 that modulate the regulation of
immune responses.
[0003] Additionally, vaccines have long been used to stimulate an
immune response against antigens of pathogens to thereby provide
protective immunity against later exposure to the pathogens. More
recently, vaccines have been developed using antigens found on
tumor cells to thereby enhance anti-tumor imunoresponsiveness. In
addition to the antigen(s) used in the vaccine, other agents may be
included in a vaccine preparation, or used in combination with the
vaccine preparation, to further boost the immune response to the
vaccine. Such agents that enhance vaccine responsiveness are
referred to in the art as adjuvants. Examples of commonly used
vaccine adjuvants include aluminum gels and salts, monophosphoryl
lipid A, MF59 oil-in-water emulsion, Freund's complete adjuvant,
Freund's incomplete adjuvant, detergents and plant saponins. These
adjuvants typically are used with protein or peptide based
vaccines. Alternative types of vaccines, such as RNA based
vaccines, are now being developed.
[0004] There exists a need in the art for additional effective
agents that enhance immune responses to an antigen of interest.
SUMMARY OF THE DISCLOSURE
[0005] Provided herein are immunomodulatory therapeutic
compositions, including lipid-based compositions such as lipid
nanoparticles, which include an RNA (e.g., messenger RNA (mRNA))
that can safely direct the body's cellular machinery to produce a
cancer protein or fragment thereof of interest, e.g., an activating
oncogene mutation peptide. In some embodiments, the RNA is a
modified RNA. The immunomodulatory therapeutic compositions,
including mRNA compositions and/or lipid nanoparticles comprising
the same are useful to induce a balanced immune response against
cancers, comprising both cellular and humoral immunity, without
risking the possibility of insertional mutagenesis, for
example.
[0006] The immunomodulatory therapeutic compositions, including
mRNA compositions and/or lipid nanoparticles of the disclosure may
be utilized in various settings depending on the prevalence of the
cancer or the degree or level of unmet medical need. The
immunomodulatory therapeutic compositions, including mRNA
compositions and lipid nanoparticles of the disclosure may be
utilized to treat and/or prevent a cancer of various stages or
degrees of metastasis. The immunomodulatory therapeutic
compositions and lipid nanoparticles of the disclosure have
superior properties in that they produce much larger antibody
titers and produce responses earlier than alternative anti-cancer
therapies including cancer vaccines. While not wishing to be bound
by theory, it is believed that the provided compositions, such as
mRNA polynucleotides, are better designed to produce the
appropriate protein conformation upon translation as the RNA co-opt
natural cellular machinery. Unlike traditional therapies and
vaccines which are manufactured ex vivo and may trigger unwanted
cellular responses, RNA of the provided compositions are presented
to the cellular system in a more native fashion.
[0007] In some aspects, the disclosure provides an immunomodulatory
therapeutic composition, comprising: one or more mRNA each
comprising an open reading frame encoding an activating oncogene
mutation peptide, and optionally one or more mRNA each comprising
an open reading frame encoding a polypeptide that enhances an
immune response to the activating oncogene mutation peptide in a
subject, wherein the immune response comprises a cellular or
humoral immune response characterized by: (i) stimulating Type I
interferon pathway signaling, (ii) stimulating NFkB pathway
signaling, (iii) stimulating an inflammatory response, (iv)
stimulating cytokine production, (v) stimulating dendritic cell
development, activity or mobilization, and (vi) a combination of
any of (i)-(v); and a pharmaceutically acceptable carrier.
[0008] In some aspects, the disclosure provides an immunomodulatory
therapeutic composition, including mRNA compositions and/or lipid
nanoparticles comprising the same, that enhances an immune response
by, for example, stimulating Type I interferon pathway signaling,
stimulating NFkB pathway signaling, stimulating an inflammatory
response, stimulating cytokine production or stimulating dendritic
cell development, activity or mobilization. Enhancement of an
immune response to an antigen of interest by an immune potentiator
mRNA results in, for example, stimulation of cytokine production,
stimulation of cellular immunity (T cell responses), such as
antigen-specific CD8.sup.+ or CD4.sup.+ T cell responses and/or
stimulation of humoral immunity (B cell responses), such as
antigen-specific antibody responses.
[0009] In some aspects, the disclosure provides an immunomodulatory
therapeutic composition wherein the activating oncogene mutation is
a KRAS mutation. In some aspects, the KRAS mutation is a G12
mutation. In some aspects, the G12 KRAS mutation is selected from
G12D, G12V, G12S, G12C, G12A, and G12R KRAS mutations. In other
aspects, the G12 KRAS mutation is selected from G12D, G12V, and
G12C KRAS mutations. In some aspects, the KRAS mutation is a G13
mutation. In some aspects, the G13 KRAS mutation is a G13D KRAS
mutation. In other aspects, the disclosure provides an
immunomodulatory therapeutic composition wherein the activating
oncogene mutation is a H-RAS or N-RAS mutation.
[0010] In some embodiments the skilled artisan will select a KRAS
mutation, a HLA subtype and a tumor type based on the guidance
provided herein and prepare a KRAS vaccine for therapy. In some
embodiments the KRAS mutation is selected from: G12C, G12V, G12D,
G13D. In some embodiments the HLA subtype is selected from:
A*02:01, C*07:01, C*04:01, C*07:02, HLA-A11 and/or HLA-C08. In some
embodiments the tumor type is selected from colorectal, pancreatic,
lung (e.g., non-small cell lung cancer (NSCLC), and
endometrioid.
[0011] In some embodiments, the HRAS mutation is a mutation at
codon 12, codon 13, or codon 61. In some embodiments, the HRAS
mutation is a 12V, 61L, or 61R mutation.
[0012] In some embodiments, the NRAS mutation is a mutation at
codon 12, codon 13, or codon 61. In some embodiments, the NRAS
mutation is a 12D, 13D, 61K, or 61R mutation.
[0013] In some aspects, the disclosure provides an immunomodulatory
therapeutic composition of any one of the foregoing or related
embodiments, wherein the mRNA has an open reading frame encoding a
concatemer of two or more activating oncogene mutation peptides. In
some aspects, the concatemer comprises 3, 4, 5, 6, 7, 8, 9, or 10
activating oncogene mutation peptides. In some aspects, the
concatemer comprises 4 activating oncogene mutation peptides.
[0014] In other aspects, the disclosure provides an
immunomodulatory therapeutic composition, comprising: an mRNA
comprising an open reading frame encoding a concatemer of two or
more activating oncogene mutation peptides, wherein the concatemer
comprises KRAS activating oncogene mutation peptides G12D, G12V,
G12C, and G13D; and one or more mRNA each comprising an open
reading frame encoding a polypeptide that enhances an immune
response to the KRAS activating oncogene mutation peptides in a
subject. In some aspects, the concatemer comprises from N- to
C-terminus G12D, G12V, G13D, and G12C. In some aspects, the
concatemer comprises from N- to C-terminus G12C, G13D, G12V, and
G12D.
[0015] Some embodiments of the present disclosure provide
immunomodulatory therapeutic compositions that include an mRNA
comprising an open reading frame encoding a concatemer of two or
more activating oncogene mutation peptides. In some embodiments, at
least two of the peptide epitopes are separated from one another by
a single Glycine. In some embodiments, the concatemer comprises
3-10 activating oncogene mutation peptides. In some such
embodiments, all of the peptide epitopes are separated from one
another by a single Glycine. In other embodiments, at least two of
the peptide epitopes are linked directly to one another without a
linker.
[0016] In some aspects, the disclosure provides an immunomodulatory
therapeutic composition, comprising: 1, 2, 3, or 4 mRNAs encoding
1, 2, 3, or 4 activating oncogene mutation peptides; and one or
more mRNA each comprising an open reading frame encoding a
polypeptide that enhances an immune response to the activating
oncogene mutation peptide in a subject. In some aspects, the
composition comprises 4 mRNAs encoding 4 activating oncogene
mutation peptides. In some aspects, the 4 mRNAs encode KRAS
activating oncogene mutation peptides G12D, G12V, G12C, and
G13D.
[0017] In some aspects, the disclosure provides an immunomodulatory
therapeutic composition of any one of the foregoing or related
embodiments, wherein the activating oncogene mutation peptide
comprises 10-30, 15-25, or 20-25 amino acids in length. In some
aspects, the activating oncogene mutation peptide comprises 20, 21,
22, 23, 24, or 25 amino acids in length. In some aspects, the
activating oncogene mutation peptide comprises 25 amino acids in
length.
[0018] In some aspects, the disclosure provides an immunomodulatory
therapeutic composition of any one of the foregoing or related
embodiments, wherein the mRNA encoding a polypeptide that enhances
an immune response to the activating oncogene mutation peptide in a
subject encodes a constitutively active human STING polypeptide. In
some aspects, the constitutively active human STING polypeptide
comprises one or more mutations selected from the group consisting
of V147L, N154S, V155M, R284M, R284K, R284T, E315Q, R375A, and
combinations thereof.
[0019] In some aspects, the constitutively active human STING
polypeptide comprises mutation V155M (e.g., having the amino acid
sequence shown in SEQ ID NO: 1 or encoded by a nucleotide sequence
shown in SEQ ID NO: 139 or 170). In some aspects the constitutively
active human STING polypeptide comprises mutations
V147L/N154S/V155M. In some aspects, the constitutively active human
STING polypeptide comprises mutations R284M/V147L/N154S/V155M.
[0020] In other aspects, the constitutively active human STING
polypeptide comprises an amino acid sequence set forth in any one
of SEQ ID NOs: 1-10 and 164. In another aspect, the constitutively
active human STING polypeptide is encoded by a nucleotide sequence
set forth in any one of SEQ ID NOs: 139-148, 165, 168, 170, 201-209
and 225. In some aspects, the constitutively active human STING
polypeptide comprises a 3' UTR comprising at least one miR-122
microRNA binding site, such as for example set forth in SEQ ID NO:
149.
[0021] In some aspects, the disclosure provides an immunomodulatory
therapeutic composition of any one of the foregoing or related
embodiments, wherein the mRNA encoding a polypeptide that enhances
an immune response to the activating oncogene mutation peptide in a
subject encodes a constitutitively active human IRF3 polypeptide.
In one aspect, the constitutively active human IRF3 polypeptide
comprises an S396D mutation. In one aspect, the constitutively
active human IRF3 polypeptide comprises an amino acid sequence set
forth in SEQ ID NO: 12 or is encoded by a nucleotide sequence set
forth in SEQ ID NO: 151 or 212. In one aspect, the constitutively
active IRF3 polypeptide is a mouse IRF3 polypeptide, for example
comprising an amino acid sequence set forth in SEQ ID NO: 11 or
encoded by the nucleotide sequence shown in SEQ ID NO: 150 or
211.
[0022] In some aspects, the disclosure provides an immunomodulatory
therapeutic composition of any one of the foregoing or related
embodiments, wherein the mRNA encoding a polypeptide that enhances
an immune response to the activating oncogene mutation peptide in a
subject encodes a constitutitively active human IRF7 polypeptide.
In one aspect, the constitutively active human IRF7 polypeptide
comprises one or more mutations selected from the group consisting
of S475D, S476D, S477D, S479D, L480D, S483D, S487D, and
combinations thereof; deletion of amino acids 247-467; and
combinations of the foregoing mutations and/or deletions. In one
embodiment, the constitutively active human IRF7 polypeptide
comprises an amino acid sequence set forth in any one of SEQ ID
NOs: 14-18. In one embodiment, the constitutively active human IRF7
polypeptide is encoded by a nucleotide sequence set forth in any
one of SEQ ID NOs: 153-157 and 214-218.
[0023] In yet other aspects, the disclosure provides an immune
potentiator mRNA encoding a polypeptide selected from the group
consisting of MyD88, TRAM, IRF1, IRF8, IRF9, TBK1, IKKi, STAT1,
STAT2, STAT4, STAT6, c-FLIP, IKK.beta., RIPK1, TAK-TAB1 fusion,
DIABLO, Btk, self-activating caspase-1 and Flt3.
[0024] In some aspects, the disclosure provides an immunomodulatory
therapeutic composition of any one of the foregoing embodiments,
wherein the composition further comprises a cancer therapeutic
agent. In some aspects, the composition further comprises an
inhibitory checkpoint polypeptide. In some aspects, the inhibitory
checkpoint polypeptide is an antibody or fragment thereof that
specifically binds to a molecule selected from the group consisting
of PD-1, PD-L1, TIM-3, VISTA, A2AR, B7-H3, B7-H4, BTLA, CTLA-4,
IDO, KIR and LAG3.
[0025] In other embodiments, the composition further comprises a
recall antigen. For example, in some embodiments, the recall
antigen is an infectious disease antigen.
[0026] In some embodiments, the composition does not comprise a
stabilization agent.
[0027] In some aspects, the disclosure provides an immunomodulatory
therapeutic composition of any one of the foregoing embodiments,
wherein the mRNA is formulated in a lipid nanoparticle. In some
aspects, the lipid nanoparticle comprises a molar ratio of about
20-60% ionizable amino lipid:5-25% phospholipid:25-55% sterol; and
0.5-15% PEG-modified lipid. In some aspects, the inonizable amino
lipid is selected from the group consisting of for example,
2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA),
dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), and
di((Z)-non-2-en-1-yl)
9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319). In some
aspects, the ionizable amino lipid comprises a compound of any of
Formulae (I), (IA), (II), (IIa), (IIb), (IIc), (IId), and (IIe). In
some aspects, the ionizable amino lipid comprises a compound of
Formula (I). In some aspects, the compound of Formula (I) is
Compound 25.
[0028] In some aspects, the disclosure provides an immunomodulatory
therapeutic composition of any one of the foregoing embodiments,
wherein each mRNA includes at least one chemical modification. In
some aspects, the chemical modification is selected from the group
consisting of pseudouridine, N1-methylpseudouridine, 2-thiouridine,
4'-thiouridine, 5-methylcytosine,
2-thio-1-methyl-1-deaza-pseudouridine,
2-thio-1-methyl-pseudouridine, 2-thio-5-aza-uridine,
2-thio-dihydropseudouridine, 2-thio-dihydrouridine,
2-thio-pseudouridine, 4-methoxy-2-thio-pseudouridine,
4-methoxy-pseudouridine, 4-thio-1-methyl-pseudouridine,
4-thio-pseudouridine, 5-aza-uridine, dihydropseudouridine,
5-methyluridine, 5-methyluridine, 5-methoxyuridine, and 2'-O-methyl
uridine. In some aspects, the chemical modification is
pseudouridine or a pseudouridine analog. In some aspects, the
chemical modification is N1-methylpseudouridine. In some aspects,
each mRNA comprises fully modified N1-methylpseudouridine.
[0029] In some aspects, the disclosure provides an immunomodulatory
therapeutic composition, including mRNA compositions and
lipid-based compositions such as lipid nanoparticles, comprising:
one or more mRNA each comprising an open reading frame encoding a
KRAS activating oncogene mutation peptide, and optionally one or
more mRNA each comprising an open reading frame encoding a
constitutively active human STING polypeptide; and a
pharmaceutically acceptable carrier. In some aspects, the
constitutively active human STING polypeptide comprises mutation
V155M. In some aspects, the constitutively active human STING
polypeptide comprises an amino acid sequence shown in SEQ ID NO: 1.
In some aspects, the constitutively active human STING polypeptide
comprises a 3' UTR comprising at least one miR-122 microRNA binding
site.
[0030] In some aspects, the disclosure provides an immunomodulatory
therapeutic composition of any one of the foregoing embodiments,
wherein the KRAS activating oncogene mutation peptide is selected
from G12D, G12V, G12S, G12C, G12A, G12R, and G13D. In some aspects,
the KRAS activating oncogene mutation peptide is selected from
G12D, G12V, G12C, and G13D.
[0031] In some aspects, the disclosure provides an immunomodulatory
therapeutic composition of any one of the foregoing embodiments,
wherein the mRNA comprises an open reading frame encoding a
concatemer of two or more KRAS activating oncogene mutation
peptides. In some aspects, the concatemer comprises 3, 4, 5, 6, 7,
8, 9 or 10 KRAS activating oncogene mutation peptides. In some
aspects, the concatemer comprises 4 KRAS activating oncogene
mutation peptides. In some aspects, the concatemer comprises G12D,
G12V, G12C, and G13D. In some aspects, the concatemer comprises
from N- to C-terminus G12D, G12V, G13D, and G12C. In some aspects,
the concatemer comprises from N- to C-terminus G12C, G13D, G12V,
and G12D.
[0032] In some aspects, the disclosure provides an immunomodulatory
therapeutic composition of any one of the foregoing embodiments,
wherein the composition comprises 1, 2, 3, or 4 mRNAs encoding 1,
2, 3, or 4 KRAS activating oncogene mutation peptides. In some
aspects, the composition comprises 4 mRNAs encoding 4 KRAS
activating oncogene mutation peptides. In some aspects, the 4 KRAS
activating oncogene mutation peptides comprise G12D, G12V, G12C,
and G13D.
[0033] In some aspects, the disclosure provides an immunomodulatory
therapeutic composition of any one of the foregoing or related
embodiments, wherein the KRAS activating oncogene mutation peptide
comprises 10-30, 15-25, or 20-25 amino acids in length. In some
aspects, the KRAS activating oncogene mutation peptide comprises
20, 21, 22, 23, 24, or 25 amino acids in length. In some aspects,
the activating oncogene mutation peptide comprises 25 amino acids
in length.
[0034] In some aspects, the disclosure provides an immunomodulatory
therapeutic composition of any one of the foregoing or related
embodiments, wherein the mRNA has an open reading frame encoding a
concatemer of two or more KRAS activating oncogene mutation
peptides and the concatemer comprises an amino acid sequence
selected from the group set forth in SEQ ID NOS: 42-47, 73 and 137.
In some aspects, wherein the mRNA encoding the concatemer comprises
a nucleotide sequence selected from the group set forth in SEQ ID
NOS: 129-131, 133, 138, 167, 169, 193-195 and 197-198.
[0035] In some aspects, the disclosure provides an immunomodulatory
therapeutic composition of any one of the foregoing or related
embodiments, wherein the composition comprises 1, 2, 3, or 4 mRNAs
encoding 1, 2, 3, or 4 KRAS activating oncogene mutation peptides,
and wherein the KRAS activating oncogene mutation peptides comprise
an amino acid sequence selected from the group set forth in SEQ ID
NOs: 36-41, 72 and 125. In some aspects, the KRAS activating
oncogene mutation peptides comprise the amino acid sequence set
forth in SEQ ID NOs: 39-41 and 72. In some aspects, the mRNA
encoding the KRAS activating oncogene mutation peptide comprises a
nucleotide sequence selected from the group set forth in SEQ ID
NOs: 126-128, 132, 190-192 and 196.
[0036] In other aspects, the disclosure provides an
immunomodulatory therapeutic composition, including mRNA
compositions and/or lipid nanoparticles comprising the same,
comprising an mRNA construct encoding at least one mutant human
KRAS antigen and a constitutively active human STING polypeptide,
for example wherein the mRNA (e.g., a modified mRNA) encodes an
amino acid sequence as set forth in any one of SEQ ID NOs:
48-71.
[0037] In some aspects, the disclosure provides an immunomodulatory
therapeutic composition of any one of the foregoing or related
embodiments, wherein each mRNA is formulated in the same or
different lipid nanoparticle. In some aspects, each mRNA encoding a
KRAS activating oncogene mutation peptide is formulated in the same
or different lipid nanoparticle. In some aspects, each mRNA
encoding constitutively active human STING is formulated in the
same or different lipid nanoparticle. In some aspects, each mRNA
encoding a KRAS activating oncogene mutation peptide is formulated
in the same lipid nanoparticle and each mRNA encoding
constitutively active human STING is formulated in a different
lipid nanoparticle. In some aspects, each mRNA encoding a KRAS
activating oncogene mutation peptide is formulated in the same
lipid nanoparticle and each mRNA encoding constitutively active
human STING is formulated in the same lipid nanoparticle as each
mRNA encoding a KRAS activating oncogene mutation peptide. In some
aspects, each mRNA encoding a KRAS activating oncogene mutation
peptide is formulated in a different lipid nanoparticle and each
mRNA encoding constitutively active human STING is formulated in
the same lipid nanoparticle as each mRNA encoding each KRAS
activating oncogene mutation peptide.
[0038] In some aspects, the disclosure provides an immunomodulatory
therapeutic composition of any one of the foregoing embodiments,
wherein the immunomodulatory therapeutic composition is formulated
in a lipid nanoparticle, wherein the lipid nanoparticle comprises a
molar ratio of about 20-60% ionizable amino lipid:5-25%
phospholipid:25-55% sterol; and 0.5-15% PEG-modified lipid. In some
aspects, the ionizable amino lipid is selected from the group
consisting of for example,
2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA),
dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), and
di((Z)-non-2-en-1-yl)
9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319). In some
aspects, the ionizable amino lipid comprises a compound of any of
Formulae (I), (IA), (II), (IIa), (IIb), (IIc), (IId), and (IIe). In
some aspects, the ionizable amino lipid comprises a compound of
Formula (I). In some aspects, the compound of Formula (I) is
Compound 25.
[0039] In certain embodiments, the lipid nanoparticle comprises
Compound 25 (as the ionizable amino lipid), DSPC (as the
phospholipid), cholesterol (as the sterol) and PEG-DMG (as the
PEG-modified lipid). In certain embodiments, the lipid nanoparticle
comprises a molar ratio of about 20-60% Compound 25:5-25%
DSPC:25-55% cholesterol; and 0.5-15% PEG-DMG. In one embodiment,
the lipid nanoparticle comprises a molar ratio of about 50%
Compound 25:about 10% DSPC:about 38.5% cholesterol:about 1.5%
PEG-DMG (i.e., Compound 25:DSPC:cholesterol:PEG-DMG at about a
50:10:38.5:1.5 ratio). In one embodiment, the lipid nanoparticle
comprises a molar ratio of 50% Compound 25:10% DSPC:38.5%
cholesterol: 1.5% PEG-DMG (i.e., Compound
25:DSPC:cholesterol:PEG-DMG at a 50:10:38.5:1.5 ratio).
[0040] In some aspects, the disclosure provides an immunomodulatory
therapeutic composition of any one of the foregoing or related
embodiments, wherein each mRNA includes at least one chemical
modification. In some aspects, the chemical modification is
selected from the group consisting of pseudouridine,
N1-methylpseudouridine, 2-thiouridine, 4'-thiouridine,
5-methylcytosine, 2-thio-1-methyl-1-deaza-pseudouridine,
2-thio-1-methyl-pseudouridine, 2-thio-5-aza-uridine,
2-thio-dihydropseudouridine, 2-thio-dihydrouridine,
2-thio-pseudouridine, 4-methoxy-2-thio-pseudouridine,
4-methoxy-pseudouridine, 4-thio-1-methyl-pseudouridine,
4-thio-pseudouridine, 5-aza-uridine, dihydropseudouridine,
5-methyluridine, 5-methyluridine, 5-methoxyuridine, and 2'-O-methyl
uridine. In some aspects, the chemical modification is
pseudouridine or a pseudouridine analog. In some aspects, the
chemical modification is N1-methylpseudouridine. In some aspects,
each mRNA comprises fully modified N1-methylpseudouridine.
[0041] In some aspects, the disclosure provides a lipid
nanoparticle comprising: an mRNA comprising an open reading frame
encoding a concatemer of 4 KRAS activating oncogene mutation
peptides, wherein the 4 KRAS activating oncogene mutation peptides
comprise G12D, G12V, G12C, and G13D; an mRNA comprising an open
reading frame encoding a constitutively active human STING
polypeptide. In some aspects, the concatemer comprises from N- to
C-terminus G12D, G12V, G13D, and G12C. In some aspects, the
concatemer comprises from N- to C-terminus G12C, G13D, G12V, and
G12D.
[0042] In some aspects, the disclosure provides lipid nanoparticle
of any one of the foregoing embodiments, wherein each KRAS
activating oncogene mutation peptide comprises 20, 21, 22, 23, 24,
or 25 amino acids in length. In some aspects, each KRAS activating
oncogene mutation peptide comprises 25 amino acids in length.
[0043] In some aspects, the disclosure provides a lipid
nanoparticle comprising: an mRNA comprising an open reading frame
encoding a concatemer of 4 KRAS activating oncogene mutation
peptides, wherein the 4 KRAS activating oncogene mutation peptides
comprise G12D, G12V, G12C, and G13D, and wherein the concatemer
comprises the amino acid sequence set forth in SEQ ID NO:137; an
mRNA comprising an open reading frame encoding a constitutively
active human STING polypeptide. In some aspects, the mRNA encoding
the concatemer of 4 KRAS activating oncogene mutation peptides
comprises the nucleotide sequence set forth in SEQ ID NO: 138, SEQ
ID NO: 167 or SEQ ID NO: 169. In some aspects, the constitutively
active human STING polypeptide comprises mutation V155M. In some
aspects, the constitutively active human STING polypeptide
comprises the amino acid sequence shown in SEQ ID NO: 1. In some
aspects, the mRNA encoding the constitutively active human STING
polypeptide comprises a 3' UTR comprising at least one miR-122
microRNA binding site. In some aspects, the mRNA encoding the
constitutively active human STING polypeptide comprises the
nucleotide sequence shown in SEQ ID NO: 139, SEQ ID NO: 168, or SEQ
ID NO: 170.
[0044] In other aspects, the disclosure provides a lipid
nanoparticle comprising:
[0045] a first mRNAs comprising an open reading frame encoding a
KRAS activating oncogene mutation peptide comprising G12D;
[0046] a second mRNA comprising an open reading frame encoding a
KRAS activating oncogene mutation peptide comprising G12V;
[0047] a third mRNA comprising an open reading frame encoding a
KRAS activating oncogene mutation peptide comprising G12C;
[0048] a fourth mRNA comprising an open reading frame encoding a
KRAS activating oncogene mutation peptide comprising G13D; and
[0049] a fifth mRNA comprising an open reading frame encoding a
constitutively active human STING polypeptide. In certain
embodiments, the mRNAs are present at a KRAS:STING mass ratio
selected from the group consisting of 1:1, 2:1, 3:1, 4:1, 5:1, 6:1,
7:1, 8:1, 9:1 and 10:1. In one embodiment, the mRNAs are present at
a KRAS:STING mass ratio of 5:1.
[0050] In some aspects of the foregoing lipid nanoparticle, each
KRAS activating oncogene mutation peptide comprises 20, 21, 22, 23,
24, or 25 amino acids in length. In some aspects, each KRAS
activating oncogene mutation peptide comprises 25 amino acids in
length.
[0051] In some aspects of the foregoing lipid nanoparticle, the
KRAS activating oncogene mutation peptides comprise the amino acid
sequences set forth in SEQ ID NOs: 39-41 and 72. In some aspects,
the mRNAs encoding the KRAS activating oncogene mutation peptides
comprise the nucleotide sequences set forth in SEQ ID NOs: 126-128,
132, 190-192 and 196.
[0052] In some aspects of the foregoing lipid nanoparticle, the
constitutively active human STING polypeptide comprises mutation
V155M. In some aspects, the constitutively active human STING
polypeptide comprises the amino acid sequence shown in SEQ ID NO:
1. In some aspects, the mRNA encoding the constitutively active
human STING polypeptide comprises a 3' UTR comprising at least one
miR-122 microRNA binding site. In some aspects, the mRNA encoding
the constitutively active human STING polypeptide comprises the
nucleotide sequence shown in SEQ ID NO: 139, SEQ ID NO: 168, or SEQ
ID NO: 170.
[0053] In some aspects, the disclosure provides a lipid
nanoparticle of any one of the foregoing embodiments, wherein the
lipid nanoparticle comprises a molar ratio of about 20-60%
ionizable amino lipid:5-25% phopholipid:25-55% sterol; and 0.5-15%
PEG-modified lipid. In some aspects, the inonizable amino lipid is
selected from the group consisting of for example,
2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA),
dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), and
di((Z)-non-2-en-1-yl)
9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319). In some
aspects, the ionizable amino lipid comprises a compound of any of
Formulae (I), (IA), (II), (IIa), (IIb), (IIc), (IId), and (IIe). In
some aspects, the ionizable amino lipid comprises a compound of
Formula (I). In some aspects, the compound of Formula (I) is
Compound 25.
[0054] In some aspects, the disclosure provides a lipid
nanoparticle of any one of the foregoing embodiments, wherein each
mRNA includes at least one chemical modification. In some aspects,
the chemical modification is selected from the group consisting of
pseudouridine, N1-methylpseudouridine, 2-thiouridine,
4'-thiouridine, 5-methylcytosine,
2-thio-1-methyl-1-deaza-pseudouridine,
2-thio-1-methyl-pseudouridine, 2-thio-5-aza-uridine,
2-thio-dihydropseudouridine, 2-thio-dihydrouridine,
2-thio-pseudouridine, 4-methoxy-2-thio-pseudouridine,
4-methoxy-pseudouridine, 4-thio-1-methyl-pseudouridine,
4-thio-pseudouridine, 5-aza-uridine, dihydropseudouridine,
5-methyluridine, 5-methyluridine, 5-methoxyuridine, and 2'-O-methyl
uridine. In some aspects, the chemical modification is
pseudouridine or a pseudouridine analog. In some aspects, the
chemical modification is N1-methylpseudouridine. In some aspects,
each mRNA comprises fully modified N1-methylpseudouridine.
[0055] In some aspects, the disclosure provides a drug product
comprising any of the foregoing or related lipid nanoparticles for
use in cancer therapy, optionally with instructions for use in
cancer therapy.
[0056] In other aspects, the disclosure provides a first lipid
nanoparticle comprising: an mRNA comprising an open reading frame
encoding a KRAS activating oncogene mutation peptide comprising
G12D; and an mRNA comprising an open reading frame encoding a
constitutively active human STING polypeptide.
[0057] In some aspects, the disclosure provides a second lipid
nanoparticle comprising: an mRNA comprising an open reading frame
encoding a KRAS activating oncogene mutation peptide comprising
G12V; and an mRNA comprising an open reading frame encoding a
constitutively active human STING polypeptide.
[0058] In some aspects, the disclosure provides a third lipid
nanoparticle comprising an mRNA comprising an open reading frame
encoding a KRAS activating oncogene mutation peptide comprising
G12C; and an mRNA comprising an open reading frame encoding a
constitutively active human STING polypeptide.
[0059] In some aspects, the disclosure provides a fourth lipid
nanoparticle comprising: an mRNA comprising an open reading frame
encoding a KRAS activating oncogene mutation peptide comprising
G13D; and an mRNA comprising an open reading frame encoding a
constitutively active human STING polypeptide.
[0060] In some aspects of the foregoing first, second, third and
fourth lipid nanoparticles, each KRAS activating oncogene mutation
peptide comprises 20, 21, 22, 23, 24, or 25 amino acids in length.
In some aspects, each KRAS activating oncogene mutation peptide
comprises 25 amino acids in length.
[0061] In some aspects of the foregoing first, second, third and
fourth lipid nanoparticles, the KRAS activating oncogene mutation
peptide comprises the amino acid sequences set forth in SEQ ID NO:
39. In some aspects, the mRNA encoding the KRAS activating oncogene
mutation peptide comprises the nucleotide sequence set forth in SEQ
ID NOs: 126 or 190.
[0062] In some aspects of the foregoing first, second, third and
fourth lipid nanoparticles, the KRAS activating oncogene mutation
peptide comprises the amino acid sequences set forth in SEQ ID NO:
40. In some aspect, the mRNA encoding the KRAS activating oncogene
mutation peptide comprises the nucleotide sequence set forth in SEQ
ID NOs: 127 or 191.
[0063] In some aspects of the foregoing first, second, third and
fourth lipid nanoparticles, the KRAS activating oncogene mutation
peptide comprises the amino acid sequences set forth in SEQ ID NO:
72. In some aspects, the mRNA encoding the KRAS activating oncogene
mutation peptide comprises the nucleotide sequence set forth in SEQ
ID NOs: 132 or 196.
[0064] In some aspects of the foregoing first, second, third and
fourth lipid nanoparticles, wherein the KRAS activating oncogene
mutation peptide comprises the amino acid sequences set forth in
SEQ ID NO: 41. In some aspects, the mRNA encoding the KRAS
activating oncogene mutation peptide comprises the nucleotide
sequence set forth in SEQ ID NOs: 128 or 192.
[0065] In some aspects of the foregoing first, second, third and
fourth lipid nanoparticles, the constitutively active human STING
polypeptide comprises mutation V155M. In some aspects, the
constitutively active human STING polypeptide comprises the amino
acid sequence shown in SEQ ID NO: 1. In some aspects, the
constitutively active human STING polypeptide comprises a 3' UTR
comprising at least one miR-122 microRNA binding site. In some
aspects, the mRNA encoding the constitutively active human STING
polypeptide comprises the nucleotide sequence shown in SEQ ID NO:
139, SEQ ID NO: 168, or SEQ ID NO: 170.
[0066] In some aspects, the disclosure provides a drug product
comprising any of the foregoing or related lipid nanoparticles for
use in cancer therapy, optionally with instructions for use in
cancer therapy. In some aspects, the disclosure provides a drug
product comprising any of the foregoing first, second, third and
fourth lipid nanoparticles, for use in cancer therapy, optionally
with instructions for use in cancer therapy.
[0067] In some aspects, the disclosure provides a drug product
comprising a first, second, third and fourth lipid nanoparticles,
for use in cancer therapy, optionally with instructions for use in
cancer therapy, wherein:
[0068] (i) the first lipid nanoparticle comprises: an mRNA
comprising an open reading frame encoding a KRAS activating
oncogene mutation peptide comprising G12D; and an mRNA comprising
an open reading frame encoding a constitutively active human STING
polypeptide;
[0069] (ii) the second lipid nanoparticle comprises: an mRNA
comprising an open reading frame encoding a KRAS activating
oncogene mutation peptide comprising G12V; and an mRNA comprising
an open reading frame encoding a constitutively active human STING
polypeptide;
[0070] (iii) the third lipid nanoparticle comprises: an mRNA
comprising an open reading frame encoding a KRAS activating
oncogene mutation peptide comprising G12C; and an mRNA comprising
an open reading frame encoding a constitutively active human STING
polypeptide; and
[0071] (iv) the fourth lipid nanoparticle comprises: an mRNA
comprising an open reading frame encoding a KRAS activating
oncogene mutation peptide comprising G13D; and an mRNA comprising
an open reading frame encoding a constitutively active human STING
polypeptide.
[0072] In any of the foregoing or related aspects, the disclosure
provides a method for treating a subject, comprising: administering
to a subject having cancer any of the foregoing or related
immunomodulatory therapeutic compositions or any of the foregoing
or related lipid nanoparticle. In some aspects, the
immunomodulatory therapeutic composition or lipid nanoparticle is
administered in combination with a cancer therapeutic agent. In
some aspects, the immunomodulatory therapeutic composition or lipid
nanoparticle is administered in combination with an inhibitory
checkpoint polypeptide. In some aspects, the inhibitory checkpoint
polypeptide is an antibody or fragment thereof that specifically
binds to a molecule selected from the group consisting of PD-1,
PD-L1, TIM-3, VISTA, A2AR, B7-H3, B7-H4, BTLA, CTLA-4, IDO, KIR and
LAG3.
[0073] Methods provided herein may be used for treating a subject
having cancer. In some embodiments, the cancer is selected from
cancer of the pancreas, peritoneum, large intestine, small
intestine, biliary tract, lung, endometrium, ovary, genital tract,
gastrointestinal tract, cervix, stomach, urinary tract, colon,
rectum, and hematopoietic and lymphoid tissues. In some
embodiments, the cancer is colorectal cancer. In some embodiments,
the cancer is pancreatic cancer. In some embodiments, the cancer is
lung cancer, such as non-small cell lung cancer (NSCLC). In some
embodiments, the cancer is selected from the group consisting of
colorectal cancer, pancreatic cancer and lung cancer (e.g.,
NSCLC).
[0074] An mRNA (e.g., mmRNA) construct of the disclosure (e.g., an
immune potentiator mRNA, antigen-encoding mRNA, or combination
thereof) can comprise, for example, a 5' UTR, a codon optimized
open reading frame encoding the polypeptide, a 3' UTR and a 3'
tailing region of linked nucleosides. In one embodiment, the mRNA
further comprises one or more microRNA (miRNA) binding sites.
[0075] In one embodiment, a modified mRNA construct of the
disclosure is fully modified. For example, in one embodiment, the
mmRNA comprises pseudouridine (.psi.), pseudouridine (.psi.) and
5-methyl-cytidine (m.sup.5C), 1-methyl-pseudouridine
(m.sup.1.psi.), 1-methyl-pseudouridine (m.sup.1.psi.) and
5-methyl-cytidine (m.sup.5C), 2-thiouridine (s.sup.2U),
2-thiouridine and 5-methyl-cytidine (m.sup.5C), 5-methoxy-uridine
(mo.sup.5U), 5-methoxy-uridine (mo.sup.5U) and 5-methyl-cytidine
(m.sup.5C), 2'-O-methyl uridine, 2'-O-methyl uridine and
5-methyl-cytidine (m.sup.5C), N6-methyl-adenosine (m.sup.6A) or
N6-methyl-adenosine (m.sup.6A) and 5-methyl-cytidine (m.sup.5C). In
another embodiment, the mmRNA comprises pseudouridine (.psi.),
N1-methylpseudouridine (m.sup.1.psi.), 2-thiouridine,
4'-thiouridine, 5-methylcytosine,
2-thio-1-methyl-1-deaza-pseudouridine,
2-thio-1-methyl-pseudouridine, 2-thio-5-aza-uridine,
2-thio-dihydropseudouridine, 2-thio-dihydrouridine,
2-thio-pseudouridine, 4-methoxy-2-thio-pseudouridine,
4-methoxy-pseudouridine, 4-thio-1-methyl-pseudouridine,
4-thio-pseudouridine, 5-aza-uridine, dihydropseudouridine,
5-methoxyuridine, or 2'-O-methyl uridine, or combinations thereof.
In yet another embodiment, the mmRNA comprises
1-methyl-pseudouridine (m.sup.1.psi.), 5-methoxy-uridine
(mo.sup.5U), 5-methyl-cytidine (m.sup.5C), pseudouridine (.psi.),
.alpha.-thio-guanosine, or .alpha.-thio-adenosine, or combinations
thereof. In some aspects, the mmRNA comprises pseudouridine or a
pseudouridine analog. In some aspects, the mmRNA comprises
N1-methylpseudouridine. In some aspects, each mmRNA comprises fully
modified N1-methylpseudouridine.
[0076] In some embodiments the dosage of the RNA polynucleotide in
the immunomodulatory therapeutic composition is 1-5 .mu.g, 5-10
.mu.g, 10-15 .mu.g, 15-20 .mu.g, 10-25 .mu.g, 20-25 .mu.g, 20-50
.mu.g, 30-50 .mu.g, 40-50 .mu.g, 40-60 .mu.g, 60-80 .mu.g, 60-100
.mu.g, 50-100 .mu.g, 80-120 .mu.g, 40-120 .mu.g, 40-150 .mu.g,
50-150 .mu.g, 50-200 .mu.g, 80-200 .mu.g, 100-200 .mu.g, 100-300
.mu.g, 120-250 .mu.g, 150-250 .mu.g, 180-280 .mu.g, 200-300 .mu.g,
30-300 .mu.g, 50-300 .mu.g, 80-300 .mu.g, 100-300 .mu.g, 40-300
.mu.g, 50-350 .mu.g, 100-350 .mu.g, 200-350 .mu.g, 300-350 .mu.g,
320-400 .mu.g, 40-380 g, 40-100 .mu.g, 100-400 .mu.g, 200-400
.mu.g, or 300-400 .mu.g per dose. In some embodiments, the
immunomodulatory therapeutic composition is administered to the
subject by intradermal or intramuscular injection. In some
embodiments, the immunomodulatory therapeutic composition is
administered to the subject on day zero. In some embodiments, a
second dose of the immunomodulatory therapeutic composition is
administered to the subject on day twenty one.
[0077] In some embodiments, a dosage of 25 micrograms of the RNA
polynucleotide is included in the immunomodulatory therapeutic
composition administered to the subject. In some embodiments, a
dosage of 10 micrograms of the RNA polynucleotide is included in
the immunomodulatory therapeutic composition administered to the
subject. In some embodiments, a dosage of 30 micrograms of the RNA
polynucleotide is included in the immunomodulatory therapeutic
composition administered to the subject. In some embodiments, a
dosage of 100 micrograms of the RNA polynucleotide is included in
the immunomodulatory therapeutic composition administered to the
subject. In some embodiments, a dosage of 50 micrograms of the RNA
polynucleotide is included in the immunomodulatory therapeutic
composition administered to the subject. In some embodiments, a
dosage of 75 micrograms of the RNA polynucleotide is included in
the immunomodulatory therapeutic composition administered to the
subject. In some embodiments, a dosage of 150 micrograms of the RNA
polynucleotide is included in the immunomodulatory therapeutic
composition administered to the subject. In some embodiments, a
dosage of 400 micrograms of the RNA polynucleotide is included in
the immunomodulatory therapeutic composition administered to the
subject. In some embodiments, a dosage of 300 micrograms of the RNA
polynucleotide is included in the immunomodulatory therapeutic
composition administered to the subject. In some embodiments, a
dosage of 200 micrograms of the RNA polynucleotide is included in
the immunomodulatory therapeutic composition administered to the
subject. In some embodiments, the RNA polynucleotide accumulates at
a 100 fold higher level in the local lymph node in comparison with
the distal lymph node. In other embodiments the immunomodulatory
therapeutic composition is chemically modified and in other
embodiments the immunomodulatory therapeutic composition is not
chemically modified.
[0078] In some embodiments, the effective amount is a total dose of
1-100 .mu.g. In some embodiments, the effective amount is a total
dose of 100 .mu.g. In some embodiments, the effective amount is a
dose of 25 .mu.g administered to the subject a total of one or two
times. In some embodiments, the effective amount is a dose of 100
.mu.g administered to the subject a total of two times. In some
embodiments, the effective amount is a dose of 1 .mu.g-10 .mu.g, 1
.mu.g-20 .mu.g, 1 .mu.g-30 .mu.g, 5 .mu.g-10 .mu.g, 5 .mu.g-20
.mu.g, 5 .mu.g-30 .mu.g, 5 .mu.g-40 .mu.g, 5 .mu.g-50 .mu.g, 10
.mu.g-15 .mu.g, 10 .mu.g-20 .mu.g, 10 .mu.g-25 .mu.g, 10 .mu.g-30
.mu.g, 10 .mu.g-40 .mu.g, 10 .mu.g-50 .mu.g, 10 .mu.g-60 .mu.g, 15
.mu.g-20 .mu.g, 15 .mu.g-25 .mu.g, 15 .mu.g-30 .mu.g, 15 .mu.g-40
.mu.g, 15 .mu.g-50 .mu.g, 20 .mu.g-25 .mu.g, 20 .mu.g-30 .mu.g, 20
.mu.g-40 .mu.g 20 .mu.g-50 .mu.g, 20 .mu.g-60 .mu.g, 20 .mu.g-70
.mu.g, 20 .mu.g-75 .mu.g, 30 .mu.g-35 .mu.g, 30 .mu.g-40 .mu.g, 30
.mu.g-45 .mu.g 30 .mu.g-50 .mu.g, 30 .mu.g-60 .mu.g, 30 .mu.g-70
.mu.g, 30 .mu.g-75 .mu.g which may be administered to the subject a
total of one or two times or more.
[0079] In some aspects, the disclosure provides a composition
(e.g., a vaccine) comprising an mRNA encoding a KRAS activating
oncogene mutation peptide and an mRNA encoding a constitutively
active human STING polypeptide wherein the mRNA encoding the KRAS
activating oncogene mutation peptide and the mRNA encoding the
constitutively active human STING polypeptide are present at a
KRAS:STING mass ratio of 1:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1,
9:1, 10:1 or 20:1, or alternatively at a STING:KRAS mass ratio of
1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, 1:10 or 1:20. In some
aspects, the mRNAs are present at a mass ratio of 5:1 of mRNA
encoding the KRAS activating oncogene mutation peptide to the mRNA
encoding the constitutively active human STING polypeptide
(KRAS:STING mass ratio of 5:1 or alternatively a STING:KRAS mass
ratio of 1:5). In some aspects, the mRNAs are present at a mass
ratio of 10:1 of mRNA encoding the KRAS activating oncogene
mutation peptide to the mRNA encoding the constitutively active
human STING polypeptide (KRAS:STING mass ratio of 10:1 or
alternatively a STING:KRAS ratio of 1:10).
[0080] Other aspects of the disclosure relate to a lipid
nanoparticle comprising:
[0081] an mRNA comprising an open reading frame encoding a
concatemer of 4 KRAS activating oncogene mutation peptides, wherein
the 4 KRAS activating oncogene mutation peptides comprise G12D,
G12V, G12C, and G13D;
[0082] an mRNA comprising an open reading frame encoding a
constitutively active human STING polypeptide;
[0083] wherein the mRNAs are present at a KRAS:STING mass ratio
selected from the group consisting of of 1:1, 2:1, 3:1, 4:1, 5:1,
6:1, 7:1, 8:1, 9:1 or 10:1.
[0084] In some aspects, the disclosure relates to a lipid
nanoparticle comprising:
[0085] a first mRNAs comprising an open reading frame encoding a
KRAS activating oncogene mutation peptide comprising G12D;
[0086] a second mRNA comprising an open reading frame encoding a
KRAS activating oncogene mutation peptide comprising G12V;
[0087] a third mRNA comprising an open reading frame encoding a
KRAS activating oncogene mutation peptide comprising G12C;
[0088] a fourth mRNA comprising an open reading frame encoding a
KRAS activating oncogene mutation peptide comprising G13D;
[0089] a fifth mRNA comprising an open reading frame encoding a
constitutively active human STING polypeptide;
[0090] wherein the first, second, third, fourth and fifth mRNAs are
present at an KRAS:STING mass ratio selected from the group
consisting of of 1:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1 or
10:1.
[0091] In some of the foregoing and related aspects, the concatemer
comprises from N- to C-terminus G12D, G12V, G13D, and G12C. In some
aspects, the concatemer comprises from N- to C-terminus G12C, G13D,
G12V, and G12D. In some aspects, each KRAS activating oncogene
mutation peptide comprises 20, 21, 22, 23, 24, or 25 amino acids in
length. In some aspects, each KRAS activating oncogene mutation
peptide comprises 25 amino acids in length. In some aspects, the
concatemer comprises an amino acid sequence set forth in SEQ ID NO:
137. In some aspects, the mRNA encoding the concatemer of 4 KRAS
activating oncogene mutation peptides comprises the nucleotide
sequence set forth in SEQ ID NO: 138, SEQ ID NO: 167 or SEQ ID NO:
169. In some aspects, the constitutively active human STING
polypeptide comprises mutation V155M. In some aspects, the
constitutively active human STING polypeptide comprises the amino
acid sequence shown in SEQ ID NO: 1. In some aspects, the mRNA
encoding the constitutively active human STING polypeptide
comprises a 3' UTR comprising at least one miR-122 microRNA binding
site. In some aspects, the mRNA encoding the constitutively active
human STING polypeptide comprises the nucleotide sequence shown in
SEQ ID NO: 139, SEQ ID NO: 168, or SEQ ID NO: 170.
[0092] In some of the foregoing and related aspects, the lipid
nanoparticle comprises mRNAs present at an KRAS:STING mass ratio of
1:1. In some aspects, the mRNAs are present at a KRAS:STING mass
ratio of 2:1. In some aspects, the mRNAs are present at a
KRAS:STING mass ratio of 3:1. In some aspects, the the mRNAs are
present at a KRAS:STING mass ratio of 4:1. In some aspects, the
mRNAs are present at a KRAS:STING mass ratio of 5:1. In some
aspects, the mRNAs are present at a KRAS:STING mass ratio of 6:1.
In some aspects, the mRNAs are present at a KRAS:STING mass ratio
of 7:1. In some aspects, the mRNAs are present at a KRAS:STING mass
ratio of 8:1. In some aspects, the mRNAs are present at a
KRAS:STING mass ratio of 9:1. In some aspects, the mRNAS are
present at a KRAS:STING mass ratio of 10:1.
[0093] In another aspect, the disclosure pertains to a lipid
nanoparticle comprising a modified mRNA of the disclosure. In one
embodiment, the lipid nanoparticle is a liposome. In another
embodiment, the lipid nanoparticle comprises a cationic and/or
ionizable amino lipid. In one embodiment, the cationic and/or
ionizable amino lipid is
2,2-dilinoleyl-4-methylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA) or
dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA). In some
aspects, the ionizable amino lipid comprises a compound of any of
Formulae (I), (IA), (II), (IIa), (IIb), (IIc), (IId), and (IIe). In
some aspects, the ionizable amino lipid comprises a compound of
Formula (I). In one embodiment, the ionizable amino lipid is
Compound 25. In one embodiment, the lipid nanoparticle further
comprises a targeting moiety conjugated to the outer surface of the
lipid nanoparticle.
[0094] In another aspect, the disclosure pertains to a
pharmaceutical composition comprising a modified mRNA of the
disclosure or a lipid nanoparticle of the disclosure, and a
pharmaceutically acceptable carrier, diluent or excipient.
[0095] In another aspect, the disclosure pertains to a method for
enhancing an immune response to an antigen(s) of interest, the
method comprising administering to a subject in need thereof a mRNA
composition of disclosure encoding an antigen(s) of interest and a
polypeptide that enhances an immune response to the antigen(s) of
interest, or lipid nanoparticle thereof, or pharmaceutical
composition thereof, such that an immune response to the antigen of
interest is enhanced in the subject. In one aspect, enhancing an
immune response in a subject comprises stimulating cytokine
production (e.g., IFN-.gamma. or TNF-.alpha.). In another aspect,
enhancing an immune response in a subject comprises stimulating
antigen-specific CD8.sup.+ T cell activity, e.g., priming,
proliferation and/or survival (e.g., increasing the effector/memory
T cell population). In one aspect, enhancing an immune response in
a subject comprises stimulating antigen-specific CD4.sup.+ T cell
activity (e.g., increasing helper T cell activity). In other
aspects, enhancing an immune response in a subject comprises
stimulating B cell responses (e.g., increasing antibody
production).
[0096] In one aspect, the disclosure provides methods for enhancing
an immune response to an activating oncogene mutation peptide,
wherein the subject is administered two different immune
potentiator mRNA (e.g., mmRNA) constructs (wherein one or both
constructs also encode, or are administered with an mRNA (e.g.,
mmRNA) construct that encodes, the activating oncogene mutation
peptide), either at the same time or sequentially. In one aspect,
the subject is administered an immune potentiator mmRNA composition
that stimulates dendritic cell development or activity prior to
administering to the subject an immune potentiator mRNA composition
that stimulates Type I interferon pathway signaling.
[0097] In other aspects, the disclosure provides methods of
stimulating an immune response to a tumor in a subject in need
thereof, wherein the method comprises administering to the subject
an effective amount of a composition comprising at least one mRNA
construct encoding a tumor antigen(s) and an mRNA construct
encoding a polypeptide that enhances an immune response to the
tumor antigen(s), or a lipid nanoparticle thereof, or a
pharmaceutical composition thereof, such that an immune response to
the tumor is stimulated in the subject. In one aspect, the tumor is
a liver cancer, a colorectal cancer, a pancreatic cancer, a
non-small cell lung cancer (NSCLC), a melanoma cancer, a cervical
cancer or a head or neck cancer.
[0098] In another aspect, the disclosure provides a composition
comprising:
[0099] (i) a first mRNA comprising an open reading frame encoding a
concatemer of 4 KRAS activating oncogene mutation peptides, wherein
the concatemer comprises from N- to C-terminus G12D, G12V, G13D,
and G12C, and
[0100] (ii) a second mRNA comprising an open reading frame encoding
a constitutively active human STING polypeptide, wherein the
constitutively active human STING polypeptide comprises mutation
V155M,
[0101] wherein the first mRNA and second mRNA are present at a
KRAS:STING mass ratio selected from the group consisting of 1:1,
2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1 or 10:1;
[0102] and a pharmaceutically acceptable carrier.
[0103] In some aspects of the foregoing composition, the concatemer
of 4 KRAS activating oncogene mutation peptides comprises the amino
acid sequence set forth in SEQ ID NO: 137. In some aspects, the
first mRNA encoding the concatemer of 4 KRAS activating oncogene
mutation peptides comprises the nucleotide sequence set forth in
SEQ ID NO: 169. In some aspects, the constitutively active human
STING polypeptide comprises the amino acid sequence shown in SEQ ID
NO: 1. In some aspects, the mRNA encoding the constitutively active
human STING polypeptide comprises the nucleotide sequence shown in
SEQ ID NO: 170. In some aspects, the first mRNA comprises a 5' UTR
comprising the nucleotide sequence set forth in SEQ ID NO: 176. In
some aspects, the second mRNA comprises a 5' UTR comprising the
nucleotide sequence set forth in SEQ ID NO: 176. In some aspects,
the second mRNA encoding the constitutively active human STING
polypeptide comprises a 3' UTR having a miR-122 microRNA binding
site. In some aspects, the miR-122 microRNA binding site comprises
the nucleotide sequence shown in SEQ ID NO: 175. In some aspects,
the first mRNA and second mRNA each comprise a poly A tail. In some
aspects, the poly A tail comprises about 100 nucleotides. In some
aspects, the first and second mRNAs each comprise a 5' Cap 1
structure. In some aspects, the first and second mRNAs each
comprise at least one chemical modification. In some aspects, the
chemical modification is N1-methylpseudouridine. In some aspects,
the first mRNA is fully modified with N1-methylpseudouridine. In
some aspects, the second mRNA is fully modified with
N1-methylpseudouridine. In some aspects, the pharmaceutically
acceptable carrier comprises a buffer solution.
[0104] In another aspect, the disclosure provides a composition
comprising:
[0105] (i) a first mRNA comprising the nucleotide sequence set
forth in SEQ ID NO: 167, and
[0106] (ii) a second mRNA comprising the nucleotide sequence set
forth in SEQ ID NO: 168,
[0107] wherein the first and second mRNA are each fully modified
with N1-methylpseudouridine, and
[0108] wherein the first mRNA and second mRNA are present at a
KRAS:STING mass ratio selected from the group consisting of 1:1,
2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1 or 10:1; and a
pharmaceutically acceptable carrier.
[0109] In one aspect of the foregoing composition, the
pharmaceutically acceptable carrier comprises a buffer
solution.
[0110] In any of the foregoing or related aspects, the disclosure
provides a composition wherein the first and second mRNAs are
present at a KRAS:STING mass ratio of 1:1.
[0111] In any of the foregoing or related aspects, the disclosure
provides a composition wherein the first and second mRNAs are
present at a KRAS:STING mass ratio of 2:1.
[0112] In any of the foregoing or related aspects, the disclosure
provides a composition wherein the first and second mRNAs are
present at a KRAS:STING mass ratio of 3:1.
[0113] In any of the foregoing or related aspects, the disclosure
provides a composition wherein the first and second mRNAs are
present at a KRAS:STING mass ratio of 4:1.
[0114] In any of the foregoing or related aspects, the disclosure
provides a composition wherein the first and second mRNAs are
present at a KRAS:STING mass ratio of 5:1.
[0115] In any of the foregoing or related aspects, the disclosure
provides a composition wherein the first and second mRNAs are
present KRAS:STING mass ratio of 6:1.
[0116] In any of the foregoing or related aspects, the disclosure
provides a composition wherein the first and second mRNAs are
present at a KRAS:STING mass ratio of 7:1.
[0117] In any of the foregoing or related aspects, the disclosure
provides a composition wherein the first and second mRNAs are
present at a KRAS:STING mass ratio of 8:1.
[0118] In any of the foregoing or related aspects, the disclosure
provides a composition wherein the first and second mRNAs are
present at a KRAS:STING mass ratio of 9:1.
[0119] In any of the foregoing or related aspects, the disclosure
provides a composition wherein the first and second mRNAs are
present at a KRAS:STING mass ratio of 10:1.
[0120] In any of the foregoing or related aspects, the disclosure
provides a composition which is formulated in a lipid nanoparticle.
In some aspects, the lipid nanoparticle comprises a molar ratio of
about 20-60% ionizable amino lipid:5-25% phospholipid:25-55%
sterol; and 0.5-15% PEG-modified lipid. In some aspects, the lipid
nanoparticle comprises a molar ratio of about 50% Compound 25:about
10% DSPC:about 38.5% cholesterol; and about 1.5% PEG-DMG.
[0121] In any of the foregoing or related aspects, the disclosure
provides a composition which is formulated for intramuscular
delivery.
[0122] In some aspects, the disclosure provides a lipid
nanoparticle comprising:
[0123] (i) a first mRNA comprising an open reading frame encoding a
concatemer of 4 KRAS activating oncogene mutation peptides, wherein
the concatemer comprises from N- to C-terminus G12D, G12V, G13D,
and G12C; and
[0124] (ii) a second mRNA comprising an open reading frame encoding
a constitutively active human STING polypeptide, wherein the
constitutively active human STING polypeptide comprises mutation
V155M,
[0125] wherein the first mRNA and second mRNA are present at a
KRAS:STING mass ratio of 5:1.
[0126] In some aspects of the foregoing lipid nanoparticle, the
concatemer of 4 KRAS activating oncogene mutation peptides
comprises the amino acid sequence set forth in SEQ ID NO: 137. In
some aspects, the first mRNA encoding the concatemer of 4 KRAS
activating oncogene mutation peptides comprises the nucleotide
sequence set forth in SEQ ID NO: 169. In some aspects, the
constitutively active human STING polypeptide comprises the amino
acid sequence shown in SEQ ID NO: 1. In some aspects, the mRNA
encoding the constitutively active human STING polypeptide
comprises the nucleotide sequence shown in SEQ ID NO: 170. In some
aspects, the first mRNA comprises a 5' UTR comprising the
nucleotide sequence shown in SEQ ID NO: 176. In some aspects, the
second mRNA comprises a 5' UTR comprising the nucleotide sequence
shown in SEQ ID NO: 176. In some aspects, the second mRNA encoding
the constitutively active human STING polypeptide comprises a 3'
UTR having a miR-122 microRNA binding site. In some aspects, the
miR-122 microRNA binding site comprises the nucleotide sequence
shown in SEQ ID NO: 175. In some aspects, the first and second
mRNAs each comprise a poly A tail. In some aspects, the poly A tail
comprises about 100 nucleotides. In some aspects, the first and
second mRNAs each comprise a 5' Cap 1 structure. In some aspects,
the first and second mRNAs each comprise at least one chemical
modification. In some aspects, the chemical modification is
N1-methylpseudouridine. In some aspects, the first mRNA is fully
modified with N1-methylpseudouridine. In some aspects, the second
mRNA is fully modified with N1-methylpseudouridine.
[0127] In some aspects, the disclosure provides a lipid
nanoparticle comprising:
[0128] (i) a first mRNA comprising the nucleotide sequence set
forth in SEQ ID NO: 167; and
[0129] (ii) a second mRNA comprising the nucleotide sequence set
forth in SEQ ID NO: 168,
[0130] wherein the first and second mRNA are each fully modified
with N1-methylpseudouridine, and
[0131] wherein the first mRNA and second mRNA are present at a
KRAS:STING mass ratio of 5:1.
[0132] In some aspects of the foregoing lipid nanoparticle, the
lipid nanoparticle comprises a molar ratio of about 20-60%
ionizable amino lipid:5-25% phospholipid:25-55% sterol; and 0.5-15%
PEG-modified lipid. In some aspects, the ionizable amino lipid
comprises a compound of any of Formulae (I), (IA), (II), (IIa),
(IIb), (IIc), (IId), and (IIe). In some aspects, the ionizable
amino lipid comprises a compound of Formula (I). In some aspects,
the compound of Formula (I) is Compound 25. In some aspects, the
lipid nanoparticle comprises a molar ratio of about 50% Compound
25:about 10% DSPC:about 38.5% cholesterol; and about 1.5%
PEG-DMG.
[0133] In any of the foregoing or related aspects, the disclosure
provides pharmaceutical composition comprising the lipid
nanoparticle, and a pharmaceutically acceptable carrier. In some
aspects, the pharmaceutical composition is formulated for
intramuscular delivery.
[0134] In any of the foregoing or related aspects, the disclosure
provides a lipid nanoparticle, and an optional pharmaceutically
acceptable carrier, or a pharmaceutical composition for use in
treating or delaying progression of cancer in an individual,
wherein the treatment comprises administration of the composition
in combination with a second composition, wherein the second
composition comprises a checkpoint inhibitor polypeptide and an
optional pharmaceutically acceptable carrier.
[0135] In any of the foregoing or related aspects, the disclosure
provides use of a lipid nanoparticle, and an optional
pharmaceutically acceptable carrier, in the manufacture of a
medicament for treating or delaying progression of cancer in an
individual, wherein the medicament comprises the lipid nanoparticle
and an optional pharmaceutically acceptable carrier and wherein the
treatment comprises administration of the medicament in combination
with a composition comprising a checkpoint inhibitor polypeptide
and an optional pharmaceutically acceptable carrier.
[0136] In any of the foregoing or related aspects, the disclosure
provides a kit comprising a container comprising a lipid
nanoparticle, and an optional pharmaceutically acceptable carrier,
or a pharmaceutical composition, and a package insert comprising
instructions for administration of the lipid nanoparticle or
pharmaceutical composition for treating or delaying progression of
cancer in an individual. In some aspects, the package insert
further comprises instructions for administration of the lipid
nanoparticle or pharmaceutical composition in combination with a
composition comprising a checkpoint inhibitor polypeptide and an
optional pharmaceutically acceptable carrier for treating or
delaying progression of cancer in an individual.
[0137] In any of the foregoing or related aspects, the disclosure
provides a kit comprising a medicament comprising a lipid
nanoparticle, and an optional pharmaceutically acceptable carrier,
or a pharmaceutical composition, and a package insert comprising
instructions for administration of the medicament alone or in
combination with a composition comprising a checkpoint inhibitor
polypeptide and an optional pharmaceutically acceptable carrier for
treating or delaying progression of cancer in an individual. In
some aspects, the kit further comprises a package insert comprising
instructions for administration of the first medicament prior to,
current with, or subsequent to administration of the second
medicament for treating or delaying progression of cancer in an
individual.
[0138] In any of the foregoing or related aspects, the disclosure
provides a lipid nanoparticle, a composition, or the use thereof,
or a kit comprising a lipid nanoparticle or a composition as
described herein, wherein the checkpoint inhibitor polypeptide
inhibits PD1, PD-L1, CTLA4, or a combination thereof. In some
aspects, the checkpoint inhibitor polypeptide is an antibody. In
some aspects, the checkpoint inhibitor polypeptide is an antibody
selected from an anti-CTLA4 antibody or antigen-binding fragment
thereof that specifically binds CTLA4, an anti-PD1 antibody or
antigen-binding fragment thereof that specifically binds PD1, an
anti-PD-L1 antibody or antigen-binding fragment thereof that
specifically binds PD-L1, and a combination thereof. In some
aspects, the checkpoint inhibitor polypeptide is an anti-PD-L1
antibody selected from atezolizumab, avelumab, or durvalumab. In
some aspects, the checkpoint inhibitor polypeptide is an
anti-CTLA-4 antibody selected from tremelimumab or ipilimumab. In
some aspects, the checkpoint inhibitor polypeptide is an anti-PD1
antibody selected from nivolumab or pembrolizumab. In some asepcts,
the checkpoint inhibitor polypeptide is an anti-PD1 antibody,
wherein the anti-PD1 antibody is pembrolizumab.
[0139] In related aspects, the disclosure provides a method of
reducing or decreasing a size of a tumor or inhibiting a tumor
growth in a subject in need thereof comprising administering to the
subject any of the foregoing or related lipid nanoparticles of the
disclosure, or any of the foregoing or related compositions of the
disclosure.
[0140] In related aspects, the disclosure provides a method
inducing an anti-tumor response in a subject with cancer comprising
administering to the subject any of the foregoing or related lipid
nanoparticles of the disclosure, or any of the foregoing or related
compositions of the disclosure. In some aspects, the anti-tumor
response comprises a T-cell response. In some aspects, the T-cell
response comprises CD8+ T cells.
[0141] In some aspects of the foregoing methods, the composition is
administered by intramuscular injection.
[0142] In some aspects of the foregoing methods, the method further
comprises administering a second composition comprising a
checkpoint inhibitor polypeptide, and an optional pharmaceutically
acceptable carrier. In some aspects, the checkpoint inhibitor
polypeptide inhibits PD1, PD-L, CTLA4, or a combination thereof. In
some aspects, the checkpoint inhibitor polypeptide is an antibody.
In some aspects, the checkpoint inhibitor polypeptide is an
antibody selected from an anti-CTLA4 antibody or antigen-binding
fragment thereof that specifically binds CTLA4, an anti-PD1
antibody or antigen-binding fragment thereof that specifically
binds PD1, an anti-PD-L1 antibody or antigen-binding fragment
thereof that specifically binds PD-L1, and a combination thereof.
In some aspects, the checkpoint inhibitor polypeptide is an
anti-PD-L1 antibody selected from atezolizumab, avelumab, or
durvalumab. In some aspects, the checkpoint inhibitor polypeptide
is an anti-CTLA-4 antibody selected from tremelimumab or
ipilimumab. In some aspects, the checkpoint inhibitor polypeptide
is an anti-PD1 antibody selected from nivolumab or pembrolizumab.
In some asepcts, the checkpoint inhibitor polypeptide is an
anti-PD1 antibody, wherein the anti-PD1 antibody is
pembrolizumab.
[0143] In some aspects of any of the foregoing or related methods,
the composition comprising the checkpoint inhibitor polypeptide is
administered by intravenous injection. In some aspects, the
composition comprising the checkpoint inhibitor polypeptide is
administered once every 2 to 3 weeks. In some aspects, the
composition comprising the checkpoint inhibitor polypeptide is
administered once every 2 weeks or once every 3 weeks. In some
aspects, the composition comprising the checkpoint inhibitor
polypeptide is administered prior to, concurrent with, or
subsequent to administration of the lipid nanoparticle or
pharmaceutical composition thereof.
[0144] In some aspects of any of the foregoing or related methods,
the subject has a histologically confirmed KRAS mutation selected
from G12D, G12V, G13D or G12C.
[0145] In some aspects of any of the foregoing or related methods,
the subject has metastatic colorectal cancer.
[0146] In some aspects of any of the foregoing or related methods,
the subject has non-small cell lung cancer (NSCLC).
[0147] In some aspects of any of the foregoing or related methods,
the subject has pancreatic cancer
[0148] In other aspects, the disclosure provides a method of
reducing or decreasing a size of a tumor, inhibiting a tumor growth
or inducing an anti-tumor response in a subject in need thereof,
comprising administering to the subject an immunomodulatory
therapeutic composition comprising: one or more first mRNA each
comprising an open reading frame encoding a KRAS activating
oncogene mutation peptide, and optionally one or more second mRNA
each comprising an open reading frame encoding a constitutively
active human STING polypeptide, and optionally wherein the first
mRNA and second mRNA are at a mass ratio selected from the group
consisting of 1:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1 or 10:1;
and a pharmaceutically acceptable carrier, thereby reducing or
decreasing a size of a tumor, inhibiting a tumor growth or inducing
an anti-tumor response in the subject. In some aspects, the
composition comprises 1, 2, 3, or 4 mRNAs encoding 1, 2, 3, or 4
KRAS activating oncogene mutation peptides. In some aspects, the
composition comprises 4 mRNAs encoding 4 KRAS activating oncogene
mutation peptides. In some aspects, the 4 KRAS activating oncogene
mutation peptides comprise G12D, G12V, G12C, and G13D.
[0149] In other aspects, the method comprises administering an
immunomodulatory therapeutic composition comprising a first,
second, third, fourth, and fifth mRNA, wherein
[0150] the first mRNA comprises an open reading frame encoding a
KRAS activating oncogene mutation peptide comprising G12D;
[0151] the second mRNA comprises an open reading frame encoding a
KRAS activating oncogene mutation peptide comprises G12V;
[0152] the third mRNA comprises an open reading frame encoding a
KRAS activating oncogene mutation peptide comprising G12C;
[0153] the fourth mRNA comprises an open reading frame encoding a
KRAS activating oncogene mutation peptide comprising G13D; and
[0154] the fifth mRNA comprises an open reading frame encoding a
constitutively active human STING polypeptide,
[0155] wherein the first, second, third, fourth and fifth mRNAs are
present at a KRAS:STING mass ratio selected from the group
consisting of 1:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1 or
10:1.
[0156] In some aspects, KRAS activating oncogene mutation peptides
comprise the amino acid sequences set forth in SEQ ID NOs: 39-41
and 72. In some aspects, the mRNA encoding the KRAS activating
oncogene mutation peptide comprises the nucleotide sequences set
forth in SEQ ID NOs: 126-128 and 132.
[0157] In other aspects, the method comprises administering an
immunomodulatory therapeutic composition comprising an mRNA
comprising an open reading frame encoding a concatemer of two or
more KRAS activating oncogene mutation peptides. In some aspects,
the concatemer comprises G12D, G12V, G12C, and G13D. In some
aspects, the concatemer comprises from N- to C-terminus G12D, G12V,
G13D, and G12C. In some aspects, the concatemer comprises from N-
to C-terminus G12C, G13D, G12V, and G12D. In some aspects, the
concatemer comprises an amino acid sequence selected from the group
set forth in SEQ ID NOs: 42-47, 73 and 137. In some aspects, the
mRNA encoding the concatemer comprises the nucleotide sequence
selected from the group set forth in SEQ ID NOs: 129-131, 133 and
138.
[0158] In some aspects, the disclosure provides a method of
reducing or decreasing a size of a tumor, inhibiting a tumor growth
or inducing an anti-tumor response in a subject in need thereof,
comprising administering to the subject a lipid nanoparticle
comprising: [0159] (i) one or more first mRNAs selected from the
group consisting of: [0160] (a) an mRNA comprising an open reading
frame encoding a KRAS activating oncogene mutation peptide
comprising G12D; [0161] (b) an mRNA comprising an open reading
frame encoding a KRAS activating oncogene mutation peptide
comprising G12V; [0162] (c) an mRNA comprising an open reading
frame encoding a KRAS activating oncogene mutation peptide
comprising G12C; [0163] (d) an mRNA comprising an open reading
frame encoding a KRAS activating oncogene mutation peptide
comprising G13D; [0164] (e) an mRNA comprising an open reading
frame encoding a concatemer of 2, 3, or 4 KRAS activating oncogene
mutation peptides, wherein the KRAS activating oncogene mutation
peptides comprise G12D, G12V, G12C, and G13D; and [0165] (f) any
combination of mRNAs set forth in (a)-(d); and [0166] (ii) one or
more second mRNAs each comprising an open reading frame encoding a
constitutively active human STING polypeptide, optionally
[0167] wherein the first mRNA and second mRNA are present at a
KRAS:STING mass ratio selected from the group consisting of 1:1,
2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1 or 10:1,
[0168] thereby reducing or decreasing a size of a tumor, inhibiting
a tumor growth or inducing an anti-tumor response in the
subject.
[0169] In some aspects, the lipid nanoparticle comprises
[0170] (i) a combination of mRNAs set forth in (a)-(d); and
[0171] (ii) a second mRNA comprising an open reading frame encoding
a constitutively active human STING polypeptide, wherein the
constitutively active human STING polypeptide comprises mutation
V155M,
[0172] wherein the first mRNA and second mRNA are present at a
KRAS:STING mass ratio selected from the group consisting of 1:1,
2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1 or 10:1.
[0173] In some aspects, the lipid nanoparticle comprises
[0174] (i) a first mRNA comprises an open reading frame encoding a
concatemer of 4 KRAS activating oncogene mutation peptides, wherein
the concatemer comprises from N- to C-terminus G12D, G12V, G13D,
and G12C; and
[0175] (ii) a second mRNA comprising an open reading frame encoding
a constitutively active human STING polypeptide, wherein the
constitutively active human STING polypeptide comprises mutation
V155M,
[0176] wherein the first mRNA and second mRNA are present at a
KRAS:STING mass ratio selected from the group consisting of 1:1,
2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1 or 10:1.
[0177] In some aspects, the disclosure provides a method of
reducing or decreasing a size of a tumor, inhibiting a tumor growth
or inducing an anti-tumor response in a subject in need thereof,
comprising administering to the subject a lipid nanoparticle
comprising:
[0178] (i) a first mRNA comprising the nucleotide sequence set
forth in SEQ ID NO: 167; and
[0179] (ii) a second mRNA comprising the nucleotide sequence set
forth in SEQ ID NO: 168,
[0180] wherein the first and second mRNA are each fully modified
with N1-methylpseudouridine, and wherein the first mRNA and second
mRNA are present at a mass ratio of 5:1. In some aspects, the lipid
nanoparticle comprises a molar ratio of about 50% Compound 25:about
10% DSPC:about 38.5% cholesterol; and about 1.5% PEG-DMG.
[0181] In some aspects, the lipid nanoparticle or composition is
administered by intramuscular injection.
[0182] In some aspects, the anti-tumor response comprises a T-cell
response, such as a CD8+ T cell response.
[0183] In some aspects, the disclosure provides a method of
reducing or decreasing a size of a tumor, inhibiting a tumor growth
or inducing an anti-tumor response in a subject in need thereof,
comprising administering to the subject an immunomodulatory
therapeutic composition or lipid nanoparticle of the disclosure in
combination with (prior to, concurrent with or consecutively) a
second composition comprising a checkpoint inhibitor polypeptide or
polynucleotide encoding the same, and an optional pharmaceutically
acceptable carrier. In some aspects, the checkpoint inhibitor
polypeptide inhibits PD1, PD-L1, CTLA4, or a combination thereof.
In some aspects,
[0184] the checkpoint inhibitor polypeptide is an antibody. In some
aspects, the checkpoint inhibitor polypeptide is an antibody
selected from an anti-CTLA4 antibody or antigen-binding fragment
thereof that specifically binds CTLA4, an anti-PD1 antibody or
antigen-binding fragment thereof that specifically binds PD1, an
anti-PD-L1 antibody or antigen-binding fragment thereof that
specifically binds PD-L1, and a combination thereof. In some
aspects, the checkpoint inhibitor polypeptide is an anti-PD-L1
antibody selected from atezolizumab, avelumab, or durvalumab. In
some aspects, the checkpoint inhibitor polypeptide is an
anti-CTLA-4 antibody selected from tremelimumab or ipilimumab. In
some aspects, the checkpoint inhibitor polypeptide is an anti-PD1
antibody selected from nivolumab or pembrolizumab.
[0185] In some aspects, the composition comprising the checkpoint
inhibitor polypeptide is administered by intravenous injection. In
some aspects, the composition comprising the checkpoint inhibitor
polypeptide is administered once every 2 to 3 weeks. In some
aspects, the composition comprising the checkpoint inhibitor
polypeptide is administered once every 2 weeks or once every 3
weeks. In some aspects, the composition comprising the checkpoint
inhibitor polypeptide is administered prior to, concurrent with, or
subsequent to administration of the lipid nanoparticle or
composition.
[0186] In some aspects, the disclosure provides methods for
treating subjects having a histologically confirmed KRAS mutation
selected from G12D, G12V, G13D or G12C. In some aspects, the
subject has a histologically confirmed HLA subtype selected from
HLA-A11 and/or HLA-C*08.
[0187] In some aspects, wherein the tumor is metastatic colorectal
cancer. In some aspects, the tumor is non-small cell lung cancer
(NSCLC). In some aspects, the tumor is pancreatic cancer.
[0188] In some aspects, the subject is administered a
chemotherapeutic agent prior to, concurrent with, or subsequent to
administration of the lipid nanoparticle or composition.
BRIEF DESCRIPTION OF THE DRAWINGS
[0189] FIG. 1 is a bar graph showing stimulation of IFN-.beta.
production in TF1a cells transfected with constitutively active
STING mmRNA constructs.
[0190] FIG. 2 is a bar graph showing activation of an
interferon-sensitive response element (ISRE) by constitutively
active STING constructs. STING variants 23a and 23b correspond to
SEQ ID NO: 1, STING variant 42 corresponds to SEQ ID NO: 2, STING
variants 19, 21a and 21b correspond to SEQ ID NO: 3, STING variant
41 corresponds to SEQ ID NO: 4, STING variant 43 corresponds to SEQ
ID NO: 5, STING variant 45 corresponds to SEQ ID NO: 6, STING
variant 46 corresponds to SEQ ID NO: 7, STING variant 47
corresponds to SEQ ID NO: 8, STING variant 56 corresponds to SEQ ID
NO: 9 and STING variant 57 corresponds to SEQ ID NO: 10.
[0191] FIGS. 3A-3B are bar graphs showing activation of an
interferon-sensitive response element (ISRE) by constitutively
active IRF3 constructs (FIG. 3A) or constitutively active IRF7
constructs (FIG. 3B). IRF3 variants 1, 3 and 4 correspond to SEQ ID
NO: 12 and IRF3 variants 2 and 5 correspond to SEQ ID NO: 11
(variants have different tags). IRF7 variant 36 corresponds to SEQ
ID NO: 18 and variant 31 is the murine version of SEQ ID NO: 18.
IRF7 variant 32 corresponds to SEQ ID NO: 17 and IRF7 variant 33
corresponds to SEQ ID NO: 14.
[0192] FIG. 4 is a bar graph showing activation of an
NF.kappa.B-luciferase reporter gene by constitutively active cFLIP
and IKK.beta. mRNA constructs.
[0193] FIG. 5 is a graph showing activation of an
NF.kappa.B-luciferase reporter gene by constitutively active RIPK1
mRNA constructs.
[0194] FIG. 6 is a bar graph showing TNF-.alpha. induction in SKOV3
cells transfected with DIABLO mmRNA constructs.
[0195] FIG. 7 is a bar graph showing interleukin 6 (IL-6) induction
in SKOV3 cells transfected with DIABLO mmRNA constructs.
[0196] FIGS. 8A-8B are graphs showing MC38 antigen-specific
responses by IFN-.gamma. intracellular staining (ICS) of day 21
(FIG. 8A) or day 35 (FIG. 8B) CD8.sup.+ spenocytes from mice
immunized with MC38 neo-antigen vaccine construct (ADRvax)
coformulated with either a STING, IRF3 or IRF7 immune potentiator
mRNA construct.
[0197] FIGS. 9A-9B are graphs showing the percentage of CD8b.sup.+
cells among live CD45.sup.+ cells in spleen or PBMCs (FIG. 9A) or
the percentage of CD62L.sup.lo cells among CD8b.sup.+ cell in
spleen or PBMCs (FIG. 9B) from mice immunized with MC38 neo-antigen
vaccine construct (ADRvax) coformulated with either a STING, IRF3
or IRF7 immune potentiator mRNA construct.
[0198] FIG. 10 depicts NRAS and KRAS mutation frequency in
colorectal cancer as identified using cBioPortal.
[0199] FIGS. 11A-11B are graphs showing intracellular staining
(ICS) of CD8.sup.+ splenocytes from mice immunized with HPV E6/E7
vaccine constructs coformulated with either a STING, IRF3 or IRF7
immune potentiator mRNA construct on day 21 post first
immunization. FIG. 11A shows E7-specific responses for IFN-.gamma.
ICS. FIG. 11B shows E7-specific responses for TNF-.alpha. ICS.
[0200] FIGS. 12A-12B are graphs showing intracellular staining
(ICS) of CD8.sup.+ splenocytes from mice immunized with HPV E6/E7
vaccine constructs coformulated with either a STING, IRF3 or IRF7
immune potentiator mRNA construct. FIG. 12A shows E6-specific
responses for IFN-.gamma. ICS. FIG. 12B shows E6-specific responses
for TNF-.alpha. ICS.
[0201] FIGS. 13A-13B are graphs showing E7-specific responses for
IFN-.gamma. intracellular staining (ICS) of day 21 (FIG. 13A) or
day 53 (FIG. 13B) CD8.sup.+ splenocytes from mice immunized with
HPV E6/E7 vaccine constructs coformulated with either a STING, IRF3
or IRF7 immune potentiator mRNA construct.
[0202] FIGS. 14A-14B are graphs showing the percentage of
CD8b.sup.+ cells among the live CD45.sup.+ cells for day 21 (FIG.
14A) or day 53 (FIG. 14B) spleen cells from mice immunized with HPV
E6/E7 vaccine constructs coformulated with either a STING, IRF3 or
IRF7 immune potentiator mRNA construct.
[0203] FIGS. 15A-15B are graphs showing E7-MHC1-tetramer staining
of day 21 (FIG. 15A) or day 53 (FIG. 15B) CD8b.sup.+ splenocytes
from mice immunized with HPV E6/E7 vaccine constructs coformulated
with either a STING, IRF3 or IRF7 immune potentiator mRNA
construct.
[0204] FIGS. 16A-16D are graphs showing that the majority of
E7-tetramer.sup.+ CD8.sup.+ cells have an "effector memory"
CD62L.sup.lo phenotype, with comparison of day 21 versus day 53
E7-tetramer.sup.+ CD8 cells demonstrating that this
"effector-memory" CD62L.sup.lo phenotype was maintained throughout
the study. FIGS. 16A (d21) and 16B (d53) show increased % of CD8
with effector memory `CD62Llo phenotype. FIGS. 16C and 16D show
increased % of E7-tetramer+ CD8 are CD62Llo.
[0205] FIGS. 17A-17C are graphs showing tumor volume from mice
vaccinated prophylactically as indicated with HPV E6/E7 construct
together with a STING immune potentiator mRNA construct (alone or
in combination with anti-CTLA-4 or anti-PD1 treatment), either
prior to or at the time of challenge with a TC1 tumor that
expresses HPV E7, showing inhibition of tumor growth by the HPV
E6/E7+STING treatment. Certain mice were treated on days -14 and -7
with soluble E6/E7+STING (FIG. 17A) or with intracellular
E6/E7+STING (FIG. 17B), with tumor challenge on day 1. Other mice
were treated on days 1 and 8 with soluble E6/E7+STING (FIG. 17C),
with tumor challenge on day 1.
[0206] FIGS. 18A-18I are graphs showing tumor volume from mice
vaccinated therapeutically as indicated with HPV E6/E7 construct
together with a STING immune potentiator mRNA construct (FIG. 18A),
alone or in combination with anti-CTLA-4 (FIG. 18B) or anti-PD1
treatment (FIG. 18C), after challenge with a TC1 tumor that
expresses HPV E7, showing inhibition of tumor growth by the HPV
E6/E7+STING treatment. FIGS. 18D-18I show control treatments.
[0207] FIG. 19 is a graph showing intracellular staining (ICS) of
CD8.sup.+ splenocytes for IFN-.gamma. from mice immunized with an
ADR vaccine construct coformulated with a STING immune potentiator
at the indicated Ag:STING ratios on day 21 post first immunization.
CD8+ cells were restimulated with either the mutant ADR antigen
composition (comprising three peptides) or the wild-type ADR
composition (as a control).
[0208] FIG. 20 is a graph showing intracellular staining (ICS) of
CD8.sup.+ splenocytes for TNF-.alpha. from mice immunized with an
ADR vaccine construct coformulated with a STING immune potentiator
at the indicated Ag:STING ratios on day 21 post first immunization.
CD8+ cells were restimulated with either the mutant ADR antigen
composition (comprising three peptides) or the wild-type ADR
composition (as a control).
[0209] FIGS. 21A-21C are graphs showing intracellular staining
(ICS) of CD8.sup.+ splenocytes for IFN-.gamma. from mice immunized
with an ADR vaccine construct coformulated with a STING immune
potentiator at the indicated Ag:STING ratios on day 21 post first
immunization. CD8+ cells were restimulated with either a mutant or
wild-type (as a control) peptide contained within the ADR antigen
composition. FIG. 21A shows responses to the Adpk1 peptide within
the ADR composition. FIG. 21B shows the response to the Reps1
peptide within the ADR composition. FIG. 21C shows the response to
the Dpagt1 peptide within the ADR composition.
[0210] FIG. 22 is a graph showing antigen-specific T cell responses
to MHC class I epitopes within the CA-132 vaccine, as measured by
ELISpot analysis for IFN-.gamma., from mice treated with a
coformulation of CA-132 and STING immune potentiator, at the
indicated different Ag:STING ratios.
[0211] FIGS. 23A-23B show results for Ag:STING ratio studies from
mice immunized with HPV E6/E7 vaccine construct coformulated with a
STING immune potentiator mRNA construct. FIG. 23A shows
intracellular staining (ICS) of CD8+ splenocytes for IFN-.gamma.
from mice immunized at the indicated Ag:STING ratios on day 21 post
immunization. FIG. 23B shows H2-Kb/E7 peptide-tetramer staining of
day 21 CD8+ splenocytes from mice immunized at the indicated
Ag:STING ratios.
[0212] FIGS. 24A-24C are bar graphs showing TNF.alpha.
intracellular staining (ICS) results for CD8+ T cells from
cynomolgus monkeys vaccinated with HPV vaccine+STING constructs,
followed by ex vivo stimulation with either HPV16 E6 peptide pool
(FIG. 24A), HPV16 E7 peptide pool (FIG. 24B) or medium (negative
control) (FIG. 24C).
[0213] FIGS. 25A-25C are bar graphs showing IL-2 intracellular
staining (ICS) results for CD8+ T cells from cynomolgus monkeys
vaccinated with HPV vaccine+STING constructs, followed by ex vivo
stimulation with either HPV16 E6 peptide pool (FIG. 25A), HPV16 E7
peptide pool (FIG. 25B) or medium (negative control) (FIG.
25C).
[0214] FIG. 26 is a graph showing ELISA results for anti-E6 IgG in
serum from cynomolgus monkeys vaccinated/immunized with HPV
vaccine+STING constructs.
[0215] FIG. 27 is a graph showing ELISA results for anti-E7 IgG in
serum from cynomolgus monkeys vaccinated/immunized with HPV
vaccine+STING constructs.
[0216] FIG. 28 is a graph showing ELISA results for anti-E6 IgG in
a two-fold dilution series of day 25 serum from cynomolgus monkeys
treated with HPV vaccine+STING construct at a 1:10 STING:Ag
ratio.
[0217] FIGS. 29A-29B are graphs showing calculated titer values of
ELISA results for anti-E6 IgG (FIG. 29A) or anti-E7 IgG (FIG. 29B)
in day 25 serum from cynomolgus monkeys treated with HPV
vaccine+STING construct at the indicated STING:Ag ratios.
[0218] FIG. 30 is a graph showing the intracellular staining (ICS)
results for CD8+ splenocytes for IFN.gamma. from mice immunized
with mutant KRAS vaccine+STING construct followed by ex vivo
stimulation with KRAS-G12V peptide.
[0219] FIG. 31 is a graph showing the intracellular staining (ICS)
results for CD8+ splenocytes for IFN.gamma. from mice immunized
with mutant KRAS vaccine+STING construct followed by ex vivo
stimulation with KRAS-G12D peptide.
[0220] FIG. 32 is a graph showing the intracellular staining (ICS)
results or CD8+ splenocytes for IFN.gamma. from mice immunized with
mutant KRAS vaccine+STING construct followed by ex vivo co-culture
with Cos7 cells virally transduced with HLA*A11 allele and pulsed
with KRAS-G12V.
[0221] FIG. 33 is a graph showing the intracellular staining (ICS)
results or CD8+ splenocytes for IFN-g from mice immunized with
mutant KRAS vaccine+STING construct followed by ex vivo co-culture
with Cos7 cells virally transduced with HLA*A11 allele and pulsed
with KRAS-G12D.
[0222] FIG. 34 is a graph showing the intracellular staining (ICS)
results or CD8+ splenocytes for IFN-g from mice immunized with an
A11 viral epitope concatemer+STING construct followed by ex vivo
stimulation with individual viral epitopes.
DETAILED DESCRIPTION
[0223] Provided herein are immunomodulatory therapeutic
compositions, including mRNA compositions and/or lipid
nanoparticles comprising the same, comprising one or more RNAs
(e.g., messenger RNAs (mRNAs)) that can safely direct the body's
cellular machinery to produce a cancer protein or fragment thereof
of interest, e.g., an activating oncogene mutation peptide. In some
embodiments, the RNA is a modified RNA. The immunomodulatory
therapeutic compositions and lipid nanoparticles of the present
disclosure may be used to induce a balanced immune response against
cancers, comprising both cellular and humoral immunity, without
risking the possibility of insertional mutagenesis, for
example.
[0224] Accordingly, in some aspects, the disclosure provides an
immunomodulatory therapeutic composition, including a lipid-based
composition such as a lipid nanoparticles, comprising: one or more
mRNA each having an open reading frame encoding an activating
oncogene mutation peptide, and optionally one or more mRNA each
having an open reading frame encoding a polypeptide that enhances
an immune response to the activating oncogene mutation peptide in a
subject, wherein the immune response comprises a cellular or
humoral immune.
[0225] In one aspect, the disclosure provides an immunomodulatory
therapeutic composition comprising four different activating
oncogene mutation peptides (e.g., KRAS G12D, G12C, G12V and G13D),
which is capable of treating patients having any one of colorectal
cancer, pancreactic carcinoma, and non-small cell lung carcinoma.
The ability to target to four different mutations and three
different cancers is a significant advantage of the compositions
and methods provided herein.
[0226] An mRNA encoding a polypeptide that enhances an immune
response to the activating oncogene mutation peptide in a subject
is also referred to herein as "an immune potentiator mRNA" or "mRNA
encoding an immune potentiator" or simply "immune potentiator." An
enhanced immune response can be a cellular response, a humoral
response or both. As used herein, a "cellular" immune response is
intended to encompass immune responses that involve or are mediated
by T cells, whereas a "humoral" immune response is intended to
encompass immune responses that involve or are mediated by B cells.
An mRNA encoding an immune potentiator may enhance an immune
response by, for example,
[0227] (i) stimulating Type I interferon pathway signaling;
[0228] (ii) stimulating NFkB pathway signaling;
[0229] (iii) stimulating an inflammatory response;
[0230] (iv) stimulating cytokine production; or
[0231] (v) stimulating dendritic cell development, activity or
mobilization; and
[0232] (vi) a combination of any of (i)-(v).
[0233] As used herein, "stimulating Type I interferon pathway
signaling" is intended to encompass activating one or more
components of the Type I interferon signaling pathway (e.g.,
modifying phosphorylation, dimerization or the like of such
components to thereby activate the pathway), stimulating
transcription from an interferon-sensitive response element (ISRE)
and/or stimulating production or secretion of Type I interferon
(e.g., IFN-.alpha., IFN-.beta., IFN-.epsilon., IFN-.kappa. and/or
IFN-.omega.). As used herein, "stimulating NFkB pathway signaling"
is intended to encompass activating one or more components of the
NFkB signaling pathway (e.g., modifying phosphorylation,
dimerization or the like of such components to thereby activate the
pathway), stimulating transcription from an NFkB site and/or
stimulating production of a gene product whose expression is
regulated by NFkB. As used herein, "stimulating an inflammatory
response" is intended to encompass stimulating the production of
inflammatory cytokines (including but not limited to Type I
interferons, IL-6 and/or TNF.alpha.). As used herein, "stimulating
dendritic cell development, activity or mobilization" is intended
to encompass directly or indirectly stimulating dendritic cell
maturation, proliferation and/or functional activity.
[0234] The present disclosure provides compositions, including mRNA
compositions and/or lipid nanoparticles comprising the same, which
include one or more mRNA constructs encoding a polypeptide that
enhances immune responses to an activating oncogene mutation
peptide (also referred to herein as "an antigen of interest"),
referred to herein as immune potentiator mRNA or immune potentiator
mRNAs, including chemically modified mRNAs (mmRNAs). The immune
potentiator mRNAs of the disclosure enhance immune responses by,
for example, activating Type I interferon pathway signaling such
that antigen-specific responses to an antigen of interest (i.e.,
activating oncogene mutation peptide(s)) are stimulated.
[0235] The immune potentiator mRNAs of the disclosure enhance
immune responses to an exogenous antigen that is administered to
the subject with the immune potentiator mRNA (e.g., an mRNA
construct encoding activating oncogene mutation peptide(s) that is
coformulated and coadministered with the immune potentiator mRNA or
an mRNA construct encoding activating oncogene mutation peptide(s)
that is formulated and administered separately from the immune
potentiator mRNA). Administration of an immune potentiator mRNA
enhances an immune response in a subject by stimulating, for
example, cytokine production, T cells responses (e.g.,
antigen-specific CD8.sup.+ or CD4.sup.+ T cell responses) or B cell
responses (e.g., antigen-specific antibody production) in the
subject.
[0236] In other aspects, the disclosure provides compositions,
including mRNA compositions and lipid nanoparticles, comprising one
or more mRNA constructs (e.g., one or more mmRNA constructs),
wherein the one or more mRNA constructs encode an activating
oncogene mutation peptide(s) and, in the same or a separate mRNA
construct, encode a polypeptide that enhances an immune response to
the antigen of interest. In some aspects, the disclosure provides
nanoparticles, e.g., lipid nanoparticles, which include an immune
potentiator mRNA that enhances an immune response, alone or in
combination with mRNAs that encode activating oncogene mutation
peptide(s). The disclosure also provides pharmaceutical
compositions comprising any of the mRNAs as described herein or
nanoparticles, e.g., lipid nanoparticles comprising any of the
mRNAs as described herein.
[0237] In other aspects, the disclosure provides methods for
enhancing an immune response to an activating oncogene mutation
peptide(s) by administering to a subject one or more mRNAs encoding
activating oncogene mutation peptide(s) and a mRNA encoding a
polypeptide that enhances an immune response to the peptide(s) of
interest, or lipid nanoparticle thereof, or pharmaceutical
composition thereof, such that an immune response to the activating
oncogene mutation peptide(s) is enhanced in the subject. The
methods of enhancing an immune response can be used, for example,
to stimulate an immunogenic response to a tumor in a subject.
Cancer Antigens of Interest
[0238] The immune potentiators mRNAs of the disclosure are useful
in combination with any type of antigen for which enhancement of an
immune response is desired, including with mRNA sequences encoding
at least one antigen of interest (on either the same or a separate
mRNA construct) to enhance immune responses against the antigen of
interest, such as a tumor antigen. Thus, the immune potentiator
mRNAs of the disclosure enhance, for example, mRNA vaccine
responses, thereby acting as genetic adjuvants.
[0239] Activating Oncogene Mutation Peptides
[0240] In one embodiment, the antigen(s) of interest is a tumor
antigen. In one embodiment, the tumor antigen comprises a tumor
neoepitope, e.g., mutant peptide from a tumor antigen. In one
embodiment, the tumor antigen is a Ras antigen. A comprehensive
survey of Ras mutations in cancer has been described in the art
(Prior, I. A. et al. (2012) Cancer Res. 72:2457-2467). Accordingly,
a Ras amino acid sequence comprising at least one mutation
associated with cancer can be used as an antigen of interest. In
one embodiment, the tumor antigen is a mutant KRAS antigen. Mutant
KRAS antigens have been implicated in acquired resistance to
certain therapeutic agents (see e.g., Misale, S. et al. (2012)
Nature 486:532-536; Diaz, L. A. et al. (2012) Nature
486:537-540).
[0241] Although attempts have been made to produce functional
immunomodulatory therapeutic compositions, including mRNA
compositions, the therapeutic efficacy of these RNA compositions
has not yet been fully established. Quite surprisingly, the
inventors have discovered a class of formulations for delivering
mRNA immunomodulatory therapeutic compositions that results in
significantly enhanced, and in many respects synergistic, immune
responses including enhanced T cell responses. KRAS is the most
frequently mutated oncogene in human cancer (.about.15%). Such KRAS
mutations are mostly conserved in a few "hotspots" and activate the
oncogene.
[0242] The immunomodulatory therapeutic compositions of the
invention include activating oncogene mutation peptides, such as
KRAS mutation peptides. Prior research has shown limited ability to
raise T cells specific to the oncogenic mutation. Much of this
research was done in the context of the most common HLA allele (A2,
which occurs in .about.50% of Caucasians). More recent work has
explored the generation of specific T cells against point mutations
in the context of less common HLA alleles (A11, C8). These findings
have significant implications for the treatment of cancer.
Oncogenic mutations are common in many cancers. The ability to
target these mutations and generate T cells that are sufficient to
kill tumors has broad applicability to cancer therapy. It is quite
surprising that delivery of antigens using mRNA would have such a
significant advantage over the delivery of peptide vaccines. Thus
the invention involves, in some aspects, the surprising finding
that activating oncogenic mutation antigens delivered in vivo in
the form of an mRNA significantly enhances the generation of T cell
effector and memory responses.
[0243] HLA class I molecules are highly polymorphic trans-membrane
glycoproteins composed of two polypeptide chains (heavy chain and
light chain). Human leukocyte antigen, the major histocompatibility
complex in humans, is specific to each individual and has
hereditary features. The class I heavy chains are encoded by three
genes: HLA-A, HLA-B and HLA-C. HLA class I molecules are important
for establishing an immune response by presenting endogenous
antigens to T lymphocytes, which initiates a chain of immune
reactions that lead to tumor cell elimination by cytotoxic T cells.
Altered levels of production of HLA class I antigens is a
widespread phenomenon in malignancies and is accompanied by
significant inhibition of anti-tumor T cell function. It represents
one of the main mechanisms used by cancer cells to evade
immuno-surveillance. Down regulated levels of HLA class I antigens
were detected in 90% of NSCLC tumors (n=65). A reduction or loss of
HLA was detected in 76% of pancreatic tumor samples (n=19). The
expression of HLA class I antigens in colon cancer was dramatically
reduced or undetectable in 96% of tumor samples (n=25).
[0244] Mounting evidence suggests that two general strategies are
utilized by tumor cells to escape immune surveillance:
immunoselection (poorly immunogenic tumor cell variants) and
immunosubversion (subversion of the immune system). A correlation
between changes in HLA class I antigens and the presence of KRAS
codon 12 mutations was demonstrated, which suggests a possible
inductive effect of KRAS codon 12 mutations on HLA class I antigen
regulation in cancer progression. Many frequent cancer mutations
are predicted to bind HLA Class I alleles with high-affinity
(IC50<=50 nM)7 and may be suitable for prophylactic cancer
vaccination.
[0245] The generation of cancer antigens that elicit a desired
immune response (e.g. T-cell responses) against targeted
polypeptide sequences in immunomodulatory therapeutic development
remains a challenging task. The invention involves technology to
overcome hurdles associated with such development. Through the use
of the technology of the invention, it is possible to elicit a
desired immune response by selecting appropriate activating
oncogene mutation peptides and formulating the mRNA encoding
peptides for effective delivery in vivo.
[0246] The immunomodulatory therapeutic compositions provide unique
therapeutic alternatives to peptide based or DNA vaccines. When the
mRNA containing immunomodulatory therapeutic composition is
delivered to a cell, the mRNA will be translated into a polypeptide
by the intracellular machinery which can then process the
polypeptide into sensitive fragments capable of being presented on
MDC and stimulating an immune response against the tumor.
[0247] The immunomodulatory therapeutic compositions described
herein include at least one ribonucleic acid (RNA) polynucleotide
having an open reading frame encoding at least one cancer antigenic
polypeptide or an immunogenic fragment thereof (e.g., an
immunogenic fragment capable of inducing an immune response to
cancer). The antigenic peptide includes an activating oncogenic
mutation. In some preferred embodiments the composition is multiple
epitopes of a mixture of activating oncogenic mutations. Many
activating oncogenic mutations are known in the art.
[0248] When oncogenes are activated they can inhibit programmed
cell death and/or cause abnormal cellular proliferation. Such
oncogene activation can lead to cancer. The KRAS gene (Ki-ras2
Kirsten rat sarcoma viral oncogene homolog) is an oncogene that
encodes a small GTPase transductor protein. KRAS relays external
signals to the cell nucleus and contributes to regulation of cell
division. Activating mutations in the KRAS gene impair the ability
of the KRAS protein to switch between active and inactive states.
KRAS activation leads to cell transformation and increased
resistance to chemotherapy and biological therapies targeting
epidermal growth factor receptors. (Jancik, Sylwia et al. Clinical
Relevance of KRAS in Human Cancers, Journal of Biomedicine and
Biotechnology, Volume 2010 Article ID 150960 (2010)). Human KRAS
amino acid sequence is provided below (UniProtKB P01116). KRAS
mutations are common in many cancers, and G12 is the site of most
common KRAS mutations.
TABLE-US-00001 >sp|P01116|1-186 (SEQ ID NO: 166)
MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGET
CLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQI
KRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQ
RVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKC
[0249] Mutant N-RAS proteins are highly prevalent in certain types
of cancers and are useful as cancer vaccines. For instance, 29% of
Cutaneous Melanoma involves a RAS mutation, of which 94% are of
N-RAS origin. This represents about 2,500 new US cases/year of the
most aggressive form of melanoma accounting for the majority of
melanoma deaths. (Channing Der, Are A11 RAS Proteins Created Equal
in Cancer?, Sep. 22, 2014, cancer.gov). There are 30,280 news cases
of multiple myeloma annually, of which 26% are NRAS*. This
represents .about.6,100 new NRAS* cases per year. Thus, the N-Ras
vaccines described herein are useful in some embodiments in the
treatment of melanoma and multiple myeloma as well as other
malignancies that harbor NRAS mutations.
[0250] Accordingly, in some aspects, the present invention provides
mRNA encoding peptide sequences resulting from certain activating
mutations in one or more oncogenes, not limited to missense SNVs
and often resulting in alternative splicing, for use as targets for
therapeutic vaccination. In some embodiments, the activating
oncogene mutation is a KRAS mutation. In some embodiments, the KRAS
mutation is a G12 mutation. In some embodiments, the G12 KRAS
mutation is selected from a G12D, G12V, G12S, G12C, G12A, and a
G12R KRAS mutation, e.g., the G12 KRAS mutation is selected from a
G12D, G12V, and a G12S KRAS mutation. In some embodiments, the G12
KRAS mutation is selected from a G12D, G12V, and a G12C KRAS
mutation. In other embodiments, the KRAS mutation is a G13
mutation, e.g., the G13 KRAS mutation is a G13D KRAS mutation. In
some embodiments, the activating oncogene mutation is a H-RAS or
N-RAS mutation.
[0251] In one embodiment, one or more mRNAs encode a mutant KRAS
peptide(s) comprising an amino acid sequence having one or more
mutations selected from G12D, G12V, G13D and G12C, and combinations
thereof. Non-limiting examples of mutant KRAS antigens include
those comprising one or more of the amino acid sequences shown in
SEQ ID NOs: 36-41 and 72, 125.
[0252] CD8+ T cells specific for the G12D or G12V mutations can be
restricted by HLA-A*02:01, A*03:01; -A*11:01, -B*35:01, -Cw*08:02,
and potentially others. Accordingly, in some embodiments, a KRAS
mutation is selected for inclusion in an immunomodulatory
therapeutic composition for a subject having T cells that are
restricted by HLA-A*02:01, A*03:01; -A*11:01, -B*35:01, or
-Cw*08:02. In some embodiments, the subject has T cells that are
HLA-A*02:01 restricted.
[0253] In one embodiment, the mutant KRAS antigen is one or more
mutant KRAS 15-mer peptides comprising a mutation selected from
G12D, G12V, G13D and G12C, non-limiting examples of which are shown
in SEQ ID NO: 36-38 and 125.
[0254] In another embodiment, the mutant KRAS antigen is one or
more mutant KRAS 25-mer peptides comprising a mutation selected
from G12D, G12V, G13D and G12C, non-limiting examples of which are
shown in SEQ ID NO: 39-41 and 72.
[0255] In another embodiment, the mutant KRAS antigen is one or
more mutant KRAS 3.times.15mer peptides (3 copies of the 15-mer
peptide) comprising a mutation selected from G12D, G12V, G13D and
G12C, non-limiting examples of which are shown in SEQ ID NO: 42-44
and 183.
[0256] In another embodiment, the mutant KRAS antigen is one or
more mutant KRAS 3.times.25mer peptides (three copies of the 25-mer
peptide) comprising a mutation selected from G12D, G12V, G13D and
G12C, non-limiting examples of which are shown in SEQ ID NO: 45-47
and 73.
[0257] In another embodiment, the mutant KRAS antigen is a 100-mer
concatemer peptide of the 25-mer peptides containing the G12D,
G12V, G13D and G12C mutations (i.e., a 100-mer concatemer of SEQ ID
NOs: 39, 40, 41 and 72). Accordingly, in one embodiment, the mutant
KRAS antigen comprises an mRNA construct encoding SEQ ID NOs: 39,
40, 41 and 72. Non-limiting examples of nucleotide sequences
encoding a concatemer of peptides containing G12D, G12V, G13D and
G12C mutations include SEQ ID NO: 138, SEQ ID NO: 167 and SEQ ID
NO: 169. Further description of mutant KRAS antigens, amino acid
sequences thereof, and mRNA sequences encoding therefor, are
disclosed in U.S. Application Ser. No. 62/453,465, the entire
contents of which is expressly incorporated herein by
reference.
[0258] Some embodiments of the present disclosure provide
immunomodulatory therapeutic compositions that include an mRNA
having an open reading frame encoding a concatemer of two or more
activating oncogene mutation peptides. In some embodiments, at
least two of the peptide epitopes are separated from one another by
a single Glycine. In some embodiments, the concatemer comprises
3-10 activating oncogene mutation peptides. In some such
embodiments, all of the peptide epitopes are separated from one
another by a single Glycine. In other embodiments, at least two of
the peptide epitopes are linked directly to one another without a
linker.
[0259] In one embodiment, a tumor antigen is encoded by an mRNA
construct that also comprises an immune potentiator (i.e., also
encodes a polypeptide that enhances an immune response against the
tumor antigen). Non-limiting examples of such constructs include
the KRAS-STING constructs encoding one of the amino acid sequences
shown in SEQ ID NOs: 48-71. Non-limiting examples of nucleotide
sequences encoding the KRAS-STING constructs are shown in SEQ ID
NOs: 160-163 and 221-224.
[0260] The disclosure provides an immunomodulatory therapeutic
composition, comprising: an mRNA having an open reading frame
encoding a concatemer of two or more activating oncogene mutation
peptides, wherein the concatemer comprises KRAS activating oncogene
mutation peptides G12D, G12V, G12C, and G13D; and one or more mRNA
each having an open reading frame encoding a polypeptide that
enhances an immune response to the KRAS activating oncogene
mutation peptides in a subject, such as a STING immune potentiator
mRNA. Such an immunomodulatory composition targets somatic point
mutations of KRAS, which constitute not only exquisitely specific
tumor neoantigens but also significant oncogenic driver mutations
in various malignancies. Unlike many neoantigens, which are largely
passenger mutations, maintenance of KRAS mutant expression is
important to cancer cells' survival as it helps drive aberrant cell
proliferation and is likely to be a truncal event (an early event
and therefore present in many tumor cells).
[0261] In order to model KRAS mutant antigens in preclinical
studies described herein examining the immune potentiating capacity
of STING, two model antigens were selected: (1) HPV E6 and E7 and
(2) the ADR concatemer of three point mutations from three genes
found in the murine cell line MC38. These antigens are appropriate
models of the KRAS mutant antigens for a number of reasons. For
example, HPV E6 and E7 are viral oncogenic proteins whose
expression is vital for the transformed phenotype, like mutant
KRAS. Accordingly, HPV E6 and E7 are suitable model antigens
because, similar to mutant KRAS, they are oncogenic drivers. The
three ADR mutant epitopes, in contrast, are stereotypical
neoantigens in that they are most likely passenger mutations.
However, ADR more effectively models other properties of KRAS
antigens encoded by our vaccine in that: (1) each antigen contains
a single missense mutation relative to its wild-type counterpart
which is likely to be more challenging to recognize as "non-self"
by the immune system than a viral antigen and (2) they are
concatemerized.
[0262] The immunomodulatory therapeutic compositions of the
disclosure may include one or more cancer antigens. In some
embodiments the immunomodulatory therapeutic composition is
composed of 2 or more, 3 or more, 4 or more, 5 or more 6 or more 7
or more, 8 or more, 9 or more antigens, e.g., activating oncogene
mutation peptides. In other embodiments the immunomodulatory
therapeutic composition is composed of 1000 or less, 900 or less,
500 or less, 100 or less, 75 or less, 50 or less, 40 or less, 30 or
less, 20 or less or 100 or less cancer antigens, e.g., activating
oncogene mutation peptides. In yet other embodiments the
immunomodulatory therapeutic composition has 3-10, 3-100, 5-100,
10-100, 15-100, 20-100, 25-100, 30-100, 35-100, 40-100, 45-100,
50-100, 55-100, 60-100, 65-100, 70-100, 75-100, 80-100, 90-100,
5-50, 10-50, 15-50, 20-50, 25-50, 30-50, 35-50, 40-50, 45-50,
100-150, 100-200, 100-300, 100-400, 100-500, 50-500, 50-800,
50-1,000, or 100-1,000 cancer antigens, e.g., activating oncogene
mutation peptides.
[0263] An epitope, also known as an antigenic determinant, as used
herein is a portion of an antigen that is recognized by the immune
system in the appropriate context, specifically by antibodies, B
cells, or T cells. Epitopes include B cell epitopes and T cell
epitopes. B-cell epitopes are peptide sequences which are required
for recognition by specific antibody producing B-cells. B cell
epitopes refer to a specific region of the antigen that is
recognized by an antibody. The portion of an antibody that binds to
the epitope is called a paratope. An epitope may be a
conformational epitope or a linear epitope, based on the structure
and interaction with the paratope. A linear, or continuous, epitope
is defined by the primary amino acid sequence of a particular
region of a protein. The sequences that interact with the antibody
are situated next to each other sequentially on the protein, and
the epitope can usually be mimicked by a single peptide.
Conformational epitopes are epitopes that are defined by the
conformational structure of the native protein. These epitopes may
be continuous or discontinuous, i.e. components of the epitope can
be situated on disparate parts of the protein, which are brought
close to each other in the folded native protein structure.
[0264] T-cell epitopes are peptide sequences which, in association
with proteins on APC, are required for recognition by specific
T-cells. T cell epitopes are processed intracellularly and
presented on the surface of APCs, where they are bound to MHC
molecules including MHC class II and MHC class I. The peptide
epitope may be any length that is reasonable for an epitope. In
some embodiments the peptide epitope is 9-30 amino acids. In other
embodiments the length is 9-22, 9-29, 9-28, 9-27, 9-26, 9-25, 9-24,
9-23, 9-21, 9-20, 9-19, 9-18, 10-22, 10-21, 10-20, 11-22, 22-21,
11-20, 12-22, 12-21, 12-20, 13-22, 13-21, 13-20, 14-19, 15-18, or
16-17 amino acids.
[0265] In some embodiments the immunomodulatory therapeutic
composition may include a recall antigen, also sometimes referred
to as a memory antigen. A recall antigen is an antigen that has
previously been encountered by an individual and for which there
are pre-existent memory lymphocytes. In some embodiments the recall
antigen may be an infectious disease antigen that the individual
has likely encountered such as an influenza antigen. The recall
antigen helps promote a more robust immune response.
[0266] The therapeutic mRNA can be delivered alone or in
combination with other cancer therapeutics such as checkpoint
inhibitors to provide a significantly enhanced immune response
against tumors. The checkpoint inhibitors can enhance the effects
of the mRNA encoding activating oncogenic peptides by eliminating
some of the obstacles to promoting an immune response, thus
allowing the activated T cells to efficiently promote an immune
response against the tumor.
[0267] The mRNA may be delivered to the subject in the form of
carrier such as a lipid nanoparticle (LNP). A number of LNPs are
known in the art. For instance some LNPs such as those which have
been used previously to deliver siRNA various in animal models as
well as in humans have been observed to cause an undesirable
inflammatory response associated with a transient IgM response,
typically leading to a reduction in antigen production and a
compromised immune response. In contrast to the findings observed
with siRNA, lipid nanoparticle-mRNA immunomodulatory therapeutic
compositions are provided herein that generate T cell responses
sufficient for therapeutic methods rather than promoting transient
IgM responses. The LNPs described herein are not liposomes. A
liposome as used herein is a lipid based structure having a simple
lipid bilayer shell with a nucleic acid payload in the core.
[0268] An mRNA construct encoding an antigen(s) of interest
typically comprises, in addition to the antigen-encoding sequences,
other structural properties as described herein for mRNA constructs
(e.g., modified nucleobases, 5' cap, 5' UTR, 3' UTR, miR binding
site(s), polyA tail, as described herein). Suitable mRNA construct
components are as described herein.
[0269] Personalized Cancer Antigens--Neoepitopes
[0270] The cancer antigens can be personalized cancer antigens.
Personalized immunomodulatory therapeutic compositions, for
instance, may include RNA encoding for one or more known cancer
antigens specific for the tumor or cancer antigens specific for
each subject, referred to as neoepitopes or subject specific
epitopes or antigens. A "subject specific cancer antigen" is an
antigen that has been identified as being expressed in a tumor of a
particular patient. The subject specific cancer antigen may or may
not be typically present in tumor samples generally. Tumor
associated antigens that are not expressed or rarely expressed in
non-cancerous cells, or whose expression in non-cancerous cells is
sufficiently reduced in comparison to that in cancerous cells and
that induce an immune response induced upon vaccination, are
referred to as neoepitopes. Neoepitopes, like tumor associated
antigens, are completely foreign to the body and thus would not
produce an immune response against healthy tissue or be masked by
the protective components of the immune system. In some embodiments
personalized immunomodulatory therapeutic compositions based on
neoepitopes are desirable because such vaccine formulations will
maximize specificity against a patient's specific tumor.
Mutation-derived neoepitopes can arise from point mutations,
non-synonymous mutations leading to different amino acids in the
protein; read-through mutations in which a stop codon is modified
or deleted, leading to translation of a longer protein with a novel
tumor-specific sequence at the C-terminus; splice site mutations
that lead to the inclusion of an intron in the mature mRNA and thus
a unique tumor-specific protein sequence; chromosomal
rearrangements that give rise to a chimeric protein with
tumor-specific sequences at the junction of 2 proteins (i.e., gene
fusion); frameshift mutations or deletions that lead to a new open
reading frame with a novel tumor-specific protein sequence; and
translocations. Thus, in some embodiments the immunomodulatory
therapeutic compositions include at least 1 cancer antigens
including mutations selected from the group consisting of
frame-shift mutations and recombinations or any of the other
mutations described herein.
[0271] Methods for generating personalized immunomodulatory
therapeutic compositions generally involve identification of
mutations, e.g., using deep nucleic acid or protein sequencing
techniques, identification of neoepitopes, e.g., using application
of validated peptide-MHC binding prediction algorithms or other
analytical techniques to generate a set of candidate T cell
epitopes that may bind to patient HLA alleles and are based on
mutations present in tumors, optional demonstration of
antigen-specific T cells against selected neoepitopes or
demonstration that a candidate neoepitope is bound to HLA proteins
on the tumor surface and development of the vaccine. The
immunomodulatory therapeutic compositions of the invention may
include multiple copies of a single neoepitope, multiple different
neoepitopes based on a single type of mutation, i.e. point
mutation, multiple different neoepitopes based on a variety of
mutation types, neoepitopes and other antigens, such as tumor
associated antigens or recall antigens.
[0272] Examples of techniques for identifying mutations include but
are not limited to dynamic allele-specific hybridization (DASH),
microplate array diagonal gel electrophoresis (MADGE),
pyrosequencing, oligonucleotide-specific ligation, the TaqMan
system as well as various DNA "chip" technologies i.e. Affymetrix
SNP chips, and methods based on the generation of small signal
molecules by invasive cleavage followed by mass spectrometry or
immobilized padlock probes and rolling-circle amplification.
[0273] The deep nucleic acid or protein sequencing techniques are
known in the art. Any type of sequence analysis method can be used.
Nucleic acid sequencing may be performed on whole tumor genomes,
tumor exomes (protein-encoding DNA), tumor transcriptomes, or
exosomes. Real-time single molecule sequencing-by-synthesis
technologies rely on the detection of fluorescent nucleotides as
they are incorporated into a nascent strand of DNA that is
complementary to the template being sequenced. Other rapid high
throughput sequencing methods also exist. Protein sequencing may be
performed on tumor proteomes. Additionally, protein mass
spectrometry may be used to identify or validate the presence of
mutated peptides bound to MHC proteins on tumor cells. Peptides can
be acid-eluted from tumor cells or from HLA molecules that are
immunoprecipitated from tumor cells, and then identified using mass
spectrometry. The results of the sequencing may be compared with
known control sets or with sequencing analysis performed on normal
tissue of the patient.
[0274] Accordingly, the present invention relates to methods for
identifying and/or detecting neoepitopes of an antigen, such as
T-cell epitopes. Specifically, the invention provides methods of
identifying and/or detecting tumor specific neoepitopes that are
useful in inducing a tumor specific immune response in a subject.
Optionally, these neoepitopes bind to class I HLA proteins with a
greater affinity than the wild-type peptide and/or are capable of
activating anti-tumor CD8 T-cells. Identical mutations in any
particular gene are rarely found across tumors.
[0275] Proteins of MHC class I are present on the surface of almost
all cells of the body, including most tumor cells. The proteins of
MHC class I are loaded with antigens that usually originate from
endogenous proteins or from pathogens present inside cells, and are
then presented to cytotoxic T-lymphocytes (CTLs). T-Cell receptors
are capable of recognizing and binding peptides complexed with the
molecules of MHC class I. Each cytotoxic T-lymphocyte expresses a
unique T-cell receptor which is capable of binding specific
MHC/peptide complexes.
[0276] Using computer algorithms, it is possible to predict
potential neoepitopes such as T-cell epitopes, i.e. peptide
sequences, which are bound by the MHC molecules of class I or class
II in the form of a peptide-presenting complex and then, in this
form, recognized by the T-cell receptors of T-lymphocytes. Examples
of programs useful for identifying peptides which will bind to MHC
include for instance: Lonza Epibase, SYFPEITHI (Rammensee et al.,
Immunogenetics, 50 (1999), 213-219) and HLA_BIND (Parker et al., J.
Immunol., 152 (1994), 163-175).
[0277] Once putative neoepitopes are selected, they can be further
tested using in vitro and/or in vivo assays. Conventional in vitro
lab assays, such as Elispot assays may be used with an isolate from
each patient, to refine the list of neoepitopes selected based on
the algorithm's predictions. Neoepitope vaccines, methods of use
thereof and methods of preparing are all described in
PCT/US2016/044918 which is incorporated herein by reference in its
entirety.
[0278] Endogenous Tumor Antigens
[0279] In another embodiment, the tumor antigen is an endogenous
tumor antigen, such as a tumor antigen that is released upon
destruction of tumor cells in situ. It has been established in the
art that natural mechanisms exist that results in cell death in
vivo leading to release of intracellular components such that an
immune response may be stimulated against the intracellular
components. Such mechanisms are referred to herein as immunogenic
cell death and include necroptosis and pyroptosis. Accordingly, in
one embodiment, an immune potentiator mRNA construct of the
disclosure is administered to a tumor-bearing subject under
conditions in which endogenous immunogenic cell death is occurring
such that one or more endogenous tumor antigens are released, to
thereby enhance an immune response against the tumor antigens. In
one embodiment, the immune potentiator mRNA construct is
administered to a tumor-bearing subject together with a second mRNA
construct encoding an "executioner mRNA construct", which
stimulates immunogenic cell death of tumor cells in the subject.
Examples of executioner mRNA constructs include those encoding
MLKL, RIPK3, RIPK1, DIABLO, FADD, GSDMD, caspase-4, caspase-5,
caspase-11, Pyrin, NLRP3 and ASC/PYCARD. Executioner mRNA
constructs, and their use in combination with an immune potentiator
mRNA construct, are described in further detail in U.S. Application
Ser. No. 62/412,933, the entire contents of which is expressly
incorporated herein by reference.
[0280] Characteristics of Cancer Antigens
[0281] The activating oncogene mutation peptides selected for
inclusion in the immunomodulatory therapeutic composition typically
will be high affinity binding peptides. In some aspect the
activating oncogene mutation peptide binds an HLA protein with
greater affinity than a wild-type peptide. The activating oncogene
mutation peptides has an IC50 of at least less than 5000 nM, at
least less than 500 nM, at least less than 250 nM, at least less
than 200 nM, at least less than 150 nM, at least less than 100 nM,
at least less than 50 nM or less in some embodiments. Typically,
peptides with predicted IC50<50 nM, are generally considered
medium to high affinity binding peptides and will be selected for
testing their affinity empirically using biochemical assays of
HLA-binding.
[0282] In some embodiments, subject specific activating oncogene
mutation peptides may be identified in a sample of a patient. For
instance, the sample may be a tissue sample or a tumor sample. For
instance, a sample of one or more tumor cells may be examined for
the presence of subject specific activating oncogene mutations. The
tumor sample may be examined using whole genome, exome or
transcriptome analysis in order to identify the subject specific
activating oncogene mutations.
[0283] Alternatively the subject specific activating oncogene
mutation peptides may be identified in an exosome of the subject.
When the activating oncogene mutation peptides are identified in an
exosome of the subject, such peptides are said to be representative
of exosome peptides of the subject.
[0284] Exosomes are small microvesicles shed by cells, typically
having a diameter of approximately 30-100 nm. Exosomes are
classically formed from the inward invagination and pinching off of
the late endosomal membrane, resulting in the formation of a
multivesicular body (MVB) laden with small lipid bilayer vesicles,
each of which contains a sample of the parent cell's cytoplasm.
Fusion of the MVB with the cell membrane results in the release of
these exosomes from the cell, and their delivery into the blood,
urine, cerebrospinal fluid, or other bodily fluids. Exosomes can be
recovered from any of these biological fluids for further
analysis.
[0285] Nucleic acids within exosomes have a role as biomarkers for
tumor antigens. An advantage of analyzing exosomes in order to
identify subject specific cancer antigens, is that the method
circumvents the need for biopsies. This can be particularly
advantageous when the patient needs to have several rounds of
therapy including identification of cancer antigens, and
vaccination.
[0286] A number of methods of isolating exosomes from a biological
sample have been described in the art. For example, the following
methods can be used: differential centrifugation, low speed
centrifugation, anion exchange and/or gel permeation
chromatography, sucrose density gradients or organelle
electrophoresis, magnetic activated cell sorting (MACS),
nanomembrane ultrafiltration concentration, Percoll gradient
isolation and using microfluidic devices. Exemplary methods are
described in US Patent Publication No. 2014/0212871 for
instance.
Immune Potentiator mRNAs
[0287] One aspect of the disclosure pertains to mRNAs that encode a
polypeptide that stimulates or enhances an immune response against
one or more antigens of interest (activating oncogene mutation
peptide(s)). Such mRNAs that enhance immune responses to an
antigen(s) of interest are referred to herein as immune potentiator
mRNA constructs or immune potentiator mRNAs, including chemically
modified mRNAs (mmRNAs). In some aspects, the disclosure provides
an mRNA encoding a polypeptide that stimulates or enhances an
immune response in a subject in need thereof (e.g., potentiates an
immune response in the subject) by, for example, inducing adaptive
immunity (e.g., by stimulating Type I interferon production),
stimulating an inflammatory response, stimulating NFkB signaling
and/or stimulating dendritic cell (DC) development, activity or
mobilization in the subject. In some aspects, administration of an
immune potentiator mRNA to a subject in need thereof enhances
cellular immunity (e.g., T cell-mediated immunity), humoral
immunity (e.g., B cell-mediated immunity) or both cellular and
humoral immunity in the subject. In some aspects, administration of
an immune potentiator mRNA stimulates cytokine production (e.g.,
inflammatory cytokine production), stimulates antigen-specific
CD8.sup.+ effector cell responses, stimulates antigen-specific
CD4.sup.+ helper cell responses, increases the effector memory
CD62L.sup.lo T cell population, stimulates B cell activity or
stimulates antigen-specific antibody production, including
combinations of the foregoing responses.
[0288] In some aspects, administration of an immune potentiator
mRNA stimulates cytokine production (e.g., inflammatory cytokine
production) and stimulates antigen-specific CD8.sup.+ effector cell
responses. In some aspects, administration of an immune potentiator
mRNA stimulates cytokine production (e.g., inflammatory cytokine
production), and stimulates antigen-specific CD4.sup.+ helper cell
responses. In some aspects, administration of an immune potentiator
mRNA stimulates cytokine production (e.g., inflammatory cytokine
production), and increases the effector memory CD62L.sup.lo T cell
population. In some aspects, administration of an immune
potentiator mRNA stimulates cytokine production (e.g., inflammatory
cytokine production), and stimulates B cell activity or stimulates
antigen-specific antibody production.
Immune Potentiators mRNAs that Stimulate Type I Interferon
[0289] In some aspects, the disclosure provides an immune
potentiator mRNA encoding a polypeptide that stimulates or enhances
an immune response against an antigen of interest by simulating or
enhancing Type I interferon pathway signaling, thereby stimulating
or enhancing Type I interferon (IFN) production. It has been
established that successful induction of anti-tumor or
anti-microbial adaptive immunity requires Type I IFN signaling (see
e.g., Fuertes, M. B. et al. (2013) Trends Immunol. 34:67-73). The
production of Type I IFNs (including IFN-.alpha., IFN-.beta.,
IFN-.epsilon., IFN-.kappa. and IFN-.omega.) plays a role in
clearance of microbial infections, such as viral infections. It has
also been appreciated that host cell DNA (for example derived from
damaged or dying cells) is capable of inducing Type I interferon
production and that the Type I IFN signaling pathway plays a role
in the development of adaptive anti-tumor immunity. However, many
pathogens and cancer cells have evolved mechanisms to reduce or
inhibit Type I interferon responses. Thus, activation (including
stimulation and/or enhancement) of the Type I IFN signaling pathway
in a subject in need thereof, by providing an immune potentiator
mRNA of the disclosure to the subject, stimulates or enhances an
immune response in the subject in a wide variety of clinical
situations, including treatment of cancer and pathogenic
infections, as well as in potentiating vaccine responses to provide
protective immunity.
[0290] Type I interferons (IFNs) are pro-inflammatory cytokines
that are rapidly produced in multiple different cell types,
typically upon viral infection, and known to have a wide variety of
effects. The canonical consequences of type I IFN production in
vivo is the activation of antimicrobial cellular programs and the
development of innate and adaptive immune responses. Type I IFN
induces a cell-intrinsic antimicrobial state in infected and
neighboring cells that limits the spread of infectious agents,
particularly viral pathogens. Type I IFN also modulates innate
immune cell activation (e.g., maturation of dendritic cells) to
promote antigen presentation and nature killer cell functions. Type
I IFN also promotes the development of high-affinity
antigen-specific T and B cell responses and immunological memory
(Ivashkiv and Donlin (2014) Nat Rev Immunol 14(1):36-49).
[0291] Type I IFN activates dendritic cells (DCs) and promotes
their T cell stimulatory capacity through autocrine signaling
(Montoya et al., (2002) Blood 99:3263-3271). Type I IFN exposure
facilitates maturation of DCs via increasing the expression of
chemokine receptors and adhesion molecules (e.g., to promote DC
migration into draining lymph nodes), co-stimulatory molecules, and
MHC class I and class II antigen presentation. DCs that mature
following type I IFN exposure can effectively prime protective T
cell responses (Wijesundara et al., (2014) Front Immunol 29(412)
and references therein).
[0292] Type I IFN can either promote or inhibit T cell activation,
proliferation, differentiation and survival depending largely on
the timing of type I IFN signaling relative to T cell receptor
signaling (Crouse et al., (2015) Nat Rev Immunol 15:231-242). Early
studies revealed that MHC-I expression is upregulated in response
to type I IFN in multiple cell types (Lindahl et al., (1976), J
Infect Dis 133(Suppl):A66-A68; Lindahl et al., (1976) Proc Natl
Acad Sci USA 17:1284-1287) which is a requirement for optimal T
cell stimulation, differentiation, expansion and cytolytic
activity. Type I IFN can exert potent co-stimulatory effects on CD8
T cells, enhancing CD8 T cell proliferation and differentiation
(Curtsinger et al., (2005) J Immunol 174:4465-4469; Kolumam et al.,
(2005) J Exp Med 202:637-650).
[0293] Similar to effects on T cells, type I IFN signaling has both
positive and negative effects on B cell responses depending on the
timing and context of exposure (Braun et al., (2002) Int Immunol
14(4):411-419; Lin et al, (1998) 187(1):79-87). The survival and
maturation of immature B cells can be inhibited by type I IFN
signaling. In contrast to immature B cells, type I IFN exposure has
been shown to promote B cell activation, antibody production and
isotype switch following viral infection or following experimental
immunization (Le Bon et al., (2006) J Immunol 176:4:2074-2078;
Swanson et al., (2010) J Exp Med 207:1485-1500).
[0294] A number of components involved in Type I IFN pathway
signaling have been established, including STING, Interferon
Regulatory Factors, such as IRF1, IRF3, IRF5, IRF7, IRF8, and IRF9,
TBK1, IKKi, MyD88 and TRAM. Additional components involved in Type
I IFN pathway signaling include TRAF3, TRAF6, IRAK-1, IRAK-4, TRIF,
IPS-1, TLR-3, TLR-4, TLR-7, TLR-8, TLR-9, RIG-1, DAI and IFI16.
[0295] Accordingly, in one embodiment, an immune potentiator mRNA
encodes any of the foregoing components involved in Type I IFN
pathway signaling.
[0296] Immune Potentiator mRNA Encoding STING
[0297] The present disclosure encompasses mRNA (including mmRNA)
encoding STING, including constitutively active forms of STING, as
immune potentiators. STING (STimulator of INterferon Genes; also
known as transmembrane protein 173 (TMEM173), mediator of IRF3
activation (MITA), methionine-proline-tyrosine-serine (MPYS), and
ER IFN stimulator (ERIS)) is a 379 amino acid, endoplasmic
reticulum (ER) resident transmembrane protein that functions as a
signaling molecule controlling the transcription of immune response
genes, including type I IFNs and pro-inflammatory cytokines
(Ishikawa & Barber, (2008) Nature 455:647-678; Ishikawa et al.,
(2009) Nature 461:788-792; Barber (2010) Nat Rev Immunol
15(12):760-770).
[0298] STING functions as a signaling adaptor linking the cytosolic
detection of DNA to the TBK1/IRF3/Type I IFN signaling axis. The
signaling adaptor functions of STING are activated through the
direct sensing of cyclic dinucleotides (CDNs). Examples of CDNs
include cyclic di-GMP (guanosine 5'-monophosphate), cyclic di-AMP
(adenosine 5'-monophosphate) and cyclic GMP-AMP (cGAMP). Initially
characterized as ubiquitous bacterial secondary messengers, CDNs
are now known to constitute a class of pathogen-associated
molecular pattern molecules (PAMPs) that activate the
TBK1/IRF3/type I IFN signaling axis via direct interaction with
STING. STING is capable of sensing aberrant DNA species and/or CDNs
in the cytosol of the cell, including CDNs derived from bacteria,
and/or from the host protein cyclic GMP-AMP synthase (cGAS). The
cGAS protein is a DNA sensor that produces cGAMP in response to
detection of DNA in the cytosol (Burdette et al., (2011) Nature
478:515-518; Sun et al., (2013) Science 339:786-791; Diner et al.,
(2013) Cell Rep 3:1355-1361; Ablasser et al., (2013) Nature
498:380-384).
[0299] Upon binding to a CDN, STING dimerizes and undergoes a
conformational change that promotes formation of a complex with
TANK-binding kinase 1 (TBK1) (Ouyang et al., (2012) Immunity
36(6):1073-1086). This complex translocates to the perinuclear
Golgi, resulting in delivery of TBK1 to endolysosomal compartments
where it phosphorylates IRF3 and NF-.kappa.B transcription factors
(Zhong et al., (2008) Immunity 29:538-550). A recent study has
shown that STING functions as a scaffold by binding to both TBK1
and IRF3 to specifically promote the phosphorylation of IRF3 by
TBK1 (Tanaka & Chen, (2012) Sci Signal 5(214):ra20). Activation
of the IRF3-, IRF7- and NF-.kappa.B-dependent signaling pathways
induces the production of cytokines and other immune
response-related proteins, such as type I IFNs, which promote
anti-pathogen and/or anti-tumor activity.
[0300] A number of studies have investigated the use of CDN
agonists of STING as potential vaccine adjuvants or
immunomodulatory agents to elicit humoral and cellular immune
responses (Dubensky et al., (2013) Ther Adv Vaccines 1(4):131-143
and references therein). Initial studies demonstrated that
administration of the CDN c-di-GMP attenuated Staphylococcus aureus
infection in vivo, reducing the number of recovered bacterial cells
in a mouse infection model yet c-di-GMP had no observable
inhibitory or bactericidal effect on bacterial cells in vitro
suggesting the reduction in bacterial cells was due to an effect on
the host immune system (Karaolis et al., (2005) Antimicrob Agents
Chemother 49:1029-1038; Karaolis et al., (2007) Infect Immun
75:4942-4950). Recent studies have shown that synthetic CDN
derivative molecules formulated with granulocyte-macrophage
colony-stimulating factor (GM-CSF)-producing cancer vaccines
(termed STINGVAX) elicit enhanced in vivo antitumor effects in
therapeutic animal models of cancer as compared to immunization
with GM-CSF vaccine alone (Fu et al., (2015) Sci Transl Med
7(283):283ra52), suggesting that CDN are potent vaccine
adjuvants.
[0301] Mutant STING proteins resulting from polymorphisms mapped to
the human TMEM173 gene have been described exhibiting a gain-of
function or constitutively active phenotype. When expressed in
vitro, mutant STING alleles were shown to potently stimulate
induction of type I IFN (Liu et al., (2014) N Engl J Med
371:507-518; Jeremiah et al., (2014) J Clin Invest 124:5516-5520;
Dobbs et al., (2015) Cell Host Microbe 18(2):157-168; Tang &
Wang, (2015) PLoS ONE 10(3):e0120090; Melki et al., (2017) J
Allergy Clin Immunol In Press; Konig et al., (2017) Ann Rheum Dis
76(2):468-472; Burdette et al. (2011) Nature 478:515-518).
[0302] Provided herein are mRNAs (e.g., mmRNAs) encoding
constitutively active forms of STING, including mutant human STING
isoforms for use as immune potentiators as described herein. mmRNAs
encoding constitutively active forms of STING, including mutant
human STING isoforms are set forth in the Sequence Listing herein.
The amino acid residue numbering for mutant human STING
polypeptides used herein corresponds to that used for the 379 amino
acid residue wild type human STING (isoform 1) available in the art
as Genbank Accession Number NP_938023.
[0303] Accordingly, in one aspect, the disclosure provides a mRNA
(e.g., mmRNA) encoding a mutant human STING protein having a
mutation at amino acid residue 155, in particular an amino acid
substitution, such as a V155M mutation. In one embodiment, the mRNA
(e.g., mmRNAs) encodes an amino acid sequence as set forth in SEQ
ID NO:1. In one embodiment, the STING V155M mutant is encoded by a
nucleotide sequence shown in SEQ ID NO: 139, SEQ ID NO: 168 or SEQ
ID NO: 170. In one embodiment, the mRNA (e.g., mmRNAs) comprises a
3' UTR sequence as shown in SEQ ID NO: 149, which includes an
miR122 binding site.
[0304] In other aspects, the disclosure provides a mRNA (e.g.,
mmRNA) encoding a mutant human STING protein having a mutation at
amino acid residue 284, such as an amino acid substitution.
Non-limiting examples of residue 284 substitutions include R284T,
R284M and R284K. In certain embodiments, the mutant human STING
protein has as a R284T mutation, for example has the amino acid
sequence set forth in SEQ ID NO: 2 or is encoded by an the
nucleotide sequence shown in SEQ ID NO: 140 or 201. In certain
embodiments, the mutant human STING protein has a R284M mutation,
for example has the amino acid sequence as set forth in SEQ ID NO:
3 or is encoded by the nucleotide sequence shown in SEQ ID NO: 141
or 202. In certain embodiments, the mutant human STING protein has
a R284K mutation, for example has the amino acid sequence as set
forth in SEQ ID NO: 4 or 164, or is encoded by the nucleotide
sequence shown in SEQ ID NO: 142, 165, 203 or 225.
[0305] In other aspects, the disclosure provides a mRNA (e.g.,
mmRNA) encoding a mutant human STING protein having a mutation at
amino acid residue 154, such as an amino acid substitution, such as
a N154S mutation. In certain embodiments, the mutant human STING
protein has a N154S mutation, for example has the amino acid
sequence as set forth in SEQ ID NO: 5 or is encoded by the
nucleotide sequence shown in SEQ ID NO: 143 or 204.
[0306] In yet other aspects, the disclosure provides a mRNA (e.g.,
mmRNA) encoding a mutant human STING protein having a mutation at
amino acid residue 147, such as an amino acid substitution, such as
a V147L mutation. In certain embodiments, the mutant human STING
protein having a V147L mutation has the amino acid sequence as set
forth in SEQ ID NO: 6 or is encoded by the nucleotide sequence
shown in SEQ ID NO: 144 or 205.
[0307] In other aspects, the disclosure provides a mRNA (e.g.,
mmRNA) encoding a mutant human STING protein having a mutation at
amino acid residue 315, such as an amino acid substitution, such as
a E315Q mutation. In certain embodiments, the mutant human STING
protein having a E315Q mutation has the amino acid sequence as set
forth in SEQ ID NO: 7 or is encoded by the nucleotide sequence
shown in SEQ ID NO: 145 or 206.
[0308] In other aspects, the disclosure provides a mRNA (e.g.,
mmRNA) encoding a mutant human STING protein having a mutation at
amino acid residue 375, such as an amino acid substitution, such as
a R375A mutation. In certain embodiments, the mutant human STING
protein having a R375A mutation has the amino acid sequence as set
forth in SEQ ID NO: 8 or is encoded by the nucleotide sequence
shown in SEQ ID NO: 146 or 207.
[0309] In other aspects, the disclosure provides a mRNA (e.g.,
mmRNA) encoding a mutant human STING protein having a one or more
or a combination of two, three, four or more of the foregoing
mutations. Accordingly, in one aspect the disclosure provides a
mRNA (e.g., mmRNA) encoding a mutant human STING protein having one
or more mutations selected from the group consisting of: V147L,
N154S, V155M, R284T, R284M, R284K, E315Q and R375A, and
combinations thereof. In other aspects, the disclosure provides a
mRNA (e.g., mmRNA) encoding a mutant human STING protein having a
combination of mutations selected from the group consisting of:
V155M and R284T; V155M and R284M; V155M and R284K; V155M and V147L;
V155M and N154S; V155M and E315Q; and V155M and R375A.
[0310] In other aspects, the disclosure provides a mRNA (e.g.,
mmRNA) encoding a mutant human STING protein having a V155M and
one, two, three or more of the following mutations: R284T; R284M;
R284K; V147L; N154S; E315Q; and R375A. In other aspects, the
disclosure provides a mRNA (e.g., mmRNA) encoding a mutant human
STING protein having V155M, V147L and N154S mutations. In other
aspects, the disclosure provides a mRNA (e.g., mmRNA) encoding a
mutant human STING protein having V155M, V147L, N154S mutations,
and, optionally, a mutation at amino acid 284. In yet other
aspects, the disclosure provides a mRNA (e.g., mmRNA) encoding a
mutant human STING protein having V155M, V147L, N154S mutations,
and a mutation at amino acid 284 selected from R284T, R284M and
R284K. In other aspects, the disclosure provides a mRNA (e.g.,
mmRNA) encoding a mutant human STING protein having V155M, V147L,
N154S, and R284T mutations. In other aspects, the disclosure
provides a mRNA (e.g., mmRNA) encoding a mutant human STING protein
having V155M, V147L, N154S, and R284M mutations. In other aspects,
the disclosure provides a mRNA (e.g., mmRNA) encoding a mutant
human STING protein having V155M, V147L, N154S, and R284K
mutations.
[0311] In other embodiments, the disclosure provides a mRNA (e.g.,
mmRNA) encoding a mutant human STING protein having a combination
of mutations at amino acid residue 147, 154, 155 and, optionally,
284, in particular amino acid substitutions, such as a V147L,
N154S, V155M and, optionally, R284M. In certain embodiments, the
mutant human STING protein has V147N, N154S and V155M mutations,
such as the amino acid sequence as set forth in SEQ ID NO: 9 or
encoded by the nucleotide sequence shown in SEQ ID NO: 147. In
certain embodiments, the mutant human STING protein has R284M,
V147N, N154S and V155M mutations, such as the amino acid sequence
as set forth in SEQ ID NO: 10 or encoded by the nucleotide sequence
shown in SEQ ID NO: 148 or 209.
[0312] In another embodiment, the disclosure provides a mRNA (e.g.,
mmRNA) encoding a mutant human STING protein that is a
constitutively active truncated form of the full-length 379 amino
acid wild type protein, such as a constitutively active human STING
polypeptide consisting of amino acids 137-379.
[0313] Immune Potentiator mRNA Encoding Immune Regulatory Factor
(IRF)
[0314] The present disclosure provides mRNA (including mmRNA)
encoding Interferon Regulatory Factors, such as IRF1, IRF3, IRF5,
IRF7, IRF8, and IRF9 as immune potentiators. The IRF transcription
factor family is involved in the regulation of gene expression
leading to the production of type I interferons (IFNs) during
innate immune responses. Nine human IRFs have been identified to
date (IRF-1-IRF-9), with each family member sharing extensive
sequence homology within their N-terminal binding domains (DBDs)
(Mamane et al., (1999) Gene 237:1-14; Taniguchi et al., (2001) Annu
Rev Immunol 19:623-655). Within the IRF family, IRF1, IRF3, IRF5,
and IRF7 have been specifically implicated as positive regulators
of type I IFN gene transcription (Honda et al., (2006) Immunity
25(3):349-360). IRF1 was the first family member discovered to
activate type I IFN gene promoters (Miyamoto et al., (1988) Cell
54:903-913). Although studies show that IRF1 participates in type I
IFN gene expression, normal induction of type I IFN was observed in
virus-infected IRF1-/- murine fibroblasts, suggesting
dispensability (Matsuyama et al., (1993) Cell 75:83-97). IRF5 was
also shown to be dispensable for type I IFN induction by viruses or
TLR agonists (Takaoka et al., (2005) Nature 434:243-249).
[0315] Accordingly, in some aspects, the disclosure provides mRNA
encoding constitutively active forms of human IRF1, IRF3, IRF5,
IRF7, IRF8, and IRF9 as immune potentiators. In some aspects, the
disclosure provides mRNA encoding constitutively active forms of
human IRF3 and/or IRF7.
[0316] During innate immune responses, IRF-3 plays a critical role
in the early induction of type I IFNs. The IRF3 transcription
factor is constitutively expressed and shuttles between the nucleus
and cytoplasm of cells in latent form, with a predominantly
cytosolic localization prior to phosphorylation (Hiscott (2007) J
Biol Chem 282(21):15325-15329; Kumar et al., (2000) Mol Cell Biol
20(11):4159-4168). Upon phosphorylation of serine residues at the
C-terminus by TBK-1 (TANK binding kinase 1; also known as T2K and
NAK) and/or IKK.epsilon. (inducible I.kappa.B kinase; also known as
IKKi), IRF3 translocates from the cytoplasm into the nucleus
(Fitzgerald et al., (2003) Nat Immuno 4(5):491-496; Sharma et al.,
(2003) Science 300:1148-1151; Hemmi et al., (2004) J Exp Med
199:1641-1650). The transcriptional activity of IRF3 is mediated by
these phosphorylation and translocation events. A model for IRF3
activation proposes that C-terminal phosphorylation induces a
conformational change in IRF3 that promotes homo- and/or
heterodimerization (e.g. with IRF7; see Honda et al., (2006)
Immunity 25(3):346-360), nuclear localization, and association with
the transcriptional co-activators CBP and/or p300 (Lin et al.,
(1999) Mol Cell Biol 19(4):2465-2474). While inactive IRF3
constitutively shuttles into and out of the nucleus, phosphorylated
IRF3 proteins remain associated with CBP and/or p300, are retained
in the nucleus, and induce transcription of IFN and other genes
(Kumar et al., (2000) Mol Cell Biol 20(11):4159-4168).
[0317] In contrast to IRF3, IRF7 exhibits a low expression level in
most cells, but is strongly induced by type I IFN-mediated
signaling, supporting the notion that IRF3 is primarily responsible
for the early induction of IFN genes and that IRF7 is involved in
the late induction phase (Sato et al., (2000) Immunity
13(4):539-548). Ligand-binding to the type I IFN receptor results
in the activation of a heterotrimeric transcriptional activator,
termed IFN-stimulated gene factor 3 (ISGF3), which consists of
IRF9, STAT1, and STAT2, and is responsible for the induction of the
IRF7 gene (Marie et al., (1998) EMBO J 17(22):6660-6669). Like
IRF3, IRF7 can partition between cytoplasm and nucleus after serine
phosphorylation of its C-terminal region, allowing its dimerization
and nuclear translocation. IRF7 forms a homodimer or a heterodimer
with IRF3, and each of these different dimers differentially acts
on the type I IFN gene family members. IRF3 is more potent in
activating the IFN-.beta. gene than the IFN-.alpha. genes, whereas
IRF7 efficiently activates both IFN-.alpha. and IFN-.beta. genes
(Marie et al., (1998) EMBO J 17(22):6660-6669).
[0318] Provided herein are mRNAs (e.g., mmRNAs) encoding
constitutively active forms of IRF3 and IRF7 including mutant human
IRF3 and mutant human IRF7 isoforms for use as immune potentiators
as described herein. mRNAs (e.g., mmRNAs) encoding constitutively
active forms of IRF3 and IRF7, including mutant human IRF3 and IRF7
isoforms are set forth in the Sequence Listing herein. The amino
acid residue numbering for mutant human IRF3 polypeptides used
herein corresponds to that used for the 427 amino acid residue wild
type human IRF3 (isoform 1) available in the art as Genbank
Accession Number NP_001562. The amino acid residue numbering for
mutant human IRF7 polypeptides used herein corresponds to that used
for the 503 amino acid residue wild type human IRF7 (isoform a)
available in the art as Genbank Accession Number NP_001563.
[0319] Accordingly, in some aspects, the disclosure provides a mRNA
(e.g., mmRNA) encoding a mutant human IRF3 protein that is
constitutively active, e.g., having a mutation at amino acid
residue 396, such as an amino acid substitution, such as a S396D
mutation, for example as set forth in the amino acid sequence of
SEQ ID NO: 12 or encoded by the nucleotide sequence shown in SEQ ID
NO: 151 or 212. In other aspects, the mRNA (e.g., mmRNA) construct
encodes a constitutively active mouse IRF3 polypeptide comprising
an S396D mutation, for example as set forth in the amino acid
sequence of SEQ ID NO: 11 or encoded by the nucleotide sequence
shown in SEQ ID NO: 150 or 211.
[0320] In other aspects, the disclosure provides a mRNA (e.g.,
mmRNA) encoding a mutant human IRF7 protein that is constitutively
active. In one aspect, the disclosure provides a mRNA (e.g., mmRNA)
encoding a constitutively active IR7 protein comprising one or more
point mutations (amino acid substitutions compared to wild-type).
In other aspects, the disclosure provides a mRNA (e.g., mmRNA)
encoding a constitutively active IR7 protein comprising a truncated
form of the protein (amino acid deletions compared to wild-type).
In yet other aspects, the disclosure provides a mRNA (e.g., mmRNA)
encoding a constitutively active IR7 protein comprising a truncated
form of the protein that also includes one or more point mutations
(a combination of amino acid deletions and amino acid substitutions
compared to wild-type).
[0321] The wild-type amino acid sequence of human IRF7 (isoform a)
is set forth in SEQ ID NO: 13, encoded by the nucleotide sequence
shown in SEQ ID NO: 152 or 213. A series of constitutively active
forms of human IRF7 were prepared comprising point mutations,
deletions, or both, as compared to the wild-type sequence. In one
aspect, the disclosure provides an immune potentiator mRNA
construct encoding a constitutively active IRF7 polypeptide
comprising one or more of the following mutations: S475D, S476D,
S477D, S479D, L480D, S483D and S487D, and combinations thereof. In
other aspects, the disclosure provides a mRNA (e.g., mmRNA)
encoding a constitutively active IRF7 polypeptide comprising
mutations S477D and S479D, as set forth in the amino acid sequence
of SEQ ID NO: 14, encoded by the nucleotide sequence shown in SEQ
ID NO: 153 or 214. In another aspect, the disclosure provides a
mRNA (e.g., mmRNA) encoding a constitutively active IRF7
polypeptide comprising mutations S475D, S477D and L480D, as set
forth in the amino acid sequence of SEQ ID NO: 15, encoded by the
nucleotide sequence shown in SEQ ID NO: 154 or 215. In other
aspects, the disclosure provides a mRNA (e.g., mmRNAs) encoding a
constitutively active IRF7 polypeptide comprising mutations S475D,
S476D, S477D, S479D, S483D and S487D, as set forth in the amino
acid sequence of SEQ ID NO: 16, encoded by the nucleotide sequence
shown in SEQ ID NO: 155 or 216. In another aspect, the disclosure
provides a mRNA (e.g., mmRNA) encoding a constitutively active IRF7
polypeptide comprising a deletion of amino acid residues 247-467
(i.e., comprising amino acid residues 1-246 and 468-503), as set
forth in the amino acid sequence of SEQ ID NO: 17, encoded by the
nucleotide sequence shown in SEQ ID NO: 156 or 217. In yet other
aspects, the disclosure provides a mRNA (e.g., mmRNA) encoding a
constitutively active IRF7 polypeptide comprising a deletion of
amino acid residues 247-467 (i.e., comprising amino acid residues
1-246 and 468-503) and further comprising mutations S475D, S476D,
S477D, S479D, S483D and S487D, as set forth in the amino acid
sequence of SEQ ID NO: 18, encoded by the nucleotide sequence shown
in SEQ ID NO: 157 or 218.
[0322] In other aspects, the disclosure provides a mRNA (e.g.,
mmRNA) encoding a truncated IRF7 inactive "null" polypeptide
construct comprising a deletion of residues 152-246 (i.e.,
comprising amino acid residues 1-151 and 247-503), as set forth in
the amino acid sequence of SEQ ID NO: 19, encoded by the nucleotide
sequence shown in SEQ ID NO: 158 or 219 (used, for example, for
control purposes). In other aspects, the disclosure provides a mRNA
(e.g., mmRNA) encoding a truncated IRF7 inactive "null" polypeptide
construct comprising a deletion of residues 1-151 (i.e., comprising
amino acid residues 152-503), as set forth in the amino acid
sequence of SEQ ID NO: 20, encoded by the nucleotide sequence shown
in SEQ ID NO: 159 or 220 (used, for example, for control
purposes).
[0323] Additional Immune Potentiator mRNAs that Activate Type I
IFN
[0324] In addition to the STING and IRF mRNA constructs described
above, the disclosure provides mRNA constructs encoding additional
components of the Type I IFN signaling pathway that can be use as
immune potentiators to enhance immune responses through activation
of the Type I IFN signaling pathway. For example, in one
embodiment, the immune potentiator mRNA construct encodes a MyD88
protein. MyD88 is known in the art to signal upstream of IRF7. In
one aspect, the disclosure provides a mRNA (e.g., mmRNA) encoding a
constitutively active MyD88 protein, such as mutant MyD88 protein
having one or more point mutations. In one aspect, the disclosure
provides a mRNA (e.g., mmRNA) encoding a mutant human or mouse
MyD88 protein having a L265P substitutions, as set forth in SEQ ID
NOs: 75 and 76, respectively.
[0325] In another aspect, an immune potentiator mRNA construct
encodes a TRAM (TICAM2) protein. TRAM is known in the art to signal
upstream of IRF3. In one aspect, the disclosure encompasses a mRNA
(e.g., mmRNA) encoding a constitutively active TRAM protein, such
as mutant TRAM protein having one or more point mutations. In
another aspect, the disclosure encompasses a wild-type TRAM protein
that is overexpressed. In one aspect, the disclosure provides a
mRNA (e.g., mmRNA) encoding a mouse TRAM protein as shown in SEQ ID
NO: 77.
[0326] In yet other aspects, the disclosure provides an immune
potentiator mRNA construct encoding a TANK-binding kinase 1 (TBK1)
or an inducible I.kappa.B kinase (IKKi, also known as
IKK.epsilon.), including constitutively active forms of TBK1 or
IKKi, as immune potentiators. TBK1 and IKKi have been demonstrated
to be components of the virus-activated kinase that phosphorylates
IRF3 and IRF7, thus acting upstream from IRF3 and IRF7 in the Type
I IFN signaling pathway (Sharma, S. et al. (2003) Science
300:1148-1151). TBK1 and IKKi are involved in the phosphorylation
and activation of transcription factors (e.g. IRF3/7 &
NF-.kappa.B) that induce expression of type I IFN genes as well as
IFN-inducible genes (Fitzgerald, K. A. et al., (2003) Nat Immunol
4(5):491-496).
[0327] Accordingly, in one aspect, the disclosure provides an
immune potentiator mRNA construct that encodes a TBK1 protein,
including a constitutively active form of TBK1, including mutant
human TBK1 isoforms. In yet other aspects, an immune potentiator
mRNA construct encodes a IKKi protein, including a constitutively
active form of IKKi, including mutant human IKKi isoforms.
Immune Potentiators mRNAs that Stimulate Inflammatory Responses
[0328] In other aspects, the disclosure provides immune potentiator
mRNA constructs that enhance an immune response by stimulating an
inflammatory response. Non-limiting examples of agents that
stimulate an inflammatory response include STAT1, STAT2, STAT4 and
STAT6. Accordingly, the disclosure provides an immune potentiator
mRNA construct encoding one or a combination of these
inflammation-inducing proteins, including a constitutively active
form.
[0329] Provided herein are mRNAs (e.g., mmRNAs) encoding
constitutively active forms of STAT6, including mutant human STAT6
isoforms for use as immune potentiators as described herein. mRNAs
(e.g., mmRNAs) encoding constitutively active forms of STAT6,
including mutant human STAT6 isoforms are set forth in the Sequence
Listing herein. The amino acid residue numbering for mutant human
STAT6 polypeptides used herein corresponds to that used for the 847
amino acid residue wild type human STAT6 (isoform 1) available in
the art as Genbank Accession Number NP_001171550.1.
[0330] In one embodiment, the disclosure provides a mRNA construct
encoding a constitutively active human STAT6 construct comprising
one or more amino acid mutations selected from the group consisting
of S407D, V547A, T548A, Y641F, and combinations thereof. In another
embodiment, the mRNA construct encodes a constitutively active
human STAT6 construct comprising V547A and T548A mutations, such as
the sequence shown in SEQ ID NO: 78. In another embodiment, the
mRNA construct encodes a constitutively active human STAT6
construct comprising a S407D mutation, such as the sequence shown
in SEQ ID NO: 79. In another embodiment, the mRNA construct encodes
a constitutively active human STAT6 construct comprising S407D,
V547A and T548A mutations, such as the sequence shown in SEQ ID NO:
80. In another embodiment, the mRNA construct encodes a
constitutively active human STAT6 construct comprising V547A, T548A
and Y641F mutations, such as the sequence shown in SEQ ID NO:
81.
Immune Potentiator mRNAs that Stimulate NFkB Signaling
[0331] In other aspects, the disclosure provides immune potentiator
mRNA constructs that enhance an immune response by stimulating an
NFkB signaling, which is known to be involved in stimulation of
immune responses. Non-limiting examples of proteins that stimulate
NFkB signaling include c-FLIP, IKK.beta., RIPK1, Btk and TAK-TAB1.
Accordingly, an immune potentiator mRNA construct of the present
disclosure can encode any of these NFkB pathway-inducing proteins,
for example in a constitutively active form.
[0332] In one embodiment, the disclosure provides an immune
potentiator mRNA construct that activates NF.kappa.B signaling
encodes a c-FLIP (cellular caspase 8 (FLICE)-like inhibitory
protein) protein (also known in the art as CASP8 and FADD-like
apoptosis regulator), including a constitutively active c-FLIP.
Provided herein are mRNAs (e.g., mmRNAs) encoding constitutively
active forms of c-FLIP, including mutant human c-FLIP isoforms for
use as immune potentiators as described herein. mRNAs (e.g.,
mmRNAs) encoding constitutively active forms of c-FLIP, including
mutant human c-FLIP isoforms are set forth in the Sequence Listing
herein. The amino acid residue numbering for mutant human c-FLIP
polypeptides used herein corresponds to that used for the 480 amino
acid residue wild type human c-FLIP (isoform 1) available in the
art as Genbank Accession Number NP_003870.
[0333] In one embodiment, the mRNA encodes a c-FLIP long (L)
isoform comprising two DED domains, a p20 domain and a p12 domain,
such as having the sequence shown in SEQ ID NO: 82. In another
embodiment, the mRNA encodes a c-FLIP short (S) isoform, encoding
amino acids 1-227, comprising two DED domains, such as having the
sequence shown in SEQ ID NO: 83. In another embodiment, the mRNA
encodes a c-FLIP p22 cleavage product, encoding amino acids 1-198,
such as having the sequence shown in SEQ ID NO: 84. In another
embodiment, the mRNA encodes a c-FLIP p43 cleavage product,
encoding amino acids 1-376, such as having the sequence shown in
SEQ ID NO: 85. In another embodiment, the mRNA encodes a c-FLIP p12
cleavage product, encoding amino acids 377-480, such as having the
sequence shown in SEQ ID NO: 86.
[0334] In another embodiment, an immune potentiator mRNA construct
that activates NF.kappa.B signaling encodes a constitutively active
IKK.alpha. mRNA construct or a constitutively active IKK.beta. mRNA
construct. In one embodiment, the constitutively active human
IKK.beta. polypeptide comprises S177E and S181E mutations, such as
the sequence shown in SEQ ID NO: 87. In another embodiment, the
constitutively active human IKK.beta. polypeptide comprises S177A
and S181A mutations, such as the sequence shown in SEQ ID NO: 88.
In another embodiment, the mRNA construct encodes a constitutively
active mouse IKK.beta. polypeptide. In one embodiment, the
constitutively active mouse IKK.beta. polypeptide comprises S177E
and S181E mutations, such as the sequence shown in SEQ ID NO: 148.
In another embodiment, the constitutively active mouse IKK.beta.
polypeptide comprises S177A and S181A mutations, such as the
sequence shown in SEQ ID NO: 89. In another embodiment, the mRNA
construct encodes a constitutively active human or mouse IKK.alpha.
polypeptide comprising a PEST mutation, such as having a sequence
as shown in SEQ ID NOs: 91-92 (human) or 95-96 (mouse). In another
embodiment, the mRNA construct encodes a constitutively active
human or mouse IKK.beta. polypeptide comprising a PEST mutation,
such as having the sequence shown in SEQ ID NOs: 93-94 (human) or
97-98 (mouse).
[0335] In another embodiment, the disclosure provides an immune
potentiator mRNA construct that activates NF.kappa.B signaling
encoding a receptor-interacting protein kinase 1 (RIPK1) protein.
Structure of DNA constucts encoding RIPK1 constructs that induce
immunogenic cell death are described in the art, for example,
Yatim, N. et al. (2015) Science 350:328-334 or Orozco, S. et al.
(2014) Cell Death Differ. 21:1511-1521, and can be used in the
design of suitable RNA constructs that are shown herein to also
active NFkB signaling (see Examples). In one embodiment, the mRNA
construct encodes RIPK1 amino acids 1-555 of a human or mouse RIPK1
polypeptide as well as an IZ domain, such as having the sequence
shown in SEQ ID N: 99 (human) or 102 (mouse). In one embodiment,
the mRNA construct encodes RIPK1 amino acids 1-555 of a human or
mouse RIPK1 polypeptide as well as EE and DM domains, such as
having the sequence shown in SEQ ID NO: 100 (human) or 103 (mouse).
In one embodiment, the mRNA construct encodes RIPK1 amino acids
1-555 of a human or mouse RIPK1 polypeptide as well as RR and DM
domains, such as having the sequence shown in SEQ ID NO: 101
(human) or 104 (mouse).
[0336] In yet another embodiment, an immune potentiator mRNA
construct that activates NF.kappa.B signaling encodes a Btk
polypeptide, such as a mutant Btk polypeptide such as a Btk(E41K)
polypeptide (e.g., encoding an ORF amino acid sequence shown in SEQ
ID NO: 114)
[0337] In yet another embodiment, an immune potentiator mRNA
construct that activates NF.kappa.B signaling encodes a TAK-TAB1
protein, such as a constitutively active TAK-TAB1.
[0338] In one embodiment, an immune potentiator mRNA construct
encodes a human TAK-TAB1 protein, such as having the sequence shown
in SEQ ID NO: 105.
Additional Immune Potentiator mRNAs
[0339] The present disclosure provides additional immune
potentiator mRNA constructs. For example, in one embodiment, an
immune potentiator mRNA construct encodes direct IAP binding
protein with low pI (DIABLO) (also known as SMAC/DIABLO). As
described in the examples herein, DIABLO constructs induce release
of cytokines. In one embodiment, the disclosure provides a mRNA
construct encoding a wild-type human DIABLO Isoform 1 sequence,
such as having the sequence shown in SEQ ID NO: 106 (corresponding
to the 239 amino acid human DIABLO isoform 1 precursor disclosed in
the art as Genbank Accession No. NP_063940.1). In another
embodiment, the mRNA construct encodes a human DIABLO Isoform 1
sequence comprising an S126L mutation, such as having the sequence
shown in SEQ ID NO: 107. In another embodiment, the mRNA construct
encodes amino acids 56-239 of human DIABLO Isoform 1, such as
having the sequence shown in SEQ ID N: 108. In another embodiment,
the mRNA construct encodes amino acids 56-239 of human DIABLO
Isoform 1 and comprises an S126L mutation, such as having the
sequence shown in SEQ ID NO: 109. In another embodiment, the mRNA
construct encodes a wild-type human DIABLO Isoform 3 sequence, such
as having the sequence shown in SEQ ID NO: 110 (corresponding to
the 195 amino acid human DIABLO isoform 3 disclosed in the art as
Genbank Accession No. NP_001265271.1). In another embodiment, the
mRNA construct encodes a human DIABLO Isoform 3 sequence comprising
an S82L mutation, such as having the sequence shown in SEQ ID NO:
110. In another embodiment, the mRNA construct encodes amino acids
56-195 of human DIABLO Isoform 3, such as having the sequence shown
in SEQ ID NO: 111. In another embodiment, the mRNA construct
encodes amino acids 56-195 of human DIABLO Isoform 3 and comprises
an S82L mutation, such as having the sequence shown in SEQ ID NO:
112.
[0340] In additional embodiments, the immune potentiator mRNA
construct encodes a SOC3 polypeptide (e.g., encoding an ORF amino
acid sequence shown in SEQ ID NO: 115) or encodes a self-activating
caspase-1 polypeptide (e.g, encoding any of the ORF amino acid
sequences shown in SEQ ID NOs: 116-119), which can promote cleavage
of pro-IL1.beta. (and pro-IL18 to their respective mature
forms.
[0341] In yet other embodiments, an immune potentiator mRNA
construct encodes a protein that modulates dendritic cell (DC)
activity, such as stimulating DC production, activity or
mobilization. A non-limiting example of a protein that stimulates
DC mobilization is FLT3. Accordingly, in one embodiment, the immune
potentiator mRNA construct encodes a FLT3 protein.
[0342] An immune potentiator mRNA construct typically comprises, in
addition to the polypeptide-encoding sequences, other structural
properties as described herein for mRNA constructs (e.g., modified
nucleobases, 5' cap, 5' UTR, 3' UTR, miR binding site(s), polyA
tail, as described herein). Suitable mRNA construct components are
as described herein.
Compositions of Cancer Antigens of Interest and Immune
Potentiators
[0343] In another aspect, the disclosure provides a composition
comprising at least one messenger RNA (e.g., modified mRNA (mmRNA))
encoding: (i) at least one antigen of interest (an activating
oncogene mutation peptide(s)); and (ii) a polypeptide that enhances
an immune response against the at least one antigen of interest (an
activating oncogene mutation peptide(s)) when the at least on mRNA
is administered to a subject, wherein said mRNA comprises one or
more modified nucleobases. Thus, the disclosure provides
compositions comprising an immune potentiator mRNA and an mRNA
encoding an antigen of interest (an activating oncogene mutation
peptide(s)), wherein a single mRNA construct can encode both the
antigen(s) or interest and the polypeptide that enhances an immune
response to the antigen(s) or, alternatively, the composition can
comprise two or more separate mRNA constructs, a first mRNA and a
second mRNA (or third or fourth mRNA), wherein the first mRNA
encodes the at least one antigen of interest and the second mRNA
encodes the polypeptide that enhances an immune response to the
antigen(s) (i.e., the second mRNA comprises the immune
potentiator).
[0344] In those embodiments comprising a first mRNA encoding an
antigen(s) of interest and a second mRNA encoding the polypeptide
that enhances an immune response to the antigen(s) of interest, the
first mRNA and the second mRNAs can be coformulated together (e.g.,
prior to coadministration), such as coformulated in the same lipid
nanoparticle.
[0345] In those embodiments comprising a single mRNA encoding both
the antigen(s) of interest and the polypeptide that enhances an
immune response to the antigen(s) of interest, the sequences
encoding the polypeptide can be positioned on the mRNA construct
either upstream or downstream of the sequences encoding the antigen
of interest. For example, non-limiting examples of mRNA constructs
encoding both an antigen and an immunostimulatory polypeptide
include those encoding at least one mutant KRAS antigen and a
constitutively active STING polypeptide, e.g., encoding an amino
acid sequence shown in any one of SEQ ID NOs: 48-71. In one
embodiment, the constitutively active STING polypeptide is located
at the N-terminal end of the construct (i.e., upstream of the
antigen-encoding sequences), as shown in SEQ ID NOs: 48-57. In
another embodiment, the constitutively active STING polypeptide is
located at the C-terminal end of the construct (i.e., downstream of
the antigen-encoding sequences), as shown in SEQ ID NOs: 58-71.
[0346] Various mRNAs encoding antigens of interest (e.g., mRNA
vaccines) that can be used in combination with an immune
potentiator mRNA of the disclosure are described in further detail
below.
mRNA Construct Components
[0347] An mRNA may be a naturally or non-naturally occurring mRNA.
An mRNA may include one or more modified nucleobases, nucleosides,
or nucleotides, as described below, in which case it may be
referred to as a "modified mRNA" or "mmRNA." As described herein
"nucleoside" is defined as a compound containing a sugar molecule
(e.g., a pentose or ribose) or derivative thereof in combination
with an organic base (e.g., a purine or pyrimidine) or a derivative
thereof (also referred to herein as "nucleobase"). As described
herein, "nucleotide" is defined as a nucleoside including a
phosphate group.
[0348] An mRNA may include a 5' untranslated region (5'-UTR), a 3'
untranslated region (3'-UTR), and/or a coding region (e.g., an open
reading frame). An exemplary 5' UTR for use in the constructs is
shown in SEQ ID NO: 21. An exemplary 3' UTR for use in the
constructs is shown in SEQ ID NO: 22. An exemplary 3' UTR
comprising miR-122 and miR-142.3p binding sites for use in the
constructs is shown in SEQ ID NO: 23. An mRNA may include any
suitable number of base pairs, including tens (e.g., 10, 20, 30,
40, 50, 60, 70, 80, 90 or 100), hundreds (e.g., 200, 300, 400, 500,
600, 700, 800, or 900) or thousands (e.g., 1000, 2000, 3000, 4000,
5000, 6000, 7000, 8000, 9000, 10,000) of base pairs. Any number
(e.g., all, some, or none) of nucleobases, nucleosides, or
nucleotides may be an analog of a canonical species, substituted,
modified, or otherwise non-naturally occurring. In certain
embodiments, all of a particular nucleobase type may be
modified.
[0349] In some embodiments, an mRNA as described herein may include
a 5' cap structure, a chain terminating nucleotide, optionally a
Kozak sequence (also known as a Kozak consensus sequence), a stem
loop, a polyA sequence, and/or a polyadenylation signal.
[0350] A 5' cap structure or cap species is a compound including
two nucleoside moieties joined by a linker and may be selected from
a naturally occurring cap, a non-naturally occurring cap or cap
analog, or an anti-reverse cap analog (ARCA). A cap species may
include one or more modified nucleosides and/or linker moieties.
For example, a natural mRNA cap may include a guanine nucleotide
and a guanine (G) nucleotide methylated at the 7 position joined by
a triphosphate linkage at their 5' positions, e.g.,
m.sup.7G(5')ppp(5')G, commonly written as m.sup.7GpppG. A cap
species may also be an anti-reverse cap analog. A non-limiting list
of possible cap species includes m.sup.7GpppG, m.sup.7Gpppm.sup.7G,
m.sup.73'dGpppG, m.sub.2.sup.7,O3'GpppG, m.sub.2.sup.7,O3'GppppG,
m.sub.2.sup.7,O2'GppppG, m.sup.7Gpppm.sup.7G, m.sup.73'dGpppG,
m.sub.2.sup.7,O3'GpppG, m.sub.2.sup.7,O3'GppppG, and
m.sub.2.sup.7,O2'GppppG.
[0351] An mRNA may instead or additionally include a chain
terminating nucleoside. For example, a chain terminating nucleoside
may include those nucleosides deoxygenated at the 2' and/or 3'
positions of their sugar group. Such species may include
3'-deoxyadenosine (cordycepin), 3'-deoxyuridine, 3'-deoxycytosine,
3'-deoxyguanosine, 3'-deoxythymine, and 2',3'-dideoxynucleosides,
such as 2',3'-dideoxyadenosine, 2',3'-dideoxyuridine,
2',3'-dideoxycytosine, 2',3'-dideoxyguanosine, and
2',3'-dideoxythymine. In some embodiments, incorporation of a chain
terminating nucleotide into an mRNA, for example at the
3'-terminus, may result in stabilization of the mRNA, as described,
for example, in International Patent Publication No. WO
2013/103659.
[0352] An mRNA may instead or additionally include a stem loop,
such as a histone stem loop. A stem loop may include 2, 3, 4, 5, 6,
7, 8, or more nucleotide base pairs. For example, a stem loop may
include 4, 5, 6, 7, or 8 nucleotide base pairs. A stem loop may be
located in any region of an mRNA. For example, a stem loop may be
located in, before, or after an untranslated region (a 5'
untranslated region or a 3' untranslated region), a coding region,
or a polyA sequence or tail. In some embodiments, a stem loop may
affect one or more function(s) of an mRNA, such as initiation of
translation, translation efficiency, and/or transcriptional
termination.
[0353] An mRNA may instead or additionally include a polyA sequence
and/or polyadenylation signal. A polyA sequence may be comprised
entirely or mostly of adenine nucleotides or analogs or derivatives
thereof. A polyA sequence may be a tail located adjacent to a 3'
untranslated region of an mRNA. In some embodiments, a polyA
sequence may affect the nuclear export, translation, and/or
stability of an mRNA.
[0354] An mRNA may instead or additionally include a microRNA
binding site.
[0355] In some embodiments, an mRNA is a bicistronic mRNA
comprising a first coding region and a second coding region with an
intervening sequence comprising an internal ribosome entry site
(IRES) sequence that allows for internal translation initiation
between the first and second coding regions, or with an intervening
sequence encoding a self-cleaving peptide, such as a 2A peptide.
IRES sequences and 2A peptides are typically used to enhance
expression of multiple proteins from the same vector. A variety of
IRES sequences are known and available in the art and may be used,
including, e.g., the encephalomyocarditis virus IRES.
[0356] In one embodiment, the polynucleotides of the present
disclosure may include a sequence encoding a self-cleaving peptide.
The self-cleaving peptide may be, but is not limited to, a 2A
peptide. A variety of 2A peptides are known and available in the
art and may be used, including e.g., the foot and mouth disease
virus (FMDV) 2A peptide, the equine rhinitis A virus 2A peptide,
the Thosea asigna virus 2A peptide, and the porcine teschovirus-1
2A peptide. 2A peptides are used by several viruses to generate two
proteins from one transcript by ribosome-skipping, such that a
normal peptide bond is impaired at the 2A peptide sequence,
resulting in two discontinuous proteins being produced from one
translation event. As a non-limiting example, the 2A peptide may
have the protein sequence: GSGATNFSLLKQAGDVEENPGP (SEQ ID NO: 24),
fragments or variants thereof. In one embodiment, the 2A peptide
cleaves between the last glycine and last proline. As another
non-limiting example, the polynucleotides of the present disclosure
may include a polynucleotide sequence encoding the 2A peptide
having the protein sequence GSGATNFSLLKQAGDVEENPGP (SEQ ID NO:24)
fragments or variants thereof. One example of a polynucleotide
sequence encoding the 2A peptide is:
GGAAGCGGAGCTACTAACTTCAGCCTGCTGAAGCAGGCTGGAGACGTGGAGGAG AACCCTGGACCT
(SEQ ID NO: 25). In one illustrative embodiment, a 2A peptide is
encoded by the following sequence:
5'-TCCGGACTCAGATCCGGGGATCTCAAAATTGTCGCTCCTGTCAAACAAACTCTTA
ACTTTGATTTACTCAAACTGGCTGGGGATGTAGAAAGCAATCCAGGTCCACTC-3'(SEQ ID NO:
26). The polynucleotide sequence of the 2A peptide may be modified
or codon optimized by the methods described herein and/or are known
in the art.
[0357] In one embodiment, this sequence may be used to separate the
coding regions of two or more polypeptides of interest. As a
non-limiting example, the sequence encoding the F2A peptide may be
between a first coding region A and a second coding region B
(A-F2Apep-B). The presence of the F2A peptide results in the
cleavage of the one long protein between the glycine and the
proline at the end of the F2A peptide sequence (NPGP is cleaved to
result in NPG and P) thus creating separate protein A (with 21
amino acids of the F2A peptide attached, ending with NPG) and
separate protein B (with 1 amino acid, P, of the F2A peptide
attached). Likewise, for other 2A peptides (P2A, T2A and E2A), the
presence of the peptide in a long protein results in cleavage
between the glycine and proline at the end of the 2A peptide
sequence (NPGP is cleaved to result in NPG and P). Protein A and
protein B may be the same or different peptides or polypeptides of
interest. In particular embodiments, protein A is a polypeptide
that induces immunogenic cell death and protein B is another
polypeptide that stimulates an inflammatory and/or immune response
and/or regulates immune responsiveness (as described further
below).
Modified mRNAs
[0358] In some embodiments, an mRNA of the disclosure comprises one
or more modified nucleobases, nucleosides, or nucleotides (termed
"modified mRNAs" or "mmRNAs"). In some embodiments, modified mRNAs
may have useful properties, including enhanced stability,
intracellular retention, enhanced translation, and/or the lack of a
substantial induction of the innate immune response of a cell into
which the mRNA is introduced, as compared to a reference unmodified
mRNA. Therefore, use of modified mRNAs may enhance the efficiency
of protein production, intracellular retention of nucleic acids, as
well as possess reduced immunogenicity.
[0359] In some embodiments, an mRNA includes one or more (e.g., 1,
2, 3 or 4) different modified nucleobases, nucleosides, or
nucleotides. In some embodiments, an mRNA includes one or more
(e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80,
90, 100, or more) different modified nucleobases, nucleosides, or
nucleotides. In some embodiments, the modified mRNA may have
reduced degradation in a cell into which the mRNA is introduced,
relative to a corresponding unmodified mRNA.
[0360] In some embodiments, the modified nucleobase is a modified
uracil. Exemplary nucleobases and nucleosides having a modified
uracil include pseudouridine (.psi.), pyridin-4-one ribonucleoside,
5-aza-uridine, 6-aza-uridine, 2-thio-5-aza-uridine, 2-thio-uridine
(s.sup.2U), 4-thio-uridine (s.sup.4U), 4-thio-pseudouridine,
2-thio-pseudouridine, 5-hydroxy-uridine (ho.sup.5U),
5-aminoallyl-uridine, 5-halo-uridine (e.g., 5-iodo-uridineor
5-bromo-uridine), 3-methyl-uridine (m.sup.3U), 5-methoxy-uridine
(mo.sup.5U), uridine 5-oxyacetic acid (cmo.sup.5U), uridine
5-oxyacetic acid methyl ester (mcmo.sup.5U),
5-carboxymethyl-uridine (cm.sup.5U), 1-carboxymethyl-pseudouridine,
5-carboxyhydroxymethyl-uridine (chm.sup.5U),
5-carboxyhydroxymethyl-uridine methyl ester (mchm.sup.5U),
5-methoxycarbonylmethyl-uridine (mcm.sup.5U),
5-methoxycarbonylmethyl-2-thio-uridine (mcm.sup.5s.sup.2U),
5-aminomethyl-2-thio-uridine (nm.sup.5s.sup.2U),
5-methylaminomethyl-uridine (mnm.sup.5U),
5-methylaminomethyl-2-thio-uridine (mnm.sup.5s.sup.2U),
5-methylaminomethyl-2-seleno-uridine (mnm.sup.5se.sup.2U),
5-carbamoylmethyl-uridine (ncm.sup.5U),
5-carboxymethylaminomethyl-uridine (cmnm.sup.5U),
5-carboxymethylaminomethyl-2-thio-uridine (cmnm.sup.5s.sup.2U),
5-propynyl-uridine, 1-propynyl-pseudouridine,
5-taurinomethyl-uridine (.tau.m.sup.5U),
1-taurinomethyl-pseudouridine, 5-taurinomethyl-2-thio-uridine
(.tau.m.sup.5s.sup.2U), 1-taurinomethyl-4-thio-pseudouridine,
5-methyl-uridine (m.sup.5U, i.e., having the nucleobase
deoxythymine), 1-methyl-pseudouridine (m.sup.1.psi.),
5-methyl-2-thio-uridine (m.sup.5s.sup.2U),
1-methyl-4-thio-pseudouridine (m.sup.1s.sup.4.psi.),
4-thio-1-methyl-pseudouridine, 3-methyl-pseudouridine
(m.sup.3.psi.), 2-thio-1-methyl-pseudouridine,
1-methyl-1-deaza-pseudouridine,
2-thio-1-methyl-1-deaza-pseudouridine, dihydrouridine (D),
dihydropseudouridine, 5,6-dihydrouridine, 5-methyl-dihydrouridine
(m.sup.5D), 2-thio-dihydrouridine, 2-thio-dihydropseudouridine,
2-methoxy-uridine, 2-methoxy-4-thio-uridine,
4-methoxy-pseudouridine, 4-methoxy-2-thio-pseudouridine,
N1-methyl-pseudouridine, 3-(3-amino-3-carboxypropyl)uridine
(acp.sup.3U), 1-methyl-3-(3-amino-3-carboxypropyl)pseudouridine
(acp.sup.3 .psi.), 5-(isopentenylaminomethyl)uridine (inm.sup.5U),
5-(isopentenylaminomethyl)-2-thio-uridine (inm.sup.5s.sup.2U),
.alpha.-thio-uridine, 2'-O-methyl-uridine (Um),
5,2'-O-dimethyl-uridine (m.sup.5Um), 2'-O-methyl-pseudouridine
(.psi.m), 2-thio-2'-O-methyl-uridine (s.sup.2Um),
5-methoxycarbonylmethyl-2'-O-methyl-uridine (mcm.sup.5Um),
5-carbamoylmethyl-2'-O-methyl-uridine (ncm.sup.5Um),
5-carboxymethylaminomethyl-2'-O-methyl-uridine (cmnm.sup.5Um),
3,2'-O-dimethyl-uridine (m.sup.3Um), and
5-(isopentenylaminomethyl)-2'-O-methyl-uridine (inm.sup.5Um),
1-thio-uridine, deoxythymidine, 2'-F-ara-uridine, 2'-F-uridine,
2'-OH-ara-uridine, 5-(2-carbomethoxyvinyl) uridine, and
5-[3-(1-E-propenylamino)]uridine.
[0361] In some embodiments, the modified nucleobase is a modified
cytosine. Exemplary nucleobases and nucleosides having a modified
cytosine include 5-aza-cytidine, 6-aza-cytidine, pseudoisocytidine,
3-methyl-cytidine (m.sup.3C), N4-acetyl-cytidine (ac.sup.4C),
5-formyl-cytidine (f.sup.5C), N4-methyl-cytidine (m.sup.4C),
5-methyl-cytidine (m.sup.5C), 5-halo-cytidine (e.g.,
5-iodo-cytidine), 5-hydroxymethyl-cytidine (hm.sup.5C),
1-methyl-pseudoisocytidine, pyrrolo-cytidine,
pyrrolo-pseudoisocytidine, 2-thio-cytidine (s.sup.2C),
2-thio-5-methyl-cytidine, 4-thio-pseudoisocytidine,
4-thio-1-methyl-pseudoisocytidine,
4-thio-1-methyl-1-deaza-pseudoisocytidine,
1-methyl-1-deaza-pseudoisocytidine, zebularine, 5-aza-zebularine,
5-methyl-zebularine, 5-aza-2-thio-zebularine, 2-thio-zebularine,
2-methoxy-cytidine, 2-methoxy-5-methyl-cytidine,
4-methoxy-pseudoisocytidine, 4-methoxy-1-methyl-pseudoisocytidine,
lysidine (k.sub.2C), .alpha.-thio-cytidine, 2'-O-methyl-cytidine
(Cm), 5,2'-O-dimethyl-cytidine (m.sup.5Cm),
N4-acetyl-2'-O-methyl-cytidine (ac.sup.4Cm),
N4,2'-O-dimethyl-cytidine (m.sup.4Cm),
5-formyl-2'-O-methyl-cytidine (f.sup.5Cm),
N4,N4,2'-O-trimethyl-cytidine (m.sup.4.sub.2Cm), 1-thio-cytidine,
2'-F-ara-cytidine, 2'-F-cytidine, and 2'-OH-ara-cytidine.
[0362] In some embodiments, the modified nucleobase is a modified
adenine. Exemplary nucleobases and nucleosides having a modified
adenine include .alpha.-thio-adenosine, 2-amino-purine, 2,
6-diaminopurine, 2-amino-6-halo-purine (e.g.,
2-amino-6-chloro-purine), 6-halo-purine (e.g., 6-chloro-purine),
2-amino-6-methyl-purine, 8-azido-adenosine, 7-deaza-adenine,
7-deaza-8-aza-adenine, 7-deaza-2-amino-purine,
7-deaza-8-aza-2-amino-purine, 7-deaza-2,6-diaminopurine,
7-deaza-8-aza-2,6-diaminopurine, 1-methyl-adenosine (m.sup.1A),
2-methyl-adenine (m.sup.2A), N6-methyl-adenosine (m.sup.6A),
2-methylthio-N6-methyl-adenosine (ms.sup.2m.sup.6A),
N6-isopentenyl-adenosine (i.sup.6A),
2-methylthio-N6-isopentenyl-adenosine (ms.sup.2i.sup.6A),
N6-(cis-hydroxyisopentenyl)adenosine (io.sup.6A),
2-methylthio-N6-(cis-hydroxyisopentenyl)adenosine
(ms.sup.2io.sup.6A), N6-glycinylcarbamoyl-adenosine (g.sup.6A),
N6-threonylcarbamoyl-adenosine (t.sup.6A),
N6-methyl-N6-threonylcarbamoyl-adenosine (m.sup.6t.sup.6A),
2-methylthio-N6-threonylcarbamoyl-adenosine (ms.sup.2g.sup.6A),
N6,N6-dimethyl-adenosine (m.sup.6.sub.2A),
N6-hydroxynorvalylcarbamoyl-adenosine (hn.sup.6A),
2-methylthio-N6-hydroxynorvalylcarbamoyl-adenosine
(ms.sup.2hn.sup.6A), N6-acetyl-adenosine (ac.sup.6A),
7-methyl-adenine, 2-methylthio-adenine, 2-methoxy-adenine,
.alpha.-thio-adenosine, 2'-O-methyl-adenosine (Am),
N6,2'-O-dimethyl-adenosine (m.sup.6Am),
N6,N6,2'-O-trimethyl-adenosine (m.sup.6.sub.2Am),
1,2'-O-dimethyl-adenosine (m.sup.1Am), 2'-O-ribosyladenosine
(phosphate) (Ar(p)), 2-amino-N6-methyl-purine, 1-thio-adenosine,
8-azido-adenosine, 2'-F-ara-adenosine, 2'-F-adenosine,
2'-OH-ara-adenosine, and
N6-(19-amino-pentaoxanonadecyl)-adenosine.
[0363] In some embodiments, the modified nucleobase is a modified
guanine. Exemplary nucleobases and nucleosides having a modified
guanine include .alpha.-thio-guanosine, inosine (I),
1-methyl-inosine (m.sup.1I), wyosine (imG), methylwyosine (mimG),
4-demethyl-wyosine (imG-14), isowyosine (imG2), wybutosine (yW),
peroxywybutosine (o.sub.2yW), hydroxywybutosine (OhyW),
undermodified hydroxywybutosine (OhyW*), 7-deaza-guanosine,
queuosine (Q), epoxyqueuosine (oQ), galactosyl-queuosine (galQ),
mannosyl-queuosine (manQ), 7-cyano-7-deaza-guanosine (preQ.sub.0),
7-aminomethyl-7-deaza-guanosine (preQ.sub.1), archaeosine
(G.sup.+), 7-deaza-8-aza-guanosine, 6-thio-guanosine,
6-thio-7-deaza-guanosine, 6-thio-7-deaza-8-aza-guanosine,
7-methyl-guanosine (m.sup.7G), 6-thio-7-methyl-guanosine,
7-methyl-inosine, 6-methoxy-guanosine, 1-methyl-guanosine
(m.sup.1G), N2-methyl-guanosine (m.sup.2G),
N2,N2-dimethyl-guanosine (m.sup.2.sub.2G), N2,7-dimethyl-guanosine
(m.sup.2,7G), N2, N2,7-dimethyl-guanosine (m.sup.2,2,7G),
8-oxo-guanosine, 7-methyl-8-oxo-guanosine,
1-methyl-6-thio-guanosine, N2-methyl-6-thio-guanosine,
N2,N2-dimethyl-6-thio-guanosine, .alpha.-thio-guanosine,
2'-O-methyl-guanosine (Gm), N2-methyl-2'-O-methyl-guanosine
(m.sup.2Gm), N2,N2-dimethyl-2'-O-methyl-guanosine
(m.sup.2.sub.2Gm), 1-methyl-2'-O-methyl-guanosine (mGm),
N2,7-dimethyl-2'-O-methyl-guanosine (m.sup.2,7Gm),
2'-O-methyl-inosine (Im), 1,2'-O-dimethyl-inosine (m.sup.1Im),
2'-O-ribosylguanosine (phosphate) (Gr(p)), 1-thio-guanosine,
06-methyl-guanosine, 2'-F-ara-guanosine, and 2'-F-guanosine.
[0364] In some embodiments, an mRNA of the disclosure includes a
combination of one or more of the aforementioned modified
nucleobases (e.g., a combination of 2, 3 or 4 of the aforementioned
modified nucleobases.)
[0365] In some embodiments, the modified nucleobase is
pseudouridine (.psi.), N1-methylpseudouridine (m.sup.1.psi.),
2-thiouridine, 4'-thiouridine, 5-methylcytosine,
2-thio-1-methyl-1-deaza-pseudouridine,
2-thio-1-methyl-pseudouridine, 2-thio-5-aza-uridine,
2-thio-dihydropseudouridine, 2-thio-dihydrouridine,
2-thio-pseudouridine, 4-methoxy-2-thio-pseudouridine,
4-methoxy-pseudouridine, 4-thio-1-methyl-pseudouridine,
4-thio-pseudouridine, 5-aza-uridine, dihydropseudouridine,
5-methoxyuridine, or 2'-O-methyl uridine. In some embodiments, an
mRNA of the disclosure includes a combination of one or more of the
aforementioned modified nucleobases (e.g., a combination of 2, 3 or
4 of the aforementioned modified nucleobases.) In one embodiment,
the modified nucleobase is N1-methylpseudouridine (m.sup.1.psi.)
and the mRNA of the disclosure is fully modified with
N1-methylpseudouridine (m.sup.1.psi.). In some embodiments,
N1-methylpseudouridine (m.sup.1.psi.) represents from 75-100% of
the uracils in the mRNA. In some embodiments,
N1-methylpseudouridine (m.sup.1.psi.) represents 100% of the
uracils in the mRNA.
[0366] In some embodiments, the modified nucleobase is a modified
cytosine. Exemplary nucleobases and nucleosides having a modified
cytosine include N4-acetyl-cytidine (ac.sup.4C), 5-methyl-cytidine
(m.sup.5C), 5-halo-cytidine (e.g., 5-iodo-cytidine),
5-hydroxymethyl-cytidine (hm.sup.5C), 1-methyl-pseudoisocytidine,
2-thio-cytidine (s.sup.2C), 2-thio-5-methyl-cytidine. In some
embodiments, an mRNA of the disclosure includes a combination of
one or more of the aforementioned modified nucleobases (e.g., a
combination of 2, 3 or 4 of the aforementioned modified
nucleobases.)
[0367] In some embodiments, the modified nucleobase is a modified
adenine. Exemplary nucleobases and nucleosides having a modified
adenine include 7-deaza-adenine, 1-methyl-adenosine (m.sup.1A),
2-methyl-adenine (m.sup.2A), N6-methyl-adenosine (m.sup.6A). In
some embodiments, an mRNA of the disclosure includes a combination
of one or more of the aforementioned modified nucleobases (e.g., a
combination of 2, 3 or 4 of the aforementioned modified
nucleobases.)
[0368] In some embodiments, the modified nucleobase is a modified
guanine. Exemplary nucleobases and nucleosides having a modified
guanine include inosine (I), 1-methyl-inosine (m.sup.1I), wyosine
(imG), methylwyosine (mimG), 7-deaza-guanosine,
7-cyano-7-deaza-guanosine (preQ.sub.0), 7-aminomethyl-7-deaza-guano
sine (preQ.sub.1), 7-methyl-guanosine (m.sup.7G),
1-methyl-guanosine (m.sup.1G), 8-oxo-guanosine,
7-methyl-8-oxo-guanosine. In some embodiments, an mRNA of the
disclosure includes a combination of one or more of the
aforementioned modified nucleobases (e.g., a combination of 2, 3 or
4 of the aforementioned modified nucleobases.)
[0369] In some embodiments, the modified nucleobase is
1-methyl-pseudouridine (m.sup.1.psi.), 5-methoxy-uridine
(mo.sup.5U), 5-methyl-cytidine (m.sup.5C), pseudouridine (.psi.),
.alpha.-thio-guanosine, or .alpha.-thio-adenosine. In some
embodiments, an mRNA of the disclosure includes a combination of
one or more of the aforementioned modified nucleobases (e.g., a
combination of 2, 3 or 4 of the aforementioned modified
nucleobases.)
[0370] In some embodiments, the mRNA comprises pseudouridine
(.psi.). In some embodiments, the mRNA comprises pseudouridine
(.psi.) and 5-methyl-cytidine (m.sup.5C). In some embodiments, the
mRNA comprises 1-methyl-pseudouridine (m.sup.1.psi.). In some
embodiments, the mRNA comprises 1-methyl-pseudouridine
(m.sup.1.psi.) and 5-methyl-cytidine (m.sup.5C). In some
embodiments, the mRNA comprises 2-thiouridine (s.sup.2U). In some
embodiments, the mRNA comprises 2-thiouridine and 5-methyl-cytidine
(m.sup.5C). In some embodiments, the mRNA comprises
5-methoxy-uridine (mo.sup.5U). In some embodiments, the mRNA
comprises 5-methoxy-uridine (mo.sup.5U) and 5-methyl-cytidine
(m.sup.5C). In some embodiments, the mRNA comprises 2'-O-methyl
uridine. In some embodiments, the mRNA comprises 2'-O-methyl
uridine and 5-methyl-cytidine (m.sup.5C). In some embodiments, the
mRNA comprises comprises N6-methyl-adenosine (m.sup.6A). In some
embodiments, the mRNA comprises N6-methyl-adenosine (m.sup.6A) and
5-methyl-cytidine (m.sup.5C).
[0371] In certain embodiments, an mRNA of the disclosure is
uniformly modified (i.e., fully modified, modified through-out the
entire sequence) for a particular modification. For example, an
mRNA can be uniformly modified with N1-methylpseudouridine
(m.sup.1.psi.) or 5-methyl-cytidine (m.sup.5C), meaning that all
uridines or all cytosine nucleosides in the mRNA sequence are
replaced with N1-methylpseudouridine (m.sup.1.psi.) or
5-methyl-cytidine (m.sup.5C). Similarly, mRNAs of the disclosure
can be uniformly modified for any type of nucleoside residue
present in the sequence by replacement with a modified residue such
as those set forth above.
[0372] In some embodiments, an mRNA of the disclosure may be
modified in a coding region (e.g., an open reading frame encoding a
polypeptide). In other embodiments, an mRNA may be modified in
regions besides a coding region. For example, in some embodiments,
a 5'-UTR and/or a 3'-UTR are provided, wherein either or both may
independently contain one or more different nucleoside
modifications. In such embodiments, nucleoside modifications may
also be present in the coding region.
[0373] Examples of nucleoside modifications and combinations
thereof that may be present in mmRNAs of the present disclosure
include, but are not limited to, those described in PCT Patent
Application Publications: WO2012045075, WO2014081507, WO2014093924,
WO2014164253, and WO2014159813.
[0374] The mmRNAs of the disclosure can include a combination of
modifications to the sugar, the nucleobase, and/or the
internucleoside linkage. These combinations can include any one or
more modifications described herein.
[0375] Examples of modified nucleosides and modified nucleoside
combinations are provided below in Table 1 and Table 2. These
combinations of modified nucleotides can be used to form the mmRNAs
of the disclosure. In certain embodiments, the modified nucleosides
may be partially or completely substituted for the natural
nucleotides of the mRNAs of the disclosure. As a non-limiting
example, the natural nucleotide uridine may be substituted with a
modified nucleoside described herein. In another non-limiting
example, the natural nucleoside uridine may be partially
substituted (e.g., about 0.1%, 1%, 5%, 10%, 15%, 20%, 25%, 30%,
35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or
99.9% of the natural uridines) with at least one of the modified
nucleoside disclosed herein.
TABLE-US-00002 TABLE 1 Combinations of Nucleoside Modifications
Modified Nucleotide Modified Nucleotide Combination
.alpha.-thio-cytidine .alpha.-thio-cytidine/5-iodo-uridine
.alpha.-thio-cytidine/N1-methyl-pseudouridine
.alpha.-thio-cytidine/.alpha.-thio-uridine
.alpha.-thio-cytidine/5-methyl-uridine
.alpha.-thio-cytidine/pseudo-uridine about 50% of the cytosines are
.alpha.-thio-cytidine pseudoisocytidine
pseudoisocytidine/5-iodo-uridine
pseudoisocytidine/N1-methyl-pseudouridine
pseudoisocytidine/.alpha.-thio-uridine
pseudoisocytidine/5-methyl-uridine pseudoisocytidine/pseudouridine
about 25% of cytosines are pseudoisocytidine
pseudoisocytidine/about 50% of uridines are N1-
methyl-pseudouridine and about 50% of uridines are pseudouridine
pseudoisocytidine/about 25% of uridines are N1-
methyl-pseudouridine and about 25% of uridines are pseudouridine
pyrrolo-cytidine pyrrolo-cytidine/5-iodo-uridine
pyrrolo-cytidine/N1-methyl-pseudouridine
pyrrolo-cytidine/.alpha.-thio-uridine
pyrrolo-cytidine/5-methyl-uridine pyrrolo-cytidine/pseudouridine
about 50% of the cytosines are pyrrolo-cytidine 5-methyl-cytidine
5-methyl-cytidine/5-iodo-uridine
5-methyl-cytidine/N1-methyl-pseudouridine
5-methyl-cytidine/.alpha.-thio-uridine
5-methyl-cytidine/5-methyl-uridine 5-methyl-cytidine/pseudouridine
about 25% of cytosines are 5-methyl-cytidine about 50% of cytosines
are 5-methyl-cytidine 5-methyl-cytidine/5-methoxy-uridine
5-methyl-cytidine/5-bromo-uridine 5-methyl-cytidine/2-thio-uridine
5-methyl-cytidine/about 50% of uridines are 2- thio-uridine about
50% of uridines are 5-methyl-cytidine/about 50% of uridines are
2-thio-uridine N4-acetyl-cytidine N4-acetyl-cytidine/5-iodo-uridine
N4-acetyl-cytidine/N1-methyl-pseudouridine
N4-acetyl-cytidine/.alpha.-thio-uridine
N4-acetyl-cytidine/5-methyl-uridine
N4-acetyl-cytidine/pseudouridine about 50% of cytosines are
N4-acetyl-cytidine about 25% of cytosines are N4-acetyl-cytidine
N4-acetyl-cytidine/5-methoxy-uridine
N4-acetyl-cytidine/5-bromo-uridine
N4-acetyl-cytidine/2-thio-uridine about 50% of cytosines are
N4-acetyl-cytidine/ about 50% of uridines are 2-thio-uridine
TABLE-US-00003 TABLE 2 Modified Nucleosides and Combinations
Thereof 1-(2,2,2-Trifluoroethyl)pseudo-UTP 1-Ethyl-pseudo-UTP
1-Methyl-pseudo-U-alpha-thio-TP 1-methyl-pseudouridine TP, ATP,
GTP, CTP 1-methyl-pseudo-UTP/5-methyl-CTP/ATP/GTP
1-methyl-pseudo-UTP/CTP/ATP/GTP 1-Propyl-pseudo-UTP 25%
5-Aminoallyl-CTP + 75% CTP/25% 5-Methoxy-UTP + 75% UTP 25%
5-Aminoallyl-CTP + 75% CTP/75% 5-Methoxy-UTP + 25% UTP 25%
5-Bromo-CTP + 75% CTP/25% 5-Methoxy-UTP + 75% UTP 25% 5-Bromo-CTP +
75% CTP/75% 5-Methoxy-UTP + 25% UTP 25% 5-Bromo-CTP + 75%
CTP/1-Methyl-pseudo-UTP 25% 5-Carboxy-CTP + 75% CTP/25%
5-Methoxy-UTP + 75% UTP 25% 5-Carboxy-CTP + 75% CTP/75%
5-Methoxy-UTP + 25% UTP 25% 5-Ethyl-CTP + 75% CTP/25% 5-Methoxy-UTP
+ 75% UTP 25% 5-Ethyl-CTP + 75% CTP/75% 5-Methoxy-UTP + 25% UTP 25%
5-Ethynyl-CTP + 75% CTP/25% 5-Methoxy-UTP + 75% UTP 25%
5-Ethynyl-CTP + 75% CTP/75% 5-Methoxy-UTP + 25% UTP 25%
5-Fluoro-CTP + 75% CTP/25% 5-Methoxy-UTP + 75% UTP 25% 5-Fluoro-CTP
+ 75% CTP/75% 5-Methoxy-UTP + 25% UTP 25% 5-Formyl-CTP + 75%
CTP/25% 5-Methoxy-UTP + 75% UTP 25% 5-Formyl-CTP + 75% CTP/75%
5-Methoxy-UTP + 25% UTP 25% 5-Hydroxymethyl-CTP + 75% CTP/25%
5-Methoxy-UTP + 75% UTP 25% 5-Hydroxymethyl-CTP + 75% CTP/75%
5-Methoxy-UTP + 25% UTP 25% 5-Iodo-CTP + 75% CTP/25% 5-Methoxy-UTP
+ 75% UTP 25% 5-Iodo-CTP + 75% CTP/75% 5-Methoxy-UTP + 25% UTP 25%
5-Methoxy-CTP + 75% CTP/25% 5-Methoxy-UTP + 75% UTP 25%
5-Methoxy-CTP + 75% CTP/75% 5-Methoxy-UTP + 25% UTP 25%
5-Methyl-CTP + 75% CTP/25% 5-Methoxy-UTP + 75% 1-Methyl- pseudo-UTP
25% 5-Methyl-CTP + 75% CTP/25% 5-Methoxy-UTP + 75% UTP 25%
5-Methyl-CTP + 75% CTP/50% 5-Methoxy-UTP + 50% 1-Methyl- pseudo-UTP
25% 5-Methyl-CTP + 75% CTP/50% 5-Methoxy-UTP + 50% UTP 25%
5-Methyl-CTP + 75% CTP/5-Methoxy-UTP 25% 5-Methyl-CTP + 75% CTP/75%
5-Methoxy-UTP + 25% 1-Methyl- pseudo-UTP 25% 5-Methyl-CTP + 75%
CTP/75% 5-Methoxy-UTP + 25% UTP 25% 5-Phenyl-CTP + 75% CTP/25%
5-Methoxy-UTP + 75% UTP 25% 5-Phenyl-CTP + 75% CTP/75%
5-Methoxy-UTP + 25% UTP 25% 5-Trifluoromethyl-CTP + 75% CTP/25%
5-Methoxy-UTP + 75% UTP 25% 5-Trifluoromethyl-CTP + 75% CTP/75%
5-Methoxy-UTP + 25% UTP 25% 5-Trifluoromethyl-CTP + 75%
CTP/1-Methyl-pseudo-UTP 25% N4-Ac-CTP + 75% CTP/25% 5-Methoxy-UTP +
75% UTP 25% N4-Ac-CTP + 75% CTP/75% 5-Methoxy-UTP + 25% UTP 25%
N4-Bz-CTP + 75% CTP/25% 5-Methoxy-UTP + 75% UTP 25% N4-Bz-CTP + 75%
CTP/75% 5-Methoxy-UTP + 25% UTP 25% N4-Methyl-CTP + 75% CTP/25%
5-Methoxy-UTP + 75% UTP 25% N4-Methyl-CTP + 75% CTP/75%
5-Methoxy-UTP + 25% UTP 25% Pseudo-iso-CTP + 75% CTP/25%
5-Methoxy-UTP + 75% UTP 25% Pseudo-iso-CTP + 75% CTP/75%
5-Methoxy-UTP + 25% UTP 25% 5-Bromo-CTP/75% CTP/Pseudo-UTP 25%
5-methoxy-UTP/25% 5-methyl-CTP/ATP/GTP 25%
5-methoxy-UTP/5-methyl-CTP/ATP/GTP 25% 5-methoxy-UTP/75%
5-methyl-CTP/ATP/GTP 25% 5-methoxy-UTP/CTP/ATP/GTP 25%
5-metoxy-UTP/50% 5-methyl-CTP/ATP/GTP 2-Amino-ATP 2-Thio-CTP
2-thio-pseudouridine TP, ATP, GTP, CTP 2-Thio-pseudo-UTP 2-Thio-UTP
3-Methyl-CTP 3-Methyl-pseudo-UTP 4-Thio-UTP 50% 5-Bromo-CTP + 50%
CTP/1-Methyl-pseudo-UTP 50% 5-Hydroxymethyl-CTP + 50%
CTP/1-Methyl-pseudo-UTP 50% 5-methoxy-UTP/5-methyl-CTP/ATP/GTP 50%
5-Methyl-CTP + 50% CTP/25% 5-Methoxy-UTP + 75% 1-Methyl- pseudo-UTP
50% 5-Methyl-CTP + 50% CTP/25% 5-Methoxy-UTP + 75% UTP 50%
5-Methyl-CTP + 50% CTP/50% 5-Methoxy-UTP + 50% 1-Methyl- pseudo-UTP
50% 5-Methyl-CTP + 50% CTP/50% 5-Methoxy-UTP + 50% UTP 50%
5-Methyl-CTP + 50% CTP/5-Methoxy-UTP 50% 5-Methyl-CTP + 50% CTP/75%
5-Methoxy-UTP + 25% 1-Methyl- pseudo-UTP 50% 5-Methyl-CTP + 50%
CTP/75% 5-Methoxy-UTP + 25% UTP 50% 5-Trifluoromethyl-CTP + 50%
CTP/1-Methyl-pseudo-UTP 50% 5-Bromo-CTP/50% CTP/Pseudo-UTP 50%
5-methoxy-UTP/25% 5-methyl-CTP/ATP/GTP 50% 5-methoxy-UTP/50%
5-methyl-CTP/ATP/GTP 50% 5-methoxy-UTP/75% 5-methyl-CTP/ATP/GTP 50%
5-methoxy-UTP/CTP/ATP/GTP 5-Aminoallyl-CTP
5-Aminoallyl-CTP/5-Methoxy-UTP 5-Aminoallyl-UTP 5-Bromo-CTP
5-Bromo-CTP/5-Methoxy-UTP 5-Bromo-CTP/1-Methyl-pseudo-UTP
5-Bromo-CTP/Pseudo-UTP 5-bromocytidine TP, ATP, GTP, UTP
5-Bromo-UTP 5-Carboxy-CTP/5-Methoxy-UTP 5-Ethyl-CTP/5-Methoxy-UTP
5-Ethynyl-CTP/5-Methoxy-UTP 5-Fluoro-CTP/5-Methoxy-UTP
5-Formyl-CTP/5-Methoxy-UTP 5-Hydroxy-methyl-CTP/5-Methoxy-UTP
5-Hydroxymethyl-CTP 5-Hydroxymethyl-CTP/1-Methyl-pseudo-UTP
5-Hydroxymethyl-CTP/5-Methoxy-UTP 5-hydroxymethyl-cytidine TP, ATP,
GTP, UTP 5-Iodo-CTP/5-Methoxy-UTP 5-Me-CTP/5-Methoxy-UTP 5-Methoxy
carbonyl methyl-UTP 5-Methoxy-CTP/5-Methoxy-UTP 5-methoxy-uridine
TP, ATP, GTP, UTP 5-methoxy-UTP 5-Methoxy-UTP
5-Methoxy-UTP/N6-Isopentenyl-ATP 5-methoxy-UTP/25%
5-methyl-CTP/ATP/GTP 5-methoxy-UTP/5-methyl-CTP/ATP/GTP
5-methoxy-UTP/75% 5-methyl-CTP/ATP/GTP 5-methoxy-UTP/CTP/ATP/GTP
5-Methyl-2-thio-UTP 5-Methylaminomethyl-UTP
5-Methyl-CTP/5-Methoxy-UTP 5-Methyl-CTP/5-Methoxy-UTP(cap 0)
5-Methyl-CTP/5-Methoxy-UTP(No cap) 5-Methyl-CTP/25% 5-Methoxy-UTP +
75% 1-Methyl-pseudo-UTP 5-Methyl-CTP/25% 5-Methoxy-UTP + 75% UTP
5-Methyl-CTP/50% 5-Methoxy-UTP + 50% 1-Methyl-pseudo-UTP
5-Methyl-CTP/50% 5-Methoxy-UTP + 50% UTP
5-Methyl-CTP/5-Methoxy-UTP/N6-Me-ATP 5-Methyl-CTP/75% 5-Methoxy-UTP
+ 25% 1-Methyl-pseudo-UTP 5-Methyl-CTP/75% 5-Methoxy-UTP + 25% UTP
5-Phenyl-CTP/5-Methoxy-UTP 5-Trifluoro-methyl-CTP/5-Methoxy-UTP
5-Trifluoromethyl-CTP 5-Trifluoromethyl-CTP/5-Methoxy-UTP
5-Trifluoromethyl-CTP/1-Methyl-pseudo-UTP
5-Trifluoromethyl-CTP/Pseudo-UTP 5-Trifluoromethyl-UTP
5-trifluromethylcytidine TP, ATP, GTP, UTP 75% 5-Aminoallyl-CTP +
25% CTP/25% 5-Methoxy-UTP + 75% UTP 75% 5-Aminoallyl-CTP + 25%
CTP/75% 5-Methoxy-UTP + 25% UTP 75% 5-Bromo-CTP + 25% CTP/25%
5-Methoxy-UTP + 75% UTP 75% 5-Bromo-CTP + 25% CTP/75% 5-Methoxy-UTP
+ 25% UTP 75% 5-Carboxy-CTP + 25% CTP/25% 5-Methoxy-UTP + 75% UTP
75% 5-Carboxy-CTP + 25% CTP/75% 5-Methoxy-UTP + 25% UTP 75%
5-Ethyl-CTP + 25% CTP/25% 5-Methoxy-UTP + 75% UTP 75% 5-Ethyl-CTP +
25% CTP/75% 5-Methoxy-UTP + 25% UTP 75% 5-Ethynyl-CTP + 25% CTP/25%
5-Methoxy-UTP + 75% UTP 75% 5-Ethynyl-CTP + 25% CTP/75%
5-Methoxy-UTP + 25% UTP 75% 5-Fluoro-CTP + 25% CTP/25%
5-Methoxy-UTP + 75% UTP 75% 5-Fluoro-CTP + 25% CTP/75%
5-Methoxy-UTP + 25% UTP 75% 5-Formyl-CTP + 25% CTP/25%
5-Methoxy-UTP + 75% UTP 75% 5-Formyl-CTP + 25% CTP/75%
5-Methoxy-UTP + 25% UTP 75% 5-Hydroxymethyl-CTP + 25% CTP/25%
5-Methoxy-UTP + 75% UTP 75% 5-Hydroxymethyl-CTP + 25% CTP/75%
5-Methoxy-UTP + 25% UTP 75% 5-Iodo-CTP + 25% CTP/25% 5-Methoxy-UTP
+ 75% UTP 75% 5-Iodo-CTP + 25% CTP/75% 5-Methoxy-UTP + 25% UTP 75%
5-Methoxy-CTP + 25% CTP/25% 5-Methoxy-UTP + 75% UTP 75%
5-Methoxy-CTP + 25% CTP/75% 5-Methoxy-UTP + 25% UTP 75%
5-methoxy-UTP/5-methyl-CTP/ATP/GTP 75% 5-Methyl-CTP + 25% CTP/25%
5-Methoxy-UTP + 75% 1-Methyl- pseudo-UTP 75% 5-Methyl-CTP + 25%
CTP/25% 5-Methoxy-UTP + 75% UTP 75% 5-Methyl-CTP + 25% CTP/50%
5-Methoxy-UTP + 50% 1-Methyl- pseudo-UTP 75% 5-Methyl-CTP + 25%
CTP/50% 5-Methoxy-UTP + 50% UTP 75% 5-Methyl-CTP + 25%
CTP/5-Methoxy-UTP 75% 5-Methyl-CTP + 25% CTP/75% 5-Methoxy-UTP +
25% 1-Methyl- pseudo-UTP 75% 5-Methyl-CTP + 25% CTP/75%
5-Methoxy-UTP + 25% UTP 75% 5-Phenyl-CTP + 25% CTP/25%
5-Methoxy-UTP + 75% UTP 75% 5-Phenyl-CTP + 25% CTP/75%
5-Methoxy-UTP + 25% UTP 75% 5-Trifluoromethyl-CTP + 25% CTP/25%
5-Methoxy-UTP + 75% UTP 75% 5-Trifluoromethyl-CTP + 25% CTP/75%
5-Methoxy-UTP + 25% UTP 75% 5-Trifluoromethyl-CTP + 25%
CTP/1-Methyl-pseudo-UTP 75% N4-Ac-CTP + 25% CTP/25% 5-Methoxy-UTP +
75% UTP 75% N4-Ac-CTP + 25% CTP/75% 5-Methoxy-UTP + 25% UTP 75%
N4-Bz-CTP + 25% CTP/25% 5-Methoxy-UTP + 75% UTP 75% N4-Bz-CTP + 25%
CTP/75% 5-Methoxy-UTP + 25% UTP 75% N4-Methyl-CTP + 25% CTP/25%
5-Methoxy-UTP + 75% UTP 75% N4-Methyl-CTP + 25% CTP/75%
5-Methoxy-UTP + 25% UTP 75% Pseudo-iso-CTP + 25% CTP/25%
5-Methoxy-UTP + 75% UTP 75% Pseudo-iso-CTP + 25% CTP/75%
5-Methoxy-UTP + 25% UTP 75% 5-Bromo-CTP/25% CTP/1-Methyl-pseudo-UTP
75% 5-Bromo-CTP/25% CTP/Pseudo-UTP 75% 5-methoxy-UTP/25%
5-methyl-CTP/ATP/GTP 75% 5-methoxy-UTP/50% 5-methyl-CTP/ATP/GTP 75%
5-methoxy-UTP/75% 5-methyl-CTP/ATP/GTP 75%
5-methoxy-UTP/CTP/ATP/GTP 8-Aza-ATP Alpha-thio-CTP CTP/25%
5-Methoxy-UTP + 75% 1-Methyl-pseudo-UTP CTP/25% 5-Methoxy-UTP + 75%
UTP CTP/50% 5-Methoxy-UTP + 50% 1-Methyl-pseudo-UTP CTP/50%
5-Methoxy-UTP + 50% UTP CTP/5-Methoxy-UTP CTP/5-Methoxy-UTP (cap 0)
CTP/5-Methoxy-UTP(No cap) CTP/75% 5-Methoxy-UTP + 25%
1-Methyl-pseudo-UTP CTP/75% 5-Methoxy-UTP + 25% UTP CTP/UTP(No cap)
N1-Me-GTP N4-Ac-CTP N4Ac-CTP/1-Methyl-pseudo-UTP
N4Ac-CTP/5-Methoxy-UTP N4-acetyl-cytidine TP, ATP, GTP, UTP
N4-Bz-CTP/5-Methoxy-UTP N4-methyl CTP N4-Methyl-CTP/5-Methoxy-UTP
Pseudo-iso-CTP/5-Methoxy-UTP PseudoU-alpha-thio-TP pseudouridine
TP, ATP, GTP, CTP pseudo-UTP/5-methyl-CTP/ATP/GTP UTP-5-oxyacetic
acid Me ester Xanthosine
[0376] According to the disclosure, polynucleotides of the
disclosure may be synthesized to comprise the combinations or
single modifications of Table 1 or Table 2.
[0377] Where a single modification is listed, the listed nucleoside
or nucleotide represents 100 percent of that A, U, G or C
nucleotide or nucleoside having been modified. Where percentages
are listed, these represent the percentage of that particular A, U,
G or C nucleobase triphosphate of the total amount of A, U, G, or C
triphosphate present. For example, the combination: 25%
5-Aminoallyl-CTP+75% CTP/25% 5-Methoxy-UTP+75% UTP refers to a
polynucleotide where 25% of the cytosine triphosphates are
5-Aminoallyl-CTP while 75% of the cytosines are CTP; whereas 25% of
the uracils are 5-methoxy UTP while 75% of the uracils are UTP.
Where no modified UTP is listed then the naturally occurring ATP,
UTP, GTP and/or CTP is used at 100% of the sites of those
nucleotides found in the polynucleotide. In this example all of the
GTP and ATP nucleotides are left unmodified.
[0378] The mRNAs of the present disclosure, or regions thereof, may
be codon optimized. Codon optimization methods are known in the art
and may be useful for a variety of purposes: matching codon
frequencies in host organisms to ensure proper folding, bias GC
content to increase mRNA stability or reduce secondary structures,
minimize tandem repeat codons or base runs that may impair gene
construction or expression, customize transcriptional and
translational control regions, insert or remove proteins
trafficking sequences, remove/add post translation modification
sites in encoded proteins (e.g., glycosylation sites), add, remove
or shuffle protein domains, insert or delete restriction sites,
modify ribosome binding sites and mRNA degradation sites, adjust
translation rates to allow the various domains of the protein to
fold properly, or to reduce or eliminate problem secondary
structures within the polynucleotide. Codon optimization tools,
algorithms and services are known in the art; non-limiting examples
include services from GeneArt (Life Technologies), DNA2.0 (Menlo
Park, Calif.) and/or proprietary methods. In one embodiment, the
mRNA sequence is optimized using optimization algorithms, e.g., to
optimize expression in mammalian cells or enhance mRNA
stability.
[0379] In certain embodiments, the present disclosure includes
polynucleotides having at least 80%, at least 85%, at least 90%, at
least 95%, at least 98%, or at least 99% sequence identity to any
of the polynucleotide sequences described herein.
[0380] mRNAs of the present disclosure may be produced by means
available in the art, including but not limited to in vitro
transcription (IVT) and synthetic methods. Enzymatic (IVT),
solid-phase, liquid-phase, combined synthetic methods, small region
synthesis, and ligation methods may be utilized. In one embodiment,
mRNAs are made using IVT enzymatic synthesis methods. Methods of
making polynucleotides by IVT are known in the art and are
described in International Application PCT/US2013/30062, the
contents of which are incorporated herein by reference in their
entirety. Accordingly, the present disclosure also includes
polynucleotides, e.g., DNA, constructs and vectors that may be used
to in vitro transcribe an mRNA described herein.
[0381] Non-natural modified nucleobases may be introduced into
polynucleotides, e.g., mRNA, during synthesis or post-synthesis. In
certain embodiments, modifications may be on internucleoside
linkages, purine or pyrimidine bases, or sugar. In particular
embodiments, the modification may be introduced at the terminal of
a polynucleotide chain or anywhere else in the polynucleotide
chain; with chemical synthesis or with a polymerase enzyme.
Examples of modified nucleic acids and their synthesis are
disclosed in PCT application No. PCT/US2012/058519. Synthesis of
modified polynucleotides is also described in Verma and Eckstein,
Annual Review of Biochemistry, vol. 76, 99-134 (1998).
[0382] Either enzymatic or chemical ligation methods may be used to
conjugate polynucleotides or their regions with different
functional moieties, such as targeting or delivery agents,
fluorescent labels, liquids, nanoparticles, etc. Conjugates of
polynucleotides and modified polynucleotides are reviewed in
Goodchild, Bioconjugate Chemistry, vol. 1(3), 165-187 (1990).
MicroRNA (miRNA) Binding Sites
[0383] Polynucleotides of the disclosure can include regulatory
elements, for example, microRNA (miRNA) binding sites,
transcription factor binding sites, structured mRNA sequences
and/or motifs, artificial binding sites engineered to act as
pseudo-receptors for endogenous nucleic acid binding molecules, and
combinations thereof. In some embodiments, polynucleotides
including such regulatory elements are referred to as including
"sensor sequences." Non-limiting examples of sensor sequences are
described in U.S. Publication 2014/0200261, the contents of which
are incorporated herein by reference in their entirety.
[0384] In some embodiments, a polynucleotide (e.g., a ribonucleic
acid (RNA), e.g., a messenger RNA (mRNA)) of the disclosure
comprises an open reading frame (ORF) encoding a polypeptide of
interest and further comprises one or more miRNA binding site(s).
Inclusion or incorporation of miRNA binding site(s) provides for
regulation of polynucleotides of the disclosure, and in turn, of
the polypeptides encoded therefrom, based on tissue-specific and/or
cell-type specific expression of naturally-occurring miRNAs.
[0385] A miRNA, e.g., a natural-occurring miRNA, is a 19-25
nucleotide long noncoding RNA that binds to a polynucleotide and
down-regulates gene expression either by reducing stability or by
inhibiting translation of the polynucleotide. A miRNA sequence
comprises a "seed" region, i.e., a sequence in the region of
positions 2-8 of the mature miRNA. A miRNA seed can comprise
positions 2-8 or 2-7 of the mature miRNA. In some embodiments, a
miRNA seed can comprise 7 nucleotides (e.g., nucleotides 2-8 of the
mature miRNA), wherein the seed-complementary site in the
corresponding miRNA binding site is flanked by an adenosine (A)
opposed to miRNA position 1. In some embodiments, a miRNA seed can
comprise 6 nucleotides (e.g., nucleotides 2-7 of the mature miRNA),
wherein the seed-complementary site in the corresponding miRNA
binding site is flanked by an adenosine (A) opposed to miRNA
position 1. See, for example, Grimson A, Farh K K, Johnston W K,
Garrett-Engele P, Lim L P, Bartel D P; Mol Cell. 2007 Jul. 6;
27(1):91-105. miRNA profiling of the target cells or tissues can be
conducted to determine the presence or absence of miRNA in the
cells or tissues. In some embodiments, a polynucleotide (e.g., a
ribonucleic acid (RNA), e.g., a messenger RNA (mRNA)) of the
disclosure comprises one or more microRNA binding sites, microRNA
target sequences, microRNA complementary sequences, or microRNA
seed complementary sequences. Such sequences can correspond to,
e.g., have complementarity to, any known microRNA such as those
taught in US Publication US2005/0261218 and US Publication
US2005/0059005, the contents of each of which are incorporated
herein by reference in their entirety.
[0386] As used herein, the term "microRNA (miRNA or miR) binding
site" refers to a sequence within a polynucleotide, e.g., within a
DNA or within an RNA transcript, including in the 5'UTR and/or
3'UTR, that has sufficient complementarity to all or a region of a
miRNA to interact with, associate with or bind to the miRNA. In
some embodiments, a polynucleotide of the disclosure comprising an
ORF encoding a polypeptide of interest and further comprises one or
more miRNA binding site(s). In exemplary embodiments, a 5'UTR
and/or 3'UTR of the polynucleotide (e.g., a ribonucleic acid (RNA),
e.g., a messenger RNA (mRNA)) comprises the one or more miRNA
binding site(s).
[0387] A miRNA binding site having sufficient complementarity to a
miRNA refers to a degree of complementarity sufficient to
facilitate miRNA-mediated regulation of a polynucleotide, e.g.,
miRNA-mediated translational repression or degradation of the
polynucleotide. In exemplary aspects of the disclosure, a miRNA
binding site having sufficient complementarity to the miRNA refers
to a degree of complementarity sufficient to facilitate
miRNA-mediated degradation of the polynucleotide, e.g.,
miRNA-guided RNA-induced silencing complex (RISC)-mediated cleavage
of mRNA. The miRNA binding site can have complementarity to, for
example, a 19-25 nucleotide miRNA sequence, to a 19-23 nucleotide
miRNA sequence, or to a 22 nucleotide miRNA sequence. A miRNA
binding site can be complementary to only a portion of a miRNA,
e.g., to a portion less than 1, 2, 3, or 4 nucleotides of the full
length of a naturally-occurring miRNA sequence. Full or complete
complementarity (e.g., full complementarity or complete
complementarity over all or a significant portion of the length of
a naturally-occurring miRNA) is preferred when the desired
regulation is mRNA degradation.
[0388] In some embodiments, a miRNA binding site includes a
sequence that has complementarity (e.g., partial or complete
complementarity) with a miRNA seed sequence. In some embodiments,
the miRNA binding site includes a sequence that has complete
complementarity with a miRNA seed sequence. In some embodiments, a
miRNA binding site includes a sequence that has complementarity
(e.g., partial or complete complementarity) with an miRNA sequence.
In some embodiments, the miRNA binding site includes a sequence
that has complete complementarity with a miRNA sequence. In some
embodiments, a miRNA binding site has complete complementarity with
a miRNA sequence but for 1, 2, or 3 nucleotide substitutions,
terminal additions, and/or truncations.
[0389] In some embodiments, the miRNA binding site is the same
length as the corresponding miRNA. In other embodiments, the miRNA
binding site is one, two, three, four, five, six, seven, eight,
nine, ten, eleven or twelve nucleotide(s) shorter than the
corresponding miRNA at the 5' terminus, the 3' terminus, or both.
In still other embodiments, the microRNA binding site is two
nucleotides shorter than the corresponding microRNA at the 5'
terminus, the 3' terminus, or both. The miRNA binding sites that
are shorter than the corresponding miRNAs are still capable of
degrading the mRNA incorporating one or more of the miRNA binding
sites or preventing the mRNA from translation.
[0390] In some embodiments, the miRNA binding site binds the
corresponding mature miRNA that is part of an active RISC
containing Dicer. In another embodiment, binding of the miRNA
binding site to the corresponding miRNA in RISC degrades the mRNA
containing the miRNA binding site or prevents the mRNA from being
translated. In some embodiments, the miRNA binding site has
sufficient complementarity to miRNA so that a RISC complex
comprising the miRNA cleaves the polynucleotide comprising the
miRNA binding site. In other embodiments, the miRNA binding site
has imperfect complementarity so that a RISC complex comprising the
miRNA induces instability in the polynucleotide comprising the
miRNA binding site. In another embodiment, the miRNA binding site
has imperfect complementarity so that a RISC complex comprising the
miRNA represses transcription of the polynucleotide comprising the
miRNA binding site.
[0391] In some embodiments, the miRNA binding site has one, two,
three, four, five, six, seven, eight, nine, ten, eleven or twelve
mismatch(es) from the corresponding miRNA.
[0392] In some embodiments, the miRNA binding site has at least
about ten, at least about eleven, at least about twelve, at least
about thirteen, at least about fourteen, at least about fifteen, at
least about sixteen, at least about seventeen, at least about
eighteen, at least about nineteen, at least about twenty, or at
least about twenty-one contiguous nucleotides complementary to at
least about ten, at least about eleven, at least about twelve, at
least about thirteen, at least about fourteen, at least about
fifteen, at least about sixteen, at least about seventeen, at least
about eighteen, at least about nineteen, at least about twenty, or
at least about twenty-one, respectively, contiguous nucleotides of
the corresponding miRNA.
[0393] By engineering one or more miRNA binding sites into a
polynucleotide of the disclosure, the polynucleotide can be
targeted for degradation or reduced translation, provided the miRNA
in question is available. This can reduce off-target effects upon
delivery of the polynucleotide. For example, if a polynucleotide of
the disclosure is not intended to be delivered to a tissue or cell
but ends up is said tissue or cell, then a miRNA abundant in the
tissue or cell can inhibit the expression of the gene of interest
if one or multiple binding sites of the miRNA are engineered into
the 5'UTR and/or 3'UTR of the polynucleotide.
[0394] Conversely, miRNA binding sites can be removed from
polynucleotide sequences in which they naturally occur in order to
increase protein expression in specific tissues. For example, a
binding site for a specific miRNA can be removed from a
polynucleotide to improve protein expression in tissues or cells
containing the miRNA.
[0395] In one embodiment, a polynucleotide of the disclosure can
include at least one miRNA-binding site in the 5'UTR and/or 3'UTR
in order to regulate cytotoxic or cytoprotective mRNA therapeutics
to specific cells such as, but not limited to, normal and/or
cancerous cells. In another embodiment, a polynucleotide of the
disclosure can include two, three, four, five, six, seven, eight,
nine, ten, or more miRNA-binding sites in the 5'-UTR and/or 3'-UTR
in order to regulate cytotoxic or cytoprotective mRNA therapeutics
to specific cells such as, but not limited to, normal and/or
cancerous cells.
[0396] Regulation of expression in multiple tissues can be
accomplished through introduction or removal of one or more miRNA
binding sites, e.g., one or more distinct miRNA binding sites. The
decision whether to remove or insert a miRNA binding site can be
made based on miRNA expression patterns and/or their profilings in
tissues and/or cells in development and/or disease. Identification
of miRNAs, miRNA binding sites, and their expression patterns and
role in biology have been reported (e.g., Bonauer et al., Curr Drug
Targets 2010 11:943-949; Anand and Cheresh Curr Opin Hematol 2011
18:171-176; Contreras and Rao Leukemia 2012 26:404-413 (2011 Dec.
20. doi: 10.1038/leu.2011.356); Bartel Cell 2009 136:215-233;
Landgraf et al, Cell, 2007 129:1401-1414; Gentner and Naldini,
Tissue Antigens. 2012 80:393-403 and all references therein; each
of which is incorporated herein by reference in its entirety).
[0397] miRNAs and miRNA binding sites can correspond to any known
sequence, including non-limiting examples described in U.S.
Publication Nos. 2014/0200261, 2005/0261218, and 2005/0059005, each
of which are incorporated herein by reference in their
entirety.
[0398] Examples of tissues where miRNA are known to regulate mRNA,
and thereby protein expression, include, but are not limited to,
liver (miR-122), muscle (miR-133, miR-206, miR-208), endothelial
cells (miR-17-92, miR-126), myeloid cells (miR-142-3p, miR-142-5p,
miR-16, miR-21, miR-223, miR-24, miR-27), adipose tissue (let-7,
miR-30c), heart (miR-1d, miR-149), kidney (miR-192, miR-194,
miR-204), and lung epithelial cells (let-7, miR-133, miR-126).
[0399] Specifically, miRNAs are known to be differentially
expressed in immune cells (also called hematopoietic cells), such
as antigen presenting cells (APCs) (e.g., dendritic cells and
macrophages), macrophages, monocytes, B lymphocytes, T lymphocytes,
granulocytes, natural killer cells, etc. Immune cell specific
miRNAs are involved in immunogenicity, autoimmunity, the immune
response to infection, inflammation, as well as unwanted immune
response after gene therapy and tissue/organ transplantation.
Immune cell specific miRNAs also regulate many aspects of
development, proliferation, differentiation and apoptosis of
hematopoietic cells (immune cells). For example, miR-142 and
miR-146 are exclusively expressed in immune cells, particularly
abundant in myeloid dendritic cells. It has been demonstrated that
the immune response to a polynucleotide can be shut-off by adding
miR-142 binding sites to the 3'-UTR of the polynucleotide, enabling
more stable gene transfer in tissues and cells. miR-142 efficiently
degrades exogenous polynucleotides in antigen presenting cells and
suppresses cytotoxic elimination of transduced cells (e.g., Annoni
A et al., blood, 2009, 114, 5152-5161; Brown B D, et al., Nat med.
2006, 12(5), 585-591; Brown B D, et al., blood, 2007, 110(13):
4144-4152, each of which is incorporated herein by reference in its
entirety).
[0400] An antigen-mediated immune response can refer to an immune
response triggered by foreign antigens, which, when entering an
organism, are processed by the antigen presenting cells and
displayed on the surface of the antigen presenting cells. T cells
can recognize the presented antigen and induce a cytotoxic
elimination of cells that express the antigen.
[0401] Introducing a miR-142 binding site into the 5'UTR and/or
3'UTR of a polynucleotide of the disclosure can selectively repress
gene expression in antigen presenting cells through miR-142
mediated degradation, limiting antigen presentation in antigen
presenting cells (e.g., dendritic cells) and thereby preventing
antigen-mediated immune response after the delivery of the
polynucleotide. The polynucleotide is then stably expressed in
target tissues or cells without triggering cytotoxic
elimination.
[0402] In one embodiment, binding sites for miRNAs that are known
to be expressed in immune cells, in particular, antigen presenting
cells, can be engineered into a polynucleotide of the disclosure to
suppress the expression of the polynucleotide in antigen presenting
cells through miRNA mediated RNA degradation, subduing the
antigen-mediated immune response. Expression of the polynucleotide
is maintained in non-immune cells where the immune cell specific
miRNAs are not expressed. For example, in some embodiments, to
prevent an immunogenic reaction against a liver specific protein,
any miR-122 binding site can be removed and a miR-142 (and/or
mirR-146) binding site can be engineered into the 5'UTR and/or
3'UTR of a polynucleotide of the disclosure.
[0403] To further drive the selective degradation and suppression
in APCs and macrophage, a polynucleotide of the disclosure can
include a further negative regulatory element in the 5'UTR and/or
3'UTR, either alone or in combination with miR-142 and/or miR-146
binding sites. As a non-limiting example, the further negative
regulatory element is a Constitutive Decay Element (CDE).
[0404] Immune cell specific miRNAs include, but are not limited to,
hsa-let-7a-2-3p, hsa-let-7a-3p, hsa-7a-5p, hsa-let-7c,
hsa-let-7e-3p, hsa-let-7e-5p, hsa-let-7g-3p, hsa-let-7g-5p,
hsa-let-7i-3p, hsa-let-7i-5p, miR-10a-3p, miR-10a-5p, miR-1184,
hsa-let-7f-1-3p, hsa-let-7f-2-5p, hsa-let-7f-5p, miR-125b-1-3p,
miR-125b-2-3p, miR-125b-5p, miR-1279, miR-130a-3p, miR-130a-5p,
miR-132-3p, miR-132-5p, miR-142-3p, miR-142-5p, miR-143-3p,
miR-143-5p, miR-146a-3p, miR-146a-5p, miR-146b-3p, miR-146b-5p,
miR-147a, miR-147b, miR-148a-5p, miR-148a-3p, miR-150-3p,
miR-150-5p, miR-151b, miR-155-3p, miR-155-5p, miR-15a-3p,
miR-15a-5p, miR-15b-5p, miR-15b-3p, miR-16-1-3p, miR-16-2-3p,
miR-16-5p, miR-17-5p, miR-181a-3p, miR-181a-5p, miR-181a-2-3p,
miR-182-3p, miR-182-5p, miR-197-3p, miR-197-5p, miR-21-5p,
miR-21-3p, miR-214-3p, miR-214-5p, miR-223-3p, miR-223-5p,
miR-221-3p, miR-221-5p, miR-23b-3p, miR-23b-5p, miR-24-1-5p,
miR-24-2-5p, miR-24-3p, miR-26a-1-3p, miR-26a-2-3p, miR-26a-5p,
miR-26b-3p, miR-26b-5p, miR-27a-3p, miR-27a-5p, miR-27b-3p,
miR-27b-5p, miR-28-3p, miR-28-5p, miR-2909, miR-29a-3p, miR-29a-5p,
miR-29b-1-5p, miR-29b-2-5p, miR-29c-3p, miR-29c-5p, miR-30e-3p,
miR-30e-5p, miR-331-5p, miR-339-3p, miR-339-5p, miR-345-3p,
miR-345-5p, miR-346, miR-34a-3p, miR-34a-5p, miR-363-3p,
miR-363-5p, miR-372, miR-377-3p, miR-377-5p, miR-493-3p,
miR-493-5p, miR-542, miR-548b-5p, miR548c-5p, miR-548i, miR-548j,
miR-548n, miR-574-3p, miR-598, miR-718, miR-935, miR-99a-3p,
miR-99a-5p, miR-99b-3p, and miR-99b-5p. Furthermore, novel miRNAs
can be identified in immune cell through micro-array hybridization
and microtome analysis (e.g., Jima D D et al, Blood, 2010,
116:e118-e127; Vaz C et al., BMC Genomics, 2010, 11, 288, the
content of each of which is incorporated herein by reference in its
entirety.)
[0405] miRNAs that are known to be expressed in the liver include,
but are not limited to, miR-107, miR-122-3p, miR-122-5p,
miR-1228-3p, miR-1228-5p, miR-1249, miR-129-5p, miR-1303,
miR-151a-3p, miR-151a-5p, miR-152, miR-194-3p, miR-194-5p,
miR-199a-3p, miR-199a-5p, miR-199b-3p, miR-199b-5p, miR-296-5p,
miR-557, miR-581, miR-939-3p, and miR-939-5p. miRNA binding sites
from any liver specific miRNA can be introduced to or removed from
a polynucleotide of the disclosure to regulate expression of the
polynucleotide in the liver. Liver specific miRNA binding sites can
be engineered alone or further in combination with immune cell
(e.g., APC) miRNA binding sites in a polynucleotide of the
disclosure.
[0406] miRNAs that are known to be expressed in the lung include,
but are not limited to, let-7a-2-3p, let-7a-3p, let-7a-5p,
miR-126-3p, miR-126-5p, miR-127-3p, miR-127-5p, miR-130a-3p,
miR-130a-5p, miR-130b-3p, miR-130b-5p, miR-133a, miR-133b, miR-134,
miR-18a-3p, miR-18a-5p, miR-18b-3p, miR-18b-5p, miR-24-1-5p,
miR-24-2-5p, miR-24-3p, miR-296-3p, miR-296-5p, miR-32-3p,
miR-337-3p, miR-337-5p, miR-381-3p, and miR-381-5p. miRNA binding
sites from any lung specific miRNA can be introduced to or removed
from a polynucleotide of the disclosure to regulate expression of
the polynucleotide in the lung. Lung specific miRNA binding sites
can be engineered alone or further in combination with immune cell
(e.g., APC) miRNA binding sites in a polynucleotide of the
disclosure.
[0407] miRNAs that are known to be expressed in the heart include,
but are not limited to, miR-1, miR-133a, miR-133b, miR-149-3p,
miR-149-5p, miR-186-3p, miR-186-5p, miR-208a, miR-208b, miR-210,
miR-296-3p, miR-320, miR-451a, miR-451b, miR-499a-3p, miR-499a-5p,
miR-499b-3p, miR-499b-5p, miR-744-3p, miR-744-5p, miR-92b-3p, and
miR-92b-5p. miRNA binding sites from any heart specific microRNA
can be introduced to or removed from a polynucleotide of the
disclosure to regulate expression of the polynucleotide in the
heart. Heart specific miRNA binding sites can be engineered alone
or further in combination with immune cell (e.g., APC) miRNA
binding sites in a polynucleotide of the disclosure.
[0408] miRNAs that are known to be expressed in the nervous system
include, but are not limited to, miR-124-5p, miR-125a-3p,
miR-125a-5p, miR-125b-1-3p, miR-125b-2-3p, miR-125b-5p,
miR-1271-3p, miR-1271-5p, miR-128, miR-132-5p, miR-135a-3p,
miR-135a-5p, miR-135b-3p, miR-135b-5p, miR-137, miR-139-5p,
miR-139-3p, miR-149-3p, miR-149-5p, miR-153, miR-181c-3p,
miR-181c-5p, miR-183-3p, miR-183-5p, miR-190a, miR-190b,
miR-212-3p, miR-212-5p, miR-219-1-3p, miR-219-2-3p, miR-23a-3p,
miR-23a-5p, miR-30a-5p, miR-30b-3p, miR-30b-5p, miR-30c-1-3p,
miR-30c-2-3p, miR-30c-5p, miR-30d-3p, miR-30d-5p, miR-329,
miR-342-3p, miR-3665, miR-3666, miR-380-3p, miR-380-5p, miR-383,
miR-410, miR-425-3p, miR-425-5p, miR-454-3p, miR-454-5p, miR-483,
miR-510, miR-516a-3p, miR-548b-5p, miR-548c-5p, miR-571,
miR-7-1-3p, miR-7-2-3p, miR-7-5p, miR-802, miR-922, miR-9-3p, and
miR-9-5p. miRNAs enriched in the nervous system further include
those specifically expressed in neurons, including, but not limited
to, miR-132-3p, miR-132-3p, miR-148b-3p, miR-148b-5p, miR-151a-3p,
miR-151a-5p, miR-212-3p, miR-212-5p, miR-320b, miR-320e,
miR-323a-3p, miR-323a-5p, miR-324-5p, miR-325, miR-326, miR-328,
miR-922 and those specifically expressed in glial cells, including,
but not limited to, miR-1250, miR-219-1-3p, miR-219-2-3p,
miR-219-5p, miR-23a-3p, miR-23a-5p, miR-3065-3p, miR-3065-5p,
miR-30e-3p, miR-30e-5p, miR-32-5p, miR-338-5p, and miR-657. miRNA
binding sites from any CNS specific miRNA can be introduced to or
removed from a polynucleotide of the disclosure to regulate
expression of the polynucleotide in the nervous system. Nervous
system specific miRNA binding sites can be engineered alone or
further in combination with immune cell (e.g., APC) miRNA binding
sites in a polynucleotide of the disclosure.
[0409] miRNAs that are known to be expressed in the pancreas
include, but are not limited to, miR-105-3p, miR-105-5p, miR-184,
miR-195-3p, miR-195-5p, miR-196a-3p, miR-196a-5p, miR-214-3p,
miR-214-5p, miR-216a-3p, miR-216a-5p, miR-30a-3p, miR-33a-3p,
miR-33a-5p, miR-375, miR-7-1-3p, miR-7-2-3p, miR-493-3p,
miR-493-5p, and miR-944. miRNA binding sites from any pancreas
specific miRNA can be introduced to or removed from a
polynucleotide of the disclosure to regulate expression of the
polynucleotide in the pancreas. Pancreas specific miRNA binding
sites can be engineered alone or further in combination with immune
cell (e.g. APC) miRNA binding sites in a polynucleotide of the
disclosure.
[0410] miRNAs that are known to be expressed in the kidney include,
but are not limited to, miR-122-3p, miR-145-5p, miR-17-5p,
miR-192-3p, miR-192-5p, miR-194-3p, miR-194-5p, miR-20a-3p,
miR-20a-5p, miR-204-3p, miR-204-5p, miR-210, miR-216a-3p,
miR-216a-5p, miR-296-3p, miR-30a-3p, miR-30a-5p, miR-30b-3p,
miR-30b-5p, miR-30c-1-3p, miR-30c-2-3p, miR30c-5p, miR-324-3p,
miR-335-3p, miR-335-5p, miR-363-3p, miR-363-5p, and miR-562. miRNA
binding sites from any kidney specific miRNA can be introduced to
or removed from a polynucleotide of the disclosure to regulate
expression of the polynucleotide in the kidney. Kidney specific
miRNA binding sites can be engineered alone or further in
combination with immune cell (e.g., APC) miRNA binding sites in a
polynucleotide of the disclosure.
[0411] miRNAs that are known to be expressed in the muscle include,
but are not limited to, let-7g-3p, let-7g-5p, miR-1, miR-1286,
miR-133a, miR-133b, miR-140-3p, miR-143-3p, miR-143-5p, miR-145-3p,
miR-145-5p, miR-188-3p, miR-188-5p, miR-206, miR-208a, miR-208b,
miR-25-3p, and miR-25-5p. miRNA binding sites from any muscle
specific miRNA can be introduced to or removed from a
polynucleotide of the disclosure to regulate expression of the
polynucleotide in the muscle. Muscle specific miRNA binding sites
can be engineered alone or further in combination with immune cell
(e.g., APC) miRNA binding sites in a polynucleotide of the
disclosure.
[0412] miRNAs are also differentially expressed in different types
of cells, such as, but not limited to, endothelial cells,
epithelial cells, and adipocytes.
[0413] miRNAs that are known to be expressed in endothelial cells
include, but are not limited to, let-7b-3p, let-7b-5p, miR-100-3p,
miR-100-5p, miR-101-3p, miR-101-5p, miR-126-3p, miR-126-5p,
miR-1236-3p, miR-1236-5p, miR-130a-3p, miR-130a-5p, miR-17-5p,
miR-17-3p, miR-18a-3p, miR-18a-5p, miR-19a-3p, miR-19a-5p,
miR-19b-1-5p, miR-19b-2-5p, miR-19b-3p, miR-20a-3p, miR-20a-5p,
miR-217, miR-210, miR-21-3p, miR-21-5p, miR-221-3p, miR-221-5p,
miR-222-3p, miR-222-5p, miR-23a-3p, miR-23a-5p, miR-296-5p,
miR-361-3p, miR-361-5p, miR-421, miR-424-3p, miR-424-5p,
miR-513a-5p, miR-92a-1-5p, miR-92a-2-5p, miR-92a-3p, miR-92b-3p,
and miR-92b-5p. Many novel miRNAs are discovered in endothelial
cells from deep-sequencing analysis (e.g., Voellenkle C et al.,
RNA, 2012, 18, 472-484, incorporated herein by reference in its
entirety). miRNA binding sites from any endothelial cell specific
miRNA can be introduced to or removed from a polynucleotide of the
disclosure to regulate expression of the polynucleotide in the
endothelial cells.
[0414] miRNAs that are known to be expressed in epithelial cells
include, but are not limited to, let-7b-3p, let-7b-5p, miR-1246,
miR-200a-3p, miR-200a-5p, miR-200b-3p, miR-200b-5p, miR-200c-3p,
miR-200c-5p, miR-338-3p, miR-429, miR-451a, miR-451b, miR-494,
miR-802 and miR-34a, miR-34b-5p, miR-34c-5p, miR-449a, miR-449b-3p,
miR-449b-5p specific in respiratory ciliated epithelial cells,
let-7 family, miR-133a, miR-133b, miR-126 specific in lung
epithelial cells, miR-382-3p, miR-382-5p specific in renal
epithelial cells, and miR-762 specific in corneal epithelial cells.
miRNA binding sites from any epithelial cell specific miRNA can be
introduced to or removed from a polynucleotide of the disclosure to
regulate expression of the polynucleotide in the epithelial
cells.
[0415] In addition, a large group of miRNAs are enriched in
embryonic stem cells, controlling stem cell self-renewal as well as
the development and/or differentiation of various cell lineages,
such as neural cells, cardiac, hematopoietic cells, skin cells,
osteogenic cells and muscle cells (e.g., Kuppusamy K T et al.,
Curr. Mol Med, 2013, 13(5), 757-764; Vidigal J A and Ventura A,
Semin Cancer Biol. 2012, 22(5-6), 428-436; Goff L A et al., PLoS
One, 2009, 4:e7192; Morin R D et al., Genome Res, 2008, 18,
610-621; Yoo J K et al., Stem Cells Dev. 2012, 21(11), 2049-2057,
each of which is incorporated herein by reference in its entirety).
miRNAs abundant in embryonic stem cells include, but are not
limited to, let-7a-2-3p, let-a-3p, let-7a-5p, let7d-3p, let-7d-5p,
miR-103a-2-3p, miR-103a-5p, miR-106b-3p, miR-106b-5p, miR-1246,
miR-1275, miR-138-1-3p, miR-138-2-3p, miR-138-5p, miR-154-3p,
miR-154-5p, miR-200c-3p, miR-200c-5p, miR-290, miR-301a-3p,
miR-301a-5p, miR-302a-3p, miR-302a-5p, miR-302b-3p, miR-302b-5p,
miR-302c-3p, miR-302c-5p, miR-302d-3p, miR-302d-5p, miR-302e,
miR-367-3p, miR-367-5p, miR-369-3p, miR-369-5p, miR-370, miR-371,
miR-373, miR-380-5p, miR-423-3p, miR-423-5p, miR-486-5p,
miR-520c-3p, miR-548e, miR-548f, miR-548g-3p, miR-548g-5p,
miR-548i, miR-548k, miR-5481, miR-548m, miR-548n, miR-548o-3p,
miR-548o-5p, miR-548p, miR-664a-3p, miR-664a-5p, miR-664b-3p,
miR-664b-5p, miR-766-3p, miR-766-5p, miR-885-3p, miR-885-5p,
miR-93-3p, miR-93-5p, miR-941, miR-96-3p, miR-96-5p, miR-99b-3p and
miR-99b-5p. Many predicted novel miRNAs are discovered by deep
sequencing in human embryonic stem cells (e.g., Morin R D et al.,
Genome Res, 2008, 18, 610-621; Goff L A et al., PLoS One, 2009,
4:e7192; Bar M et al., Stem cells, 2008, 26, 2496-2505, the content
of each of which is incorporated herein by reference in its
entirety).
[0416] In one embodiment, the binding sites of embryonic stem cell
specific miRNAs can be included in or removed from the 3'UTR of a
polynucleotide of the disclosure to modulate the development and/or
differentiation of embryonic stem cells, to inhibit the senescence
of stem cells in a degenerative condition (e.g. degenerative
diseases), or to stimulate the senescence and apoptosis of stem
cells in a disease condition (e.g. cancer stem cells).
[0417] Many miRNA expression studies are conducted to profile the
differential expression of miRNAs in various cancer cells/tissues
and other diseases. Some miRNAs are abnormally over-expressed in
certain cancer cells and others are under-expressed. For example,
miRNAs are differentially expressed in cancer cells (WO2008/154098,
US2013/0059015, US2013/0042333, WO2011/157294); cancer stem cells
(US2012/0053224); pancreatic cancers and diseases (US2009/0131348,
US2011/0171646, US2010/0286232, U.S. Pat. No. 8,389,210); asthma
and inflammation (U.S. Pat. No. 8,415,096); prostate cancer
(US2013/0053264); hepatocellular carcinoma (WO2012/151212,
US2012/0329672, WO2008/054828, U.S. Pat. No. 8,252,538); lung
cancer cells (WO2011/076143, WO2013/033640, WO2009/070653,
US2010/0323357); cutaneous T cell lymphoma (WO2013/011378);
colorectal cancer cells (WO2011/0281756, WO2011/076142); cancer
positive lymph nodes (WO2009/100430, US2009/0263803);
nasopharyngeal carcinoma (EP2112235); chronic obstructive pulmonary
disease (US2012/0264626, US2013/0053263); thyroid cancer
(WO2013/066678); ovarian cancer cells (US2012/0309645,
WO2011/095623); breast cancer cells (WO2008/154098, WO2007/081740,
US2012/0214699), leukemia and lymphoma (WO2008/073915,
US2009/0092974, US2012/0316081, US2012/0283310, WO2010/018563), the
content of each of which is incorporated herein by reference in its
entirety.
[0418] As a non-limiting example, miRNA binding sites for miRNAs
that are over-expressed in certain cancer and/or tumor cells can be
removed from the 3'UTR of a polynucleotide of the disclosure,
restoring the expression suppressed by the over-expressed miRNAs in
cancer cells, thus ameliorating the corresponsive biological
function, for instance, transcription stimulation and/or
repression, cell cycle arrest, apoptosis and cell death. Normal
cells and tissues, wherein miRNAs expression is not up-regulated,
will remain unaffected.
[0419] miRNA can also regulate complex biological processes such as
angiogenesis (e.g., miR-132) (Anand and Cheresh Curr Opin Hematol
2011 18:171-176). In the polynucleotides of the disclosure, miRNA
binding sites that are involved in such processes can be removed or
introduced, in order to tailor the expression of the
polynucleotides to biologically relevant cell types or relevant
biological processes. In this context, the polynucleotides of the
disclosure are defined as auxotrophic polynucleotides.
[0420] In some embodiments, the therapeutic window and/or
differential expression (e.g., tissue-specific expression) of a
polypeptide of the disclosure may be altered by incorporation of a
miRNA binding site into an mRNA encoding the polypeptide. In one
example, an mRNA may include one or more miRNA binding sites that
are bound by miRNAs that have higher expression in one tissue type
as compared to another. In another example, an mRNA may include one
or more miRNA binding sites that are bound by miRNAs that have
lower expression in a cancer cell as compared to a non-cancerous
cell of the same tissue of origin. When present in a cancer cell
that expresses low levels of such an miRNA, the polypeptide encoded
by the mRNA typically will show increased expression.
[0421] Liver cancer cells (e.g., hepatocellular carcinoma cells)
typically express low levels of miR-122 as compared to normal liver
cells. Therefore, an mRNA encoding a polypeptide that includes at
least one miR-122 binding site (e.g., in the 3'-UTR of the mRNA)
will typically express comparatively low levels of the polypeptide
in normal liver cells and comparatively high levels of the
polypeptide in liver cancer cells.
[0422] In some embodiments, the mRNA includes at least one miR-122
binding site, at least two miR-122 binding sites, at least three
miR-122 binding sites, at least four miR-122 binding sites, or at
least five miR-122 binding sites. In one aspect, the miRNA binding
site binds miR-122 or is complementary to miR-122. In another
aspect, the miRNA binding site binds to miR-122-3p or miR-122-5p.
In a particular aspect, the miRNA binding site comprises a
nucleotide sequence at least 80%, at least 85%, at least 90%, at
least 95%, or 100% identical to SEQ ID NO: 175, wherein the miRNA
binding site binds to miR-122. In another particular aspect, the
miRNA binding site comprises a nucleotide sequence at least 80%, at
least 85%, at least 90%, at least 95%, or 100% identical to SEQ ID
NO: 173, wherein the miRNA binding site binds to miR-122. These
sequences are shown below in Table 3.
[0423] In some embodiments, a polynucleotide of the disclosure
comprises a miRNA binding site, wherein the miRNA binding site
comprises one or more nucleotide sequences selected from Table 3,
including one or more copies of any one or more of the miRNA
binding site sequences. In some embodiments, a polynucleotide of
the disclosure further comprises at least one, two, three, four,
five, six, seven, eight, nine, ten, or more of the same or
different miRNA binding sites selected from Table 3, including any
combination thereof. In some embodiments, the miRNA binding site
binds to miR-142 or is complementary to miR-142. In some
embodiments, the miR-142 comprises SEQ ID NO: 27. In some
embodiments, the miRNA binding site binds to miR-142-3p or
miR-142-5p. In some embodiments, the miR-142-3p binding site
comprises SEQ ID NO: 29. In some embodiments, the miR-142-5p
binding site comprises SEQ ID NO: 31. In some embodiments, the
miRNA binding site comprises a nucleotide sequence at least 80%, at
least 85%, at least 90%, at least 95%, or 100% identical to SEQ ID
NO: 29 or SEQ ID NO: 31
TABLE-US-00004 TABLE 3 Representative microRNAs and microRNA
binding sites SEQ ID NO. Description Sequence 27 miR-142
GACAGUGCAGUCACCCAUAAAGUAGAAAGCAC UACUAACAGCACUGGAGGGUGUAGUGUUUCC
UACUUUAUGGAUGAGUGUACUGUG 28 miR-142-3p UGUAGUGUUUCCUACUUUAUGGA 29
miR-142-3p UCCAUAAAGUAGGAAACACUACA binding site 30 miR-142-5p
CAUAAAGUAGAAAGCACUACU 31 miR-142-5p AGUAGUGCUUUCUACUUUAUG binding
site 171 miR-122 CCUUAGCAGAGCUGUGGAGUGUGACAAUGGU
GUUUGUGUCUAAACUAUCAAACGCCAUUAUCA CACUAAAUAGCUACUGCUAGGC 172
miR-122-3p AACGCCAUUAUCACACUAAAUA 173 miR-122-3p
UAUUUAGUGUGAUAAUGGCGUU binding site 174 miR-122-5p
UGGAGUGUGACAAUGGUGUUUG 175 miR-122-5p CAAACACCAUUGUCACACUCCA
binding site
[0424] In some embodiments, a miRNA binding site is inserted in the
polynucleotide of the disclosure in any position of the
polynucleotide (e.g., the 5'UTR and/or 3'UTR). In some embodiments,
the 5'UTR comprises a miRNA binding site. In some embodiments, the
3'UTR comprises a miRNA binding site. In some embodiments, the
5'UTR and the 3'UTR comprise a miRNA binding site. The insertion
site in the polynucleotide can be anywhere in the polynucleotide as
long as the insertion of the miRNA binding site in the
polynucleotide does not interfere with the translation of a
functional polypeptide in the absence of the corresponding miRNA;
and in the presence of the miRNA, the insertion of the miRNA
binding site in the polynucleotide and the binding of the miRNA
binding site to the corresponding miRNA are capable of degrading
the polynucleotide or preventing the translation of the
polynucleotide.
[0425] In some embodiments, a miRNA binding site is inserted in at
least about 30 nucleotides downstream from the stop codon of an ORF
in a polynucleotide of the disclosure comprising the ORF. In some
embodiments, a miRNA binding site is inserted in at least about 10
nucleotides, at least about 15 nucleotides, at least about 20
nucleotides, at least about 25 nucleotides, at least about 30
nucleotides, at least about 35 nucleotides, at least about 40
nucleotides, at least about 45 nucleotides, at least about 50
nucleotides, at least about 55 nucleotides, at least about 60
nucleotides, at least about 65 nucleotides, at least about 70
nucleotides, at least about 75 nucleotides, at least about 80
nucleotides, at least about 85 nucleotides, at least about 90
nucleotides, at least about 95 nucleotides, or at least about 100
nucleotides downstream from the stop codon of an ORF in a
polynucleotide of the disclosure. In some embodiments, a miRNA
binding site is inserted in about 10 nucleotides to about 100
nucleotides, about 20 nucleotides to about 90 nucleotides, about 30
nucleotides to about 80 nucleotides, about 40 nucleotides to about
70 nucleotides, about 50 nucleotides to about 60 nucleotides, about
45 nucleotides to about 65 nucleotides downstream from the stop
codon of an ORF in a polynucleotide of the disclosure.
[0426] miRNA gene regulation can be influenced by the sequence
surrounding the miRNA such as, but not limited to, the species of
the surrounding sequence, the type of sequence (e.g., heterologous,
homologous, exogenous, endogenous, or artificial), regulatory
elements in the surrounding sequence and/or structural elements in
the surrounding sequence. The miRNA can be influenced by the 5'UTR
and/or 3'UTR. As a non-limiting example, a non-human 3'UTR can
increase the regulatory effect of the miRNA sequence on the
expression of a polypeptide of interest compared to a human 3'UTR
of the same sequence type.
[0427] In one embodiment, other regulatory elements and/or
structural elements of the 5'UTR can influence miRNA mediated gene
regulation. One example of a regulatory element and/or structural
element is a structured IRES (Internal Ribosome Entry Site) in the
5'UTR, which is necessary for the binding of translational
elongation factors to initiate protein translation. EIF4A2 binding
to this secondarily structured element in the 5'-UTR is necessary
for miRNA mediated gene expression (Meijer H A et al., Science,
2013, 340, 82-85, incorporated herein by reference in its
entirety). The polynucleotides of the disclosure can further
include this structured 5'UTR in order to enhance microRNA mediated
gene regulation.
[0428] At least one miRNA binding site can be engineered into the
3'UTR of a polynucleotide of the disclosure. In this context, at
least two, at least three, at least four, at least five, at least
six, at least seven, at least eight, at least nine, at least ten,
or more miRNA binding sites can be engineered into a 3'UTR of a
polynucleotide of the disclosure. For example, 1 to 10, 1 to 9, 1
to 8, 1 to 7, 1 to 6, 1 to 5, 1 to 4, 1 to 3, 2, or 1 miRNA binding
sites can be engineered into the 3'UTR of a polynucleotide of the
disclosure. In one embodiment, miRNA binding sites incorporated
into a polynucleotide of the disclosure can be the same or can be
different miRNA sites. A combination of different miRNA binding
sites incorporated into a polynucleotide of the disclosure can
include combinations in which more than one copy of any of the
different miRNA sites are incorporated. In another embodiment,
miRNA binding sites incorporated into a polynucleotide of the
disclosure can target the same or different tissues in the body. As
a non-limiting example, through the introduction of tissue-,
cell-type-, or disease-specific miRNA binding sites in the 3'-UTR
of a polynucleotide of the disclosure, the degree of expression in
specific cell types (e.g., hepatocytes, myeloid cells, endothelial
cells, cancer cells, etc.) can be reduced.
[0429] In one embodiment, a miRNA binding site can be engineered
near the 5' terminus of the 3'UTR, about halfway between the 5'
terminus and 3' terminus of the 3'UTR and/or near the 3' terminus
of the 3'UTR in a polynucleotide of the disclosure. As a
non-limiting example, a miRNA binding site can be engineered near
the 5' terminus of the 3'UTR and about halfway between the 5'
terminus and 3' terminus of the 3'UTR. As another non-limiting
example, a miRNA binding site can be engineered near the 3'
terminus of the 3'UTR and about halfway between the 5' terminus and
3' terminus of the 3'UTR. As yet another non-limiting example, a
miRNA binding site can be engineered near the 5' terminus of the
3'UTR and near the 3' terminus of the 3'UTR.
[0430] In another embodiment, a 3'UTR can comprise 1, 2, 3, 4, 5,
6, 7, 8, 9, or 10 miRNA binding sites. The miRNA binding sites can
be complementary to a miRNA, miRNA seed sequence, and/or miRNA
sequences flanking the seed sequence.
[0431] In one embodiment, a polynucleotide of the disclosure can be
engineered to include more than one miRNA site expressed in
different tissues or different cell types of a subject. As a
non-limiting example, a polynucleotide of the disclosure can be
engineered to include miR-192 and miR-122 to regulate expression of
the polynucleotide in the liver and kidneys of a subject. In
another embodiment, a polynucleotide of the disclosure can be
engineered to include more than one miRNA site for the same
tissue.
[0432] In some embodiments, the therapeutic window and or
differential expression associated with the polypeptide encoded by
a polynucleotide of the disclosure can be altered with a miRNA
binding site. For example, a polynucleotide encoding a polypeptide
that provides a death signal can be designed to be more highly
expressed in cancer cells by virtue of the miRNA signature of those
cells. Where a cancer cell expresses a lower level of a particular
miRNA, the polynucleotide encoding the binding site for that miRNA
(or miRNAs) would be more highly expressed. Hence, the polypeptide
that provides a death signal triggers or induces cell death in the
cancer cell. Neighboring noncancer cells, harboring a higher
expression of the same miRNA would be less affected by the encoded
death signal as the polynucleotide would be expressed at a lower
level due to the effects of the miRNA binding to the binding site
or "sensor" encoded in the 3'UTR. Conversely, cell survival or
cytoprotective signals can be delivered to tissues containing
cancer and non-cancerous cells where a miRNA has a higher
expression in the cancer cells--the result being a lower survival
signal to the cancer cell and a larger survival signal to the
normal cell. Multiple polynucleotides can be designed and
administered having different signals based on the use of miRNA
binding sites as described herein.
[0433] In some embodiments, the expression of a polynucleotide of
the disclosure can be controlled by incorporating at least one
sensor sequence in the polynucleotide and formulating the
polynucleotide for administration. As a non-limiting example, a
polynucleotide of the disclosure can be targeted to a tissue or
cell by incorporating a miRNA binding site and formulating the
polynucleotide in a lipid nanoparticle comprising a cationic lipid,
including any of the lipids described herein.
[0434] A polynucleotide of the disclosure can be engineered for
more targeted expression in specific tissues, cell types, or
biological conditions based on the expression patterns of miRNAs in
the different tissues, cell types, or biological conditions.
Through introduction of tissue-specific miRNA binding sites, a
polynucleotide of the disclosure can be designed for optimal
protein expression in a tissue or cell, or in the context of a
biological condition.
[0435] In some embodiments, a polynucleotide of the disclosure can
be designed to incorporate miRNA binding sites that either have
100% identity to known miRNA seed sequences or have less than 100%
identity to miRNA seed sequences. In some embodiments, a
polynucleotide of the disclosure can be designed to incorporate
miRNA binding sites that have at least: 60%, 65%, 70%, 75%, 80%,
85%, 90%, 95%, 96%, 97%, 98%, or 99% identity to known miRNA seed
sequences. The miRNA seed sequence can be partially mutated to
decrease miRNA binding affinity and as such result in reduced
downmodulation of the polynucleotide. In essence, the degree of
match or mis-match between the miRNA binding site and the miRNA
seed can act as a rheostat to more finely tune the ability of the
miRNA to modulate protein expression. In addition, mutation in the
non-seed region of a miRNA binding site can also impact the ability
of a miRNA to modulate protein expression.
[0436] In one embodiment, a miRNA sequence can be incorporated into
the loop of a stem loop.
[0437] In another embodiment, a miRNA seed sequence can be
incorporated in the loop of a stem loop and a miRNA binding site
can be incorporated into the 5' or 3' stem of the stem loop.
[0438] In one embodiment, a translation enhancer element (TEE) can
be incorporated on the 5'end of the stem of a stem loop and a miRNA
seed can be incorporated into the stem of the stem loop. In another
embodiment, a TEE can be incorporated on the 5' end of the stem of
a stem loop, a miRNA seed can be incorporated into the stem of the
stem loop and a miRNA binding site can be incorporated into the 3'
end of the stem or the sequence after the stem loop. The miRNA seed
and the miRNA binding site can be for the same and/or different
miRNA sequences.
[0439] In one embodiment, the incorporation of a miRNA sequence
and/or a TEE sequence changes the shape of the stem loop region
which can increase and/or decrease translation. (see e.g, Kedde et
al., "A Pumilio-induced RNA structure switch in p27-3'UTR controls
miR-221 and miR-22 accessibility." Nature Cell Biology. 2010,
incorporated herein by reference in its entirety).
[0440] In one embodiment, the 5'-UTR of a polynucleotide of the
disclosure can comprise at least one miRNA sequence. The miRNA
sequence can be, but is not limited to, a 19 or 22 nucleotide
sequence and/or a miRNA sequence without the seed.
[0441] In one embodiment the miRNA sequence in the 5'UTR can be
used to stabilize a polynucleotide of the disclosure described
herein.
[0442] In another embodiment, a miRNA sequence in the 5'UTR of a
polynucleotide of the disclosure can be used to decrease the
accessibility of the site of translation initiation such as, but
not limited to a start codon. See, e.g., Matsuda et al., PLoS One.
2010 11(5):e15057; incorporated herein by reference in its
entirety, which used antisense locked nucleic acid (LNA)
oligonucleotides and exon-junction complexes (EJCs) around a start
codon (-4 to +37 where the A of the AUG codons is +1) in order to
decrease the accessibility to the first start codon (AUG). Matsuda
showed that altering the sequence around the start codon with an
LNA or EJC affected the efficiency, length and structural stability
of a polynucleotide. A polynucleotide of the disclosure can
comprise a miRNA sequence, instead of the LNA or EJC sequence
described by Matsuda et al, near the site of translation initiation
in order to decrease the accessibility to the site of translation
initiation. The site of translation initiation can be prior to,
after or within the miRNA sequence. As a non-limiting example, the
site of translation initiation can be located within a miRNA
sequence such as a seed sequence or binding site. As another
non-limiting example, the site of translation initiation can be
located within a miR-122 sequence such as the seed sequence or the
mir-122 binding site.
[0443] In some embodiments, a polynucleotide of the disclosure can
include at least one miRNA in order to dampen the antigen
presentation by antigen presenting cells. The miRNA can be the
complete miRNA sequence, the miRNA seed sequence, the miRNA
sequence without the seed, or a combination thereof. As a
non-limiting example, a miRNA incorporated into a polynucleotide of
the disclosure can be specific to the hematopoietic system. As
another non-limiting example, a miRNA incorporated into a
polynucleotide of the disclosure to dampen antigen presentation is
miR-142-3p.
[0444] In some embodiments, a polynucleotide of the disclosure can
include at least one miRNA in order to dampen expression of the
encoded polypeptide in a tissue or cell of interest. As a
non-limiting example, a polynucleotide of the disclosure can
include at least one miR-122 binding site in order to dampen
expression of an encoded polypeptide of interest in the liver. As
another non-limiting example a polynucleotide of the disclosure can
include at least one miR-142-3p binding site, miR-142-3p seed
sequence, miR-142-3p binding site without the seed, miR-142-5p
binding site, miR-142-5p seed sequence, miR-142-5p binding site
without the seed, miR-146 binding site, miR-146 seed sequence
and/or miR-146 binding site without the seed sequence.
[0445] In some embodiments, a polynucleotide of the disclosure can
comprise at least one miRNA binding site in the 3'UTR in order to
selectively degrade mRNA therapeutics in the immune cells to subdue
unwanted immunogenic reactions caused by therapeutic delivery. As a
non-limiting example, the miRNA binding site can make a
polynucleotide of the disclosure more unstable in antigen
presenting cells. Non-limiting examples of these miRNAs include
mir-142-5p, mir-142-3p, mir-146a-5p, and mir-146-3p.
[0446] In one embodiment, a polynucleotide of the disclosure
comprises at least one miRNA sequence in a region of the
polynucleotide that can interact with a RNA binding protein.
[0447] In some embodiments, the polynucleotide of the disclosure
(e.g., a RNA, e.g., a mRNA) comprising (i) a sequence-optimized
nucleotide sequence (e.g., an ORF) and (ii) a miRNA binding site
(e.g., a miRNA binding site that binds to miR-142).
[0448] In some embodiments, the polynucleotide of the disclosure
comprises a uracil-modified sequence encoding a polypeptide
disclosed herein and a miRNA binding site disclosed herein, e.g., a
miRNA binding site that binds to miR-142 or miR-122. In some
embodiments, the uracil-modified sequence encoding a polypeptide
comprises at least one chemically modified nucleobase, e.g.,
5-methoxyuracil. In some embodiments, at least 95% of a type of
nucleobase (e.g., uracil) in a uracil-modified sequence encoding a
polypeptide of the disclosure are modified nucleobases. In some
embodiments, at least 95% of uricil in a uracil-modified sequence
encoding a polypeptide is 5-methoxyuridine. In some embodiments,
the polynucleotide comprising a nucleotide sequence encoding a
polypeptide disclosed herein and a miRNA binding site is formulated
with a delivery agent, e.g., a compound having the Formula (I),
e.g., any of Compounds 1-147.
Modified Polynucleotides Comprising Functional RNA Elements
[0449] The present disclosure provides synthetic polynucleotides
comprising a modification (e.g., an RNA element), wherein the
modification provides a desired translational regulatory activity.
In some embodiments, the disclosure provides a polynucleotide
comprising a 5' untranslated region (UTR), an initiation codon, a
full open reading frame encoding a polypeptide, a 3' UTR, and at
least one modification, wherein the at least one modification
provides a desired translational regulatory activity, for example,
a modification that promotes and/or enhances the translational
fidelity of mRNA translation. In some embodiments, the desired
translational regulatory activity is a cis-acting regulatory
activity. In some embodiments, the desired translational regulatory
activity is an increase in the residence time of the 43S
pre-initiation complex (PIC) or ribosome at, or proximal to, the
initiation codon. In some embodiments, the desired translational
regulatory activity is an increase in the initiation of polypeptide
synthesis at or from the initiation codon. In some embodiments, the
desired translational regulatory activity is an increase in the
amount of polypeptide translated from the full open reading frame.
In some embodiments, the desired translational regulatory activity
is an increase in the fidelity of initiation codon decoding by the
PIC or ribosome. In some embodiments, the desired translational
regulatory activity is inhibition or reduction of leaky scanning by
the PIC or ribosome. In some embodiments, the desired translational
regulatory activity is a decrease in the rate of decoding the
initiation codon by the PIC or ribosome. In some embodiments, the
desired translational regulatory activity is inhibition or
reduction in the initiation of polypeptide synthesis at any codon
within the mRNA other than the initiation codon. In some
embodiments, the desired translational regulatory activity is
inhibition or reduction of the amount of polypeptide translated
from any open reading frame within the mRNA other than the full
open reading frame. In some embodiments, the desired translational
regulatory activity is inhibition or reduction in the production of
aberrant translation products. In some embodiments, the desired
translational regulatory activity is a combination of one or more
of the foregoing translational regulatory activities.
[0450] Accordingly, the present disclosure provides a
polynucleotide, e.g., an mRNA, comprising an RNA element that
comprises a sequence and/or an RNA secondary structure(s) that
provides a desired translational regulatory activity as described
herein. In some aspects, the mRNA comprises an RNA element that
comprises a sequence and/or an RNA secondary structure(s) that
promotes and/or enhances the translational fidelity of mRNA
translation. In some aspects, the mRNA comprises an RNA element
that comprises a sequence and/or an RNA secondary structure(s) that
provides a desired translational regulatory activity, such as
inhibiting and/or reducing leaky scanning. In some aspects, the
disclosure provides an mRNA that comprises an RNA element that
comprises a sequence and/or an RNA secondary structure(s) that
inhibits and/or reduces leaky scanning thereby promoting the
translational fidelity of the mRNA.
[0451] In some embodiments, the RNA element comprises natural
and/or modified nucleotides. In some embodiments, the RNA element
comprises of a sequence of linked nucleotides, or derivatives or
analogs thereof, that provides a desired translational regulatory
activity as described herein. In some embodiments, the RNA element
comprises a sequence of linked nucleotides, or derivatives or
analogs thereof, that forms or folds into a stable RNA secondary
structure, wherein the RNA secondary structure provides a desired
translational regulatory activity as described herein. RNA elements
can be identified and/or characterized based on the primary
sequence of the element (e.g., GC-rich element), by RNA secondary
structure formed by the element (e.g. stem-loop), by the location
of the element within the RNA molecule (e.g., located within the 5'
UTR of an mRNA), by the biological function and/or activity of the
element (e.g., "translational enhancer element"), and any
combination thereof.
[0452] In some aspects, the disclosure provides an mRNA having one
or more structural modifications that inhibits leaky scanning
and/or promotes the translational fidelity of mRNA translation,
wherein at least one of the structural modifications is a GC-rich
RNA element. In some aspects, the disclosure provides a modified
mRNA comprising at least one modification, wherein at least one
modification is a GC-rich RNA element comprising a sequence of
linked nucleotides, or derivatives or analogs thereof, preceding a
Kozak consensus sequence in a 5' UTR of the mRNA. In one
embodiment, the GC-rich RNA element is located about 30, about 25,
about 20, about 15, about 10, about 5, about 4, about 3, about 2,
or about 1 nucleotide(s) upstream of a Kozak consensus sequence in
the 5' UTR of the mRNA. In another embodiment, the GC-rich RNA
element is located 15-30, 15-20, 15-25, 10-15, or 5-10 nucleotides
upstream of a Kozak consensus sequence. In another embodiment, the
GC-rich RNA element is located immediately adjacent to a Kozak
consensus sequence in the 5' UTR of the mRNA.
[0453] In any of the foregoing or related aspects, the disclosure
provides a GC-rich RNA element which comprises a sequence of 3-30,
5-25, 10-20, 15-20, about 20, about 15, about 12, about 10, about
7, about 6 or about 3 nucleotides, derivatives or analogs thereof,
linked in any order, wherein the sequence composition is 70-80%
cytosine, 60-70% cytosine, 50%-60% cytosine, 40-50% cytosine,
30-40% cytosine bases. In any of the foregoing or related aspects,
the disclosure provides a GC-rich RNA element which comprises a
sequence of 3-30, 5-25, 10-20, 15-20, about 20, about 15, about 12,
about 10, about 7, about 6 or about 3 nucleotides, derivatives or
analogs thereof, linked in any order, wherein the sequence
composition is about 80% cytosine, about 70% cytosine, about 60%
cytosine, about 50% cytosine, about 40% cytosine, or about 30%
cytosine.
[0454] In any of the foregoing or related aspects, the disclosure
provides a GC-rich RNA element which comprises a sequence of 20,
19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, or 3
nucleotides, or derivatives or analogs thereof, linked in any
order, wherein the sequence composition is 70-80% cytosine, 60-70%
cytosine, 50%-60% cytosine, 40-50% cytosine, or 30-40% cytosine. In
any of the foregoing or related aspects, the disclosure provides a
GC-rich RNA element which comprises a sequence of 20, 19, 18, 17,
16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, or 3 nucleotides, or
derivatives or analogs thereof, linked in any order, wherein the
sequence composition is about 80% cytosine, about 70% cytosine,
about 60% cytosine, about 50% cytosine, about 40% cytosine, or
about 30% cytosine.
[0455] In some embodiments, the disclosure provides a modified mRNA
comprising at least one modification, wherein at least one
modification is a GC-rich RNA element comprising a sequence of
linked nucleotides, or derivatives or analogs thereof, preceding a
Kozak consensus sequence in a 5' UTR of the mRNA, wherein the
GC-rich RNA element is located about 30, about 25, about 20, about
15, about 10, about 5, about 4, about 3, about 2, or about 1
nucleotide(s) upstream of a Kozak consensus sequence in the 5' UTR
of the mRNA, and wherein the GC-rich RNA element comprises a
sequence of 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17,
18, 19, or 20 nucleotides, or derivatives or analogs thereof,
linked in any order, wherein the sequence composition is >50%
cytosine. In some embodiments, the sequence composition is >55%
cytosine, >60% cytosine, >65% cytosine, >70% cytosine,
>75% cytosine, >80% cytosine, >85% cytosine, or >90%
cytosine.
[0456] In other aspects, the disclosure provides a modified mRNA
comprising at least one modification, wherein at least one
modification is a GC-rich RNA element comprising a sequence of
linked nucleotides, or derivatives or analogs thereof, preceding a
Kozak consensus sequence in a 5' UTR of the mRNA, wherein the
GC-rich RNA element is located about 30, about 25, about 20, about
15, about 10, about 5, about 4, about 3, about 2, or about 1
nucleotide(s) upstream of a Kozak consensus sequence in the 5' UTR
of the mRNA, and wherein the GC-rich RNA element comprises a
sequence of about 3-30, 5-25, 10-20, 15-20 or about 20, about 15,
about 12, about 10, about 6 or about 3 nucleotides, or derivatives
or analogues thereof, wherein the sequence comprises a repeating
GC-motif, wherein the repeating GC-motif is [CCG]n, wherein n=1 to
10, n=2 to 8, n=3 to 6, or n=4 to 5. In some embodiments, the
sequence comprises a repeating GC-motif [CCG]n, wherein n=1, 2, 3,
4 or 5. In some embodiments, the sequence comprises a repeating
GC-motif [CCG]n, wherein n=1, 2, or 3. In some embodiments, the
sequence comprises a repeating GC-motif [CCG]n, wherein n=1. In
some embodiments, the sequence comprises a repeating GC-motif
[CCG]n, wherein n=2. In some embodiments, the sequence comprises a
repeating GC-motif [CCG]n, wherein n=3. In some embodiments, the
sequence comprises a repeating GC-motif [CCG]n, wherein n=4 (SEQ ID
NO: 177). In some embodiments, the sequence comprises a repeating
GC-motif [CCG]n, wherein n=5 (SEQ ID NO: 178).
[0457] In another aspect, the disclosure provides a modified mRNA
comprising at least one modification, wherein at least one
modification is a GC-rich RNA element comprising a sequence of
linked nucleotides, or derivatives or analogs thereof, preceding a
Kozak consensus sequence in a 5' UTR of the mRNA, wherein the
GC-rich RNA element comprises any one of the sequences set forth in
Table 4. In one embodiment, the GC-rich RNA element is located
about 30, about 25, about 20, about 15, about 10, about 5, about 4,
about 3, about 2, or about 1 nucleotide(s) upstream of a Kozak
consensus sequence in the 5' UTR of the mRNA. In another
embodiment, the GC-rich RNA element is located about 15-30, 15-20,
15-25, 10-15, or 5-10 nucleotides upstream of a Kozak consensus
sequence. In another embodiment, the GC-rich RNA element is located
immediately adjacent to a Kozak consensus sequence in the 5' UTR of
the mRNA.
[0458] In other aspects, the disclosure provides a modified mRNA
comprising at least one modification, wherein at least one
modification is a GC-rich RNA element comprising the sequence V1
[CCCCGGCGCC] (SEQ ID NO: 179) as set forth in Table 4, or
derivatives or analogs thereof, preceding a Kozak consensus
sequence in the 5' UTR of the mRNA. In some embodiments, the
GC-rich element comprises the sequence V1 as set forth in Table 4
located immediately adjacent to and upstream of the Kozak consensus
sequence in the 5' UTR of the mRNA. In some embodiments, the
GC-rich element comprises the sequence V1 as set forth in Table 4
located 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 bases upstream of the Kozak
consensus sequence in the 5' UTR of the mRNA. In other embodiments,
the GC-rich element comprises the sequence V1 as set forth in Table
4 located 1-3, 3-5, 5-7, 7-9, 9-12, or 12-15 bases upstream of the
Kozak consensus sequence in the 5' UTR of the mRNA.
[0459] In other aspects, the disclosure provides a modified mRNA
comprising at least one modification, wherein at least one
modification is a GC-rich RNA element comprising the sequence V2
[CCCCGGC] as set forth in Table 4, or derivatives or analogs
thereof, preceding a Kozak consensus sequence in the 5' UTR of the
mRNA. In some embodiments, the GC-rich element comprises the
sequence V2 as set forth in Table 4 located immediately adjacent to
and upstream of the Kozak consensus sequence in the 5' UTR of the
mRNA. In some embodiments, the GC-rich element comprises the
sequence V2 as set forth in Table 4 located 1, 2, 3, 4, 5, 6, 7, 8,
9 or 10 bases upstream of the Kozak consensus sequence in the 5'
UTR of the mRNA. In other embodiments, the GC-rich element
comprises the sequence V2 as set forth in Table 4 located 1-3, 3-5,
5-7, 7-9, 9-12, or 12-15 bases upstream of the Kozak consensus
sequence in the 5' UTR of the mRNA.
[0460] In other aspects, the disclosure provides a modified mRNA
comprising at least one modification, wherein at least one
modification is a GC-rich RNA element comprising the sequence EK
[GCCGCC] as set forth in Table 4, or derivatives or analogs
thereof, preceding a Kozak consensus sequence in the 5' UTR of the
mRNA. In some embodiments, the GC-rich element comprises the
sequence EK as set forth in Table 4 located immediately adjacent to
and upstream of the Kozak consensus sequence in the 5' UTR of the
mRNA. In some embodiments, the GC-rich element comprises the
sequence EK as set forth in Table 4 located 1, 2, 3, 4, 5, 6, 7, 8,
9 or 10 bases upstream of the Kozak consensus sequence in the 5'
UTR of the mRNA. In other embodiments, the GC-rich element
comprises the sequence EK as set forth in Table 4 located 1-3, 3-5,
5-7, 7-9, 9-12, or 12-15 bases upstream of the Kozak consensus
sequence in the 5' UTR of the mRNA.
[0461] In yet other aspects, the disclosure provides a modified
mRNA comprising at least one modification, wherein at least one
modification is a GC-rich RNA element comprising the sequence
V1[CCCCGGCGCC] (SEQ ID NO: 179) as set forth in Table 4, or
derivatives or analogs thereof, preceding a Kozak consensus
sequence in the 5' UTR of the mRNA, wherein the 5' UTR comprises
the following sequence shown in Table 4:
TABLE-US-00005 (SEQ ID NO: 180)
GGGAAATAAGAGAGAAAAGAAGAGTAAGAAGAAATATAAGA.
[0462] In some embodiments, the GC-rich element comprises the
sequence V1 as set forth in Table 4 located immediately adjacent to
and upstream of the Kozak consensus sequence in the 5' UTR sequence
shown in Table 4. In some embodiments, the GC-rich element
comprises the sequence V1 as set forth in Table 4 located 1, 2, 3,
4, 5, 6, 7, 8, 9 or 10 bases upstream of the Kozak consensus
sequence in the 5' UTR of the mRNA, wherein the 5' UTR comprises
the following sequence shown in Table 4:
TABLE-US-00006 (SEQ ID NO: 180)
GGGAAATAAGAGAGAAAAGAAGAGTAAGAAGAAATATAAGA.
[0463] In other embodiments, the GC-rich element comprises the
sequence V1 as set forth in Table 4 located 1-3, 3-5, 5-7, 7-9,
9-12, or 12-15 bases upstream of the Kozak consensus sequence in
the 5' UTR of the mRNA, wherein the 5' UTR comprises the following
sequence shown in Table 4:
TABLE-US-00007 (SEQ ID NO: 180)
GGGAAATAAGAGAGAAAAGAAGAGTAAGAAGAAATATAAGA.
[0464] In some embodiments, the 5' UTR comprises the following
sequence set forth in Table 4:
TABLE-US-00008 (SEQ ID NO: 181)
GGGAAATAAGAGAGAAAAGAAGAGTAAGAAGAAATATAAGACCCCGGCGC CGCCACC
In some embodiments, the 5' UTR comprises the following sequence
set forth in Table 4:
TABLE-US-00009 (SEQ ID NO: 182)
GGGAAATAAGAGAGAAAAGAAGAGTAAGAAGAAATATAAGACCCCGGCGC CACC
TABLE-US-00010 TABLE 4 SEQ ID NO: 5' UTRs 5'UTR Sequence 176
Standard GGGAAATAAGAGAGAAAAGAAGAGTAAGAA GAAATATAAGAGCCACC 180 UTR
GGGAAATAAGAGAGAAAAGAAGAGTAAGA AGAAATATAAGA 181 V1-UTR
GGGAAATAAGAGAGAAAAGAAGAGTAAGAA GAAATATAAGACCCCGGCGCCGCCACC 182
V2-UTR GGGAAATAAGAGAGAAAAGAAGAGTAAGAA GAAATATAAGACCCCGGCGCCACC SEQ
ID NO: GC-Rich RNA Elements Sequence K0 (Traditional Kozak
[GCCA/GCC] consensus) EK [GCCGCC] 179 V1 [CCCCGGCGCC] V2 [CCCCGGC]
(CCG).sub.n, where n = 1-10 [CCG].sub.n (GCC).sub.n, where n = 1-10
[GCC].sub.n 177 (CCG).sub.n, where n = 4 [CCGCCGCCGCCG] 178
(CCG).sub.n, where n = 5 [CCGCCGCCGCCGCCG]
[0465] In another aspect, the disclosure provides a modified mRNA
comprising at least one modification, wherein at least one
modification is a GC-rich RNA element comprising a stable RNA
secondary structure comprising a sequence of nucleotides, or
derivatives or analogs thereof, linked in an order which forms a
hairpin or a stem-loop. In one embodiment, the stable RNA secondary
structure is upstream of the Kozak consensus sequence. In another
embodiment, the stable RNA secondary structure is located about 30,
about 25, about 20, about 15, about 10, or about 5 nucleotides
upstream of the Kozak consensus sequence. In another embodiment,
the stable RNA secondary structure is located about 20, about 15,
about 10 or about 5 nucleotides upstream of the Kozak consensus
sequence. In another embodiment, the stable RNA secondary structure
is located about 5, about 4, about 3, about 2, about 1 nucleotides
upstream of the Kozak consensus sequence. In another embodiment,
the stable RNA secondary structure is located about 15-30, about
15-20, about 15-25, about 10-15, or about 5-10 nucleotides upstream
of the Kozak consensus sequence. In another embodiment, the stable
RNA secondary structure is located 12-15 nucleotides upstream of
the Kozak consensus sequence. In another embodiment, the stable RNA
secondary structure has a deltaG of about -30 kcal/mol, about -20
to -30 kcal/mol, about -20 kcal/mol, about -10 to -20 kcal/mol,
about -10 kcal/mol, about -5 to -10 kcal/mol.
[0466] In another embodiment, the modification is operably linked
to an open reading frame encoding a polypeptide and wherein the
modification and the open reading frame are heterologous.
[0467] In another embodiment, the sequence of the GC-rich RNA
element is comprised exclusively of guanine (G) and cytosine (C)
nucleobases.
[0468] RNA elements that provide a desired translational regulatory
activity as described herein can be identified and characterized
using known techniques, such as ribosome profiling. Ribosome
profiling is a technique that allows the determination of the
positions of PICs and/or ribosomes bound to mRNAs (see e.g.,
Ingolia et al., (2009) Science 324(5924):218-23, incorporated
herein by reference). The technique is based on protecting a region
or segment of mRNA, by the PIC and/or ribosome, from nuclease
digestion. Protection results in the generation of a 30-bp fragment
of RNA termed a `footprint`. The sequence and frequency of RNA
footprints can be analyzed by methods known in the art (e.g.,
RNA-seq). The footprint is roughly centered on the A-site of the
ribosome. If the PIC or ribosome dwells at a particular position or
location along an mRNA, footprints generated at these position
would be relatively common. Studies have shown that more footprints
are generated at positions where the PIC and/or ribosome exhibits
decreased processivity and fewer footprints where the PIC and/or
ribosome exhibits increased processivity (Gardin et al., (2014)
eLife 3:e03735). In some embodiments, residence time or the time of
occupancy of a the PIC or ribosome at a discrete position or
location along an polynucleotide comprising any one or more of the
RNA elements described herein is determined by ribosome
profiling.
Preparation of High Purity RNA
[0469] In order to enhance the purity of synthetically produced
RNA, modified in vitro transcription (IVT) processes which produce
RNA preparations having vastly different properties from RNA
produced using a traditional IVT process may be used. The RNA
preparations produced according to these methods have properties
that enable the production of qualitatively and quantitatively
superior compositions. Even when coupled with extensive
purification processes, RNA produced using traditional IVT methods
is qualitatively and quantitatively distinct from the RNA
preparations produced by the modified IVT processes. For instance,
the purified RNA preparations are less immunogenic in comparison to
RNA preparations made using traditional IVT. Additionally,
increased protein expression levels with higher purity are produced
from the purified RNA preparations.
[0470] Traditional IVT reactions are performed by incubating a DNA
template with an RNA polymerase and equimolar quantities of
nucleotide triphosphates, including GTP, ATP, CTP, and UTP in a
transcription buffer. An RNA transcript having a 5' terminal
guanosine triphosphate is produced from this reaction. These
reactions also result in the production of a number of impurities
such as double stranded and single stranded RNAs which are
immunostimulatory and may have an additive impact. The purity
methods described herein prevent formation of reverse complements
and thus prevent the innate immune recognition of both species. In
some embodiments the modified IVT methods result in the production
of RNA having significantly reduced T cell activity than an RNA
preparation made using prior art methods with equimolar NTPs. The
prior art attempts to remove these undesirable components using a
series of subsequent purification steps. Such purification methods
are undesirable because they involve additional time and resources
and also result in the incorporation of residual organic solvents
in the final product, which is undesirable for a pharmaceutical
product. It is labor and capital intensive to scale up processes
like reverse phase chromatography (RP): utilizing for instance
explosion proof facilities, HPLC columns and purification systems
rated for high pressure, high temperature, flammable solvents etc.
The scale and throughput for large scale manufacture are limited by
these factors. Subsequent purification is also required to remove
alkylammonium ion pair utilized in RP process. In contrast the
methods described herein even enhance currently utilized methods
(eg RP). Lower impurity load leads to higher purification recovery
of full length RNA devoid of cytokine inducing contaminants eg.
higher quality of materials at the outset.
[0471] The modified IVT methods involve the manipulation of one or
more of the reaction parameters in the IVT reaction to produce a
RNA preparation of highly functional RNA without one or more of the
undesirable contaminants produced using the prior art processes.
One parameter in the IVT reaction that may be manipulated is the
relative amount of a nucleotide or nucleotide analog in comparison
to one or more other nucleotides or nucleotide analogs in the
reaction mixture (e.g., disparate nucleotide amounts or
concentration). For instance, the IVT reaction may include an
excess of a nucleotides, e.g., nucleotide monophosphate, nucleotide
diphosphate or nucleotide triphosphate and/or an excess of
nucleotide analogs and/or nucleoside analogs. The methods produce a
high yield product which is significantly more pure than products
produced by traditional IVT methods.
[0472] Nucleotide analogs are compounds that have the general
structure of a nucleotide or are structurally similar to a
nucleotide or portion thereof. In particular, nucleotide analogs
are nucleotides which contain, for example, an analogue of the
nucleic acid portion, sugar portion and/or phosphate groups of the
nucleotide. Nucleotides include, for instance, nucleotide
monophosphates, nucleotide diphosphates, and nucleotide
triphosphates. A nucleotide analog, as used herein is structurally
similar to a nucleotide or portion thereof but does not have the
typical nucleotide structure (nucleobase-ribose-phosphate).
Nucleoside analogs are compounds that have the general structure of
a nucleoside or are structurally similar to a nucleoside or portion
thereof. In particular, nucleoside analogs are nucleosides which
contain, for example, an analogue of the nucleic acid and/or sugar
portion of the nucleoside.
[0473] The nucleotide analogs useful in the methods are
structurally similar to nucleotides or portions thereof but, for
example, are not polymerizable by T7. Nucleotide/nucleoside analogs
as used herein (including C, T, A, U, G, dC, dT, dA, dU, or dG
analogs) include for instance, antiviral nucleotide analogs,
phosphate analogs (soluble or immobilized, hydrolyzable or
non-hydrolyzable), dinucleotide, trinucleotide, tetranucleotide,
e.g., a cap analog, or a precursor/substrate for enzymatic capping
(vaccinia, or ligase), a nucleotide labelled with a functional
group to facilitate ligation/conjugation of cap or 5' moiety
(IRES), a nucleotide labelled with a 5' PO4 to facilitate ligation
of cap or 5' moiety, or a nucleotide labelled with a functional
group/protecting group that can be chemically or enzymatically
cleavable. Antiviral nucleotide/nucleoside analogs include but are
not limited to Ganciclovir, Entecavir, Telbivudine, Vidarabine and
Cidofovir.
[0474] The IVT reaction typically includes the following: an RNA
polymerase, e.g., a T7 RNA polymerase at a final concentration of,
e.g., 1000-12000 U/mL, e.g., 7000 U/mL; the DNA template at a final
concentration of, e.g., 10-70 nM, e.g., 40 nM; nucleotides (NTPs)
at a final concentration of e.g., 0.5-10 mM, e.g., 7.5 mM each;
magnesium at a final concentration of, e.g., 12-60 mM, e.g.,
magnesium acetate at 40 mM; a buffer such as, e.g., HEPES or Tris
at a pH of, e.g., 7-8.5, e.g. 40 mM Tris HCl, pH 8. In some
embodiments 5 mM dithiothreitol (DTT) and/or 1 mM spermidine may be
included. In some embodiments, an RNase inhibitor is included in
the IVT reaction to ensure no RNase induced degradation during the
transcription reaction. For example, murine RNase inhibitor can be
utilized at a final concentration of 1000 U/mL. In some embodiments
a pyrophosphatase is included in the IVT reaction to cleave the
inorganic pyrophosphate generated following each nucleotide
incorporation into two units of inorganic phosphate. This ensures
that magnesium remains in solution and does not precipitate as
magnesium pyrophosphate. For example, an E. coli inorganic
pyrophosphatase can be utilized at a final concentration of 1
U/mL.
[0475] Similar to traditional methods, the modified method may also
be produced by forming a reaction mixture comprising a DNA
template, and one or more NTPs such as ATP, CTP, UTP, GTP (or
corresponding analog of aforementioned components) and a buffer.
The reaction is then incubated under conditions such that the RNA
is transcribed. However, the modified methods utilize the presence
of an excess amount of one or more nucleotides and/or nucleotide
analogs that can have significant impact on the end product. These
methods involve a modification in the amount (e.g., molar amount or
quantity) of nucleotides and/or nucleotide analogs in the reaction
mixture. In some aspects, one or more nucleotides and/or one or
more nucleotide analogs may be added in excess to the reaction
mixture. An excess of nucleotides and/or nucleotide analogs is any
amount greater than the amount of one or more of the other
nucleotides such as NTPs in the reaction mixture. For instance, an
excess of a nucleotide and/or nucleotide analog may be a greater
amount than the amount of each or at least one of the other
individual NTPs in the reaction mixture or may refer to an amount
greater than equimolar amounts of the other NTPs.
[0476] In the embodiment when the nucleotide and/or nucleotide
analog that is included in the reaction mixture is an NTP, the NTP
may be present in a higher concentration than all three of the
other NTPs included in the reaction mixture. The other three NTPs
may be in an equimolar concentration to one another. Alternatively
one or more of the three other NTPs may be in a different
concentration than one or more of the other NTPs.
[0477] Thus, in some embodiments the IVT reaction may include an
equimolar amount of nucleotide triphosphate relative to at least
one of the other nucleotide triphosphates.
[0478] In some embodiments the RNA is produced by a process or is
preparable by a process comprising
[0479] (a) forming a reaction mixture comprising a DNA template and
NTPs including adenosine triphosphate (ATP), cytidine triphosphate
(CTP), uridine triphosphate (UTP), guanosine triphosphate (GTP) and
optionally guanosine diphosphate (GDP), and (eg. buffer containing
T7 co-factor eg. magnesium).
[0480] (b) incubating the reaction mixture under conditions such
that the RNA is transcribed,
wherein the concentration of at least one of GTP, CTP, ATP, and UTP
is at least 2.times. greater than the concentration of any one or
more of ATP, CTP or UTP or the reaction further comprises a
nucleotide analog and wherein the concentration of the nucleotide
analog is at least 2.times. greater than the concentration of any
one or more of ATP, CTP or UTP.
[0481] In some embodiments the ratio of concentration of GTP to the
concentration of any one ATP, CTP or UTP is at least 2:1, at least
3:1, at least 4:1, at least 5:1 or at least 6:1. The ratio of
concentration of GTP to concentration of ATP, CTP and UTP is, in
some embodiments 2:1, 4:1 and 4:1, respectively. In other
embodiments the ratio of concentration of GTP to concentration of
ATP, CTP and UTP is 3:1, 6:1 and 6:1, respectively. The reaction
mixture may comprise GTP and GDP and wherein the ratio of
concentration of GTP plus GDP to the concentration of any one of
ATP, CTP or UTP is at least 2:1, at least 3:1, at least 4:1, at
least 5:1 or at least 6:1 In some embodiments the ratio of
concentration of GTP plus GDP to concentration of ATP, CTP and UTP
is 3:1, 6:1 and 6:1, respectively.
[0482] In some embodiments the method involves incubating the
reaction mixture under conditions such that the RNA is transcribed,
wherein the effective concentration of phosphate in the reaction is
at least 150 mM phosphate, at least 160 mM, at least 170 mM, at
least 180 mM, at least 190 mM, at least 200 mM, at least 210 mM or
at least 220 mM. The effective concentration of phosphate in the
reaction may be 180 mM. The effective concentration of phosphate in
the reaction in some embodiments is 195 mM. In other embodiments
the effective concentration of phosphate in the reaction is 225
mM.
[0483] In other embodiments the RNA is produced by a process or is
preparable by a process comprising wherein a buffer
magnesium-containing buffer is used when forming the reaction
mixture comprising a DNA template and ATP, CTP, UTP, GTP. In some
embodiments the magnesium-containing buffer comprises Mg2+ and
wherein the molar ratio of concentration of ATP plus CTP plus UTP
pus GTP to concentration of Mg2+ is at least 1.0, at least 1.25, at
least 1.5, at least 1.75, at least 1.85, at least 3 or higher. The
molar ratio of concentration of ATP plus CTP plus UTP pus GTP to
concentration of Mg2+ may be 1.5. The molar ratio of concentration
of ATP plus CTP plus UTP pus GTP to concentration of Mg2+ in some
embodiments is 1.88. The molar ratio of concentration of ATP plus
CTP plus UTP pus GTP to concentration of Mg2+ in some embodiments
is 3.
[0484] In some embodiments the composition is produced by a process
which does not comprise an dsRNase (e.g., RNaseII) treatment step.
In other embodiments the composition is produced by a process which
does not comprise a reverse phase (RP) chromatography purification
step. In yet other embodiments the composition is produced by a
process which does not comprise a high-performance liquid
chromatography (HPLC) purification step.
[0485] In some embodiments the ratio of concentration of GTP to the
concentration of any one ATP, CTP or UTP is at least 2:1, at least
3:1, at least 4:1, at least 5:1 or at least 6:1 to produce the
RNA.
[0486] The purity of the products may be assessed using known
analytical methods and assays. For instance, the amount of reverse
complement transcription product or cytokine-inducing RNA
contaminant may be determined by high-performance liquid
chromatography (such as reverse-phase chromatography,
size-exclusion chromatography), Bioanalyzer chip-based
electrophoresis system, ELISA, flow cytometry, acrylamide gel, a
reconstitution or surrogate type assay. The assays may be performed
with or without nuclease treatment (P1, RNase III, RNase H etc.) of
the RNA preparation. Electrophoretic/chromatographic/mass spec
analysis of nuclease digestion products may also be performed.
[0487] In some embodiments the purified RNA preparations comprise
contaminant transcripts that have a length less than a full length
transcript, such as for instance at least 100, 200, 300, 400, 500,
600, 700, 800, or 900 nucleotides less than the full length.
Contaminant transcripts can include reverse or forward
transcription products (transcripts) that have a length less than a
full length transcript, such as for instance at least 100, 200,
300, 400, 500, 600, 700, 800, or 900 nucleotides less than the full
length. Exemplary forward transcripts include, for instance,
abortive transcripts. In certain embodiments the composition
comprises a tri-phosphate poly-U reverse complement of less than 30
nucleotides. In some embodiments the composition comprises a
tri-phosphate poly-U reverse complement of any length hybridized to
a full length transcript. In other embodiments the composition
comprises a single stranded tri-phosphate forward transcript. In
other embodiments the composition comprises a single stranded RNA
having a terminal tri-phosphate-G. In other embodiments the
composition comprises single or double stranded RNA of less than 12
nucleotides or base pairs (including forward or reverse complement
transcripts). In any of these embodiments the composition may
include less than 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, 9%,
8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or 0.5% of any one of or
combination of these less than full length transcripts.
Delivery Vehicles
General
[0488] The mRNAs of the disclosure may be formulated in
nanoparticles or other delivery vehicles, e.g., to protect them
from degradation when delivered to a subject. Illustrative
nanoparticles are described in Panyam, J. & Labhasetwar, V.
Adv. Drug Deliv. Rev. 55, 329-347 (2003) and Peer, D. et al. Nature
Nanotech. 2, 751-760 (2007). In certain embodiments, an mRNA of the
disclosure is encapsulated within a nanoparticle. In particular
embodiments, a nanoparticle is a particle having at least one
dimension (e.g., a diameter) less than or equal to 1000 nM, less
than or equal to 500 nM or less than or equal to 100 nM. In
particular embodiments, a nanoparticle includes a lipid. Lipid
nanoparticles include, but are not limited to, liposomes and
micelles. Any of a number of lipids may be present, including
cationic and/or ionizable lipids, anionic lipids, neutral lipids,
amphipathic lipids, PEGylated lipids, and/or structural lipids.
Such lipids can be used alone or in combination. In particular
embodiments, a lipid nanoparticle comprises one or more mRNAs
described herein.
[0489] In some embodiments, the lipid nanoparticle formulations of
the mRNAs described herein may include one or more (e.g., 1, 2, 3,
4, 5, 6, 7, or 8) cationic and/or ionizable lipids. Such cationic
and/or ionizable lipids include, but are not limited to,
3-(didodecylamino)-N1,N1,4-tridodecyl-1-piperazineethanamine
(KL10),
N1-[2-(didodecylamino)ethyl]-N1,N4,N4-tridodecyl-1,4-piperazinediethanami-
ne (KL22), 14,25-ditridecyl-15,18,21,24-tetraaza-octatriacontane
(KL25), 1,2-dilinoleyloxy-N,N-dimethylaminopropane (DLin-DMA),
2,2-dilinoleyl-4-dimethylaminomethyl-[1,3]-dioxolane (DLin-K-DMA),
heptatriaconta-6,9,28,31-tetraen-19-yl 4-(dimethylamino)butanoate
(DLin-MC3-DMA),
2,2-dilinoleyl-4-(2-dimethylaminoethyl)-[1,3]-dioxolane
(DLin-KC2-DMA),
2-({8-[(3.beta.)-cholest-5-en-3-yloxy]octyl}oxy)-N,N-dimethyl-3-[(9Z,12Z)-
-octadeca-9,12-dien-1-yloxy]propan-1-amine (Octyl-CLinDMA),
(2R)-2-({8-[(3.beta.)-cholest-5-en-3-yloxy]octyl}oxy)-N,N-dimethyl-3-[(9Z-
,12Z)-octadeca-9,12-dien-1-yloxy]propan-1-amine (Octyl-CLinDMA
(2R)),
(2S)-2-({8-[(3.beta.)-cholest-5-en-3-yloxy]octyl}oxy)-N,N-dimethyl-3-[(9Z-
,12Z)-octadeca-9,12-dien-1-yloxy]propan-1-amine (Octyl-CLinDMA
(2S)).N,N-dioleyl-N,N-dimethylammonium chloride ("DODAC");
N-(2,3-dioleyloxy)propyl-N,N--N-triethylammonium chloride
("DOTMA"); N,N-distearyl-N,N-dimethylammonium bromide ("DDAB");
N-(2,3-dioleoyloxy)propyl)-N,N,N-trimethylammonium chloride
("DOTAP"); 1,2-Dioleyloxy-3-trimethylaminopropane chloride salt
("DOTAP.Cl");
3-.beta.-(N--(N',N'-dimethylaminoethane)-carbamoyl)cholesterol
("DC-Chol"),
N-(1-(2,3-dioleyloxy)propyl)-N-2-(sperminecarboxamido)ethyl)-N,N-dimethyl-
-ammonium trifluoracetate ("DOSPA"), dioctadecylamidoglycyl
carboxyspermine ("DOGS"), 1,2-dioleoyl-3-dimethylammonium propane
("DODAP"), N,N-dimethyl-2,3-dioleyloxy)propylamine ("DODMA"), and
N-(1,2-dimyristyloxyprop-3-yl)-N,N-dimethyl-N-hydroxyethyl ammonium
bromide ("DMRIE"). Additionally, a number of commercial
preparations of cationic and/or ionizable lipids can be used, such
as, e.g., LIPOFECTIN.RTM. (including DOTMA and DOPE, available from
GIBCO/BRL), and LIPOFECTAMINE.RTM. (including DOSPA and DOPE,
available from GIBCO/BRL). KL10, KL22, and KL25 are described, for
example, in U.S. Pat. No. 8,691,750, which is incorporated herein
by reference in its entirety. In particular embodiments, the lipid
is DLin-MC3-DMA or DLin-KC2-DMA.
[0490] Anionic lipids suitable for use in lipid nanoparticles of
the disclosure include, but are not limited to,
phosphatidylglycerol, cardiolipin, diacylphosphatidylserine,
diacylphosphatidic acid, N-dodecanoyl phosphatidylethanoloamine,
N-succinyl phosphatidylethanolamine, N-glutaryl
phosphatidylethanolamine, lysylphosphatidylglycerol, and other
anionic modifying groups joined to neutral lipids.
[0491] Neutral lipids suitable for use in lipid nanoparticles of
the disclosure include, but are not limited to,
diacylphosphatidylcholine, diacylphosphatidylethanolamine,
ceramide, sphingomyelin, dihydrosphingomyelin, cephalin, and
cerebrosides. Lipids having a variety of acyl chain groups of
varying chain length and degree of saturation are available or may
be isolated or synthesized by well-known techniques. Additionally,
lipids having mixtures of saturated and unsaturated fatty acid
chains can be used. In some embodiments, the neutral lipids used in
the disclosure are DOPE, DSPC, DPPC, POPC, or any related
phosphatidylcholine. In some embodiments, the neutral lipid may be
composed of sphingomyelin, dihydrosphingomyeline, or phospholipids
with other head groups, such as serine and inositol.
[0492] In some embodiments, amphipathic lipids are included in
nanoparticles of the disclosure. Exemplary amphipathic lipids
suitable for use in nanoparticles of the disclosure include, but
are not limited to, sphingolipids, phospholipids, and aminolipids.
In some embodiments, a phospholipid is selected from the group
consisting of 1,2-dilinoleoyl-sn-glycero-3-phosphocholine (DLPC),
1,2-dimyristoyl-sn-glycero-phosphocholine (DMPC),
1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC),
1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC),
1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC),
1,2-diundecanoyl-sn-glycero-phosphocholine (DUPC),
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC),
1,2-di-O-octadecenyl-sn-glycero-3-phosphocholine (18:0 Diether PC),
1-oleoyl-2-cholesterylhemisuccinoyl-sn-glycero-3-phosphocholine
(OChemsPC), 1-hexadecyl-sn-glycero-3-phosphocholine (C16 Lyso PC),
1,2-dilinolenoyl-sn-glycero-3-phosphocholine,
1,2-diarachidonoyl-sn-glycero-3-phosphocholine,
1,2-didocosahexaenoyl-sn-glycero-3-phosphocholine,
1,2-dioleoyl-sn-glycero-3-phosphoetha nolamine (DOPE),
1,2-diphytanoyl-sn-glycero-3-phosphoethanolamine (ME 16.0 PE),
1,2-distearoyl-sn-glycero-3-phosphoethanolamine,
1,2-dilinoleoyl-sn-glycero-3-phosphoethanolamine,
1,2-dilinolenoyl-sn-glycero-3-phosphoethanolamine,
1,2-diarachidonoyl-sn-glycero-3-phosphoethanolamine,
1,2-didocosahexaenoyl-sn-glycero-3-phosphoethanolamine,
1,2-dioleoyl-sn-glycero-3-phospho-rac-(1-glycerol) sodium salt
(DOPG), and sphingomyelin. Other phosphorus-lacking compounds, such
as sphingolipids, glycosphingolipid families, diacylglycerols, and
.beta.-acyloxyacids, may also be used. Additionally, such
amphipathic lipids can be readily mixed with other lipids, such as
triglycerides and sterols.
[0493] In some embodiments, the lipid component of a nanoparticle
of the disclosure may include one or more PEGylated lipids. A
PEGylated lipid (also known as a PEG lipid or a PEG-modified lipid)
is a lipid modified with polyethylene glycol. The lipid component
may include one or more PEGylated lipids. A PEGylated lipid may be
selected from the non-limiting group consisting of PEG-modified
phosphatidylethanolamines, PEG-modified phosphatidic acids,
PEG-modified ceramides, PEG-modified dialkylamines, PEG-modified
diacylglycerols, and PEG-modified dialkylglycerols. For example, a
PEGylated lipid may be PEG-c-DOMG, PEG-DMG, PEG-DLPE, PEG-DMPE,
PEG-DPPC, or a PEG-DSPE lipid.
[0494] A lipid nanoparticle of the disclosure may include one or
more structural lipids. Exemplary, non-limiting structural lipids
that may be present in the lipid nanoparticles of the disclosure
include cholesterol, fecosterol, sitosterol, campesterol,
stigmasterol, brassicasterol, ergosterol, tomatidine, tomatine,
ursolic acid, or alpha-tocopherol.
[0495] In some embodiments, one or more mRNA of the disclosure may
be formulated in a lipid nanoparticle having a diameter from about
1 nm to about 900 nm, e.g., about 1 nm to about 100 nm, about 1 nm
to about 200 nm, about 1 nm to about 300 nm, about 1 nm to about
400 nm, about 1 nm to about 500 nm, about 1 nm to about 600 nm,
about 1 nm to about 700 nm, about 1 nm to 800 nm, about 1 nm to
about 900 nm. In some embodiments, the nanoparticle may have a
diameter from about 10 nm to about 300 nm, about 20 nm to about 200
nm, about 30 nm to about 100 nm, or about 40 nm to about 80 nm. In
some embodiments, the nanoparticle may have a diameter from about
30 nm to about 300 nm, about 40 nm to about 200 nm, about 50 nm to
about 150 nm, about 70 to about 110 nm, or about 80 nm to about 120
nm. In one embodiment, an mRNA may be formulated in a lipid
nanoparticle having a diameter from about 10 to about 100 nm
including ranges in between such as, but not limited to, about 10
to about 20 nm, about 10 to about 30 nm, about 10 to about 40 nm,
about 10 to about 50 nm, about 10 to about 60 nm, about 10 to about
70 nm, about 10 to about 80 nm, about 10 to about 90 nm, about 20
to about 30 nm, about 20 to about 40 nm, about 20 to about 50 nm,
about 20 to about 60 nm, about 20 to about 70 nm, about 20 to about
80 nm, about 20 to about 90 nm, about 20 to about 100 nm, about 30
to about 40 nm, about 30 to about 50 nm, about 30 to about 60 nm,
about 30 to about 70 nm, about 30 to about 80 nm, about 30 to about
90 nm, about 30 to about 100 nm, about 40 to about 50 nm, about 40
to about 60 nm, about 40 to about 70 nm, about 40 to about 80 nm,
about 40 to about 90 nm, about 40 to about 100 nm, about 50 to
about 60 nm, about 50 to about 70 nm about 50 to about 80 nm, about
50 to about 90 nm, about 50 to about 100 nm, about 60 to about 70
nm, about 60 to about 80 nm, about 60 to about 90 nm, about 60 to
about 100 nm, about 70 to about 80 nm, about 70 to about 90 nm,
about 70 to about 100 nm, about 80 to about 90 nm, about 80 to
about 100 nm, and/or about 90 to about 100 nm. In one embodiment,
an mRNA may be formulated in a lipid nanoparticle having a diameter
from about 30 nm to about 300 nm, about 40 nm to about 200 nm,
about 50 nm to about 150 nm, about 70 to about 110 nm, or about 80
nm to about 120 nm including ranges in between.
[0496] In some embodiments, a lipid nanoparticle may have a
diameter greater than 100 nm, greater than 150 nm, greater than 200
nm, greater than 250 nm, greater than 300 nm, greater than 350 nm,
greater than 400 nm, greater than 450 nm, greater than 500 nm,
greater than 550 nm, greater than 600 nm, greater than 650 nm,
greater than 700 nm, greater than 750 nm, greater than 800 nm,
greater than 850 nm, greater than 900 nm, or greater than 950
nm.
[0497] In some embodiments, the particle size of the lipid
nanoparticle may be increased and/or decreased. The change in
particle size may be able to help counter a biological reaction
such as, but not limited to, inflammation, or may increase the
biological effect of the mRNA delivered to a patient or
subject.
[0498] In certain embodiments, it is desirable to target a
nanoparticle, e.g., a lipid nanoparticle, of the disclosure using a
targeting moiety that is specific to a cell type and/or tissue
type. In some embodiments, a nanoparticle may be targeted to a
particular cell, tissue, and/or organ using a targeting moiety. In
particular embodiments, a nanoparticle comprises one or more mRNA
described herein and a targeting moiety. Exemplary non-limiting
targeting moieties include ligands, cell surface receptors,
glycoproteins, vitamins (e.g., riboflavin) and antibodies (e.g.,
full-length antibodies, antibody fragments (e.g., Fv fragments,
single chain Fv (scFv) fragments, Fab' fragments, or F(ab')2
fragments), single domain antibodies, camelid antibodies and
fragments thereof, human antibodies and fragments thereof,
monoclonal antibodies, and multispecific antibodies (e.g.,
bispecific antibodies)). In some embodiments, the targeting moiety
may be a polypeptide. The targeting moiety may include the entire
polypeptide (e.g., peptide or protein) or fragments thereof. A
targeting moiety is typically positioned on the outer surface of
the nanoparticle in such a manner that the targeting moiety is
available for interaction with the target, for example, a cell
surface receptor. A variety of different targeting moieties and
methods are known and available in the art, including those
described, e.g., in Sapra et al., Prog. Lipid Res. 42(5):439-62,
2003 and Abra et al., J. Liposome Res. 12:1-3, 2002.
[0499] In some embodiments, a lipid nanoparticle (e.g., a liposome)
may include a surface coating of hydrophilic polymer chains, such
as polyethylene glycol (PEG) chains (see, e.g., Allen et al.,
Biochimica et Biophysica Acta 1237: 99-108, 1995; DeFrees et al.,
Journal of the American Chemistry Society 118: 6101-6104, 1996;
Blume et al., Biochimica et Biophysica Acta 1149: 180-184, 1993;
Klibanov et al., Journal of Liposome Research 2: 321-334, 1992;
U.S. Pat. No. 5,013,556; Zalipsky, Bioconjugate Chemistry 4:
296-299, 1993; Zalipsky, FEBS Letters 353: 71-74, 1994; Zalipsky,
in Stealth Liposomes Chapter 9 (Lasic and Martin, Eds) CRC Press,
Boca Raton Fla., 1995). In one approach, a targeting moiety for
targeting the lipid nanoparticle is linked to the polar head group
of lipids forming the nanoparticle. In another approach, the
targeting moiety is attached to the distal ends of the PEG chains
forming the hydrophilic polymer coating (see, e.g., Klibanov et
al., Journal of Liposome Research 2: 321-334, 1992; Kirpotin et
al., FEBS Letters 388: 115-118, 1996).
[0500] Standard methods for coupling the targeting moiety or
moieties may be used. For example, phosphatidylethanolamine, which
can be activated for attachment of targeting moieties, or
derivatized lipophilic compounds, such as lipid-derivatized
bleomycin, can be used. Antibody-targeted liposomes can be
constructed using, for instance, liposomes that incorporate protein
A (see, e.g., Renneisen et al., J. Bio. Chem., 265:16337-16342,
1990 and Leonetti et al., Proc. Natl. Acad. Sci. (USA),
87:2448-2451, 1990). Other examples of antibody conjugation are
disclosed in U.S. Pat. No. 6,027,726. Examples of targeting
moieties can also include other polypeptides that are specific to
cellular components, including antigens associated with neoplasms
or tumors. Polypeptides used as targeting moieties can be attached
to the liposomes via covalent bonds (see, for example Heath,
Covalent Attachment of Proteins to Liposomes, 149 Methods in
Enzymology 111-119 (Academic Press, Inc. 1987)). Other targeting
methods include the biotin-avidin system.
[0501] In some embodiments, a lipid nanoparticle of the disclosure
includes a targeting moiety that targets the lipid nanoparticle to
a cell including, but not limited to, hepatocytes, colon cells,
epithelial cells, hematopoietic cells, epithelial cells,
endothelial cells, lung cells, bone cells, stem cells, mesenchymal
cells, neural cells, cardiac cells, adipocytes, vascular smooth
muscle cells, cardiomyocytes, skeletal muscle cells, beta cells,
pituitary cells, synovial lining cells, ovarian cells, testicular
cells, fibroblasts, B cells, T cells, reticulocytes, leukocytes,
granulocytes, and tumor cells (including primary tumor cells and
metastatic tumor cells). In particular embodiments, the targeting
moiety targets the lipid nanoparticle to a hepatocyte. In other
embodiments, the targeting moiety targets the lipid nanoparticle to
a colon cell. In some embodiments, the targeting moiety targets the
lipid nanoparticle to a liver cancer cell (e.g., a hepatocellular
carcinoma cell) or a colorectal cancer cell (e.g., a primary tumor
or a metastasis).
[0502] Lipid Nanoparticles
[0503] In one set of embodiments, lipid nanoparticles (LNPs) are
provided. In one embodiment, a lipid nanoparticle comprises lipids
including an ionizable lipid, a structural lipid, a phospholipid,
and one or more mRNAs. Each of the LNPs described herein may be
used as a formulation for the mRNA described herein. In one
embodiment, a lipid nanoparticle comprises an ionizable lipid, a
structural lipid, a phospholipid, a PEG-modified lipid and one or
more mRNAs. In some embodiments, the LNP comprises an ionizable
lipid, a PEG-modified lipid, a sterol and a phospholipid. In some
embodiments, the LNP has a molar ratio of about 20-60% ionizable
lipid:about 5-25% phospholipid:about 25-55% sterol; and about
0.5-15% PEG-modified lipid. In some embodiments, the LNP comprises
a molar ratio of about 50% ionizable lipid, about 1.5% PEG-modified
lipid, about 38.5% cholesterol and about 10% phospholipid. In some
embodiments, the LNP comprises a molar ratio of about 55% ionizable
lipid, about 2.5% PEG lipid, about 32.5% cholesterol and about 10%
phospholipid. In some embodiments, the ionizable lipid is an
ionizable amino or cationic lipid and the neutral lipid is a
phospholipid, and the sterol is a cholesterol. In some embodiments,
the LNP has a molar ratio of 50:38.5:10:1.5 of ionizable
lipid:cholesterol:DSPC
(1,2-dioctadecanoyl-sn-glycero-3-phosphocholine):PEG-DMG.
[0504] a. Ionizable Lipid
[0505] The present disclosure provides pharmaceutical compositions
with advantageous properties. For example, the lipids described
herein (e.g. those having any of Formula (I), (IA), (II), (IIa),
(IIb), (IIc), (IId), (IIe), (III), (IV), (V), or (VI) may be
advantageously used in lipid nanoparticle compositions for the
delivery of therapeutic and/or prophylactic agents to mammalian
cells or organs. For example, the lipids described herein have
little or no immunogenicity. For example, the lipid compounds
disclosed hereinhave a lower immunogenicity as compared to a
reference lipid (e.g., MC3, KC2, or DLinDMA). For example, a
formulation comprising a lipid disclosed herein and a therapeutic
or prophylactic agent has an increased therapeutic index as
compared to a corresponding formulation which comprises a reference
lipid (e.g., MC3, KC2, or DLinDMA) and the same therapeutic or
prophylactic agent. In particular, the present application provides
pharmaceutical compositions comprising:
[0506] (a) a polynucleotide comprising a nucleotide sequence
encoding a polypeptide of interest; and
[0507] (b) a delivery agent.
[0508] In some embodiments, the delivery agent comprises a lipid
compound having the Formula (I)
##STR00001##
[0509] wherein
[0510] R.sub.1 is selected from the group consisting of C.sub.5-30
alkyl, C.sub.5-20 alkenyl, --R*YR'', --YR'', and --R''M'R';
[0511] R.sub.2 and R.sub.3 are independently selected from the
group consisting of H, C.sub.1-14 alkyl, C.sub.2-14 alkenyl,
--R*YR'', --YR'', and --R*OR'', or R.sub.2 and R.sub.3, together
with the atom to which they are attached, form a heterocycle or
carbocycle;
[0512] R.sub.4 is selected from the group consisting of a C.sub.3-6
carbocycle, --(CH.sub.2).sub.nQ, --(CH.sub.2).sub.nCHQR, --CHQR,
--CQ(R).sub.2, and unsubstituted C.sub.1-6 alkyl, where Q is
selected from a carbocycle, heterocycle, --OR,
--O(CH.sub.2).sub.nN(R).sub.2, --C(O)OR, --OC(O)R, --CX.sub.3,
--CX.sub.2H, --CXH.sub.2, --CN, --N(R).sub.2, --C(O)N(R).sub.2,
--N(R)C(O)R, --N(R)S(O).sub.2R, --N(R)C(O)N(R).sub.2,
--N(R)C(S)N(R).sub.2, --N(R)R.sub.8, --O(CH.sub.2).sub.nOR,
--N(R)C(.dbd.NR.sub.9)N(R).sub.2,
--N(R)C(.dbd.CHR.sub.9)N(R).sub.2, --OC(O)N(R).sub.2, --N(R)C(O)OR,
--N(OR)C(O)R, --N(OR)S(O).sub.2R, --N(OR)C(O)OR,
--N(OR)C(O)N(R).sub.2, --N(OR)C(S)N(R).sub.2,
--N(OR)C(.dbd.NR.sub.9)N(R).sub.2,
--N(OR)C(.dbd.CHR.sub.9)N(R).sub.2, --C(.dbd.NR.sub.9)N(R).sub.2,
--C(.dbd.NR.sub.9)R, --C(O)N(R)OR, and --C(R)N(R).sub.2C(O)OR, and
each n is independently selected from 1, 2, 3, 4, and 5;
[0513] each R.sub.5 is independently selected from the group
consisting of C.sub.1-3 alkyl, C.sub.2-3 alkenyl, and H;
[0514] each R.sub.6 is independently selected from the group
consisting of C.sub.1-3 alkyl, C.sub.2-3 alkenyl, and H;
[0515] M and M' are independently selected from --C(O)O--,
--OC(O)--, --C(O)N(R')--, --N(R')C(O)--, --C(O)--, --C(S)--,
--C(S)S--, --SC(S)--, --CH(OH)--, --P(O)(OR')O--, --S(O).sub.2--,
--S--S--, an aryl group, and a heteroaryl group;
[0516] R.sub.7 is selected from the group consisting of C.sub.1-3
alkyl, C.sub.2-3 alkenyl, and H;
[0517] R.sub.8 is selected from the group consisting of C.sub.3-6
carbocycle and heterocycle;
[0518] R.sub.9 is selected from the group consisting of H, CN,
NO.sub.2, C.sub.1-6 alkyl, --OR, --S(O).sub.2R,
--S(O).sub.2N(R).sub.2, C.sub.2-6 alkenyl, C.sub.3-6 carbocycle and
heterocycle;
[0519] each R is independently selected from the group consisting
of C.sub.1-3 alkyl, C.sub.2-3 alkenyl, and H;
[0520] each R' is independently selected from the group consisting
of C.sub.1-18 alkyl, C.sub.2-18 alkenyl, --R*YR'', --YR'', and
H;
[0521] each R'' is independently selected from the group consisting
of C.sub.3-14 alkyl and C.sub.3-14 alkenyl;
[0522] each R* is independently selected from the group consisting
of C.sub.1-12 alkyl and C.sub.2-12 alkenyl;
[0523] each Y is independently a C.sub.3-6 carbocycle;
[0524] each X is independently selected from the group consisting
of F, Cl, Br, and I; and m is selected from 5, 6, 7, 8, 9, 10, 11,
12, and 13, or salts or stereoisomers thereof.
[0525] In some embodiments, a subset of compounds of Formula (I)
includes those in which
[0526] R.sub.1 is selected from the group consisting of C.sub.5-20
alkyl, C.sub.5-20 alkenyl, --R*YR'', --YR'', and --R''M'R';
[0527] R.sub.2 and R.sub.3 are independently selected from the
group consisting of H, C.sub.1-14 alkyl, C.sub.2-14 alkenyl,
--R*YR'', --YR'', and --R*OR'', or R.sub.2 and R.sub.3, together
with the atom to which they are attached, form a heterocycle or
carbocycle;
[0528] R.sub.4 is selected from the group consisting of a C.sub.3-6
carbocycle, --(CH.sub.2).sub.nQ, --(CH.sub.2).sub.nCHQR, --CHQR,
--CQ(R).sub.2, and unsubstituted C.sub.1-6 alkyl, where Q is
selected from a carbocycle, heterocycle, --OR,
--O(CH.sub.2).sub.nN(R).sub.2, --C(O)OR, --OC(O)R, --CX.sub.3,
--CX.sub.2H, --CXH.sub.2, --CN, --N(R).sub.2, --C(O)N(R).sub.2,
--N(R)C(O)R, --N(R)S(O).sub.2R, --N(R)C(O)N(R).sub.2,
--N(R)C(S)N(R).sub.2, and --C(R)N(R).sub.2C(O)OR, and each n is
independently selected from 1, 2, 3, 4, and 5;
[0529] each R.sub.5 is independently selected from the group
consisting of C.sub.1-3 alkyl, C.sub.2-3 alkenyl, and H;
[0530] each R.sub.6 is independently selected from the group
consisting of C.sub.1-3 alkyl, C.sub.2-3 alkenyl, and H;
[0531] M and M' are independently selected from --C(O)O--,
--OC(O)--, --C(O)N(R')--, --N(R')C(O)--, --C(O)--, --C(S)--,
--C(S)S--, --SC(S)--, --CH(OH)--, --P(O)(OR')O--, --S(O).sub.2--,
an aryl group, and a heteroaryl group;
[0532] R.sub.7 is selected from the group consisting of C.sub.1-3
alkyl, C.sub.2-3 alkenyl, and H;
[0533] each R is independently selected from the group consisting
of C.sub.1-3 alkyl, C.sub.2-3 alkenyl, and H;
[0534] each R' is independently selected from the group consisting
of C.sub.1-18 alkyl, C.sub.2-18 alkenyl, --R*YR'', --YR'', and
H;
[0535] each R'' is independently selected from the group consisting
of C.sub.3-14 alkyl and C.sub.3-14 alkenyl;
[0536] each R* is independently selected from the group consisting
of C.sub.1-12 alkyl and C.sub.2-12 alkenyl;
[0537] each Y is independently a C.sub.3-6 carbocycle;
[0538] each X is independently selected from the group consisting
of F, Cl, Br, and I; and m is selected from 5, 6, 7, 8, 9, 10, 11,
12, and 13,
[0539] or salts or stereoisomers thereof, wherein alkyl and alkenyl
groups may be linear or branched.
[0540] In some embodiments, a subset of compounds of Formula (I)
includes those in which when R.sub.4 is --(CH.sub.2).sub.nQ,
--(CH.sub.2).sub.nCHQR, --CHQR, or --CQ(R).sub.2, then (i) Q is not
--N(R).sub.2 when n is 1, 2, 3, 4 or 5, or (ii) Q is not 5, 6, or
7-membered heterocycloalkyl when n is 1 or 2.
[0541] In another embodiments, another subset of compounds of
Formula (I) includes those in which
[0542] R.sub.1 is selected from the group consisting of C.sub.5-30
alkyl, C.sub.5-20 alkenyl, --R*YR'', --YR'', and --R''M'R';
[0543] R.sub.2 and R.sub.3 are independently selected from the
group consisting of H, C.sub.1-14 alkyl, C.sub.2-14 alkenyl,
--R*YR'', --YR'', and --R*OR'', or R.sub.2 and R.sub.3, together
with the atom to which they are attached, form a heterocycle or
carbocycle;
[0544] R.sub.4 is selected from the group consisting of a C.sub.3-6
carbocycle, --(CH.sub.2).sub.nQ, --(CH.sub.2).sub.nCHQR, --CHQR,
--CQ(R).sub.2, and unsubstituted C.sub.1-6 alkyl, where Q is
selected from a C.sub.3-6 carbocycle, a 5- to 14-membered
heteroaryl having one or more heteroatoms selected from N, O, and
S, --OR, --O(CH.sub.2).sub.nN(R).sub.2, --C(O)OR, --OC(O)R,
--CX.sub.3, --CX.sub.2H, --CXH.sub.2, --CN, --C(O)N(R).sub.2,
--N(R)C(O)R, --N(R)S(O).sub.2R, --N(R)C(O)N(R).sub.2,
--N(R)C(S)N(R).sub.2, --CRN(R).sub.2C(O)OR, --N(R)R.sub.8,
--O(CH.sub.2).sub.nOR, --N(R)C(.dbd.NR.sub.9)N(R).sub.2,
--N(R)C(.dbd.CHR.sub.9)N(R).sub.2, --O C(O)N(R).sub.2,
--N(R)C(O)OR, --N(OR)C(O)R, --N(OR)S(O).sub.2R, --N(OR)C(O)OR,
--N(OR)C(O)N(R).sub.2, --N(OR)C(S)N(R).sub.2,
--N(OR)C(.dbd.NR.sub.9)N(R).sub.2,
--N(OR)C(.dbd.CHR.sub.9)N(R).sub.2, --C(.dbd.NR.sub.9)N(R).sub.2,
--C (.dbd.NR.sub.9)R, --C(O)N(R)OR, and a 5- to 14-membered
heterocycloalkyl having one or more heteroatoms selected from N, O,
and S which is substituted with one or more substituents selected
from oxo (.dbd.O), OH, amino, and C.sub.1-3 alkyl, and each n is
independently selected from 1, 2, 3, 4, and 5;
[0545] each R.sub.5 is independently selected from the group
consisting of C.sub.1-3 alkyl, C.sub.2-3 alkenyl, and H;
[0546] each R.sub.6 is independently selected from the group
consisting of C.sub.1-3 alkyl, C.sub.2-3 alkenyl, and H;
[0547] M and M' are independently selected from --C(O)O--,
--OC(O)--, --C(O)N(R')--, --N(R')C(O)--, --C(O)--, --C(S)--,
--C(S)S--, --SC(S)--, --CH(OH)--, --P(O)(OR')O--, --S(O).sub.2--,
--S--S--, an aryl group, and a heteroaryl group;
[0548] R.sub.7 is selected from the group consisting of C.sub.1-3
alkyl, C.sub.2-3 alkenyl, and H;
[0549] R.sub.8 is selected from the group consisting of C.sub.3-6
carbocycle and heterocycle;
[0550] R.sub.9 is selected from the group consisting of H, CN,
NO.sub.2, C.sub.1-6 alkyl, --OR, --S(O).sub.2R,
--S(O).sub.2N(R).sub.2, C.sub.2-6 alkenyl, C.sub.3-6 carbocycle and
heterocycle;
[0551] each R is independently selected from the group consisting
of C.sub.1-3 alkyl, C.sub.2-3 alkenyl, and H;
[0552] each R' is independently selected from the group consisting
of C.sub.1-18 alkyl, C.sub.2-18 alkenyl, --R*YR'', --YR'', and
H;
[0553] each R'' is independently selected from the group consisting
of C.sub.3-14 alkyl and C.sub.3-14 alkenyl;
[0554] each R* is independently selected from the group consisting
of C.sub.1-12 alkyl and C.sub.2-12 alkenyl;
[0555] each Y is independently a C.sub.3-6 carbocycle;
[0556] each X is independently selected from the group consisting
of F, Cl, Br, and I; and
[0557] m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13,
[0558] or salts or stereoisomers thereof.
[0559] In another embodiments, another subset of compounds of
Formula (I) includes those in which
[0560] R.sub.1 is selected from the group consisting of C.sub.5-30
alkyl, C.sub.5-20 alkenyl, --R*YR'', --YR'', and --R''M'R';
[0561] R.sub.2 and R.sub.3 are independently selected from the
group consisting of H, C.sub.1-14 alkyl, C.sub.2-14 alkenyl,
--R*YR'', --YR'', and --R*OR'', or R.sub.2 and R.sub.3, together
with the atom to which they are attached, form a heterocycle or
carbocycle;
[0562] R.sub.4 is selected from the group consisting of a C.sub.3-6
carbocycle, --(CH.sub.2).sub.nQ, --(CH.sub.2).sub.nCHQR, --CHQR,
--CQ(R).sub.2, and unsubstituted C.sub.1-6 alkyl, where Q is
selected from a C.sub.3-6 carbocycle, a 5- to 14-membered
heteroaryl having one or more heteroatoms selected from N, O, and
S, --OR, --O(CH.sub.2).sub.nN(R).sub.2, --C(O)OR, --OC(O)R,
--CX.sub.3, --CX.sub.2H, --CXH.sub.2, --CN, --C(O)N(R).sub.2,
--N(R)C(O)R, --N(R)S(O).sub.2R, --N(R)C(O)N(R).sub.2,
--N(R)C(S)N(R).sub.2, --CRN(R).sub.2C(O)OR, and a 5- to 14-membered
heterocycloalkyl having one or more heteroatoms selected from N, O,
and S which is substituted with one or more substituents selected
from oxo (.dbd.O), OH, amino, and C.sub.1-3 alkyl, and each n is
independently selected from 1, 2, 3, 4, and 5;
[0563] each R.sub.5 is independently selected from the group
consisting of C.sub.1-3 alkyl, C.sub.2-3 alkenyl, and H;
[0564] each R.sub.6 is independently selected from the group
consisting of C.sub.1-3 alkyl, C.sub.2-3 alkenyl, and H;
[0565] M and M' are independently selected from --C(O)O--,
--OC(O)--, --C(O)N(R')--, --N(R')C(O)--, --C(O)--, --C(S)--,
--C(S)S--, --SC(S)--, --CH(OH)--, --P(O)(OR')O--, --S(O).sub.2--,
an aryl group, and a heteroaryl group;
[0566] R.sub.7 is selected from the group consisting of C.sub.1-3
alkyl, C.sub.2-3 alkenyl, and H;
[0567] each R is independently selected from the group consisting
of C.sub.1-3 alkyl, C.sub.2-3 alkenyl, and H;
[0568] each R' is independently selected from the group consisting
of C.sub.1-18 alkyl, C.sub.2-18 alkenyl, --R*YR'', --YR'', and
H;
[0569] each R'' is independently selected from the group consisting
of C.sub.3-14 alkyl and C.sub.3-14 alkenyl;
[0570] each R* is independently selected from the group consisting
of C.sub.1-12 alkyl and C.sub.2-12 alkenyl;
[0571] each Y is independently a C.sub.3-6 carbocycle;
[0572] each X is independently selected from the group consisting
of F, Cl, Br, and I; and
[0573] m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13,
[0574] or salts or stereoisomers thereof.
[0575] In yet another embodiments, another subset of compounds of
Formula (I) includes those in which
[0576] R.sub.1 is selected from the group consisting of C.sub.5-20
alkyl, C.sub.5-20 alkenyl, --R*YR'', --YR'', and --R''M'R';
[0577] R.sub.2 and R.sub.3 are independently selected from the
group consisting of H, C.sub.1-14 alkyl, C.sub.2-14 alkenyl,
--R*YR'', --YR'', and --R*OR'', or R.sub.2 and R.sub.3, together
with the atom to which they are attached, form a heterocycle or
carbocycle;
[0578] R.sub.4 is selected from the group consisting of a C.sub.3-6
carbocycle, --(CH.sub.2).sub.nQ, --(CH.sub.2).sub.nCHQR, --CHQR,
--CQ(R).sub.2, and unsubstituted C.sub.1-6 alkyl, where Q is
selected from a C.sub.3-6 carbocycle, a 5- to 14-membered
heterocycle having one or more heteroatoms selected from N, O, and
S, --OR, --O(CH.sub.2).sub.nN(R).sub.2, --C(O)OR, --OC(O)R,
--CX.sub.3, --CX.sub.2H, --CXH.sub.2, --CN, --C(O)N(R).sub.2,
--N(R)C(O)R, --N(R)S(O).sub.2R, --N(R)C(O)N(R).sub.2,
--N(R)C(S)N(R).sub.2, --CRN(R).sub.2C(O)OR, --N(R)R.sub.8,
--O(CH.sub.2).sub.nOR, --N(R)C(.dbd.NR.sub.9)N(R).sub.2,
--N(R)C(.dbd.CHR.sub.9)N(R).sub.2, --OC(O)N(R).sub.2, --N(R)C(O)OR,
--N(OR)C(O)R, --N(OR)S(O).sub.2R, --N(OR)C(O)OR,
--N(OR)C(O)N(R).sub.2, --N(OR)C(S)N(R).sub.2,
--N(OR)C(.dbd.NR.sub.9)N(R).sub.2,
--N(OR)C(.dbd.CHR.sub.9)N(R).sub.2, --C(.dbd.NR.sub.9)R,
--C(O)N(R)OR, and --C(.dbd.NR.sub.9)N(R).sub.2, and each n is
independently selected from 1, 2, 3, 4, and 5; and when Q is a 5-
to 14-membered heterocycle and (i) R.sub.4 is --(CH.sub.2).sub.nQ
in which n is 1 or 2, or (ii) R.sub.4 is --(CH.sub.2).sub.nCHQR in
which n is 1, or (iii) R.sub.4 is --CHQR, and --CQ(R).sub.2, then Q
is either a 5- to 14-membered heteroaryl or 8- to 14-membered
heterocycloalkyl;
[0579] each R.sub.5 is independently selected from the group
consisting of C.sub.1-3 alkyl, C.sub.2-3 alkenyl, and H;
[0580] each R.sub.6 is independently selected from the group
consisting of C.sub.1-3 alkyl, C.sub.2-3 alkenyl, and H;
[0581] M and M' are independently selected from --C(O)O--,
--OC(O)--, --C(O)N(R')--, --N(R')C(O)--, --C(O)--, --C(S)--,
--C(S)S--, --SC(S)--, --CH(OH)--, --P(O)(OR')O--, --S(O).sub.2--,
--S--S--, an aryl group, and a heteroaryl group;
[0582] R.sub.7 is selected from the group consisting of C.sub.1-3
alkyl, C.sub.2-3 alkenyl, and H;
[0583] R.sub.8 is selected from the group consisting of C.sub.3-6
carbocycle and heterocycle;
[0584] R.sub.9 is selected from the group consisting of H, CN,
NO.sub.2, C.sub.1-6 alkyl, --OR, --S(O).sub.2R,
--S(O).sub.2N(R).sub.2, C.sub.2-6 alkenyl, C.sub.3-6 carbocycle and
heterocycle;
[0585] each R is independently selected from the group consisting
of C.sub.1-3 alkyl, C.sub.2-3 alkenyl, and H;
[0586] each R' is independently selected from the group consisting
of C.sub.1-18 alkyl, C.sub.2-18 alkenyl, --R*YR'', --YR'', and
H;
[0587] each R'' is independently selected from the group consisting
of C.sub.3-14 alkyl and C.sub.3-14 alkenyl;
[0588] each R* is independently selected from the group consisting
of C.sub.1-12 alkyl and C.sub.2-12 alkenyl;
[0589] each Y is independently a C.sub.3-6 carbocycle;
[0590] each X is independently selected from the group consisting
of F, Cl, Br, and I; and
[0591] m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13,
[0592] or salts or stereoisomers thereof.
[0593] In yet another embodiments, another subset of compounds of
Formula (I) includes those in which
[0594] R.sub.1 is selected from the group consisting of C.sub.5-20
alkyl, C.sub.5-20 alkenyl, --R*YR'', --YR'', and --R''M'R';
[0595] R.sub.2 and R.sub.3 are independently selected from the
group consisting of H, C.sub.1-14 alkyl, C.sub.2-14 alkenyl,
--R*YR'', --YR'', and --R*OR'', or R.sub.2 and R.sub.3, together
with the atom to which they are attached, form a heterocycle or
carbocycle;
[0596] R.sub.4 is selected from the group consisting of a C.sub.3-6
carbocycle, --(CH.sub.2).sub.nQ, --(CH.sub.2).sub.nCHQR, --CHQR,
--CQ(R).sub.2, and unsubstituted C.sub.1-6 alkyl, where Q is
selected from a C.sub.3-6 carbocycle, a 5- to 14-membered
heterocycle having one or more heteroatoms selected from N, O, and
S, --OR, --O(CH.sub.2).sub.nN(R).sub.2, --C(O)OR, --OC(O)R,
--CX.sub.3, --CX.sub.2H, --CXH.sub.2, --CN, --C(O)N(R).sub.2,
--N(R)C(O)R, --N(R)S(O).sub.2R, --N(R)C(O)N(R).sub.2,
--N(R)C(S)N(R).sub.2, --CRN(R).sub.2C(O)OR, and each n is
independently selected from 1, 2, 3, 4, and 5; and when Q is a 5-
to 14-membered heterocycle and (i) R.sub.4 is --(CH.sub.2).sub.nQ
in which n is 1 or 2, or (ii) R.sub.4 is --(CH.sub.2).sub.nCHQR in
which n is 1, or (iii) R.sub.4 is --CHQR, and --CQ(R).sub.2, then Q
is either a 5- to 14-membered heteroaryl or 8- to 14-membered
heterocycloalkyl;
[0597] each R.sub.5 is independently selected from the group
consisting of C.sub.1-3 alkyl, C.sub.2-3 alkenyl, and H;
[0598] each R.sub.6 is independently selected from the group
consisting of C.sub.1-3 alkyl, C.sub.2-3 alkenyl, and H;
[0599] M and M' are independently selected from --C(O)O--,
--OC(O)--, --C(O)N(R')--, --N(R')C(O)--, --C(O)--, --C(S)--,
--C(S)S--, --SC(S)--, --CH(OH)--, --P(O)(OR')O--, --S(O).sub.2--,
an aryl group, and a heteroaryl group;
[0600] R.sub.7 is selected from the group consisting of C.sub.1-3
alkyl, C.sub.2-3 alkenyl, and H;
[0601] each R is independently selected from the group consisting
of C.sub.1-3 alkyl, C.sub.2-3 alkenyl, and H;
[0602] each R' is independently selected from the group consisting
of C.sub.1-18 alkyl, C.sub.2-18 alkenyl, --R*YR'', --YR'', and
H;
[0603] each R'' is independently selected from the group consisting
of C.sub.3-14 alkyl and C.sub.3-14 alkenyl;
[0604] each R* is independently selected from the group consisting
of C.sub.1-12 alkyl and C.sub.2-12 alkenyl;
[0605] each Y is independently a C.sub.3-6 carbocycle;
[0606] each X is independently selected from the group consisting
of F, Cl, Br, and I; and
[0607] m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13,
[0608] or salts or stereoisomers thereof.
[0609] In still another embodiments, another subset of compounds of
Formula (I) includes those in which
[0610] R.sub.1 is selected from the group consisting of C.sub.5-30
alkyl, C.sub.5-20 alkenyl, --R*YR'', --YR'', and --R''M'R';
[0611] R.sub.2 and R.sub.3 are independently selected from the
group consisting of H, C.sub.1-14 alkyl, C.sub.2-14 alkenyl,
--R*YR'', --YR'', and --R*OR'', or R.sub.2 and R.sub.3, together
with the atom to which they are attached, form a heterocycle or
carbocycle;
[0612] R.sub.4 is selected from the group consisting of a C.sub.3-6
carbocycle, --(CH.sub.2).sub.nQ, --(CH.sub.2).sub.nCHQR, --CHQR,
--CQ(R).sub.2, and unsubstituted C.sub.1-6 alkyl, where Q is
selected from a C.sub.3-6 carbocycle, a 5- to 14-membered
heteroaryl having one or more heteroatoms selected from N, O, and
S, --OR, --O(CH.sub.2).sub.nN(R).sub.2, --C(O)OR, --OC(O)R,
--CX.sub.3, --CX.sub.2H, --CXH.sub.2, --CN, --C(O)N(R).sub.2,
--N(R)C(O)R, --N(R)S(O).sub.2R, --N(R)C(O)N(R).sub.2,
--N(R)C(S)N(R).sub.2, --CRN(R).sub.2C(O)OR, --N(R)R.sub.8,
--O(CH.sub.2).sub.nOR, --N(R)C(.dbd.NR.sub.9)N(R).sub.2,
--N(R)C(.dbd.CHR.sub.9)N(R).sub.2, --OC(O)N(R).sub.2, --N(R)C(O)OR,
--N(OR)C(O)R, --N(OR)S(O).sub.2R, --N(OR)C(O)OR,
--N(OR)C(O)N(R).sub.2, --N(OR)C(S)N(R).sub.2,
--N(OR)C(.dbd.NR.sub.9)N(R).sub.2,
--N(OR)C(.dbd.CHR.sub.9)N(R).sub.2, --C(.dbd.NR.sub.9)R,
--C(O)N(R)OR, and --C(.dbd.NR.sub.9)N(R).sub.2, and each n is
independently selected from 1, 2, 3, 4, and 5;
[0613] each R.sub.5 is independently selected from the group
consisting of C.sub.1-3 alkyl, C.sub.2-3 alkenyl, and H;
[0614] each R.sub.6 is independently selected from the group
consisting of C.sub.1-3 alkyl, C.sub.2-3 alkenyl, and H;
[0615] M and M' are independently selected from --C(O)O--,
--OC(O)--, --C(O)N(R')--, --N(R')C(O)--, --C(O)--, --C(S)--,
--C(S)S--, --SC(S)--, --CH(OH)--, --P(O)(OR')O--, --S(O).sub.2--,
--S--S--, an aryl group, and a heteroaryl group;
[0616] R.sub.7 is selected from the group consisting of C.sub.1-3
alkyl, C.sub.2-3 alkenyl, and H;
[0617] R.sub.8 is selected from the group consisting of C.sub.3-6
carbocycle and heterocycle;
[0618] R.sub.9 is selected from the group consisting of H, CN,
NO.sub.2, C.sub.1-6 alkyl, --OR, --S(O).sub.2R,
--S(O).sub.2N(R).sub.2, C.sub.2-6 alkenyl, C.sub.3-6 carbocycle and
heterocycle;
[0619] each R is independently selected from the group consisting
of C.sub.1-3 alkyl, C.sub.2-3 alkenyl, and H;
[0620] each R' is independently selected from the group consisting
of C.sub.1-18 alkyl, C.sub.2-18 alkenyl, --R*YR'', --YR'', and
H;
[0621] each R'' is independently selected from the group consisting
of C.sub.3-14 alkyl and C.sub.3-14 alkenyl;
[0622] each R* is independently selected from the group consisting
of C.sub.1-12 alkyl and C.sub.2-12 alkenyl;
[0623] each Y is independently a C.sub.3-6 carbocycle;
[0624] each X is independently selected from the group consisting
of F, Cl, Br, and I; and
[0625] m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13,
[0626] or salts or stereoisomers thereof.
[0627] In still another embodiments, another subset of compounds of
Formula (I) includes those in which
[0628] R.sub.1 is selected from the group consisting of C.sub.5-20
alkyl, C.sub.5-20 alkenyl, --R*YR'', --YR'', and --R''M'R';
[0629] R.sub.2 and R.sub.3 are independently selected from the
group consisting of H, C.sub.1-14 alkyl, C.sub.2-14 alkenyl,
--R*YR'', --YR'', and --R*OR'', or R.sub.2 and R.sub.3, together
with the atom to which they are attached, form a heterocycle or
carbocycle;
[0630] R.sub.4 is selected from the group consisting of a C.sub.3-6
carbocycle, --(CH.sub.2).sub.nQ, --(CH.sub.2).sub.nCHQR, --CHQR,
--CQ(R).sub.2, and unsubstituted C.sub.1-6 alkyl, where Q is
selected from a C.sub.3-6 carbocycle, a 5- to 14-membered
heteroaryl having one or more heteroatoms selected from N, O, and
S, --OR, --O(CH.sub.2).sub.nN(R).sub.2, --C(O)OR, --OC(O)R,
--CX.sub.3, --CX.sub.2H, --CXH.sub.2, --CN, --C(O)N(R).sub.2,
--N(R)C(O)R, --N(R)S(O).sub.2R, --N(R)C(O)N(R).sub.2,
--N(R)C(S)N(R).sub.2, --CRN(R).sub.2C(O)OR, and each n is
independently selected from 1, 2, 3, 4, and 5;
[0631] each R.sub.5 is independently selected from the group
consisting of C.sub.1-3 alkyl, C.sub.2-3 alkenyl, and H;
[0632] each R.sub.6 is independently selected from the group
consisting of C.sub.1-3 alkyl, C.sub.2-3 alkenyl, and H;
[0633] M and M' are independently selected from --C(O)O--,
--OC(O)--, --C(O)N(R')--, --N(R')C(O)--, --C(O)--, --C(S)--,
--C(S)S--, --SC(S)--, --CH(OH)--, --P(O)(OR')O--, --S(O).sub.2--,
an aryl group, and a heteroaryl group;
[0634] R.sub.7 is selected from the group consisting of C.sub.1-3
alkyl, C.sub.2-3 alkenyl, and H;
[0635] each R is independently selected from the group consisting
of C.sub.1-3 alkyl, C.sub.2-3 alkenyl, and H;
[0636] each R' is independently selected from the group consisting
of C.sub.1-18 alkyl, C.sub.2-18 alkenyl, --R*YR'', --YR'', and
H;
[0637] each R'' is independently selected from the group consisting
of C.sub.3-14 alkyl and C.sub.3-14 alkenyl;
[0638] each R* is independently selected from the group consisting
of C.sub.1-12 alkyl and C.sub.2-12 alkenyl;
[0639] each Y is independently a C.sub.3-6 carbocycle;
[0640] each X is independently selected from the group consisting
of F, Cl, Br, and I; and
[0641] m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13,
[0642] or salts or stereoisomers thereof.
[0643] In yet another embodiments, another subset of compounds of
Formula (I) includes those in which
[0644] R.sub.1 is selected from the group consisting of C.sub.5-30
alkyl, C.sub.5-20 alkenyl, --R*YR'', --YR'', and --R''M'R';
[0645] R.sub.2 and R.sub.3 are independently selected from the
group consisting of H, C.sub.2-14 alkyl, C.sub.2-14 alkenyl,
--R*YR'', --YR'', and --R*OR'', or R.sub.2 and R.sub.3, together
with the atom to which they are attached, form a heterocycle or
carbocycle;
[0646] R.sub.4 is --(CH.sub.2).sub.nQ or --(CH.sub.2).sub.nCHQR,
where Q is --N(R).sub.2, and n is selected from 3, 4, and 5;
[0647] each R.sub.5 is independently selected from the group
consisting of C.sub.1-3 alkyl, C.sub.2-3 alkenyl, and H;
[0648] each R.sub.6 is independently selected from the group
consisting of C.sub.1-3 alkyl, C.sub.2-3 alkenyl, and H;
[0649] M and M' are independently selected from --C(O)O--,
--OC(O)--, --C(O)N(R')--, --N(R')C(O)--, --C(O)--, --C(S)--,
--C(S)S--, --SC(S)--, --CH(OH)--, --P(O)(OR')O--, --S(O).sub.2--,
--S--S--, an aryl group, and a heteroaryl group;
[0650] R.sub.7 is selected from the group consisting of C.sub.1-3
alkyl, C.sub.2-3 alkenyl, and H;
[0651] each R is independently selected from the group consisting
of C.sub.1-3 alkyl, C.sub.2-3 alkenyl, and H;
[0652] each R' is independently selected from the group consisting
of C.sub.1-18 alkyl, C.sub.2-18 alkenyl, --R*YR'', --YR'', and
H;
[0653] each R'' is independently selected from the group consisting
of C.sub.3-14 alkyl and C.sub.3-14 alkenyl;
[0654] each R* is independently selected from the group consisting
of C.sub.1-12 alkyl and C.sub.1-12 alkenyl;
[0655] each Y is independently a C.sub.3-6 carbocycle;
[0656] each X is independently selected from the group consisting
of F, Cl, Br, and I; and
[0657] m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13,
[0658] or salts or stereoisomers thereof.
[0659] In yet another embodiments, another subset of compounds of
Formula (I) includes those in which
[0660] R.sub.1 is selected from the group consisting of C.sub.5-20
alkyl, C.sub.5-20 alkenyl, --R*YR'', --YR'', and --R''M'R';
[0661] R.sub.2 and R.sub.3 are independently selected from the
group consisting of H, C.sub.2-14 alkyl, C.sub.2-14 alkenyl,
--R*YR'', --YR'', and --R*OR'', or R.sub.2 and R.sub.3, together
with the atom to which they are attached, form a heterocycle or
carbocycle;
[0662] R.sub.4 is --(CH.sub.2).sub.nQ or --(CH.sub.2).sub.nCHQR,
where Q is --N(R).sub.2, and n is selected from 3, 4, and 5;
[0663] each R.sub.5 is independently selected from the group
consisting of C.sub.1-3 alkyl, C.sub.2-3 alkenyl, and H;
[0664] each R.sub.6 is independently selected from the group
consisting of C.sub.1-3 alkyl, C.sub.2-3 alkenyl, and H;
[0665] M and M' are independently selected from --C(O)O--,
--OC(O)--, --C(O)N(R')--, --N(R')C(O)--, --C(O)--, --C(S)--,
--C(S)S--, --SC(S)--, --CH(OH)--, --P(O)(OR')O--, --S(O).sub.2--,
an aryl group, and a heteroaryl group;
[0666] R.sub.7 is selected from the group consisting of C.sub.1-3
alkyl, C.sub.2-3 alkenyl, and H;
[0667] each R is independently selected from the group consisting
of C.sub.1-3 alkyl, C.sub.2-3 alkenyl, and H;
[0668] each R' is independently selected from the group consisting
of C.sub.1-18 alkyl, C.sub.2-18 alkenyl, --R*YR'', --YR'', and
H;
[0669] each R'' is independently selected from the group consisting
of C.sub.3-14 alkyl and C.sub.3-14 alkenyl;
[0670] each R* is independently selected from the group consisting
of C.sub.1-12 alkyl and C.sub.1-12 alkenyl;
[0671] each Y is independently a C.sub.3-6 carbocycle;
[0672] each X is independently selected from the group consisting
of F, Cl, Br, and I; and
[0673] m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13,
[0674] or salts or stereoisomers thereof.
[0675] In still other embodiments, another subset of compounds of
Formula (I) includes those in which
[0676] R.sub.1 is selected from the group consisting of C.sub.5-30
alkyl, C.sub.5-20 alkenyl, --R*YR'', --YR'', and --R''M'R';
[0677] R.sub.2 and R.sub.3 are independently selected from the
group consisting of C.sub.1-14 alkyl, C.sub.2-14 alkenyl, --R*YR'',
--YR'', and --R*OR'', or R.sub.2 and R.sub.3, together with the
atom to which they are attached, form a heterocycle or
carbocycle;
[0678] R.sub.4 is selected from the group consisting of
--(CH.sub.2).sub.nQ, --(CH.sub.2).sub.nCHQR, --CHQR, and
--CQ(R).sub.2, where Q is --N(R).sub.2, and n is selected from 1,
2, 3, 4, and 5;
[0679] each R.sub.5 is independently selected from the group
consisting of C.sub.1-3 alkyl, C.sub.2-3 alkenyl, and H;
[0680] each R.sub.6 is independently selected from the group
consisting of C.sub.1-3 alkyl, C.sub.2-3 alkenyl, and H;
[0681] M and M' are independently selected from --C(O)O--,
--OC(O)--, --C(O)N(R')--, --N(R')C(O)--, --C(O)--, --C(S)--,
--C(S)S--, --SC(S)--, --CH(OH)--, --P(O)(OR')O--, --S(O).sub.2--,
--S--S--, an aryl group, and a heteroaryl group;
[0682] R.sub.7 is selected from the group consisting of C.sub.1-3
alkyl, C.sub.2-3 alkenyl, and H;
[0683] each R is independently selected from the group consisting
of C.sub.1-3 alkyl, C.sub.2-3 alkenyl, and H;
[0684] each R' is independently selected from the group consisting
of C.sub.1-18 alkyl, C.sub.2-18 alkenyl, --R*YR'', --YR'', and
H;
[0685] each R'' is independently selected from the group consisting
of C.sub.3-14 alkyl and C.sub.3-14 alkenyl;
[0686] each R* is independently selected from the group consisting
of C.sub.1-12 alkyl and C.sub.1-12 alkenyl;
[0687] each Y is independently a C.sub.3-6 carbocycle;
[0688] each X is independently selected from the group consisting
of F, Cl, Br, and I; and
[0689] m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13,
[0690] or salts or stereoisomers thereof.
[0691] In still other embodiments, another subset of compounds of
Formula (I) includes those in which
[0692] R.sub.1 is selected from the group consisting of C.sub.5-20
alkyl, C.sub.5-20 alkenyl, --R*YR'', --YR'', and --R''M'R';
[0693] R.sub.2 and R.sub.3 are independently selected from the
group consisting of C.sub.1-14 alkyl, C.sub.2-14 alkenyl, --R*YR'',
--YR'', and --R*OR'', or R.sub.2 and R.sub.3, together with the
atom to which they are attached, form a heterocycle or
carbocycle;
[0694] R.sub.4 is selected from the group consisting of
--(CH.sub.2).sub.nQ, --(CH.sub.2).sub.nCHQR, --CHQR, and
--CQ(R).sub.2, where Q is --N(R).sub.2, and n is selected from 1,
2, 3, 4, and 5;
[0695] each R.sub.5 is independently selected from the group
consisting of C.sub.1-3 alkyl, C.sub.2-3 alkenyl, and H;
[0696] each R.sub.6 is independently selected from the group
consisting of C.sub.1-3 alkyl, C.sub.2-3 alkenyl, and H;
[0697] M and M' are independently selected from --C(O)O--,
--OC(O)--, --C(O)N(R')--, --N(R')C(O)--, --C(O)--, --C(S)--,
--C(S)S--, --SC(S)--, --CH(OH)--, --P(O)(OR')O--, --S(O).sub.2--,
an aryl group, and a heteroaryl group;
[0698] R.sub.7 is selected from the group consisting of C.sub.1-3
alkyl, C.sub.2-3 alkenyl, and H;
[0699] each R is independently selected from the group consisting
of C.sub.1-3 alkyl, C.sub.2-3 alkenyl, and H;
[0700] each R' is independently selected from the group consisting
of C.sub.1-18 alkyl, C.sub.2-18 alkenyl, --R*YR'', --YR'', and
H;
[0701] each R'' is independently selected from the group consisting
of C.sub.3-14 alkyl and C.sub.3-14 alkenyl;
[0702] each R* is independently selected from the group consisting
of C.sub.1-12 alkyl and C.sub.1-12 alkenyl;
[0703] each Y is independently a C.sub.3-6 carbocycle;
[0704] each X is independently selected from the group consisting
of F, Cl, Br, and I; and
[0705] m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13,
[0706] or salts or stereoisomers thereof.
[0707] In certain embodiments, a subset of compounds of Formula (I)
includes those of Formula (IA):
##STR00002##
[0708] or a salt or stereoisomer thereof, wherein 1 is selected
from 1, 2, 3, 4, and 5; m is selected from 5, 6, 7, 8, and 9;
M.sub.1 is a bond or M'; R.sub.4 is unsubstituted C.sub.1-3 alkyl,
or --(CH.sub.2).sub.nQ, in which Q is OH, --NHC(S)N(R).sub.2,
--NHC(O)N(R).sub.2, --N(R)C(O)R, --N(R)S(O).sub.2R, --N(R)R.sub.8,
--NHC(.dbd.NR.sub.9)N(R).sub.2, --NHC(.dbd.CHR.sub.9)N(R).sub.2,
--OC(O)N(R).sub.2, --N(R)C(O)OR, heteroaryl, or heterocycloalkyl; M
and M' are independently selected from --C(O)O--, --OC(O)--,
--C(O)N(R')--, --P(O)(OR')O--, --S--S--, an aryl group, and a
heteroaryl group; and
[0709] R.sub.2 and R.sub.3 are independently selected from the
group consisting of H, C.sub.1-14 alkyl, and C.sub.2-14
alkenyl.
[0710] In some embodiments, a subset of compounds of Formula (I)
includes those of Formula (IA), or a salt or stereoisomer
thereof,
[0711] wherein
[0712] 1 is selected from 1, 2, 3, 4, and 5; m is selected from 5,
6, 7, 8, and 9;
[0713] M.sub.1 is a bond or M';
[0714] R.sub.4 is unsubstituted C.sub.1-3 alkyl, or
--(CH.sub.2).sub.nQ, in which Q is OH, --NHC(S)N(R).sub.2, or
--NHC(O)N(R).sub.2;
[0715] M and M' are independently selected from --C(O)O--,
--OC(O)--, --C(O)N(R')--, --P(O)(OR')O--, an aryl group, and a
heteroaryl group; and
[0716] R.sub.2 and R.sub.3 are independently selected from the
group consisting of H, C.sub.1-14 alkyl, and C.sub.2-14
alkenyl.
[0717] In certain embodiments, a subset of compounds of Formula (I)
includes those of Formula (II):
##STR00003##
[0718] or a salt or stereoisomer thereof, wherein 1 is selected
from 1, 2, 3, 4, and 5; M.sub.1 is a bond or M'; R.sub.4 is
unsubstituted C.sub.1-3 alkyl, or --(CH.sub.2).sub.nQ, in which n
is 2, 3, or 4, and Q is OH, --NHC(S)N(R).sub.2, --NHC(O)N(R).sub.2,
--N(R)C(O)R, --N(R)S(O).sub.2R, --N(R)R.sub.8,
--NHC(.dbd.NR.sub.9)N(R).sub.2, --NHC(.dbd.CHR.sub.9)N(R).sub.2,
--OC(O)N(R).sub.2, --N(R)C(O)OR, heteroaryl, or heterocycloalkyl; M
and M' are independently selected from --C(O)O--, --OC(O)--,
--C(O)N(R')--, --P(O)(OR')O--, --S--S--, an aryl group, and a
heteroaryl group; and
[0719] R.sub.2 and R.sub.3 are independently selected from the
group consisting of H, C.sub.1-14 alkyl, and C.sub.2-14
alkenyl.
[0720] In some embodiments, a subset of compounds of Formula (I)
includes those of Formula (II), or a salt or stereoisomer thereof,
wherein
[0721] 1 is selected from 1, 2, 3, 4, and 5;
[0722] M.sub.1 is a bond or M';
[0723] R.sub.4 is unsubstituted C.sub.1-3 alkyl, or
--(CH.sub.2).sub.nQ, in which n is 2, 3, or 4, and Q is OH,
--NHC(S)N(R).sub.2, or --NHC(O)N(R).sub.2;
[0724] M and M' are independently selected from --C(O)O--,
--OC(O)--, --C(O)N(R')--, --P(O)(OR')O--, an aryl group, and a
heteroaryl group; and
[0725] R.sub.2 and R.sub.3 are independently selected from the
group consisting of H, C.sub.1-14 alkyl, and C.sub.2-14
alkenyl.
[0726] In some embodiments, the compound of formula (I) is of the
formula (IIa),
##STR00004##
[0727] or a salt thereof, wherein R.sub.4 is as described
above.
[0728] In some embodiments, the compound of formula (I) is of the
formula (IIb),
##STR00005##
[0729] or a salt thereof, wherein R.sub.4 is as described
above.
[0730] In some embodiments, the compound of formula (I) is of the
formula (IIc),
##STR00006##
[0731] or a salt thereof, wherein R.sub.4 is as described
above.
[0732] In some embodiments, the compound of formula (I) is of the
formula (IIe):
##STR00007##
[0733] or a salt thereof, wherein R.sub.4 is as described
above.
[0734] In some embodiments, the compound of formula (IIa), (IIb),
(IIc), or (IIe) comprises an R.sub.4 which is selected from
--(CH.sub.2).sub.nQ and --(CH.sub.2).sub.nCHQR, wherein Q, R and n
are as defined above.
[0735] In some embodiments, Q is selected from the group consisting
of --OR, --OH, --O(CH.sub.2).sub.nN(R).sub.2, --OC(O)R, --CX.sub.3,
--CN, --N(R)C(O)R, --N(H)C(O)R, --N(R)S(O).sub.2R,
--N(H)S(O).sub.2R, --N(R)C(O)N(R).sub.2, --N(H)C(O)N(R).sub.2,
--N(H)C(O)N(H)(R), --N(R)C(S)N(R).sub.2, --N(H)C(S)N(R).sub.2,
--N(H)C(S)N(H)(R), and a heterocycle, wherein R is as defined
above. In some aspects, n is 1 or 2. In some embodiments, Q is OH,
--NHC(S)N(R).sub.2, or --NHC(O)N(R).sub.2.
[0736] In some embodiments, the compound of formula (I) is of the
formula (IId),
##STR00008##
[0737] or a salt thereof, wherein R.sub.2 and R.sub.3 are
independently selected from the group consisting of C.sub.5-14
alkyl and C.sub.5-14 alkenyl, n is selected from 2, 3, and 4, and
R', R'', R.sub.5, R.sub.6 and m are as defined above.
[0738] In some aspects of the compound of formula (IId), R.sub.2 is
C.sub.8 alkyl. In some aspects of the compound of formula (IId),
R.sub.3 is C.sub.5-C.sub.9 alkyl. In some aspects of the compound
of formula (IId), m is 5, 7, or 9. In some aspects of the compound
of formula (IId), each R.sub.5 is H. In some aspects of the
compound of formula (IId), each R.sub.6 is H.
[0739] In another aspect, the present application provides a lipid
composition (e.g., a lipid nanoparticle (LNP)) comprising: (1) a
compound having the formula (I); (2) optionally a helper lipid
(e.g. a phospholipid); (3) optionally a structural lipid (e.g. a
sterol); and (4) optionally a lipid conjugate (e.g. a PEG-lipid).
In exemplary embodiments, the lipid composition (e.g., LNP) further
comprises a polynucleotide encoding a polypeptide of interest,
e.g., a polynucleotide encapsulated therein.
[0740] As used herein, the term "alkyl" or "alkyl group" means a
linear or branched, saturated hydrocarbon including one or more
carbon atoms (e.g., one, two, three, four, five, six, seven, eight,
nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen,
seventeen, eighteen, nineteen, twenty, or more carbon atoms).
[0741] The notation "C.sub.1-14 alkyl" means a linear or branched,
saturated hydrocarbon including 1-14 carbon atoms. An alkyl group
can be optionally substituted.
[0742] As used herein, the term "alkenyl" or "alkenyl group" means
a linear or branched hydrocarbon including two or more carbon atoms
(e.g., two, three, four, five, six, seven, eight, nine, ten,
eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen,
eighteen, nineteen, twenty, or more carbon atoms) and at least one
double bond.
[0743] The notation "C.sub.2-14 alkenyl" means a linear or branched
hydrocarbon including 2-14 carbon atoms and at least one double
bond. An alkenyl group can include one, two, three, four, or more
double bonds. For example, C.sub.18 alkenyl can include one or more
double bonds. A C.sub.18 alkenyl group including two double bonds
can be a linoleyl group. An alkenyl group can be optionally
substituted.
[0744] As used herein, the term "carbocycle" or "carbocyclic group"
means a mono- or multi-cyclic system including one or more rings of
carbon atoms. Rings can be three, four, five, six, seven, eight,
nine, ten, eleven, twelve, thirteen, fourteen, or fifteen membered
rings.
[0745] The notation "C.sub.3-6 carbocycle" means a carbocycle
including a single ring having 3-6 carbon atoms. Carbocycles can
include one or more double bonds and can be aromatic (e.g., aryl
groups). Examples of carbocycles include cyclopropyl, cyclopentyl,
cyclohexyl, phenyl, naphthyl, and 1,2-dihydronaphthyl groups.
Carbocycles can be optionally substituted.
[0746] As used herein, the term "heterocycle" or "heterocyclic
group" means a mono- or multi-cyclic system including one or more
rings, where at least one ring includes at least one heteroatom.
Heteroatoms can be, for example, nitrogen, oxygen, or sulfur atoms.
Rings can be three, four, five, six, seven, eight, nine, ten,
eleven, or twelve membered rings. Heterocycles can include one or
more double bonds and can be aromatic (e.g., heteroaryl groups).
Examples of heterocycles include imidazolyl, imidazolidinyl,
oxazolyl, oxazolidinyl, thiazolyl, thiazolidinyl, pyrazolidinyl,
pyrazolyl, isoxazolidinyl, isoxazolyl, isothiazolidinyl,
isothiazolyl, morpholinyl, pyrrolyl, pyrrolidinyl, furyl,
tetrahydrofuryl, thiophenyl, pyridinyl, piperidinyl, quinolyl, and
isoquinolyl groups. Heterocycles can be optionally substituted.
[0747] As used herein, a "biodegradable group" is a group that can
facilitate faster metabolism of a lipid in a subject. A
biodegradable group can be, but is not limited to, --C(O)O--,
--OC(O)--, --C(O)N(R')--, --N(R')C(O)--, --C(O)--, --C(S)--,
--C(S)S--, --SC(S)--, --CH(OH)--, --P(O)(OR')O--, --S(O).sub.2--,
an aryl group, and a heteroaryl group.
[0748] As used herein, an "aryl group" is a carbocyclic group
including one or more aromatic rings. Examples of aryl groups
include phenyl and naphthyl groups.
[0749] As used herein, a "heteroaryl group" is a heterocyclic group
including one or more aromatic rings. Examples of heteroaryl groups
include pyrrolyl, furyl, thiophenyl, imidazolyl, oxazolyl, and
thiazolyl. Both aryl and heteroaryl groups can be optionally
substituted. For example, M and M' can be selected from the
non-limiting group consisting of optionally substituted phenyl,
oxazole, and thiazole. In the formulas herein, M and M' can be
independently selected from the list of biodegradable groups
above.
[0750] Alkyl, alkenyl, and cyclyl (e.g., carbocyclyl and
heterocyclyl) groups can be optionally substituted unless otherwise
specified. Optional substituents can be selected from the group
consisting of, but are not limited to, a halogen atom (e.g., a
chloride, bromide, fluoride, or iodide group), a carboxylic acid
(e.g., --C(O)OH), an alcohol (e.g., a hydroxyl, --OH), an ester
(e.g., --C(O)OR or --OC(O)R), an aldehyde (e.g., --C(O)H), a
carbonyl (e.g., --C(O)R, alternatively represented by C.dbd.O), an
acyl halide (e.g., --C(O)X, in which X is a halide selected from
bromide, fluoride, chloride, and iodide), a carbonate (e.g.,
--OC(O)OR), an alkoxy (e.g., --OR), an acetal (e.g.,
--C(OR).sub.2R'''', in which each OR are alkoxy groups that can be
the same or different and R'''' is an alkyl or alkenyl group), a
phosphate (e.g., P(O).sub.4.sup.3-), a thiol (e.g., --SH), a
sulfoxide (e.g., --S(O)R), a sulfinic acid (e.g., --S(O)OH), a
sulfonic acid (e.g., --S(O).sub.2OH), a thial (e.g., --C(S)H), a
sulfate (e.g., S(O).sub.4.sup.2-), a sulfonyl (e.g.,
--S(O).sub.2--), an amide (e.g., --C(O)NR.sub.2, or --N(R)C(O)R),
an azido (e.g., --N.sub.3), a nitro (e.g., --NO.sub.2), a cyano
(e.g., --CN), an isocyano (e.g., --NC), an acyloxy (e.g.,
--OC(O)R), an amino (e.g., --NR.sub.2, --NRH, or --NH.sub.2), a
carbamoyl (e.g., --OC(O)NR.sub.2, --OC(O)NRH, or --OC(O)NH.sub.2),
a sulfonamide (e.g., --S(O).sub.2NR.sub.2, --S(O).sub.2NRH,
--S(O).sub.2NH.sub.2, --N(R)S(O).sub.2R, --N(H)S(O).sub.2R,
--N(R)S(O).sub.2H, or --N(H)S(O).sub.2H), an alkyl group, an
alkenyl group, and a cyclyl (e.g., carbocyclyl or heterocyclyl)
group.
[0751] In any of the preceding, R is an alkyl or alkenyl group, as
defined herein. In some embodiments, the substituent groups
themselves can be further substituted with, for example, one, two,
three, four, five, or six substituents as defined herein. For
example, a C.sub.1-6 alkyl group can be further substituted with
one, two, three, four, five, or six substituents as described
herein.
[0752] The compounds of any one of formulae (I), (IA), (II), (IIa),
(IIb), (IIc), (IId), and (IIe) include one or more of the following
features when applicable.
[0753] In some embodiments, R.sub.4 is selected from the group
consisting of a C.sub.3-6 carbocycle, --(CH.sub.2).sub.nQ,
--(CH.sub.2).sub.nCHQR, --CHQR, and --CQ(R).sub.2, where Q is
selected from a C.sub.3-6 carbocycle, 5- to 14-membered aromatic or
non-aromatic heterocycle having one or more heteroatoms selected
from N, O, S, and P, --OR, --O(CH.sub.2).sub.nN(R).sub.2, --C(O)OR,
--OC(O)R, --CX.sub.3, --CX.sub.2H, --CXH.sub.2, --CN, --N(R).sub.2,
--C(O)N(R).sub.2, --N(R)C(O)R, --N(R)S(O).sub.2R,
--N(R)C(O)N(R).sub.2, --N(R)C(S)N(R).sub.2, and
--C(R)N(R).sub.2C(O)OR, and each n is independently selected from
1, 2, 3, 4, and 5.
[0754] In another embodiment, R.sub.4 is selected from the group
consisting of a C.sub.3-6 carbocycle, --(CH.sub.2).sub.nQ,
--(CH.sub.2).sub.nCHQR, --CHQR, and --CQ(R).sub.2, where Q is
selected from a C.sub.3-6 carbocycle, a 5- to 14-membered
heteroaryl having one or more heteroatoms selected from N, O, and
S, --OR, --O(CH.sub.2).sub.nN(R).sub.2, --C(O)OR, --OC(O)R,
--CX.sub.3, --CX.sub.2H, --CXH.sub.2, --CN, --C(O)N(R).sub.2,
--N(R)C(O)R, --N(R)S(O).sub.2R, --N(R)C(O)N(R).sub.2,
--N(R)C(S)N(R).sub.2, --C(R)N(R).sub.2C(O)OR, and a 5- to
14-membered heterocycloalkyl having one or more heteroatoms
selected from N, O, and S which is substituted with one or more
substituents selected from oxo (.dbd.O), OH, amino, and C.sub.1-3
alkyl, and each n is independently selected from 1, 2, 3, 4, and
5.
[0755] In another embodiment, R.sub.4 is selected from the group
consisting of a C.sub.3-6 carbocycle, --(CH.sub.2).sub.nQ,
--(CH.sub.2).sub.nCHQR, --CHQR, and --CQ(R).sub.2, where Q is
selected from a C.sub.3-6 carbocycle, a 5- to 14-membered
heterocycle having one or more heteroatoms selected from N, O, and
S, --OR, --O(CH.sub.2).sub.nN(R).sub.2, --C(O)OR, --OC(O)R,
--CX.sub.3, --CX.sub.2H, --CXH.sub.2, --CN, --C(O)N(R).sub.2,
--N(R)C(O)R, --N(R)S(O).sub.2R, --N(R)C(O)N(R).sub.2,
--N(R)C(S)N(R).sub.2, --C(R)N(R).sub.2C(O)OR, and each n is
independently selected from 1, 2, 3, 4, and 5; and when Q is a 5-
to 14-membered heterocycle and (i) R.sub.4 is --(CH.sub.2).sub.nQ
in which n is 1 or 2, or (ii) R.sub.4 is --(CH.sub.2).sub.nCHQR in
which n is 1, or (iii) R.sub.4 is --CHQR, and --CQ(R).sub.2, then Q
is either a 5- to 14-membered heteroaryl or 8- to 14-membered
heterocycloalkyl.
[0756] In another embodiment, R.sub.4 is selected from the group
consisting of a C.sub.3-6 carbocycle, --(CH.sub.2).sub.nQ,
--(CH.sub.2).sub.nCHQR, --CHQR, and --CQ(R).sub.2, where Q is
selected from a C.sub.3-6 carbocycle, a 5- to 14-membered
heteroaryl having one or more heteroatoms selected from N, O, and
S, --OR, --O(CH.sub.2).sub.nN(R).sub.2, --C(O)OR, --OC(O)R,
--CX.sub.3, --CX.sub.2H, --CXH.sub.2, --CN, --C(O)N(R).sub.2,
--N(R)C(O)R, --N(R)S(O).sub.2R, --N(R)C(O)N(R).sub.2,
--N(R)C(S)N(R).sub.2, --C(R)N(R).sub.2C(O)OR, and each n is
independently selected from 1, 2, 3, 4, and 5.
[0757] In another embodiment, R.sub.4 is unsubstituted C.sub.1-4
alkyl, e.g., unsubstituted methyl.
[0758] In certain embodiments, the disclosure provides a compound
having the Formula (I), wherein R.sub.4 is --(CH.sub.2).sub.nQ or
--(CH.sub.2).sub.nCHQR, where Q is --N(R).sub.2, and n is selected
from 3, 4, and 5.
[0759] In certain embodiments, the disclosure provides a compound
having the Formula (I), wherein R.sub.4 is selected from the group
consisting of --(CH.sub.2).sub.nQ, --(CH.sub.2).sub.nCHQR, --CHQR,
and --CQ(R).sub.2, where Q is --N(R).sub.2, and n is selected from
1, 2, 3, 4, and 5.
[0760] In certain embodiments, the disclosure provides a compound
having the Formula (I), wherein R.sub.2 and R.sub.3 are
independently selected from the group consisting of C.sub.2-14
alkyl, C.sub.2-14 alkenyl, --R*YR'', --YR'', and --R*OR'', or
R.sub.2 and R.sub.3, together with the atom to which they are
attached, form a heterocycle or carbocycle, and R.sub.4 is
--(CH.sub.2).sub.nQ or --(CH.sub.2).sub.nCHQR, where Q is
--N(R).sub.2, and n is selected from 3, 4, and 5.
[0761] In certain embodiments, R.sub.2 and R.sub.3 are
independently selected from the group consisting of C.sub.2-14
alkyl, C.sub.2-14 alkenyl, --R*YR'', --YR'', and --R*OR'', or
R.sub.2 and R.sub.3, together with the atom to which they are
attached, form a heterocycle or carbocycle.
[0762] In some embodiments, R.sub.1 is selected from the group
consisting of C.sub.5-20 alkyl and C.sub.5-20 alkenyl.
[0763] In other embodiments, R.sub.1 is selected from the group
consisting of --R*YR'', --YR'', and --R''M'R'.
[0764] In certain embodiments, R.sub.1 is selected from --R*YR''
and --YR''. In some embodiments, Y is a cyclopropyl group. In some
embodiments, R* is C.sub.8 alkyl or C.sub.8 alkenyl. In certain
embodiments, R'' is C.sub.3-12 alkyl. For example, R'' can be
C.sub.3 alkyl. For example, R'' can be C.sub.4-8 alkyl (e.g.,
C.sub.4, C.sub.5, C.sub.6, C.sub.7, or C.sub.8 alkyl).
[0765] In some embodiments, R.sub.1 is C.sub.5-20 alkyl. In some
embodiments, R.sub.1 is C.sub.6 alkyl. In some embodiments, R.sub.1
is C.sub.8 alkyl. In other embodiments, R.sub.1 is C.sub.9 alkyl.
In certain embodiments, R.sub.1 is C.sub.14 alkyl. In other
embodiments, R.sub.1 is C.sub.18 alkyl.
[0766] In some embodiments, R.sub.1 is C.sub.5-20 alkenyl. In
certain embodiments, R.sub.1 is C.sub.18 alkenyl.
[0767] In some embodiments, R.sub.1 is linoleyl.
[0768] In certain embodiments, R.sub.1 is branched (e.g.,
decan-2-yl, undecan-3-yl, dodecan-4-yl, tridecan-5-yl,
tetradecan-6-yl, 2-methylundecan-3-yl, 2-methyldecan-2-yl,
3-methylundecan-3-yl, 4-methyldodecan-4-yl, or heptadeca-9-yl). In
certain embodiments, R.sub.1 is
##STR00009##
[0769] In certain embodiments, R.sub.1 is unsubstituted C.sub.5-20
alkyl or C.sub.5-20 alkenyl. In certain embodiments, R' is
substituted C.sub.5-20 alkyl or C.sub.5-20 alkenyl (e.g.,
substituted with a C.sub.3-6 carbocycle such as
1-cyclopropylnonyl).
[0770] In other embodiments, R.sub.1 is --R''M'R'.
[0771] In some embodiments, R' is selected from --R*YR'' and
--YR''. In some embodiments, Y is C.sub.3-8 cycloalkyl. In some
embodiments, Y is C.sub.6-10 aryl. In some embodiments, Y is a
cyclopropyl group. In some embodiments, Y is a cyclohexyl group. In
certain embodiments, R* is C.sub.1 alkyl.
[0772] In some embodiments, R'' is selected from the group
consisting of C.sub.3-12 alkyl and C.sub.3-12 alkenyl. In some
embodiments, R'' adjacent to Y is C.sub.1 alkyl. In some
embodiments, R'' adjacent to Y is C.sub.4-9 alkyl (e.g., C.sub.4,
C.sub.5, C.sub.6, C.sub.7 or C.sub.8 or C.sub.9 alkyl).
[0773] In some embodiments, R' is selected from C.sub.4 alkyl and
C.sub.4 alkenyl. In certain embodiments, R' is selected from
C.sub.5 alkyl and C.sub.5 alkenyl. In some embodiments, R' is
selected from C.sub.6 alkyl and C.sub.6 alkenyl. In some
embodiments, R' is selected from C.sub.7 alkyl and C.sub.7 alkenyl.
In some embodiments, R' is selected from C.sub.9 alkyl and C.sub.9
alkenyl.
[0774] In other embodiments, R' is selected from C.sub.11 alkyl and
C.sub.11 alkenyl. In other embodiments, R' is selected from
C.sub.12 alkyl, C.sub.12 alkenyl, C.sub.13 alkyl, C.sub.13 alkenyl,
C.sub.14 alkyl, C.sub.14 alkenyl, C.sub.15 alkyl, C.sub.15 alkenyl,
C.sub.16 alkyl, C.sub.16 alkenyl, C.sub.17 alkyl, C.sub.17 alkenyl,
C.sub.18 alkyl, and C.sub.18 alkenyl. In certain embodiments, R' is
branched (e.g., decan-2-yl, undecan-3-yl, dodecan-4-yl,
tridecan-5-yl, tetradecan-6-yl, 2-methylundecan-3-yl,
2-methyldecan-2-yl, 3-methylundecan-3-yl, 4-methyldodecan-4-yl or
heptadeca-9-yl). In certain embodiments, R' is
##STR00010##
[0775] In certain embodiments, R' is unsubstituted C.sub.1-18
alkyl. In certain embodiments, R' is substituted C.sub.1-8i alkyl
(e.g., C.sub.1-15 alkyl substituted with a C.sub.3-6 carbocycle
such as 1-cyclopropylnonyl).
[0776] In some embodiments, R'' is selected from the group
consisting of C.sub.3-14 alkyl and C.sub.3-14 alkenyl. In some
embodiments, R'' is C.sub.3 alkyl, C.sub.4 alkyl, C.sub.5 alkyl,
C.sub.6 alkyl, C.sub.7 alkyl, or C.sub.8 alkyl. In some
embodiments, R'' is C.sub.9 alkyl, C.sub.10 alkyl, C.sub.11 alkyl,
C.sub.12 alkyl, C.sub.13 alkyl, or C.sub.14 alkyl.
[0777] In some embodiments, M' is --C(O)O--. In some embodiments,
M' is --OC(O)--.
[0778] In other embodiments, M' is an aryl group or heteroaryl
group. For example, M' can be selected from the group consisting of
phenyl, oxazole, and thiazole.
[0779] In some embodiments, M is --C(O)O--. In some embodiments, M
is --OC(O)--. In some embodiments, M is --C(O)N(R')--. In some
embodiments, M is --P(O)(OR')O--.
[0780] In other embodiments, M is an aryl group or heteroaryl
group. For example, M can be selected from the group consisting of
phenyl, oxazole, and thiazole.
[0781] In some embodiments, M is the same as M'. In other
embodiments, M is different from M'.
[0782] In some embodiments, each R.sub.5 is H. In certain such
embodiments, each R.sub.6 is also H.
[0783] In some embodiments, R.sub.7 is H. In other embodiments,
R.sub.7 is C.sub.1-3 alkyl (e.g., methyl, ethyl, propyl, or
i-propyl).
[0784] In some embodiments, R.sub.2 and R.sub.3 are independently
C.sub.5-14 alkyl or C.sub.5-14 alkenyl.
[0785] In some embodiments, R.sub.2 and R.sub.3 are the same. In
some embodiments, R.sub.2 and R.sub.3 are C.sub.8 alkyl. In certain
embodiments, R.sub.2 and R.sub.3 are C.sub.2 alkyl. In other
embodiments, R.sub.2 and R.sub.3 are C.sub.3 alkyl. In some
embodiments, R.sub.2 and R.sub.3 are C.sub.4 alkyl. In certain
embodiments, R.sub.2 and R.sub.3 are C.sub.5 alkyl. In other
embodiments, R.sub.2 and R.sub.3 are C.sub.6 alkyl. In some
embodiments, R.sub.2 and R.sub.3 are C.sub.7 alkyl.
[0786] In other embodiments, R.sub.2 and R.sub.3 are different. In
certain embodiments, R.sub.2 is C.sub.8 alkyl.
[0787] In some embodiments, R.sub.3 is C.sub.1-7 (e.g., C.sub.1,
C.sub.2, C.sub.3, C.sub.4, C.sub.5, C.sub.6, or C.sub.7 alkyl) or
C.sub.9 alkyl.
[0788] In some embodiments, R.sub.7 and R.sub.3 are H.
[0789] In certain embodiments, R.sub.2 is H.
[0790] In some embodiments, m is 5, 7, or 9.
[0791] In some embodiments, R.sub.4 is selected from
--(CH.sub.2).sub.nQ and --(CH.sub.2).sub.nCHQR.
[0792] In some embodiments, Q is selected from the group consisting
of --OR, --OH, --O(CH.sub.2).sub.nN(R).sub.2, --OC(O)R, --CX.sub.3,
--CN, --N(R)C(O)R, --N(H)C(O)R, --N(R)S(O).sub.2R,
--N(H)S(O).sub.2R, --N(R)C(O)N(R).sub.2, --N(H)C(O)N(R).sub.2,
--N(H)C(O)N(H)(R), --N(R)C(S)N(R).sub.2, --N(H)C(S)N(R).sub.2,
--N(H)C(S)N(H)(R), --C(R)N(R).sub.2C(O)OR, a carbocycle, and a
heterocycle.
[0793] In certain embodiments, Q is --OH.
[0794] In certain embodiments, Q is a substituted or unsubstituted
5- to 10-membered heteroaryl, e.g., Q is an imidazole, a
pyrimidine, a purine, 2-amino-1,9-dihydro-6H-purin-6-one-9-yl (or
guanin-9-yl), adenin-9-yl, cytosin-1-yl, or uracil-1-yl. In certain
embodiments, Q is a substituted 5- to 14-membered heterocycloalkyl,
e.g., substituted with one or more substituents selected from oxo
(.dbd.O), OH, amino, and C.sub.1-3 alkyl. For example, Q is
4-methylpiperazinyl, 4-(4-methoxybenzyl)piperazinyl, or
isoindolin-2-yl-1,3-dione.
[0795] In certain embodiments, Q is an unsubstituted or substituted
C.sub.6-10 aryl (such as phenyl) or C.sub.3-6 cycloalkyl.
[0796] In some embodiments, n is 1. In other embodiments, n is 2.
In further embodiments, n is 3. In certain other embodiments, n is
4. For example, R.sub.4 can be --(CH.sub.2).sub.2OH. For example,
R.sub.4 can be --(CH.sub.2).sub.3OH. For example, R.sub.4 can be
--(CH.sub.2).sub.4OH. For example, R.sub.4 can be benzyl. For
example, R.sub.4 can be 4-methoxybenzyl.
[0797] In some embodiments, R.sub.4 is a C.sub.3-6 carbocycle. In
some embodiments, R.sub.4 is a C.sub.3-6 cycloalkyl. For example,
R.sub.4 can be cyclohexyl optionally substituted with e.g., OH,
halo, C.sub.1-6 alkyl, etc. For example, R.sub.4 can be
2-hydroxycyclohexyl.
[0798] In some embodiments, R is H.
[0799] In some embodiments, R is unsubstituted C.sub.1-3 alkyl or
unsubstituted C.sub.2-3 alkenyl. For example, R.sub.4 can be
--CH.sub.2CH(OH)CH.sub.3 or --CH.sub.2CH(OH)CH.sub.2CH.sub.3.
[0800] In some embodiments, R is substituted C.sub.1-3 alkyl, e.g.,
CH.sub.2OH. For example, R.sub.4 can be
--CH.sub.2CH(OH)CH.sub.2OH.
[0801] In some embodiments, R.sub.2 and R.sub.3, together with the
atom to which they are attached, form a heterocycle or carbocycle.
In some embodiments, R.sub.2 and R.sub.3, together with the atom to
which they are attached, form a 5- to 14-membered aromatic or
non-aromatic heterocycle having one or more heteroatoms selected
from N, O, S, and P. In some embodiments, R.sub.2 and R.sub.3,
together with the atom to which they are attached, form an
optionally substituted C.sub.3-20 carbocycle (e.g., C.sub.3-18
carbocycle, C.sub.3-15 carbocycle, C.sub.3-12 carbocycle, or
C.sub.3-10 carbocycle), either aromatic or non-aromatic. In some
embodiments, R.sub.2 and R.sub.3, together with the atom to which
they are attached, form a C.sub.3-6 carbocycle. In other
embodiments, R.sub.2 and R.sub.3, together with the atom to which
they are attached, form a C.sub.6 carbocycle, such as a cyclohexyl
or phenyl group. In certain embodiments, the heterocycle or
C.sub.3-6 carbocycle is substituted with one or more alkyl groups
(e.g., at the same ring atom or at adjacent or non-adjacent ring
atoms). For example, R.sub.2 and R.sub.3, together with the atom to
which they are attached, can form a cyclohexyl or phenyl group
bearing one or more C.sub.5 alkyl substitutions. In certain
embodiments, the heterocycle or C.sub.3-6 carbocycle formed by
R.sub.2 and R.sub.3, is substituted with a carbocycle groups. For
example, R.sub.2 and R.sub.3, together with the atom to which they
are attached, can form a cyclohexyl or phenyl group that is
substituted with cyclohexyl. In some embodiments, R.sub.2 and
R.sub.3, together with the atom to which they are attached, form a
C.sub.7-15 carbocycle, such as a cycloheptyl, cyclopentadecanyl, or
naphthyl group.
[0802] In some embodiments, R.sub.4 is selected from
--(CH.sub.2).sub.nQ and --(CH.sub.2).sub.nCHQR. In some
embodiments, Q is selected from the group consisting of --OR, --OH,
--O(CH.sub.2).sub.nN(R).sub.2, --OC(O)R, --CX.sub.3, --CN,
--N(R)C(O)R, --N(H)C(O)R, --N(R)S(O).sub.2R, --N(H)S(O).sub.2R,
--N(R)C(O)N(R).sub.2, --N(H)C(O)N(R).sub.2, --N(H)C(O)N(H)(R),
--N(R)C(S)N(R).sub.2, --N(H)C(S)N(R).sub.2, --N(H)C(S)N(H)(R), and
a heterocycle. In other embodiments, Q is selected from the group
consisting of an imidazole, a pyrimidine, and a purine.
[0803] In some embodiments, R.sub.2 and R.sub.3, together with the
atom to which they are attached, form a heterocycle or carbocycle.
In some embodiments, R.sub.2 and R.sub.3, together with the atom to
which they are attached, form a C.sub.3-6 carbocycle, such as a
phenyl group. In certain embodiments, the heterocycle or C.sub.3-6
carbocycle is substituted with one or more alkyl groups (e.g., at
the same ring atom or at adjacent or non-adjacent ring atoms). For
example, R.sub.2 and R.sub.3, together with the atom to which they
are attached, can form a phenyl group bearing one or more C.sub.5
alkyl substitutions.
[0804] In some embodiments, the pharmaceutical compositions of the
present disclosure, the compound of formula (I) is selected from
the group consisting of:
##STR00011## ##STR00012## ##STR00013## ##STR00014## ##STR00015##
##STR00016## ##STR00017## ##STR00018## ##STR00019## ##STR00020##
##STR00021## ##STR00022## ##STR00023## ##STR00024## ##STR00025##
##STR00026## ##STR00027## ##STR00028## ##STR00029## ##STR00030##
##STR00031## ##STR00032## ##STR00033## ##STR00034## ##STR00035##
##STR00036## ##STR00037## ##STR00038## ##STR00039## ##STR00040##
##STR00041## ##STR00042##
and salts and isomers thereof.
[0805] In other embodiments, the compound of Formula (I) is
selected from the group consisting of Compound 1-Compound 147, or
salt or stereoisomers thereof.
[0806] In some embodiments ionizable lipids including a central
piperazine moiety are provided. The lipids described herein may be
advantageously used in lipid nanoparticle compositions for the
delivery of therapeutic and/or prophylactic agents to mammalian
cells or organs. For example, the lipids described herein have
little or no immunogenicity. For example, the lipid compounds
disclosed hereinhave a lower immunogenicity as compared to a
reference lipid (e.g., MC3, KC2, or DLinDMA). For example, a
formulation comprising a lipid disclosed herein and a therapeutic
or prophylactic agent has an increased therapeutic index as
compared to a corresponding formulation which comprises a reference
lipid (e.g., MC3, KC2, or DLinDMA) and the same therapeutic or
prophylactic agent.
[0807] In some embodiments, the delivery agent comprises a lipid
compound having the formula (III)
##STR00043##
[0808] or salts or stereoisomers thereof, wherein
[0809] ring A is
##STR00044##
[0810] t is 1 or 2;
[0811] A.sub.1 and A.sub.2 are each independently selected from CH
or N;
[0812] Z is CH.sub.2 or absent wherein when Z is CH.sub.2, the
dashed lines (1) and (2) each represent a single bond; and when Z
is absent, the dashed lines (1) and (2) are both absent;
[0813] R.sub.1, R.sub.2, R.sub.3, R.sub.4, and R.sub.5 are
independently selected from the group consisting of C.sub.5-20
alkyl, C.sub.5-20 alkenyl, --R''MR', --R*YR'', --YR'', and
--R*OR'';
[0814] each M is independently selected from the group consisting
of --C(O)O--, --OC(O)--, --OC(O)O--, --C(O)N(R')--, --N(R')C(O)--,
--C(O)--, --C(S)--, --C(S)S--, --SC(S)--, --CH(OH)--,
--P(O)(OR')O--, --S(O).sub.2--, an aryl group, and a heteroaryl
group;
[0815] X.sup.1, X.sup.2, and X.sup.3 are independently selected
from the group consisting of a bond, --CH.sub.2--,
--(CH.sub.2).sub.2--, --CHR--, --CHY--, --C(O)--, --C(O)O--,
--OC(O)--, --C(O)--CH.sub.2--, --CH.sub.2--C(O)--,
--C(O)O--CH.sub.2--, --OC(O)--CH.sub.2--, --CH.sub.2--C(O)O--,
--CH.sub.2--OC(O)--, --CH(OH)--, --C(S)--, and --CH(SH--;
[0816] each Y is independently a C.sub.3-6 carbocycle;
[0817] each R* is independently selected from the group consisting
of C.sub.1-12 alkyl and C.sub.2-12 alkenyl;
[0818] each R is independently selected from the group consisting
of C.sub.1-3 alkyl and a C.sub.3-6 carbocycle;
[0819] each R' is independently selected from the group consisting
of C.sub.1-12 alkyl, C.sub.2-12 alkenyl, and H; and
[0820] each R'' is independently selected from the group consisting
of C.sub.3-12 alkyl and C.sub.3-12 alkenyl,
[0821] wherein when ring A is
##STR00045##
then
[0822] i) at least one of X.sup.1, X.sup.2, and X.sup.3 is not
--CH.sub.2--; and/or
[0823] ii) at least one of R.sub.1, R.sub.2, R.sub.3, R.sub.4, and
R.sub.5 is --R''MR'.
[0824] In some embodiments, the compound is of any of formulae
(IIIa1)-(IIIa6):
##STR00046##
[0825] The compounds of Formula (III) or any of (IIIa1)-(IIIa6)
include one or more of the following features when applicable.
[0826] In some embodiments, ring A is
##STR00047##
[0827] In some embodiments, ring A is
##STR00048##
[0828] In some embodiments, ring A is
##STR00049##
[0829] In some embodiments, ring A is
##STR00050##
[0830] In some embodiments, ring A is
##STR00051##
[0831] In some embodiments, ring A is
##STR00052##
wherein ring, in which the N atom is connected with X.sup.2.
[0832] In some embodiments, Z is CH.sub.2.
[0833] In some embodiments, Z is absent.
[0834] In some embodiments, at least one of A.sub.1 and A.sub.2 is
N.
[0835] In some embodiments, each of A.sub.1 and A.sub.2 is N.
[0836] In some embodiments, each of A.sub.1 and A.sub.2 is CH.
[0837] In some embodiments, A.sub.1 is N and A.sub.2 is CH.
[0838] In some embodiments, A.sub.1 is CH and A.sub.2 is N.
[0839] In some embodiments, at least one of X.sup.1, X.sup.2, and
X.sup.3 is not --CH.sub.2--. For example, in certain embodiments,
X.sup.1 is not --CH.sub.2--. In some embodiments, at least one of
X.sup.1, X.sup.2, and X.sup.3 is --C(O)--.
[0840] In some embodiments, X.sup.2 is --C(O)--, --C(O)O--,
--OC(O)--, --C(O)--CH.sub.2--, --CH.sub.2--C(O)--,
--C(O)O--CH.sub.2--, --OC(O)--CH.sub.2--, --CH.sub.2--C(O)O--, or
--CH.sub.2--OC(O)--.
[0841] In some embodiments, X.sup.3 is --C(O)--, --C(O)O--,
--OC(O)--, --C(O)--CH.sub.2--, --CH.sub.2--C(O)--,
--C(O)O--CH.sub.2--, --OC(O)--CH.sub.2--, --CH.sub.2--C(O)O--, or
--CH.sub.2--OC(O)--. In other embodiments, X.sup.3 is
--CH.sub.2--.
[0842] In some embodiments, X.sup.3 is a bond or
--(CH.sub.2).sub.2--.
[0843] In some embodiments, R.sub.1 and R.sub.2 are the same. In
certain embodiments, R.sub.1, R.sub.2, and R.sub.3 are the same. In
some embodiments, R.sub.4 and R.sub.5 are the same. In certain
embodiments, R.sub.1, R.sub.2, R.sub.3, R.sub.4, and R.sub.5 are
the same.
[0844] In some embodiments, at least one of R.sub.1, R.sub.2,
R.sub.3, R.sub.4, and R.sub.5 is --R''MR'. In some embodiments, at
most one of R.sub.1, R.sub.2, R.sub.3, R.sub.4, and R.sub.5 is
--R''MR'. For example, at least one of R.sub.1, R.sub.2, and
R.sub.3 may be --R''MR', and/or at least one of R.sub.4 and R.sub.5
is --R''MR'. In certain embodiments, at least one M is --C(O)O--.
In some embodiments, each M is --C(O)O--. In some embodiments, at
least one M is --OC(O)--. In some embodiments, each M is --OC(O)--.
In some embodiments, at least one M is --OC(O)O--. In some
embodiments, each M is --OC(O)O--. In some embodiments, at least
one R'' is C.sub.3 alkyl. In certain embodiments, each R'' is
C.sub.3 alkyl. In some embodiments, at least one R'' is C.sub.5
alkyl. In certain embodiments, each R'' is C.sub.5 alkyl. In some
embodiments, at least one R'' is C.sub.6 alkyl. In certain
embodiments, each R'' is C.sub.6 alkyl. In some embodiments, at
least one R'' is C.sub.7 alkyl. In certain embodiments, each R'' is
C.sub.7 alkyl. In some embodiments, at least one R' is C.sub.5
alkyl. In certain embodiments, each R' is C.sub.5 alkyl. In other
embodiments, at least one R' is C.sub.1 alkyl. In certain
embodiments, each R' is C.sub.1 alkyl. In some embodiments, at
least one R' is C.sub.2 alkyl. In certain embodiments, each R' is
C.sub.2 alkyl.
[0845] In some embodiments, at least one of R.sub.1, R.sub.2,
R.sub.3, R.sub.4, and R.sub.5 is C.sub.12 alkyl. In certain
embodiments, each of R.sub.1, R.sub.2, R.sub.3, R.sub.4, and
R.sub.5 are C.sub.12 alkyl.
[0846] In certain embodiments, the compound is selected from the
group consisting of:
##STR00053## ##STR00054## ##STR00055## ##STR00056## ##STR00057##
##STR00058## ##STR00059##
[0847] In some embodiments, the delivery agent comprises Compound
236.
[0848] In some embodiments, the delivery agent comprises a compound
having the formula (IV)
##STR00060##
[0849] or salts or stereoisomer thereof, wherein
[0850] A.sub.1 and A.sub.2 are each independently selected from CH
or N and at least one of A.sub.1 and A.sub.2 is N;
[0851] Z is CH.sub.2 or absent wherein when Z is CH.sub.2, the
dashed lines (1) and (2) each represent a single bond; and when Z
is absent, the dashed lines (1) and (2) are both absent;
[0852] R.sub.1, R.sub.2, R.sub.3, R.sub.4, and R.sub.5 are
independently selected from the group consisting of C.sub.6-20
alkyl and C.sub.6-20 alkenyl;
[0853] wherein when ring A is
##STR00061##
then
[0854] i) R.sub.1, R.sub.2, R.sub.3, R.sub.4, and R.sub.5 are the
same, wherein R.sub.1 is not C.sub.12 alkyl, C.sub.18 alkyl, or
C.sub.18 alkenyl;
[0855] ii) only one of R.sub.1, R.sub.2, R.sub.3, R.sub.4, and
R.sub.5 is selected from C.sub.6-20 alkenyl;
[0856] iii) at least one of R.sub.1, R.sub.2, R.sub.3, R.sub.4, and
R.sub.5 have a different number of carbon atoms than at least one
other of R.sub.1, R.sub.2, R.sub.3, R.sub.4, and R.sub.5;
[0857] iv) R.sub.1, R.sub.2, and R.sub.3 are selected from
C.sub.6-20 alkenyl, and R.sub.4 and R.sub.5 are selected from
C.sub.6-20 alkyl; or
[0858] v) R.sub.1, R.sub.2, and R.sub.3 are selected from
C.sub.6-20 alkyl, and R.sub.4 and R.sub.5 are selected from
C.sub.6-20 alkenyl.
[0859] In some embodiments, the compound is of formula (IVa):
##STR00062##
[0860] The compounds of Formula (IV) or (IVa) include one or more
of the following features when applicable.
[0861] In some embodiments, Z is CH.sub.2.
[0862] In some embodiments, Z is absent.
[0863] In some embodiments, at least one of A.sub.1 and A.sub.2 is
N.
[0864] In some embodiments, each of A.sub.1 and A.sub.2 is N.
[0865] In some embodiments, each of A.sub.1 and A.sub.2 is CH.
[0866] In some embodiments, A.sub.1 is N and A.sub.2 is CH.
[0867] In some embodiments, A.sub.1 is CH and A.sub.2 is N.
[0868] In some embodiments, R.sub.1, R.sub.2, R.sub.3, R.sub.4, and
R.sub.5 are the same, and are not C.sub.12 alkyl, C.sub.18 alkyl,
or C.sub.18 alkenyl. In some embodiments, R.sub.1, R.sub.2,
R.sub.3, R.sub.4, and R.sub.5 are the same and are C.sub.9 alkyl or
C.sub.14 alkyl.
[0869] In some embodiments, only one of R.sub.1, R.sub.2, R.sub.3,
R.sub.4, and R.sub.5 is selected from C.sub.6-20 alkenyl. In
certain such embodiments, R.sub.1, R.sub.2, R.sub.3, R.sub.4, and
R.sub.5 have the same number of carbon atoms. In some embodiments,
R.sub.4 is selected from C.sub.5-20 alkenyl. For example, R.sub.4
may be C.sub.12 alkenyl or C.sub.18 alkenyl.
[0870] In some embodiments, at least one of R.sub.1, R.sub.2,
R.sub.3, R.sub.4, and R.sub.5 have a different number of carbon
atoms than at least one other of R.sub.1, R.sub.2, R.sub.3,
R.sub.4, and R.sub.5.
[0871] In certain embodiments, R.sub.1, R.sub.2, and R.sub.3 are
selected from C.sub.6-20 alkenyl, and R.sub.4 and R.sub.5 are
selected from C.sub.6-20 alkyl. In other embodiments, R.sub.1,
R.sub.2, and R.sub.3 are selected from C.sub.6-20 alkyl, and
R.sub.4 and R.sub.5 are selected from C.sub.6-20 alkenyl. In some
embodiments, R.sub.1, R.sub.2, and R.sub.3 have the same number of
carbon atoms, and/or R.sub.4 and R.sub.5 have the same number of
carbon atoms. For example, R.sub.1, R.sub.2, and R.sub.3, or
R.sub.4 and R.sub.5, may have 6, 8, 9, 12, 14, or 18 carbon atoms.
In some embodiments, R.sub.1, R.sub.2, and R.sub.3, or R.sub.4 and
R.sub.5, are C.sub.18 alkenyl (e.g., linoleyl). In some
embodiments, R.sub.1, R.sub.2, and R.sub.3, or R.sub.4 and R.sub.5,
are alkyl groups including 6, 8, 9, 12, or 14 carbon atoms.
[0872] In some embodiments, R.sub.1 has a different number of
carbon atoms than R.sub.2, R.sub.3, R.sub.4, and R.sub.5. In other
embodiments, R.sub.3 has a different number of carbon atoms than
R.sub.1, R.sub.2, R.sub.4, and R.sub.5. In further embodiments,
R.sub.4 has a different number of carbon atoms than R.sub.1,
R.sub.2, R.sub.3, and R.sub.5.
[0873] In some embodiments, the compound is selected from the group
consisting of:
##STR00063## ##STR00064##
[0874] In other embodiments, the delivery agent comprises a
compound having the formula (V)
##STR00065##
[0875] or salts or stereoisomers thereof, in which
[0876] A.sub.3 is CH or N;
[0877] A.sub.4 is CH.sub.2 or NH; and at least one of A.sub.3 and
A.sub.4 is N or NH;
[0878] Z is CH.sub.2 or absent wherein when Z is CH.sub.2, the
dashed lines (1) and (2) each represent a single bond; and when Z
is absent, the dashed lines (1) and (2) are both absent;
[0879] R.sub.1, R.sub.2, and R.sub.3 are independently selected
from the group consisting of C.sub.5-20 alkyl, C.sub.5-20 alkenyl,
--R''MR', --R*YR'', --YR'', and --R*OR'';
[0880] each M is independently selected from --C(O)O--, --OC(O)--,
--C(O)N(R')--, --N(R')C(O)--, --C(O)--, --C(S)--, --C(S)S--,
--SC(S)--, --CH(OH)--, --P(O)(OR')O--, --S(O).sub.2--, an aryl
group, and a heteroaryl group;
[0881] X.sup.1 and X.sup.2 are independently selected from the
group consisting of --CH.sub.2--, --(CH.sub.2).sub.2--, --CHR--,
--CHY--, --C(O)--, --C(O)O--, --OC(O)--, --C(O)--CH.sub.2--,
--CH.sub.2--C(O)--, --C(O)O--CH.sub.2--, --OC(O)--CH.sub.2--,
--CH.sub.2--C(O)O--, --CH.sub.2--OC(O)--, --CH(OH)--, --C(S)--, and
--CH(SH)--;
[0882] each Y is independently a C.sub.3-6 carbocycle;
[0883] each R* is independently selected from the group consisting
of C.sub.1-12 alkyl and C.sub.2-12 alkenyl;
[0884] each R is independently selected from the group consisting
of C.sub.1-3 alkyl and a C.sub.3-6 carbocycle;
[0885] each R' is independently selected from the group consisting
of C.sub.1-12 alkyl, C.sub.2-12 alkenyl, and H; and
[0886] each R'' is independently selected from the group consisting
of C.sub.3-12 alkyl and C.sub.3-12 alkenyl.
[0887] In some embodiments, the compound is of formula (Va):
##STR00066##
[0888] The compounds of Formula (V) or (Va) include one or more of
the following features when applicable.
[0889] In some embodiments, Z is CH.sub.2.
[0890] In some embodiments, Z is absent.
[0891] In some embodiments, at least one of A.sub.3 and A.sub.4 is
N or NH.
[0892] In some embodiments, A.sub.3 is N and A.sub.4 is NH.
[0893] In some embodiments, A.sub.3 is N and A.sub.4 is
CH.sub.2.
[0894] In some embodiments, A.sub.3 is CH and A.sub.4 is NH.
[0895] In some embodiments, at least one of X.sup.1 and X.sup.2 is
not --CH.sub.2--. For example, in certain embodiments, X.sup.1 is
not --CH.sub.2--. In some embodiments, at least one of X.sup.1 and
X.sup.2 is --C(O)--.
[0896] In some embodiments, X.sup.2 is --C(O)--, --C(O)O--,
--OC(O)--, --C(O)--CH.sub.2--, --CH.sub.2--C(O)--,
--C(O)O--CH.sub.2--, --OC(O)--CH.sub.2--, --CH.sub.2--C(O)O--, or
--CH.sub.2--OC(O)--.
[0897] In some embodiments, R.sub.1, R.sub.2, and R.sub.3 are
independently selected from the group consisting of C.sub.5-20
alkyl and C.sub.5-20 alkenyl. In some embodiments, R.sub.1,
R.sub.2, and R.sub.3 are the same. In certain embodiments, R.sub.1,
R.sub.2, and R.sub.3 are C.sub.6, C.sub.9, C.sub.12, or C.sub.14
alkyl. In other embodiments, R.sub.1, R.sub.2, and R.sub.3 are
C.sub.18 alkenyl. For example, R.sub.1, R.sub.2, and R.sub.3 may be
linoleyl.
[0898] In some embodiments, the compound is selected from the group
consisting of:
##STR00067##
[0899] In other embodiments, the delivery agent comprises a
compound having the formula (VI):
##STR00068##
[0900] or salts or stereoisomers thereof, in which
[0901] A.sub.6 and A.sub.7 are each independently selected from CH
or N, wherein at least one of A.sub.6 and A.sub.7 is N;
[0902] Z is CH.sub.2 or absent wherein when Z is CH.sub.2, the
dashed lines (1) and (2) each represent a single bond; and when Z
is absent, the dashed lines (1) and (2) are both absent;
[0903] X.sup.4 and X.sup.5 are independently selected from the
group consisting of --CH.sub.2--, --CH.sub.2).sub.2--, --CHR--,
--CHY--, --C(O)--, --C(O)O--, --OC(O)--, --C(O)--CH.sub.2--,
--CH.sub.2--C(O)--, --C(O)O--CH.sub.2--, --OC(O)--CH.sub.2--,
--CH.sub.2--C(O)O--, --CH.sub.2--OC(O)--, --CH(OH)--, --C(S)--, and
--CH(SH)--;
[0904] R.sub.1, R.sub.2, R.sub.3, R.sub.4, and R.sub.5 each are
independently selected from the group consisting of C.sub.5-20
alkyl, C.sub.5-20 alkenyl, --R''MR', --R*YR'', --YR'', and
--R*OR'';
[0905] each M is independently selected from the group consisting
of --C(O)O--, --OC(O)--, --C(O)N(R')--, --N(R')C(O)--, --C(O)--,
--C(S)--, --C(S)S--, --SC(S)--, --CH(OH)--, --P(O)(OR')O--,
--S(O).sub.2-- an aryl group, and a heteroaryl group;
[0906] each Y is independently a C.sub.3-6 carbocycle;
[0907] each R* is independently selected from the group consisting
of C.sub.1-12 alkyl and C.sub.2-12 alkenyl;
[0908] each R is independently selected from the group consisting
of C.sub.1-3 alkyl and a C.sub.3-6 carbocycle;
[0909] each R' is independently selected from the group consisting
of C.sub.1-12 alkyl, C.sub.2-12 alkenyl, and H; and
[0910] each R'' is independently selected from the group consisting
of C.sub.3-12 alkyl and C.sub.3-12 alkenyl.
[0911] In some embodiments, R.sub.1, R.sub.2, R.sub.3, R.sub.4, and
R.sub.5 each are independently selected from the group consisting
of C.sub.6-20 alkyl and C.sub.6-20 alkenyl.
[0912] In some embodiments, R.sub.1 and R.sub.2 are the same. In
certain embodiments, R.sub.1, R.sub.2, and R.sub.3 are the same. In
some embodiments, R.sub.4 and R.sub.5 are the same. In certain
embodiments, R.sub.1, R.sub.2, R.sub.3, R.sub.4, and R.sub.5 are
the same.
[0913] In some embodiments, at least one of R.sub.1, R.sub.2,
R.sub.3, R.sub.4, and R.sub.5 is C.sub.9-12 alkyl. In certain
embodiments, each of R.sub.1, R.sub.2, R.sub.3, R.sub.4, and
R.sub.5 independently is C.sub.9, C.sub.12 or C.sub.14 alkyl. In
certain embodiments, each of R.sub.1, R.sub.2, R.sub.3, R.sub.4,
and R.sub.5 is C.sub.9 alkyl.
[0914] In some embodiments, A.sub.6 is N and A.sub.7 is N. In some
embodiments, A.sub.6 is CH and A.sub.7 is N.
[0915] In some embodiments, X.sup.4 is --CH.sub.2-- and X.sup.5 is
--C(O)--. In some embodiments, X.sup.4 and X.sup.5 are
--C(O)--.
[0916] In some embodiments, when A.sub.6 is N and A.sub.7 is N, at
least one of X.sup.4 and X.sup.5 is not --CH.sub.2--, e.g., at
least one of X.sup.4 and X.sup.5 is --C(O)--. In some embodiments,
when A.sub.6 is N and A.sub.7 is N, at least one of R.sub.1,
R.sub.2, R.sub.3, R.sub.4, and R.sub.5 is --R''MR'.
[0917] In some embodiments, at least one of R.sub.1, R.sub.2,
R.sub.3, R.sub.4, and R.sub.5 is not --R''MR'.
[0918] In some embodiments, the compound is
##STR00069##
[0919] In other embodiments, the delivery agent comprises a
compound having the formula:
##STR00070##
[0920] Amine moieties of the lipid compounds disclosed herein can
be protonated under certain conditions. For example, the central
amine moiety of a lipid according to formula (I) is typically
protonated (i.e., positively charged) at a pH below the pKa of the
amino moiety and is substantially not charged at a pH above the
pKa. Such lipids can be referred to ionizable amino lipids.
[0921] In one specific embodiment, the ionizable amino lipid is
Compound 18. In another embodiment, the ionizable amino lipid is
Compound 236.
[0922] In some embodiments, the amount the ionizable amino lipid,
e.g., compound of formula (I) ranges from about 1 mol % to 99 mol %
in the lipid composition.
[0923] In one embodiment, the amount of the ionizable amino lipid,
e.g., compound of formula (I) is at least about 1, 2, 3, 4, 5, 6,
7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23,
24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40,
41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57,
58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74,
75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91,
92, 93, 94, 95, 96, 97, 98, or 99 mol % in the lipid
composition.
[0924] In one embodiment, the amount of the ionizable amino lipid,
e.g., the compound of formula (I) ranges from about 30 mol % to
about 70 mol %, from about 35 mol % to about 65 mol %, from about
40 mol % to about 60 mol %, and from about 45 mol % to about 55 mol
% in the lipid composition.
[0925] In one specific embodiment, the amount of the ionizable
amino lipid, e.g., compound of formula (I) is about 50 mol % in the
lipid composition.
[0926] In addition to the ionizable amino lipid disclosed herein,
e.g., compound of formula (I), the lipid composition of the
pharmaceutical compositions disclosed herein can comprise
additional components such as phospholipids, structural lipids,
PEG-lipids, and any combination thereof.
[0927] b. Phospholipids
[0928] The lipid composition of the pharmaceutical composition
disclosed herein can comprise one or more phospholipids, for
example, one or more saturated or (poly)unsaturated phospholipids
or a combination thereof. In general, phospholipids comprise a
phospholipid moiety and one or more fatty acid moieties.
[0929] A phospholipid moiety can be selected, for example, from the
non-limiting group consisting of phosphatidyl choline, phosphatidyl
ethanolamine, phosphatidyl glycerol, phosphatidyl serine,
phosphatidic acid, 2-lysophosphatidyl choline, and a
sphingomyelin.
[0930] A fatty acid moiety can be selected, for example, from the
non-limiting group consisting of lauric acid, myristic acid,
myristoleic acid, palmitic acid, palmitoleic acid, stearic acid,
oleic acid, linoleic acid, alpha-linolenic acid, erucic acid,
phytanoic acid, arachidic acid, arachidonic acid, eicosapentaenoic
acid, behenic acid, docosapentaenoic acid, and docosahexaenoic
acid.
[0931] Particular phospholipids can facilitate fusion to a
membrane. For example, a cationic phospholipid can interact with
one or more negatively charged phospholipids of a membrane (e.g., a
cellular or intracellular membrane). Fusion of a phospholipid to a
membrane can allow one or more elements (e.g., a therapeutic agent)
of a lipid-containing composition (e.g., LNPs) to pass through the
membrane permitting, e.g., delivery of the one or more elements to
a target tissue.
[0932] Non-natural phospholipid species including natural species
with modifications and substitutions including branching,
oxidation, cyclization, and alkynes are also contemplated. For
example, a phospholipid can be functionalized with or cross-linked
to one or more alkynes (e.g., an alkenyl group in which one or more
double bonds is replaced with a triple bond). Under appropriate
reaction conditions, an alkyne group can undergo a copper-catalyzed
cycloaddition upon exposure to an azide. Such reactions can be
useful in functionalizing a lipid bilayer of a nanoparticle
composition to facilitate membrane permeation or cellular
recognition or in conjugating a nanoparticle composition to a
useful component such as a targeting or imaging moiety (e.g., a
dye).
[0933] Phospholipids include, but are not limited to,
glycerophospholipids such as phosphatidylcholines,
phosphatidylethanolamines, phosphatidylserines,
phosphatidylinositols, phosphatidy glycerols, and phosphatidic
acids. Phospholipids also include phosphosphingolipid, such as
sphingomyelin.
[0934] Examples of phospholipids include, but are not limited to,
the following:
##STR00071##
[0935] In certain embodiments, a phospholipid useful or potentially
useful in the present invention is an analog or variant of DSPC
(1,2-dioctadecanoyl-sn-glycero-3-phosphocholine). In certain
embodiments, a phospholipid useful or potentially useful in the
present invention is a compound of Formula (IX):
##STR00072##
[0936] (or a salt thereof, wherein:
[0937] each R.sup.1 is independently optionally substituted alkyl;
or optionally two R.sup.1 are joined together with the intervening
atoms to form optionally substituted monocyclic carbocyclyl or
optionally substituted monocyclic heterocyclyl; or optionally three
R.sup.1 are joined together with the intervening atoms to form
optionally substituted bicyclic carbocyclyl or optionally
substitute bicyclic heterocyclyl;
[0938] n is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;
[0939] m is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;
[0940] A is of the formula:
##STR00073##
[0941] each instance of L.sup.2 is independently a bond or
optionally substituted C.sub.1-6 alkylene, wherein one methylene
unit of the optionally substituted C.sub.1-6 alkylene is optionally
replaced with --O--, --N(R.sup.N)--, --S--, --C(O)--,
--C(O)N(R.sup.N)--, --NR.sup.NC(O)--, --C(O)O--, --OC(O)--,
--OC(O)O--, --OC(O)N(R.sup.N)--, --NR.sup.NC(O)O--, or
--NR.sup.NC(O)N(R.sup.N)--;
[0942] each instance of R.sup.2 is independently optionally
substituted C.sub.1-30 alkyl, optionally substituted C.sub.1-30
alkenyl, or optionally substituted C.sub.1-30 alkynyl; optionally
wherein one or more methylene units of R.sup.2 are independently
replaced with optionally substituted carbocyclylene, optionally
substituted heterocyclylene, optionally substituted arylene,
optionally substituted heteroarylene, --N(R.sup.N)--, --O--, --S--,
--C(O)--, --C(O)N(R.sup.N)--, --NR.sup.NC(O)--,
--NR.sup.NC(O)N(R.sup.N)--, --C(O)O--, --OC(O)--, --OC(O)O--,
--OC(O)N(R.sup.N)--, --NR.sup.NC(O)O--, --C(O)S--, --SC(O)--,
--C(.dbd.NR.sup.N)--, --C(.dbd.NR.sup.N)N(R.sup.N)--,
--NR.sup.NC(.dbd.NR.sup.N)--,
--NR.sup.NC(.dbd.NR.sup.N)N(R.sup.N)--, --C(S)--,
--C(S)N(R.sup.N)--, --NR.sup.NC(S)--, --NR.sup.NC(S)N(R.sup.N)--,
--S(O)--, --OS(O)--, --S(O)O--, --OS(O)O--, --OS(O).sub.2--,
--S(O).sub.2O--, --OS(O).sub.2O--, --N(R.sup.N)S(O)--,
--S(O)N(R.sup.N)--, --N(R.sup.N)S(O)N(R.sup.N)--,
--OS(O)N(R.sup.N)--, --N(R.sup.N)S(O)O--, --S(O).sub.2--,
--N(R.sup.N)S(O).sub.2-, --S(O).sub.2N(R.sup.N)--,
--N(R.sup.N)S(O).sub.2N(R.sup.N)--, --OS(O).sub.2N(R.sup.N)--, or
--N(R.sup.N)S(O).sub.2O--;
[0943] each instance of R.sup.N is independently hydrogen,
optionally substituted alkyl, or a nitrogen protecting group;
[0944] Ring B is optionally substituted carbocyclyl, optionally
substituted heterocyclyl, optionally substituted aryl, or
optionally substituted heteroaryl; and
[0945] p is 1 or 2;
[0946] provided that the compound is not of the formula:
##STR00074##
[0947] wherein each instance of R.sup.2 is independently
unsubstituted alkyl, unsubstituted alkenyl, or unsubstituted
alkynyl.
[0948] i) Phospholipid Head Modifications
[0949] In certain embodiments, a phospholipid useful or potentially
useful in the present invention comprises a modified phospholipid
head (e.g., a modified choline group). In certain embodiments, a
phospholipid with a modified head is DSPC, or analog thereof, with
a modified quaternary amine. For example, in embodiments of Formula
(IX), at least one of R.sup.1 is not methyl. In certain
embodiments, at least one of R.sup.1 is not hydrogen or methyl. In
certain embodiments, the compound of Formula (IX) is of one of the
following formulae:
##STR00075##
[0950] or a salt thereof, wherein:
[0951] each t is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, or
10;
[0952] each u is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;
and
[0953] each v is independently 1, 2, or 3.
[0954] In certain embodiments, the compound of Formula (IX) is of
one of the following formulae:
##STR00076##
[0955] or a salt thereof.
[0956] In certain embodiments, a compound of Formula (IX) is one of
the following:
##STR00077##
[0957] or a salt thereof.
[0958] In certain embodiments, a compound of Formula (IX) is of
Formula (IX-a):
##STR00078##
[0959] or a salt thereof.
[0960] In certain embodiments, phospholipids useful or potentially
useful in the present invention comprise a modified core. In
certain embodiments, a phospholipid with a modified core described
herein is DSPC, or analog thereof, with a modified core structure.
For example, in certain embodiments of Formula (IX-a), group A is
not of the following formula:
##STR00079##
[0961] In certain embodiments, the compound of Formula (IX-a) is of
one of the following formulae:
##STR00080##
[0962] or a salt thereof.
[0963] In certain embodiments, a compound of Formula (IX) is one of
the following:
##STR00081##
[0964] or salts thereof.
[0965] In certain embodiments, a phospholipid useful or potentially
useful in the present invention comprises a cyclic moiety in place
of the glyceride moiety. In certain embodiments, a phospholipid
useful in the present invention is DSPC
(1,2-dioctadecanoyl-sn-glycero-3-phosphocholine), or analog
thereof, with a cyclic moiety in place of the glyceride moiety. In
certain embodiments, the compound of Formula (IX) is of Formula
(IX-b):
##STR00082##
[0966] or a salt thereof.
[0967] In certain embodiments, the compound of Formula (IX-b) is of
Formula (IX-b-1):
##STR00083##
[0968] or a salt thereof, wherein:
[0969] w is 0, 1, 2, or 3.
[0970] In certain embodiments, the compound of Formula (IX-b) is of
Formula (IX-b-2):
##STR00084##
[0971] or a salt thereof.
[0972] In certain embodiments, the compound of Formula (IX-b) is of
Formula (IX-b-3):
##STR00085##
[0973] or a salt thereof.
[0974] In certain embodiments, the compound of Formula (IX-b) is of
Formula (IX-b-4):
##STR00086##
[0975] or a salt thereof.
[0976] In certain embodiments, the compound of Formula (IX-b) is
one of the following:
##STR00087## [0977] or salts thereof.
[0978] (ii) Phospholipid Tail Modifications
[0979] In certain embodiments, a phospholipid useful or potentially
useful in the present invention comprises a modified tail. In
certain embodiments, a phospholipid useful or potentially useful in
the present invention is DSPC
(1,2-dioctadecanoyl-sn-glycero-3-phosphocholine), or analog
thereof, with a modified tail. As described herein, a "modified
tail" may be a tail with shorter or longer aliphatic chains,
aliphatic chains with branching introduced, aliphatic chains with
substituents introduced, aliphatic chains wherein one or more
methylenes are replaced by cyclic or heteroatom groups, or any
combination thereof. For example, in certain embodiments, the
compound of (IX) is of Formula (IX-a), or a salt thereof, wherein
at least one instance of R.sup.2 is each instance of R.sup.2 is
optionally substituted C.sub.1-30 alkyl, wherein one or more
methylene units of R.sup.2 are independently replaced with
optionally substituted carbocyclylene, optionally substituted
heterocyclylene, optionally substituted arylene, optionally
substituted heteroarylene, --N(R.sup.N)--, --O--, --S--, --C(O)--,
--C(O)N(R.sup.N)--, --NR.sup.NC(O)--, --NR.sup.NC(O)N(R.sup.N)--,
--C(O)O--, --OC(O)--, --OC(O)O--, --OC(O)N(R.sup.N)--,
--NR.sup.NC(O)O--, --C(O)S--, --SC(O)--, --C(.dbd.NR.sup.N)--,
--C(.dbd.NR.sup.N)N(R.sup.N)--, --NR.sup.NC(.dbd.NR.sup.N)--,
--NR.sup.NC(.dbd.NR.sup.N)N(R.sup.N)--, --C(S)--,
--C(S)N(R.sup.N)--, --NR.sup.NC(S)--, --NR.sup.NC(S)N(R.sup.N)--,
--S(O)--, --OS(O)--, --S(O)O--, --OS(O)O--, --OS(O).sub.2--,
--S(O).sub.2O--, --OS(O).sub.2O--, --N(R.sup.N)S(O)--,
--S(O)N(R.sup.N)--, --N(R.sup.N)S(O)N(R.sup.N)--,
--OS(O)N(R.sup.N)--, --N(R.sup.N)S(O)O--, --S(O).sub.2--,
--N(R.sup.N)S(O).sub.2--, --S(O).sub.2N(R.sup.N)--,
--N(R.sup.N)S(O).sub.2N(R.sup.N)--, --OS(O).sub.2N(R.sup.N)--, or
--N(R.sup.N)S(O).sub.2O--.
[0980] In certain embodiments, the compound of Formula (IX) is of
Formula (IX-c):
##STR00088##
[0981] or a salt thereof, wherein:
[0982] each x is independently an integer between 0-30, inclusive;
and
[0983] each instance is G is independently selected from the group
consisting of optionally substituted carbocyclylene, optionally
substituted heterocyclylene, optionally substituted arylene,
optionally substituted heteroarylene, --N(R.sup.N)--, --O--, --S--,
--C(O)--, --C(O)N(R.sup.N)--, --NR.sup.NC(O)--,
--NR.sup.NC(O)N(R.sup.N)--, --C(O)O--, --OC(O)--, --OC(O)O--,
--OC(O)N(R.sup.N)--, --NR.sup.NC(O)O--, --C(O)S--, --SC(O)--,
--C(.dbd.NR.sup.N)--, --C(.dbd.NR.sup.N)N(R.sup.N)--,
--NR.sup.NC(.dbd.NR.sup.N)--,
--NR.sup.NC(.dbd.NR.sup.N)N(R.sup.N)--, --C(S)--,
--C(S)N(R.sup.N)--, --NR.sup.NC(S)--, --NR.sup.NC(S)N(R.sup.N)--,
--S(O)--, --OS(O)--, --S(O)O--, --OS(O)O--, --OS(O).sub.2--,
--S(O).sub.2O--, --OS(O).sub.2O--, --N(R.sup.N)S(O)--,
--S(O)N(R.sup.N)--, --N(R.sup.N)S(O)N(R.sup.N)--,
--OS(O)N(R.sup.N)--, --N(R.sup.N)S(O)O--, --S(O).sub.2--,
--N(R.sup.N)S(O).sub.2--, --S(O).sub.2N(R.sup.N)--,
--N(R.sup.N)S(O).sub.2N(R.sup.N)--, --OS(O).sub.2N(R.sup.N)--, or
--N(R.sup.N)S(O).sub.2O--. Each possibility represents a separate
embodiment of the present invention.
[0984] In certain embodiments, the compound of Formula (IX-c) is of
Formula (IX-c-1):
##STR00089##
[0985] or salt thereof, wherein:
[0986] each instance of v is independently 1, 2, or 3.
[0987] In certain embodiments, the compound of Formula (IX-c) is of
Formula (IX-c-2):
##STR00090##
[0988] or a salt thereof.
[0989] In certain embodiments, the compound of Formula (IX-c) is of
the following formula:
##STR00091##
[0990] or a salt thereof.
[0991] In certain embodiments, the compound of Formula (IX-c) is
the following:
##STR00092##
[0992] or a salt thereof.
[0993] In certain embodiments, the compound of Formula (IX-c) is of
Formula (IX-c-3):
##STR00093##
[0994] or a salt thereof.
[0995] In certain embodiments, the compound of Formula (IX-c) is of
the following formulae:
##STR00094##
[0996] or a salt thereof.
[0997] In certain embodiments, the compound of Formula (IX-c) is
the following:
##STR00095##
[0998] or a salt thereof.
[0999] In certain embodiments, a phospholipid useful or potentially
useful in the present invention comprises a modified phosphocholine
moiety, wherein the alkyl chain linking the quaternary amine to the
phosphoryl group is not ethylene (e.g., n is not 2). Therefore, in
certain embodiments, a phospholipid useful or potentially useful in
the present invention is a compound of Formula (IX), wherein n is
1, 3, 4, 5, 6, 7, 8, 9, or 10. For example, in certain embodiments,
a compound of Formula (IX) is of one of the following formulae:
##STR00096##
[1000] or a salt thereof.
[1001] In certain embodiments, a compound of Formula (IX) is one of
the following:
##STR00097## ##STR00098##
or salts thereof.
[1002] c. Alternative Lipids
[1003] In certain embodiments, an alternative lipid is used in
place of a phospholipid of the invention. Non-limiting examples of
such alternative lipids include the following:
##STR00099## ##STR00100##
[1004] d. Structural Lipids
[1005] The lipid composition of a pharmaceutical composition
disclosed herein can comprise one or more structural lipids. As
used herein, the term "structural lipid" refers to sterols and also
to lipids containing sterol moieties.
[1006] Incorporation of structural lipids in the lipid nanoparticle
may help mitigate aggregation of other lipids in the particle.
Structural lipids can be selected from the group including but not
limited to, cholesterol, fecosterol, sitosterol, ergosterol,
campesterol, stigmasterol, brassicasterol, tomatidine, tomatine,
ursolic acid, alpha-tocopherol, hopanoids, phytosterols, steroids,
and mixtures thereof. In some embodiments, the structural lipid is
a sterol. As defined herein, "sterols" are a subgroup of steroids
consisting of steroid alcohols. In certain embodiments, the
structural lipid is a steroid. In certain embodiments, the
structural lipid is cholesterol. In certain embodiments, the
structural lipid is an analog of cholesterol. In certain
embodiments, the structural lipid is alpha-tocopherol. Examples of
structural lipids include, but are not limited to, the
following:
##STR00101##
[1007] In one embodiment, the amount of the structural lipid (e.g.,
an sterol such as cholesterol) in the lipid composition of a
pharmaceutical composition disclosed herein ranges from about 20
mol % to about 60 mol %, from about 25 mol % to about 55 mol %,
from about 30 mol % to about 50 mol %, or from about 35 mol % to
about 45 mol %.
[1008] In one embodiment, the amount of the structural lipid (e.g.,
an sterol such as cholesterol) in the lipid composition disclosed
herein ranges from about 25 mol % to about 30 mol %, from about 30
mol % to about 35 mol %, or from about 35 mol % to about 40 mol
%.
[1009] In one embodiment, the amount of the structural lipid (e.g.,
a sterol such as cholesterol) in the lipid composition disclosed
herein is about 24 mol %, about 29 mol %, about 34 mol %, or about
39 mol %.
[1010] In some embodiments, the amount of the structural lipid
(e.g., an sterol such as cholesterol) in the lipid composition
disclosed herein is at least about 20, 21, 22, 23, 24, 25, 26, 27,
28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44,
45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, or 60
mol %.
[1011] e. Polyethylene Glycol (PEG)-Lipids
[1012] The lipid composition of a pharmaceutical composition
disclosed herein can comprise one or more a polyethylene glycol
(PEG) lipid.
[1013] As used herein, the term "PEG-lipid" refers to polyethylene
glycol (PEG)-modified lipids. Non-limiting examples of PEG-lipids
include PEG-modified phosphatidylethanolamine and phosphatidic
acid, PEG-ceramide conjugates (e.g., PEG-CerC14 or PEG-CerC20),
PEG-modified dialkylamines and PEG-modified
1,2-diacyloxypropan-3-amines. Such lipids are also referred to as
PEGylated lipids. For example, a PEG lipid can be PEG-c-DOMG,
PEG-DMG, PEG-DLPE, PEG-DMPE, PEG-DPPC, or a PEG-DSPE lipid.
[1014] In some embodiments, the PEG-lipid includes, but not limited
to 1,2-dimyristoyl-sn-glycerol methoxypolyethylene glycol
(PEG-DMG),
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene
glycol)] (PEG-DSPE), PEG-disteryl glycerol (PEG-DSG),
PEG-dipalmetoleyl, PEG-dioleyl, PEG-distearyl, PEG-diacylglycamide
(PEG-DAG), PEG-dipalmitoyl phosphatidylethanolamine (PEG-DPPE), or
PEG-1,2-dimyristyloxlpropyl-3-amine (PEG-c-DMA).
[1015] In one embodiment, the PEG-lipid is selected from the group
consisting of a PEG-modified phosphatidylethanolamine, a
PEG-modified phosphatidic acid, a PEG-modified ceramide, a
PEG-modified dialkylamine, a PEG-modified diacylglycerol, a
PEG-modified dialkylglycerol, and mixtures thereof.
[1016] In some embodiments, the lipid moiety of the PEG-lipids
includes those having lengths of from about C.sub.14 to about
C.sub.22, preferably from about C.sub.14 to about C.sub.16. In some
embodiments, a PEG moiety, for example an mPEG-NH.sub.2, has a size
of about 1000, 2000, 5000, 10,000, 15,000 or 20,000 daltons. In one
embodiment, the PEG-lipid is PEG.sub.2k-DMG.
[1017] In one embodiment, the lipid nanoparticles described herein
can comprise a PEG lipid which is a non-diffusible PEG.
Non-limiting examples of non-diffusible PEGs include PEG-DSG and
PEG-DSPE.
[1018] PEG-lipids are known in the art, such as those described in
U.S. Pat. No. 8,158,601 and International Publ. No. WO 2015/130584
A2, which are incorporated herein by reference in their
entirety.
[1019] In general, some of the other lipid components (e.g., PEG
lipids) of various formulae, described herein may be synthesized as
described International Patent Application No. PCT/US2016/000129,
filed Dec. 10, 2016, entitled "Compositions and Methods for
Delivery of Therapeutic Agents," which is incorporated herein by
reference in its entirety.
[1020] The lipid component of a lipid nanoparticle composition may
include one or more molecules comprising polyethylene glycol, such
as PEG or PEG-modified lipids. Such species may be alternately
referred to as PEGylated lipids. A PEG lipid is a lipid modified
with polyethylene glycol. A PEG lipid may be selected from the
non-limiting group including PEG-modified
phosphatidylethanolamines, PEG-modified phosphatidic acids,
PEG-modified ceramides, PEG-modified dialkylamines, PEG-modified
diacylglycerols, PEG-modified dialkylglycerols, and mixtures
thereof. For example, a PEG lipid may be PEG-c-DOMG, PEG-DMG,
PEG-DLPE, PEG-DMPE, PEG-DPPC, or a PEG-DSPE lipid.
[1021] In some embodiments the PEG-modified lipids are a modified
form of PEG DMG. PEG-DMG has the following structure:
##STR00102##
[1022] In one embodiment, PEG lipids useful in the present
invention can be PEGylated lipids described in International
Publication No. WO2012099755, the contents of which is incorporated
herein by reference in its entirety. Any of these exemplary PEG
lipids described herein may be modified to comprise a hydroxyl
group on the PEG chain. In certain embodiments, the PEG lipid is a
PEG-OH lipid. As generally defined herein, a "PEG-OH lipid" (also
referred to herein as "hydroxy-PEGylated lipid") is a PEGylated
lipid having one or more hydroxyl (--OH) groups on the lipid. In
certain embodiments, the PEG-OH lipid includes one or more hydroxyl
groups on the PEG chain. In certain embodiments, a PEG-OH or
hydroxy-PEGylated lipid comprises an --OH group at the terminus of
the PEG chain. Each possibility represents a separate embodiment of
the present invention.
[1023] In certain embodiments, a PEG lipid useful in the present
invention is a compound of Formula (VII). Provided herein are
compounds of Formula (VII):
##STR00103##
[1024] or salts thereof, wherein:
[1025] R.sup.3 is --OR.sup.O;
[1026] R.sup.O is hydrogen, optionally substituted alkyl, or an
oxygen protecting group;
[1027] r is an integer between 1 and 100, inclusive;
[1028] L.sup.1 is optionally substituted C.sub.1-10 alkylene,
wherein at least one methylene of the optionally substituted
C.sub.1-10 alkylene is independently replaced with optionally
substituted carbocyclylene, optionally substituted heterocyclylene,
optionally substituted arylene, optionally substituted
heteroarylene, O, N(R.sup.N), S, C(O), C(O)N(R.sup.N),
NR.sup.NC(O), C(O)O, --OC(O), OC(O)O, OC(O)N(R.sup.N),
NR.sup.NC(O)O, or NR.sup.NC(O)N(R.sup.N);
[1029] D is a moiety obtained by click chemistry or a moiety
cleavable under physiological conditions;
[1030] m is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;
[1031] A is of the formula:
##STR00104##
[1032] each instance of L.sup.2 is independently a bond or
optionally substituted C.sub.1-6 alkylene, wherein one methylene
unit of the optionally substituted C.sub.1-6 alkylene is optionally
replaced with O, N(R.sup.N), S, C(O), C(O)N(R.sup.N), NR.sup.NC(O),
C(O)O, OC(O), OC(O)O, OC(O)N(R.sup.N), --NR.sup.NC(O)O, or
NR.sup.NC(O)N(R.sup.N);
[1033] each instance of R.sup.2 is independently optionally
substituted C.sub.1-30 alkyl, optionally substituted C.sub.1-30
alkenyl, or optionally substituted C.sub.1-30 alkynyl; optionally
wherein one or more methylene units of R.sup.2 are independently
replaced with optionally substituted carbocyclylene, optionally
substituted heterocyclylene, optionally substituted arylene,
optionally substituted heteroarylene, N(R.sup.N), O, S, C(O),
C(O)N(R.sup.N), NR.sup.NC(O), --NR.sup.NC(O)N(R.sup.N), C(O)O,
OC(O), OC(O)O, OC(O)N(R.sup.N), NR.sup.NC(O)O, C(O)S, SC(O),
--C(.dbd.NR.sup.N), C(.dbd.NR.sup.N)N(R.sup.N),
NR.sup.NC(.dbd.NR.sup.N), NR.sup.NC(.dbd.NR.sup.N)N(R.sup.N), C(S),
C(S)N(R.sup.N), NR.sup.NC(S), NR.sup.NC(S)N(R.sup.N), S(O), OS(O),
S(O)O, OS(O)O, OS(O).sub.2, S(O).sub.20, OS(O).sub.20,
N(R.sup.N)S(O), --S(O)N(R.sup.N), N(R.sup.N)S(O)N(R.sup.N),
OS(O)N(R.sup.N), N(R.sup.N)S(O)O, S(O).sub.2, N(R.sup.N)S(O).sub.2,
S(O).sub.2N(R.sup.N), N(R.sup.N)S(O).sub.2N(R.sup.N),
OS(O).sub.2N(R.sup.N), or N(R.sup.N)S(O).sub.2O;
[1034] each instance of R.sup.N is independently hydrogen,
optionally substituted alkyl, or a nitrogen protecting group;
[1035] Ring B is optionally substituted carbocyclyl, optionally
substituted heterocyclyl, optionally substituted aryl, or
optionally substituted heteroaryl; and
[1036] p is 1 or 2.
[1037] In certain embodiments, the compound of Formula (VII) is a
PEG-OH lipid (i.e., R.sup.3 is --OR.sup.O, and R.sup.O is
hydrogen). In certain embodiments, the compound of Formula (VII) is
of Formula (VII-OH):
##STR00105##
[1038] or a salt thereof.
[1039] In certain embodiments, D is a moiety obtained by click
chemistry (e.g., triazole). In certain embodiments, the compound of
Formula (VII) is of Formula (VII-a-1) or (VII-a-2):
##STR00106##
[1040] or a salt thereof.
[1041] In certain embodiments, the compound of Formula (VII) is of
one of the following formulae:
##STR00107##
[1042] or a salt thereof, wherein
[1043] s is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
[1044] In certain embodiments, the compound of Formula (VII) is of
one of the following formulae:
##STR00108##
[1045] or a salt thereof.
[1046] In certain embodiments, a compound of Formula (VII) is of
one of the following formulae:
##STR00109##
[1047] or a salt thereof.
[1048] In certain embodiments, a compound of Formula (VII) is of
one of the following formulae:
##STR00110##
[1049] or a salt thereof.
[1050] In certain embodiments, D is a moiety cleavable under
physiological conditions (e.g., ester, amide, carbonate, carbamate,
urea). In certain embodiments, a compound of Formula (VII) is of
Formula (VII-b-1) or (VII-b-2):
##STR00111##
[1051] or a salt thereof.
[1052] In certain embodiments, a compound of Formula (VII) is of
Formula (VII-b-1-OH) or (VII-b-2-OH):
##STR00112##
[1053] or a salt thereof.
[1054] In certain embodiments, the compound of Formula (VII) is of
one of the following formulae:
##STR00113##
[1055] or a salt thereof.
[1056] In certain embodiments, a compound of Formula (VII) is of
one of the following formulae:
##STR00114##
[1057] or a salt thereof.
[1058] In certain embodiments, a compound of Formula (VII) is of
one of the following formulae:
##STR00115##
[1059] or a salt thereof.
[1060] In certain embodiments, a compound of Formula (VII) is of
one of the following formulae:
##STR00116##
[1061] or salts thereof.
[1062] In certain embodiments, a PEG lipid useful in the present
invention is a PEGylated fatty acid. In certain embodiments, a PEG
lipid useful in the present invention is a compound of Formula
(VIII). Provided herein are compounds of Formula (VIII):
##STR00117##
[1063] or a salts thereof, wherein:
[1064] R.sup.3 is --OR.sup.O;
[1065] R.sup.O is hydrogen, optionally substituted alkyl or an
oxygen protecting group;
[1066] r is an integer between 1 and 100, inclusive;
[1067] R.sup.5 is optionally substituted C.sub.10-40 alkyl,
optionally substituted C.sub.10-40 alkenyl, or optionally
substituted C.sub.10-40 alkynyl; and optionally one or more
methylene groups of R.sup.5 are replaced with optionally
substituted carbocyclylene, optionally substituted heterocyclylene,
optionally substituted arylene, optionally substituted
heteroarylene, N(R.sup.N), O, S, C(O), --C(O)N(R.sup.N),
NR.sup.NC(O), NR.sup.NC(O)N(R.sup.N), C(O)O, OC(O), OC(O)O,
OC(O)N(R.sup.N), --NR.sup.NC(O)O, C(O)S, SC(O), C(.dbd.NR.sup.N),
C(.dbd.NR.sup.N)N(R.sup.N), NR.sup.NC(.dbd.NR.sup.N),
NR.sup.NC(.dbd.NR.sup.N)N(R.sup.N), --C(S), C(S)N(R.sup.N),
NR.sup.NC(S), NR.sup.NC(S)N(R.sup.N), S(O), OS(O), S(O)O, OS(O)O,
OS(O).sub.2, --S(O).sub.2O, OS(O).sub.2O, N(R.sup.N)S(O),
S(O)N(R.sup.N), N(R.sup.N)S(O)N(R.sup.N), OS(O)N(R.sup.N),
N(R.sup.N)S(O)O, --S(O).sub.2, N(R.sup.N)S(O).sub.2,
S(O).sub.2N(R.sup.N), N(R.sup.N)S(O).sub.2N(R.sup.N),
OS(O).sub.2N(R.sup.N), or N(R.sup.N)S(O).sub.2O; and
[1068] each instance of R.sup.N is independently hydrogen,
optionally substituted alkyl, or a nitrogen protecting group.
[1069] In certain embodiments, the compound of Formula (VIII) is of
Formula (VIII-OH):
##STR00118##
[1070] or a salt thereof. In some embodiments, r is 45.
[1071] In certain embodiments, a compound of Formula (VIII) is of
one of the following formulae:
##STR00119##
[1072] or a salt thereof. In some embodiments, r is 45.
[1073] In yet other embodiments the compound of Formula (VIII)
is:
##STR00120##
[1074] or a salt thereof.
[1075] In one embodiment, the compound of Formula (VIII) is
##STR00121##
[1076] In one embodiment, the amount of PEG-lipid in the lipid
composition of a pharmaceutical composition disclosed herein ranges
from about 0.1 mol % to about 5 mol %, from about 0.5 mol % to
about 5 mol %, from about 1 mol % to about 5 mol %, from about 1.5
mol % to about 5 mol %, from about 2 mol % to about 5 mol % mol %,
from about 0.1 mol % to about 4 mol %, from about 0.5 mol % to
about 4 mol %, from about 1 mol % to about 4 mol %, from about 1.5
mol % to about 4 mol %, from about 2 mol % to about 4 mol %, from
about 0.1 mol % to about 3 mol %, from about 0.5 mol % to about 3
mol %, from about 1 mol % to about 3 mol %, from about 1.5 mol % to
about 3 mol %, from about 2 mol % to about 3 mol %, from about 0.1
mol % to about 2 mol %, from about 0.5 mol % to about 2 mol %, from
about 1 mol % to about 2 mol %, from about 1.5 mol % to about 2 mol
%, from about 0.1 mol % to about 1.5 mol %, from about 0.5 mol % to
about 1.5 mol %, or from about 1 mol % to about 1.5 mol %.
[1077] In one embodiment, the amount of PEG-lipid in the lipid
composition disclosed herein is about 2 mol %. In one embodiment,
the amount of PEG-lipid in the lipid composition disclosed herein
is about 1.5 mol %.
[1078] In one embodiment, the amount of PEG-lipid in the lipid
composition disclosed herein is at least about 0.1, 0.2, 0.3, 0.4,
0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8,
1.9, 2, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3, 3.1, 3.2,
3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6,
4.7, 4.8, 4.9, or 5 mol %.
[1079] In some aspects, the lipid composition of the pharmaceutical
compositions disclosed herein does not comprise a PEG-lipid.
[1080] f. Other Ionizable Amino Lipids
[1081] The lipid composition of the pharmaceutical composition
disclosed herein can comprise one or more ionizable amino lipids in
addition to or instead of a lipid according to Formula (I), (II),
(III), (IV), (V), or (VI).
[1082] Ionizable lipids can be selected from the non-limiting group
consisting of
3-(didodecylamino)-N1,N1,4-tridodecyl-1-piperazineethanamine
(KL10),
N1-[2-(didodecylamino)ethyl]-N1,N4,N4-tridodecyl-1,4-piperazinediethanami-
ne (KL22), 14,25-ditridecyl-15,18,21,24-tetraaza-octatriacontane
(KL25), 1,2-dilinoleyloxy-N,N-dimethylaminopropane (DLin-DMA),
2,2-dilinoleyl-4-dimethylaminomethyl-[1,3]-dioxolane (DLin-K-DMA),
heptatriaconta-6,9,28,31-tetraen-19-yl 4-(dimethylamino)butanoate
(DLin-MC3-DMA),
2,2-dilinoleyl-4-(2-dimethylaminoethyl)-[1,3]-dioxolane
(DLin-KC2-DMA), 1,2-dioleyloxy-N,N-dimethylaminopropane (DODMA),
(13Z,165Z)--N,N-dimethyl-3-nonydocosa-13-16-dien-1-amine (L608),
2-({8-[(3.beta.)-cholest-5-en-3-yloxy]octyl}oxy)-N,N-dimethyl-3-[(9Z,12Z)-
-octadeca-9,12-dien-1-yloxy]propan-1-amine (Octyl-CLinDMA),
(2R)-2-({8-[(3.beta.)-cholest-5-en-3-yloxy]octyl}oxy)-N,N-dimethyl-3-[(9Z-
,12Z)-octadeca-9,12-dien-1-yloxy]propan-1-amine (Octyl-CLinDMA
(2R)), and
(2S)-2-({8-[(3.beta.)-cholest-5-en-3-yloxy]octyl}oxy)-N,N-dimethyl-3-[(9Z-
,12Z)-octadeca-9,12-dien-1-yloxy]propan-1-amine (Octyl-CLinDMA
(2S)). In addition to these, an ionizable amino lipid can also be a
lipid including a cyclic amine group.
[1083] Ionizable lipids can also be the compounds disclosed in
International Publication No. WO 2017/075531 A1, incorporated
herein by reference in its entirety. For example, the ionizable
amino lipids include, but not limited to:
##STR00122##
[1084] and any combination thereof.
[1085] Ionizable lipids can also be the compounds disclosed in
International Publication No. WO 2015/199952 A1, incorporated
herein by reference in its entirety. For example, the ionizable
amino lipids include, but not limited to:
##STR00123## ##STR00124##
[1086] and any combination thereof.
[1087] g. Nanoparticle Compositions
[1088] The lipid composition of a pharmaceutical composition
disclosed herein can include one or more components in addition to
those described above. For example, the lipid composition can
include one or more permeability enhancer molecules, carbohydrates,
polymers, surface altering agents (e.g., surfactants), or other
components. For example, a permeability enhancer molecule can be a
molecule described by U.S. Patent Application Publication No.
2005/0222064. Carbohydrates can include simple sugars (e.g.,
glucose) and polysaccharides (e.g., glycogen and derivatives and
analogs thereof).
[1089] A polymer can be included in and/or used to encapsulate or
partially encapsulate a pharmaceutical composition disclosed herein
(e.g., a pharmaceutical composition in lipid nanoparticle form). A
polymer can be biodegradable and/or biocompatible. A polymer can be
selected from, but is not limited to, polyamines, polyethers,
polyamides, polyesters, polycarbamates, polyureas, polycarbonates,
polystyrenes, polyimides, polysulfones, polyurethanes,
polyacetylenes, polyethylenes, polyethyleneimines, polyisocyanates,
polyacrylates, polymethacrylates, polyacrylonitriles, and
polyarylates.
[1090] The ratio between the lipid composition and the
polynucleotide range can be from about 10:1 to about 60:1
(wt/wt).
[1091] In some embodiments, the ratio between the lipid composition
and the polynucleotide can be about 10:1, 11:1, 12:1, 13:1, 14:1,
15:1, 16:1, 17:1, 18:1, 19:1, 20:1, 21:1, 22:1, 23:1, 24:1, 25:1,
26:1, 27:1, 28:1, 29:1, 30:1, 31:1, 32:1, 33:1, 34:1, 35:1, 36:1,
37:1, 38:1, 39:1, 40:1, 41:1, 42:1, 43:1, 44:1, 45:1, 46:1, 47:1,
48:1, 49:1, 50:1, 51:1, 52:1, 53:1, 54:1, 55:1, 56:1, 57:1, 58:1,
59:1 or 60:1 (wt/wt). In some embodiments, the wt/wt ratio of the
lipid composition to the polynucleotide encoding a therapeutic
agent is about 20:1 or about 15:1.
[1092] In one embodiment, the lipid nanoparticles described herein
can comprise polynucleotides (e.g., mRNA) in a lipid:polynucleotide
weight ratio of 5:1, 10:1, 15:1, 20:1, 25:1, 30:1, 35:1, 40:1,
45:1, 50:1, 55:1, 60:1 or 70:1, or a range or any of these ratios
such as, but not limited to, 5:1 to about 10:1, from about 5:1 to
about 15:1, from about 5:1 to about 20:1, from about 5:1 to about
25:1, from about 5:1 to about 30:1, from about 5:1 to about 35:1,
from about 5:1 to about 40:1, from about 5:1 to about 45:1, from
about 5:1 to about 50:1, from about 5:1 to about 55:1, from about
5:1 to about 60:1, from about 5:1 to about 70:1, from about 10:1 to
about 15:1, from about 10:1 to about 20:1, from about 10:1 to about
25:1, from about 10:1 to about 30:1, from about 10:1 to about 35:1,
from about 10:1 to about 40:1, from about 10:1 to about 45:1, from
about 10:1 to about 50:1, from about 10:1 to about 55:1, from about
10:1 to about 60:1, from about 10:1 to about 70:1, from about 15:1
to about 20:1, from about 15:1 to about 25:1, from about 15:1 to
about 30:1, from about 15:1 to about 35:1, from about 15:1 to about
40:1, from about 15:1 to about 45:1, from about 15:1 to about 50:1,
from about 15:1 to about 55:1, from about 15:1 to about 60:1 or
from about 15:1 to about 70:1.
[1093] In one embodiment, the lipid nanoparticles described herein
can comprise the polynucleotide in a concentration from
approximately 0.1 mg/ml to 2 mg/ml such as, but not limited to, 0.1
mg/ml, 0.2 mg/ml, 0.3 mg/ml, 0.4 mg/ml, 0.5 mg/ml, 0.6 mg/ml, 0.7
mg/ml, 0.8 mg/ml, 0.9 mg/ml, 1.0 mg/ml, 1.1 mg/ml, 1.2 mg/ml, 1.3
mg/ml, 1.4 mg/ml, 1.5 mg/ml, 1.6 mg/ml, 1.7 mg/ml, 1.8 mg/ml, 1.9
mg/ml, 2.0 mg/ml or greater than 2.0 mg/ml.
[1094] In some embodiments, the pharmaceutical compositions
disclosed herein are formulated as lipid nanoparticles (LNP).
Accordingly, the present disclosure also provides nanoparticle
compositions comprising (i) a lipid composition comprising a
delivery agent such as a compound of Formula (I) or (III) as
described herein, and (ii) a polynucleotide encoding a polypeptide
of interest. In such nanoparticle composition, the lipid
composition disclosed herein can encapsulate the polynucleotide
encoding a polypeptide of interest.
[1095] Nanoparticle compositions are typically sized on the order
of micrometers or smaller and can include a lipid bilayer.
Nanoparticle compositions encompass lipid nanoparticles (LNPs),
liposomes (e.g., lipid vesicles), and lipoplexes. For example, a
nanoparticle composition can be a liposome having a lipid bilayer
with a diameter of 500 nm or less.
[1096] Nanoparticle compositions include, for example, lipid
nanoparticles (LNPs), liposomes, and lipoplexes. In some
embodiments, nanoparticle compositions are vesicles including one
or more lipid bilayers. In certain embodiments, a nanoparticle
composition includes two or more concentric bilayers separated by
aqueous compartments. Lipid bilayers can be functionalized and/or
crosslinked to one another. Lipid bilayers can include one or more
ligands, proteins, or channels.
[1097] In some embodiments, the nanoparticle compositions of the
present disclosure comprise at least one compound according to
Formula (I), (III), (IV), (V), or (VI). For example, the
nanoparticle composition can include one or more of Compounds
1-147, or one or more of Compounds 1-342. Nanoparticle compositions
can also include a variety of other components. For example, the
nanoparticle composition may include one or more other lipids in
addition to a lipid according to Formula (I), (II), (III), (IV),
(V), or (VI), such as (i) at least one phospholipid, (ii) at least
one structural lipid, (iii) at least one PEG-lipid, or (iv) any
combination thereof. Inclusion of structural lipid can be optional,
for example when lipids according to formula III are used in the
lipid nanoparticle compositions of the invention.
[1098] In some embodiments, the nanoparticle composition comprises
a compound of Formula (I), (e.g., Compounds 18, 25, 26 or 48). In
some embodiments, the nanoparticle composition comprises a compound
of Formula (I) (e.g., Compounds 18, 25, 26 or 48) and a
phospholipid (e.g., DSPC).
[1099] In some embodiments, the nanoparticle composition comprises
a compound of Formula (III) (e.g., Compound 236). In some
embodiments, the nanoparticle composition comprises a compound of
Formula (III) (e.g., Compound 236) and a phospholipid (e.g., DOPE
or DSPC).
[1100] In some embodiments, the nanoparticle composition comprises
a lipid composition consisting or consisting essentially of
compound of Formula (I) (e.g., Compounds 18, 25, 26 or 48). In some
embodiments, the nanoparticle composition comprises a lipid
composition consisting or consisting essentially of a compound of
Formula (I) (e.g., Compounds 18, 25, 26 or 48) and a phospholipid
(e.g., DSPC).
[1101] In some embodiments, the nanoparticle composition comprises
a lipid composition consisting or consisting essentially of
compound of Formula (III) (e.g., Compound 236). In some
embodiments, the nanoparticle composition comprises a lipid
composition consisting or consisting essentially of a compound of
Formula (III) (e.g., Compound 236) and a phospholipid (e.g., DOPE
or DSPC).
[1102] In one embodiment, a lipid nanoparticle comprises an
ionizable lipid, a structural lipid, a phospholipid, a PEG-modified
lipid, and mRNA. In some embodiments, the LNP comprises an
ionizable lipid, a PEG-modified lipid, a sterol and a phospholipid.
In some embodiments, the LNP has a molar ratio of about 20-60%
ionizable lipid:about 5-25% phospholipid:about 25-55% sterol; and
about 0.5-15% PEG-modified lipid. In some embodiments, the LNP
comprises a molar ratio of about 50% ionizable lipid, about 1.5%
PEG-modified lipid, about 38.5% cholesterol and about 10%
phospholipid. In some embodiments, the LNP comprises a molar ratio
of about 55% ionizable lipid, about 2.5% PEG lipid, about 32.5%
cholesterol and about 10% phospholipid. In some embodiments, the
ionizable lipid is an ionizable amino lipid, the neutral lipid is a
phospholipid, and the sterol is a cholesterol. In some embodiments,
the LNP has a molar ratio of 50:38.5:10:1.5 of ionizable
lipid:cholesterol:DSPC:PEG lipid. In some embodiments, the
ionizable lipid is Compound 18 or Compound 236, and the PEG lipid
is Compound 428 or PEG-DMG.
[1103] In some embodiments, the LNP has a molar ratio of
50:38.5:10:1.5 of Compound 18:Cholesterol:Phospholipid:Compound
428. In some embodiments, the LNP has a molar ratio of
50:38.5:10:1.5 of Compound 18:Cholesterol:DSPC:Compound 428. In
some embodiments, the LNP has a molar ratio of 50:38.5:10:1.5 of
Compound 18:Cholesterol:Phospholipid:PEG-DMG. In some embodiments,
the LNP has a molar ratio of 50:38.5:10:1.5 of Compound
18:Cholesterol:DSPC:PEG-DMG.
[1104] In some embodiments, the LNP has a molar ratio of
50:38.5:10:1.5 of Compound 236:Cholesterol:Phospholipid:Compound
428. In some embodiments, the LNP has a molar ratio of
50:38.5:10:1.5 of Compound 236:Cholesterol:DSPC:Compound 428.
[1105] In some embodiments, the LNP has a molar ratio of
40:38.5:20:1.5 of Compound 18:Cholesterol:Phospholipid:Compound
428. In some embodiments, the LNP has a molar ratio of
40:38.5:20:1.5 of Compound 18:Cholesterol:DSPC:Compound 428. In
some embodiments, the LNP has a molar ratio of 40:38.5:20:1.5 of
Compound 18:Cholesterol:Phospholipid:PEG-DMG. In some embodiments,
the LNP has a molar ratio of 40:38.5:20:1.5 of Compound
18:Cholesterol:DSPC:PEG-DMG.
[1106] In some embodiments, a nanoparticle composition can have the
formulation of Compound 18:Phospholipid:Chol:Compound 428 with a
mole ratio of 50:10:38.5:1.5. In some embodiments, a nanoparticle
composition can have the formulation of Compound
18:DSPC:Chol:Compound 428 with a mole ratio of 50:10:38.5:1.5. In
some embodiments, a nanoparticle composition can have the
formulation of Compound 18:Phospholipid:Chol:PEG-DMG with a mole
ratio of 50:10:38.5:1.5. In some embodiments, a nanoparticle
composition can have the formulation of Compound
18:DSPC:Chol:PEG-DMG with a mole ratio of 50:10:38.5:1.5.
[1107] In some embodiments, the LNP has a polydispersity value of
less than 0.4. In some embodiments, the LNP has a net neutral
charge at a neutral pH. In some embodiments, the LNP has a mean
diameter of 50-150 nm. In some embodiments, the LNP has a mean
diameter of 80-100 nm.
[1108] As generally defined herein, the term "lipid" refers to a
small molecule that has hydrophobic or amphiphilic properties.
Lipids may be naturally occurring or synthetic. Examples of classes
of lipids include, but are not limited to, fats, waxes,
sterol-containing metabolites, vitamins, fatty acids,
glycerolipids, glycerophospholipids, sphingolipids, saccharolipids,
and polyketides, and prenol lipids. In some instances, the
amphiphilic properties of some lipids leads them to form liposomes,
vesicles, or membranes in aqueous media.
[1109] In some embodiments, a lipid nanoparticle (LNP) may comprise
an ionizable lipid. As used herein, the term "ionizable lipid" has
its ordinary meaning in the art and may refer to a lipid comprising
one or more charged moieties. In some embodiments, an ionizable
lipid may be positively charged or negatively charged. An ionizable
lipid may be positively charged, in which case it can be referred
to as "cationic lipid". In certain embodiments, an ionizable lipid
molecule may comprise an amine group, and can be referred to as an
ionizable amino lipids. As used herein, a "charged moiety" is a
chemical moiety that carries a formal electronic charge, e.g.,
monovalent (+1, or -1), divalent (+2, or -2), trivalent (+3, or
-3), etc. The charged moiety may be anionic (i.e., negatively
charged) or cationic (i.e., positively charged). Examples of
positively-charged moieties include amine groups (e.g., primary,
secondary, and/or tertiary amines), ammonium groups, pyridinium
group, guanidine groups, and imidizolium groups. In a particular
embodiment, the charged moieties comprise amine groups. Examples of
negatively-charged groups or precursors thereof, include
carboxylate groups, sulfonate groups, sulfate groups, phosphonate
groups, phosphate groups, hydroxyl groups, and the like. The charge
of the charged moiety may vary, in some cases, with the
environmental conditions, for example, changes in pH may alter the
charge of the moiety, and/or cause the moiety to become charged or
uncharged. In general, the charge density of the molecule may be
selected as desired.
[1110] It should be understood that the terms "charged" or "charged
moiety" does not refer to a "partial negative charge" or "partial
positive charge" on a molecule. The terms "partial negative charge"
and "partial positive charge" are given its ordinary meaning in the
art. A "partial negative charge" may result when a functional group
comprises a bond that becomes polarized such that electron density
is pulled toward one atom of the bond, creating a partial negative
charge on the atom. Those of ordinary skill in the art will, in
general, recognize bonds that can become polarized in this way.
[1111] In some embodiments, the ionizable lipid is an ionizable
amino lipid, sometimes referred to in the art as an "ionizable
cationic lipid". In one embodiment, the ionizable amino lipid may
have a positively charged hydrophilic head and a hydrophobic tail
that are connected via a linker structure.
[1112] In addition to these, an ionizable lipid may also be a lipid
including a cyclic amine group.
[1113] In one embodiment, the ionizable lipid may be selected from,
but not limited to, a ionizable lipid described in International
Publication Nos. WO2013086354 and WO2013116126; the contents of
each of which are incorporated herein by reference in their
entirety.
[1114] In yet another embodiment, the ionizable lipid may be
selected from, but not limited to, formula CLI-CLXXXXII of U.S.
Pat. No. 7,404,969; each of which is incorporated herein by
reference in their entirety.
[1115] In one embodiment, the lipid may be a cleavable lipid such
as those described in International Publication No. WO2012170889,
incorporated herein by reference in its entirety. In one
embodiment, the lipid may be synthesized by methods known in the
art and/or as described in International Publication Nos.
WO2013086354; the contents of each of which are incorporated herein
by reference in their entirety.
[1116] Nanoparticle compositions can be characterized by a variety
of methods. For example, microscopy (e.g., transmission electron
microscopy or scanning electron microscopy) can be used to examine
the morphology and size distribution of a nanoparticle composition.
Dynamic light scattering or potentiometry (e.g., potentiometric
titrations) can be used to measure zeta potentials. Dynamic light
scattering can also be utilized to determine particle sizes.
Instruments such as the Zetasizer Nano ZS (Malvern Instruments Ltd,
Malvern, Worcestershire, UK) can also be used to measure multiple
characteristics of a nanoparticle composition, such as particle
size, polydispersity index, and zeta potential.
[1117] In some embodiments, the nanoparticle composition comprises
a lipid composition consisting or consisting essentially of
compound of Formula (I) (e.g., Compounds 18, 25, 26 or 48). In some
embodiments, the nanoparticle composition comprises a lipid
composition consisting or consisting essentially of a compound of
Formula (I) (e.g., Compounds 18, 25, 26 or 48) and a phospholipid
(e.g., DSPC or MSPC).
[1118] Nanoparticle compositions can be characterized by a variety
of methods. For example, microscopy (e.g., transmission electron
microscopy or scanning electron microscopy) can be used to examine
the morphology and size distribution of a nanoparticle composition.
Dynamic light scattering or potentiometry (e.g., potentiometric
titrations) can be used to measure zeta potentials. Dynamic light
scattering can also be utilized to determine particle sizes.
Instruments such as the Zetasizer Nano ZS (Malvern Instruments Ltd,
Malvern, Worcestershire, UK) can also be used to measure multiple
characteristics of a nanoparticle composition, such as particle
size, polydispersity index, and zeta potential.
[1119] The size of the nanoparticles can help counter biological
reactions such as, but not limited to, inflammation, or can
increase the biological effect of the polynucleotide.
[1120] As used herein, "size" or "mean size" in the context of
nanoparticle compositions refers to the mean diameter of a
nanoparticle composition.
[1121] In one embodiment, the polynucleotide encoding a polypeptide
of interest are formulated in lipid nanoparticles having a diameter
from about 10 to about 100 nm such as, but not limited to, about 10
to about 20 nm, about 10 to about 30 nm, about 10 to about 40 nm,
about 10 to about 50 nm, about 10 to about 60 nm, about 10 to about
70 nm, about 10 to about 80 nm, about 10 to about 90 nm, about 20
to about 30 nm, about 20 to about 40 nm, about 20 to about 50 nm,
about 20 to about 60 nm, about 20 to about 70 nm, about 20 to about
80 nm, about 20 to about 90 nm, about 20 to about 100 nm, about 30
to about 40 nm, about 30 to about 50 nm, about 30 to about 60 nm,
about 30 to about 70 nm, about 30 to about 80 nm, about 30 to about
90 nm, about 30 to about 100 nm, about 40 to about 50 nm, about 40
to about 60 nm, about 40 to about 70 nm, about 40 to about 80 nm,
about 40 to about 90 nm, about 40 to about 100 nm, about 50 to
about 60 nm, about 50 to about 70 nm, about 50 to about 80 nm,
about 50 to about 90 nm, about 50 to about 100 nm, about 60 to
about 70 nm, about 60 to about 80 nm, about 60 to about 90 nm,
about 60 to about 100 nm, about 70 to about 80 nm, about 70 to
about 90 nm, about 70 to about 100 nm, about 80 to about 90 nm,
about 80 to about 100 nm and/or about 90 to about 100 nm.
[1122] In one embodiment, the nanoparticles have a diameter from
about 10 to 500 nm. In one embodiment, the nanoparticle has a
diameter greater than 100 nm, greater than 150 nm, greater than 200
nm, greater than 250 nm, greater than 300 nm, greater than 350 nm,
greater than 400 nm, greater than 450 nm, greater than 500 nm,
greater than 550 nm, greater than 600 nm, greater than 650 nm,
greater than 700 nm, greater than 750 nm, greater than 800 nm,
greater than 850 nm, greater than 900 nm, greater than 950 nm or
greater than 1000 nm.
[1123] In some embodiments, the largest dimension of a nanoparticle
composition is 1 am or shorter (e.g., 1 am, 900 nm, 800 nm, 700 nm,
600 nm, 500 nm, 400 nm, 300 nm, 200 nm, 175 nm, 150 nm, 125 nm, 100
nm, 75 nm, 50 nm, or shorter).
[1124] A nanoparticle composition can be relatively homogenous. A
polydispersity index can be used to indicate the homogeneity of a
nanoparticle composition, e.g., the particle size distribution of
the nanoparticle composition. A small (e.g., less than 0.3)
polydispersity index generally indicates a narrow particle size
distribution. A nanoparticle composition can have a polydispersity
index from about 0 to about 0.25, such as 0.01, 0.02, 0.03, 0.04,
0.05, 0.06, 0.07, 0.08, 0.09, 0.10, 0.11, 0.12, 0.13, 0.14, 0.15,
0.16, 0.17, 0.18, 0.19, 0.20, 0.21, 0.22, 0.23, 0.24, or 0.25. In
some embodiments, the polydispersity index of a nanoparticle
composition disclosed herein can be from about 0.10 to about
0.20.
[1125] The zeta potential of a nanoparticle composition can be used
to indicate the electrokinetic potential of the composition. For
example, the zeta potential can describe the surface charge of a
nanoparticle composition. Nanoparticle compositions with relatively
low charges, positive or negative, are generally desirable, as more
highly charged species can interact undesirably with cells,
tissues, and other elements in the body. In some embodiments, the
zeta potential of a nanoparticle composition disclosed herein can
be from about -10 mV to about +20 mV, from about -10 mV to about
+15 mV, from about 10 mV to about +10 mV, from about -10 mV to
about +5 mV, from about -10 mV to about 0 mV, from about -10 mV to
about -5 mV, from about -5 mV to about +20 mV, from about -5 mV to
about +15 mV, from about -5 mV to about +10 mV, from about -5 mV to
about +5 mV, from about -5 mV to about 0 mV, from about 0 mV to
about +20 mV, from about 0 mV to about +15 mV, from about 0 mV to
about +10 mV, from about 0 mV to about +5 mV, from about +5 mV to
about +20 mV, from about +5 mV to about +15 mV, or from about +5 mV
to about +10 mV.
[1126] In some embodiments, the zeta potential of the lipid
nanoparticles can be from about 0 mV to about 100 mV, from about 0
mV to about 90 mV, from about 0 mV to about 80 mV, from about 0 mV
to about 70 mV, from about 0 mV to about 60 mV, from about 0 mV to
about 50 mV, from about 0 mV to about 40 mV, from about 0 mV to
about 30 mV, from about 0 mV to about 20 mV, from about 0 mV to
about 10 mV, from about 10 mV to about 100 mV, from about 10 mV to
about 90 mV, from about 10 mV to about 80 mV, from about 10 mV to
about 70 mV, from about 10 mV to about 60 mV, from about 10 mV to
about 50 mV, from about 10 mV to about 40 mV, from about 10 mV to
about 30 mV, from about 10 mV to about 20 mV, from about 20 mV to
about 100 mV, from about 20 mV to about 90 mV, from about 20 mV to
about 80 mV, from about 20 mV to about 70 mV, from about 20 mV to
about 60 mV, from about 20 mV to about 50 mV, from about 20 mV to
about 40 mV, from about 20 mV to about 30 mV, from about 30 mV to
about 100 mV, from about 30 mV to about 90 mV, from about 30 mV to
about 80 mV, from about 30 mV to about 70 mV, from about 30 mV to
about 60 mV, from about 30 mV to about 50 mV, from about 30 mV to
about 40 mV, from about 40 mV to about 100 mV, from about 40 mV to
about 90 mV, from about 40 mV to about 80 mV, from about 40 mV to
about 70 mV, from about 40 mV to about 60 mV, and from about 40 mV
to about 50 mV. In some embodiments, the zeta potential of the
lipid nanoparticles can be from about 10 mV to about 50 mV, from
about 15 mV to about 45 mV, from about 20 mV to about 40 mV, and
from about 25 mV to about 35 mV. In some embodiments, the zeta
potential of the lipid nanoparticles can be about 10 mV, about 20
mV, about 30 mV, about 40 mV, about 50 mV, about 60 mV, about 70
mV, about 80 mV, about 90 mV, and about 100 mV.
[1127] The term "encapsulation efficiency" of a polynucleotide
describes the amount of the polynucleotide that is encapsulated by
or otherwise associated with a nanoparticle composition after
preparation, relative to the initial amount provided. As used
herein, "encapsulation" can refer to complete, substantial, or
partial enclosure, confinement, surrounding, or encasement.
[1128] Encapsulation efficiency is desirably high (e.g., close to
100%). The encapsulation efficiency can be measured, for example,
by comparing the amount of the polynucleotide in a solution
containing the nanoparticle composition before and after breaking
up the nanoparticle composition with one or more organic solvents
or detergents.
[1129] Fluorescence can be used to measure the amount of free
polynucleotide in a solution. For the nanoparticle compositions
described herein, the encapsulation efficiency of a polynucleotide
can be at least 50%, for example 50%, 55%, 60%, 65%, 70%, 75%, 80%,
85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%. In
some embodiments, the encapsulation efficiency can be at least 80%.
In certain embodiments, the encapsulation efficiency can be at
least 90%.
[1130] The amount of a polynucleotide present in a pharmaceutical
composition disclosed herein can depend on multiple factors such as
the size of the polynucleotide, desired target and/or application,
or other properties of the nanoparticle composition as well as on
the properties of the polynucleotide.
[1131] For example, the amount of an mRNA useful in a nanoparticle
composition can depend on the size (expressed as length, or
molecular mass), sequence, and other characteristics of the mRNA.
The relative amounts of a polynucleotide in a nanoparticle
composition can also vary.
[1132] The relative amounts of the lipid composition and the
polynucleotide present in a lipid nanoparticle composition of the
present disclosure can be optimized according to considerations of
efficacy and tolerability. For compositions including an mRNA as a
polynucleotide, the N:P ratio can serve as a useful metric.
[1133] As the N:P ratio of a nanoparticle composition controls both
expression and tolerability, nanoparticle compositions with low N:P
ratios and strong expression are desirable. N:P ratios vary
according to the ratio of lipids to RNA in a nanoparticle
composition.
[1134] In general, a lower N:P ratio is preferred. The one or more
RNA, lipids, and amounts thereof can be selected to provide an N:P
ratio from about 2:1 to about 30:1, such as 2:1, 3:1, 4:1, 5:1,
6:1, 7:1, 8:1, 9:1, 10:1, 12:1, 14:1, 16:1, 18:1, 20:1, 22:1, 24:1,
26:1, 28:1, or 30:1. In certain embodiments, the N:P ratio can be
from about 2:1 to about 8:1. In other embodiments, the N:P ratio is
from about 5:1 to about 8:1. In certain embodiments, the N:P ratio
is between 5:1 and 6:1. In one specific aspect, the N:P ratio is
about is about 5.67:1.
[1135] In addition to providing nanoparticle compositions, the
present disclosure also provides methods of producing lipid
nanoparticles comprising encapsulating a polynucleotide. Such
method comprises using any of the pharmaceutical compositions
disclosed herein and producing lipid nanoparticles in accordance
with methods of production of lipid nanoparticles known in the art.
See, e.g., Wang et al. (2015) "Delivery of oligonucleotides with
lipid nanoparticles" Adv. Drug Deliv. Rev. 87:68-80; Silva et al.
(2015) "Delivery Systems for Biopharmaceuticals. Part I:
Nanoparticles and Microparticles" Curr. Pharm. Technol. 16:
940-954; Naseri et al. (2015) "Solid Lipid Nanoparticles and
Nanostructured Lipid Carriers: Structure, Preparation and
Application" Adv. Pharm. Bull. 5:305-13; Silva et al. (2015) "Lipid
nanoparticles for the delivery of biopharmaceuticals" Curr. Pharm.
Biotechnol. 16:291-302, and references cited therein.
[1136] Applications Related to Nanoparticles
[1137] It has been discovered that the immunomodulatory therapeutic
compositions described herein are superior to current compositions
in several ways. First, the lipid nanoparticle (LNP) delivery is
superior to other formulations including liposome or protamine
based approaches described in the literature and no additional
adjuvants are to be necessary. The use of LNPs enables the
effective delivery of chemically modified or unmodified mRNA
compositions. Both modified and unmodified LNP formulated mRNA
compositions are superior to conventional compositions by a
significant degree. In some embodiments the immunomodulatory
therapeutic compositions of the invention are superior to
conventional compositions by a factor of at least 10 fold, 20 fold,
40 fold, 50 fold, 100 fold, 500 fold or 1,000 fold.
[1138] Although attempts have been made to produce functional RNA
vaccines, including mRNA vaccines and self-replicating RNA
vaccines, the therapeutic efficacy of these RNA vaccines have not
yet been fully established. Quite surprisingly, the inventors have
discovered, according to aspects of the invention, a class of
formulations for delivering immunomodulatory therapeutic
compositions in vivo that results in significantly enhanced, and in
many respects synergistic, immune responses including enhanced
antigen generation and functional antibody production with
neutralization capability. These results can be achieved even when
significantly lower doses of the mRNA are administered in
comparison with mRNA doses used in other classes of lipid based
formulations. The formulations of the invention have demonstrated
significant unexpected in vivo immune responses sufficient to
establish the efficacy of functional mRNA compositions as
immunomodulatory therapeutic agents. Additionally, self-replicating
RNA vaccines rely on viral replication pathways to deliver enough
RNA to a cell to produce an immunogenic response. The formulations
of the invention do not require viral replication to produce enough
protein to result in a strong immune response. Thus, the mRNA of
the invention are not self-replicating RNA and do not include
components necessary for viral replication.
[1139] The invention involves, in some aspects, the surprising
finding that lipid nanoparticle (LNP) formulations significantly
enhance the effectiveness of mRNA compositions, including
chemically modified and unmodified mRNA immunomodulatory
therapeutic compositions. The efficacy of mRNA containing
immunomodulatory therapeutic compositions formulated in LNP was
examined in vivo using several distinct tumor antigens. In addition
to providing an enhanced immune response, the formulations of the
invention generate a more rapid immune response with fewer doses of
antigen than other compositions tested. The mRNA-LNP formulations
of the invention also produce quantitatively and qualitatively
better immune responses than compositions formulated in a different
carriers. Additionally, the mRNA-LNP formulations of the invention
are superior to other compositions even when the dose of mRNA is
lower than other compositions.
[1140] The LNP used in the studies described herein has been used
previously to deliver siRNA in various animal models as well as in
humans. In view of the observations made in association with the
siRNA delivery of LNP formulations, the fact that LNP is useful in
cancer immunomodulatory therapeutic compositions is quite
surprising. It has been observed that therapeutic delivery of siRNA
formulated in LNP causes an undesirable inflammatory response
associated with a transient IgM response, typically leading to a
reduction in antigen production and a compromised immune response.
In contrast to the findings observed with siRNA, the LNP-mRNA
formulations of the invention are demonstrated herein to generate
enhanced IgG levels, sufficient for prophylactic and therapeutic
methods rather than transient IgM responses.
Pharmaceutical Compositions
[1141] The present disclosure includes pharmaceutical compositions
comprising an mRNA or a nanoparticle (e.g., a lipid nanoparticle)
described herein, in combination with one or more pharmaceutically
acceptable excipient, carrier or diluent. In particular
embodiments, the mRNA is present in a nanoparticle, e.g., a lipid
nanoparticle. In particular embodiments, the mRNA or nanoparticle
is present in a pharmaceutical composition. In various embodiments,
the one or more mRNA present in the pharmaceutical composition is
encapsulated in a nanoparticle, e.g., a lipid nanoparticle. In
particular embodiments, the molar ratio of the first mRNA to the
second mRNA is about 1:50, about 1:25, about 1:10, about 1:5, about
1:4, about 1:3, about 1:2, about 1:1, about 2:1, about 3:1, about
4:1, or about 5:1, about 10:1, about 25:1 or about 50:1. In
particular embodiments, the molar ratio of the first mRNA to the
second mRNA is greater than 1:1.
[1142] In some embodiments, a composition described herein
comprises an mRNA encoding an antigen of interest (Ag) and an mRNA
encoding a polypeptide that enhances an immune response to the
antigen of interest (e.g., immune potentiator, e.g., STING
polypeptide) (IP) wherein the mRNA encoding the antigen of interest
(Ag) and the mRNA encoding the polypeptide that enhances an immune
response to the antigen of interest (e.g., immune potentiator,
e.g., STING polypeptide)(IP) are formulated at an Ag:IP mass ratio
of 1:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1 or 20:1 (or
alternatively, an IP:Ag mass ratio of 1:1, 1:2, 1:3, 1:4, 1:5, 1:6,
1:7, 1:8, 1:9, 1:10 or 1:20). In some embodiments, the composition
is formulated at an Ag:IP mass ratio of 1:1. 1.25:1, 1.50:1,
1.75:1, 2.0:1, 2.25:1, 2.50:1, 2.75:1, 3.0:1, 3.25:1, 3.50:1,
3.75:1, 4.0:1, 4.25:1, 4.50:1, 4.75:1 or 5:1 of mRNA encoding the
antigen of interest to the mRNA encoding the polypeptide that
enhances an immune to the antigen of interest (e.g., immune
potentiator, e.g., STING polypeptide). In some embodiments, the
composition is formulated at a mass ratio of 5:1 of mRNA encoding
the antigen of interest to the mRNA encoding the polypeptide that
enhances an immune to the antigen of interest (e.g., immune
potentiator, e.g., STING polypeptide) (Ag:IP mass ratio of 5:1, or
alternatively an IP:Ag mass ratio of 1:5). In some embodiments, the
composition is formulated at a mass ratio of 10:1 of mRNA encoding
the antigen of interest to the mRNA encoding the polypeptide that
enhances an immune to the antigen of interest (e.g., immune
potentiator, e.g., STING polypeptide) (Ag:IP mass ratio of 10:1, or
alternatively an IP:Ag mass ratio of 1:10).
[1143] In some embodiments, a composition described herein
comprises an mRNA encoding a KRAS activating oncogene mutation
peptide and an mRNA encoding a constitutively active human STING
polypeptide wherein the mRNA encoding the KRAS activating oncogene
mutation peptide and the mRNA encoding the constitutively active
human STING polypeptide are present at a KRAS:STING mass ratio of
1:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1 or 20:1, or
alternatively a STING:KRAS mass ratio of 1:1, 1:2, 1:3, 1:4, 1:5,
1:6, 1:7, 1:8, 1:9, 1:10 or 1:20. In some embodiments, the mRNAs
are present at a KRAS:STING mass ratio of 1:1. 1.25:1, 1.50:1,
1.75:1, 2.0:1, 2.25:1, 2.50:1, 2.75:1, 3.0:1, 3.25:1, 3.50:1,
3.75:1, 4.0:1, 4.25:1, 4.50:1, 4.75:1 or 5:1 of mRNA encoding the
antigen of interest to the mRNA encoding the polypeptide that
enhances an immune to the antigen of interest (e.g., immune
potentiator, e.g., STING polypeptide). In some embodiments, the
mRNAs are present at a mass ratio of 5:1 of mRNA encoding the KRAS
activating oncogene mutation peptide to the mRNA encoding the
constitutively active human STING polypeptide (KRAS:STING mass
ratio of 5:1, or alternatively STING:KRAS mass ratio of 1:5). In
some embodiments, the mRNAs are present at a mass ratio of 10:1 of
mRNA encoding the KRAS activating oncogene mutation peptide to the
mRNA encoding the constitutively active human STING polypeptide
(KRAS:STING mass ratio of 10:1, or alternatively STING:KRAS mass
ratio of 1:10).
[1144] Pharmaceutical compositions may optionally include one or
more additional active substances, for example, therapeutically
and/or prophylactically active substances. Pharmaceutical
compositions of the present disclosure may be sterile and/or
pyrogen-free. General considerations in the formulation and/or
manufacture of pharmaceutical agents may be found, for example, in
Remington: The Science and Practice of Pharmacy 21.sup.st ed.,
Lippincott Williams & Wilkins, 2005 (incorporated herein by
reference in its entirety). In particular embodiments, a
pharmaceutical composition comprises an mRNA and a lipid
nanoparticle, or complexes thereof.
[1145] Formulations of the pharmaceutical compositions described
herein may be prepared by any method known or hereafter developed
in the art of pharmacology. In general, such preparatory methods
include the step of bringing the active ingredient into association
with an excipient and/or one or more other accessory ingredients,
and then, if necessary and/or desirable, dividing, shaping and/or
packaging the product into a desired single- or multi-dose
unit.
[1146] Relative amounts of the active ingredient, the
pharmaceutically acceptable excipient, and/or any additional
ingredients in a pharmaceutical composition in accordance with the
disclosure will vary, depending upon the identity, size, and/or
condition of the subject treated and further depending upon the
route by which the composition is to be administered. By way of
example, the composition may include between 0.1% and 100%, e.g.,
between 0.5% and 70%, between 1% and 30%, between 5% and 80%, or at
least 80% (w/w) active ingredient.
[1147] The mRNAs of the disclosure can be formulated using one or
more excipients to: (1) increase stability; (2) increase cell
transfection; (3) permit the sustained or delayed release (e.g.,
from a depot formulation of the mRNA); (4) alter the
biodistribution (e.g., target the mRNA to specific tissues or cell
types); (5) increase the translation of a polypeptide encoded by
the mRNA in vivo; and/or (6) alter the release profile of a
polypeptide encoded by the mRNA in vivo. In addition to traditional
excipients such as any and all solvents, dispersion media,
diluents, or other liquid vehicles, dispersion or suspension aids,
surface active agents, isotonic agents, thickening or emulsifying
agents, preservatives, excipients of the present disclosure can
include, without limitation, lipidoids, liposomes, lipid
nanoparticles (e.g., liposomes and micelles), polymers, lipoplexes,
core-shell nanoparticles, peptides, proteins, carbohydrates, cells
transfected with mRNAs (e.g., for transplantation into a subject),
hyaluronidase, nanoparticle mimics and combinations thereof.
Accordingly, the formulations of the disclosure can include one or
more excipients, each in an amount that together increases the
stability of the mRNA, increases cell transfection by the mRNA,
increases the expression of a polypeptide encoded by the mRNA,
and/or alters the release profile of a mRNA-encoded polypeptide.
Further, the mRNAs of the present disclosure may be formulated
using self-assembled nucleic acid nanoparticles.
[1148] Various excipients for formulating pharmaceutical
compositions and techniques for preparing the composition are known
in the art (see Remington: The Science and Practice of Pharmacy,
21st Edition, A. R. Gennaro, Lippincott, Williams & Wilkins,
Baltimore, Md., 2006; incorporated herein by reference in its
entirety). The use of a conventional excipient medium may be
contemplated within the scope of the present disclosure, except
insofar as any conventional excipient medium may be incompatible
with a substance or its derivatives, such as by producing any
undesirable biological effect or otherwise interacting in a
deleterious manner with any other component(s) of the
pharmaceutical composition. Excipients may include, for example:
antiadherents, antioxidants, binders, coatings, compression aids,
disintegrants, dyes (colors), emollients, emulsifiers, fillers
(diluents), film formers or coatings, glidants (flow enhancers),
lubricants, preservatives, printing inks, sorbents, suspensing or
dispersing agents, sweeteners, and waters of hydration. Exemplary
excipients include, but are not limited to: butylated
hydroxytoluene (BHT), calcium carbonate, calcium phosphate
(dibasic), calcium stearate, croscarmellose, crosslinked polyvinyl
pyrrolidone, citric acid, crospovidone, cysteine, ethylcellulose,
gelatin, hydroxypropyl cellulose, hydroxypropyl methylcellulose,
lactose, magnesium stearate, maltitol, mannitol, methionine,
methylcellulose, methyl paraben, microcrystalline cellulose,
polyethylene glycol, polyvinyl pyrrolidone, povidone,
pregelatinized starch, propyl paraben, retinyl palmitate, shellac,
silicon dioxide, sodium carboxymethyl cellulose, sodium citrate,
sodium starch glycolate, sorbitol, starch (corn), stearic acid,
sucrose, talc, titanium dioxide, vitamin A, vitamin E, vitamin C,
and xylitol.
[1149] In some embodiments, the formulations described herein may
include at least one pharmaceutically acceptable salt. Examples of
pharmaceutically acceptable salts that may be included in a
formulation of the disclosure include, but are not limited to, acid
addition salts, alkali or alkaline earth metal salts, mineral or
organic acid salts of basic residues such as amines; alkali or
organic salts of acidic residues such as carboxylic acids; and the
like. Representative acid addition salts include acetate, acetic
acid, adipate, alginate, ascorbate, aspartate, benzenesulfonate,
benzene sulfonic acid, benzoate, bisulfate, borate, butyrate,
camphorate, camphorsulfonate, citrate, cyclopentanepropionate,
digluconate, dodecylsulfate, ethanesulfonate, fumarate,
glucoheptonate, glycerophosphate, hemisulfate, heptonate,
hexanoate, hydrobromide, hydrochloride, hydroiodide,
2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl
sulfate, malate, maleate, malonate, methanesulfonate,
2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate,
palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate,
phosphate, picrate, pivalate, propionate, stearate, succinate,
sulfate, tartrate, thiocyanate, toluenesulfonate, undecanoate,
valerate salts, and the like. Representative alkali or alkaline
earth metal salts include sodium, lithium, potassium, calcium,
magnesium, and the like, as well as nontoxic ammonium, quaternary
ammonium, and amine cations, including, but not limited to
ammonium, tetramethylammonium, tetraethylammonium, methylamine,
dimethylamine, trimethylamine, triethylamine, ethylamine, and the
like.
[1150] In some embodiments, the formulations described herein may
contain at least one type of polynucleotide. As a non-limiting
example, the formulations may contain 1, 2, 3, 4, 5 or more than 5
mRNAs described herein. In some embodiments, the formulations
described herein may contain at least one mRNA encoding a
polypeptide and at least one nucleic acid sequence such as, but not
limited to, an siRNA, an shRNA, a snoRNA, and an miRNA.
[1151] Liquid dosage forms for e.g., parenteral administration
include, but are not limited to, pharmaceutically acceptable
emulsions, microemulsions, nanoemulsions, solutions, suspensions,
syrups, and/or elixirs. In addition to active ingredients, liquid
dosage forms may comprise inert diluents commonly used in the art
such as, for example, water or other solvents, solubilizing agents
and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl
carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate,
propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in
particular, cottonseed, groundnut, corn, germ, olive, castor, and
sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene
glycols and fatty acid esters of sorbitan, and mixtures thereof.
Besides inert diluents, oral compositions can include adjuvants
such as wetting agents, emulsifying and/or suspending agents. In
certain embodiments for parenteral administration, compositions are
mixed with solubilizing agents such as CREMAPHOR.RTM., alcohols,
oils, modified oils, glycols, polysorbates, cyclodextrins,
polymers, and/or combinations thereof.
[1152] Injectable preparations, for example, sterile injectable
aqueous or oleaginous suspensions may be formulated according to
the known art using suitable dispersing agents, wetting agents,
and/or suspending agents. Sterile injectable preparations may be
sterile injectable solutions, suspensions, and/or emulsions in
nontoxic parenterally acceptable diluents and/or solvents, for
example, as a solution in 1,3-butanediol. Among the acceptable
vehicles and solvents that may be employed are water, Ringer's
solution, U.S.P., and isotonic sodium chloride solution. Sterile,
fixed oils are conventionally employed as a solvent or suspending
medium. For this purpose any bland fixed oil can be employed
including synthetic mono- or diglycerides. Fatty acids such as
oleic acid can be used in the preparation of injectables.
Injectable formulations can be sterilized, for example, by
filtration through a bacterial-retaining filter, and/or by
incorporating sterilizing agents in the form of sterile solid
compositions which can be dissolved or dispersed in sterile water
or other sterile injectable medium prior to use.
[1153] In some embodiments, pharmaceutical compositions including
at least one mRNA described herein are administered to mammals
(e.g., humans). Although the descriptions of pharmaceutical
compositions provided herein are principally directed to
pharmaceutical compositions which are suitable for administration
to humans, it will be understood by the skilled artisan that such
compositions are generally suitable for administration to any other
animal, e.g., to a non-human mammal. Modification of pharmaceutical
compositions suitable for administration to humans in order to
render the compositions suitable for administration to various
animals is well understood, and the ordinarily skilled veterinary
pharmacologist can design and/or perform such modification with
merely ordinary, if any, experimentation. Subjects to which
administration of the pharmaceutical compositions is contemplated
include, but are not limited to, humans and/or other primates;
mammals, including commercially relevant mammals such as cattle,
pigs, horses, sheep, cats, dogs, mice, and/or rats; and/or birds,
including commercially relevant birds such as poultry, chickens,
ducks, geese, and/or turkeys. In particular embodiments, a subject
is provided with two or more mRNAs described herein. In particular
embodiments, the first and second mRNAs are provided to the subject
at the same time or at different times, e.g., sequentially. In
particular embodiments, the first and second mRNAs are provided to
the subject in the same pharmaceutical composition or formulation,
e.g., to facilitate uptake of both mRNAs by the same cells.
[1154] The present disclosure also includes kits comprising a
container comprising a mRNA encoding a polypeptide that enhances an
immune response. In another embodiment, the kit comprises a
container comprising a mRNA encoding a polypeptide that enhances an
immune response, as well as one or more additional mRNAs encoding
one or more antigens or interest. In other embodiments, the kit
comprises a first container comprising the mRNA encoding a
polypeptide that enhances an immune response and a second container
comprising one or more mRNAs encoding one or more antigens of
interest. In particular embodiments, the mRNAs for enhancing an
immune response and the mRNA(s) encoding an antigen(s) are present
in the same or different nanoparticles and/or pharmaceutical
compositions. In particular embodiments, the mRNAs are lyophilized,
dried, or freeze-dried.
Methods of Enhancing Immune Responses
[1155] The disclosure provides a method for enhancing an immune
response to an antigen of interest in a subject, e.g., a human
subject. In one embodiment, the method comprises administering to
the subject a composition of the disclosure (or lipid nanoparticle
thereof, or pharmaceutical composition thereof) comprising at least
one mRNA construct encoding: (i) at least one antigen of interest
and (ii) a polypeptide that enhances an immune response against the
antigen(s) of interest, such that an immune response to the
antigen(s) of interest is enhanced. In one embodiment, enhancing an
immune response comprises stimulating cytokine production. In
another embodiment, enhancing an immune response comprises
enhancing cellular immunity (T cell responses), such as stimulating
antigen-specific CD8.sup.+ T cell activity, stimulating
antigen-specific CD4.sup.+ T cell activity or increasing the
percentage of "effector memory" CD62L.sup.lo T cells. In another
embodiment, enhancing an immune response comprises enhancing
humoral immunity (B cell responses), such as stimulating
antigen-specific antibody production.
[1156] In one embodiment of the method, the immune potentiator mRNA
encodes a polypeptide that stimulates Type I interferon pathway
signaling (e.g., the immune potentiator encodes a polypeptide such
as STING, IRF3, IRF7 or any of the additional immune potentiators
described herein). In various other embodiment of the method, the
immune potentiator encodes a polypeptide that stimulates NFkB
pathway signaling, stimulates an inflammatory response or
stimulates dendritic cell development, activity or mobilization. In
one embodiment, the method comprises administering to the subject
an mRNA composition that stimulates dendritic cell development,
activity or mobilization prior to administering to the subject an
mRNA composition that stimulates Type I interferon pathway
signaling. For example, the mRNA composition that stimulates
dendritic cell development or activity can be administered 1-30
days, e.g., 3 days, 5 days, 7 days, 10 days, 14 days, 21 days, 28
days, prior to administering the mRNA composition that stimulates
Type I interferon pathway signaling.
[1157] Enhancement of an immune response in a subject against an
antigen(s) of interest by an immune potenitator of the disclosure
can be evaluated by a variety of methods established in the art for
assessing immune responses, including but not limited to the
methods described in the Examples. For example, in various
embodiments, enhancement is evaluated by levels of intracellular
staining (ICS) of CD8.sup.+ cells for IFN-.gamma. or TNF-.alpha.,
percentage of splenic or peripheral CD8b.sup.+ cells, or percentage
of splenic or peripheral "effector memory" CD62L.sup.lo cells.
[1158] Compositions of the disclosure are administered to the
subject at an effective amount. In general, an effective amount of
the composition will allow for efficient production of the encoded
polypeptide in the cell. Metrics for efficiency may include
polypeptide translation (indicated by polypeptide expression),
level of mRNA degradation, and immune response indicators.
Therapeutic Methods
[1159] The methods of the disclosure for enhancing an immune
response to an antigen(s) of interest in a subject can be used in a
variety of clinical or therapeutic applications. For example, the
methods can be used to stimulate anti-tumor immunity in a subject
with a tumor. Accordingly, in one aspect, the disclosure pertains
to a method of stimulating an immunogenic response to a tumor in a
subject in need thereof, the method comprising administering to the
subject a composition of the disclosure (or lipid nanoparticle
thereof, or pharmaceutical composition thereof) comprising at least
one mRNA construct encoding: (i) at least one tumor antigen of
interest and (ii) a polypeptide that enhances an immune response
against the tumor antigen(s) of interest, such that an immune
response to the tumor antigen(s) of interest is enhanced. Suitable
tumor antigens of interest include those described herein (e.g.
tumor neoantigens, including mutant KRAS antigens). In one
embodiment of the method, the subject is administered a mutant KRAS
antigen-STING mRNA construct encoding a sequence shown in any of
SEQ ID NOs: 107-130.
[1160] The disclosure also provides methods of treating or
preventing a cancer in a subject in need thereof that involve
providing or administering at least one mRNA composition described
herein (i.e., an immune potentiator mRNA and an antigen-encoding
mRNA, in the same or separate mRNA constructs) to the subject. In
related embodiments, the subject is provided with or administered a
nanoparticle (e.g., a lipid nanoparticle) comprising the mRNA(s).
In further related embodiments, the subject is provided with or
administered a pharmaceutical composition of the disclosure to the
subject. In particular embodiments, the pharmaceutical composition
comprises an mRNA(s) encoding an antigen and an immunostimulatory
polypeptide as described herein, or it comprises a nanoparticle
comprising the mRNA(s). In particular embodiments, the mRNA(s) is
present in a nanoparticle, e.g., a lipid nanoparticle. In
particular embodiments, the mRNA(s) or nanoparticle is present in a
pharmaceutical composition.
[1161] In certain embodiments, the subject in need thereof has been
diagnosed with a cancer, or is considered to be at risk of
developing a cancer. In some embodiments, the cancer is liver
cancer, colorectal cancer, a melanoma cancer, a pancreatic cancer,
a NSCLC, a cervical cancer or a head or neck cancer. In particular
embodiments, the liver cancer is hepatocellular carcinoma. In some
embodiments, the colorectal cancer is a primary tumor or a
metastasis. In some embodiments, the cancer is a hematopoetic
cancer. In some embodiments, the cancer is an acute myeloid
leukemia, a chronic myeloid leukemia, a chronic myelomonocytic
leukemia, a myelodystrophic syndrome (including refractory anemias
and refractory cytopenias) or a myeloproliferative neoplasm or
disease (including polycythemia vera, essential thrombocytosis and
primary myelofibrosis). In other embodiments, the cancer is a
blood-based cancer or a hematopoetic cancer. Selectivity for a
particular cancer type can be achieved through the combination of
use of an appropriate LNP formulation (e.g., targeting specific
cell types) in combination with appropriate regulatory site(s)
(e.g., microRNAs) engineered into the mRNA constructs.
[1162] In some embodiments, the mRNA(s), nanoparticle, or
pharmaceutical composition is administered to the patient
parenterally. In particular embodiments, the subject is a mammal,
e.g., a human. In various embodiments, the subject is provided with
an effective amount of the mRNA(s).
[1163] The methods of treating cancer can further include treatment
of the subject with additional agents that enhance an anti-tumor
response in the subject and/or that are cytotoxic to the tumor
(e.g., chemotherapeutic agents). Suitable therapeutic agents for
use in combination therapy include small molecule chemotherapeutic
agents, including protein tyrosine kinase inhibitors, as well as
biological anti-cancer agents, such as anti-cancer antibodies,
including but not limited to those discussed further below.
Combination therapy can include administering to the subject an
immune checkpoint inhibitor to enhance anti-tumor immunity, such as
PD-1 inhibitors, PD-L1 inhibitors and CTLA-4 inhibitors. Other
modulators of immune checkpoints may target OX-40, OX-40L or ICOS.
In one embodiment, an agent that modulates an immune checkpoint is
an antibody. In another embodiment, an agent that modulates an
immune checkpoint is a protein or small molecule modulator. In
another embodiment, the agent (such as an mRNA) encodes an antibody
modulator of an immune checkpoint. Non-limiting examples of immune
checkpoint inhibitors that can be used in combination therapy
include pembrolizumab, alemtuzumab, nivolumab, pidilizumab,
ofatumumab, rituximab, MEDI0680 and PDR001, AMP-224, PF-06801591,
BGB-A317, REGN2810, SHR-1210, TSR-042, affimer, avelumab
(MSB0010718C), atezolizumab (MPDL3280A), durvalumab (MEDI4736),
BMS936559, ipilimumab, tremelimumab, AGEN1884, MEDI6469 and
MOXR0916.
[1164] A pharmaceutical composition including one or more mRNAs of
the disclosure may be administered to a subject by any suitable
route. In some embodiments, compositions of the disclosure are
administered by one or more of a variety of routes, including
parenteral (e.g., subcutaneous, intracutaneous, intravenous,
intraperitoneal, intramuscular, intraarticular, intraarterial,
intrasynovial, intrasternal, intrathecal, intralesional, or
intracranial injection, as well as any suitable infusion
technique), oral, trans- or intra-dermal, interdermal, rectal,
intravaginal, topical (e.g. by powders, ointments, creams, gels,
lotions, and/or drops), mucosal, nasal, buccal, enteral, vitreal,
intratumoral, sublingual, intranasal; by intratracheal
instillation, bronchial instillation, and/or inhalation; as an oral
spray and/or powder, nasal spray, and/or aerosol, and/or through a
portal vein catheter. In some embodiments, a composition may be
administered intravenously, intramuscularly, intradermally,
intra-arterially, intratumorally, subcutaneously, or by inhalation.
In some embodiments, a composition is administered intramuscularly.
However, the present disclosure encompasses the delivery of
compositions of the disclosure by any appropriate route taking into
consideration likely advances in the sciences of drug delivery. In
general, the most appropriate route of administration will depend
upon a variety of factors including the nature of the
pharmaceutical composition including one or more mRNAs (e.g., its
stability in various bodily environments such as the bloodstream
and gastrointestinal tract), and the condition of the patient
(e.g., whether the patient is able to tolerate particular routes of
administration).
[1165] In certain embodiments, compositions of the disclosure may
be administered at dosage levels sufficient to deliver from about
0.0001 mg/kg to about 10 mg/kg, from about 0.001 mg/kg to about 10
mg/kg, from about 0.005 mg/kg to about 10 mg/kg, from about 0.01
mg/kg to about 10 mg/kg, from about 0.1 mg/kg to about 10 mg/kg,
from about 1 mg/kg to about 10 mg/kg, from about 2 mg/kg to about
10 mg/kg, from about 5 mg/kg to about 10 mg/kg, from about 0.0001
mg/kg to about 5 mg/kg, from about 0.001 mg/kg to about 5 mg/kg,
from about 0.005 mg/kg to about 5 mg/kg, from about 0.01 mg/kg to
about 5 mg/kg, from about 0.1 mg/kg to about 10 mg/kg, from about 1
mg/kg to about 5 mg/kg, from about 2 mg/kg to about 5 mg/kg, from
about 0.0001 mg/kg to about 1 mg/kg, from about 0.001 mg/kg to
about 1 mg/kg, from about 0.005 mg/kg to about 1 mg/kg, from about
0.01 mg/kg to about 1 mg/kg, or from about 0.1 mg/kg to about 1
mg/kg in a given dose, where a dose of 1 mg/kg provides 1 mg of
mRNA or nanoparticle per 1 kg of subject body weight. In particular
embodiments, a dose of about 0.005 mg/kg to about 5 mg/kg of mRNA
or nanoparticle of the disclosure may be administrated.
[1166] A dose may be administered one or more times per day, in the
same or a different amount, to obtain a desired level of mRNA
expression and/or effect (e.g., a therapeutic effect). The desired
dosage may be delivered, for example, three times a day, two times
a day, once a day, every other day, every third day, every week,
every two weeks, every three weeks, or every four weeks. In certain
embodiments, the desired dosage may be delivered using multiple
administrations (e.g., two, three, four, five, six, seven, eight,
nine, ten, eleven, twelve, thirteen, fourteen, or more
administrations). In some embodiments, a single dose may be
administered, for example, prior to or after a surgical procedure
or in the instance of an acute disease, disorder, or condition. The
specific therapeutically effective, prophylactically effective, or
otherwise appropriate dose level for any particular patient will
depend upon a variety of factors including the severity and
identify of a disorder being treated, if any; the one or more mRNAs
employed; the specific composition employed; the age, body weight,
general health, sex, and diet of the patient; the time of
administration, route of administration, and rate of excretion of
the specific pharmaceutical composition employed; the duration of
the treatment; drugs used in combination or coincidental with the
specific pharmaceutical composition employed; and like factors well
known in the medical arts.
[1167] The immunomodulatory therapeutic compositions RNA (e.g.,
mRNA) and lipid nanoparticles of the disclosure may be administered
by any route which results in a therapeutically effective outcome.
These include, but are not limited, to intradermal, intramuscular,
intranasal, and/or subcutaneous administration. The present
disclosure provides methods comprising administering RNA
compositions and lipid nanoparticles of the disclosure to a subject
in need thereof. The exact amount required will vary from subject
to subject, depending on the species, age, and general condition of
the subject, the severity of the disease, the particular
composition, its mode of administration, its mode of activity, and
the like. RNA compositions and lipid nanoparticles of the
disclosure are typically formulated in dosage unit form for ease of
administration and uniformity of dosage. It will be understood,
however, that the total daily usage of RNA (e.g., mRNA)
compositions may be decided by the attending physician within the
scope of sound medical judgment. The specific therapeutically
effective, prophylactically effective, or appropriate imaging dose
level for any particular patient will depend upon a variety of
factors including the disorder being treated and the severity of
the disorder; the activity of the specific compound employed; the
specific composition employed; the age, body weight, general
health, sex and diet of the patient; the time of administration,
route of administration, and rate of excretion of the specific
compound employed; the duration of the treatment; drugs used in
combination or coincidental with the specific compound employed;
and like factors well known in the medical arts.
[1168] The effective amount of an RNA composition or lipid
nanoparticle of the disclosure, as provided herein, may be as low
as 10 .mu.g, administered for example as a single dose or as two 5
.mu.g doses. In some embodiments, the effective amount is a total
dose of 10 .mu.g-300 .mu.g. For example, the effective amount may
be a total dose of 10 .mu.g, 20 .mu.g, 25 .mu.g, 30 .mu.g, 35
.mu.g, 40 .mu.g, 45 .mu.g, 50 .mu.g, 55 .mu.g, 60 .mu.g, 65 .mu.g,
70 .mu.g, 75 .mu.g, 80 .mu.g, 85 .mu.g, 90 .mu.g, 95 .mu.g, 100
.mu.g, 110 .mu.g, 120 .mu.g, 130 .mu.g, 140 .mu.g, 150 .mu.g, 160
.mu.g, 170 .mu.g, 180 .mu.g, 190 .mu.g or 200 .mu.g, 210 .mu.g, 220
.mu.g, 230 .mu.g, 240 .mu.g, 250 .mu.g, 260 .mu.g, 270 .mu.g, 280
.mu.g, 290 .mu.g or 300 .mu.g. In some embodiments, the effective
amount is a total dose of 10 .mu.g-300 .mu.g. In some embodiments,
the effective amount is a total dose of 30 .mu.g-100 .mu.g or 50
.mu.g-200 .mu.g.
[1169] In some embodiments, RNA (e.g., mRNA) compositions and lipid
nanoparticles may be administered at dosage levels sufficient to
deliver 0.0001 mg/kg to 100 mg/kg, 0.001 mg/kg to 0.05 mg/kg, 0.005
mg/kg to 0.05 mg/kg, 0.001 mg/kg to 0.005 mg/kg, 0.05 mg/kg to 0.5
mg/kg, 0.01 mg/kg to 50 mg/kg, 0.1 mg/kg to 40 mg/kg, 0.5 mg/kg to
30 mg/kg, 0.01 mg/kg to 10 mg/kg, 0.1 mg/kg to 10 mg/kg, or 1 mg/kg
to 25 mg/kg, of subject body weight per day, one or more times a
day, per week, per month, etc. to obtain the desired therapeutic,
diagnostic, prophylactic, or imaging effect (see e.g., the range of
unit doses described in International Publication No. WO2013078199,
herein incorporated by reference in its entirety). The desired
dosage may be delivered three times a day, two times a day, once a
day, every other day, every third day, every week, every two weeks,
every three weeks, every four weeks, every 2 months, every three
months, every 6 months, etc. In certain embodiments, the desired
dosage may be delivered using multiple administrations (e.g., two,
three, four, five, six, seven, eight, nine, ten, eleven, twelve,
thirteen, fourteen, or more administrations). When multiple
administrations are employed, split dosing regimens such as those
described herein may be used. In exemplary embodiments, RNA (e.g.,
mRNA) compositions may be administered at dosage levels sufficient
to deliver 0.0005 mg/kg to 0.01 mg/kg, e.g., about 0.0005 mg/kg to
about 0.0075 mg/kg, e.g., about 0.0005 mg/kg, about 0.001 mg/kg,
about 0.002 mg/kg, about 0.003 mg/kg, about 0.004 mg/kg or about
0.005 mg/kg.
[1170] In some embodiments, RNA (e.g., mRNA) compositions may be
administered once or twice (or more) at dosage levels sufficient to
deliver 0.025 mg/kg to 0.250 mg/kg, 0.025 mg/kg to 0.500 mg/kg,
0.025 mg/kg to 0.750 mg/kg, or 0.025 mg/kg to 1.0 mg/kg.
[1171] In some embodiments, RNA (e.g., mRNA) compositions may be
administered twice (e.g., Day 0 and Day 7, Day 0 and Day 14, Day 0
and Day 21, Day 0 and Day 28, Day 0 and Day 60, Day 0 and Day 90,
Day 0 and Day 120, Day 0 and Day 150, Day 0 and Day 180, Day 0 and
3 months later, Day 0 and 6 months later, Day 0 and 9 months later,
Day 0 and 12 months later, Day 0 and 18 months later, Day 0 and 2
years later, Day 0 and 5 years later, or Day 0 and 10 years later)
at a total dose of or at dosage levels sufficient to deliver a
total dose of 0.0100 mg, 0.025 mg, 0.050 mg, 0.075 mg, 0.100 mg,
0.125 mg, 0.150 mg, 0.175 mg, 0.200 mg, 0.225 mg, 0.250 mg, 0.275
mg, 0.300 mg, 0.325 mg, 0.350 mg, 0.375 mg, 0.400 mg, 0.425 mg,
0.450 mg, 0.475 mg, 0.500 mg, 0.525 mg, 0.550 mg, 0.575 mg, 0.600
mg, 0.625 mg, 0.650 mg, 0.675 mg, 0.700 mg, 0.725 mg, 0.750 mg,
0.775 mg, 0.800 mg, 0.825 mg, 0.850 mg, 0.875 mg, 0.900 mg, 0.925
mg, 0.950 mg, 0.975 mg, or 1.0 mg. Higher and lower dosages and
frequency of administration are encompassed by the present
disclosure. For example, a RNA (e.g., mRNA) composition may be
administered three or four times.
[1172] In some embodiments, RNA (e.g., mRNA) compositions or lipid
nanoparticles comprising the same may be administered twice (e.g.,
Day 0 and Day 7, Day 0 and Day 14, Day 0 and Day 21, Day 0 and Day
28, Day 0 and Day 60, Day 0 and Day 90, Day 0 and Day 120, Day 0
and Day 150, Day 0 and Day 180, Day 0 and 3 months later, Day 0 and
6 months later, Day 0 and 9 months later, Day 0 and 12 months
later, Day 0 and 18 months later, Day 0 and 2 years later, Day 0
and 5 years later, or Day 0 and 10 years later) at a total dose of
or at dosage levels sufficient to deliver a total dose of 0.010 mg,
0.025 mg, 0.100 mg or 0.400 mg.
[1173] In some embodiments, the RNA (e.g., mRNA)composition or
lipid nanoparticles comprising the same for use in a method of
vaccinating a subject is administered the subject a single dosage
of between 10 .mu.g/kg and 400 .mu.g/kg of the nucleic acid vaccine
in an effective amount to vaccinate the subject. In some
embodiments, the RNA composition or lipid nanoparticles comprising
the same for use in a method of vaccinating a subject is
administered the subject a single dosage of between 10 .mu.g and
400 .mu.g of the nucleic acid vaccine in an effective amount to
vaccinate the subject. In some embodiments, a RNA (e.g., mRNA)
composition or lipid nanoparticles comprising the same for use in a
method of vaccinating a subject is administered to the subject as a
single dosage of 25-1000 .mu.g (e.g., a single dosage of mRNA
encoding an antigen). In some embodiments, a RNA composition is
administered to the subject as a single dosage of 25, 50, 100, 150,
200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800,
850, 900, 950 or 1000 .mu.g. For example, a RNA composition may be
administered to a subject as a single dose of 25-100, 25-500,
50-100, 50-500, 50-1000, 100-500, 100-1000, 250-500, 250-1000, or
500-1000 .mu.g. In some embodiments, a RNA (e.g., mRNA) composition
or lipid nanoparticles comprising the same for use in a method of
vaccinating a subject is administered to the subject as two
dosages, the combination of which equals 25-1000 .mu.g of the RNA
(e.g., mRNA) composition.
[1174] An RNA (e.g., mRNA) composition or lipid nanoparticles
comprising the same described herein can be formulated into a
dosage form described herein, such as an intranasal, intratracheal,
or injectable (e.g., intravenous, intraocular, intravitreal,
intramuscular, intradermal, intracardiac, intraperitoneal, and
subcutaneous).
[1175] In some embodiments, a pharmaceutical composition of the
disclosure may be administered in combination with another agent,
for example, another therapeutic agent, a prophylactic agent,
and/or a diagnostic agent. By "in combination with," it is not
intended to imply that the agents must be administered at the same
time and/or formulated for delivery together, although these
methods of delivery are within the scope of the present disclosure.
For example, one or more compositions including one or more
different mRNAs may be administered in combination. Compositions
can be administered concurrently with, prior to, or subsequent to,
one or more other desired therapeutics or medical procedures. In
general, each agent will be administered at a dose and/or on a time
schedule determined for that agent. In some embodiments, the
present disclosure encompasses the delivery of compositions of the
disclosure, or imaging, diagnostic, or prophylactic compositions
thereof in combination with agents that improve their
bioavailability, reduce and/or modify their metabolism, inhibit
their excretion, and/or modify their distribution within the
body.
[1176] Exemplary therapeutic agents that may be administered in
combination with the compositions of the disclosure include, but
are not limited to, cytotoxic, chemotherapeutic, and other
therapeutic agents. Cytotoxic agents may include, for example,
taxol, cytochalasin B, gramicidin D, ethidium bromide, emetine,
mitomycin, etoposide, teniposide, vincristine, vinblastine,
colchicine, doxorubicin, daunorubicin, dihydroxyanthracinedione,
mitoxantrone, mithramycin, actinomycin D, 1-dehydrotestosterone,
glucocorticoids, procaine, tetracaine, lidocaine, propranolol,
puromycin, maytansinoids, rachelmycin, and analogs thereof.
Radioactive ions may also be used as therapeutic agents and may
include, for example, radioactive iodine, strontium, phosphorous,
palladium, cesium, iridium, cobalt, yttrium, samarium, and
praseodymium. Other therapeutic agents may include, for example,
antimetabolites (e.g., methotrexate, 6-mercaptopurine,
6-thioguanine, cytarabine, and 5-fluorouracil, and decarbazine),
alkylating agents (e.g., mechlorethamine, thiotepa, chlorambucil,
rachelmycin, melphalan, carmustine, lomustine, cyclophosphamide,
busulfan, dibromomannitol, streptozotocin, mitomycin C, and
cis-dichlorodiamine platinum (II) (DDP), and cisplatin),
anthracyclines (e.g., daunorubicin and doxorubicin), antibiotics
(e.g., dactinomycin, bleomycin, mithramycin, and anthramycin), and
anti-mitotic agents (e.g., vincristine, vinblastine, taxol, and
maytansinoids).
[1177] The particular combination of therapies (therapeutics or
procedures) to employ in a combination regimen will take into
account compatibility of the desired therapeutics and/or procedures
and the desired therapeutic effect to be achieved. It will also be
appreciated that the therapies employed may achieve a desired
effect for the same disorder (for example, a composition useful for
treating cancer may be administered concurrently with a
chemotherapeutic agent), or they may achieve different effects
(e.g., control of any adverse effects).
[1178] Immune checkpoint inhibitors such as pembrolizumab or
nivolumab, which target the interaction between programmed death
receptor 1/programmed death ligand 1 (PD-1/PD-L1) and PD-L2, have
been recently approved for the treatment of various malignancies
and are currently being investigated in clinical trials for various
cancers including melanoma, head and neck squamous cell carcinoma
(HNSCC).
[1179] Accordingly, one aspect of the disclosure relates to
combination therapy in which a subject is previously treated with a
PD-1 antagonist prior to administration of a lipid nanoparticle or
composition of the present disclosure. In another aspect, the
subject has been treated with a monoclonal antibody that binds to
PD-1 prior to administration of a lipid nanoparticle or composition
of the present disclosure. In another aspect, the subject has been
administered a lipid nanoparticle or composition of the disclosure
prior to treatment with an anti-PD-1 monoclonal antibody therapy.
In some aspects, the anti-PD-1 monoclonal antibody therapy
comprises nivolumab, pembrolizumab, pidilizumab, or any combination
thereof. In some aspects, the anti-PD-1 monoclonal antibody
comprises pembrolizumab.
[1180] In another aspect, the subject has been treated with a
monoclonal antibody that binds to PD-L1 prior to administration of
a lipid nanoparticle or composition of the present disclosure. In
another aspect, the subject is administered a lipid nanoparticle or
composition prior to treatment with an anti-PD-L1 monoclonal
antibody therapy. In some aspects, the anti-PD-L1 monoclonal
antibody therapy comprises durvalumab, avelumab, MEDI473,
BMS-936559, aezolizumab, or any combination thereof.
[1181] In some aspects, the subject has been treated with a CTLA-4
antagonist prior to treatment with the compositions of present
disclosure. In another aspect, the subject has been previously
treated with a monoclonal antibody that binds to CTLA-4 prior to
administration of a lipid nanoparticle or composition of the
present disclosure. In some aspects, the subject has been
administered a lipid nanoparticle or composition prior to treatment
with an anti-CTLA-4 monoclonal antibody. In some aspects, the
anti-CTLA-4 antibody therapy comprises ipilimumab or
tremelimumab.
[1182] In any of the foregoing or related aspects, the disclosure
provides a lipid nanoparticle, and an optional pharmaceutically
acceptable carrier, or a pharmaceutical composition for use in
treating or delaying progression of cancer in an individual,
wherein the treatment comprises administration of the composition
in combination with a second composition, wherein the second
composition comprises a checkpoint inhibitor polypeptide and an
optional pharmaceutically acceptable carrier.
[1183] In any of the foregoing or related aspects, the disclosure
provides use of a lipid nanoparticle, and an optional
pharmaceutically acceptable carrier, in the manufacture of a
medicament for treating or delaying progression of cancer in an
individual, wherein the medicament comprises the lipid nanoparticle
and an optional pharmaceutically acceptable carrier and wherein the
treatment comprises administration of the medicament in combination
with a composition comprising a checkpoint inhibitor polypeptide
and an optional pharmaceutically acceptable carrier.
[1184] In any of the foregoing or related aspects, the disclosure
provides a kit comprising a container comprising a lipid
nanoparticle, and an optional pharmaceutically acceptable carrier,
or a pharmaceutical composition, and a package insert comprising
instructions for administration of the lipid nanoparticle or
pharmaceutical composition for treating or delaying progression of
cancer in an individual. In some aspects, the package insert
further comprises instructions for administration of the lipid
nanoparticle or pharmaceutical composition in combination with a
composition comprising a checkpoint inhibitor polypeptide and an
optional pharmaceutically acceptable carrier for treating or
delaying progression of cancer in an individual.
[1185] In any of the foregoing or related aspects, the disclosure
provides a kit comprising a medicament comprising a lipid
nanoparticle, and an optional pharmaceutically acceptable carrier,
or a pharmaceutical composition, and a package insert comprising
instructions for administration of the medicament alone or in
combination with a composition comprising a checkpoint inhibitor
polypeptide and an optional pharmaceutically acceptable carrier for
treating or delaying progression of cancer in an individual. In
some aspects, the kit further comprises a package insert comprising
instructions for administration of the first medicament prior to,
current with, or subsequent to administration of the second
medicament for treating or delaying progression of cancer in an
individual.
[1186] In any of the foregoing or related aspects, the disclosure
provides a lipid nanoparticle, a composition, or the use thereof,
or a kit comprising a lipid nanoparticle or a composition as
described herein, wherein the checkpoint inhibitor polypeptide
inhibits PD1, PD-L1, CTLA4, or a combination thereof. In some
aspects, the checkpoint inhibitor polypeptide is an antibody. In
some aspects, the checkpoint inhibitor polypeptide is an antibody
selected from an anti-CTLA4 antibody or antigen-binding fragment
thereof that specifically binds CTLA4, an anti-PD1 antibody or
antigen-binding fragment thereof that specifically binds PD1, an
anti-PD-L1 antibody or antigen-binding fragment thereof that
specifically binds PD-L1, and a combination thereof. In some
aspects, the checkpoint inhibitor polypeptide is an anti-PD-L1
antibody selected from atezolizumab, avelumab, or durvalumab. In
some aspects, the checkpoint inhibitor polypeptide is an
anti-CTLA-4 antibody selected from tremelimumab or ipilimumab. In
some aspects, the checkpoint inhibitor polypeptide is an anti-PD1
antibody selected from nivolumab or pembrolizumab. In some asepcts,
the checkpoint inhibitor polypeptide is an anti-PD1 antibody,
wherein the anti-PD1 antibody is pembrolizumab.
[1187] In related aspects, the disclosure provides a method of
reducing or decreasing a size of a tumor or inhibiting a tumor
growth in a subject in need thereof comprising administering to the
subject any of the foregoing or related lipid nanoparticles of the
disclosure, or any of the foregoing or related compositions of the
disclosure.
[1188] In related aspects, the disclosure provides a method
inducing an anti-tumor response in a subject with cancer comprising
administering to the subject any of the foregoing or related lipid
nanoparticles of the disclosure, or any of the foregoing or related
compositions of the disclosure. In some aspects, the anti-tumor
response comprises a T-cell response. In some aspects, the T-cell
response comprises CD8+ T cells.
[1189] In some aspects of the foregoing methods, the method further
comprises administering a second composition comprising a
checkpoint inhibitor polypeptide, and an optional pharmaceutically
acceptable carrier. In some aspects, the checkpoint inhibitor
polypeptide inhibits PD1, PD-L, CTLA4, or a combination thereof. In
some aspects, the checkpoint inhibitor polypeptide is an antibody.
In some aspects, the checkpoint inhibitor polypeptide is an
antibody selected from an anti-CTLA4 antibody or antigen-binding
fragment thereof that specifically binds CTLA4, an anti-PD1
antibody or antigen-binding fragment thereof that specifically
binds PD1, an anti-PD-L1 antibody or antigen-binding fragment
thereof that specifically binds PD-L1, and a combination thereof.
In some aspects, the checkpoint inhibitor polypeptide is an
anti-PD-L1 antibody selected from atezolizumab, avelumab, or
durvalumab. In some aspects, the checkpoint inhibitor polypeptide
is an anti-CTLA-4 antibody selected from tremelimumab or
ipilimumab. In some aspects, the checkpoint inhibitor polypeptide
is an anti-PD1 antibody selected from nivolumab or pembrolizumab.
In some asepcts, the checkpoint inhibitor polypeptide is an
anti-PD1 antibody, wherein the anti-PD1 antibody is
pembrolizumab.
[1190] In some aspects of any of the foregoing or related methods,
the composition comprising the checkpoint inhibitor polypeptide is
administered by intravenous injection. In some aspects, the
composition comprising the checkpoint inhibitor polypeptide is
administered once every 2 to 3 weeks. In some aspects, the
composition comprising the checkpoint inhibitor polypeptide is
administered once every 2 weeks or once every 3 weeks. In some
aspects, the composition comprising the checkpoint inhibitor
polypeptide is administered prior to, concurrent with, or
subsequent to administration of the lipid nanoparticle or
pharmaceutical composition thereof.
[1191] In some aspects of any of the foregoing or related methods,
the subject has a histologically confirmed KRAS mutation selected
from G12D, G12V, G13D or G12C.
[1192] In some aspects of any of the foregoing or related methods,
the subject has metastatic colorectal cancer.
[1193] In some aspects of any of the foregoing or related methods,
the subject has non-small cell lung cancer (NSCLC).
[1194] In some aspects of any of the foregoing or related methods,
the subject has pancreatic cancer.
[1195] In any of the foregoing or related aspects, the disclosure
provides pharmaceutical composition comprising the lipid
nanoparticle, and a pharmaceutically acceptable carrier. In some
aspects, the pharmaceutical composition is formulated for
intramuscular delivery.
Other Embodiments of the Disclosure
[1196] E1. An immunomodulatory therapeutic composition,
comprising:
[1197] one or more mRNA each having an open reading frame encoding
an activating oncogene mutation peptide;
[1198] one or more mRNA each having an open reading frame encoding
a polypeptide that enhances an immune response to the activating
oncogene mutation peptide in a subject, wherein the immune response
comprises a cellular or humoral immune response characterized
by:
[1199] (i) stimulating Type I interferon pathway signaling,
[1200] (ii) stimulating NFkB pathway signaling,
[1201] (iii) stimulating an inflammatory response,
[1202] (iv) stimulating cytokine production,
[1203] (v) stimulating dendritic cell development, activity or
mobilization, and
[1204] (vi) a combination of any of (i)-(v); and
[1205] a pharmaceutically acceptable carrier.
E2. The immunomodulatory therapeutic composition of embodiment 1,
wherein the activating oncogene mutation is a KRAS mutation. E3.
The immunomodulatory therapeutic composition of embodiment 2,
wherein the KRAS mutation is a G12 mutation. E4. The
immunomodulatory therapeutic composition of embodiment 3, wherein
the G12 KRAS mutation is selected from G12D, G12V, G12S, G12C,
G12A, and G12R KRAS mutations. E5. The immunomodulatory therapeutic
composition of embodiment 3, wherein the G12 KRAS mutation is
selected from G12D, G12V, and G12C KRAS mutations. E6. The
immunomodulatory therapeutic composition of any one of embodiments
2-5, wherein the KRAS mutation is a G13 mutation. E7. The
immunomodulatory therapeutic composition of embodiment 6, wherein
the G13 KRAS mutation is a G13D KRAS mutation. E8. The
immunomodulatory therapeutic composition of embodiment 1, wherein
the activating oncogene mutation is a H-RAS or N-RAS mutation. E9.
The immunomodulatory therapeutic composition of any one of
embodiments 1-8, wherein the mRNA has an open reading frame
encoding a concatemer of two or more activating oncogene mutation
peptides. E10. The immunomodulatory therapeutic composition of
embodiment 9, wherein the concatemer comprises 3, 4, 5, 6, 7, 8, 9,
or 10 activating oncogene mutation peptides. E11. The
immunomodulatory therapeutic composition of embodiment 9, wherein
the concatemer comprises 4 activating oncogene mutation peptides.
E12. The immunomodulatory therapeutic composition of embodiment 11,
wherein the concatemer comprises KRAS activating oncogene mutation
peptides G12D, G12V, G12C, and G13D. E13. The immunomodulatory
therapeutic composition of embodiment 12, wherein the concatemer
comprises from N- to C-terminus G12D, G12V, G13D, and G12C. E14.
The immunomodulatory therapeutic composition of embodiment 12,
wherein the concatemer comprises from N- to C-terminus G12C, G13D,
G12V, and G12D. E15. The immunomodulatory therapeutic composition
of any one of embodiments 1-8, wherein the composition comprises 1,
2, 3, or 4 mRNAs encoding 1, 2, 3, or 4 activating oncogene
mutation peptides. E16. The immunomodulatory therapeutic
composition of embodiment 15, wherein the composition comprises 4
mRNAs encoding 4 activating oncogene mutation peptides. E17. The
immunomodulatory therapeutic composition of embodiment 16, wherein
the 4 mRNAs encode KRAS activating oncogene mutation peptides G12D,
G12V, G12C, and G13D. E18. The immunomodulatory therapeutic
composition of any one of embodiments 1-17, wherein the activating
oncogene mutation peptide comprises 10-30, 15-25, or 20-25 amino
acids in length. E19. The immunomodulatory therapeutic composition
of embodiment 18, wherein the activating oncogene mutation peptide
comprises 20, 21, 22, 23, 24, or 25 amino acids in length. E20. The
immunomodulatory therapeutic composition of embodiment 19, wherein
the activating oncogene mutation peptide comprises 25 amino acids
in length. E21. The immunomodulatory therapeutic composition of any
one of embodiments 1-20, wherein the mRNA encoding a polypeptide
that enhances an immune response to the activating oncogene
mutation peptide in a subject encodes a constitutively active human
STING polypeptide. E22. The immunomodulatory therapeutic
composition of embodiment 21, wherein the constitutively active
human STING polypeptide comprises one or more mutations selected
from the group consisting of V147L, N154S, V155M, R284M, R284K,
R284T, E315Q, R375A, and combinations thereof. E23. The
immunomodulatory therapeutic composition of embodiment 22, wherein
the constitutively active human STING polypeptide comprises
mutation V155M. E24. The immunomodulatory therapeutic composition
of embodiment 22, wherein the constitutively active human STING
polypeptide comprises mutations V147L/N154S/V155M. E25. The
immunomodulatory therapeutic composition of embodiment 22, wherein
the constitutively active human STING polypeptide comprises
mutations R284M/V147L/N154S/V155M. E26. The immunomodulatory
therapeutic composition of embodiment 22, wherein the
constitutively active human STING polypeptide comprises an amino
acid sequence shown in any one of SEQ ID NOs: 1-10 and 164. E27.
The immunomodulatory therapeutic composition of any one of
embodiments 21-26, wherein the mRNA encoding the constitutively
active human STING polypeptide comprises a 3' UTR comprising at
least one miR-122 microRNA binding site. E28. The immunomodulatory
therapeutic composition of any one of embodiments 1-20, wherein the
mRNA encoding a polypeptide that enhances an immune response to the
activating oncogene mutation peptide in a subject encodes a
constitutively active human IRF3 polypeptide. E29. The
immunomodulatory therapeutic composition of embodiment 28, wherein
the constitutively active human IRF3 polypeptide comprises an S396D
mutation. E30. The immunomodulatory therapeutic composition of
embodiment 28, wherein the constitutively active human IRF3
polypeptide comprises an amino acid sequence shown in SEQ ID NOs:
12. E31. The immunomodulatory therapeutic composition of any one of
embodiments 1-20, wherein the mRNA encoding a polypeptide that
enhances an immune response to the activating oncogene mutation
peptide in a subject encodes a constitutively active human IRF7
polypeptide. E32. The immunomodulatory therapeutic composition of
embodiment 31, wherein the constitutively active human IRF7
polypeptide comprises one or more mutations selected from the group
consisting of S475D, S476D, S477D, S479D, L480D, S483D, S487D,
deletion of amino acids 247-467, deletion of amino acid residues
152-246, deletion of amino acid residues 1-151, and combinations
thereof. E33. The immunomodulatory therapeutic composition of
embodiment 31, wherein the constitutively active human IRF7
polypeptide comprises an amino acid sequence shown in any one of
SEQ ID NOs: 14-18. E34. The immunomodulatory therapeutic
composition of any one of embodiments 1-33, wherein the composition
further comprises a cancer therapeutic agent. E35. The
immunomodulatory therapeutic composition of any one of embodiments
1-33, wherein the composition further comprises an inhibitory
checkpoint polypeptide. E36. The immunomodulatory therapeutic
composition of embodiment 35, wherein the inhibitory checkpoint
polypeptide is an antibody or fragment thereof that specifically
binds to a molecule selected from the group consisting of PD-1,
PD-L, TIM-3, VISTA, A2AR, B7-H3, B7-H4, BTLA, CTLA-4, IDO, KIR and
LAG3. E37. The immunomodulatory therapeutic composition of any one
of embodiments 1-33, wherein the mRNA is formulated in a lipid
nanoparticle. E38. The immunomodulatory therapeutic composition of
embodiment 37, wherein the lipid nanoparticle comprises a molar
ratio of about 20-60% ionizable amino lipid:5-25%
phospholipid:25-55% sterol; and 0.5-15% PEG-modified lipid. E39.
The immunomodulatory therapeutic composition of embodiment 38,
wherein the ionizable amino lipid is selected from the group
consisting of for example,
2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA),
dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), and
di((Z)-non-2-en-1-yl)
9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319). E40.
The immunomodulatory therapeutic composition of any one of
embodiments 1-39, wherein each mRNA includes at least one chemical
modification. E41. The immunomodulatory therapeutic composition of
embodiment 40, wherein the chemical modification is selected from
the group consisting of pseudouridine, N1-methylpseudouridine,
2-thiouridine, 4'-thiouridine, 5-methylcytosine,
2-thio-1-methyl-1-deaza-pseudouridine,
2-thio-1-methyl-pseudouridine, 2-thio-5-aza-uridine,
2-thio-dihydropseudouridine, 2-thio-dihydrouridine,
2-thio-pseudouridine, 4-methoxy-2-thio-pseudouridine,
4-methoxy-pseudouridine, 4-thio-1-methyl-pseudouridine,
4-thio-pseudouridine, 5-aza-uridine, dihydropseudouridine,
5-methyluridine, 5-methyluridine, 5-methoxyuridine, and 2'-O-methyl
uridine. E42. An immunomodulatory therapeutic composition,
comprising:
[1206] one or more mRNA each having an open reading frame encoding
a KRAS activating oncogene mutation peptide;
[1207] one or more mRNA each having an open reading frame encoding
a constitutively active human STING polypeptide; and
[1208] a pharmaceutically acceptable carrier.
E43. The immunomodulatory therapeutic composition of embodiment 42,
wherein the constitutively active human STING polypeptide comprises
mutation V155M. E44. The immunomodulatory therapeutic composition
of embodiment 43, wherein the constitutively active human STING
polypeptide comprises an amino acid sequence shown in SEQ ID NO: 1.
E45. The immunomodulatory therapeutic composition of any one of
embodiments 42-44, wherein the mRNA encoding the constitutively
active human STING polypeptide comprises a 3' UTR comprising at
least one miR-122 microRNA binding site. E46. The immunomodulatory
therapeutic composition of any one of embodiments 42-45, wherein
the KRAS activating oncogene mutation peptide is selected from
G12D, G12V, G12S, G12C, G12A, G12R, and G13D. E47. The
immunomodulatory therapeutic composition of embodiment 46, wherein
the KRAS activating oncogene mutation peptide is selected from
G12D, G12V, G12C, and G13D. E48. The immunomodulatory therapeutic
composition of any one of embodiments 42-47, wherein the mRNA has
an open reading frame encoding a concatemer of two or more KRAS
activating oncogene mutation peptides. E49. The immunomodulatory
therapeutic composition of embodiment 48, wherein the concatemer
comprises 3, 4, 5, 6, 7, 8, 9 or 10 KRAS activating oncogene
mutation peptides. E50. The immunomodulatory therapeutic
composition of embodiment 49, wherein the concatemer comprises 4
KRAS activating oncogene mutation peptides. E51. The
immunomodulatory therapeutic composition of embodiment 50, wherein
the concatemer comprises G12D, G12V, G12C, and G13D. E52. The
immunomodulatory therapeutic composition of embodiment 51, wherein
the concatemer comprises from N- to C-terminus G12D, G12V, G13D,
and G12C. E53. The immunomodulatory therapeutic composition of
embodiment 51, wherein the concatemer comprises from N- to
C-terminus G12C, G13D, G12V, and G12D. E54. The immunomodulatory
therapeutic composition of any one of embodiments 42-47, wherein
the composition comprises 1, 2, 3, or 4 mRNAs encoding 1, 2, 3, or
4 KRAS activating oncogene mutation peptides. E55. The
immunomodulatory therapeutic composition of embodiment 54, wherein
the composition comprises 4 mRNAs encoding 4 KRAS activating
oncogene mutation peptides. E56. The immunomodulatory therapeutic
composition of embodiment 54, wherein the 4 KRAS activating
oncogene mutation peptides comprise G12D, G12V, G12C, and G13D.
E57. The immunomodulatory therapeutic composition of any one of
embodiments 42-56, wherein the KRAS activating oncogene mutation
peptide comprises 10-30, 15-25, or 20-25 amino acids in length.
E58. The immunomodulatory therapeutic composition of embodiment 57,
wherein the KRAS activating oncogene mutation peptide comprises 20,
21, 22, 23, 24, or 25 amino acids in length. E59. The
immunomodulatory therapeutic composition of embodiment 58, wherein
the activating oncogene mutation peptide comprises 25 amino acids
in length. E60. The immunomodulatory therapeutic composition of
embodiment 51, wherein the concatemer comprises an amino acid
sequence selected from the group set forth in SEQ ID NOs: 42-47, 73
and 137. E61. The immunomodulatory therapeutic composition of
embodiment 51, wherein the mRNA encoding the concatemer comprises
the nucleotide sequence selected from the group set forth in SEQ ID
NOs: 129-131, 133 and 138. E62. The immunomodulatory therapeutic
composition of embodiment 54, wherein the KRAS activating oncogene
mutation peptides comprise an amino acid sequence selected from the
group set forth in SEQ ID NOs: 36-41, 72 and 125. E63. The
immunomodulatory therapeutic composition of embodiment 54, wherein
the KRAS activating oncogene mutation peptides comprise the amino
acid sequence set forth in SEQ ID NOs: 39-41. E64. The
immunomodulatory therapeutic composition of embodiment 55, wherein
the KRAS activating oncogene mutation peptides comprise the amino
acid sequences set forth in SEQ ID NOs: 39-41 and 72. E65. The
immunomodulatory therapeutic composition of embodiment 63, wherein
the mRNA encoding the KRAS activating oncogene mutation peptide
comprises a nucleotide sequence selected from the group set forth
in SEQ ID NOs: 126-128. E66. The immunomodulatory therapeutic
composition of embodiment 64, wherein the mRNA encoding the KRAS
activating oncogene mutation peptide comprises the nucleotide
sequences set forth in SEQ ID NOs: 126-128 and 132. E67. The
immunomodulatory therapeutic composition of any one of embodiments
42-66, wherein each mRNA is formulated in the same or different
lipid nanoparticle. E68. The immunomodulatory therapeutic
composition of embodiment 67, wherein each mRNA encoding a KRAS
activating oncogene mutation peptide is formulated in the same or
different lipid nanoparticle. E69. The immunomodulatory therapeutic
composition of embodiment 68, wherein each mRNA encoding
constitutively active human STING is formulated in the same or
different lipid nanoparticle. E70. The immunomodulatory therapeutic
composition of any one of embodiments 68-69, wherein each mRNA
encoding a KRAS activating oncogene mutation peptide is formulated
in the same lipid nanoparticle and each mRNA encoding
constitutively active human STING is formulated in a different
lipid nanoparticle. E71. The immunomodulatory therapeutic
composition of any one of embodiments 68-69, wherein each mRNA
encoding a KRAS activating oncogene mutation peptide is formulated
in the same lipid nanoparticle and each mRNA encoding
constitutively active human STING is formulated in the same lipid
nanoparticle as each mRNA encoding a KRAS activating oncogene
mutation peptide. E72. The immunomodulatory therapeutic composition
of any one of embodiments 68-69, wherein each mRNA encoding a KRAS
activating oncogene mutation peptide is formulated in a different
lipid nanoparticle and each mRNA encoding constitutively active
human STING is formulated in the same lipid nanoparticle as each
mRNA encoding each KRAS activating oncogene mutation peptide. E73.
The immunomodulatory therapeutic composition of any one of
embodiments 68-72, wherein the lipid nanoparticle comprises a molar
ratio of about 20-60% ionizable amino lipid:5-25%
phospholipid:25-55% sterol; and 0.5-15% PEG-modified lipid. E74.
The immunomodulatory therapeutic composition of embodiment 73,
wherein the ionizable amino lipid is selected from the group
consisting of for example,
2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA),
dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), and
di((Z)-non-2-en-1-yl)
9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319). E75.
The immunomodulatory therapeutic composition of any one of
embodiments 42-74, wherein each mRNA includes at least one chemical
modification. E76. The immunomodulatory therapeutic composition of
embodiment 75, wherein the chemical modification is selected from
the group consisting of pseudouridine, N1-methylpseudouridine,
2-thiouridine, 4'-thiouridine, 5-methylcytosine,
2-thio-1-methyl-1-deaza-pseudouridine,
2-thio-1-methyl-pseudouridine, 2-thio-5-aza-uridine,
2-thio-dihydropseudouridine, 2-thio-dihydrouridine,
2-thio-pseudouridine, 4-methoxy-2-thio-pseudouridine,
4-methoxy-pseudouridine, 4-thio-1-methyl-pseudouridine,
4-thio-pseudouridine, 5-aza-uridine, dihydropseudouridine,
5-methyluridine, 5-methyluridine, 5-methoxyuridine, and 2'-O-methyl
uridine. E77. A lipid nanoparticle comprising:
[1209] an mRNA having an open reading frame encoding a concatemer
of 4 KRAS activating oncogene mutation peptides, wherein the 4 KRAS
activating oncogene mutation peptides comprise G12D, G12V, G12C,
and G13D; and
[1210] an mRNA having an open reading frame encoding a
constitutively active human STING polypeptide.
E78. The lipid nanoparticle of embodiment 77, wherein the
concatemer comprises from N- to C-terminus G12D, G12V, G13D, and
G12C. E79. The lipid nanoparticle of embodiment 77, wherein the
concatemer comprises from N- to C-terminus G12C, G13D, G12V, and
G12D. E80. The lipid nanoparticle of any one of embodiments 77 to
79, wherein each KRAS activating oncogene mutation peptide
comprises 20, 21, 22, 23, 24, or 25 amino acids in length. E81. The
lipid nanoparticle of embodiment 80, wherein each KRAS activating
oncogene mutation peptide comprises 25 amino acids in length. E82.
The lipid nanoparticle of embodiment 77, wherein the concatemer
comprises an amino acid sequence set forth in SEQ ID NO: 137. E83.
The lipid nanoparticle of embodiment 77, wherein the mRNA encoding
the concatemer of 4 KRAS activating oncogene mutation peptides
comprises the nucleotide sequence set forth in SEQ ID NO: 138. E84.
The lipid nanoparticle of any one of embodiments 77-83, wherein the
constitutively active human STING polypeptide comprises mutation
V155M. E85. The lipid nanoparticle of embodiment 84, wherein the
constitutively active human STING polypeptide comprises the amino
acid sequence shown in SEQ ID NO: 1. E86. The lipid nanoparticle of
embodiment 84, wherein the mRNA encoding the constitutively active
human STING polypeptide comprises a 3' UTR comprising at least one
miR-122 microRNA binding site. E87. The lipid nanoparticle of
embodiment 84, wherein the mRNA encoding the constitutively active
human STING polypeptide comprises the nucleotide sequence shown in
SEQ ID NO: 139. E88. A lipid nanoparticle comprising:
[1211] an mRNA having an open reading frame encoding a KRAS
activating oncogene mutation peptide comprising G12D;
[1212] an mRNA having an open reading frame encoding a KRAS
activating oncogene mutation peptide comprising G12V;
[1213] an mRNA having an open reading frame encoding a KRAS
activating oncogene mutation peptide comprising G12C;
[1214] an mRNA having an open reading frame encoding a KRAS
activating oncogene mutation peptide comprising G13D; and
[1215] an mRNA having an open reading frame encoding a
constitutively active human STING polypeptide.
E89. The lipid nanoparticle of embodiment 88, wherein each KRAS
activating oncogene mutation peptide comprises 20, 21, 22, 23, 24,
or 25 amino acids in length. E90. The lipid nanoparticle of
embodiment 89, wherein each KRAS activating oncogene mutation
peptide comprises 25 amino acids in length. E91. The lipid
nanoparticle of embodiment 88, wherein the KRAS activating oncogene
mutation peptides comprise the amino acid sequences set forth in
SEQ ID NOs: 39-41 and 72. E92. The lipid nanoparticle of embodiment
88, wherein the mRNAs encoding the KRAS activating oncogene
mutation peptides comprise the nucleotide sequences set forth in
SEQ ID NOs: 126-128 and 132. E93. The lipid nanoparticle of any one
of embodiments 88-92, wherein the constitutively active human STING
polypeptide comprises mutation V155M. E94. The lipid nanoparticle
of embodiment 93, wherein the constitutively active human STING
polypeptide comprises the amino acid sequence shown in SEQ ID NO:
1. E95. The lipid nanoparticle of embodiment 94, wherein the mRNA
encoding the constitutively active human STING polypeptide
comprises a 3' UTR comprising at least one miR-122 microRNA binding
site. E96. The lipid nanoparticle of embodiment 94, wherein the
mRNA encoding the constitutively active human STING polypeptide
comprises the nucleotide sequence shown in SEQ ID NO: 139. E97. A
lipid nanoparticle comprising:
[1216] an mRNA having an open reading frame encoding a KRAS
activating oncogene mutation peptide comprising G12D; and
[1217] an mRNA having an open reading frame encoding a
constitutively active human STING polypeptide.
E98. A lipid nanoparticle comprising:
[1218] an mRNA having an open reading frame encoding a KRAS
activating oncogene mutation peptide comprising G12V; and
[1219] an mRNA having an open reading frame encoding a
constitutively active human STING polypeptide.
E99. A lipid nanoparticle comprising:
[1220] an mRNA having an open reading frame encoding a KRAS
activating oncogene mutation peptide comprising G12C; and
[1221] an mRNA having an open reading frame encoding a
constitutively active human STING polypeptide.
E100. A lipid nanoparticle comprising:
[1222] an mRNA having an open reading frame encoding a KRAS
activating oncogene mutation peptide comprising G13D; and
[1223] an mRNA having an open reading frame encoding a
constitutively active human STING polypeptide.
E101. The lipid nanoparticle of any one of embodiments 97-100,
wherein each KRAS activating oncogene mutation peptide comprises
20, 21, 22, 23, 24, or 25 amino acids in length. E102. The lipid
nanoparticle of embodiment 101, wherein each KRAS activating
oncogene mutation peptide comprises 25 amino acids in length. E103.
The lipid nanoparticle of embodiment 97, wherein the KRAS
activating oncogene mutation peptide comprises the amino acid
sequence set forth in SEQ ID NO: 39. E104. The lipid nanoparticle
of embodiment 97, wherein the mRNA encoding the KRAS activating
oncogene mutation peptide comprises the nucleotide sequence set
forth in SEQ ID NOs: 126. E105. The lipid nanoparticle of
embodiment 98, wherein the KRAS activating oncogene mutation
peptide comprises the amino acid sequence set forth in SEQ ID
NO:40. E106. The lipid nanoparticle of embodiment 98, wherein the
mRNA encoding the KRAS activating oncogene mutation peptide
comprises the nucleotide sequence set forth in SEQ ID NOs: 127.
E107. The lipid nanoparticle of embodiment 99, wherein the KRAS
activating oncogene mutation peptide comprises the amino acid
sequence set forth in SEQ ID NO: 72. E108. The lipid nanoparticle
of embodiment 99, wherein the mRNA encoding the KRAS activating
oncogene mutation peptide comprises the nucleotide sequence set
forth in SEQ ID NO: 132. E109. The lipid nanoparticle of embodiment
100, wherein the KRAS activating oncogene mutation peptide
comprises the amino acid sequence set forth in SEQ ID NO: 41. E110.
The lipid nanoparticle of embodiment 100, wherein the mRNA encoding
the KRAS activating oncogene mutation peptide comprises the
nucleotide sequence set forth in SEQ ID NO: 128. E111. The lipid
nanoparticle of any one of embodiments 97-110, wherein the
constitutively active human STING polypeptide comprises mutation
V155M. E112. The lipid nanoparticle of embodiment 111, wherein the
constitutively active human STING polypeptide comprises the amino
acid sequence shown in SEQ ID NO: 1. E113. The lipid nanoparticle
of embodiment 111, wherein the mRNA encoding the constitutively
active human STING polypeptide comprises a 3' UTR comprising at
least one miR-122 microRNA binding site. E114. The lipid
nanoparticle of embodiment 111, wherein the mRNA encoding the
constitutively active human STING polypeptide comprises the
nucleotide sequence shown in SEQ ID NO: 139. E115. A method for
treating a subject, comprising: administering to a subject having
cancer the immunomodulatory therapeutic composition of any one of
embodiments 1-76 or the lipid nanoparticle of any one of
embodiments 77-114. E116. The method of embodiment 115, wherein
immunomodulatory therapeutic composition or lipid nanoparticle is
administered in combination with a cancer therapeutic agent. E117.
The method of embodiment 115 or 116, wherein immunomodulatory
therapeutic composition or lipid nanoparticle is administered in
combination with an inhibitory checkpoint polypeptide. E118. The
method of embodiment 117, wherein the inhibitory checkpoint
polypeptide is an antibody or fragment thereof that specifically
binds to a molecule selected from the group consisting of PD-1,
PD-L1, TIM-3, VISTA, A2AR, B7-H3, B7-H4, BTLA, CTLA-4, IDO, KIR and
LAG3. E119. The method of any one of embodiments 115-118, wherein
the cancer is selected from cancer of the pancreas, peritoneum,
large intestine, small intestine, biliary tract, lung, endometrium,
ovary, genital tract, gastrointestinal tract, cervix, stomach,
urinary tract, colon, rectum, and hematopoietic and lymphoid
tissues. E120. The method of embodiment 113, wherein the cancer is
colorectal cancer. E121. A lipid nanoparticle comprising:
[1224] a first mRNA having an open reading frame encoding a
concatemer of 4 KRAS activating oncogene mutation peptides, wherein
the 4 KRAS activating oncogene mutation peptides comprise G12D,
G12V, G12C, and G13D; and
[1225] a second mRNA having an open reading frame encoding a
constitutively active human STING polypeptide,
[1226] wherein the first mRNA and second mRNA are present at a
KRAS:STING mass ratio selected from the group consisting of 1:1,
2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1 or 10:1.
E122. The lipid nanoparticle of embodiment 121, wherein the
concatemer comprises from N- to C-terminus G12D, G12V, G13D, and
G12C. E123. The lipid nanoparticle of embodiment 121, wherein the
concatemer comprises from N- to C-terminus G12C, G13D, G12V, and
G12D. E124. The lipid nanoparticle of any one of embodiments 121 to
123, wherein each KRAS activating oncogene mutation peptide
comprises 20, 21, 22, 23, 24, or 25 amino acids in length. E125.
The lipid nanoparticle of embodiment 124, wherein each KRAS
activating oncogene mutation peptide comprises 25 amino acids in
length. E126. The lipid nanoparticle of embodiment 121, wherein the
concatemer comprises an amino acid sequence set forth in SEQ ID NO:
137. E127. The lipid nanoparticle of embodiment 121, wherein the
mRNA encoding the concatemer of 4 KRAS activating oncogene mutation
peptides comprises the nucleotide sequence set forth in SEQ ID NO:
138. E128. The lipid nanoparticle of any one of embodiments
121-127, wherein the constitutively active human STING polypeptide
comprises mutation V155M. E129. The lipid nanoparticle of
embodiment 128, wherein the constitutively active human STING
polypeptide comprises the amino acid sequence shown in SEQ ID NO:
1. E130. The lipid nanoparticle of embodiment 128, wherein the mRNA
encoding the constitutively active human STING polypeptide
comprises a 3' UTR comprising at least one miR-122 microRNA binding
site. E131. The lipid nanoparticle of embodiment 128, wherein the
mRNA encoding the constitutively active human STING polypeptide
comprises the nucleotide sequence shown in SEQ ID NO: 139. E132. A
lipid nanoparticle comprising:
[1227] a first mRNA having an open reading frame encoding a KRAS
activating oncogene mutation peptide comprising G12D;
[1228] a second mRNA having an open reading frame encoding a KRAS
activating oncogene mutation peptide comprising G12V;
[1229] a third mRNA having an open reading frame encoding a KRAS
activating oncogene mutation peptide comprising G12C;
[1230] a fourth mRNA having an open reading frame encoding a KRAS
activating oncogene mutation peptide comprising G13D; and
[1231] a fifth mRNA having an open reading frame encoding a
constitutively active human STING polypeptide,
[1232] wherein the first, second, third, fourth and fifth mRNAs are
present at a KRAS:STING mass ratio selected from the group
consisting of 1:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1 or
10:1.
E133. The lipid nanoparticle of embodiment 132, wherein each KRAS
activating oncogene mutation peptide comprises 20, 21, 22, 23, 24,
or 25 amino acids in length. E134. The lipid nanoparticle of
embodiment 133, wherein each KRAS activating oncogene mutation
peptide comprises 25 amino acids in length. E135. The lipid
nanoparticle of embodiment 132, wherein the KRAS activating
oncogene mutation peptides comprise the amino acid sequences set
forth in SEQ ID NOs: 39-41 and 72. E136. The lipid nanoparticle of
embodiment 132, wherein the mRNAs encoding the KRAS activating
oncogene mutation peptides comprise the nucleotide sequences set
forth in SEQ ID NOs: 126-128 and 132. E137. The lipid nanoparticle
of any one of embodiments 132-136, wherein the constitutively
active human STING polypeptide comprises mutation V155M. E138. The
lipid nanoparticle of embodiment 137, wherein the constitutively
active human STING polypeptide comprises the amino acid sequence
shown in SEQ ID NO: 1. E139. The lipid nanoparticle of embodiment
138, wherein the mRNA encoding the constitutively active human
STING polypeptide comprises a 3' UTR comprising at least one
miR-122 microRNA binding site. E140. The lipid nanoparticle of
embodiment 137, wherein the mRNA encoding the constitutively active
human STING polypeptide comprises the nucleotide sequence shown in
SEQ ID NO: 139. E141. The lipid nanoparticle of any one of
embodiments 121-131, wherein the first and second mRNAs are present
at a KRAS:STING mass ratio of 1:1. E142. The lipid nanoparticle of
any one of embodiments 121-131, wherein the first and second mRNAs
are present at a KRAS:STING mass ratio of 2:1. E143. The lipid
nanoparticle of any one of embodiments 121-131, wherein the first
and second mRNAs are present at a KRAS:STING mass ratio of 3:1.
E144. The lipid nanoparticle of any one of embodiments 121-131,
wherein the first and second mRNAs are present at a KRAS:STING mass
ratio of 4:1. E145. The lipid nanoparticle of any one of
embodiments 121-131, wherein the first and second mRNAs are present
at a KRAS:STING mass ratio of 5:1. E146. The lipid nanoparticle of
any one of embodiments 121-131, wherein the first and second mRNAs
are present KRAS:STING mass ratio of 6:1. E147. The lipid
nanoparticle of any one of embodiments 121-131, wherein the first
and second mRNAs are present at a KRAS:STING mass ratio of 7:1.
E148. The lipid nanoparticle of any one of embodiments 121-131,
wherein the first and second mRNAs are present at a KRAS:STING mass
ratio of 8:1. E149. The lipid nanoparticle of any one of
embodiments 121-140, wherein the first and second mRNAs are present
at a KRAS:STING mass ratio of 9:1. E150. The lipid nanoparticle of
any one of embodiments 121-140, wherein the first and second mRNAs
are present at a KRAS:STING mass ratio of 10:1. E151. A composition
comprising:
[1233] (i) a first mRNA having an open reading frame encoding a
concatemer of 4 KRAS activating oncogene mutation peptides, wherein
the concatemer comprises from N- to C-terminus G12D, G12V, G13D,
and G12C, and
[1234] (ii) a second mRNA having an open reading frame encoding a
constitutively active human STING polypeptide, wherein the
constitutively active human STING polypeptide comprises mutation
V155M,
[1235] wherein the first mRNA and second mRNA are present at a
KRAS:STING mass ratio selected from the group consisting of 1:1,
2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1 or 10:1;
[1236] and a pharmaceutically acceptable carrier.
E152. The composition of embodiment 151, wherein the concatemer of
4 KRAS activating oncogene mutation peptides comprises the amino
acid sequence set forth in SEQ ID NO: 137. E153. The composition of
embodiment 151 or 152, wherein the first mRNA encoding the
concatemer of 4 KRAS activating oncogene mutation peptides
comprises the nucleotide sequence set forth in SEQ ID NO: 169.
E154. The composition of any one of embodiments 151-153, wherein
the constitutively active human STING polypeptide comprises the
amino acid sequence shown in SEQ ID NO: 1. E155. The composition of
any one of embodiments 151-154, wherein the mRNA encoding the
constitutively active human STING polypeptide comprises the
nucleotide sequence shown in SEQ ID NO: 170. E156. The composition
of any one of embodiments 151-155, wherein the first mRNA comprises
a 5' UTR comprising the nucleotide sequence set forth in SEQ ID NO:
176. E157. The composition of any one of embodiments 151-155,
wherein the second mRNA comprises a 5' UTR comprising the
nucleotide sequence set forth in SEQ ID NO: 176. E158. The
composition of any one of embodiments 151-157, wherein the second
mRNA encoding the constitutively active human STING polypeptide
comprises a 3' UTR having a miR-122 microRNA binding site. E159.
The composition of embodiment 158, wherein the miR-122 microRNA
binding site comprises the nucleotide sequence shown in SEQ ID NO:
175. E160. The composition of any one of embodiments 151-159,
wherein the first mRNA and second mRNA each comprise a poly A tail.
E161. The composition of embodiment 160, wherein the poly A tail
comprises about 100 nucleotides. E162. The composition of any one
of embodiments 151-161, wherein the first and second mRNAs each
comprise a 5' Cap 1 structure. E163. The composition of any one of
embodiments 151-162, wherein the first and second mRNAs each
comprise at least one chemical modification. E164. The composition
of embodiment 163, wherein the chemical modification is
N1-methylpseudouridine. E165. The composition of embodiment 164,
wherein the first mRNA is fully modified with
N1-methylpseudouridine. E166. The composition of embodiment 164,
wherein the second mRNA is fully modified with
N1-methylpseudouridine. E167. The composition of any one of
embodiments 151-166, wherein the pharmaceutically acceptable
carrier comprises a buffer solution. E168. A composition
comprising:
[1237] (i) a first mRNA comprising the nucleotide sequence set
forth in SEQ ID NO: 167, and
[1238] (ii) a second mRNA comprising the nucleotide sequence set
forth in SEQ ID NO: 168,
[1239] wherein the first and second mRNA are each fully modified
with N1-methylpseudouridine, and
[1240] wherein the first mRNA and second mRNA are present at a
KRAS:STING mass ratio selected from the group consisting of 1:1,
2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1 or 10:1;
[1241] and a pharmaceutically acceptable carrier.
E169. The composition of embodiment 168, wherein the
pharmaceutically acceptable carrier comprises a buffer solution.
E170. The composition of any one of embodiments 151-169, wherein
the first and second mRNAs are present at a KRAS:STING mass ratio
of 1:1. E171. The composition of any one of embodiments 151-169,
wherein the first and second mRNAs are present at a KRAS:STING mass
ratio of 2:1. E172. The composition of any one of embodiments
151-169, wherein the first and second mRNAs are present at a
KRAS:STING mass ratio of 3:1. E173. The composition of any one of
embodiments 151-169, wherein the first and second mRNAs are present
at a KRAS:STING mass ratio of 4:1. E174. The composition of any one
of embodiments 151-169, wherein the first and second mRNAs are
present at a KRAS:STING mass ratio of 5:1. E175. The composition of
any one of embodiments 151-169, wherein the first and second mRNAs
are present KRAS:STING mass ratio of 6:1. E176. The composition of
any one of embodiments 151-169, wherein the first and second mRNAs
are present at a KRAS:STING mass ratio of 7:1. E177. The
composition of any one of embodiments 151-169, wherein the first
and second mRNAs are present at a KRAS:STING mass ratio of 8:1.
E178. The composition of any one of embodiments 151-169, wherein
the first and second mRNAs are present at a KRAS:STING mass ratio
of 9:1. E179. The composition of any one of embodiments 151-169,
wherein the first and second mRNAs are present at a KRAS:STING mass
ratio of 10:1. E180. The composition of any one of embodiments
151-179, which is formulated in a lipid nanoparticle. E181. The
composition of embodiment 180, wherein the lipid nanoparticle
comprises a molar ratio of about 20-60% ionizable amino lipid:5-25%
phospholipid:25-55% sterol; and 0.5-15% PEG-modified lipid. E182.
The composition of embodiment 181, wherein the lipid nanoparticle
comprises a molar ratio of about 50% Compound 25:about 10%
DSPC:about 38.5% cholesterol; and about 1.5% PEG-DMG. E183. The
composition of any one of embodiments 151-182, which is formulated
for intramuscular delivery. E184. A lipid nanoparticle
comprising:
[1242] (i) a first mRNA having an open reading frame encoding a
concatemer of 4 KRAS activating oncogene mutation peptides, wherein
the concatemer comprises from N- to C-terminus G12D, G12V, G13D,
and G12C; and
[1243] (ii) a second mRNA having an open reading frame encoding a
constitutively active human STING polypeptide, wherein the
constitutively active human STING polypeptide comprises mutation
V155M,
[1244] wherein the first mRNA and second mRNA are present at a
KRAS:STING mass ratio of 5:1.
E185. The lipid nanoparticle of embodiment 184, wherein the
concatemer of 4 KRAS activating oncogene mutation peptides
comprises the amino acid sequence set forth in SEQ ID NO: 137.
E186. The lipid nanoparticle of embodiment 184 or 185, wherein the
first mRNA encoding the concatemer of 4 KRAS activating oncogene
mutation peptides comprises the nucleotide sequence set forth in
SEQ ID NO: 169. E187. The lipid nanoparticle of any one of
embodiments 184-186, wherein the constitutively active human STING
polypeptide comprises the amino acid sequence shown in SEQ ID NO:
1. E188. The lipid nanoparticle of any one of embodiments 184-187,
wherein the mRNA encoding the constitutively active human STING
polypeptide comprises the nucleotide sequence shown in SEQ ID NO:
170. E189. The lipid nanoparticle of any one of embodiments
184-188, wherein the first mRNA comprises a 5' UTR comprising the
nucleotide sequence shown in SEQ ID NO: 176. E190. The lipid
nanoparticle of any one of embodiments 184-188, wherein the second
mRNA comprises a 5' UTR comprising the nucleotide sequence shown in
SEQ ID NO: 176. E191. The lipid nanoparticle of any one of
embodiments 184-190, wherein the second mRNA encoding the
constitutively active human STING polypeptide comprises a 3' UTR
having a miR-122 microRNA binding site. E192. The lipid
nanoparticle of embodiment 191, wherein the miR-122 microRNA
binding site comprises the nucleotide sequence shown in SEQ ID NO:
175. E193. The lipid nanoparticle of any one of embodiments
184-192, wherein the first and second mRNAs each comprise a poly A
tail. E194. The lipid nanoparticle of embodiment 193, wherein the
poly A tail comprises about 100 nucleotides. E195. The lipid
nanoparticle of any one of embodiments 184-194, wherein the first
and second mRNAs each comprise a 5' Cap 1 structure. E196. The
lipid nanoparticle of any one of embodiments 184-195, wherein the
first and second mRNAs each comprise at least one chemical
modification. E197. The lipid nanoparticle of embodiment 196,
wherein the chemical modification is N1-methylpseudouridine. E198.
The lipid nanoparticle of embodiment 197, wherein the first mRNA is
fully modified with N1-methylpseudouridine. E199. The lipid
nanoparticle of embodiment 197, wherein the second mRNA is fully
modified with N1-methylpseudouridine. E200. A lipid nanoparticle
comprising:
[1245] (i) a first mRNA comprising the nucleotide sequence set
forth in SEQ ID NO: 167; and
[1246] (ii) a second mRNA comprising the nucleotide sequence set
forth in SEQ ID NO: 168,
[1247] wherein the first and second mRNA are each fully modified
with N1-methylpseudouridine, and
[1248] wherein the first mRNA and second mRNA are present at a
KRAS:STING mass ratio of 5:1.
E201. The lipid nanoparticle of any one of embodiments 184-200,
wherein the lipid nanoparticle comprises a molar ratio of about
20-60% ionizable amino lipid:5-25% phospholipid:25-55% sterol; and
0.5-15% PEG-modified lipid. E202. The lipid nanoparticle of
embodiment 201, wherein the lipid nanoparticle comprises a molar
ratio of about 50% Compound 25:about 10% DSPC:about 38.5%
cholesterol; and about 1.5% PEG-DMG. E203. A pharmaceutical
composition comprising the lipid nanoparticle of any one of
embodiments 184-202, and a pharmaceutically acceptable carrier.
E204. The pharmaceutical composition of embodiment 203 which is
formulated for intramuscular delivery. E205. The lipid nanoparticle
of any one of embodiments 184-202, and an optional pharmaceutically
acceptable carrier, or the pharmaceutical composition of any one of
embodiments 203-204 for use in treating or delaying progression of
cancer in an individual, wherein the treatment comprises
administration of the composition in combination with a second
composition, wherein the second composition comprises a checkpoint
inhibitor polypeptide and an optional pharmaceutically acceptable
carrier. E206. Use of a lipid nanoparticle of any one of
embodiments 184-202, and an optional pharmaceutically acceptable
carrier, in the manufacture of a medicament for treating or
delaying progression of cancer in an individual, wherein the
medicament comprises the lipid nanoparticle and an optional
pharmaceutically acceptable carrier and wherein the treatment
comprises administration of the medicament in combination with a
composition comprising a checkpoint inhibitor polypeptide and an
optional pharmaceutically acceptable carrier. E207. A kit
comprising a container comprising the lipid nanoparticle of any one
of embodiments 184-202, and an optional pharmaceutically acceptable
carrier, or the pharmaceutical composition of any one of
embodiments 203-204, and a package insert comprising instructions
for administration of the lipid nanoparticle or pharmaceutical
composition for treating or delaying progression of cancer in an
individual. E208. The kit of embodiment 207, wherein the package
insert further comprises instructions for administration of the
lipid nanoparticle or pharmaceutical composition in combination
with a composition comprising a checkpoint inhibitor polypeptide
and an optional pharmaceutically acceptable carrier for treating or
delaying progression of cancer in an individual. E209. A kit
comprising a medicament comprising a lipid nanoparticle of any one
of embodiments 184-202, and an optional pharmaceutically acceptable
carrier, or the pharmaceutical composition of any one of
embodiments 203-204, and a package insert comprising instructions
for administration of the medicament alone or in combination with a
composition comprising a checkpoint inhibitor polypeptide and an
optional pharmaceutically acceptable carrier for treating or
delaying progression of cancer in an individual. E210. The kit of
embodiment 209, wherein the kit further comprises a package insert
comprising instructions for administration of the first medicament
prior to, current with, or subsequent to administration of the
second medicament for treating or delaying progression of cancer in
an individual. E211. The lipid nanoparticle of any one of
embodiments 184-202, the composition of any one of embodiments
203-204, the use of embodiments 205-206 or the kit of any one of
embodiments 207-210, wherein the checkpoint inhibitor polypeptide
inhibits PD1, PD-L1, CTLA4, or a combination thereof. E212. The
lipid nanoparticle of any one of embodiments 184-202, the
composition of embodiments 203-204, the use of embodiment 205-206
or the kit of any one of embodiments 207-210, wherein the
checkpoint inhibitor polypeptide is an antibody. E213. The lipid
nanoparticle of any one of embodiments 184-202, the composition of
embodiments 203-204, the use of embodiment 205-206 or the kit of
any one of embodiments 207-210, wherein the checkpoint inhibitor
polypeptide is an antibody selected from an anti-CTLA4 antibody or
antigen-binding fragment thereof that specifically binds CTLA4, an
anti-PD1 antibody or antigen-binding fragment thereof that
specifically binds PD1, an anti-PD-L1 antibody or antigen-binding
fragment thereof that specifically binds PD-L1, and a combination
thereof. E214. The lipid nanoparticle of any one of embodiments
184-202, the composition of embodiments 203-204, the use of
embodiment 205-206 or the kit of any one of embodiments 207-210,
wherein the checkpoint inhibitor polypeptide is an anti-PD-L1
antibody selected from atezolizumab, avelumab, or durvalumab. E215.
The lipid nanoparticle of any one of embodiments 184-202, the
composition of embodiments 203-204, the use of embodiment 205-206
or the kit of any one of embodiments 197-200, wherein the
checkpoint inhibitor polypeptide is an anti-CTLA-4 antibody
selected from tremelimumab or ipilimumab. E216. The lipid
nanoparticle of any one of embodiments 184-202, the composition of
embodiments 203-204, the use of embodiment 205-206 or the kit of
any one of embodiments 197-200, wherein the checkpoint inhibitor
polypeptide is an anti-PD1 antibody selected from nivolumab or
pembrolizumab. E217. A method of reducing or decreasing a size of a
tumor or inhibiting a tumor growth in a subject in need thereof
comprising administering to the subject the lipid nanoparticle of
any one of embodiments 184-202 or the composition of any one of
embodiments 203-204. E218. A method of inducing an anti-tumor
response in a subject with cancer, comprising administering to the
subject the lipid nanoparticle of any one of embodiments 184-202 or
the composition of any one of embodiments 203-204. E219. The method
of embodiment 218, wherein the anti-tumor response comprises a
T-cell response. E220. The method of embodiment 219, wherein the
T-cell response comprises CD8+ T cells. E221. The method of any one
of embodiments 217-220, wherein the composition is administered by
intramuscular injection. E222. The method of any one of embodiments
217-220, further comprising administering a second composition
comprising a checkpoint inhibitor polypeptide, and an optional
pharmaceutically acceptable carrier. E223. The method of embodiment
222, wherein the checkpoint inhibitor polypeptide inhibits PD1,
PD-L1, CTLA4, or a combination thereof. E224. The method of
embodiment 223, wherein the checkpoint inhibitor polypeptide is an
antibody. E225. The method of embodiment 224, wherein the
checkpoint inhibitor polypeptide is an antibody selected from an
anti-CTLA4 antibody or antigen-binding fragment thereof that
specifically binds CTLA4, an anti-PD1 antibody or antigen-binding
fragment thereof that specifically binds PD1, an anti-PD-L1
antibody or antigen-binding fragment thereof that specifically
binds PD-L1, and a combination thereof. E226. The method of
embodiment 225, wherein the checkpoint inhibitor polypeptide is an
anti-PD-L1 antibody selected from atezolizumab, avelumab, or
durvalumab. E227. The method of embodiment 225, wherein the
checkpoint inhibitor polypeptide is an anti-CTLA-4 antibody
selected from tremelimumab or ipilimumab. E228. The method of
embodiment 225, wherein the checkpoint inhibitor polypeptide is an
anti-PD1 antibody selected from nivolumab or pembrolizumab. E229.
The method of any one of embodiments 222-228, wherein the
composition comprising the checkpoint inhibitor polypeptide is
administered by intravenous injection. E230. The method of
embodiment 229, wherein the composition comprising the checkpoint
inhibitor polypeptide is administered once every 2 to 3 weeks.
E231. The method of embodiment 229, wherein the composition
comprising the checkpoint inhibitor polypeptide is administered
once every 2 weeks or once every 3 weeks. E232. The method of any
one of embodiments 222-231, wherein the composition comprising the
checkpoint inhibitor polypeptide is administered prior to,
concurrent with, or subsequent to administration of the lipid
nanoparticle or pharmaceutical composition thereof. E233. The
method of any one of embodiments 217-232, wherein the subject has a
histologically confirmed KRAS mutation selected from G12D, G12V,
G13D or G12C. E234. The method of any one of embodiments 217-233,
wherein the tumor is metastatic colorectal cancer. E235. The method
of any of embodiments 217-233, wherein the tumor is non-small cell
lung cancer (NSCLC). E236. The method of any of embodiments
217-233, wherein the tumor is pancreatic cancer. E237. An
immunomodulatory therapeutic composition, comprising: one or more
mRNA each having an open reading frame encoding an activating
oncogene mutation peptide, and a pharmaceutically acceptable
carrier or excipient. E238. The immunomodulatory therapeutic
composition of embodiment 237, wherein the activating oncogene
mutation is a KRAS mutation E239. The immunomodulatory therapeutic
composition of embodiment 238, wherein the KRAS mutation is a G12
mutation. E240. The immunomodulatory therapeutic composition of
embodiment 239, wherein the G12 KRAS mutation is selected from a
G12D, G12V, G12S, G12C, G12A, and a G12R KRAS mutation E241. The
immunomodulatory therapeutic composition of embodiment 239, wherein
the G12 KRAS mutation is selected from a G12D, G12V, and a G12S
KRAS mutation. E242. The immunomodulatory therapeutic composition
of embodiment 238, wherein the KRAS mutation is a G13 mutation.
E243. The immunomodulatory therapeutic composition of embodiment
242, wherein the G13 KRAS mutation is a G13D KRAS mutation. E244.
The immunomodulatory therapeutic composition of embodiment 237,
wherein the activating oncogene mutation is a H-RAS or N-RAS
mutation. E245. The immunomodulatory therapeutic composition of any
one of embodiments 237-244, wherein the mRNA has an open reading
frame encoding a concatemer of two or more activating oncogene
mutation peptides. E246. The immunomodulatory therapeutic
composition of embodiment 245, wherein at least two of the peptide
epitopes are separated from one another by a single Glycine. E247.
The immunomodulatory therapeutic composition of any one of
embodiments 245-246, wherein the concatemer comprises 3-10
activating oncogene mutation peptides. E248. The activating
oncogene mutation peptides of any one of embodiments 245-247,
wherein all of the peptide epitopes are separated from one another
by a single Glycine. E249. The activating oncogene mutation
peptides of any one of embodiments 245-247, wherein at least two of
the peptide epitopes are linked directly to one another without a
linker. E250. The immunomodulatory therapeutic composition of any
one of embodiments 237-249, wherein the composition further
comprises a cancer therapeutic agent. E251. The immunomodulatory
therapeutic composition of any one of embodiments 237-250, wherein
the composition further comprises an inhibitory checkpoint
polypeptide. E252. The immunomodulatory therapeutic composition of
embodiment 251, wherein the inhibitory checkpoint polypeptide is an
antibody or fragment thereof that specifically binds to a molecule
selected from the group consisting of PD-1, TIM-3, VISTA, A2AR,
B7-H3, B7-H4, BTLA, CTLA-4, IDO, KIR and LAG3. E253. The
immunomodulatory therapeutic composition of any one of embodiments
237-252, wherein the composition further comprises a recall
antigen. E254. The immunomodulatory therapeutic composition of
embodiment 253, wherein the recall antigen is an infectious disease
antigen. E255. The immunomodulatory therapeutic composition of any
one of embodiments 237-254, wherein the composition does not
comprise a stabilization agent. E256. The immunomodulatory
therapeutic composition of any one of embodiments 237-255, wherein
the mRNA is formulated in a lipid nanoparticle carrier. E257. The
immunomodulatory therapeutic composition of embodiment 256, wherein
the lipid nanoparticle carrier comprises a molar ratio of about
20-60% cationic lipid:5-25% non-cationic lipid:25-55% sterol; and
0.5-15% PEG-modified lipid. E258. The immunomodulatory therapeutic
composition of embodiment 257, wherein the cationic lipid is
selected from the group consisting of for example,
2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA),
dilinoleyl-methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), and
di((Z)-non-2-en-1-yl)
9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319). E259.
The immunomodulatory therapeutic composition of any one of
embodiments 237-258, wherein the mRNA includes at least one
chemical modification. E260. The immunomodulatory therapeutic
composition of embodiment 259, wherein the chemical modification is
selected from the group consisting of pseudouridine,
N1-methylpseudouridine, 2-thiouridine, 4'-thiouridine,
5-methylcytosine, 2-thio-1-methyl-1-deaza-pseudouridine,
2-thio-1-methyl-pseudouridine, 2-thio-5-aza-uridine,
2-thio-dihydropseudouridine, 2-thio-dihydrouridine,
2-thio-pseudouridine, 4-methoxy-2-thio-pseudouridine,
4-methoxy-pseudouridine, 4-thio-1-methyl-pseudouridine,
4-thio-pseudouridine, 5-aza-uridine, dihydropseudouridine,
5-methyluridine, 5-methyluridine, 5-methoxyuridine, and 2'-O-methyl
uridine. E261. A method for treating a subject, comprising:
administering to a subject having cancer an immunomodulatory
therapeutic composition of any one of embodiments 237-260. E262.
The method of embodiment 261, wherein immunomodulatory therapeutic
composition is administered in combination with a cancer
therapeutic agent. E263. The method of embodiment 261 or 260,
wherein immunomodulatory therapeutic composition is administered in
combination with an inhibitory checkpoint polypeptide. E264. The
method of embodiment 263, wherein the inhibitory checkpoint
polypeptide is an antibody or fragment thereof that specifically
binds to a molecule selected from the group consisting of PD-1,
TIM-3, VISTA, A2AR, B7-H3, B7-H4, BTLA, CTLA-4, IDO, KIR and LAG3.
E265. The method of any one of embodiments 261-264, wherein the
cancer is selected from cancer of the pancreas, peritoneum, large
intestine, small intestine, biliary tract, lung, endometrium,
ovary, genital tract, gastrointestinal tract, cervix, stomach,
urinary tract, colon, rectum, and hematopoietic and lymphoid
tissues. E266. The method of embodiment 265, wherein the cancer is
colorectal cancer.
Definitions
[1249] Administering: As used herein, "administering" refers to a
method of delivering a composition to a subject or patient. A
method of administration may be selected to target delivery (e.g.,
to specifically deliver) to a specific region or system of a body.
For example, an administration may be parenteral (e.g.,
subcutaneous, intracutaneous, intravenous, intraperitoneal,
intramuscular, intraarticular, intraarterial, intrasynovial,
intrasternal, intrathecal, intralesional, or intracranial
injection, as well as any suitable infusion technique), oral,
trans- or intra-dermal, interdermal, rectal, intravaginal, topical
(e.g. by powders, ointments, creams, gels, lotions, and/or drops),
mucosal, nasal, buccal, enteral, vitreal, intratumoral, sublingual,
intranasal; by intratracheal instillation, bronchial instillation,
and/or inhalation; as an oral spray and/or powder, nasal spray,
and/or aerosol, and/or through a portal vein catheter.
[1250] Approximately, about: As used herein, the terms
"approximately" or "about," as applied to one or more values of
interest, refers to a value that is similar to a stated reference
value. In certain embodiments, the term "approximately" or "about"
refers to a range of values that fall within 25%, 20%, 19%, 18%,
17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%,
2%, 1%, or less in either direction (greater than or less than) of
the stated reference value unless otherwise stated or otherwise
evident from the context (except where such number would exceed
100% of a possible value).
[1251] Cancer: As used herein, "cancer" is a condition involving
abnormal and/or unregulated cell growth. The term cancer
encompasses benign and malignant cancers. Exemplary non-limiting
cancers include adrenal cortical cancer, advanced cancer, anal
cancer, aplastic anemia, bileduct cancer, bladder cancer, bone
cancer, bone metastasis, brain tumors, brain cancer, breast cancer,
childhood cancer, cancer of unknown primary origin, Castleman
disease, cervical cancer, colorectal cancer, endometrial cancer,
esophagus cancer, Ewing family of tumors, eye cancer, gallbladder
cancer, gastrointestinal carcinoid tumors, gastrointestinal stromal
tumors, gestational trophoblastic disease, Hodgkin disease, Kaposi
sarcoma, renal cell carcinoma, laryngeal and hypopharyngeal cancer,
acute lymphocytic leukemia, acute myeloid leukemia, chronic
lymphocytic leukemia, chronic myeloid leukemia, chronic
myelomonocytic leukemia, myelodysplastic syndrome (including
refractory anemias and refractory cytopenias), myeloproliferative
neoplasms or diseases (including polycythemia vera, essential
thrombocytosis and primary myelofibrosis), liver cancer (e.g.,
hepatocellular carcinoma), non-small cell lung cancer, small cell
lung cancer, lung carcinoid tumor, lymphoma of the skin, malignant
mesothelioma, multiple myeloma, myelodysplasia syndrome, nasal
cavity and paranasal sinus cancer, nasopharyngeal cancer,
neuroblastoma, non-Hodgkin lymphoma, oral cavity and oropharyngeal
cancer, osteosarcoma, ovarian cancer, pancreatic cancer, penile
cancer, pituitary tumors, prostate cancer, retinoblastoma,
rhabdomyosarcoma, salivary gland cancer, sarcoma in adult soft
tissue, basal and squamous cell skin cancer, melanoma, small
intestine cancer, stomach cancer, testicular cancer, throat cancer,
thymus cancer, thyroid cancer, uterine sarcoma, vaginal cancer,
vulvar cancer, Waldenstrom macroglobulinemia, Wilms tumor and
secondary cancers caused by cancer treatment. In particular
embodiments, the cancer is liver cancer (e.g., hepatocellular
carcinoma) or colorectal cancer. In other embodiments, the cancer
is a blood-based cancer or a hematopoetic cancer.
[1252] Cleavable Linker: As used herein, the term "cleavable
linker" refers to a linker, typically a peptide linker (e.g., about
5-30 amino acids in length, typically about 10-20 amino acids in
length) that can be incorporated into multicistronic mRNA
constructs such that equimolar levels of multiple genes can be
produced from the same mRNA. Non-limiting examples of cleavable
linkers include the 2A family of peptides, including F2A, P2A, T2A
and E2A, first discovered in picornaviruses, that when incorporated
into an mRNA construct (e.g., between two polypeptide domains)
function by making the ribosome skip the synthesis of a peptide
bond at C-terminus of the 2A element, thereby leading to separation
between the end of the 2A sequence and the next peptide
downstream.
[1253] Conjugated: As used herein, the term "conjugated," when used
with respect to two or more moieties, means that the moieties are
physically associated or connected with one another, either
directly or via one or more additional moieties that serves as a
linking agent, to form a structure that is sufficiently stable so
that the moieties remain physically associated under the conditions
in which the structure is used, e.g., physiological conditions. In
some embodiments, two or more moieties may be conjugated by direct
covalent chemical bonding. In other embodiments, two or more
moieties may be conjugated by ionic bonding or hydrogen
bonding.
[1254] Contacting: As used herein, the term "contacting" means
establishing a physical connection between two or more entities.
For example, contacting a cell with an mRNA or a lipid nanoparticle
composition means that the cell and mRNA or lipid nanoparticle are
made to share a physical connection. Methods of contacting cells
with external entities both in vivo, in vitro, and ex vivo are well
known in the biological arts. In exemplary embodiments of the
disclosure, the step of contacting a mammalian cell with a
composition (e.g., an isolated mRNA, nanoparticle, or
pharmaceutical composition of the disclosure) is performed in vivo.
For example, contacting a lipid nanoparticle composition and a cell
(for example, a mammalian cell) which may be disposed within an
organism (e.g., a mammal) may be performed by any suitable
administration route (e.g., parenteral administration to the
organism, including intravenous, intramuscular, intradermal, and
subcutaneous administration). For a cell present in vitro, a
composition (e.g., a lipid nanoparticle or an isolated mRNA) and a
cell may be contacted, for example, by adding the composition to
the culture medium of the cell and may involve or result in
transfection. Moreover, more than one cell may be contacted by a
nanoparticle composition.
[1255] Encapsulate: As used herein, the term "encapsulate" means to
enclose, surround, or encase. In some embodiments, a compound,
polynucleotide (e.g., an mRNA), or other composition may be fully
encapsulated, partially encapsulated, or substantially
encapsulated. For example, in some embodiments, an mRNA of the
disclosure may be encapsulated in a lipid nanoparticle, e.g., a
liposome.
[1256] Effective amount: As used herein, the term "effective
amount" of an agent is that amount sufficient to effect beneficial
or desired results, for example, clinical results, and, as such, an
"effective amount" depends upon the context in which it is being
applied. For example, in the context of administering an agent that
treats cancer, an effective amount of an agent is, for example, an
amount sufficient to achieve treatment, as defined herein, of
cancer, as compared to the response obtained without administration
of the agent. In some embodiments, a therapeutically effective
amount is an amount of an agent to be delivered (e.g., nucleic
acid, drug, therapeutic agent, diagnostic agentor prophylactic
agent) that is sufficient, when administered to a subject suffering
from or susceptible to an infection, disease, disorder, and/or
condition, to treat, improve symptoms of, diagnose, prevent, and/or
delay the onset of the infection, disease, disorder, and/or
condition.
[1257] Expression: As used herein, "expression" of a nucleic acid
sequence refers to one or more of the following events: (1)
production of an RNA template from a DNA sequence (e.g., by
transcription); (2) processing of an RNA transcript (e.g., by
splicing, editing, 5' cap formation, and/or 3' end processing); (3)
translation of an RNA into a polypeptide or protein; and (4)
post-translational modification of a polypeptide or protein.
[1258] Identity: As used herein, the term "identity" refers to the
overall relatedness between polymeric molecules, e.g., between
polynucleotide molecules (e.g., DNA molecules and/or RNA molecules)
and/or between polypeptide molecules. Calculation of the percent
identity of two polynucleotide sequences, for example, can be
performed by aligning the two sequences for optimal comparison
purposes (e.g., gaps can be introduced in one or both of a first
and a second nucleic acid sequences for optimal alignment and
non-identical sequences can be disregarded for comparison
purposes). In certain embodiments, the length of a sequence aligned
for comparison purposes is at least 30%, at least 40%, at least
50%, at least 60%, at least 70%, at least 80%, at least 90%, at
least 95%, or 100% of the length of the reference sequence. The
nucleotides at corresponding nucleotide positions are then
compared. When a position in the first sequence is occupied by the
same nucleotide as the corresponding position in the second
sequence, then the molecules are identical at that position. The
percent identity between the two sequences is a function of the
number of identical positions shared by the sequences, taking into
account the number of gaps, and the length of each gap which needs
to be introduced for optimal alignment of the two sequences. The
comparison of sequences and determination of percent identity
between two sequences can be accomplished using a mathematical
algorithm. For example, the percent identity between two nucleotide
sequences can be determined using methods such as those described
in Computational Molecular Biology, Lesk, A. M., ed., Oxford
University Press, New York, 1988; Biocomputing: Informatics and
Genome Projects, Smith, D. W., ed., Academic Press, New York, 1993;
Sequence Analysis in Molecular Biology, von Heinje, G., Academic
Press, 1987; Computer Analysis of Sequence Data, Part I, Griffin,
A. M., and Griffin, H. G., eds., Humana Press, New Jersey, 1994;
and Sequence Analysis Primer, Gribskov, M. and Devereux, J., eds.,
M Stockton Press, New York, 1991; each of which is incorporated
herein by reference. For example, the percent identity between two
nucleotide sequences can be determined using the algorithm of
Meyers and Miller (CABIOS, 1989, 4:11-17), which has been
incorporated into the ALIGN program (version 2.0) using a PAM120
weight residue table, a gap length penalty of 12 and a gap penalty
of 4. The percent identity between two nucleotide sequences can,
alternatively, be determined using the GAP program in the GCG
software package using an NWSgapdna.CMP matrix. Methods commonly
employed to determine percent identity between sequences include,
but are not limited to those disclosed in Carillo, H., and Lipman,
D., SIAM J Applied Math., 48:1073 (1988); incorporated herein by
reference. Techniques for determining identity are codified in
publicly available computer programs. Exemplary computer software
to determine homology between two sequences include, but are not
limited to, GCG program package, Devereux et al., Nucleic Acids
Research, 12(1): 387, 1984, BLASTP, BLASTN, and FASTA, Altschul, S.
F. et al., J. Molec. Biol., 215, 403, 1990.
[1259] Fragment: A "fragment," as used herein, refers to a portion.
For example, fragments of proteins may include polypeptides
obtained by digesting full-length protein isolated from cultured
cells or obtained through recombinant DNA techniques.
[1260] GC-rich: As used herein, the term "GC-rich" refers to the
nucleobase composition of a polynucleotide (e.g., mRNA), or any
portion thereof (e.g., an RNA element), comprising guanine (G)
and/or cytosine (C) nucleobases, or derivatives or analogs thereof,
wherein the GC-content is greater than about 50%. The term
"GC-rich" refers to all, or to a portion, of a polynucleotide,
including, but not limited to, a gene, a non-coding region, a 5'
UTR, a 3' UTR, an open reading frame, an RNA element, a sequence
motif, or any discrete sequence, fragment, or segment thereof which
comprises about 50% GC-content. In some embodiments of the
disclosure, GC-rich polynucleotides, or any portions thereof, are
exclusively comprised of guanine (G) and/or cytosine (C)
nucleobases.
[1261] GC-content: As used herein, the term "GC-content" refers to
the percentage of nucleobases in a polynucleotide (e.g., mRNA), or
a portion thereof (e.g., an RNA element), that are either guanine
(G) and cytosine (C) nucleobases, or derivatives or analogs
thereof, (from a total number of possible nucleobases, including
adenine (A) and thymine (T) or uracil (U), and derivatives or
analogs thereof, in DNA and in RNA). The term "GC-content" refers
to all, or to a portion, of a polynucleotide, including, but not
limited to, a gene, a non-coding region, a 5' or 3' UTR, an open
reading frame, an RNA element, a sequence motif, or any discrete
sequence, fragment, or segment thereof.
[1262] Genetic Adjuvant: A "genetic adjuvant", as used herein,
refers to an mRNA construct (e.g., an mmRNA construct) that
enhances the immune response to a vaccine, for example by
stimulating cytokine production and/or by stimulating the
production of antigen-specific effector cells (e.g., CD8 T cells).
A genetic adjuvant mRNA construct can, for example, encode a
polypeptide that stimulates Type I interferon (e.g., activates Type
I interferon pathway signaling) or that promotes dendritic cell
development or activity.
[1263] Heterologous: As used herein, "heterologous" indicates that
a sequence (e.g., an amino acid sequence or the polynucleotide that
encodes an amino acid sequence) is not normally present in a given
polypeptide or polynucleotide. For example, an amino acid sequence
that corresponds to a domain or motif of one protein may be
heterologous to a second protein.
[1264] Hydrophobic amino acid: As used herein, a "hydrophobic amino
acid" is an amino acid having an uncharged, nonpolar side chain.
Examples of naturally occurring hydrophobic amino acids are alanine
(Ala), valine (Val), leucine (Leu), isoleucine (Ile), proline
(Pro), phenylalanine (Phe), methionine (Met), and tryptophan
(Trp).
[1265] Immune Potentiator: An "immune potentiator", as used herein,
refers to an mRNA construct (e.g., an mmRNA construct) that
enhances an immune response, e.g., to an antigen of interest
(either an endogenous antigen in a subject to which the immune
potentiator is administered or to an exogenous antigen that is
coadministered with the immune potentiator), for example by
stimulating T cell, B cell or dendritic cell responses, including
but not limited to cytokine production, stimulating antibody
production or stimulating the production of antigen-specific immune
cells (e.g., CD8.sup.+ T cells or CD4.sup.+ T cells).
[1266] Initiation Codon: As used herein, the term "initiation
codon", used interchangeably with the term "start codon", refers to
the first codon of an open reading frame that is translated by the
ribosome and is comprised of a triplet of linked
adenine-uracil-guanine nucleobases. The initiation codon is
depicted by the first letter codes of adenine (A), uracil (U), and
guanine (G) and is often written simply as "AUG". Although natural
mRNAs may use codons other than AUG as the initiation codon, which
are referred to herein as "alternative initiation codons", the
initiation codons of polynucleotides described herein use the AUG
codon. During the process of translation initiation, the sequence
comprising the initiation codon is recognized via complementary
base-pairing to the anticodon of an initiator tRNA
(Met-tRNA.sub.i.sup.Met) bound by the ribosome. Open reading frames
may contain more than one AUG initiation codon, which are referred
to herein as "alternate initiation codons".
[1267] The initiation codon plays a critical role in translation
initiation. The initiation codon is the first codon of an open
reading frame that is translated by the ribosome. Typically, the
initiation codon comprises the nucleotide triplet AUG, however, in
some instances translation initiation can occur at other codons
comprised of distinct nucleotides. The initiation of translation in
eukaryotes is a multistep biochemical process that involves
numerous protein-protein, protein-RNA, and RNA-RNA interactions
between messenger RNA molecules (mRNAs), the 40S ribosomal subunit,
other components of the translation machinery (e.g., eukaryotic
initiation factors; eIFs). The current model of mRNA translation
initiation postulates that the pre-initiation complex
(alternatively "43S pre-initiation complex"; abbreviated as "PIC")
translocates from the site of recruitment on the mRNA (typically
the 5' cap) to the initiation codon by scanning nucleotides in a 5'
to 3' direction until the first AUG codon that resides within a
specific translation-promotive nucleotide context (the Kozak
sequence) is encountered (Kozak (1989) J Cell Biol 108:229-241).
Scanning by the PIC ends upon complementary base-pairing between
nucleotides comprising the anticodon of the initiator
Met-tRNA.sub.i.sup.Met transfer RNA and nucleotides comprising the
initiation codon of the mRNA. Productive base-pairing between the
AUG codon and the Met-tRNA.sub.i.sup.Met anticodon elicits a series
of structural and biochemical events that culminate in the joining
of the large 60S ribosomal subunit to the PIC to form an active
ribosome that is competent for translation elongation.
[1268] Insertion: As used herein, an "insertion" or an "addition"
refers to a change in an amino acid or nucleotide sequence
resulting in the addition of one or more amino acid residues or
nucleotides, respectively, to a molecule as compared to a reference
sequence, for example, the sequence found in a naturally-occurring
molecule. In some embodiments, an insertion may be a
replacement.
[1269] Insertion Site: As used herein, an "insertion site" is a
position or region of a scaffold polypeptide that is amenable to
insertion of an amino acid sequence of a heterologous polypeptide.
It is to be understood that an insertion site also may refer to the
position or region of the polynucleotide that encodes the
polypeptide (e.g., a codon of a polynucleotide that codes for a
given amino acid in the scaffold polypeptide). In some embodiments,
insertion of an amino acid sequence of a heterologous polypeptide
into a scaffold polypeptide has little to no effect on the
stability (e.g., conformational stability), expression level, or
overall secondary structure of the scaffold polypeptide.
[1270] Isolated: As used herein, the term "isolated" refers to a
substance or entity that has been separated from at least some of
the components with which it was associated (whether in nature or
in an experimental setting). Isolated substances may have varying
levels of purity in reference to the substances from which they
have been associated. Isolated substances and/or entities may be
separated from at least about 10%, about 20%, about 30%, about 40%,
about 50%, about 60%, about 70%, about 80%, about 90%, or more of
the other components with which they were initially associated. In
some embodiments, isolated agents are more than about 80%, about
85%, about 90%, about 91%, about 92%, about 93%, about 94%, about
95%, about 96%, about 97%, about 98%, about 99%, or more than about
99% pure. As used herein, a substance is "pure" if it is
substantially free of other components.
[1271] Kozak Sequence: The term "Kozak sequence" (also referred to
as "Kozak consensus sequence") refers to a translation initiation
enhancer element to enhance expression of a gene or open reading
frame, and which in eukaryotes, is located in the 5' UTR. The Kozak
consensus sequence was originally defined as the sequence GCCRCC,
where R=a purine, following an analysis of the effects of single
mutations surrounding the initiation codon (AUG) on translation of
the preproinsulin gene (Kozak (1986) Cell 44:283-292).
Polynucleotides disclosed herein comprise a Kozak consensus
sequence, or a derivative or modification thereof. (Examples of
translational enhancer compositions and methods of use thereof, see
U.S. Pat. No. 5,807,707 to Andrews et al., incorporated herein by
reference in its entirety; U.S. Pat. No. 5,723,332 to Chernajovsky,
incorporated herein by reference in its entirety; U.S. Pat. No.
5,891,665 to Wilson, incorporated herein by reference in its
entirety.) Leaky scanning: A phenomenon known as "leaky scanning"
can occur whereby the PIC bypasses the initiation codon and instead
continues scanning downstream until an alternate or alternative
initiation codon is recognized. Depending on the frequency of
occurrence, the bypass of the initiation codon by the PIC can
result in a decrease in translation efficiency. Furthermore,
translation from this downstream AUG codon can occur, which will
result in the production of an undesired, aberrant translation
product that may not be capable of eliciting the desired
therapeutic response. In some cases, the aberrant translation
product may in fact cause a deleterious response (Kracht et al.,
(2017) Nat Med 23(4):501-507).
[1272] Liposome: As used herein, by "liposome" is meant a structure
including a lipid-containing membrane enclosing an aqueous
interior. Liposomes may have one or more lipid membranes. Liposomes
include single-layered liposomes (also known in the art as
unilamellar liposomes) and multi-layered liposomes (also known in
the art as multilamellar liposomes).
[1273] Metastasis: As used herein, the term "metastasis" means the
process by which cancer spreads from the place at which it first
arose as a primary tumor to distant locations in the body. A
secondary tumor that arose as a result of this process may be
referred to as "a metastasis."
[1274] Modified: As used herein "modified" or "modification" refers
to a changed state or a change in composition or structure of a
polynucleotide (e.g., mRNA). Polynucleotides may be modified in
various ways including chemically, structurally, and/or
functionally. For example, polynucleotides may be structurally
modified by the incorporation of one or more RNA elements, wherein
the RNA element comprises a sequence and/or an RNA secondary
structure(s) that provides one or more functions (e.g.,
translational regulatory activity). Accordingly, polynucleotides of
the disclosure may be comprised of one or more modifications (e.g.,
may include one or more chemical, structural, or functional
modifications, including any combination thereof).
[1275] mRNA: As used herein, an "mRNA" refers to a messenger
ribonucleic acid. An mRNA may be naturally or non-naturally
occurring. For example, an mRNA may include modified and/or
non-naturally occurring components such as one or more nucleobases,
nucleosides, nucleotides, or linkers. An mRNA may include a cap
structure, a chain terminating nucleoside, a stem loop, a polyA
sequence, and/or a polyadenylation signal. An mRNA may have a
nucleotide sequence encoding a polypeptide. Translation of an mRNA,
for example, in vivo translation of an mRNA inside a mammalian
cell, may produce a polypeptide. Traditionally, the basic
components of an mRNA molecule include at least a coding region, a
5'-untranslated region (5'-UTR), a 3'UTR, a 5' cap and a polyA
sequence.
[1276] microRNA (miRNA): As used herein, a "microRNA (miRNA)" is a
small non-coding RNA molecule which may function in
post-transcriptional regulation of gene expression (e.g., by RNA
silencing, such as by cleavage of the mRNA, destabilization of the
mRNA by shortening its polyA tail, and/or by interfering with the
efficiency of translation of the mRNA into a polypeptide by a
ribosome). A mature miRNA is typically about 22 nucleotides
long.
[1277] microRNA-122 (miR-122): As used herein, "microRNA-122
(miR-122)" refers to any native miR-122 from any vertebrate source,
including, for example, humans, unless otherwise indicated. miR-122
is typically highly expressed in the liver, where it may regulate
fatty-acid metabolism. miR-122 levels are reduced in liver cancer,
for example, hepatocellular carcinoma. miR-122 is one of the most
highly-expressed miRNAs in the liver, where it regulates targets
including but not limited to CAT-1, CD320, AldoA, Hjv, Hfe, ADAM10,
IGFR1, CCNG1, and ADAM17. Mature human miR-122 may have a sequence
of AACGCCAUUAUCACACUAAAUA (SEQ ID NO: 172, corresponding to
hsa-miR-122-3p) or UGGAGUGUGACAAUGGUGUUUG (SEQ ID NO: 174,
corresponding to hsa-miR-122-5p).
[1278] microRNA-21 (miR-21): As used herein, "microRNA-21 (miR-21)"
refers to any native miR-21 from any vertebrate source, including,
for example, humans, unless otherwise indicated. miR-21 levels are
increased in liver cancer, for example, hepatocellular carcinoma,
as compared to normal liver. Mature human miR-21 may have a
sequence of UAGCUUAUCAGACUGAUGUUGA (SEQ ID NO: 34, corresponding to
has-miR-21-5p) or 5'-CAACACCAGUCGAUGGGCUGU-3' (SEQ ID NO: 35,
corresponding to has-miR-21-3p).
[1279] microRNA-142 (miR-142): As used herein, "microRNA-142
(miR-142)" refers to any native miR-142 from any vertebrate source,
including, for example, humans, unless otherwise indicated. miR-142
is typically highly expressed in myeloid cells. Mature human
miR-142 may have a sequence of UGUAGUGUUUCCUACUUUAUGGA (SEQ ID NO:
28, corresponding to hsa-miR-142-3p) or CAUAAAGUAGAAAGCACUACU (SEQ
ID NO: 30, corresponding to hsa-miR-142-5p).
[1280] microRNA (miRNA) binding site: As used herein, a "microRNA
(miRNA) binding site" refers to a miRNA target site or a miRNA
recognition site, or any nucleotide sequence to which a miRNA binds
or associates. In some embodiments, a miRNA binding site represents
a nucleotide location or region of a polynucleotide (e.g., an mRNA)
to which at least the "seed" region of a miRNA binds. It should be
understood that "binding" may follow traditional Watson-Crick
hybridization rules or may reflect any stable association of the
miRNA with the target sequence at or adjacent to the microRNA
site.
[1281] miRNA seed: As used herein, a "seed" region of a miRNA
refers to a sequence in the region of positions 2-8 of a mature
miRNA, which typically has perfect Watson-Crick complementarity to
the miRNA binding site. A miRNA seed may include positions 2-8 or
2-7 of a mature miRNA. In some embodiments, a miRNA seed may
comprise 7 nucleotides (e.g., nucleotides 2-8 of a mature miRNA),
wherein the seed-complementary site in the corresponding miRNA
binding site is flanked by an adenine (A) opposed to miRNA position
1. In some embodiments, a miRNA seed may comprise 6 nucleotides
(e.g., nucleotides 2-7 of a mature miRNA), wherein the
seed-complementary site in the corresponding miRNA binding site is
flanked by an adenine (A) opposed to miRNA position 1. When
referring to a miRNA binding site, an miRNA seed sequence is to be
understood as having complementarity (e.g., partial, substantial,
or complete complementarity) with the seed sequence of the miRNA
that binds to the miRNA binding site.
[1282] Modified: As used herein "modified" refers to a changed
state or structure of a molecule of the disclosure. Molecules may
be modified in many ways including chemically, structurally, and
functionally. In one embodiment, the mRNA molecules of the present
disclosure are modified by the introduction of non-natural
nucleosides and/or nucleotides, e.g., as it relates to the natural
ribonucleotides A, U, G, and C. Noncanonical nucleotides such as
the cap structures are not considered "modified" although they
differ from the chemical structure of the A, C, G, U
ribonucleotides.
[1283] Nanoparticle: As used herein, "nanoparticle" refers to a
particle having any one structural feature on a scale of less than
about 1000 nm that exhibits novel properties as compared to a bulk
sample of the same material. Routinely, nanoparticles have any one
structural feature on a scale of less than about 500 nm, less than
about 200 nm, or about 100 nm. Also routinely, nanoparticles have
any one structural feature on a scale of from about 50 nm to about
500 nm, from about 50 nm to about 200 nm or from about 70 to about
120 mn. In exemplary embodiments, a nanoparticle is a particle
having one or more dimensions of the order of about 1-1000 nm. In
other exemplary embodiments, a nanoparticle is a particle having
one or more dimensions of the order of about 10-500 nm. In other
exemplary embodiments, a nanoparticle is a particle having one or
more dimensions of the order of about 50-200 nm. A spherical
nanoparticle would have a diameter, for example, of between about
50-100 or 70-120 nanometers. A nanoparticle most often behaves as a
unit in terms of its transport and properties. it is noted that
novel properties that differentiate nanoparticles from the
corresponding bulk material typically develop at a size scale of
under 1000 nm, or at a size of about 100 nm, but nanoparticles can
be of a larger size, for example, for particles that are oblong,
tubular, and the like. Although the size of most molecules would
fit into the above outline, individual molecules are usually not
referred to as nanoparticles.
[1284] Nucleic acid: As used herein, the term "nucleic acid" is
used in its broadest sense and encompasses any compound and/or
substance that includes a polymer of nucleotides. These polymers
are often referred to as polynucleotides. Exemplary nucleic acids
or polynucleotides of the disclosure include, but are not limited
to, ribonucleic acids (RNAs), deoxyribonucleic acids (DNAs),
DNA-RNA hybrids, RNAi-inducing agents, RNAi agents, siRNAs, shRNAs,
miRNAs, antisense RNAs, ribozymes, catalytic DNA, RNAs that induce
triple helix formation, threose nucleic acids (TNAs), glycol
nucleic acids (GNAs), peptide nucleic acids (PNAs), locked nucleic
acids (LNAs, including LNA having a .beta.-D-ribo configuration,
a-LNA having an a-L-ribo configuration (a diastereomer of LNA),
2'-amino-LNA having a 2'-amino functionalization, and
2'-amino-a-LNA having a 2'-amino functionalization) or hybrids
thereof.
[1285] Nucleic Acid Structure: As used herein, the term "nucleic
acid structure" (used interchangeably with "polynucleotide
structure") refers to the arrangement or organization of atoms,
chemical constituents, elements, motifs, and/or sequence of linked
nucleotides, or derivatives or analogs thereof, that comprise a
nucleic acid (e.g., an mRNA). The term also refers to the
two-dimensional or three-dimensional state of a nucleic acid.
Accordingly, the term "RNA structure" refers to the arrangement or
organization of atoms, chemical constituents, elements, motifs,
and/or sequence of linked nucleotides, or derivatives or analogs
thereof, comprising an RNA molecule (e.g., an mRNA) and/or refers
to a two-dimensional and/or three dimensional state of an RNA
molecule. Nucleic acid structure can be further demarcated into
four organizational categories referred to herein as "molecular
structure", "primary structure", "secondary structure", and
"tertiary structure" based on increasing organizational
complexity.
[1286] Nucleobase: As used herein, the term "nucleobase"
(alternatively "nucleotide base" or "nitrogenous base") refers to a
purine or pyrimidine heterocyclic compound found in nucleic acids,
including any derivatives or analogs of the naturally occurring
purines and pyrimidines that confer improved properties (e.g.,
binding affinity, nuclease resistance, chemical stability) to a
nucleic acid or a portion or segment thereof. Adenine, cytosine,
guanine, thymine, and uracil are the nucleobases predominately
found in natural nucleic acids. Other natural, non-natural, and/or
synthetic nucleobases, as known in the art and/or described herein,
can be incorporated into nucleic acids.
[1287] Nucleoside/Nucleotide: As used herein, the term "nucleoside"
refers to a compound containing a sugar molecule (e.g., a ribose in
RNA or a deoxyribose in DNA), or derivative or analog thereof,
covalently linked to a nucleobase (e.g., a purine or pyrimidine),
or a derivative or analog thereof (also referred to herein as
"nucleobase"), but lacking an internucleoside linking group (e.g.,
a phosphate group). As used herein, the term "nucleotide" refers to
a nucleoside covalently bonded to an internucleoside linking group
(e.g., a phosphate group), or any derivative, analog, or
modification thereof that confers improved chemical and/or
functional properties (e.g., binding affinity, nuclease resistance,
chemical stability) to a nucleic acid or a portion or segment
thereof.
[1288] Open Reading Frame: As used herein, the term "open reading
frame", abbreviated as "ORF", refers to a segment or region of an
mRNA molecule that encodes a polypeptide. The ORF comprises a
continuous stretch of non-overlapping, in-frame codons, beginning
with the initiation codon and ending with a stop codon, and is
translated by the ribosome.
[1289] Patient: As used herein, "patient" refers to a subject who
may seek or be in need of treatment, requires treatment, is
receiving treatment, will receive treatment, or a subject who is
under care by a trained professional for a particular disease or
condition. In particular embodiments, a patient is a human patient.
In some embodiments, a patient is a patient suffering from cancer
(e.g., liver cancer or colorectal cancer).
[1290] Pharmaceutically acceptable: The phrase "pharmaceutically
acceptable" is employed herein to refer to those compounds,
materials, compositions, and/or dosage forms which are, within the
scope of sound medical judgment, suitable for use in contact with
the tissues of human beings and animals without excessive toxicity,
irritation, allergic response, or other problem or complication,
commensurate with a reasonable benefit/risk ratio
[1291] Pharmaceutically acceptable excipient: The phrase
"pharmaceutically acceptable excipient," as used herein, refers any
ingredient other than the compounds described herein (for example,
a vehicle capable of suspending or dissolving the active compound)
and having the properties of being substantially nontoxic and
non-inflammatory in a patient. Excipients may include, for example:
antiadherents, antioxidants, binders, coatings, compression aids,
disintegrants, dyes (colors), emollients, emulsifiers, fillers
(diluents), film formers or coatings, flavors, fragrances, glidants
(flow enhancers), lubricants, preservatives, printing inks,
sorbents, suspensing or dispersing agents, sweeteners, and waters
of hydration. Exemplary excipients include, but are not limited to:
butylated hydroxytoluene (BHT), calcium carbonate, calcium
phosphate (dibasic), calcium stearate, croscarmellose, crosslinked
polyvinyl pyrrolidone, citric acid, crospovidone, cysteine,
ethylcellulose, gelatin, hydroxypropyl cellulose, hydroxypropyl
methylcellulose, lactose, magnesium stearate, maltitol, mannitol,
methionine, methylcellulose, methyl paraben, microcrystalline
cellulose, polyethylene glycol, polyvinyl pyrrolidone, povidone,
pregelatinized starch, propyl paraben, retinyl palmitate, shellac,
silicon dioxide, sodium carboxymethyl cellulose, sodium citrate,
sodium starch glycolate, sorbitol, starch (corn), stearic acid,
sucrose, talc, titanium dioxide, vitamin A, vitamin E, vitamin C,
and xylitol.
[1292] Pharmaceutically acceptable salts: As used herein,
"pharmaceutically acceptable salts" refers to derivatives of the
disclosed compounds wherein the parent compound is modified by
converting an existing acid or base moiety to its salt form (e.g.,
by reacting the free base group with a suitable organic acid).
Examples of pharmaceutically acceptable salts include, but are not
limited to, mineral or organic acid salts of basic residues such as
amines; alkali or organic salts of acidic residues such as
carboxylic acids; and the like. Representative acid addition salts
include acetate, acetic acid, adipate, alginate, ascorbate,
aspartate, benzenesulfonate, benzene sulfonic acid, benzoate,
bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate,
cyclopentanepropionate, digluconate, dodecylsulfate,
ethanesulfonate, fumarate, glucoheptonate, glycerophosphate,
hemisulfate, heptonate, hexanoate, hydrobromide, hydrochloride,
hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate,
laurate, lauryl sulfate, malate, maleate, malonate,
methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate,
oleate, oxalate, palmitate, pamoate, pectinate, persulfate,
3-phenylpropionate, phosphate, picrate, pivalate, propionate,
stearate, succinate, sulfate, tartrate, thiocyanate,
toluenesulfonate, undecanoate, valerate salts, and the like.
Representative alkali or alkaline earth metal salts include sodium,
lithium, potassium, calcium, magnesium, and the like, as well as
nontoxic ammonium, quaternary ammonium, and amine cations,
including, but not limited to ammonium, tetramethylammonium,
tetraethylammonium, methylamine, dimethylamine, trimethylamine,
triethylamine, ethylamine, and the like. The pharmaceutically
acceptable salts of the present disclosure include the conventional
non-toxic salts of the parent compound formed, for example, from
non-toxic inorganic or organic acids. The pharmaceutically
acceptable salts of the present disclosure can be synthesized from
the parent compound which contains a basic or acidic moiety by
conventional chemical methods. Generally, such salts can be
prepared by reacting the free acid or base forms of these compounds
with a stoichiometric amount of the appropriate base or acid in
water or in an organic solvent, or in a mixture of the two;
generally, nonaqueous media like ether, ethyl acetate, ethanol,
isopropanol, or acetonitrile are preferred. Lists of suitable salts
are found in Remington's Pharmaceutical Sciences, 17th ed., Mack
Publishing Company, Easton, Pa., 1985, p. 1418, Pharmaceutical
Salts: Properties, Selection, and Use, P. H. Stahl and C. G.
Wermuth (eds.), Wiley-VCH, 2008, and Berge et al., Journal of
Pharmaceutical Science, 66, 1-19 (1977), each of which is
incorporated herein by reference in its entirety.
[1293] Polypeptide: As used herein, the term "polypeptide" or
"polypeptide of interest" refers to a polymer of amino acid
residues typically joined by peptide bonds that can be produced
naturally (e.g., isolated or purified) or synthetically.
[1294] Pre-Initiation Complex (PIC): As used herein, the term
"pre-initiation complex" (alternatively "43S pre-initiation
complex"; abbreviated as "PIC") refers to a ribonucleoprotein
complex comprising a 40S ribosomal subunit, eukaryotic initiation
factors (eIF1, eIF1A, eIF3, eIF5), and the
eIF2-GTP-Met-tRNA.sub.i.sup.Met ternary complex, that is
intrinsically capable of attachment to the 5' cap of an mRNA
molecule and, after attachment, of performing ribosome scanning of
the 5' UTR.
[1295] RNA element: As used herein, the term "RNA element" refers
to a portion, fragment, or segment of an RNA molecule that provides
a biological function and/or has biological activity (e.g.,
translational regulatory activity). Modification of a
polynucleotide by the incorporation of one or more RNA elements,
such as those described herein, provides one or more desirable
functional properties to the modified polynucleotide. RNA elements,
as described herein, can be naturally-occurring, non-naturally
occurring, synthetic, engineered, or any combination thereof. For
example, naturally-occurring RNA elements that provide a regulatory
activity include elements found throughout the transcriptomes of
viruses, prokaryotic and eukaryotic organisms (e.g., humans). RNA
elements in particular eukaryotic mRNAs and translated viral RNAs
have been shown to be involved in mediating many functions in
cells. Exemplary natural RNA elements include, but are not limited
to, translation initiation elements (e.g., internal ribosome entry
site (IRES), see Kieft et al., (2001) RNA 7(2):194-206),
translation enhancer elements (e.g., the APP mRNA translation
enhancer element, see Rogers et al., (1999) J Biol Chem
274(10):6421-6431), mRNA stability elements (e.g., AU-rich elements
(AREs), see Garneau et al., (2007) Nat Rev Mol Cell Biol
8(2):113-126), translational repression element (see e.g., Blumer
et al., (2002) Mech Dev 110(1-2):97-112), protein-binding RNA
elements (e.g., iron-responsive element, see Selezneva et al.,
(2013) J Mol Biol 425(18):3301-3310), cytoplasmic polyadenylation
elements (Villalba et al., (2011) Curr Opin Genet Dev
21(4):452-457), and catalytic RNA elements (e.g., ribozymes, see
Scott et al., (2009) Biochim Biophys Acta 1789(9-10):634-641).
[1296] Residence time: As used herein, the term "residence time"
refers to the time of occupancy of a pre-initiation complex (PIC)
or a ribosome at a discrete position or location along an mRNA
molecule.
[1297] Substantially: As used herein, the term "substantially"
refers to the qualitative condition of exhibiting total or
near-total extent or degree of a characteristic or property of
interest. One of ordinary skill in the biological arts will
understand that biological and chemical phenomena rarely, if ever,
go to completion and/or proceed to completeness or achieve or avoid
an absolute result. The term "substantially" is therefore used
herein to capture the potential lack of completeness inherent in
many biological and chemical phenomena.
[1298] Suffering from: An individual who is "suffering from" a
disease, disorder, and/or condition has been diagnosed with or
displays one or more symptoms of a disease, disorder, and/or
condition.
[1299] Targeting moiety: As used herein, a "targeting moiety" is a
compound or agent that may target a nanoparticle to a particular
cell, tissue, and/or organ type.
[1300] Therapeutic Agent: The term "therapeutic agent" refers to
any agent that, when administered to a subject, has a therapeutic,
diagnostic, and/or prophylactic effect and/or elicits a desired
biological and/or pharmacological effect.
[1301] Transfection: As used herein, the term "transfection" refers
to methods to introduce a species (e.g., a polynucleotide, such as
a mRNA) into a cell.
[1302] Translational Regulatory Activity: As used herein, the term
"translational regulatory activity" (used interchangeably with
"translational regulatory function") refers to a biological
function, mechanism, or process that modulates (e.g., regulates,
influences, controls, varies) the activity of the translational
apparatus, including the activity of the PIC and/or ribosome. In
some aspects, the desired translation regulatory activity promotes
and/or enhances the translational fidelity of mRNA translation. In
some aspects, the desired translational regulatory activity reduces
and/or inhibits leaky scanning. Subject: As used herein, the term
"subject" refers to any organism to which a composition in
accordance with the disclosure may be administered, e.g., for
experimental, diagnostic, prophylactic, and/or therapeutic
purposes. Typical subjects include animals (e.g., mammals such as
mice, rats, rabbits, non-human primates, and humans) and/or plants.
In some embodiments, a subject may be a patient.
[1303] Treating: As used herein, the term "treating" refers to
partially or completely alleviating, ameliorating, improving,
relieving, delaying onset of, inhibiting progression of, reducing
severity of, and/or reducing incidence of one or more symptoms or
features of a particular infection, disease, disorder, and/or
condition. For example, "treating" cancer may refer to inhibiting
survival, growth, and/or spread of a tumor. Treatment may be
administered to a subject who does not exhibit signs of a disease,
disorder, and/or condition and/or to a subject who exhibits only
early signs of a disease, disorder, and/or condition for the
purpose of decreasing the risk of developing pathology associated
with the disease, disorder, and/or condition.
[1304] Preventing: As used herein, the term "preventing" refers to
partially or completely inhibiting the onset of one or more
symptoms or features of a particular infection, disease, disorder,
and/or condition.
[1305] Tumor: As used herein, a "tumor" is an abnormal growth of
tissue, whether benign or malignant.
[1306] Unmodified: As used herein, "unmodified" refers to any
substance, compound or molecule prior to being changed in any way.
Unmodified may, but does not always, refer to the wild type or
native form of a biomolecule. Molecules may undergo a series of
modifications whereby each modified molecule may serve as the
"unmodified" starting molecule for a subsequent modification.
[1307] Uridine Content: The terms "uridine content" or "uracil
content" are interchangeable and refer to the amount of uracil or
uridine present in a certain nucleic acid sequence. Uridine content
or uracil content can be expressed as an absolute value (total
number of uridine or uracil in the sequence) or relative (uridine
or uracil percentage respect to the total number of nucleobases in
the nucleic acid sequence).
[1308] Uridine-Modified Sequence: The terms "uridine-modified
sequence" refers to a sequence optimized nucleic acid (e.g., a
synthetic mRNA sequence) with a different overall or local uridine
content (higher or lower uridine content) or with different uridine
patterns (e.g., gradient distribution or clustering) with respect
to the uridine content and/or uridine patterns of a candidate
nucleic acid sequence. In the content of the present disclosure,
the terms "uridine-modified sequence" and "uracil-modified
sequence" are considered equivalent and interchangeable.
[1309] A "high uridine codon" is defined as a codon comprising two
or three uridines, a "low uridine codon" is defined as a codon
comprising one uridine, and a "no uridine codon" is a codon without
any uridines. In some embodiments, a uridine-modified sequence
comprises substitutions of high uridine codons with low uridine
codons, substitutions of high uridine codons with no uridine
codons, substitutions of low uridine codons with high uridine
codons, substitutions of low uridine codons with no uridine codons,
substitution of no uridine codons with low uridine codons,
substitutions of no uridine codons with high uridine codons, and
combinations thereof. In some embodiments, a high uridine codon can
be replaced with another high uridine codon. In some embodiments, a
low uridine codon can be replaced with another low uridine codon.
In some embodiments, a no uridine codon can be replaced with
another no uridine codon. A uridine-modified sequence can be
uridine enriched or uridine rarefied.
[1310] Uridine Enriched: As used herein, the terms "uridine
enriched" and grammatical variants refer to the increase in uridine
content (expressed in absolute value or as a percentage value) in a
sequence optimized nucleic acid (e.g., a synthetic mRNA sequence)
with respect to the uridine content of the corresponding candidate
nucleic acid sequence. Uridine enrichment can be implemented by
substituting codons in the candidate nucleic acid sequence with
synonymous codons containing less uridine nucleobases. Uridine
enrichment can be global (i.e., relative to the entire length of a
candidate nucleic acid sequence) or local (i.e., relative to a
subsequence or region of a candidate nucleic acid sequence).
[1311] Uridine Rarefied: As used herein, the terms "uridine
rarefied" and grammatical variants refer to a decrease in uridine
content (expressed in absolute value or as a percentage value) in
an sequence optimized nucleic acid (e.g., a synthetic mRNA
sequence) with respect to the uridine content of the corresponding
candidate nucleic acid sequence. Uridine rarefication can be
implemented by substituting codons in the candidate nucleic acid
sequence with synonymous codons containing less uridine
nucleobases. Uridine rarefication can be global (i.e., relative to
the entire length of a candidate nucleic acid sequence) or local
(i.e., relative to a subsequence or region of a candidate nucleic
acid sequence).
EQUIVALENTS AND SCOPE
[1312] Those skilled in the art will recognize, or be able to
ascertain using no more than routine experimentation, many
equivalents to the specific embodiments in accordance with the
disclosure described herein. The scope of the present disclosure is
not intended to be limited to the Description below, but rather is
as set forth in the appended claims.
[1313] In the claims, articles such as "a," "an," and "the" may
mean one or more than one unless indicated to the contrary or
otherwise evident from the context. Claims or descriptions that
include "or" between one or more members of a group are considered
satisfied if one, more than one, or all of the group members are
present in, employed in, or otherwise relevant to a given product
or process unless indicated to the contrary or otherwise evident
from the context. The disclosure includes embodiments in which
exactly one member of the group is present in, employed in, or
otherwise relevant to a given product or process. The disclosure
includes embodiments in which more than one, or all of the group
members are present in, employed in, or otherwise relevant to a
given product or process.
[1314] It is also noted that the terms "comprising", "comprise",
"comprises", "having", "have" and "has" are intended to be open and
permit but does not require the inclusion of additional elements or
steps. When these terms are used herein, the term "consisting of"
is thus also encompassed and disclosed.
[1315] Where ranges are given, endpoints are included. Furthermore,
it is to be understood that unless otherwise indicated or otherwise
evident from the context and understanding of one of ordinary skill
in the art, values that are expressed as ranges can assume any
specific value or subrange within the stated ranges in different
embodiments of the disclosure, to the tenth of the unit of the
lower limit of the range, unless the context clearly dictates
otherwise.
[1316] All cited sources, for example, references, publications,
databases, database entries, and art cited herein, are incorporated
into this application by reference, even if not expressly stated in
the citation. In case of conflicting statements of a cited source
and the instant application, the statement in the instant
application shall control.
EXAMPLES
[1317] The disclosure will be more fully understood by reference to
the following examples. They should not, however, be construed as
limiting the scope of the disclosure. It is understood that the
examples and embodiments described herein are for illustrative
purposes only and that various modifications or changes in light
thereof will be suggested to persons skilled in the art and are to
be included within the spirit and purview of this application and
scope of the appended claims.
Example 1: STING Immune Potentiator mRNA Constructs
[1318] In this example, a series of mmRNA constructs that encoded
constitutively activated forms of human STING were made and tested
for their ability to stimulate interferon-.beta. (IFN-.beta.)
production. The human STING protein encoded by the constructs was
constitutively activated through introduction of one or more point
mutations. The following single or combination point mutations were
tested: (i) V155M; (ii) R284T; (iii) V147L/N154S/V155M; and (iv)
R284M/V147L/N154S/V155M. These constructs typically also encoded an
epitope tag at either the N-terminus or C-terminus to facilitate
detection. Different epitope tags were tested (FLAG, Myc, CT, HA,
V5). Additionally, all constructs contained a Cap 1 5' Cap
(7mG(5')ppp(5')NlmpNp), 5' UTR, 3' UTR, a poly A tail of 100
nucleotides and were fully modified with 1-methyl-pseudouridine
(m1.psi.). The ORF amino acid sequences of representative
constitutively active human STING constructs without any epitope
tag are shown in SEQ ID NOs: 1-10. An exemplary 5' UTR for use in
the constructs is shown in SEQ ID NO: 21. An exemplary 3' UTR for
use in the constructs is shown in SEQ ID NO: 22. An exemplary 3'
UTR comprising miR-122 and miR-142.3p binding sites for use in the
constructs is shown in SEQ ID NO: 23.
[1319] To determine whether constitutively active STING constructs
could stimulate IFN-.beta. production, the constructs were
transfected into human TF1a cells. Wild-type (non-constitutively
active) human and mouse STING constructs were used as negative
controls. Twenty-five thousand cells/well were plated in 96 well
plates and the mmRNA constructs (250 ng) were transfected into them
using Lipofectamine 2000. After 24 and 48 hours, supernatants were
harvested and IFN-.beta. levels were determined by standard ELISA.
The results are shown in FIG. 1, which demonstrate that the
constitutively active STING constructs stimulated IFN-.beta.
production, as compared to the wild-type (non-constitutively
active) human and mouse STING controls. While all four mutant STING
constructs stimulated IFN-.beta. production, the V155M mutant and
the R284T mutant showed the highest activity. These results
demonstrate the ability of constitutively active STING mRNA
constructs to enhance immune responses through stimulation of
IFN-.beta. production.
[1320] In a second set of experiments, a reporter gene whose
transcription was driven by an interferon-sensitive response
element (ISRE) was used to test the ability of a panel of
constitutively active STING mRNA constructs to activate the ISRE in
a STING KO reporter mouse line. The results are shown in FIG. 2,
which demonstrates that the constitutively active STING constructs
stimulated reporter gene expression, thereby indicating that the
constructs were capable of activating the interferon-sensitive
response element (ISRE).
Example 2: IRF3 and IRF7 Immune Potentiator mRNA Constructs
[1321] In this example, a series of mmRNA constructs that encoded
constitutively activated forms of IRF3 or IRF7 were made and tested
for their ability to activate an interferon-sensitive response
element (ISRE). The ORF amino acid sequences of representative
constitutively active mouse and human IRF3 constructs, comprising a
S396D point mutation, without any epitope tag are shown in SEQ ID
NOs: 11-12. The ORF amino acid sequence of a wild-type human IRF7
construct without any epitope tag is shown in SEQ ID NO: 13. The
ORF amino acid sequences of representative constitutively active
human IRF7 constructs without any epitope tag are shown in SEQ ID
NOs: 14-18. The ORF amino acid sequences of representative
truncated human IRF7 constructs (inactive "null" mutations) without
any epitope tag are shown in SEQ ID NOs: 19-20. These constructs
typically also encoded an epitope tag at either the N-terminus or
C-terminus to facilitate detection. Different epitope tags were
tested (FLAG, Myc, CT, HA, V5). Additionally, all constructs
contained a Cap 1 5' Cap (7mG(5')ppp(5')NlmpNp), 5' UTR, 3' UTR, a
poly A tail of 100 nucleotides and were fully modified with
1-methyl-pseudouridine (m1.psi.). An exemplary 5' UTR for use in
the constructs is shown in SEQ ID NO: 21. An exemplary 3' UTR for
use in the constructs is shown in SEQ ID NO: 22. An exemplary 3'
UTR comprising miR-122 and miR-142.3p binding sites for use in the
constructs is shown in SEQ ID NO: 23.
[1322] A reporter gene whose transcription was driven by an
interferon-sensitive response element (ISRE) was used to test the
ability of constitutively active IRF3 and IRF7 mRNA constructs to
activate the ISRE. The results are shown in FIGS. 3A-3B, which
demonstrate that the constitutively active IRF3 constructs (FIG.
3A) and the constitutively active IRF7 constructs (FIG. 3B)
stimulated reporter gene expression, thereby indicating that the
constructs were capable of activating the interferon-sensitive
response element (ISRE).
Example 3: IKK.beta., cFLIP and RIPK1 Immune Potentiator mRNA
Constructs
[1323] In this example, a luciferase reporter gene whose
transcription was driven by the NF.kappa.B signaling pathway was
used to test the ability of constitutively active IKK, cFLIP and
RIPK1 mRNA constructs to activate NF.kappa.B signaling.
[1324] Constitutively active IKK.beta. construct comprised the
following two point mutations: S177E/S181E. Constitutively active
IKK.alpha. or IKK.beta. constructs comprised PEST mutations. The
ORF amino acid sequences of constitutively active IKK.beta.
constructs without any epitope tag are shown in SEQ ID NOs: 87-90.
The ORF amino acid sequences of constitutively active IKK.alpha. or
IKK.beta. constructs comprising a PEST mutation, without any
epitope tag, are shown in SEQ ID NOs: 91-98. Constitutively active
cFLIP constructs comprised cFLIP-L, cFLIP-S (aa 1-227), cFLIP p22
(aa 1-198), cFLIP p43 (aa 1-376) or cFLIP p12 (aa 377-480). The ORF
amino acid sequences of the cFLIP constructs without any epitope
tag are shown in SEQ ID NOs: 82-86. Structures of various
constitutively active RIPK1 constructs are described further in,
for example, Yatim, N. et al. (2015) Science 350:328-334 or Orozco,
S. et al. (2014) Cell Death Differ. 21:1511-1521. The ORF amino
acid sequences of the constitutively active RIPK1 constructs
without any epitope tag are shown in SEQ ID NOs: 99-104. In
addition to the open reading frame, all constructs contained a Cap
1 5' Cap (7mG(5')ppp(5')NlmpNp), 5' UTR, 3' UTR, a poly A tail of
100 nucleotides and were fully modified with 1-methyl-pseudouridine
(m1.psi.). An exemplary 5' UTR for use in the constructs is shown
in SEQ ID NO: 21. An exemplary 3' UTR for use in the constructs is
shown in SEQ ID NO: 22. An exemplary 3' UTR comprising miR-122 and
miR-142.3p binding sites for use in the constructs is shown in SEQ
ID NO: 23.
[1325] In a first series of experiments, either the cFLIP or
IKK.beta. constructs (12.5 ng RNA) were transfected into B16F10,
MC38 or HEK293 cells, together with the NF.kappa.B-luc reporter
gene and the Dual Luc Assay was performed 24 hours
post-transfection as an indicator of activation of NF.kappa.B
signaling. The results are shown in FIG. 4, which demonstrates that
the constitutively active cFLIP and IKK.beta. constructs stimulated
reporter gene expression, thereby indicating that the constructs
were capable of activating the NF.kappa.B signaling pathway. In a
second series of experiments, the RIPK1 constructs were transfected
into B16F10 cells, together with the NF.kappa.B-luc reporter gene
and the Dual Luc Assay was performed 24 hours post-transfection as
an indicator of activation of NF.kappa.B signaling. The results are
shown in FIG. 5, which demonstrates that the constitutively active
RIPK1 constructs stimulated reporter gene expression, thereby
indicating that the constructs were capable of activating the
NF.kappa.B signaling pathway.
Example 4: DIABLO Immune Potentiator mRNA Constructs
[1326] In this example, a series of mmRNA constructs that encoded
DIABLO were made and tested for their ability to induce cytokine
production. These constructs typically also encoded an epitope tag
at either the N-terminus or C-terminus to facilitate detection.
Different epitope tags were tested (FLAG, Myc, CT, HA, V5).
Additionally, all constructs contained a Cap 1 5' Cap
(7mG(5')ppp(5')NlmpNp), 5' UTR, 3' UTR, a poly A tail of 100
nucleotides and were fully modified with 1-methyl-pseudouridine
(m1.psi.). The ORF amino acid sequences of the DIABLO constructs
without any epitope tag are shown in SEQ ID NOs: 106-113. An
exemplary 5' UTR for use in the constructs is shown in SEQ ID NO:
21. An exemplary 3' UTR for use in the constructs is shown in SEQ
ID NO: 22. An exemplary 3' UTR comprising miR-122 and miR-142.3p
binding sites for use in the constructs is shown in SEQ ID NO:
23.
[1327] To determine wither the DIABLO constructs could induce
cytokine production, the constructs were transfected into SKOV3
cells. Ten thousand cells/well were plated in 96 well plates and
the mmRNA constructs were transfected into them using Lipofectamine
2000. Stimulation of cytokine production by the DIABLO mmRNA
constructs in the SKOV3 cells was measured. The results, shown in
FIG. 6 for TNF-.alpha. and in FIG. 7 for interleukin 6 (IL-6),
demonstrate that a number of the DIABLO mmRNA constructs stimulate
production of cytokines by the SKOV3 cells.
Example 5: Immune Potentiator mRNAs Enhance MC38 Cancer Vaccine
Responses
[1328] In this example, the potency and durability of responses to
an MC38 mRNA-based cancer vaccine used in combination with STING,
IRF3 or IRF7 immune potentiator mRNA constructs were examined. The
MC38 murine tumor model has been used to identify immunogenic
mutant peptides containing neoepitopes capable of stimulating
anti-tumor T cell responses (see e.g., Yadav, M. et al. (2014)
Nature 515:572-576). Thus, a cancer vaccination approach that leads
to a robust and durable immune response against tumor neoepitopes
is highly desirable.
[1329] The MC38 vaccine used in this example was an mRNA construct
encoding an ADR concatemer of three 25mer mutant peptides
containing tumor neoepitopes derived from Adpgk, Dpagt1, and Reps1
(this vaccine is also referred to herein as ADRvax). The mRNA
construct encodes the open reading frame shown in SEQ ID NO: 120,
which also includes an N-terminal His-tag for easy detection. Mice
were immunized intramuscularly with the ADRvax mRNA vaccine (at a
dose of 0.25 mg/kg) on days 0 and 14, combination with either a
control mRNA construct (NTFIX), or a STING, IRF3 or IRF7 immune
potentiator mRNA construct (at a dose of 0.25 mg/kg). The
constitutively active STING immune potentiator contained a V155M
mutation (mouse version corresponding to SEQ ID NO: 1). The
constitutively active IRF3 immune potentiator contained a S396D
mutation (corresponding to SEQ ID NO: 12). The constitutively
active IRF7 immune potentiator contained an internal deletion and
six point mutations (mouse version corresponding to SEQ ID NO: 18).
The MC38 vaccine construct and the genetic adjuvant construct were
coformulated in MC3 lipid nanoparticles.
[1330] At day 21 and 35, CD8.sup.+ spleen cells from mice in each
test group were restimulated ex vivo for 4 hours at 37 degrees C.
in the presence of GolgiPlug.TM. (containing Brefeldin A; BD
Biosciences) with either wild-type or mutant MC38 ADR peptides (1
.mu.g/ml per peptide) and CD8 vaccine responses were assessed by
intracellular staining (ICS) for IFN-.gamma.. Representative ICS
results for MC38 ADR-specific responses by day 21 and day 35
CD8.sup.+spleen cells for IFN-.gamma. are shown in FIG. 8A (day 21)
and FIG. 8B (day 31). Similar results were observed for ICS for
TNF-.alpha. and for CD8.sup.+PBMCs. The results demonstrate that
CD8 vaccine responses were greatly enhanced by the STING immune
potentiator construct, and moderately enhanced by the IRF3 and IRF7
immune potentiator constructs. An initial improvement in the
antigen-specific CD8 response for mice treated with immune
potentiators was observed at day 21 (approximately 5% versus 1% for
STING treatment vs. control), which continued to improve by day 35
(up to 15% for STING treatment compared to control), thereby
demonstrating the durability of the response.
[1331] The percentage of CD8b.sup.+ cells among the live CD45.sup.+
cells was also examined. The results for day 35 spleen cells and
PBMCs are shown in FIG. 9A, which demonstrates that the genetic
adjuvants expand the total CD8b.sup.+ population. As demonstrated
in FIG. 9B, the majority of the CD8.sup.+ spleen cells and PBMCs
were found to have an "effector memory" CD62L.sup.lo phenotype.
Additional staining experiments demonstrated that the STING and
IRF7 immune potentiator construct slightly reduced the % of total
Foxp3.sup.+ Treg CD4 Tcells (data not shown). Additional staining
experiments demonstrated that the immune potentiators did not
change the % of CD138.sup.+ plasmablasts (data not shown).
Example 6: KRAS-STING mRNA Constructs
[1332] A comprehensive survey of Ras mutations in various cancer
types has been reported (Prior, I. A. et al. (2012) Cancer Res.
72:2457-2467). This survey demonstrated that the top four most
frequent mutations of KRAS in colorectal cancer, pancreatic cancer
and non-small cell lung cancer are G12D, G12V, G13D and G12C. A
series of mutant KRAS mRNA constructs were prepared that encoded
one or more KRAS peptides containing one of these four mutations,
for use as KRAS anti-tumor mRNA-based vaccines. Furthermore, to
examine the effect of mRNA-based immune potentiators on KRAS
vaccine responses, a series of mRNA constructs were prepared that
encoded one or more mutant KRAS peptides linked at the N-terminus
or the C-terminus to sequence encoding STING as an immune
potentiator. Thus, in these KRAS-STING mRNA constructs, the vaccine
antigen(s) and the immune potentiator are encoded by the same mRNA
construct.
[1333] Mutant KRAS peptide mRNA constructs were prepared that
encoded: a 15mer peptide having the G12D, G12V or the G13D mutation
(the amino acid sequence of which is shown in SEQ ID NOs: 36-38,
respectively); a 25mer peptide having the G12D, G12V or the G13D
mutation (SEQ ID NOs: 39-41, respectively); three copies of the
15mer peptide having the G12D, G12V or the G13D mutation (SEQ ID
NOs: 42-44, respectively); or three copies of the 25mer peptide
having the G12D, G12V or the G13D mutation (SEQ ID NOs: 45-47,
respectively). Additional constructs encoded one copy or three
copies of a 25mer peptide having a G12C mutation (SEQ ID NOs:
72-73, respectively) or a wild-type 25mer peptide (SEQ ID NO: 74).
In certain embodiments, a G12C KRAS mutation may be used in
combination with a G12D, G12V or G13D mutation, or combinations
thereof. Nucleotide sequences encoding these mutant KRAS peptides
are provided in Example 7.
[1334] Mutant KRAS peptide-STING mRNA constructs, having the STING
coding sequence at the N-terminus, were prepared that encoded: a
15mer peptide having the G12D, G12V or the G13D mutation (the amino
acid sequence of which is shown in SEQ ID NOs: 48-50,
respectively); a 25mer peptide having the G12D, G12V or the G13D
mutation (SEQ ID NOs: 51-53, respectively); three copies of the
15mer peptide having the G12D, G12V or the G13D mutation (SEQ ID
NOs: 54-56, respectively); or three copies of the 25mer peptide
having the G12D, G12V or the G13D mutation (SEQ ID NOs: 57-59,
respectively). In certain embodiments, a G12C KRAS mutation may be
used in combination with a G12D, G12V or G13D mutation, or
combinations thereof. Representative nucleotide sequences encoding
these KRAS peptide-STING constructs having the STING coding
sequence at the N-terminus are shown in SEQ ID NOs: 160 and
162.
[1335] Mutant KRAS peptide-STING mRNA constructs, having the STING
coding sequence at the C-terminus, were prepared that encoded: a
15mer peptide having the G12D, G12V or the G13D mutation (the amino
acid sequence of which is shown in SEQ ID NOs: 60-62,
respectively); a 25mer peptide having the G12D, G12V or the G13D
mutation (SEQ ID NOs: 63-65, respectively); three copies of the
15mer peptide having the G12D, G12V or the G13D mutation (SEQ ID
NOs: 66-68, respectively); or three copies of the 25mer peptide
having the G12D, G12V or the G13D mutation (SEQ ID NOs: 69-70,
respectively). In certain embodiments, a G12C KRAS mutation may be
used in combination with a G12D, G12V or G13D mutation, or
combinations thereof. Representative nucleotide sequences encoding
these KRAS peptide-STING constructs having the STING coding
sequence at the C-terminus are shown in SEQ ID NOs: 161 and
163.
[1336] These constructs can also encoded an epitope tag at either
the N-terminus or C-terminus to facilitate detection. Different
epitope tags can be used (e.g., FLAG, Myc, CT, HA, V5).
Additionally, all constructs contained a Cap 1 5' Cap
(7mG(5')ppp(5')NlmpNp), 5' UTR, 3' UTR, a poly A tail and were
fully modified with 1-methyl-pseudouridine (m1.psi.). An exemplary
5' UTR for use in the constructs is shown in SEQ ID NO: 21. An
exemplary 3' UTR for use in the constructs is shown in SEQ ID NO:
22. An exemplary 3' UTR comprising miR-122 and miR-142.3p binding
sites for use in the constructs is shown in SEQ ID NO: 23.
[1337] To test vaccine responses in mice treated either with a KRAS
mutant peptide(s) mRNA vaccine construct or with a KRAS mutant
peptide(s) vaccine-STING immune potentiator mRNA construct, mice
(HLA-A*11:01 or HLA-A*2:01; Taconic) are immunized with a KRAS
mutant peptide vaccine mRNA construct (e.g., encoding one of SEQ ID
NOs: 36-47) or with a KRAS mutant peptide vaccine-STING immune
potentiator mRNA construct (e.g., encoding one of SEQ ID NOs:
48-71). Mice are immunized intramuscularly on day 1 and day 15 (0.5
mg/kg) and sacrificed at day 22. To test CD8 vaccine responses,
CD8.sup.+ spleen cells and PBMCs are restimulated ex vivo for 5
hours at 37 degrees C. in the presence of GolgiPlug.TM. (containing
Brefeldin A; BD Biosciences) with either mutant KRAS peptides
(G12D, G12V or G13D) or with wild type KRAS peptide (2 .mu.g/ml per
peptide). CD8 vaccine responses can then be assessed by
intracellular staining (ICS) for IFN-.gamma. and/or TNF-.alpha..
Enhanced ICS responses for IFN-.gamma. and/or TNF-.alpha. in mice
treated with the KRAS mutant peptide vaccine-STING immune
potentiator mRNA construct, as compared to treatment with the KRAS
mutant peptide vaccine mRNA construct, indicates that the STING
immune potentiator enhances KRAS-specific CD8 vaccine
responses.
Example 7: Use of Immune Potentiator mRNA Construct in Combination
with Activating Oncogene KRAS Mutant Peptide mRNA Constructs
[1338] In this example, mutant KRAS peptide mRNA constructs are
used in combination with a separate constitutively active STING
immune potentiator mRNA construct to enhance immune responses to
the mutant KRAS peptides.
[1339] The most frequently mutated oncogene in cancer is KRAS,
which is mutated in roughly 30% of epithelial cancers, primarily
lung, colorectal and pancreatic cancers (Pylayeva-Gupta Y, et al.,
Nat Rev Cancer, Vol. 11(11): 761-774, 2011). The 4 most prevalent
KRAS mutant antigens in these three malignancies are G12D, G12V,
G13D and G12C, which constitute 80-90% of the KRAS mutations (Prior
et al. Cancer Res. 2012 May 15; 72(10): 2457-2467; Cox A D et al,
Nat Rev Drug Discov, Vol. 13(11): 828-851, 2011). KRAS mutations
occur mostly in a couple of "hotspots" and activate the oncogene.
Prior research has shown limited ability to raise T cells specific
to the oncogenic mutation. However, much of this was done in the
context of the most common HLA allele (A2, which occurs in
.about.50% of Caucasians). More recently, it has been demonstrated
that (a) specific T cells can be generated against point mutations
in the context of less common HLA alleles (A11, C8), and (b)
growing these cells ex-vivo and transferring them back to the
patient has mediated a dramatic tumor response in a patient with
lung cancer. (N Engl J Med 2016; 375:2255-2262 Dec. 8, 2016 DOI:
10.1056/NEJMoa1609279).
[1340] KRAS mutations occur in approximately 40% of colorectal
cancers. As shown in Table 5 below, in CRC (colorectal cancer),
only 3 mutations (G12V, G12D, and G13D) account for 96% of KRAS
mutations in this malignancy. Furthermore, all CRC patients get
typed for KRAS mutations as standard of care.
TABLE-US-00011 TABLE 5 COSMIC* case counts All cancers % CRC % G12S
1849 1% G12V 9213 4% 5215 29% G12C 435 2% G12D 13634 7% 8083 44%
G12A 2179 1% G12R 1244 1% G13D 5084 2% 4267 23% 18% 96% Tested
208629 18271
*http://cancer.sanger.ac.uk/cosmic/gene/analysis?In=KRAS
[1341] In another COSMIC data set, 73.68% of KRAS mutations in
colorectal cancer are accounted for by these 3 mutations (G12V,
G12D, and G13D) (Table 6).
TABLE-US-00012 TABLE 6 colon % rectal % total % 12D 635 35.04 178
33.46 813 34.68 12V 364 20.09 124 23.31 488 20.82 13D 338 18.65 88
16.54 426 18.17 73.68
[1342] Prior et al. investigated and summarized isoform-specific
point mutation specificity for HRAS, KRAS and NRAS, respectively.
Data representing total number of tumors with each point mutation
were collated from COSMIC v52 release. The most frequent mutations
for each isoform for each cancer type are reported (see Table 2 of
Prior et al.). In addition, secondary KRAS mutations have been
identified in EGFR blockade resistant patients. RAS is downstream
of EGFR and it has been found to constitute a mechanism of
resistance to EGFR blockade therapies. EGFR blockade resistant KRAS
mutant tumors can be targeted using compositions and methods
disclosed herein. In a few cases, more than one KRAS mutation was
identified in the same patient (up to four different mutations
co-occur). Diaz et al. report these secondary KRAS mutations after
acquisition of EGFR blockade (see Supplementary Table 2), and
Misale et al. reports secondary KRAS mutations after EGFR blockade
(see FIG. 3b) (Diaz et al. The molecular evolution of acquired
resistance to targeted EGFR blockade in colorectal cancers, Nature
486: 537 (2012); Misale et al. Emergence of KRAS mutations and
acquired resistance to anti-EGFR therapy in colorectal cancer,
Nature 486: 532 (2012)). This mutational spectrum appears to be at
least somewhat different than primary tumor missense mutants in
colorectal cancer. As shown in FIG. 10, NRAS is also mutated in
colorectal cancer, but at a lower frequency than KRAS, based on
analysis available in cBioPortal and Prior et al.
[1343] In addition to identification of KRAS mutations in
colorectal cancer, such mutations have been found in non-small cell
lung carcinoma and pancreatic cancer. Table 7 provides the
frequencies of four KRAS mutations in these three cancers.
TABLE-US-00013 TABLE 7 NSCLC.sup.1 (30% mutant Colorectal.sup.2
Pancreatic.sup.3 KRAS KRAS.sup.4) (45% mutant KRAS.sup.4) (95%
mutant KRAS.sup.4) Allele % Breakdown % Breakdown % Breakdown G12C
46% 8% 2% G12V 20% 22% 30% G12D 11% 36% 51% G13D 3% 19% <1%
total 80% 85% 83% .sup.1Mellema et al. Comparison of clinical
outcome after first-line platinum-based chemotherapy in different
types of KRAS mutated advanced NSCLC, Lung Cancer 90: 2 (2015)
(Table 1) .sup.2Neumann et al, Frequency and type of KRAS mutations
in routine diagnostic analysis of metastatic colorectal cancer,
Pathology Research and Practice 205 (2009) (FIG. 1) .sup.3Kirsten
L. Bryant, Joseph D. Mancias, Alec C. Kimmelman, Channing J. Der,
KRAS: feeding pancreatic cancer proliferation, In Trends in
Biochemical Sciences, 39: 2, 2014 (FIG. 2) .sup.4Adrienne D. Cox et
al., Drugging the undruggable RAS: Mission Possible?, Nature
Reviews Drug Discovery 13, 828-851 (2014) (Table 1)
[1344] In this example, animals are administered an
immunomodulatory therapeutic composition that includes an mRNA
encoding at least one activating oncogene mutation peptide, e.g.,
at least one activating KRAS mutation, alone or in combination with
an immune potentiator mRNA construct, e.g. a constitutively active
STING mRNA construct, e.g., encoding a sequence as shown in any of
SEQ ID NOs: 1-10, such as for example a mRNA construct encoding a
constitutively active human STING protein comprising a V155M
mutation, having the amino acid sequence shown in SEQ ID NO: 1 and
encoded the nucleotide sequence shown in SEQ ID NO: 139.
[1345] Exemplary KRAS mutant peptide sequences and mRNA constructs
are shown in Tables 8-10.
TABLE-US-00014 TABLE 8 KRAS mutant peptide sequences 9 AA sequence
15mer 25mer G12D VVGADGVGK MKLVVVGADGVGKSAL
MTEYKLVVVGADGVGKSALTIQLIQ (SEQ ID NO: 121) (SEQ ID NO: 36) (SEQ ID
NO: 39) G12V VVGAVGVGK MKLVVVGAVGVGKSAL MTEYKLVVVGAVGVGKSALTIQLIQ
(SEQ ID NO: 122) (SEQ ID NO: 37) (SEQ ID NO: 40) G13D VGAGDVGKS
MLVVVGAGDVGKSALT MTEYKLVVVGAGDVGKSALTIQLIQ (SEQ ID NO: 123) (SEQ ID
NO: 38) (SEQ ID NO: 41) G12C VVGACGVGK MKLVVVGACGVGKSA
MTEYKLVVVGACGVGKSALTIQLIQ (SEQ ID NO: 124) (SEQ ID NO: 125) (SEQ ID
NO: 72) WT MTEYKLVVVGAGGVGKSALTIQLIQ (SEQ ID NO: 74)
TABLE-US-00015 TABLE 9 KRAS mutant amino acid sequences KRAS MUTANT
AMINO ACID SEQUENCE KRAS(G12D)15mer MKLVVVGADGVGKSAL (SEQ ID NO:
36) KRAS(G12V)15mer MKLVVVGAVGVGKSAL (SEQ ID NO: 37)
KRAS(G13D)15mer MLVVVGAGDVGKSALT (SEQ ID NO: 38) KRAS(G12D)25mer
MTEYKLVVVGADGVGKSALTIQLIQ (SEQ ID NO: 39) KRAS(G12V)25mer
MTEYKLVVVGAVGVGKSALTIQLIQ (SEQ ID NO: 40) KRAS(G13D)25mer
MTEYKLVVVGAGDVGKSALTIQLIQ (SEQ ID NO: 41) KRAS(G12D)15mer^3
MKLVVVGADGVGKSALKLVVVGADGVGKSALKLVVVGADGVG KSAL (SEQ ID NO: 42)
KRAS(G12V)15mer^3 MKLVVVGAVGVGKSALKLVVVGAVGVGKSALKLVVVGAVGVG KSAL
(SEQ ID NO: 43) KRAS(G13D)15mer^3
MLVVVGAGDVGKSALTLVVVGAGDVGKSALTLVVVGAGDVGK SALT (SEQ ID NO: 44)
KRAS(G12D)25mer^3 MTEYKLVVVGADGVGKSALTIQLIQMTEYKLVVVGADGVGKSA
LTIQLIQMTEYKLVVVGADGVGKSALTIQLIQ (SEQ ID NO: 45) KRAS(G12V)25mer^3
MTEYKLVVVGAVGVGKSALTIQLIQMTEYKLVVVGAVGVGKSA
LTIQLIQMTEYKLVVVGAVGVGKSALTIQLIQ (SEQ ID NO: 46) KRAS(G13D)25mer^3
MTEYKLVVVGAGDVGKSALTIQLIQMTEYKLVVVGAGDVGKSA
LTIQLIQMTEYKLVVVGAGDVGKSALTIQLIQ (SEQ ID NO: 47) KRAS(G12C)25mer
MTEYKLVVVGACGVGKSALTIQLIQ (SEQ ID NO: 72) KRAS(G12C)25mer^3
MTEYKLVVVGACGVGKSALTIQLIQMTEYKLVVVGACGVGKSA
LTIQLIQMTEYKLVVVGACGVGKSALTIQLIQ (SEQ ID NO: 73) KRAS(WT)25mer
MTEYKLVVVGAGGVGKSALTIQLIQ (SEQ ID NO: 74)
TABLE-US-00016 TABLE 10 KRAS mutant antigen mRNA sequences mRNA Orf
Sequence (Amino Name Acid) Orf Sequence (Nucleotide) KRAS
MTEYKLVVVGADG ATGACCGAGTACAAGCTGGTGGTGGTGGGCGCCG (G12D)
VGKSALTIQLIQ ACGGCGTGGGCAAGAGCGCCCTGACCATCCAGCT 25mer (SEQ ID NO:
39) GATCCAG (SEQ ID NO: 126) KRAS MTEYKLVVVGAVG
ATGACCGAGTACAAGCTGGTGGTGGTGGGCGCCG (G12V) VGKSALTIQLIQ
TGGGCGTGGGCAAGAGCGCCCTGACCATCCAGCT 25mer (SEQ ID NO: 40) GATCCAG
(SEQ ID NO: 127) KRAS MTEYKLVVVGAGD
ATGACCGAGTACAAGCTGGTGGTGGTGGGCGCCG (G13D) VGKSALTIQLIQ
GCGACGTGGGCAAGAGCGCCCTGACCATCCAGCT 25mer (SEQ ID NO: 41) GATCCAG
(SEQ ID NO: 128) KRAS MTEYKLVVVGADG
ATGACCGAGTACAAGTTAGTGGTTGTGGGCGCCG (G12D) VGKSALTIQLIQMTE
ACGGCGTGGGCAAGAGCGCCCTCACCATCCAGCT 25mer^3 YKLVVVGADGVGK
TATCCAGATGACGGAATATAAGTTAGTAGTAGTG SALTIQLIQMTEYKL
GGAGCCGACGGTGTCGGCAAGTCCGCTTTGACCA VVVGADGVGKSAL
TTCAACTTATTCAGATGACAGAGTATAAGCTGGTC TIQLIQ (SEQ ID NO:
GTTGTAGGCGCAGACGGCGTTGGAAAGTCGGCAC 45) TGACGATCCAGTTGATCCAG (SEQ ID
NO: 129) KRAS MTEYKLVVVGAVG ATGACCGAGTACAAGCTCGTCGTGGTGGGCGCCG
(G12V) VGKSALTIQLIQMTE TGGGCGTGGGCAAGAGCGCCCTAACCATCCAGTT 25mer^3
YKLVVVGAVGVGK GATCCAGATGACCGAATATAAGCTCGTGGTAGTC SALTIQLIQMTEYKL
GGAGCGGTGGGCGTTGGCAAGTCAGCGCTAACAA VVVGAVGVGKSAL
TACAACTAATCCAAATGACCGAATACAAGCTAGT TIQLIQ (SEQ ID NO:
TGTAGTCGGTGCCGTCGGCGTTGGAAAGTCAGCC 46) CTTACAATTCAGCTCATTCAG (SEQ
ID NO: 130) KRAS MTEYKLVVVGAGD ATGACCGAGTACAAGCTCGTAGTGGTTGGCGCCG
(G13D) VGKSALTIQLIQMTE GCGACGTGGGCAAGAGCGCCCTAACCATCCAGCT 25mer^3
YKLVVVGAGDVGK CATCCAGATGACAGAATATAAGCTTGTGGTTGTG SALTIQLIQMTEYKL
GGAGCAGGAGACGTGGGAAAGAGTGCGTTGACG VVVGAGDVGKSAL
ATTCAACTCATACAGATGACCGAATACAAGTTGG TIQLIQ (SEQ ID NO:
TGGTGGTCGGCGCAGGTGACGTTGGTAAGTCTGC 47) ACTAACTATACAACTGATCCAG (SEQ
ID NO: 190) KRAS MTEYKLVVVGACG ATGACCGAGTACAAGCTGGTGGTGGTGGGCGCCT
(G12C) VGKSALTIQLIQ GCGGCGTGGGCAAGAGCGCCCTGACCATCCAGCT 25mer (SEQ
ID NO: 72) GATCCAG (SEQ ID NO: 132) KRAS MTEYKLVVVGACG
ATGACCGAGTACAAGCTCGTGGTTGTTGGCGCCTG (G12C) VGKSALTIQLIQMTE
CGGCGTGGGCAAGAGCGCCCTCACCATCCAGCTC 25mer^3 YKLVVVGACGVGK
ATCCAGATGACAGAGTATAAGTTAGTCGTTGTCG SALTIQLIQMTEYKL
GAGCTTGCGGAGTTGGAAAGTCGGCGCTCACCAT VVVGACGVGKSAL
TCAACTCATACAAATGACAGAATATAAGTTAGTG TIQLIQ (SEQ ID NO:
GTGGTGGGTGCGTGTGGCGTTGGCAAGAGTGCGC 73) TTACTATCCAGCTCATTCAG (SEQ ID
NO: 184) KRAS MTEYKLVVVGAGG ATGACCGAGTACAAGCTGGTGGTGGTGGGCGCCG (WT)
VGKSALTIQLIQ GCGGCGTGGGCAAGAGCGCCCTGACCATCCAGCT 25mer (SEQ ID NO:
74) GATCCAG (SEQ ID NO: 133) Chemistry: uridines modified N1-methyl
pseudouridine (m1.PSI.) Cap: C1 Tail: T100 5' UTR Sequence
(standard 5' Flank (includes Production FP + T7 site + 5'UTR)):
TCAAGCTTTTGGACCCTCGTACAGAAGCTAATACGACTCACTATAGGGAAATAAGAGAGA
AAAGAAGAGTAAGAAGAAATATAAGAGCCACC (SEQ ID NO: 21) 5' UTR Sequence
(No Promoter): GGGAAATAAGAGAGAAAAGAAGAGTAAGAAGAAATATAAGAGCCACC (SEQ
ID NO: 134) 3' UTR Sequence (Human 3' UTR no XbaI):
TGATAATAGGCTGGAGCCTCGGTGGCCATGCTTCTTGCCCCTTGGGCCTCCCCCCAGCCCCT
CCTCCCCTTCCTGCACCCGTACCCCCGTGGTCTTTGAATAAAGTCTGAGTGGGCGGC (SEQ ID
NO: 22)
[1346] In a first study to examine the effect of a STING immune
potentiator mRNA construct on KRAS antigen responses in vivo,
HLA-A*2:01 Tg mice (Taconic, strain 9659F, n=4) are administered
mRNA encoding various forms of mutated KRAS peptide antigens as
follows: mRNA encoding mutated KRAS (alone or in combination with
STING) administered on day 1, bleed taken on day 8, mRNA encoding
mutated KRAS (alone or in combination with STING) administered on
day 15, animal sacrificed on day 22. The test groups are shown in
Table 11 as follows:
TABLE-US-00017 TABLE 11 Test/Control Immune Dosing TEST group Group
Material Potentiator Vehicle Route Regimen KRAS-MUT 1 KRAS G12D
None (NTFIX) Compound 25 IM Day 1, 15 2 KRAS G12V None (NTFIX)
Compound 25 IM Day 1, 15 3 KRAS G13D None (NTFIX) Compound 25 IM
Day 1, 15 4 KRAS G12C None (NTFIX) Compound 25 IM Day 1, 15
KRAS-MUT + 5 KRAS G12D STING (V155M) Compound 25 IM Day 1, 15 STING
6 KRAS G12V STING (V155M) Compound 25 IM Day 1, 15 7 KRAS G13D
STING (V155M) Compound 25 IM Day 1, 15 8 KRAS G12C STING (V155M)
Compound 25 IM Day 1, 15 No Ag 9 NTFIX NTFIX Compound 25 IM Day 1,
15 STING Only 10 NTFIX STING V155M) Compound 25 IM Day 1, 15
[1347] mRNA is administered to animals at a dose of 0.5 mg/kg (10
ug per 20-g animal). The KRAS and STING constructs are administered
at a 1:1 ratio. Ex vivo restimulation (2 ug/ml per peptide) is
tested for 4 hours at 37 degrees Celsius in the presence of
GolgiPlug (Brefeldin A). Intracellular cytokine staining (ICS) is
tested for KRAS G12D, KRAS G12V, KRAS G13D, KRAS WT, and no
peptide.
[1348] mRNA encoding KRAS mutations, alone or in combination with
mRNA encoding constitutively active STING, is tested for the
ability to generate T cells. Efficacy of mRNA encoding KRAS
mutations is compared, for example, to peptide vaccination. The
effect of the STING immune potentiator is determined by comparing
treatment with the KRAS mutant peptides alone versus in combination
with the STING immune potentiator. For example, CD8 vaccine
responses can be assessed by intracellular staining (ICS) for
IFN-.gamma. and/or TNF-.alpha. as described herein. Enhanced ICS
responses for IFN-.gamma. and/or TNF-.alpha. in mice treated with
the KRAS mutant peptide vaccine in combination with the STING
immune potentiator mRNA construct, as compared to treatment with
the KRAS mutant peptide vaccine mRNA construct alone, indicates
that the STING immune potentiator enhances KRAS-specific CD8
vaccine responses.
[1349] In a second study to examine the effect of the STING immune
potentiator mRNA construct on immune responses to various different
forms of the mutant KRAS peptide antigen mRNA constructs,
HLA*A*11:01 Tg mice (Taconic, strain 9660F, n=4) are administered
mRNA encoding various different forms of mutated KRAS peptide
antigen mRNA constructs in combination with a STING immune
potentiator mRNA construct as follows: mRNA encoding mutated KRAS
in combination with STING administered on day 1, bleed taken on day
8, mRNA encoding mutated KRAS in combination with STING
administered on day 15, animal sacrificed on day 22.
[1350] The types of mutated KRAS constructs tested were as follows:
(i) mRNA encoding a single mutant KRAS 25mer peptide antigen
containing either the G12D, G12V, G13D or G12C mutation
("singlet"); (ii) mRNA encoding a concatemer of three 25mer peptide
antigens (thus creating a 75mer), one of each containing the G12D,
G12V and G13D mutations ("KRAS-3MUT"); (iii) mRNA encoding a
concatemer of four 25mer peptide antigens (thus creating a 100mer),
one of each containing the G12D, G12V, G13D and G12C mutations
("KRAS-4MUT"); or (iv) four separate mRNAs coadministered together,
each encoding a single mutant KRAS 25mer peptide antigen containing
either the G12D, G12V, G13D or G12C mutation
("Single.times.4").
[1351] The amino acid and nucleotide sequences of the G12D 25mer
are shown in SEQ ID NOs: 39 and 126, respectively. The amino acid
and nucleotide sequences of the G12V 25mer are shown in SEQ ID NOs:
40 and 127, respectively. The amino acid and nucleotide sequences
of the G13D 25mer are shown in SEQ ID NOs: 41 and 128,
respectively. The amino acid and nucleotide sequences of the G12C
25mer are shown in SEQ ID NOs: 72 and 132 respectively. The amino
acid and nucleotide sequences of the KRAS-3MUT 75mer are shown in
SEQ ID NOs: 135 and 136, respectively. The amino acid and
nucleotide sequences of the KRAS-4MUT 100mer are shown in SEQ ID
NOs: 137 and 138, respectively.
[1352] The test groups are shown in Table 12 as follows:
TABLE-US-00018 TABLE 12 Test/Control Immune Dosing TEST group Group
Material Potentiator Vehicle Route Regimen KRAS-MUT 1 KRAS G12D
STING (V155M) Compound 25 IM Day 1, 15 Singlet 2 KRAS G12V STING
(V155M) Compound 25 IM Day 1, 15 3 KRAS G13D STING (V155M) Compound
25 IM Day 1, 15 4 KRAS G12C STING (V155M) Compound 25 IM Day 1, 15
KRAS-MUT 5 KRAS-3MUT STING (V155M) Compound 25 IM Day 1, 15
Concatemer 6 KRAS-4MUT STING (V155M) Compound 25 IM Day 1, 15
Single X 4 7 G12D + G12V + STING (V155M) Compound 25 IM Day 1, 15
G12C + G13D STING Only 8 NTFIX STING (V155M) Compound 25 IM Day 1,
15
[1353] mRNA is administered to animals at a dose of 0.5 mg/kg (10
ug per 20-g animal). The KRAS and STING constructs are administered
at a 5:1 ratio. Ex vivo restimulation (2 ug/ml per peptide) is
carried out for 5 hours at 37 degrees Celsius in the presence of
GolgiPlug (Brefeldin A). Intracellular cytokine staining (ICS) is
tested for KRAS G12D, KRAS G12V, KRAS G13D, G12C, KRAS WT, and no
peptide.
[1354] The ability of the various mRNAs encoding KRAS mutations in
combination with mRNA encoding constitutively active STING to
generate T cell responses is tested to allow for comparison of the
effect of the STING immune potentiator on the various different
KRAS constructs. For example, CD8 vaccine responses can be assessed
by intracellular staining (ICS) for IFN-.gamma. and/or TNF-.alpha.
as described herein.
Example 8: Immune Potentiator mRNAs Enhance HPV Vaccine
Responses
[1355] In this example, the potency and durability of responses to
a human papillomavirus (HPV) E6/E7 mRNA-based vaccine used in
combination with STING, IRF3 or IRF7 immune potentiators were
examined. A specific immune response to human papillomavirus (HPV)
in the cervical microenvironment is known to play a key role in
eradicating infection and eliminating mutated cells. However,
high-risk HPVs are known to modulate immune cells to create an
immunosuppressive microenvironment (see e.g., Prata, T. T. et al.
(2015) Immunology 146:113-121). Thus, an HPV vaccination approach
that leads to a robust and durable immune response is highly
desirable.
[1356] The HPV vaccines used in this example were mRNA constructs
encoding either intracellular or soluble forms of HPV 16 antigens
E6 and E7, referred to herein as iE6/E7 and sE6/E7, respectively.
To create the soluble format, a signal peptide required for
secretion was fused to the N-terminal of the antigen. The sequence
of the signal peptide was derived from the Ig kappa chain V-III
region HAH. Mice were immunized intramuscularly with either the
iE6/E7 or sE6/E7 mRNA vaccine (at a dose of 0.25 mg/kg) on days 0
and 14, combination with either a control mRNA contruct (NTFIX), or
a STING, IRF3 or IRF7 immune potentiator mRNA construct (at a dose
of 0.25 mg/kg). The constitutively active STING immune potentiator
contained a V155M mutation (mouse version corresponding to SEQ ID
NO: 1). The constitutively active IRF3 immune potentiator contained
a S396D mutation (corresponding to SEQ ID NO: 12). The
constitutively active IRF7 immune potentiator contained an internal
deletion and six point mutations (mouse version corresponding to
SEQ ID NO: 18). The HPV vaccine construct and the immune
potentiator construct were coformulated in MC3 lipid
nanoparticles.
[1357] At day 21 and 53, spleen cells and peripheral blood
mononuclear cells (PBMC) from mice in each test group were
restimulated ex vivo for 4 hours at 37 degrees C. in the presence
of GolgiPlug.TM. (containing Brefeldin A; BD Biosciences) with
either: an E6 peptide pool (containing 37 E6 peptides, the
sequences of which are shown in SEQ ID NOs: 36-72), an E7 peptide
pool (containing 22 E7 peptides, the sequences of which are shown
in SEQ ID NOs: 73-94), E6 single peptides (8 individual peptides),
E7 single peptides (7 individual peptides) or no peptides
(control). CD8 vaccine responses were assessed by intracellular
staining (ICS) for IFN-.gamma. or TNF-.alpha..
[1358] Representative ICS results for E7-specific responses by day
21 spleen cells for IFN-.gamma. and TNF-.alpha. are shown in FIG.
11A (IFN-.gamma.) and FIG. 11B (TNF-.alpha.). Representative ICS
results for E6-specific responses by day 21 spleen cells for
IFN-.gamma. and TNF-.alpha. are shown in FIG. 12A (IFN-.gamma.) and
FIG. 12B (TNF-.alpha.). The results in FIGS. 11A-11B and 12A-12B
demonstrate that CD8 vaccine responses (to both the intracellular
and soluble antigen format) were greatly enhanced when the STING,
IRF3 or IRF7 immune potentiators were co-formulated with the
vaccine, with the E7 epitope being stronger and less variable than
the E6 epitope and with the soluble form of antigen being stronger
than the intracellular form of antigen. This enhanced CD8 vaccine
responses by the immune potentiators was shown to be durable, as
evidenced by the representative day 21 versus day 53 E7-specific
spleen cell IFN-.gamma. ICS data shown in FIGS. 13A and 13B,
respectively. Similar results to the spleen cell data were observed
for the PBMC experiments (data not shown).
[1359] The percentage of CD8b.sup.+ cells among the live CD45.sup.+
cells was also examined. The results for day 21 versus day 53
spleen cells are shown in FIGS. 14A and 14B, respectively. The
results demonstrate that the immune potentiators (in particular the
STING construct) expand the total CD8b.sup.+ population on day 21
but not day 53.
[1360] The ability of the immune potentiator constructs to enhance
the CD8 vaccine response was further confirmed by E7-MHC1-tetramer
staining. Representative results for day 21 versus day 53 spleen
cells are shown in FIGS. 15A and 15B, respectively. The
E7-MHC-1-tetramer staining results were consistent with the ICS
results discussed above, although they were more variable. As
demonstrated in FIGS. 16A-16D, the majority of the tetramer
positive CD8 cells were found to have an "effector memory"
CD62L.sup.lo phenotype. Comparison of day 21 versus day 53
E7-tetramer.sup.+ CD8 cells demonstrated that this
"effector-memory"CD62L.sup.lo phenotype was maintained throughout
the study. Additional staining experiments demonstrated that the
immune potentiators slightly reduced the % of total Foxp3.sup.+
Treg CD4 Tcells (data not shown) and did not change the % of
CD138.sup.+ plasmablasts (data not shown).
Example 9: Prophylactic or Therapeutic Vaccination with HPV Vaccine
in Combination with STING Immune Potentiator Inhibits Tumor
Growth
[1361] In this example, mice were treated with an HPV vaccine in
combination with a STING immune potentiator either prior to, at the
same time as, or after challenge with TC1 tumor cells. TC-1 is an
HPV16 E7-expressing murine tumor model known in the art (see e.g.,
Bartkowiak et al. (2015) Proc. Natl. Acad. Sci. USA
112:E5290-5299). The HPV vaccines used in this example were mRNA
constructs encoding either intracellular or soluble forms of HPV 16
antigens E6 and E7, referred to herein as iE6/E7 and sE6/E7,
respectively, as described in Example 8. The constitutively active
STING immune potentiator used in this example contained a V155M
mutation, as described in Example 8. The HPV vaccine construct and
the immune potentiator construct were coformulated in MC3 lipid
nanoparticles. Certain mice were also treated with an immune
checkpoint inhibitor (either anti-CTLA-4 or anti-PD-1).
[1362] In a first set of experiments examining the prophylactic
activity of the HPV+STING vaccination, C57/B6 mice were treated by
intramuscular injection with 0.5 mg/kg of the HPV+STING vaccine
(encoding either sE6/E7 or iE6/E7) on either (i) days -7 and -14,
or (ii) days 1 and 8, followed by subcutaneous injection of
2.times.10.sup.5 TC1 cells on day 1. Certain mice were also treated
on days 6, 9 and 12 with either anti-CTLA-4 or anti-PD-1.
Representative results, reported as tumor volume over time, are
shown in the graphs of FIGS. 17A-17C, wherein FIGS. 17A and 17B
show data for mice treated on days -14 and -7 with either sE6/E7
(FIG. 17A) or iE6/E7 (FIG. 17B) and FIG. 17C shows data for mice
treated on days 1 and 8 with sE6/E7. The results demonstrate that
all of the mice treated with the HPV+STING vaccine (alone or in
combination with immune checkpoint inhibitors) showed complete
inhibition of tumor growth over several weeks, as compared to the
control mice (treated with the control mRNA construct NTFIX, alone
or in combination with an immune checkpoint inhibitor). Thus, these
experiments demonstrate that prophylactic vaccination (i.e., prior
to or at the same time as tumor challenge) with the HPV vaccine
together with the STING immune potentiator is effective in
preventing growth of HPV-expressing tumor cells in vivo.
[1363] In a second set of experiments examining the therapeutic
activity of the HPV+STING vaccination, C57/B6 mice were
administered 2.times.10.sup.5 TC1 cells subcutaneously on day 1,
followed by treatment by intramuscular injection with 0.5 mg/kg of
the HPV+STING vaccine (encoding sE6/E7) on days 8 and 15. Certain
mice were also treated on days 13, 16 and 19 with either
anti-CTLA-4 or anti-PD-1. Representative results, reported as tumor
volume over time, are shown in the graphs of FIGS. 18A-18I. The
results demonstrate that the mice treated with the HPV+STING
vaccine (alone or in combination with immune checkpoint inhibitors)
showed tumor regression (FIGS. 18A-18C), as compared to the control
mice treated with the control mRNA construct NTFIX, alone or in
combination with an immune checkpoint inhibitor (FIGS. 18D-18F) or
the control mice treated with the sE6/E7 construct in combination
with the control DMXAA construct, alone or in combination with an
immune checkpoint inhibitor (FIGS. 18G-18I). Thus, these
experiments demonstrate that therapeutic vaccination (i.e.,
subsequent to tumor challenge) with the HPV vaccine together with
the STING immune potentiator is effective in inducing regression of
HPV-expressing tumors in vivo.
Example 10. Determining Optimal Antigen:Immune Potentiator Mass
Ratio in mRNA Vaccine Design
[1364] In this example, studies were performed in animals treated
with an antigen of interest in combination with an immune
potentiator at different Ag:Immune Potentiator ratios, followed by
examination of T cell responses to the antigen, to determine
optimal Ag:Immune Potentiator ratios in enhancing the immune
response to the antigen of interest.
[1365] In a first set of experiments, mice were treated with an
MC38 vaccine encoding an ADR concatemer of three 25mer mutant
peptides containing tumor neoepitopes derived from Adpgk, Dpagt1,
and Reps1 (this vaccine is also referred to herein as ADRvax), as
described in Example 5, in combination with a constitutively active
STING immune potentiator construct. The constitutively active STING
immune potentiator used in this example contained a V155M mutation,
as described in Example 1. The ADRvax and STING constructs were
coformulated in a lipid nanoparticle (comprising Compound 25
(Cmp25)) at varying Ag:STING ratios, according to the study design
summarized below in Table 13.
TABLE-US-00019 TABLE 13 STING Total Ag:STING Ag dose dose NTFIX
mRNA Dosing Group ratio (.mu.g) (.mu.g) (.mu.g) (.mu.g) Vehicle
Route Regimen 1 No Ag control 0 3 3 6 Cmp25 IM Day 1, 15 2 1:1 3 3
0 3 5:1 0.6 2.4 4 10:1 0.3 2.7 5 20:1 0.15 2.85 6 1:0 (No STING) 0
3 7 1:1 5 5 0 10 8 1:0 (No STING) 0 5
[1366] Mice were dosed intramuscularly on days 1 and 15. At day 21,
CD8.sup.+ spleen cells from mice in each test group were
restimulated ex vivo for 4 hours at 37 degrees C. in the presence
of GolgiPlug.TM. (containing Brefeldin A; BD Biosciences) with
either wild-type or mutant MC38 ADR peptides (1 .mu.g/ml per
peptide, pooled) and CD8 vaccine responses were assessed by
intracellular staining (ICS) for IFN-.gamma. or TNF-.alpha..
Representative ICS results for MC38 ADR-specific responses by day
21 CD8.sup.+spleen cells for IFN-.gamma. are shown in FIG. 19 and
for TNF-.alpha. are shown in FIG. 20. Additionally, CD8 vaccine
responses to each of the three individual epitopes within ADRvax
(i.e., peptides Adpk1, Reps1 and Dpagt1) were also assessed by ICS
for IFN-.gamma. following stimulation with the individual epitopes.
The results are shown in FIG. 21A (for peptide Adpk1), FIG. 21B
(for peptide Reps1) and FIG. 21C (for peptide Dpagt1).
[1367] The results demonstrate that all Ag:STING ratios tested
(ranging from 1:1 to 20:1) showed an adjuvant effect of STING as
compared to control. For the ADRvax antigen as a whole, the optimal
Ag:STING ratio was found to be 5:1. For the individual peptide
epitopes within ADRvax, the optimal Ag:STING ratio for the Adpgk1
peptide was 5:1, whereas the optimal Ag:STING ratio for the Reps1
peptide was 10:1 (the responses to the third peptide, Dpagt1, were
very low with or without STING, consistent with it being a
non-dominant epitope as was known in the art). STING was also found
to increase the total percentage of CD8+ cells among CD45+ T cells,
with dose responses observed (data not shown) and was found to
increase the total percentage of CD62L cells among CD44hi CD8+
cells (effector/memory subset), with dose responses observed (data
not shown). Furthermore, results obtained from PBMC cells were
consistent with the spleen cell results (data not shown). Thus,
these experiments confirmed the ability of STING to act as an
immune potentiator in enhancing immune responses against the ADRvax
antigen and, moreover, demonstrated the determination of an optimal
Ag:Immune Potentiator ratio for treatment, with ratios other than
1:1 being found to be most optimal (e.g., ratios of 5:1 or 10:1
being more effective than 1:1). The results further indicate that
the optimal Ag:Immune Potentiator ratio may differ depending on the
particular antigen of interest used.
[1368] In a second set of experiments, non-human primates were
treated with an HPV vaccine encoding intracellular E6/E7 (iE6/E7),
as described in Example 8, in combination with the constitutively
active STING immune potentiator construct at varying Ag:STING
ratios (lipid nanoparticles comprising Compound 25), according to
the study design summarized below in Table 14:
TABLE-US-00020 TABLE 14 Ag:STING .mu.g .mu.g .mu.g Total Ag Group
Treatment Ratio Ag STING NTFIX n Dose 1 STING only -- -- 100 -- 3
100 .mu.g 2 Ag:STING 1:1 50 50 -- 3 Ag:STING 5:1 83.33 16.67 -- 4
Ag:STING 10:1 90.9 9.09 5 Ag only -- 90 -- 10
No clinical findings were observed 24 hours after the first dose
(administered intramuscularly), indicating no injection site
reactions and that the initial treatment was received safely. After
an initial dosing on Day 1, animals have a two week recover period
and then are given a second dose at day 14, followed by another two
week recovery period. Further safety analysis is determined by
clinical pathology (clinical chemistry, hematology and coagulation)
at days 2, 16 and 30. Anti-antibody and ELISpot analysis or ICS for
IFN-.gamma. for CD4 and CD8 cells are performed to assess
enhancement of immune responses to the HPV vaccine by STING at the
varying ratios tested.
[1369] In a third set of experiments, a model concatemeric antigen
using known murine epitopes was tested in mice in combination with
the constitutively active STING immune potentiator at varying
ratios. The concatemeric antigen, referred to herein as CA-132,
comprises 20 known murine epitopes thought to be presented on MHC
Class I and Class II antigens of the CB6 mouse. These epitopes were
sourced from the IEDB.org website, a public database of epitopes
sourced from the literature. Class I epitopes are expected to be
presented on MHC Class I molecules and trigger a CD8+ response,
while Class II epitopes are expected to be presented on MHC Class
II molecules and trigger CD4+ T cell responses. The CA-132 antigen
construct encodes both Class I and Class II epitopes, allowing for
assessment of both CD4 and CD8 T cell responses. Moreover, it is
believed that inclusion of Class II epitopes in the concatemeric
antigen (thus triggering a CD4 response) helps induce a stronger
CD8 T cell response. Thus, the approach to the design of the CA-132
antigen can also be used in the design of other concatemeric
antigen constructs.
[1370] The CA-132 antigen construct and STING immune potentiator
construct were coformulated in lipid nanoparticles comprising
Compound 25 and administered intramuscularly to CB6 mice at the
following dosages: CA-132 alone at 1 .mu.g, 3 .mu.g or 10 .mu.g,
STING alone at 3 .mu.g, CA-132+STING at either 3 .mu.g each or 1
.mu.g each (1:1 ratio), CA-132 at 3 .mu.g and STING at 1 .mu.g
(Ag:STING ratio of 3:1) or CA-132 at 1 .mu.g and STING at 3 .mu.g
(Ag:STING ratio of 1:3). Antigen-specific T cell responses to the
Class I epitopes within the CA-132 antigen construct were examined
by ELISpot analysis for IFN-.gamma., the results of which are shown
in FIG. 22. The results demonstrated an increase in IFN-.gamma.
responses to the Class I epitopes when formulated with STING.
[1371] In a fourth series of experiments, the HPV vaccine model
described in Example 8 was used to study the effect of varying
ratios of E6/E7 antigen to constitutively active STING immune
potentiator. Mice were immunized intramuscularly with the iE6/E7
mRNA vaccine (3 .mu.g or 5 .mu.g) in combination with the V155M
constitutively active STING immune potentiator mRNA construct at
Ag:STING ratios of 1:1, 5:1, 10:1, 20:1 or 0.4:1. The HPV vaccine
construct and the immune potentiator construct were coformulated in
MC3 lipid nanoparticles. HPV vaccine or STING in combination with
only a control mRNA (NTFIX) were used as controls.
[1372] At day 21, spleen cells from mice in each test group were
restimulated ex vivo for 4 hours at 37 degrees C. in the presence
of GolgiPlug.TM. (containing Brefeldin A; BD Biosciences) with an
E7 peptide pool (described in Example 8). CD8 vaccine responses
were assessed by intracellular staining (ICS) for IFN-.gamma.. The
results are shown in FIG. 23A. The results demonstrate that STING
enhanced the antigen-specific T cell responses at all Ag:STING
ratios tested. The largest enhancement was observed for the mice
treated with the higher dose of antigen (5 .mu.g) at a 1:1 ratio
with STING and for the mice treated at an Ag:STING ratio of 0.4:1
(3 .mu.g Ag to 7 .mu.g STING).
[1373] The ability of STING to enhance the CD8 vaccine response in
the HPV model at various Ag:STING ratios tested was further
confirmed by H2-Kb/E7 peptide-tetramer staining. Representative
results for day 21 spleen cells are shown in FIG. 23B. The
E7-MHC-1-tetramer staining results were consistent with the ICS
results discussed above, although they were more variable.
[1374] In summary, these studies confirmed the ability of the STING
immune potentiator construct to enhance immune responses to an
antigen of interest and demonstrated the determination of optimal
Ag:STING ratios for treatment.
Example 11: Immune Potentiation by STING in Non-Human Primates
[1375] In this example, non-human primates (cynomolgus monkeys)
were treated with mRNAs encoding an HPV vaccine in combination with
a STING immune potentiator, followed by assessment of
antigen-specific T cell and antibody responses. The HPV vaccine
construct used in this example is described in Example 8. The
constitutively active STING immune potentiator construct used in
this example contained a V155M mutation, as described in Example 8.
The HPV vaccine construct and the immune potentiator mRNA
constructs were coformulated in lipid nanoparticles comprising:
Compound 25:Cholesterol:DSPC:PEG-DMG, at ratios of 50:38.5:10:1.5,
respectively. Different ratios of STING:Ag were tested. Control
animals were treated with mRNAs encoding either the HPV antigens
alone or the STING immune potentiator alone.
[1376] Fifteen male cynomolgus monkeys, 2-5 years old and weighing
2-5 kg, were treated according to the study design shown below in
Table 15:
TABLE-US-00021 TABLE 15 Total mRNA STING HPV Ag Group Desc. Ratio
(.mu.g) NTFIX (.mu.g) (.mu.g) n 1 Ag only 100 10 90 3 2 STING only
100 100 0 3 3 STING:Ag 1:1 100 50 50 3 4 STING:Ag 1:5 100 17 83 3 5
STING:Ag 1:10 100 9 91 3
[1377] A pre-dose sample of PBMCs were collected on day -4,
followed by treatment of the animals intramuscularly with the mRNA
LNPs on day 1 and day 15. A post-dose sample of PBMCs was collected
on day 29. No toxicity or other major clinical observations were
noted during the study, indicating the mRNA LNPs were
well-tolerated.
[1378] To examine the ability of the STING immune potentiator to
enhance antigen-specific CD8+ T cell responses, intracellular
cytokine staining (ICS) for TNF.alpha. and IL-2 was conducted.
PBMCs were stimulated ex vivo with the HPV16 E6 peptide pool or the
HPV16 E7 peptide pool for 6 hours at 37.degree. C. Stimulation with
PMA/ionomycin was used as a positive control and stimulation with
medium alone was used as a negative control.
[1379] Representative results for ICS for TNF.alpha. are shown in
FIGS. 24A-24C, wherein FIG. 24A shows results for ex vivo
stimulation with the E6 peptide pool, FIG. 24B shows the results
for ex vivo stimulation with the E7 peptide pool and FIG. 24C shows
the results for ex vivo stimulation with the medium control. No
increase in TNF.alpha.+ CD8 T cell frequency was observed between
the pre- and post-dose group immunized with antigen alone (Group
1). Immunization with STING treatment alone (Group 2) had a
marginal effect on TNF.alpha.+ CD8 T cell frequency. In contrast,
groups immunized with STING+Ag (Groups 3, 4, 5) showed a
significant increase in antigen-specific TNF.alpha.+ CD8 T cells.
Furthermore, Group 5, which was immunized with a "matching" antigen
dose of STING:Ag (1:10 ratio), showed a significant increase in
antigen-specific TNF.alpha.+ CD8 T cells when compared to the Group
1 and Group 2 controls.
[1380] Representative results for ICS for IL-2 are shown in FIGS.
25A-25C, wherein FIG. 25A shows results for ex vivo stimulation
with the E6 peptide pool, FIG. 25B shows the results for ex vivo
stimulation with the E7 peptide pool and FIG. 25C shows the results
for ex vivo stimulation with the medium control. A moderate
increase in IL-2+ CD8 T cell frequency between the pre- and
post-dose was observed in all immunized animals (Groups 1-5).
However, the increase in IL-2+ CD8 T cells was most detectable in
the groups treated with STING:Ag at ratios of 1:1 and 1:5 (Groups 3
and 4), whereas animals treated with STING:Ag at a 1:10 ratio did
not exhibit increased IL-2+ CD8 T cells as compared to controls.
The increase in IL-2 is consistent with the known ability of
subsets of T cells to secrete IL-2 during active T cell
responses.
[1381] To examine the effect of STING:Ag treatment in the NHPs on
antigen-specific antibody responses, E6-specific and E7-specific
ELISAs were performed. Plates were coated with either recombinant
E6 (Prospec; #HPV-005 His HPV16 E6) or recombinant E7 (ProteinX;
#2003207 His HPV16 E7). A mouse anti-E6 monoclonal antibody from
Alpha Diagnostics International (#HPV16E6 1-M) was used as a
positive control. A mouse anti-E7 monoclonal antibody from
Fisher/Life Technologies (#280006-EA) was used as a positive
control. An anti-mouse IgG-HRP antibody from Jackson ImmunoResearch
(#715-035-150) was used as the secondary antibody for the positive
controls. Anti-monkey IgG-HRP from Abcam (#ab112767) was used as
the secondary antibody for the NHP serum.
[1382] Plates were coated with recombinant E6 or E7 (500 ng/well;
100 .mu.l/well) at 4.degree. C. overnight and then blocked with TBS
SuperBlock for 1 hour at room temperature. Primary antibody was
added (100 .mu.l/well) and incubated for 1 hour at room
temperature. Positive control antibodies were serially diluted. NHP
serum was diluted 1:5000. After washing, secondary antibody was
added (100 .mu.l/well) and incubated for 1 hour at room
temperature. Positive control anti-mouse IgG-HRP was diluted
1:5000. For the NHP serums, anti-monkey IgG-HRP was diluted
1:30,000. Color was developed for 5 minutes (anti-E6) or for 10
minutes (anti-E7), then stopped and read at 450 nm.
[1383] Representative results for anti-HPV16 E6 IgG are shown in
FIG. 26. Representative results for anti-HPV16 E7 IgG are shown in
FIG. 27. The results for both anti-E6 and anti-E7 demonstrate that
treatment of the animals with STING:Ag, particularly at ratios of
1:5 and 1:10 led to increased antigen-specific antibody
responses.
[1384] To further study the antigen-specific IgG response, further
ELISA studies were performed using a two-fold dilution series for
day 25 serums. As shown in FIG. 28, the two-fold dilution series
for the animals treated at a 1:10 STING:Ag ratio exhibited a clear
enhancement in the levels of anti-HPV16 E6-specific IgG antibodies,
as compared to animals treated with the HPV vaccine alone.
Calculated titer values from these ELISA studies with the day 25
serum two-fold dilution series for anti-E6 IgG and anti-E7 IgG are
shown in FIGS. 29A and 29B, respectively. The calculated titer
values, particularly for the anti-E6 specific response, confirm the
enhancement by the STING immune potentiator, with the 1:10 STING:Ag
ratio showing the greatest enhancement.
[1385] Accordingly, the results described herein for the non-human
primate study confirm that STING immunopotentiates antigen-specific
T cell and antibody responses against an mRNA vaccine antigen in
vivo.
Example 12: Immunogenicity of Various KRAS-STING Vaccine Formats in
HLA*A11 Transgenic Mice
[1386] In this example, to examine the effect of the STING immune
potentiator mRNA construct on immune responses to various different
forms of the mutant KRAS peptide antigen mRNA constructs,
HLA*A*11:01 Tg mice (Taconic, strain 9660F, n=3) were administered
mRNA encoding various different forms of mutated KRAS peptide
antigen mRNA constructs in combination with a STING immune
potentiator mRNA construct as follows: mRNA encoding mutated KRAS
in combination with STING administered on days 0 and 14, animals
sacrificed on day 21. Mice were aged 6-9 weeks at day 0. mRNA was
administered to the animals at a dose of 0.5 mg/kg (10 ug per 20-g
animal). The KRAS and STING constructs are administered at a 5:1
ratio (Ag:STING).
[1387] The types of mutated KRAS constructs tested were as follows:
(i) mRNA encoding a single mutant KRAS 25mer peptide antigen
containing either the G12D, G12V, G13D or G12C mutation
("monomer"); (ii) mRNA encoding a concatemer of three 25mer peptide
antigens (thus creating a 75mer), one of each containing the G12D,
G12V and G13D mutations ("KRAS-3MUT concatemer"); (iii) mRNA
encoding a concatemer of four 25mer peptide antigens (thus creating
a 100mer), one of each containing the G12D, G12V, G13D and G12C
mutations ("KRAS-4MUT concatemer"); or (iv) four separate mRNAs
coadministered together, each encoding a single mutant KRAS 25mer
peptide antigen containing either the G12D, G12V, G13D or G12C
mutation ("pooled monomers"). The amino acid and nucleotide
sequences of the constructs are as described in Example 7. An
A11-viral epitope concatemer antigen was also tested in combination
with STING or a control mRNA (NTFIX) ("validated A11 Ag").
[1388] The test groups are shown in Table 16 as follows:
TABLE-US-00022 TABLE 16 Test/Control Immune Dosing TEST group Group
Material Potentiator Vehicle Route Regimen KRAS-MUT 1 KRAS G12D
STING (V155M) Compound 25 IM Day 1, 14 Monomer 2 KRAS G12V STING
(V155M) Compound 25 IM Day 1, 14 3 KRAS G13D STING (V155M) Compound
25 IM Day 1, 14 4 KRAS G12C STING (V155M) Compound 25 IM Day 1, 14
KRAS-MUT 5 KRAS-3MUT STING (V155M) Compound 25 IM Day 1, 14
Concatemer 6 KRAS-4MUT STING (V155M) Compound 25 IM Day 1, 14 7
KRAS-4MUT.var1 STING (V155M) Compound 25 IM Day 1, 14 Pooled 8 G12D
+ G12V + STING (V155M) Compound 25 IM Day 1, 14 Monomers G12C +
G13D Validated 9 A11-Viral epitope STING (V155M) Compound 25 IM Day
1, 14 A11 Ags concatemer 10 A11-Viral epitope NTFIX Compound 25 IM
Day 1, 14 concatemer
[1389] In a first set of experiments to evaluate antigen-specific
CD8+ T cell responses to the KRAS antigens, day 21 spleen cells
from the mice were restimulated ex vivo with KRAS monomer peptides
(2 ug/ml per peptide) for 5 hours at 37 degrees Celsius in the
presence of GolgiPlug (Brefeldin A). Intracellular cytokine
staining (ICS)(IFN-.gamma.) was performed for KRAS G12D
(aa*7/8-16), KRAS G12V (aa*7/8-16), KRAS G13D (aa*7/8-16), G12C
(aa*7/8-16), KRAS WT (aa*7/8-16) and no peptide.
[1390] The ICS results for KRAS-G12V-specific responses are shown
in FIG. 30. The ICS results for KRAS-G12D-specific responses are
shown in FIG. 31. These results demonstrate that anti-KRAS-G12V and
anti-KRAS-G12D specific CD8+ T cells were detected in mice
immunized with the corresponding KRAS-STING vaccine (monomer or
concatemer) and restimulated with the cognate peptide. Comparable %
IFN-gamma positive CD8+ T cells were seen when the KRAS mutations
were administered to the mice as a monomer or as concatemers. The
responses observed with G12V were stronger than the responses
observed with G12D. In this experiment, anti-KRAS G12C and
anti-KRAS G13D responses were not observed (data not shown).
[1391] In a second set of experiments to evaluate antigen-specific
CD8+ T cell responses to KRAS antigens, day 21 spleen cells from
the mice were co-cultured with HLA*A11-expressing target cells
(Cos7-A11 cells) that had been pulsed with the corresponding KRAS
peptides (G12V, G12D or WT control), followed by ICS (IFN-.gamma.).
The Cos7-A11 co-culture results for KRAS-G12V-specific responses
are shown in FIG. 32. The Cos7-A11 co-culture results for
KRAS-G12D-specific responses are shown in FIG. 33. These results
demonstrate that anti-KRAS-G12V and anti-KRAS-G12D specific CD8+ T
cell responses were detected in mice immunized with the
corresponding KRAS-STING vaccine (monomer or concatemer) and
restimulated with the A11+ expressing cell line pulsed with G12V or
G12D. Thus, the results in this second set of experiments with
respect to detection of antigen-specific CD8+ T cell responses to
the KRAS antigens were very similar to the results from the first
set of experiments using restimulation with cognate peptides.
[1392] Finally, the ability of STING to potentiate antigen-specific
response to known A*11-restricted viral epitopes was evaluated
using day 21 spleen cells from the mice immunized with an A11-viral
epitope concatemer. Eight viral epitopes (EBV BRLF1, FLU, HIV NEF,
EBV, HBV core antigen, HCV, CMV and BCL-2L1) (25 amino acids each)
were concatemerized and encoded by mRNA for use as an antigen in
combination with STING in the A11-transgenic mice (treatment group
9 in Table 16). The A11-viral epitope concatemer was also
co-administered with an NTFIX control mRNA (treatment group 10 in
Table 16). Five of the eight epitopes (EBV BRLF1, FLU, HIV NEF,
EBV, HBV core antigen) were validated A11 binders with relatively
low predicted IC50s; the other three epitopes (HCV, CMV and
BCL-2L1) had more moderate predicted affinities for A11 but have
not been experimentally validated. The amino acid sequences for the
viral epitopes, as well as their IC50s, are shown below in Table
17:
TABLE-US-00023 TABLE 17 Literature Gene Peptide ann_IC50 % rank
validation EBV ATIGTAMYK (SEQ ID NO: 226) 6.03 0.2 Y BRLF1 FLU
SIIPSGPLK (SEQ ID NO: 227) 5 0.25 Y HIV NEF AVDLSHFLK (SEQ ID NO:
228) 20.31 0.25 Y EBV AVFDRKSDAK (SEQ ID NO: 229) 55.63 0.5 Y HBV
YVNVNMGLK (SEQ ID NO: 230) 69.82 0.5 Y core antigen HCV RVCEKMALY
(SEQ ID NO: 231) 304.91 1.3 CMV KLGGALQAK (SEQ ID NO: 232) 736.59
1.6
[1393] Day 21 spleen cells were restimulated ex vivo with the
individual A*11 viral epitopes, followed by ICS (IFN-.gamma. and
TNF-.alpha.), to detect antigen-specific CD8+ T cell responses.
Antigen-specific CD8+ T cell responses were observed for four out
of the eight viral epitopes (EBV, EBV BRLF1, FLU and HIV NEF) and,
as shown in FIG. 34, STING potentiated T cell responses for these
four viral epitopes.
[1394] A repeat study was performed in HLA*A11 transgenic mice
using the KRAS-4MUT concatemer, at either a low dose (10 .mu.g) or
a high dose (30 .mu.g), in combination with the STING immune
potentiator mRNA at an Ag:STING ratio of 5:1. Significant
enhancement of G12V-specific CD8 T cell responses by the STING
immune potentiator construct was again observed, with the greatest
enhancement being seen at the higher dose of antigen tested (30
.mu.g).
[1395] Accordingly, the results described herein for HLA*A11
transgenic mice demonstrate that STING immunopotentiates
antigen-specific T cell anti-KRAS responses, as well as anti-viral
responses to other A11-restricted viral antigens, and is able to
immunopotentiate responses to vaccine antigens in various formats
(monomers and concatemers).
Other Embodiments
[1396] It is to be understood that while the present disclosure has
been described in conjunction with the detailed description
thereof, the foregoing description is intended to illustrate and
not limit the scope of the present disclosure, which is defined by
the scope of the appended claims. Other aspects, advantages, and
alterations are within the scope of the following claims.
[1397] All references described herein are incorporated by
reference in their entireties.
TABLE-US-00024 SEQUENCE LISTING SUMMARY SEQ ID NO: SEQUENCE 1
MPHSSLHPSIPCPRGHGAQKAALVLLSACLVTLWGLGEPPEHTLRYLVLHLASLQLGLLLNGVCSLAEELRH-
IHSRYRGS
YWRTVRACLGCPLRRGALLLLSIYFYYSLPNAVGPPFTWMLALLGLSQALNILLGLKGLAPAEISAVCEKGNF-
NMAHGL
AWSYYIGYLRLILPELQARIRTYNQHYNNLLRGAVSQRLYILLPLDCGVPDNLSMADPNIRFLDKLPQQTGDH-
AGIKDR
VYSNSIYELLENGQRAGTCVLEYATPLQTLFAMSQYSQAGFSREDRLEQAKLFCRTLEDILADAPESQNNCRL-
IAYQEP
ADDSSFSLSQEVLRHLRQEEKEEVTVGSLKTSAVPSTSTMSQEPELLISGMEKPLPLRTDFS
(huSTING(V155M); no epitope tag) 2
MPHSSLHPSIPCPRGHGAQKAALVLLSACLVTLWGLGEPPEHTLRYLVLHLASLQLGLLLNGVCSLAEELRH-
IHSRYRGS
YWRTVRACLGCPLRRGALLLLSIYFYYSLPNAVGPPFTWMLALLGLSQALNILLGLKGLAPAEISAVCEKGNF-
NVAHGL
AWSYYIGYLRLILPELQARIRTYNQHYNNLLRGAVSQRLYILLPLDCGVPDNLSMADPNIRFLDKLPQQTGDH-
AGIKDR
VYSNSIYELLENGQRAGTCVLEYATPLQTLFAMSQYSQAGFSREDtLEQAKLFCRTLEDILADAPESQNNCRL-
IAYQEPA
DDSSFSLSQEVLRHLRQEEKEEVTVGSLKTSAVPSTSTMSQEPELLISGMEKPLPLRTDFS (Hu
STING(R284T); no epitope tag) 3
MPHSSLHPSIPCPRGHGAQKAALVLLSACLVTLWGLGEPPEHTLRYLVLHLASLQLGLLLNGVCSLAEELRH-
IHSRYRGS
YWRTVRACLGCPLRRGALLLLSIYFYYSLPNAVGPPFTWMLALLGLSQALNILLGLKGLAPAEISAVCEKGNF-
NVAHGL
AWSYYIGYLRLILPELQARIRTYNQHYNNLLRGAVSQRLYILLPLDCGVPDNLSMADPNIRFLDKLPQQTGDH-
AGIKDR
VYSNSIYELLENGQRAGTCVLEYATPLQTLFAMSQYSQAGFSREDmLEQAKLFCRTLEDILADAPESQNNCRL-
IAYQEP
ADDSSFSLSQEVLRHLRQEEKEEVTVGSLKTSAVPSTSTMSQEPELLISGMEKPLPLRTDFS (hu
STING (R284M); no epitope tag) 4
MPHSSLHPSIPCPRGHGAQKAALVLLSACLVTLWGLGEPPEHTLRYLVLHLASLQLGLLLNGVCSLAEELRH-
IHSRYRGS
YWRTVRACLGCPLRRGALLLLSIYFYYSLPNAVGPPFTWMLALLGLSQALNILLGLKGLAPAEISAVCEKGNF-
NVAHGL
AWSYYIGYLRLILPELQARIRTYNQHYNNLLRGAVSQRLYILLPLDCGVPDNLSMADPNIRFLDKLPQQTGDH-
AGIKDR
VYSNSIYELLENGQRAGTCVLEYATPLQTLFAMSQYSQAGFSREDkLEQAKLFCRTLEDILADAPESQNNCRL-
IAYQEP
ADDSSFSLSQEVLRHLRQEEKEEVTVGSLKTSAVPSTSTMSQEPELLISGMEKPLPLRTDFS (Hu
STING (R284K); no epitope tag) 5
MPHSSLHPSIPCPRGHGAQKAALVLLSACLVTLWGLGEPPEHTLRYLVLHLASLQLGLLLNGVCSLAEELRH-
IHSRYRGS
YWRTVRACLGCPLRRGALLLLSIYFYYSLPNAVGPPFTWMLALLGLSQALNILLGLKGLAPAEISAVCEKGNF-
sVAHGLA
WSYYIGYLRLILPELQARIRTYNQHYNNLLRGAVSQRLYILLPLDCGVPDNLSMADPNIRFLDKLPQQTGDHA-
GIKDRV
YSNSIYELLENGQRAGTCVLEYATPLQTLFAMSQYSQAGFSREDRLEQAKLFCRTLEDILADAPESQNNCRLI-
AYQEPA
DDSSFSLSQEVLRHLRQEEKEEVTVGSLKTSAVPSTSTMSQEPELLISGMEKPLPLRTDFS (Hu
STING(N154S); no epitope tag) 6
MPHSSLHPSIPCPRGHGAQKAALVLLSACLVTLWGLGEPPEHTLRYLVLHLASLQLGLLLNGVCSLAEELRH-
IHSRYRGS
YWRTVRACLGCPLRRGALLLLSIYFYYSLPNAVGPPFTWMLALLGLSQALNILLGLKGLAPAEISAICEKGNF-
NVAHGLA
WSYYIGYLRLILPELQARIRTYNQHYNNLLRGAVSQRLYILLPLDCGVPDNLSMADPNIRFLDKLPQQTGDHA-
GIKDRV
YSNSIYELLENGQRAGTCVLEYATPLQTLFAMSQYSQAGFSREDRLEQAKLFCRTLEDILADAPESQNNCRLI-
AYQEPA
DDSSFSLSQEVLRHLRQEEKEEVTVGSLKTSAVPSTSTMSQEPELLISGMEKPLPLRTDFS (Hu
STING(V147L); no epitope tag) 7
MPHSSLHPSIPCPRGHGAQKAALVLLSACLVTLWGLGEPPEHTLRYLVLHLASLQLGLLLNGVCSLAEELRH-
IHSRYRGS
YWRTVRACLGCPLRRGALLLLSIYFYYSLPNAVGPPFTWMLALLGLSQALNILLGLKGLAPAEISAVCEKGNF-
NVAHGL
AWSYYIGYLRLILPELQARIRTYNQHYNNLLRGAVSQRLYILLPLDCGVPDNLSMADPNIRFLDKLPQQTGDH-
AGIKDR
VYSNSIYELLENGQRAGTCVLEYATPLQTLFAMSQYSQAGFSREDRLEQAKLFCRTLEDILADAPESQNNCRL-
IAYQqP
ADDSSFSLSQEVLRHLRQEEKEEVTVGSLKTSAVPSTSTMSQEPELLISGMEKPLPLRTDFS (Hu
STING (E315Q); no epitope tag) 8
MPHSSLHPSIPCPRGHGAQKAALVLLSACLVTLWGLGEPPEHTLRYLVLHLASLQLGLLLNGVCSLAEELRH-
IHSRYRGS
YWRTVRACLGCPLRRGALLLLSIYFYYSLPNAVGPPFTWMLALLGLSQALNILLGLKGLAPAEISAVCEKGNF-
NVAHGL
AWSYYIGYLRLILPELQARIRTYNQHYNNLLRGAVSQRLYILLPLDCGVPDNLSMADPNIRFLDKLPQQTGDH-
AGIKDR
VYSNSIYELLENGQRAGTCVLEYATPLQTLFAMSQYSQAGFSREDRLEQAKLFCRTLEDILADAPESQNNCRL-
IAYQEP
ADDSSFSLSQEVLRHLRQEEKEEVTVGSLKTSAVPSTSTMSQEPELLISGMEKPLPLaTDFS (Hu
STING (R375A); no epitope tag) 9
MPHSSLHPSIPCPRGHGAQKAALVLLSACLVTLWGLGEPPEHTLRYLVLHLASLQLGLLLNGVCSLAEELRH
IHSRYRGSYWRTVRACLGCPLRRGALLLLSIYFYYSLPNAVGPPFTWMLALLGLSQALNILLGLKGLAPAEIS
ALCEKGNFSMAHGLAWSYYIGYLRLILPELQARIRTYNQHYNNLLRGAVSQRLYILLPLDCGVPDNLSMAD
PNIRFLDKLPQQTGDHAGIKDRVYSNSIYELLENGQRAGTCVLEYATPLQTLFAMSQYSQAGFSREDRLEQ
AKLFCRTLEDILADAPESQNNCRLIAYQEPADDSSFSLSQEVLRHLRQEEKEEVTVGSLKTSAVPSTSTMSQE
PELLISGMEKPLPLRTDFS (Hu STING(V147L/N154S/V155M); no epitope tag)
10
MPHSSLHPSIPCPRGHGAQKAALVLLSACLVTLWGLGEPPEHTLRYLVLHLASLQLGLLLNGVCSLAEELR-
H
IHSRYRGSYWRTVRACLGCPLRRGALLLLSIYFYYSLPNAVGPPFTWMLALLGLSQALNILLGLKGLAPAEIS
ALCEKGNFSMAHGLAWSYYIGYLRLILPELQARIRTYNQHYNNLLRGAVSQRLYILLPLDCGVPDNLSMAD
PNIRFLDKLPQQTGDHAGIKDRVYSNSIYELLENGQRAGTCVLEYATPLQTLFAMSQYSQAGFSREDMLEQ
AKLFCRTLEDILADAPESQNNCRLIAYQEPADDSSFSLSQEVLRHLRQEEKEEVTVGSLKTSAVPSTSTMSQE
PELLISGMEKPLPLRTDFS (Hu STING(R284M/V147L/N154S/V155M); no epitope
tag) 11
METPKPRILPWLVSQLDLGQLEGVAWLDESRTRFRIPWKHGLRQDAQMADFGIFQAWAEASGAYTPGKDKP-
DVST
WKRNFRSALNRKEVLRLAADNSKDPYDPHKVYEFVTPGARDFVHLGASPDTNGKSSLPHSQENLPKLFDGLIL-
GPLKD
EGSSDLAIVSDPSQQLPSPNVNNFLNPAPQENPLKQLLAEEQWEFEVTAFYRGRQVFQQTLFCPGGLRLVGST-
ADMT
LPWQPVTLPDPEGFLTDKLVKEYVGQVLKGLGNGLALWQAGQCLWAQRLGHSHAFWALGEELLPDSGRGPDGE-
V
HKDKDGAVFDLRPFVADLIAFMEGSGHSPRYTLWFCMGEMWPQDQPWVKRLVMVKVVPTCLKELLEMAREGGA
SSLKTVDLHIDNSQPISLTSDQYKAYLQDLVEDMDFQATGNI (super mouse IRF3 S396D;
no epitope tag) 12
MGTPKPRILPWLVSQLDLGQLEGVAWVNKSRTRFRIPWKHGLRQDAQQEDFGIFQAWAEATGAYVPGRDKP-
DLPT
WKRNFRSALNRKEGLRLAEDRSKDPHDPHKIYEFVNSGVGDFSQPDTSPDTNGGGSTSDTQEDILDELLGNMV-
LAPL
PDPGPPSLAVAPEPCPQPLRSPSLDNPTPFPNLGPSENPLKRLLVPGEEWEFEVTAFYRGRQVFQQTISCPEG-
LRLVGS
EVGDRTLPGWPVTLPDPGMSLTDRGVMSYVRHVLSCLGGGLALWRAGQWLWAQRLGHCHTYWAVSEELLPNSG
HGPDGEVPKDKEGGVFDLGPFIVDLITFTEGSGRSPRYALWFCVGESWPQDQPWTKRLVMVKVVPTCLRALVE-
MA RVGGASSLENTVDLHIDNSHPLSLTSDQYKAYLQDLVEGMDFQGPGET (super human
IRF3 S396D; no epitope tag) 13
MALAPERAAPRVLFGEWLLGEISSGCYEGLQWLDEARTCFRVPWKHFARKDLSEADARIFKAWAVARGRWP-
PSSRG
GGPPPEAETAERAGWKTNFRCALRSTRRFVMLRDNSGDPADPHKVYALSRELCWREGPGTDQTEAEAPAAVPP-
PQ
GGPPGPFLAHTHAGLQAPGPLPAPAGDKGDLLLQAVQQSCLADHLLTASWGADPVPTKAPGEGQEGLPLTGAC-
AG
GPGLPAGELYGWAVETTPSPgpqpaalttgeaaapesphqaepylspspsactavqepspgaldvtimykgrt-
vlqkvvghpsctflyg
ppdpavratdpqqvafpspaelpdqkqlryteellrhvapglhlelrgpqlwarrmgkckvywevggppgsas-
pstpacllprncdtpifdfrvf
fqelvefrarqrrgsprytiylgfgqdlsagrpkekslvlvklepwlcrvhlegtqrEGVSSLDSSSLSLCLS-
SANSLYDDIECFLMELEQPA (Wild-type Hu IRF7 isoform A; P037 without
epitope tag) 14
MALAPERAAPRVLFGEWLLGEISSGCYEGLQWLDEARTCFRVPWKHFARKDLSEADARIFKAWAVARGRWP-
PSSRG
GGPPPEAETAERAGWKTNFRCALRSTRRFVMLRDNSGDPADPHKVYALSRELCWREGPGTDQTEAEAPAAVPP-
PQ
GGPPGPFLAHTHAGLQAPGPLPAPAGDKGDLLLQAVQQSCLADHLLTASWGADPVPTKAPGEGQEGLPLTGAC-
AG
GPGLPAGELYGWAVETTPSPgpqpaalttgeaaapesphqaepylspspsactavqepspgaldvtimykgrt-
vlqkvvghpsctflyg
ppdpavratdpqqvafpspaelpdqkqlryteellrhvapglhlelrgpqlwarrmgkckvywevggppgsas-
pstpacllprncdtpifdfrvf
fqelvefrarqrrgsprytiylgfgqdlsagrpkekslvlvklepwlcrvhlegtqrEGVSSLDSSdLdLCLS-
SANSLYDDIECFLMELEQPA (constitutively active Hu IRF7 S477D/S479D;
P033 without epitope tag) 15
MALAPERAAPRVLFGEWLLGEISSGCYEGLQWLDEARTCFRVPWKHFARKDLSEADARIFKAWAVARGRWP-
PSSRG
GGPPPEAETAERAGWKTNFRCALRSTRRFVMLRDNSGDPADPHKVYALSRELCWREGPGTDQTEAEAPAAVPP-
PQ
GGPPGPFLAHTHAGLQAPGPLPAPAGDKGDLLLQAVQQSCLADHLLTASWGADPVPTKAPGEGQEGLPLTGAC-
AG
GPGLPAGELYGWAVETTPSPgpqpaalttgeaaapesphqaepylspspsactavqepspgaldvtimykgrt-
vlqkvvghpsctflyg
ppdpavratdpqqvafpspaelpdqkqlryteellrhvapglhlelrgpqlwarrmgkckvywevggppgsas-
pstpacllprncdtpifdfrvf
fqelvefrarqrrgsprytiylgfgqdlsagrpkekslvlvklepwlcrvhlegtqrEGVSSLDdSdLSdCLS-
SANSLYDDIECFLMELEQPA (constitutively active Hu IRF7
S475D/S477D/L480D; P034 without epitope tag) 16
MALAPERAAPRVLFGEWLLGEISSGCYEGLQWLDEARTCFRVPWKHFARKDLSEADARIFKAWAVARGRWP-
PSSRG
GGPPPEAETAERAGWKTNFRCALRSTRRFVMLRDNSGDPADPHKVYALSRELCWREGPGTDQTEAEAPAAVPP-
PQ
GGPPGPFLAHTHAGLQAPGPLPAPAGDKGDLLLQAVQQSCLADHLLTASWGADPVPTKAPGEGQEGLPLTGAC-
AG
GPGLPAGELYGWAVETTPSPgpqpaalttgeaaapesphqaepylspspsactavqepspgaldvtimykgrt-
vlqkvvghpsctflyg
ppdpavratdpqqvafpspaelpdqkqlryteellrhvapglhlelrgpqlwarrmgkckvywevggppgsas-
pstpacllprncdtpifdfrvf
fqelvefrarqrrgsprytiylgfgqdlsagrpkekslvlvklepwlcrvhlegtqrEGVSSLDdddLdLCLd-
SANdLYDDIECFLMELEQPA (constitutively active Hu IRF7
S475D/S476D/S477D/S479D/S483D/S487D; P035 without epitope tag) 17
MALAPERAAPRVLFGEWLLGEISSGCYEGLQWLDEARTCFRVPWKHFARKDLSEADARIFKAWAVARGRWP-
PSSRG
GGPPPEAETAERAGWKTNFRCALRSTRRFVMLRDNSGDPADPHKVYALSRELCWREGPGTDQTEAEAPAAVPP-
PQ
GGPPGPFLAHTHAGLQAPGPLPAPAGDKGDLLLQAVQQSCLADHLLTASWGADPVPTKAPGEGQEGLPLTGAC-
AG GPGLPAGELYGWAVETTPSPEGVSSLDSSSLSLCLSSANSLYDDIECFLMELEQPA
(constitutively active truncated Hu IRF7 1-246 + 468-503; P032
without epitope tag) 18
MALAPERAAPRVLFGEWLLGEISSGCYEGLQWLDEARTCFRVPWKHFARKDLSEADARIFKAWAVARGRWP-
PSSRG
GGPPPEAETAERAGWKTNFRCALRSTRRFVMLRDNSGDPADPHKVYALSRELCWREGPGTDQTEAEAPAAVPP-
PQ
GGPPGPFLAHTHAGLQAPGPLPAPAGDKGDLLLQAVQQSCLADHLLTASWGADPVPTKAPGEGQEGLPLTGAC-
AG GPGLPAGELYGWAVETTPSPEGVSSLDdddLdLCLdSANdLYDDIECFLMELEQPA
(constitutively active truncated Hu IRF7 1-246 + 468-503 plus
S475D/S476D/S477D/S479D/S483D/S487D; P036 without epitope tag) 19
MALAPERAAPRVLFGEWLLGEISSGCYEGLQWLDEARTCFRVPWKHFARKDLSEADARIFKAWAVARGRWP-
PSSRG
GGPPPEAETAERAGWKTNFRCALRSTRRFVMLRDNSGDPADPHKVYALSRELCWREGPGTDQTEAEAPAAVPP-
PQ
gpqpaalttgeaaapesphqaepylspspsactavqepspgaldvtimykgrtvlqkvvghpsctflygppdp-
avratdpqqvafpspaelpd
qkqlryteellrhvapglhlelrgpqlwarrmgkckvywevggppgsaspstpacllprncdtpifdfrvffq-
elvefrarqrrgsprytiylgfgqdl
sagrpkekslvlvklepwlcrvhlegtqrEGVSSLDSSSLSLCLSSANSLYDDIECFLMELEQPA
(truncated Hu IRF7 1-151 + 247-503; P038 without epitope tag; null
mutation) 20
MGGPPGPFLAHTHAGLQAPGPLPAPAGDKGDLLLQAVQQSCLADHLLTASWGADPVPTKAPGEGQEGLPLT-
GACA
GGPGLPAGELYGWAVETTPSPgpqpaalttgeaaapesphqaepylspspsactavqepspgaldvtimykgr-
tvlqkvvghpsctfly
gppdpavratdpqqvafpspaelpdqkqlryteellrhvapglhlelrgpqlwarrmgkckvywevggppgsa-
spstpacllprncdtpifdfr
vffqelvefrarqrrgsprytiylgfgqdlsagrpkekslvlvklepwlcrvhlegtqrEGVSSLDSSSLSLC-
LSSANSLYDDIECFLMELEQPA (truncated Hu IRF7 152-503; P039 without
epitope tag; null mutation) 21
TCAAGCTTTTGGACCCTCGTACAGAAGCTAATACGACTCACTATAGGGAAATAAGAGAGAAAAGAAGAGTA-
AGA AGAAATATAAGAGCCACC (5' UTR) 22
TGATAATAGGCTGGAGCCTCGGTGGCCATGCTTCTTGCCCCTTGGGCCTCCCCCCAGCCCCTCCTCCCCTT-
CCTGC ACCCGTACCCCCGTGGTCTTTGAATAAAGTCTGAGTGGGCGGC
(3' UTR) 23
TGATAATAGGCTGGAGCCTCGGTGGCCATGCTTCTTGCCCCTTGGGCCCAAACACCATTGTCACACTCCAT-
CCCC
CCAGCCCCTCCTCCCCTTCCTCCATAAAGTAGGAAACACTACATGCACCCGTACCCCCGTGGTCTTTGAATAA-
AGT CTGAGTGGGCGGC (3' UTR with mi-122 and mi-142.3p sites) 24
GSGATNFSLLKQAGDVEENPGP (2A peptide amino acid sequence) 25
GGAAGCGGAGCTACTAACTTCAGCCTGCTGAAGCAGGCTGGAGACGTGGAGGAGAACCCTGGACCT
(Nucleotide sequence encoding 2A peptide) 26
TCCGGACTCAGATCCGGGGATCTCAAAATTGTCGCTCCTGTCAAACAAACTCTTAACTTTGATTTACTCAA-
ACTGG CTGGGGATGTAGAAAGCAATCCAGGTCCACTC (Nucleotide sequence
encoding 2A peptide) 27
GACAGUGCAGUCACCCAUAAAGUAGAAAGCACUACUAACAGCACUGGAGGGUGUAGUGUUUCCUACUUUA
UGGAUGAGUGUACUGUG (miR-142) 28 UGUAGUGUUUCCUACUUUAUGGA (miR-142-3p)
29 UCCAUAAAGUAGGAAACACUACA (miR-142-3p binding site) 30
CAUAAAGUAGAAAGCACUACU (miR-142-5p) 31 AGUAGUGCUUUCUACUUUAUG
(miR-142-5p binding site) 32 AACGCCAUUAUCACACUAAAUA (miR-122-3p) 33
UGGAGUGUGACAAUGGUGUUUG (miR-122-5p) 34 UAGCUUAUCAGACUGAUGUUGA
(miR-21-5p) 35 CAACACCAGUCGAUGGGCUGU (miR-21-3p) 36
MKLVVVGADGVGKSAL (KRAS(G12D)15mer) 37 MKLVVVGAVGVGKSAL
(KRAS(G12V)15mer) 38 MLVVVGAGDVGKSALT (KRAS(G13D)15mer) 39
MTEYKLVVVGADGVGKSALTIQLIQ (KRAS(G12D)25mer) 40
MTEYKLVVVGAVGVGKSALTIQLIQ (KRAS(G12V)25mer) 41
MTEYKLVVVGAGDVGKSALTIQLIQ (KRAS(G13D)25mer) 42
MKLVVVGADGVGKSALKLVVVGADGVGKSALKLVVVGADGVGKSAL (KRAS(G12D)15mer^3)
43 MKLVVVGAVGVGKSALKLVVVGAVGVGKSALKLVVVGAVGVGKSAL
(KRAS(G12V)15mer^3) 44
MLVVVGAGDVGKSALTLVVVGAGDVGKSALTLVVVGAGDVGKSALT (KRAS(G13D)15mer^3)
45
MTEYKLVVVGADGVGKSALTIQLIQMTEYKLVVVGADGVGKSALTIQLIQMTEYKLVVVGADGVGKSALTI-
QLIQ (KRAS(G12D)25mer^3) 46
MTEYKLVVVGAVGVGKSALTIQLIQMTEYKLVVVGAVGVGKSALTIQLIQMTEYKLVVVGAVGVGKSALTI-
QLIQ (KRAS(G12V)25mer^3) 47
MTEYKLVVVGAGDVGKSALTIQLIQMTEYKLVVVGAGDVGKSALTIQLIQMTEYKLVVVGAGDVGKSALTI-
QLIQ (KRAS(G13D)25mer^3) 48
MPHSSLHPSIPCPRGHGAQKAALVLLSACLVTLWGLGEPPEHTLRYLVLHLASLQLGLLLNGVCSLAEELR-
HIHSRYR
GSYWRTVRACLGCPLRRGALLLLSIYFYYSLPNAVGPPFTWMLALLGLSQALNILLGLKGLAPAEISAVCEKG-
NFNM
AHGLAWSYYIGYLRLILPELQARIRTYNQHYNNLLRGAVSQRLYILLPLDCGVPDNLSMADPNIRFLDKLPQQ-
TGDH
AGIKDRVYSNSIYELLENGQRAGTCVLEYATPLQTLFAMSQYSQAGFSREDRLEQAKLFCRTLEDILADAPES-
QNNC
RLIAYQEPADDSSFSLSQEVLRHLRQEEKEEVTVGSLKTSAVPSTSTMSQEPELLISGMEKPLPLRTDFSATN-
FSLLKQ AGDVEENPGPMKLVVVGADGVGKSAL (KRAS(G12D)15mer_nt.STING(V155M))
49
MPHSSLHPSIPCPRGHGAQKAALVLLSACLVTLWGLGEPPEHTLRYLVLHLASLQLGLLLNGVCSLAEELR-
HIHSRYR
GSYWRTVRACLGCPLRRGALLLLSIYFYYSLPNAVGPPFTWMLALLGLSQALNILLGLKGLAPAEISAVCEKG-
NFNM
AHGLAWSYYIGYLRLILPELQARIRTYNQHYNNLLRGAVSQRLYILLPLDCGVPDNLSMADPNIRFLDKLPQQ-
TGDH
AGIKDRVYSNSIYELLENGQRAGTCVLEYATPLQTLFAMSQYSQAGFSREDRLEQAKLFCRTLEDILADAPES-
QNNC
RLIAYQEPADDSSFSLSQEVLRHLRQEEKEEVTVGSLKTSAVPSTSTMSQEPELLISGMEKPLPLRTDFSATN-
FSLLKQ AGDVEENPGPMKLVVVGAVGVGKSAL (KRAS(G12V)15mer_nt.STING(V155M)
50
MPHSSLHPSIPCPRGHGAQKAALVLLSACLVTLWGLGEPPEHTLRYLVLHLASLQLGLLLNGVCSLAEELR-
HIHSRYR
GSYWRTVRACLGCPLRRGALLLLSIYFYYSLPNAVGPPFTWMLALLGLSQALNILLGLKGLAPAEISAVCEKG-
NFNM
AHGLAWSYYIGYLRLILPELQARIRTYNQHYNNLLRGAVSQRLYILLPLDCGVPDNLSMADPNIRFLDKLPQQ-
TGDH
AGIKDRVYSNSIYELLENGQRAGTCVLEYATPLQTLFAMSQYSQAGFSREDRLEQAKLFCRTLEDILADAPES-
QNNC
RLIAYQEPADDSSFSLSQEVLRHLRQEEKEEVTVGSLKTSAVPSTSTMSQEPELLISGMEKPLPLRTDFSATN-
FSLLKQ AGDVEENPGPMLVVVGAGDVGKSALT (KRAS(G13D)15mer_nt.STING(V155M)
51
MPHSSLHPSIPCPRGHGAQKAALVLLSACLVTLWGLGEPPEHTLRYLVLHLASLQLGLLLNGVCSLAEELR-
HIHSRYR
GSYWRTVRACLGCPLRRGALLLLSIYFYYSLPNAVGPPFTWMLALLGLSQALNILLGLKGLAPAEISAVCEKG-
NFNM
AHGLAWSYYIGYLRLILPELQARIRTYNQHYNNLLRGAVSQRLYILLPLDCGVPDNLSMADPNIRFLDKLPQQ-
TGDH
AGIKDRVYSNSIYELLENGQRAGTCVLEYATPLQTLFAMSQYSQAGFSREDRLEQAKLFCRTLEDILADAPES-
QNNC
RLIAYQEPADDSSFSLSQEVLRHLRQEEKEEVTVGSLKTSAVPSTSTMSQEPELLISGMEKPLPLRTDFSATN-
FSLLKQ AGDVEENPGPMTEYKLVVVGADGVGKSALTIQLIQ
(KRAS(G12D)25mer_nt.STING(V155M)) 52
MPHSSLHPSIPCPRGHGAQKAALVLLSACLVTLWGLGEPPEHTLRYLVLHLASLQLGLLLNGVCSLAEELR-
HIHSRYR
GSYWRTVRACLGCPLRRGALLLLSIYFYYSLPNAVGPPFTWMLALLGLSQALNILLGLKGLAPAEISAVCEKG-
NFNM
AHGLAWSYYIGYLRLILPELQARIRTYNQHYNNLLRGAVSQRLYILLPLDCGVPDNLSMADPNIRFLDKLPQQ-
TGDH
AGIKDRVYSNSIYELLENGQRAGTCVLEYATPLQTLFAMSQYSQAGFSREDRLEQAKLFCRTLEDILADAPES-
QNNC
RLIAYQEPADDSSFSLSQEVLRHLRQEEKEEVTVGSLKTSAVPSTSTMSQEPELLISGMEKPLPLRTDFSATN-
FSLLKQ AGDVEENPGPMTEYKLVVVGAVGVGKSALTIQLIQ
(KRAS(G12V)25mer_nt.STING(V155M) 53
MPHSSLHPSIPCPRGHGAQKAALVLLSACLVTLWGLGEPPEHTLRYLVLHLASLQLGLLLNGVCSLAEELR-
HIHSRYR
GSYWRTVRACLGCPLRRGALLLLSIYFYYSLPNAVGPPFTWMLALLGLSQALNILLGLKGLAPAEISAVCEKG-
NFNM
AHGLAWSYYIGYLRLILPELQARIRTYNQHYNNLLRGAVSQRLYILLPLDCGVPDNLSMADPNIRFLDKLPQQ-
TGDH
AGIKDRVYSNSIYELLENGQRAGTCVLEYATPLQTLFAMSQYSQAGFSREDRLEQAKLFCRTLEDILADAPES-
QNNC
RLIAYQEPADDSSFSLSQEVLRHLRQEEKEEVTVGSLKTSAVPSTSTMSQEPELLISGMEKPLPLRTDFSATN-
FSLLKQ AGDVEENPGPMTEYKLVVVGAGDVGKSALTIQLIQ
(KRAS(G13D)25mer_nt.STING(V155M) 54
MPHSSLHPSIPCPRGHGAQKAALVLLSACLVTLWGLGEPPEHTLRYLVLHLASLQLGLLLNGVCSLAEELR-
HIHSRYRGS
YWRTVRACLGCPLRRGALLLLSIYFYYSLPNAVGPPFTWMLALLGLSQALNILLGLKGLAPAEISAVCEKGNF-
NMAHGL
AWSYYIGYLRLILPELQARIRTYNQHYNNLLRGAVSQRLYILLPLDCGVPDNLSMADPNIRFLDKLPQQTGDH-
AGIKDR
VYSNSIYELLENGQRAGTCVLEYATPLQTLFAMSQYSQAGFSREDRLEQAKLFCRTLEDILADAPESQNNCRL-
IAYQEP
ADDSSFSLSQEVLRHLRQEEKEEVTVGSLKTSAVPSTSTMSQEPELLISGMEKPLPLRTDFSATNFSLLKQAG-
DVEENP GPMKLVVVGADGVGKSALKLVVVGADGVGKSALKLVVVGADGVGKSAL
(KRAS(G12D)15mer^3_nt.STING(V155M)) 55
MPHSSLHPSIPCPRGHGAQKAALVLLSACLVTLWGLGEPPEHTLRYLVLHLASLQLGLLLNGVCSLAEELR-
HIHSRYRGS
YWRTVRACLGCPLRRGALLLLSIYFYYSLPNAVGPPFTWMLALLGLSQALNILLGLKGLAPAEISAVCEKGNF-
NMAHGL
AWSYYIGYLRLILPELQARIRTYNQHYNNLLRGAVSQRLYILLPLDCGVPDNLSMADPNIRFLDKLPQQTGDH-
AGIKDR
VYSNSIYELLENGQRAGTCVLEYATPLQTLFAMSQYSQAGFSREDRLEQAKLFCRTLEDILADAPESQNNCRL-
IAYQEP
ADDSSFSLSQEVLRHLRQEEKEEVTVGSLKTSAVPSTSTMSQEPELLISGMEKPLPLRTDFSATNFSLLKQAG-
DVEENP GPMKLVVVGAVGVGKSALKLVVVGAVGVGKSALKLVVVGAVGVGKSAL
(KRAS(G12V)15mer^3_nt.STING(V155M) 56
MPHSSLHPSIPCPRGHGAQKAALVLLSACLVTLWGLGEPPEHTLRYLVLHLASLQLGLLLNGVCSLAEELR-
HIHSRYRGS
YWRTVRACLGCPLRRGALLLLSIYFYYSLPNAVGPPFTWMLALLGLSQALNILLGLKGLAPAEISAVCEKGNF-
NMAHGL
AWSYYIGYLRLILPELQARIRTYNQHYNNLLRGAVSQRLYILLPLDCGVPDNLSMADPNIRFLDKLPQQTGDH-
AGIKDR
VYSNSIYELLENGQRAGTCVLEYATPLQTLFAMSQYSQAGFSREDRLEQAKLFCRTLEDILADAPESQNNCRL-
IAYQEP
ADDSSFSLSQEVLRHLRQEEKEEVTVGSLKTSAVPSTSTMSQEPELLISGMEKPLPLRTDFSATNFSLLKQAG-
DVEENP GPMLVVVGAGDVGKSALTLVVVGAGDVGKSALTLVVVGAGDVGKSALT
(KRAS(G13D)15mer^3_nt.STING(V155M) 57
MPHSSLHPSIPCPRGHGAQKAALVLLSACLVTLWGLGEPPEHTLRYLVLHLASLQLGLLLNGVCSLAEELR-
HIHSRYRGS
YWRTVRACLGCPLRRGALLLLSIYFYYSLPNAVGPPFTWMLALLGLSQALNILLGLKGLAPAEISAVCEKGNF-
NMAHGL
AWSYYIGYLRLILPELQARIRTYNQHYNNLLRGAVSQRLYILLPLDCGVPDNLSMADPNIRFLDKLPQQTGDH-
AGIKDR
VYSNSIYELLENGQRAGTCVLEYATPLQTLFAMSQYSQAGFSREDRLEQAKLFCRTLEDILADAPESQNNCRL-
IAYQEP
ADDSSFSLSQEVLRHLRQEEKEEVTVGSLKTSAVPSTSTMSQEPELLISGMEKPLPLRTDFSATNFSLLKQAG-
DVEENP
GPMTEYKLVVVGADGVGKSALTIQLIQMTEYKLVVVGADGVGKSALTIQLIQMTEYKLVVVGADGVGKSALTI-
QLIQ (KRAS(G12D)25mer^3_nt.STING(V155M)) 58
MPHSSLHPSIPCPRGHGAQKAALVLLSACLVTLWGLGEPPEHTLRYLVLHLASLQLGLLLNGVCSLAEELR-
HIHSRYRGS
YWRTVRACLGCPLRRGALLLLSIYFYYSLPNAVGPPFTWMLALLGLSQALNILLGLKGLAPAEISAVCEKGNF-
NMAHGL
AWSYYIGYLRLILPELQARIRTYNQHYNNLLRGAVSQRLYILLPLDCGVPDNLSMADPNIRFLDKLPQQTGDH-
AGIKDR
VYSNSIYELLENGQRAGTCVLEYATPLQTLFAMSQYSQAGFSREDRLEQAKLFCRTLEDILADAPESQNNCRL-
IAYQEP
ADDSSFSLSQEVLRHLRQEEKEEVTVGSLKTSAVPSTSTMSQEPELLISGMEKPLPLRTDFSATNFSLLKQAG-
DVEENP
GPMTEYKLVVVGAVGVGKSALTIQLIQMTEYKLVVVGAVGVGKSALTIQLIQMTEYKLVVVGAVGVGKSALTI-
QLIQ (KRAS(G12V)25mer^3_nt.STING(V155M) 59
MPHSSLHPSIPCPRGHGAQKAALVLLSACLVTLWGLGEPPEHTLRYLVLHLASLQLGLLLNGVCSLAEELR-
HIHSRYRGS
YWRTVRACLGCPLRRGALLLLSIYFYYSLPNAVGPPFTWMLALLGLSQALNILLGLKGLAPAEISAVCEKGNF-
NMAHGL
AWSYYIGYLRLILPELQARIRTYNQHYNNLLRGAVSQRLYILLPLDCGVPDNLSMADPNIRFLDKLPQQTGDH-
AGIKDR
VYSNSIYELLENGQRAGTCVLEYATPLQTLFAMSQYSQAGFSREDRLEQAKLFCRTLEDILADAPESQNNCRL-
IAYQEP
ADDSSFSLSQEVLRHLRQEEKEEVTVGSLKTSAVPSTSTMSQEPELLISGMEKPLPLRTDFSATNFSLLKQAG-
DVEENP
GPMTEYKLVVVGAGDVGKSALTIQLIQMTEYKLVVVGAGDVGKSALTIQLIQMTEYKLVVVGAGDVGKSALTI-
QLIQ (KRAS(G13D)25mer^3_nt.STING(V155M) 60
MKLVVVGADGVGKSALATNFSLLKQAGDVEENPGPMPHSSLHPSIPCPRGHGAQKAALVLLSACLVTLWGL-
GEP
PEHTLRYLVLHLASLQLGLLLNGVCSLAEELRHIHSRYRGSYWRTVRACLGCPLRRGALLLLSIYFYYSLPNA-
VGPPFT
WMLALLGLSQALNILLGLKGLAPAEISAVCEKGNFNMAHGLAWSYYIGYLRLILPELQARIRTYNQHYNNLLR-
GAV
SQRLYILLPLDCGVPDNLSMADPNIRFLDKLPQQTGDHAGIKDRVYSNSIYELLENGQRAGTCVLEYATPLQT-
LFAM
SQYSQAGFSREDRLEQAKLFCRTLEDILADAPESQNNCRLIAYQEPADDSSFSLSQEVLRHLRQEEKEEVTVG-
SLKTS AVPSTSTMSQEPELLISGMEKPLPLRTDFS
(KRAS(G12D)15mer_ct.STING(V155M)) 61
MKLVVVGAVGVGKSALATNFSLLKQAGDVEENPGPMPHSSLHPSIPCPRGHGAQKAALVLLSACLVTLWGL-
GEP
PEHTLRYLVLHLASLQLGLLLNGVCSLAEELRHIHSRYRGSYWRTVRACLGCPLRRGALLLLSIYFYYSLPNA-
VGPPFT
WMLALLGLSQALNILLGLKGLAPAEISAVCEKGNFNMAHGLAWSYYIGYLRLILPELQARIRTYNQHYNNLLR-
GAV
SQRLYILLPLDCGVPDNLSMADPNIRFLDKLPQQTGDHAGIKDRVYSNSIYELLENGQRAGTCVLEYATPLQT-
LFAM
SQYSQAGFSREDRLEQAKLFCRTLEDILADAPESQNNCRLIAYQEPADDSSFSLSQEVLRHLRQEEKEEVTVG-
SLKTS AVPSTSTMSQEPELLISGMEKPLPLRTDFS
(KRAS(G12V)15mer_ct.STING(V155M) 62
MLVVVGAGDVGKSALTATNFSLLKQAGDVEENPGPMPHSSLHPSIPCPRGHGAQKAALVLLSACLVTLWGL-
GEP
PEHTLRYLVLHLASLQLGLLLNGVCSLAEELRHIHSRYRGSYWRTVRACLGCPLRRGALLLLSIYFYYSLPNA-
VGPPFT
WMLALLGLSQALNILLGLKGLAPAEISAVCEKGNFNMAHGLAWSYYIGYLRLILPELQARIRTYNQHYNNLLR-
GAV
SQRLYILLPLDCGVPDNLSMADPNIRFLDKLPQQTGDHAGIKDRVYSNSIYELLENGQRAGTCVLEYATPLQT-
LFAM
SQYSQAGFSREDRLEQAKLFCRTLEDILADAPESQNNCRLIAYQEPADDSSFSLSQEVLRHLRQEEKEEVTVG-
SLKTS AVPSTSTMSQEPELLISGMEKPLPLRTDFS
(KRAS(G13D)15mer_ct.STING(V155M) 63
MTEYKLVVVGADGVGKSALTIQLIQATNFSLLKQAGDVEENPGPMPHSSLHPSIPCPRGHGAQKAALVLLS-
ACLVT
LWGLGEPPEHTLRYLVLHLASLQLGLLLNGVCSLAEELRHIHSRYRGSYWRTVRACLGCPLRRGALLLLSIYF-
YYSLPN
AVGPPFTWMLALLGLSQALNILLGLKGLAPAEISAVCEKGNFNMAHGLAWSYYIGYLRLILPELQARIRTYNQ-
HYN
NLLRGAVSQRLYILLPLDCGVPDNLSMADPNIRFLDKLPQQTGDHAGIKDRVYSNSIYELLENGQRAGTCVLE-
YATP
LQTLFAMSQYSQAGFSREDRLEQAKLFCRTLEDILADAPESQNNCRLIAYQEPADDSSFSLSQEVLRHLRQEE-
KEEV TVGSLKTSAVPSTSTMSQEPELLISGMEKPLPLRTDFS
(KRAS(G12D)25mer_ct.STING(V155M)) 64
MTEYKLVVVGAVGVGKSALTIQLIQATNFSLLKQAGDVEENPGPMPHSSLHPSIPCPRGHGAQKAALVLLS-
ACLVT
LWGLGEPPEHTLRYLVLHLASLQLGLLLNGVCSLAEELRHIHSRYRGSYWRTVRACLGCPLRRGALLLLSIYF-
YYSLPN
AVGPPFTWMLALLGLSQALNILLGLKGLAPAEISAVCEKGNFNMAHGLAWSYYIGYLRLILPELQARIRTYNQ-
HYN
NLLRGAVSQRLYILLPLDCGVPDNLSMADPNIRFLDKLPQQTGDHAGIKDRVYSNSIYELLENGQRAGTCVLE-
YATP
LQTLFAMSQYSQAGFSREDRLEQAKLFCRTLEDILADAPESQNNCRLIAYQEPADDSSFSLSQEVLRHLRQEE-
KEEV TVGSLKTSAVPSTSTMSQEPELLISGMEKPLPLRTDFS
(KRAS(G12V)25mer_ct.STING(V155M) 65
MTEYKLVVVGAGDVGKSALTIQLIQATNFSLLKQAGDVEENPGPMPHSSLHPSIPCPRGHGAQKAALVLLS-
ACLVT
LWGLGEPPEHTLRYLVLHLASLQLGLLLNGVCSLAEELRHIHSRYRGSYWRTVRACLGCPLRRGALLLLSIYF-
YYSLPN
AVGPPFTWMLALLGLSQALNILLGLKGLAPAEISAVCEKGNFNMAHGLAWSYYIGYLRLILPELQARIRTYNQ-
HYN
NLLRGAVSQRLYILLPLDCGVPDNLSMADPNIRFLDKLPQQTGDHAGIKDRVYSNSIYELLENGQRAGTCVLE-
YATP
LQTLFAMSQYSQAGFSREDRLEQAKLFCRTLEDILADAPESQNNCRLIAYQEPADDSSFSLSQEVLRHLRQEE-
KEEV TVGSLKTSAVPSTSTMSQEPELLISGMEKPLPLRTDFS
(KRAS(G13D)25mer_ct.STING(V155M) 66
MKLVVVGADGVGKSALKLVVVGADGVGKSALKLVVVGADGVGKSALATNFSLLKQAGDVEENPGPMPHSSL-
HPSIP
CPRGHGAQKAALVLLSACLVTLWGLGEPPEHTLRYLVLHLASLQLGLLLNGVCSLAEELRHIHSRYRGSYWRT-
VRACLG
CPLRRGALLLLSIYFYYSLPNAVGPPFTWMLALLGLSQALNILLGLKGLAPAEISAVCEKGNFNMAHGLAWSY-
YIGYLRL
ILPELQARIRTYNQHYNNLLRGAVSQRLYILLPLDCGVPDNLSMADPNIRFLDKLPQQTGDHAGIKDRVYSNS-
IYELLEN
GQRAGTCVLEYATPLQTLFAMSQYSQAGFSREDRLEQAKLFCRTLEDILADAPESQNNCRLIAYQEPADDSSF-
SLSQEV LRHLRQEEKEEVTVGSLKTSAVPSTSTMSQEPELLISGMEKPLPLRTDFS
(KRAS(G12D)15mer^3_ct.STING(V155M)) 67
MKLVVVGAVGVGKSALKLVVVGAVGVGKSALKLVVVGAVGVGKSALATNFSLLKQAGDVEENPGPMPHSSL-
HPSIP
CPRGHGAQKAALVLLSACLVTLWGLGEPPEHTLRYLVLHLASLQLGLLLNGVCSLAEELRHIHSRYRGSYWRT-
VRACLG
CPLRRGALLLLSIYFYYSLPNAVGPPFTWMLALLGLSQALNILLGLKGLAPAEISAVCEKGNFNMAHGLAWSY-
YIGYLRL
ILPELQARIRTYNQHYNNLLRGAVSQRLYILLPLDCGVPDNLSMADPNIRFLDKLPQQTGDHAGIKDRVYSNS-
IYELLEN
GQRAGTCVLEYATPLQTLFAMSQYSQAGFSREDRLEQAKLFCRTLEDILADAPESQNNCRLIAYQEPADDSSF-
SLSQEV LRHLRQEEKEEVTVGSLKTSAVPSTSTMSQEPELLISGMEKPLPLRTDFS
(KRAS(G12V)15mer^3_ct.STING(V155M) 68
MLVVVGAGDVGKSALTLVVVGAGDVGKSALTLVVVGAGDVGKSALTATNFSLLKQAGDVEENPGPMPHSSL-
HPSIP
CPRGHGAQKAALVLLSACLVTLWGLGEPPEHTLRYLVLHLASLQLGLLLNGVCSLAEELRHIHSRYRGSYWRT-
VRACLG
CPLRRGALLLLSIYFYYSLPNAVGPPFTWMLALLGLSQALNILLGLKGLAPAEISAVCEKGNFNMAHGLAWSY-
YIGYLRL
ILPELQARIRTYNQHYNNLLRGAVSQRLYILLPLDCGVPDNLSMADPNIRFLDKLPQQTGDHAGIKDRVYSNS-
IYELLEN
GQRAGTCVLEYATPLQTLFAMSQYSQAGFSREDRLEQAKLFCRTLEDILADAPESQNNCRLIAYQEPADDSSF-
SLSQEV LRHLRQEEKEEVTVGSLKTSAVPSTSTMSQEPELLISGMEKPLPLRTDFS
(KRAS(G13D)15mer^3_ct.STING(V155M) 69
MTEYKLVVVGADGVGKSALTIQLIQMTEYKLVVVGADGVGKSALTIQLIQMTEYKLVVVGADGVGKSALTI-
QLIQATN
FSLLKQAGDVEENPGPMPHSSLHPSIPCPRGHGAQKAALVLLSACLVTLWGLGEPPEHTLRYLVLHLASLQLG-
LLLNG
VCSLAEELRHIHSRYRGSYWRTVRACLGCPLRRGALLLLSIYFYYSLPNAVGPPFTWMLALLGLSQALNILLG-
LKGLAPA
EISAVCEKGNFNMAHGLAWSYYIGYLRLILPELQARIRTYNQHYNNLLRGAVSQRLYILLPLDCGVPDNLSMA-
DPNIRF
LDKLPQQTGDHAGIKDRVYSNSIYELLENGQRAGTCVLEYATPLQTLFAMSQYSQAGFSREDRLEQAKLFCRT-
LEDILA
DAPESQNNCRLIAYQEPADDSSFSLSQEVLRHLRQEEKEEVTVGSLKTSAVPSTSTMSQEPELLISGMEKPLP-
LRTDFS (KRAS(G12D)25mer^3_ct.STING(V155M)) 70
MTEYKLVVVGAVGVGKSALTIQLIQMTEYKLVVVGAVGVGKSALTIQLIQMTEYKLVVVGAVGVGKSALTI-
QLIQATN
FSLLKQAGDVEENPGPMPHSSLHPSIPCPRGHGAQKAALVLLSACLVTLWGLGEPPEHTLRYLVLHLASLQLG-
LLLNG
VCSLAEELRHIHSRYRGSYWRTVRACLGCPLRRGALLLLSIYFYYSLPNAVGPPFTWMLALLGLSQALNILLG-
LKGLAPA
EISAVCEKGNFNMAHGLAWSYYIGYLRLILPELQARIRTYNQHYNNLLRGAVSQRLYILLPLDCGVPDNLSMA-
DPNIRF
LDKLPQQTGDHAGIKDRVYSNSIYELLENGQRAGTCVLEYATPLQTLFAMSQYSQAGFSREDRLEQAKLFCRT-
LEDILA
DAPESQNNCRLIAYQEPADDSSFSLSQEVLRHLRQEEKEEVTVGSLKTSAVPSTSTMSQEPELLISGMEKPLP-
LRTDFS (KRAS(G12V)25mer^3_ct.STING(V155M) 71
MTEYKLVVVGAGDVGKSALTIQLIQMTEYKLVVVGAGDVGKSALTIQLIQMTEYKLVVVGAGDVGKSALTI-
QLIQATN
FSLLKQAGDVEENPGPMPHSSLHPSIPCPRGHGAQKAALVLLSACLVTLWGLGEPPEHTLRYLVLHLASLQLG-
LLLNG
VCSLAEELRHIHSRYRGSYWRTVRACLGCPLRRGALLLLSIYFYYSLPNAVGPPFTWMLALLGLSQALNILLG-
LKGLAPA
EISAVCEKGNFNMAHGLAWSYYIGYLRLILPELQARIRTYNQHYNNLLRGAVSQRLYILLPLDCGVPDNLSMA-
DPNIRF
LDKLPQQTGDHAGIKDRVYSNSIYELLENGQRAGTCVLEYATPLQTLFAMSQYSQAGFSREDRLEQAKLFCRT-
LEDILA
DAPESQNNCRLIAYQEPADDSSFSLSQEVLRHLRQEEKEEVTVGSLKTSAVPSTSTMSQEPELLISGMEKPLP-
LRTDFS (KRAS(G13D)25mer^3_ct.STING(V155M) 72
MTEYKLVVVGACGVGKSALTIQLIQ (KRAS(G12C)25mer) 73
MTEYKLVVVGACGVGKSALTIQLIQMTEYKLVVVGACGVGKSALTIQLIQMTEYKLVVVGACGVGKSALTI-
QLIQ (KRAS(G12C)25mer^3) 74 MTEYKLVVVGAGGVGKSALTIQLIQ
(KRAS(WT)25mer) 75
MSAGDPRVGSGSLDSFMFSIPLVALNVGVRRRLSLFLNPRTPVAADWTLLAEEMGFEYLEIRELETRPDPT-
RSLLDAW
QGRSGASVGRLLELLALLDREDILKELKSRIEEDCQKYLGKQQNQESEKPLQVARVESSVPQTKELGGITTLD-
DPLGQTP
ELFDAFICYCPNDIEFVQEMIRQLEQTDYRLKLCVSDRDVLPGTCVWSIASELIEKRCRRMVVVVSDDYLQSK-
ECDFQT KFALSLSPGVQQKRPIPIKYKAMKKDFPSILRFITICDYTNPCTKSWFWTRLAKALSLP
(human myd88(L265P); P4027 without epitope tag) 76
MAAGGPGAGSAAPVSSTSSLPLAALNMRVRRRLSLFLNVRTQVAADWTALAEEMDFEYLEIRQLETQADPT-
GRLLD
AWQGRPGASVGRLLELLTKLGRDDVLLELGPSIEEDCQKYILKQQQEEAEKPLQVAAVDSSVPRTAELAGITT-
LDDPLG
HMPERFDAFICYCPSDIQFVQEMIRQLEQTNYRLKLCVSDRDVLPGTCVWSIASELIEKRCRRMVVVVSDDYL-
QSKEC
DFQTKFALSLSPGAHQKRPIPIKYKAMKKEFPSILRFITVCDYTNPCTKSWFWTRLAKALSLP
(mouse myd88(L265P); P4028 without epitope tag) 77
MGVGKSKLDKCPLSWHKKDSVDADQDGHESDSKNSEEACLRGFVEQSSGSEPPTGEQDQPEAKGAGPEEQD-
EEEF
LKFVILHAEDDTDEALRVQDLLQNDFGIRPGIVFAEMPCGRLHLQNLDDAVNGSAWTILLLTENFLRDTWCNF-
QFYTS
LMNSVSRQHKYNSVIPMRPLNSPLPRERTPLALQTINALEEESQGFSTQVERIFRESVFERQQSIWKETRSVS-
QKQFIA (Mouse TRAM (TICAM2); P4033 without epitope tag) 78
MSLWGLVSKMPPEKVQRLYVDFPQHLRHLLGDWLESQPWEFLVGSDAFCCNLASALLSDTVQHLQASVGEQ-
GEGS
TILQHISTLESIYQRDPLKLVATFRQILQGEKKAVMEQFRHLPMPFHWKQEELKFKTGLRRLQHRVGEIHLLR-
EALQKG
AEAGQVSLHSLIETPANGTGPSEALAMLLQETTGELEAAKALVLKRIQIWKRQQQLAGNGAPFEESLAPLQER-
CESLV
DIYSQLQQEVGAAGGELEPKTRASLTGRLDEVLRTLVTSCFLVEKQPPQVLKTQTKFQAGVRFLLGLRFLGAP-
AKPPLV
RADMVTEKQARELSVPQGPGAGAESTGEIINNTVPLENSIPGNCCSALFKNLLLKKIKRCERKGTESVTEEKC-
AVLFSAS
FTLGPGKLPIQLQALSLPLVVIVHGNQDNNAKATILWDNAFSEMDRVPFVVAERVPWEKMCETLNLKFMAEVG-
TNR
GLLPEHFLFLAQKIFNDNSLSMEAFQHRSVSWSQFNKEILLGRGFTFWQWFDGVLDLTKRCLRSYWSDRLIIG-
FISKQY
AASLLLNEPDGTFLLRFSDSEIGGITIAHVIRGQDGSPQIENIQPFSAKDLSIRSLGDRIRDLAQLKNLYPKK-
PKDEAFRSH
YKPEQMGKDGRGYVPATIKMTVERDQPLPTPELQMPTMVPSYDLGMAPDSSMSMQLGPDMVPQVYPPHSHSIP-
P
YQGLSPEESVNVLSAFQEPHLQMPPSLGQMSLPFDQPHPQGLLPCQPQEHAVSSPDPLLCSDVTMVEDSCLSQ-
PVT
AFPQGTWIGEDIFPPLLPPTEQDLTKLLLEGQGESGGGSLGAQPLLQPSHYGQSGISMSHMDLRANPSW
(STAT6 V547A/T548A); P008 with no epitope tag) 79
MSLWGLVSKMPPEKVQRLYVDFPQHLRHLLGDWLESQPWEFLVGSDAFCCNLASALLSDTVQHLQASVGEQ-
GEGS
TILQHISTLESIYQRDPLKLVATFRQILQGEKKAVMEQFRHLPMPFHWKQEELKFKTGLRRLQHRVGEIHLLR-
EALQKG
AEAGQVSLHSLIETPANGTGPSEALAMLLQETTGELEAAKALVLKRIQIWKRQQQLAGNGAPFEESLAPLQER-
CESLV
DIYSQLQQEVGAAGGELEPKTRASLTGRLDEVLRTLVTSCFLVEKQPPQVLKTQTKFQAGVRFLLGLRFLGAP-
AKPPLV
RADMVTEKQARELSVPQGPGAGAESTGEIINNTVPLENSIPGNCCSALFKNLLLKKIKRCERKGTESVTEEKC-
AVLFSAS
FTLGPGKLPIQLQALDLPLVVIVHGNQDNNAKATILWDNAFSEMDRVPFVVAERVPWEKMCETLNLKFMAEVG-
TN
RGLLPEHFLFLAQKIFNDNSLSMEAFQHRSVSWSQFNKEILLGRGFTFWQWFDGVLDLTKRCLRSYWSDRLII-
GFISKQ
YVTSLLLNEPDGTFLLRFSDSEIGGITIAHVIRGQDGSPQIENIQPFSAKDLSIRSLGDRIRDLAQLKNLYPK-
KPKDEAFRS
HYKPEQMGKDGRGYVPATIKMTVERDQPLPTPELQMPTMVPSYDLGMAPDSSMSMQLGPDMVPQVYPPHSHSI
PPYQGLSPEESVNVLSAFQEPHLQMPPSLGQMSLPFDQPHPQGLLPCQPQEHAVSSPDPLLCSDVTMVEDSCL-
SQP
VTAFPQGTWIGEDIFPPLLPPTEQDLTKLLLEGQGESGGGSLGAQPLLQPSHYGQSGISMSHMDLRANPSW
(STAT6 (S407D); P009 with no epitope tag) 80
MSLWGLVSKMPPEKVQRLYVDFPQHLRHLLGDWLESQPWEFLVGSDAFCCNLASALLSDTVQHLQASVGEQ-
GEGS
TILQHISTLESIYQRDPLKLVATFRQILQGEKKAVMEQFRHLPMPFHWKQEELKFKTGLRRLQHRVGEIHLLR-
EALQKG
AEAGQVSLHSLIETPANGTGPSEALAMLLQETTGELEAAKALVLKRIQIWKRQQQLAGNGAPFEESLAPLQER-
CESLV
DIYSQLQQEVGAAGGELEPKTRASLTGRLDEVLRTLVTSCFLVEKQPPQVLKTQTKFQAGVRFLLGLRFLGAP-
AKPPLV
RADMVTEKQARELSVPQGPGAGAESTGEIINNTVPLENSIPGNCCSALFKNLLLKKIKRCERKGTESVTEEKC-
AVLFSAS
FTLGPGKLPIQLQALDLPLVVIVHGNQDNNAKATILWDNAFSEMDRVPFVVAERVPWEKMCETLNLKFMAEVG-
TN
RGLLPEHFLFLAQKIFNDNSLSMEAFQHRSVSWSQFNKEILLGRGFTFWQWFDGVLDLTKRCLRSYWSDRLII-
GFISKQ
YAASLLLNEPDGTFLLRFSDSEIGGITIAHVIRGQDGSPQIENIQPFSAKDLSIRSLGDRIRDLAQLKNLYPK-
KPKDEAFRS
HYKPEQMGKDGRGYVPATIKMTVERDQPLPTPELQMPTMVPSYDLGMAPDSSMSMQLGPDMVPQVYPPHSHSI
PPYQGLSPEESVNVLSAFQEPHLQMPPSLGQMSLPFDQPHPQGLLPCQPQEHAVSSPDPLLCSDVTMVEDSCL-
SQP
VTAFPQGTWIGEDIFPPLLPPTEQDLTKLLLEGQGESGGGSLGAQPLLQPSHYGQSGISMSHMDLRANPSW
(STAT6 (S407D/V547A/T548A); P010 with no epitope tag) 81
MSLWGLVSKMPPEKVQRLYVDFPQHLRHLLGDWLESQPWEFLVGSDAFCCNLASALLSDTVQHLQASVGEQ-
GEGS
TILQHISTLESIYQRDPLKLVATFRQILQGEKKAVMEQFRHLPMPFHWKQEELKFKTGLRRLQHRVGEIHLLR-
EALQKG
AEAGQVSLHSLIETPANGTGPSEALAMLLQETTGELEAAKALVLKRIQIWKRQQQLAGNGAPFEESLAPLQER-
CESLV
DIYSQLQQEVGAAGGELEPKTRASLTGRLDEVLRTLVTSCFLVEKQPPQVLKTQTKFQAGVRFLLGLRFLGAP-
AKPPLV
RADMVTEKQARELSVPQGPGAGAESTGEIINNTVPLENSIPGNCCSALFKNLLLKKIKRCERKGTESVTEEKC-
AVLFSAS
FTLGPGKLPIQLQALSLPLVVIVHGNQDNNAKATILWDNAFSEMDRVPFVVAERVPWEKMCETLNLKFMAEVG-
TNR
GLLPEHFLFLAQKIFNDNSLSMEAFQHRSVSWSQFNKEILLGRGFTFWQWFDGVLDLTKRCLRSYWSDRLIIG-
FISKQY
AASLLLNEPDGTFLLRFSDSEIGGITIAHVIRGQDGSPQIENIQPFSAKDLSIRSLGDRIRDLAQLKNLYPKK-
PKDEAFRSH
YKPEQMGKDGRGFVPATIKMTVERDQPLPTPELQMPTMVPSYDLGMAPDSSMSMQLGPDMVPQVYPPHSHSIP-
P
YQGLSPEESVNVLSAFQEPHLQMPPSLGQMSLPFDQPHPQGLLPCQPQEHAVSSPDPLLCSDVTMVEDSCLSQ-
PVT
AFPQGTWIGEDIFPPLLPPTEQDLTKLLLEGQGESGGGSLGAQPLLQPSHYGQSGISMSHMDLRANPSW
(STAT6 (V547A/T548A/Y641F); P011 with no epitope tag) 82
SAEVIHQVEEALDTDEKEMLLFLCRDVAIDVVPPNVRDLLDILRERGKLSVGDLAELLYRVRRFDLLKRIL-
KMDRKAVET
HLLRNPHLVSDYRVLMAEIGEDLDKSDVSSLIFLMKDYMGRGKISKEKSFLDLVVELEKLNLVAPDQLDLLEK-
CLKNIHRI
DLKTKIQKYKQSVQGAGTSYRNVLQAAIQKSLKDPSNNFRLHNGRSKEQRLKEQLGAQQEPVKKSIQESEAFL-
PQSIPE
ERYKMKSKPLGICLIIDCIGNETELLRDTFTSLGYEVQKFLHLSMHGISQILGQFACMPEHRDYDSFVCVLVS-
RGGSQSV
YGVDQTHSGLPLHHIRRMFMGDSCPYLAGKPKMFFIQNYVVSEGQLEDSSLLEVDGPAMKNVEFKAQKRGLCT-
VHR
EADFFWSLCTADMSLLEQSHSSPSLYLQCLSQKLRQERKRPLLDLHIELNGYMYDWNSRVSAKEKYYVWLQHT-
LRKKL ILSYT (hu-cFLIP-L; P1006 without epitope tag) 83
SAEVIHQVEEALDTDEKEMLLFLCRDVAIDVVPPNVRDLLDILRERGKLSVGDLAELLYRVRRFDLLKRIL-
KMDRKAVET
HLLRNPHLVSDYRVLMAEIGEDLDKSDVSSLIFLMKDYMGRGKISKEKSFLDLVVELEKLNLVAPDQLDLLEK-
CLKNIHRI
DLKTKIQKYKQSVQGAGTSYRNVLQAAIQKSLKDPSNNFRLHNGRSKEQRLKEQLGAQQEPVKKS
(hu-cFLIP-S(1-227); P1007 without epitope tag) 84
SAEVIHQVEEALDTDEKEMLLFLCRDVAIDVVPPNVRDLLDILRERGKLSVGDLAELLYRVRRFDLLKRIL-
KMDRKAVET
HLLRNPHLVSDYRVLMAEIGEDLDKSDVSSLIFLMKDYMGRGKISKEKSFLDLVVELEKLNLVAPDQLDLLEK-
CLKNIHRI DLKTKIQKYKQSVQGAGTSYRNVLQAAIQKSLKD (hu-cFLIP-p22(1-198);
P1008 without epitope tag) 85
SAEVIHQVEEALDTDEKEMLLFLCRDVAIDVVPPNVRDLLDILRERGKLSVGDLAELLYRVRRFDLLKRIL-
KMDRKAVET
HLLRNPHLVSDYRVLMAEIGEDLDKSDVSSLIFLMKDYMGRGKISKEKSFLDLVVELEKLNLVAPDQLDLLEK-
CLKNIHRI
DLKTKIQKYKQSVQGAGTSYRNVLQAAIQKSLKDPSNNFRLHNGRSKEQRLKEQLGAQQEPVKKSIQESEAFL-
PQSIPE
ERYKMKSKPLGICLIIDCIGNETELLRDTFTSLGYEVQKFLHLSMHGISQILGQFACMPEHRDYDSFVCVLVS-
RGGSQSV YGVDQTHSGLPLHHIRRMFMGDSCPYLAGKPKMFFIQNYVVSEGQLEDSSLLEVD
(hu-cFLIP-p43(1-376); P1009 without epitope tag) 86
GPAMKNVEFKAQKRGLCTVHREADFFWSLCTADMSLLEQSHSSPSLYLQCLSQKLRQERKRPLLDLHIELN-
GYMYD WNSRVSAKEKYYVWLQHTLRKKLILSYT (hu-cFLIP-p12(377-480); P1010
without epitope tag) 87
MSWSPSLTTQTCGAWEMKERLGTGGFGNVIRWHNQETGEQIAIKQCRQELSPRNRERWCLEIQIMRRLTH
PNVVAARDVPEGMQNLAPNDLPLLAMEYCQGGDLRKYLNQFENCCGLREGAILTLLSDIASALRYLHEN
RIIHRDLKPENIVLQQGEQRLIHKIIDLGYAKELDQGELCTEFVGTLQYLAPELLEQQKYTVTVDYWSFGTLA-
F
ECITGFRPFLPNWQPVQWHSKVRQKSEVDIVVSEDLNGTVKFSSSLPYPNNLNSVLAERLEKWLQLMLM
WHPRQRGTDPTYGPNGCFKALDDILNLKLVHILNMVTGTIHTYPVTEDESLQSLKARIQQDTGIPEEDQELL
QEAGLALIPDKPATQCISDGKLNEGHTLDMDLVFLFDNSKITYETQISPRPQPESVSCILQEPKRNLAFFQLR-
K
VWGQVWHSIQTLKEDCNRLQQGQRAAMMNLLRNNSCLSKMKNSMASMSQQLKAKLDFFKTSIQIDLEK
YSEQTEFGITSDKLLLAWREMEQAVELCGRENEVKLLVERMMALQTDIVDLQRSPMGRKQGGTLDDLEEQ
ARELYRRLREKPRDQRTEGDSQEMVRLLLQAIQSFEKKVRVIYTQLSKTVVCKQKALELLPKVEEVVSLMN
EDEKTVVRLQEKRQKELWNLLKIACSKVRGPVSGSPDSMNASRLSQPGQLMSQPSTASNSLPEPAKKSEEL
VAEAHNLCTLLENAIQDTVREQDQSFTALDWSWLQTEEEEHSCLEQAS
(hulKK2ca(S177E/S181E); P4005 without epitope tag) 88
MSWSPSLTTQTCGAWEMKERLGTGGFGNVIRWHNQETGEQIAIKQCRQELSPRNRERWCLEIQIMRRLTH
PNVVAARDVPEGMQNLAPNDLPLLAMEYCQGGDLRKYLNQFENCCGLREGAILTLLSDIASALRYLHEN
RIIHRDLKPENIVLQQGEQRLIHKIIDLGYAKELDQGALCTAFVGTLQYLAPELLEQQKYTVTVDYWSFGTLA-
F
ECITGFRPFLPNWQPVQWHSKVRQKSEVDIVVSEDLNGTVKFSSSLPYPNNLNSVLAERLEKWLQLMLM
WHPRQRGTDPTYGPNGCFKALDDILNLKLVHILNMVTGTIHTYPVTEDESLQSLKARIQQDTGIPEEDQELL
QEAGLALIPDKPATQCISDGKLNEGHTLDMDLVFLFDNSKITYETQISPRPQPESVSCILQEPKRNLAFFQLR-
K
VWGQVWHSIQTLKEDCNRLQQGQRAAMMNLLRNNSCLSKMKNSMASMSQQLKAKLDFFKTSIQIDLEK
YSEQTEFGITSDKLLLAWREMEQAVELCGRENEVKLLVERMMALQTDIVDLQRSPMGRKQGGTLDDLEEQ
ARELYRRLREKPRDQRTEGDSQEMVRLLLQAIQSFEKKVRVIYTQLSKTVVCKQKALELLPKVEEVVSLMN
EDEKTVVRLQEKRQKELWNLLKIACSKVRGPVSGSPDSMNASRLSQPGQLMSQPSTASNSLPEPAKKSEEL
VAEAHNLCTLLENAIQDTVREQDQSFTALDWSWLQTEEEEHSCLEQAS
(hulKK2null(S177A/S181A); P4006 without epitope tag) 89
MSWSPSLPTQTCGAWEMKERLGTGGFGNVIRWHNQATGEQIAIKQCRQELSPKNRNRWCLEIQIMRRLNHP-
N
VVAARDVPEGMQNLAPNDLPLLAMEYCQGGDLRRYLNQFENCCGLREGAVLTLLSDIASALRYLHENRIIHRD-
LK
PENIVLQQGEKRLIHKIIDLGYAKELDQGELCTEFVGTLQYLAPELLEQQKYTVTVDYWSFGTLAFECITGFR-
PFLPN
WQPVQWHSKVRQKSEVDIVVSEDLNGAVKFSSSLPFPNNLNSVLAERLEKWLQLMLMWHPRQRGTDPQYGP
NGCFRALDDILNLKLVHVLNMVTGTVHTYPVTEDESLQSLKTRIQENTGILETDQELLQKAGLVLLPDKPATQ-
CISD
SKTNEGLTLDMDLVFLLDNSKINYETQITPRPPPESVSCILQEPKRNLSFFQLRKVWGQVWHSIQTLKEDCNR-
LQQ
GQRAAMMSLLRNNSCLSKMKNAMASTAQQLKAKLDFFKTSIQIDLEKYKEQTEFGITSDKLLLAWREMEQAVE-
Q
CGRENDVKHLVERMMALQTDIVDLQRSPMGRKQGGTLDDLEEQARELYRKLREKPRDQRTEGDSQEMVRLLLQ
AIQSFEKKVRVIYTQLSKTVVCKQKALELLPKVEEVVSLMNEDERTVVRLQEKRQKELWNLLKIACSKVRGPV-
SGSP
DSMNVSRLSHPGQLMSQPSSACDSLPESDKKSEELVAEAHALCSRLESALQDTVKEQDRSFTTLDWSWLQMED-
EE RCSLEQACD (mulKK2ca(S177E/S181E); P4002 without epitope tag) 90
MSWSPSLPTQTCGAWEMKERLGTGGFGNVIRWHNQATGEQIAIKQCRQELSPKNRNRWCLEIQIMRRLNHP-
N
VVAARDVPEGMQNLAPNDLPLLAMEYCQGGDLRRYLNQFENCCGLREGAVLTLLSDIASALRYLHENRIIHRD-
LK
PENIVLQQGEKRLIHKIIDLGYAKELDQGALCTAFVGTLQYLAPELLEQQKYTVTVDYWSFGTLAFECITGFR-
PFLPN
WQPVQWHSKVRQKSEVDIVVSEDLNGAVKFSSSLPFPNNLNSVLAERLEKWLQLMLMWHPRQRGTDPQYGP
NGCFRALDDILNLKLVHVLNMVTGTVHTYPVTEDESLQSLKTRIQENTGILETDQELLQKAGLVLLPDKPATQ-
CISD
SKTNEGLTLDMDLVFLLDNSKINYETQITPRPPPESVSCILQEPKRNLSFFQLRKVWGQVWHSIQTLKEDCNR-
LQQ
GQRAAMMSLLRNNSCLSKMKNAMASTAQQLKAKLDFFKTSIQIDLEKYKEQTEFGITSDKLLLAWREMEQAVE-
Q
CGRENDVKHLVERMMALQTDIVDLQRSPMGRKQGGTLDDLEEQARELYRKLREKPRDQRTEGDSQEMVRLLLQ
AIQSFEKKVRVIYTQLSKTVVCKQKALELLPKVEEVVSLMNEDERTVVRLQEKRQKELWNLLKIACSKVRGPV-
SGSP
DSMNVSRLSHPGQLMSQPSSACDSLPESDKKSEELVAEAHALCSRLESALQDTVKEQDRSFTTLDWSWLQMED-
EE RCSLEQACD mulKK2null(S177A/S181A); P4003 without epitope tag) 91
MERPPGLRPGAGGPWEMRERLGTGGFGNVCLYQHRELDLKIAIKSCRLELSTKNRERWCHEIQIMKKLNHA-
NVVKA
CDVPEELNILIHDVPLLAMEYCSGGDLRKLLNKPENCCGLKESQILSLLSDIGSGIRYLHENKIIHRDLKPEN-
IVLQDVGGK
IIHKIIDLGYAKDVDQGELCTEFVGTLQYLAPELFENKPYTATVDYWSFGTMVFECIAGYRPFLHHLQPFTWH-
EKIKKKD
PKCIFACEEMSGEVRFSSHLPQPNSLCSLVVEPMENWLQLMLNWDPQQRGGPVDLTLKQPRCFVLMDHILNLK-
IVH
ILNMTSAKIISFLLPPDESLHSLQSRIERETGINTGSQELLSETGISLDPRKPASQCVLDGVRGCDSYMVYLF-
DKSKTVYEG
PFASRSLSDCVNYIVQDSKIQLPIIQLRKVWAEAVHYVSGLKEDYSRLFQGQRAAMLSLLRYNANLTKMKNTL-
ISASQQ
LKAKLEFFHKSIQLDLERYSEQMTYGISSEKMLKAWKEMEEKAIHYAEVGVIGYLEDQIMSLHAEIMELQKSP-
YRRQG
DLMESLEQRAIDLYKQLKHRPSDHSYSDSTEMVKIIVHTVQSQDRVLKELFGHLSKLLGCKQKIIDLLPKVEV-
ALSNIKEA
DNTVMFMQGKRQKEIWHLLKIACTQAAARALVGAALEGAVAPQAAAWLPPAAAEHDHALACVVAPQDGEAAAQ
MIEENLNCLGHLAAIIHEANEEQGNSMMNLDWSWLTE Human constitutively active
IKK alpha (PEST mutation) P.4013 without epitope tag 92
MERPPGLRPGAGGPWEMRERLGTGGFGNVCLYQHRELDLKIAIKSCRLELSTKNRERWCHEIQIMKKLNHA-
NVVKA
CDVPEELNILIHDVPLLAMEYCSGGDLRKLLNKPENCCGLKESQILSLLSDIGSGIRYLHENKIIHRDLKPEN-
IVLQDVGGK
IIHKIIDLGYAKDVDQGELCTEFVGTLQYLAPELFENKPYTATVDYWSFGTMVFECIAGYRPFLHHLQPFTWH-
EKIKKKD
PKCIFACEEMSGEVRFSSHLPQPNSLCSLVVEPMENWLQLMLNWDPQQRGGVDLTLKQPRCFVLMDHILNLKI-
VH
ILNMTSAKIISFLLPPDESLHSLQSRIERETGINTGSQELLSETGISLDPRKPASQCVLDGVRGCDSYMVYLF-
DKSKTVYEG
PFASRSLSDCVNYIVQDSKIQLPIIQLRKVWAEAVHYVSGLKEDYSRLFQGQRAAMLSLLRYNANLTKMKNTL-
ISASQQ
LKAKLEFFHKSIQLDLERYSEQMTYGISSEKMLKAWKEMEEKAIHYAEVGVIGYLEDQIMSLHAEIMELQKSP-
YRRQG
DLMESLEQRAIDLYKQLKHRPSDHSYSDSTEMVKIIVHTVQSQDRVLKELFGHLSKLLGCKQKIIDLLPKVEV-
ALSNIKEA
DNTVMFMQGKRQKEIWHLLKIACTQAAARALVGAALEGAVAPQAAAWLPPAAAEHDHALACVVAPQDGEAAAQ
MIEENLNCLGHLAAIIHEANEEQGNSMMNLDWSWLTE Human constitutively active
IKK alpha (PEST mutation) P.4014 without epitope tag 93
MSWSPSLTTQTCGAWEMKERLGTGGFGNVIRWHNQETGEQIAIKQCRQELSPRNRERWCLEIQIMRRLTHP-
NVVA
ARDVPEGMQNLAPNDLPLLAMEYCQGGDLRKYLNQFENCCGLREGAILTIISDIASALRYLHENRIIHRDLKP-
ENIVLQ
QGEQRLIHKIIDLGYAKELDQGELCTEFVGTLQYLAPELLEQQKYVTVDYWSFGTLAFECITGFRPFLPNWQP-
VQWH
SKVRQKSEVDIVVSEDLNGTVKFSSSLPYPNNLNSVLAERLEKWLQLMLMWHPRQRGTDPTYGPNGCFKALDD-
ILNL
KLVHILNMVTGTIHTYPVTEDESLQSLKARIQQDTGIPEEDQELLQEAGLALIPDKPATQCISDGKLNEGHTL-
DMDLVFL
FDNISKITYETQISPRPQPESVSCILQEPKRNLAFFQLRKVWGQVWHSIQTLKEDCNRLQQGQRAAMMNLLRN-
NSCLS
KMKNSMASMSQQLKAKLDFFKTISIQIDLEKYSEQTEFGITSDKLLLAWREMEQAVELCGRENEVKLLVERMM-
ALQT
DIVDLQRSPMGRKQGGTLDDLEEQARELYRRLREKPRDQRTEGDSQEMVRLLLQAIQSFEKKVRVIYTQLSKT-
VVCKQ
KALELLPKVEEVVSLMNEDEKTVVRLQEKRQKELWNLLKIACSKVRGPVAGAPDAMNAARLAQPGQLMAQPAT-
AA NALPEPAKKAEELVAEAHNLCTLLENAIQDTVREQDQSFTALDWSWLQTEEEEHSCLEQAS
Human constitutively active IKK beta (PEST mutation) P.4015 without
epitope tag 94
MSWSPSLTTQTCGAWEMKERLGTGGFGNVIRWHNQETGEQIAIKQCRQELSPRNRERWCLEIQIMRRLTHP-
NVVA
ARDVPEGMQNLAPNDLPLLAMEYCQGGDLRKYLNQFENCCGLREGAILTLLSDIASALRYLHENRIIHRDLKP-
ENIVLQ
QGEQRLIHKIIDLGYAKELDQGELCTEFVGTLQYLAPELLEQQKYTVTVDYWSFGTLAFECITGFRPFLPNWQ-
PVQWH
SKVRQKSEVDIVVSEDLNGTVKFSSSLPYPNNLNSVLAERLEKWLQLMLMWHPRQRGTDPTYGPNGCFKALDD-
ILNL
KLVHILNMVTGTIHTYPVTEDESLQSLKARIQQDTGIPEEDQELLQEAGLALIPDKPATQCISDGKLNEGHTL-
DMDLVFL
FDNSKITYETQISPRPQPESVSCILQEPKRNLAFFQLRKVWGQVWHSIQTLKEDCNRLQQGQRAAMMNLLRNN-
SCLS
KMKNSMASMSQQLKAKLDFFKTSIQIDLEKYSEQTEFGITSDKLLLAWREMEQAVELCGRENEVKLLVERMMA-
LQT
DIVDLQRSPMGRKQGGTLDDLEEQARELYRRLREKPRDQRTEGDSQEMVRLLLQAIQSFEKKVRVIYTQLSKT-
VVCKQ
KALELLPKVEEVVSLMNEDEKTVVRLQEKRQKELWNLLKIACSKVRGPVAGAPDAMNARRLAQPGQLMAQPAT-
AA NALPEPAKKAEELVAEAHNLCTLLENAIQDTVREQDQSFTALDWSWLQTEEEEHSCLEQAS
Human constitutively active IKK beta (PEST mutation) P.4016 without
epitope tag 95
MERPPGLRPGAGGPWEMRERLGTGGFGNVSLYQHRELDLKIAIKSCRLELSSKNRERWCHEIQIMKKLDHA-
NVVKA
CDVPEELNFLINDVPLLAMEYCSGGDLRKLLNKPENCCGLKESQILSLLSDIGSGIRYLHENKIIHRDLKPEN-
IVLQDVGG
KTIHKIIDLGYAKDVDQGELCTEFVGTLQYLAPELFENKPYTATVDYWSFGTMVFECIAGYRPFLHHLQPFTW-
HEKIKK
KDPKCIFACEEMTGEVRFSSHLPQPNSLCSLIVEPMESWLQLMLNWDPQQRGGPIDLTLKQPRCFALMDHILN-
LKIV
HILNMTSAKIISFLLPCDESLHSLQSRIERETGINTGSQELLSETGISLDPRKPASQCVLDGVRGCDSYMVYL-
FDKSKTVYE
GPFASRSLSDCVNYIVQDSKIQLPIIQLRKVWAEAVHYVSGLKEDYSRLFQGQRAAMLSLLRYNANLTKMKNT-
LISASQ
QLKAKLEFFRKSIQLDLERYSEQMTYGISSEKMLKAWKEMEEKAIHYSEVGVIGYLEDQIMSLHTEIMELQKS-
PYGRRQ
GDLMESLEQRAIDLYKQLKHRPPDHLYSDSTEMVKIIVHTVQSQDRVLKELFGHLSKLLGCKQKIIDLLPKVE-
VALSNIKE
ADNTVMFMQGKRQKEIWHLLKIACTQAAARALVGAALEGAVAPPVAAWLPPALADREHPLTCVVAPQDGEALA-
Q MIEENLNCLGHLAAIIREANEDQSSSLMSLDWSWLAE Mouse constitutively active
IKK alpha (PEST mutation) P.4017 without epitope tag 96
MERPPGLRPGAGGPWEMRERLGTGGFGNVSLYQHRELDLKIAIKSCRLELSSKNRERWCHEIQIMKKLDHA-
NVVKA
CDVPEELNFLINDVPLLAMEYCSGGDLRKLLNKPENCCGLKESQILSLLSDIGSGIRYLHENKIIHRDLKPEN-
IVLQDVGG
KTIHKIIDLGYAKDVDQGELCTEFVGTLQYLAPELFENKPYTATVDYWSFGTMVFECIAGYRPFLHHLQPFTW-
HEKIKK
KDPKCIFACEEMTGEVRFSSHLPQPNSLCSLIVEPMESWLQLMLNWDPQQRGGPIDLTLKQPRCFALMDHILN-
LKIV
HILNMTSAKIISFLLPCDESLHSLQSRIERETGINTGSQELLSETGISLDPRKPASQCVLDGVRGCDSYMVYL-
FDKSKTVYE
GPFASRSLSDCVNYIVQDSKIQLPIIQLRKVWAEAVHYVSGLKEDYSRLFQGQRAAMLSLLRYNANLTKMKNT-
LISASQ
QLKAKLEFFRKSIQLDLERYSEQMTYGISSEKMLKAWKEMEEKAIHYSEVGVIGYLEDQIMSLHTEIMELQKS-
PYGRRQ
GDLMESLEQRAIDLYKQLKHRPPDHLYSDSTEMVKIIVHTVQSQDRVLKELFGHLSKLLGCKQKIIDLLPKVE-
VALSNIKE
ADNTVMFMQGKRQKEIWHLLKIACTQAAARALVGAALEGAVAPPVAAWLPPALADREHPLTCVVAPQDGEALA-
Q MIEENLNCLGHLAAIIREANEDQSSSLMSLDWSWLAE Mouse constitutively active
IKK alpha (PEST mutation) P.4018 without epitope tag 97
MSWSPSLPTQTCGAWEMKERLGTGGFGNVIRWHNQATGEQIAIKQCRQELSPKNRNRWCLEIQIMRRLNHP-
NVV
AARDVPEGMQNLAPNDLPLLAMEYCQGGDLRRYLNQFENCCGLREGAVLTLLSDIASALRYLHENRIIHRDLK-
PENIV
LQQGEKRLIHKIIDLGYAKELDQGELCTEFVGTLQYLAPELLEQQKYTVTVDYWSFGTLAFECITGFRPFLPN-
WQPVQ
WHSKVRQKSEVDIVVSEDLNGAVKFSSSLPFPNNLNSVLAERLEKWLQLMLMWHPRQRGTDPQYGPNGCFRAL-
DD
ILNLKLVHVLNMVTGTVHTYPVTEDESLQSLKTRIQENTGILETDQELLQKAGLVLLPDKPATQCISDSKTNE-
GLTLDM
DLVFLLDNSKINYETQITPRPPPESVSCILQEPKRNLSFFQLRKVWGQVWHSIQTLKEDCNRLQQGQRAAMMS-
LLRN
NSCLSKMKNAMASTAQQLKAKLDFFKTSIQIDLEKYKEQTEFGITSDKLLLAWREMEQAVEQCGRENDVKHLV-
ERM
MALQTDIVDLQRSPMGRKQGGTLDDLEEQARELYRKLREKPRDQRTEGDSQEMVRLLLQAIQSFEKKVRVIYT-
QLSK
TVVCKQKALELLPKVEEVVSLMNEDERTVVRLQEKRQKELWNLLKIACSKVRGPVAGAPDAMNVARLAHPGQL-
MA
QPASACDALPESDKKAEELVAEAHALCSRLESALQDTVKEQDRSFTTLDWSWLQMEDEERCSLEQACD
Mouse constitutively active IKK beta (PEST mutation) P.4019 without
epitope tag 98
MSWSPSLPTQTCGAWEMKERLGTGGFGNVIRWHNQATGEQIAIKQCRQELSPKNRNRWCLEIQIMRRLNHP-
NVV
AARDVPEGMQNLAPNDLPLLAMEYCQGGDLRRYLNQFENCCGLREGAVLTLLSDIASALRYLHENRIIHRDLK-
PENIV
LQQGEKRLIHKIIDLGYAKELDQGELCTEFVGTLQYLAPELLEQQKYTVTVDYWSFGTLAFECITGFRPFLPN-
WQPVQ
WHSKVRQKSEVDIVVSEDLNGAVKFSSSLPFPNNLNSVLAERLEKWLQLMLMWHPRQRGTDPQYGPNGCFRAL-
DD
ILNLKLVHVLNMVTGTVHTYPVTEDESLQSLKTRIQENTGILETDQELLQKAGLVLLPDKPATQCISDSKTNE-
GLTLDM
DLVFLLDNSKINYETQITPRPPPESVSCILQEPKRNLSFFQLRKVWGQVWHSIQTLKEDCNRLQQGQRAAMMS-
LLRN
NSCLSKMKNAMASTAQQLKAKLDFFKTSIQIDLEKYKEQTEFGITSDKLLLAWREMEQAVEQCGRENDVKHLV-
ERM
MALQTDIVDLQRSPMGRKQGGTLDDLEEQARELYRKLREKPRDQRTEGDSQEMVRLLLQAIQSFEKKVRVIYT-
QLSK
TVVCKQKALELLPKVEEVVSLMNEDERTVVRLQEKRQKELWNLLKIACSKVRGPVAGAPDAMNVARLAHPGQL-
MA
QPASACDALPESDKKAEELVAEAHALCSRLESALQDTVKEQDRSFTTLDWSWLQMEDEERCSLEQACD
Mouse constitutively active IKK beta (PEST mutation) P.4020 without
epitope tag 99
MQPDMSLNVIKMKSSDFLESAELDSGGFGKVSLCFHRTQGLMIMKTVYKGPNCIEHNEALLEEAKMMNRLR-
HSRVV
KLLGVIIEEGKYSLVMEYMEKGNLMHVLKAEMSTPLSVKGRIILEIIEGMCYLHGKGVIHKDLKPENILVDND-
FHIKIADL
GLASFKMWSKLNNEEHNELREVDGTAKKNGGTLYYMAPEHLNDVNAKPTEKSDVYSFAVVLWAIFANKEPYEN-
AIC
EQQLIMCIKSGNRPDVDDITEYCPREIISLMKLCWEANPEARPTFPGIEEKFRPFYLSQLEESVEEDVKSLKK-
EYSNENAV
VKRMQSLQLDCVAVPSSRSNSATEQPGSLHSSQGLGMGPVEESWFAPSLEHPQEENEPSLQSKLQDEANYHLY-
GSR
MDRQTKQQPRQNVAYNREEERRRRVSHDPFAQQRPYENFQNTEGKGTAYSSAASHGNAVHQPSGLTSQPQVLY-
Q
NNGLYSSHGFGTRPLDPGTAGPRVWYRPIPSHMPSLHNIPVPETNYLGNTPTMPFSSLPPTDESIKYTIYNST-
GIQIGA YNYMEIGGTSSSGGIKKEIEAIKKEQEAIKKKIEAIEKEIEA
(huRIPK1(1-555).IZ.TM; TH1021 without epitope tag) 100
MQPDMSLNVIKMKSSDFLESAELDSGGFGKVSLCFHRTQGLMIMKTVYKGPNCIEHNEALLEEAKMMNRL-
RHSRVV
KLLGVIIEEGKYSLVMEYMEKGNLMHVLKAEMSTPLSVKGRIILEIIEGMCYLHGKGVIHKDLKPENILVDND-
FHIKIADL
GLASFKMWSKLNNEEHNELREVDGTAKKNGGTLYYMAPEHLNDVNAKPTEKSDVYSFAVVLWAIFANKEPYEN-
AIC
EQQLIMCIKSGNRPDVDDITEYCPREIISLMKLCWEANPEARPTFPGIEEKFRPFYLSQLEESVEEDVKSLKK-
EYSNENAV
VKRMQSLQLDCVAVPSSRSNSATEQPGSLHSSQGLGMGPVEESWFAPSLEHPQEENEPSLQSKLQDEANYHLY-
GSR
MDRQTKQQPRQNVAYNREEERRRRVSHDPFAQQRPYENFQNTEGKGTAYSSAASHGNAVHQPSGLTSQPQVLY-
Q
NNGLYSSHGFGTRPLDPGTAGPRVWYRPIPSHMPSLHNIPVPETNYLGNTPTMPFSSLPPTDESIKYTIYNST-
GIQIGA
YNYMEIGGTSSSGSDGSGSGSGSITIRAAFLEKENTALRTEIAELEKEVGRCENIVSKYETRYGPL
(huRIPK1(1-555).EE.DM; TH1022 without epitope tag) 101
MQPDMSLNVIKMKSSDFLESAELDSGGFGKVSLCFHRTQGLMIMKTVYKGPNCIEHNEALLEEAKMMNRL-
RHSRVV
KLLGVIIEEGKYSLVMEYMEKGNLMHVLKAEMSTPLSVKGRIILEIIEGMCYLHGKGVIHKDLKPENILVDND-
FHIKIADL
GLASFKMWSKLNNEEHNELREVDGTAKKNGGTLYYMAPEHLNDVNAKPTEKSDVYSFAVVLWAIFANKEPYEN-
AIC
EQQLIMCIKSGNRPDVDDITEYCPREIISLMKLCWEANPEARPTFPGIEEKFRPFYLSQLEESVEEDVKSLKK-
EYSNENAV
VKRMQSLQLDCVAVPSSRSNSATEQPGSLHSSQGLGMGPVEESWFAPSLEHPQEENEPSLQSKLQDEANYHLY-
GSR
MDRQTKQQPRQNVAYNREEERRRRVSHDPFAQQRPYENFQNTEGKGTAYSSAASHGNAVHQPSGLTSQPQVLY-
Q
NNGLYSSHGFGTRPLDPGTAGPRVWYRPIPSHMPSLHNIPVPETNYLGNTPTMPFSSLPPTDESIKYTIYNST-
GIQIGA
YNYMEIGGTSSSGSDGSGSGSGSLEIRAAFLEKENTALRTRAAELRKRVGRCRNIVSKYETRYGPL
(huRIPK1(1-555).RR.DM; TH1023 without epitope tag) 102
MQPDMSLDNIKMASSDLLEKTDLDSGGFGKVSLCYHRSHGFVILKKVYTGPNRAEYNEVLLEEGKMMHRL-
RHSRVV
KLLGIIIEEGNYSLVMEYMEKGNLMHVLKTQIDVPLSLKGRIIVEAIEGMCYLHDKGVIHKDLKPENILVDRD-
FHIKIADL
GVASFKTWSKLTKEKDNKQKEVSSTTKKNNGGTLYYMAPEHLNDINAKPTEKSDVYSFGIVLWAIFAKKEPYE-
NVICTE
QFVICIKSGNRPNVEEILEYCPREIISLMERCWQAIPEDRPTFLGIEEEFRPFYLSHFEEYVEEDVASLKKEY-
PDQSPVLQR
MFSLQHDCVPLPPSRSNSEQPGSLHSSQGLQMGPVEESWFSSSPEYPQDENDRSVQAKLQEEASYHAFGIFAE-
KQTK
PQPRQNEAYNREEERKRRVSHDPFAQQRARENIKSAGARGHSDPSTTSRGIAVQQLSWPATQTVWNNGLYNQH-
G
FGTTGTGVWYPPNLSQMYSTYKTPVPETNIPGSTPTMPYFSGPVADDLIKYTIFNSSGIQIGNHNYMDVGLNS-
QPPN NTCKEESTSGGIKKEIEAIKKEQEAIKKKIEAIEKEIEA (msRIPK1(1-555).IZ.TM;
TH1024 without epitope tag) 103
MQPDMSLDNIKMASSDLLEKTDLDSGGFGKVSLCYHRSHGFVILKKVYTGPNRAEYNEVLLEEGKMMHRL-
RHSRVV
KLLGIIIEEGNYSLVMEYMEKGNLMHVLKTQIDVPLSLKGRIIVEAIEGMCYLHDKGVIHKDLKPENILVDRD-
FHIKIADL
GVASFKTWSKLTKEKDNKQKEVSSTTKKNNGGTLYYMAPEHLNDINAKPTEKSDVYSFGIVLWAIFAKKEPYE-
NVICTE
QFVICIKSGNRPNVEEILEYCPREIISLMERCWQAIPEDRPTFLGIEEEFRPFYLSHFEEYVEEDVASLKKEY-
PDQSPVLQR
MFSLQHDCVPLPPSRSNSEQPGSLHSSQGLQMGPVEESWFSSSPEYPQDENDRSVQAKLQEEASYHAFGIFAE-
KQTK
PQPRQNEAYNREEERKRRVSHDPFAQQRARENIKSAGARGHSDPSTTSRGIAVQQLSWPATQTVWNNGLYNQH-
G
FGTTGTGVWYPPNLSQMYSTYKTPVPETNIPGSTPTMPYFSGPVADDLIKYTIFNSSGIQIGNHNYMDVGLNS-
QPPN
NTCKEESTSGSDGSGSGSGSITIRAAFLEKENTALRTEIAELEKEVGRCENIVSKYETRYGPL
(msRIPK1(1-555).EE.DM; TH1025 without epitope tag) 104
MQPDMSLDNIKMASSDLLEKTDLDSGGFGKVSLCYHRSHGFVILKKVYTGPNRAEYNEVLLEEGKMMHRL-
RHSRVV
KLLGIIIEEGNYSLVMEYMEKGNLMHVLKTQIDVPLSLKGRIIVEAIEGMCYLHDKGVIHKDLKPENILVDRD-
FHIKIADL
GVASFKTWSKLTKEKDNKQKEVSSTTKKNNGGTLYYMAPEHLNDINAKPTEKSDVYSFGIVLWAIFAKKEPYE-
NVICTE
QFVICIKSGNRPNVEEILEYCPREIISLMERCWQAIPEDRPTFLGIEEEFRPFYLSHFEEYVEEDVASLKKEY-
PDQSPVLQR
MFSLQHDCVPLPPSRSNSEQPGSLHSSQGLQMGPVEESWFSSSPEYPQDENDRSVQAKLQEEASYHAFGIFAE-
KQTK
PQPRQNEAYNREEERKRRVSHDPFAQQRARENIKSAGARGHSDPSTTSRGIAVQQLSWPATQTVWNNGLYNQH-
G
FGTTGTGVWYPPNLSQMYSTYKTPVPETNIPGSTPTMPYFSGPVADDLIKYTIFNSSGIQIGNHNYMDVGLNS-
QPPN
NTCKEESTSGSDGSGSGSGSLEIRAAFLEKENTALRTRAAELRKRVGRCRNIVSKYETRYGPL
(msRIPK1(1-555).RR.DM; TH1026 without epitope tag) 105
MSTASAASSSSSSSAGEMIEAPSQVLNFEEIDYKEIEVEEVVGRGAFGVVCKAKWRAKDVAIKQIESESE-
RKAFIVELRQ
LSRVNHPNIVKLYGACLNPVCLVMEYAEGGSLYNVLHGAEPLPYYTAAHAMSWCLQCSQGVAYLHSMQPKALI-
HRD
LKPPNLLLVAGGTVLKICDFGTACDIQTHMTNNKGSAAWMAPEVFEGSNYSEKCDVFSWGIILWEVITRRKPF-
DEIG
GPAFRIMWAVHNGTRPPLIKNLPKPIESLMTRCWSKDPSQRPSMEEIVKIMTHLMRYFPGADEPLQYPCQEFG-
GGG
GQSPTLTLQSTNTHTQSSSSSSDGGLFRSRPAHSLPPGEDGRVEPYVDFAEFYRLWSVDHGEQSVVTAP
(human TAK1-TAB1; P4031 without epitope tag) 106
MAALKSWLSRSVTSFFRYRQCLCVPVVANFKKRCFSELIRPWHKTVTIGFGVTLCAVPIAQKSEPHSLSS-
EALMRRAVS
LVTDSTSTFLSQTTYALIEAITEYTKAVYTLTSLYRQYTSLLGKMNSEEEDEVWQVIIGARAEMTSKHQEYLK-
LETTWMT
AVGLSEMAAEAAYQTGADQASITARNHIQLVKLQVEEVHQLSRKAETKLAEAQIEELRQKTQEEGEERAESEQ-
EAYLR ED (Diablo.1; without epitope tag) 107
MAALKSWLSRSVTSFFRYRQCLCVPVVANFKKRCFSELIRPWHKTVTIGFGVTLCAVPIAQKSEPHSLSS-
EALMRRAVS
LVTDSTSTFLSQTTYALIEAITEYTKAVYTLTSLYRQYTSLLGKMNLEEEDEVWQVIIGARAEMTSKHQEYLK-
LETTWMT
AVGLSEMAAEAAYQTGADQASITARNHIQLVKLQVEEVHQLSRKAETKLAEAQIEELRQKTQEEGEERAESEQ-
EAYLR ED (Diablo.1(S126L); without epitope tag) 108
MAVPIAQKSEPHSLSSEALMRRAVSLVTDSTSTFLSQTTYALIEAITEYTKAVYTLTSLYRQYTSLLGKM-
NSEEEDEVWQ
VIIGARAEMTSKHQEYLKLETTWMTAVGLSEMAAEAAYQTGADQASITARNHIQLVKLQVEEVHQLSRKAETK-
LAEA QIEELRQKTQEEGEERAESEQEAYLRED (Diablo.1(56-239); without
epitope tag) 109
MAVPIAQKSEPHSLSSEALMRRAVSLVTDSTSTFLSQTTYALIEAITEYTKAVYTLTSLYRQYTSLLGKM-
NLEEEDEVWQ
VIIGARAEMTSKHQEYLKLETTWMTAVGLSEMAAEAAYQTGADQASITARNHIQLVKLQVEEVHQLSRKAETK-
LAEA QIEELRQKTQEEGEERAESEQEAYLRED (Diablo.1(56-239/S126L); without
epitope tag) 110
MAALKSWLSRSVTSFFRYRQCLCVPVVANFKKRCFSELIRPWHKTVTIGFGVTLCAVPIAQAVYTLTSLY-
RQYTSLLGK
MNSEEEDEVWQVIIGARAEMTSKHQEYLKLETTWMTAVGLSEMAAEAAYQTGADQASITARNHIQLVKLQVEE-
VH QLSRKAETKLAEAQIEELRQKTQEEGEERAESEQEAYLRED (Diablo.3; TH2003
without epitope tag) 111
MAALKSWLSRSVTSFFRYRQCLCVPVVANFKKRCFSELIRPWHKTVTIGFGVTLCAVPIAQAVYTLTSLY-
RQYTSLLGK
MNLEEEDEVWQVIIGARAEMTSKHQEYLKLETTWMTAVGLSEMAAEAAYQTGADQASITARNHIQLVKLQVEE-
VH QLSRKAETKLAEAQIEELRQKTQEEGEERAESEQEAYLRED (Diablo.3(S82L);
TH2001 without epitope tag) 112
MAVPIAQAVYTLTSLYRQYTSLLGKMNSEEEDEVWQVIIGARAEMTSKHQEYLKLETTWMTAVGLSEMAA-
EAAYQT
GADQASITARNHIQLVKLQVEEVHQLSRKAETKLAEAQIEELRQKTQEEGEERAESEQEAYLRED
(Diablo.3(56-195); TH2002 without epitope tag) 113
MAVPIAQAVYTLTSLYRQYTSLLGKMNLEEEDEVWQVIIGARAEMTSKHQEYLKLETTWMTAVGLSEMAA-
EAAYQT
GADQASITARNHIQLVKLQVEEVHQLSRKAETKLAEAQIEELRQKTQEEGEERAESEQEAYLRED
(Diablo.3(56-195/S82L); without epitope tag) 114
MAAVILESIFLKRSQQKKKTSPLNFKKRLFLLTVHKLSYYKYDFERGRRGSKKGSIDVEKITCVETVVPE-
KNPPPERQIPRR
GEESSEMEQISIIERFPYPFQVVYDEGPLYVFSPTEELRKRWIHQLKNVIRYNSDLVQKYHPCFWIDGQYLCC-
SQTAKN
AMGCQILENRNGSLKPGSSHRKTKKPLPPTPEEDQILKKPLPPEPAAAPVSTSELKKVVALYDYMPMNANDLQ-
LRKG
DEYFILEESNLPWWRARDKNGQEGYIPSNYVTEAEDSIEMYEWYSKHMTRSQAEQLLKQEGKEGGFIVRDSSK-
AGKY
TVSVFAKSTGDPQGVIRHYVVCSTPOSQYYLAEKHLFSTIPELINYHQHNSAGLISRLKYPVSQQNKNAPSTA-
GLGYGS
WEIDPKDLTFLKELGTGQFGVVKYGKWRGQYDVAIKMIKEGSMSEDEFIEEAKVMMNLSHEKLVQLYGVCTKQ-
RPIF
IITEYMANGCLLNYLREMRHRFQTQQLLEMCKDVCEAMEYLESKQFLHRDLAARNCLVNDQGVVKVSDFGLSR-
YVL
DDEYTSSVGSKFPVRWSPPEVLMYSKFSSKSDIWAFGVLMWEIYSLGKMPYERFTNSETAEHIAQGLRLYRPH-
LASEK VYTIMYSCWHEKADERPTFKILLSNILDVMDEES (Btk(E41K); P4029 without
epitope tag) 115
MVTHSKFPAAGMSRPLDTSLRLKTFSSKSEYQLVVNAVRKLQESGFYWSAVTGGEANLLLSAEPAGTFLI-
RDSSDQRH
FFTLSVKTQSGTKNLRIQCEGGSFSLQSDPRSTQPVPRFDCVLKLVHHYMPPPGAPSFRSPPTEPSSEVPEQP-
SAQPLP
GSPPRRAYYIYSGGEKIPLVLSRPLSSNVATLQHLCRKTVNGHLDSYEKVTQLPGPIREFLDQYDAPL
(SOCS3; P4030 without epitope tag) 116
MRMKQIEDKIEEILSKIYHINEIARIKKLIGEADQTSGNYLNMQDSQGVLSSFPAPQAVQDNPAMPTSSG-
SEGNVKL
CSLEEAQRIWKQKSAEIYPIMDKSSRTRLALIICNEEFDSIPRRTGAEVDITGMTMLLQNLGYSVDVKKNLTA-
SDMTTEL
EAFAHRPEHKTSDSTFLVFMSHGIREGICGKKHSEQVPDILQLNAIFNMLNTKNCPSLKDKPKVIIIQACRGD-
SPGVVW
FKDSVGVSGNLSLPTTEEFEDDAIKKAHIEKDFIAFCSSTPDNVSWRHPTMGSVFIGRLIEHMQEYACSCDVE-
EIFRKVR FSFEQPDGRAQMPTTERVTLTRCFYLFPGH (IZ_hsCASP1 (self-activating
human Caspase 1); P2024 without epitope tag) 117
MRMKQLEDKIEELLSKIYHLENEIARLKKLIGEADQTSGNYLNMQDSQGVLSSFPAPQAVQDNPAMPTSS-
GSEGNVK
LCSLEEAQRIWKQKSAEIYPIMDKSSRTRLALIICNEEFDSIPRRTGAEVDITGMTMLLQNLGYSVDVKIKNL-
TASDMTTE
LEAFAHRPEHKTSDSTFLVFMSHGIREGICGKKHSEQVPDILQLNAIFNMLNTKNCPSLKDKPKVIIIQACRG-
DSPGVV
WFKDSVGVSGNLSLPTTEEFEDDAIKKAHIEKDFIAFCSSTPDNVSWRHPTMGSVFIGRLIEHMQEYACSCDV-
EEIFRK VRFSFEQPDGRAQMPTTERVTLTRCFYLFPGH (DM_hsCASP1
(self-activating human Caspase 1); P2025 without epitope tag) 118
MRMKQIEDKIEEILSKIYHIENEIARIKKLIGERSAPSAETFVATEDSKGGHPSSSETKEEQNKEDGTFP-
GLTGTLKFCPLE
KAQKLWKENPSEIYPIMNTTTRTRLALIICNTEFQHLSPRVGAQVDLREMKLLLEDLGYTVKVKENLTALEMV-
KEVKEF
AACPEHKTSDSTFLVFMSHGIQEGICGTTYSNEVSDILKVDTIFQMMNTLKCPSLKDKPKVIIIQACRGEKQG-
VVLLKDS
VRDSEEDFLTDAIFEDDGIKKAHIEKDFIAFCSSTPDNVSWRHPVRGSLFIESLIKHMKEYAWSCDLEDIFRK-
VRFSFEQP EFRLQMPTADRVTLTKRFYLFPGH (IZ_mmCASP1 (self-activating
mouse Caspase 1); P2026 without epitope tag) 119
MRMKQLEDKIEELLSKIYHLENEIARLKKLIGERSARSAETFVATEDSKGGHPSSSETKEEQNKEDGTFP-
GLTGTLKFCPL
EKAQKLWKENPSEIYPIMNTTTRTRLALIICNTEFQHLSPRVGAQVDLREMKLLLEDLGYTVKVKENLTALEM-
VKEVKE
FAACPEHKTSDSTFLVFMSHGIQEGICGTTYSNEVSDILKVDTIFQMMNTLKCPSLKDKPKVIIIQACRGEKQ-
GVVLLKD
SVRDSEEDFLTDAIFEDDGIKKAHIEKDFIAFCSSTPDNVSWRHPVRGSLFIESLIKHMKEYAWSCDLEDIFR-
KVRFSFEQ PEFRLQMPTADRVTLTKRFYLFPGH (DM_mmCASP1 (self-activating
mouse Caspase 1); P2027 without epitope tag) 120
MHHHHHHHHHHGKPIPNPLLGLDSTGIPVHLELASMTNMELMSSIVHQQVFPTEAGQSLVISASIIVFNL-
LELEGDYR GRVLELFRAAQLANDVVLQIMELCGATR (ADR concatemer with HIS tag)
121 VVGADGVGK (KRAS G12D 9mer) 122 VVGAVGVGK (KRAS G12V 9mer) 123
VGAGDVGKS (KRAS G13D 9mer) 124 VVGACGVGK (KRAS G12C 9mer) 125
MKLVVVGACGVGKSA (KRAS G12C 15mer) 126
ATGACCGAGTACAAGCTGGTGGTGGTGGGCGCCGACGGCGTGGGCAAGAGCGCCCTGACCATCCAGCTGA-
TCC AG (KRAS G12D 25mer nucleotide sequence) 127
ATGACCGAGTACAAGCTGGTGGTGGTGGGCGCCGTGGGCGTGGGCAAGAGCGCCCTGACCATCCAGCTGA-
TCC AG (KRAS G12V 25mer nucleotide sequence) 128
ATGACCGAGTACAAGCTGGTGGTGGTGGGCGCCGGCGACGTGGGCAAGAGCGCCCTGACCATCCAGCTGA-
TCC AG (KRAS G13D 25mer nucleotide sequence) 129
ATGACCGAGTACAAGTTAGTGGTTGTGGGCGCCGACGGCGTGGGCAAGAGCGCCCTCACCATCCAGCTTA-
TCCA
GATGACGGAATATAAGTTAGTAGTAGTGGGAGCCGACGGTGTCGGCAAGTCCGCTTTGACCATTCAACTTATT-
C
AGATGACAGAGTATAAGCTGGTCGTTGTAGGCGCAGACGGCGTTGGAAAGTCGGCACTGACGATCCAGTTGAT
CCAG (KRAS G12D 25mer^3 nucleotide sequence) 130
ATGACCGAGTACAAGCTCGTCGTGGTGGGCGCCGTGGGCGTGGGCAAGAGCGCCCTAACCATCCAGTTGA-
TCC
AGATGACCGAATATAAGCTCGTGGTAGTCGGAGCGGTGGGCGTTGGCAAGTCAGCGCTAACAATACAACTAAT
CCAAATGACCGAATACAAGCTAGTTGTAGTCGGTGCCGTCGGCGTTGGAAAGTCAGCCCTTACAATTCAGCTC-
AT TCAG (KRAS G12V 25mer^3 nucleotide sequence) 131
ATGACCGAGTACAAGCTCGTAGTGGTTGGCGCCGGCGACGTGGGCAAGAGCGCCCTAACCATCCAGCTCA-
TCCA
GATGACAGAATATAAGCTTGTGGTTGTGGGAGCAGGAGACGTGGGAAAGAGTGCGTTGACGATTCAACTCATA
CAGATGACCGAATACAAGTTGGTGGTGGTCGGCGCAGGTGACGTTGGTAAGTCTGCACTAACTATACAACTGA-
T CCAG (KRAS G13D 25mer^3 nucleotide sequence) 132
ATGACCGAGTACAAGCTGGTGGTGGTGGGCGCCTGCGGCGTGGGCAAGAGCGCCCTGACCATCCAGCTGA-
TCC AG (KRAS G12C 25mer nucleotide sequence) 133
ATGACCGAGTACAAGCTGGTGGTGGTGGGCGCCGGCGGCGTGGGCAAGAGCGCCCTGACCATCCAGCTGA-
TCC AG (KRAS WT 25mer nucleotide sequence) 134
GGGAAATAAGAGAGAAAAGAAGAGTAAGAAGAAATATAAGAGCCACC (5' UTR sequence;
no promoter) 135
MTEYKLVVVGADGVGKSALTIQLIQMTEYKLVVVGAVGVGKSALTIQLIQMTEYKLVVVGAGDVGKSALT-
IQLIQ (KRAS(G12D G12V G13D) 75mer "3MUT" aa. seq) 136
ATGACCGAGTACAAGCTCGTTGTAGTCGGCGCCGACGGCGTGGGCAAGAGCGCCTTGACCATCCAGTTGA-
TCCA
GATGACCGAATATAAGTTGGTGGTGGTAGGCGCAGTGGGAGTTGGCAAGTCAGCACTCACAATTCAGCTCATT-
C
AAATGACAGAATACAAGTTAGTCGTTGTAGGAGCAGGCGACGTCGGCAAGAGTGCCTTAACCATTCAACTAAT-
C CAG (KRAS(G12D G12V G13D) 75mer "3MUT" nt. seq) 137
MTEYKLVVVGADGVGKSALTIQLIQMTEYKLVVVGAVGVGKSALTIQLIQMTEYKLVVVGAGDVGKSALT-
IQLIQMTE YKLVVVGACGVGKSALTIQLIQ (KRAS(G12D G12V G13D G12C) 100mer
"4MUT" aa. seq) 138
ATGACCGAGTACAAGCTCGTGGTCGTCGGCGCCGACGGGGTAGGCAAGTCCGCTCTGACCATTCAGCTCA-
TCCA
GATGACGGAGTACAAACTCGTGGTAGTGGGAGCCGTGGGTGTGGGCAAGAGCGCGCTCACCATCCAACTCATC
CAAATGACCGAATATAAACTCGTCGTGGTGGGAGCCGGCGACGTGGGAAAGAGCGCCCTTACCATCCAGTTAA-
T
CCAGATGACAGAATACAAGCTGGTGGTGGTCGGTGCCTGCGGCGTGGGTAAGTCCGCCCTGACAATCCAGCTG
ATCCAG (KRAS(G12D G12V G13D G12C) 100mer "4MUT" nt. seq) 139
ATGCCCCACAGTAGCCTCCACCCCAGCATCCCCTGCCCCAGAGGCCACGGCGCACAGAAGGCCGCCCTGG-
TGCT
GCTGAGCGCCTGTCTGGTGACCCTGTGGGGTCTGGGCGAGCCCCCCGAGCACACCCTGCGGTACCTCGTGCTG-
C
ATCTGGCCAGCCTGCAGCTGGGCCTGCTGCTGAACGGCGTGTGCAGCCTGGCCGAAGAGCTGAGACACATCCA-
C
AGCAGATACAGAGGCTCCTACTGGAGAACCGTCAGAGCCTGCCTCGGCTGTCCCCTGAGAAGAGGCGCCCTGC-
T
GCTCCTGAGCATCTACTTCTACTACAGCCTGCCCAACGCCGTGGGCCCCCCCTTCACCTGGATGCTGGCCCTG-
CTG
GGCCTGAGCCAGGCCCTGAACATCCTGCTGGGCCTGAAGGGCTTGGCCCCCGCCGAGATCTCCGCCGTGTGCG-
A
GAAGGGCAACTTCAACATGGCCCATGGCCTTGCCTGGTCCTACTACATCGGCTACCTGAGACTGATCCTGCCC-
GA
GCTGCAGGCCAGAATCAGAACCTACAACCAGCACTACAACAACCTGCTGAGAGGCGCCGTGAGCCAAAGACTG-
T
ACATCCTGCTGCCCCTGGACTGCGGCGTGCCCGACAACCTTAGCATGGCCGACCCCAACATCAGATTCCTGGA-
CA
AGCTGCCCCAGCAGACCGGCGACCACGCCGGCATCAAGGACAGAGTGTACAGCAACAGCATCTACGAGCTGCT
GGAGAACGGCCAGAGAGCCGGCACCTGCGTGCTGGAGTACGCCACCCCCCTGCAGACCCTGTTCGCCATGAGC
CAGTACAGCCAGGCCGGCTTCAGCAGAGAGGACAGACTGGAGCAAGCCAAGCTGTTCTGCAGAACCCTGGAGG
ACATCCTGGCGGACGCCCCCGAGAGCCAAAACAACTGCAGACTGATCGCCTACCAGGAGCCCGCCGACGACAG
CAGCTTCAGCCTGAGCCAGGAAGTGCTGAGACACCTGAGACAGGAAGAGAAGGAGGAGGTGACCGTGGGAAG
CCTGAAGACCAGCGCCGTGCCCAGCACCAGCACCATGAGCCAGGAGCCCGAGCTGCTGATCAGCGGCATGGAG
AAGCCCCTGCCCCTGAGAACCGACTTCAGC (huSTING(V155M); no epitope tag;
nucleotide sequence) 140
ATGCCTCACAGCAGCCTGCACCCTAGCATCCCTTGCCCTAGAGGCCACGGCGCCCAGAAGGCCGCCCTGG-
TGCT
GCTGAGCGCCTGCCTGGTGACCCTGTGGGGCCTGGGCGAGCCTCCTGAGCACACCCTGAGATACCTGGTGCTG-
C
ACCTGGCCAGCCTGCAGCTGGGCCTGCTGCTGAACGGCGTGTGCAGCCTGGCCGAGGAGCTGAGACACATCCA
CAGCAGATACAGAGGCAGCTACTGGAGAACCGTGAGAGCCTGCCTGGGCTGCCCTCTGAGAAGAGGCGCCCTG
CTGCTGCTGAGCATCTACTTCTACTACAGCCTGCCTAACGCCGTGGGCCCTCCTTTCACCTGGATGCTGGCCC-
TGC
TGGGCCTGAGCCAGGCCCTGAACATCCTGCTGGGCCTGAAGGGCCTGGCCCCTGCCGAGATCAGCGCCGTGTG
CGAGAAGGGCAACTTCAACGTGGCCCACGGCCTGGCCTGGAGCTACTACATCGGCTACCTGAGACTGATCCTG-
C
CTGAGCTGCAGGCCAGAATCAGAACCTACAACCAGCACTACAACAACCTGCTGAGAGGCGCCGTGAGCCAGAG
ACTGTACATCCTGCTGCCTCTGGACTGCGGCGTGCCTGACAACCTGAGCATGGCCGACCCTAACATCAGATTC-
CT
GGACAAGCTGCCTCAGCAGACCGGCGACCACGCCGGCATCAAGGACAGAGTGTACAGCAACAGCATCTACGAG
CTGCTGGAGAACGGCCAGAGAGCCGGCACCTGCGTGCTGGAGTACGCCACCCCTCTGCAGACCCTGTTCGCCA-
T
GAGCCAGTACAGCCAGGCCGGCTTCAGCAGAGAGGACACCCTGGAGCAGGCCAAGCTGTTCTGCAGAACCCTG
GAGGACATCCTGGCCGACGCCCCTGAGAGCCAGAACAACTGCAGACTGATCGCCTACCAGGAGCCTGCCGACG
ACAGCAGCTTCAGCCTGAGCCAGGAGGTGCTGAGACACCTGAGACAGGAGGAGAAGGAGGAGGTGACCGTGG
GCAGCCTGAAGACCAGCGCCGTGCCTAGCACCAGCACCATGAGCCAGGAGCCTGAGCTGCTGATCAGCGGCAT
GGAGAAGCCTCTGCCTCTGAGAACCGACTTCAGC (Hu STING(R284T); no epitope
tag; nucleotide sequence) 141
ATGCCCCACAGCAGCCTGCACCCCTCCATCCCCTGTCCCAGAGGCCACGGCGCCCAGAAGGCCGCCCTGG-
TGCT
GCTGAGCGCCTGCCTGGTGACCTTATGGGGCCTGGGCGAGCCCCCCGAGCACACCCTGAGATACCTGGTCCTG-
C
ACCTGGCCAGCCTCCAGCTGGGCCTGCTGCTCAACGGCGTGTGTAGCCTGGCCGAGGAGCTGAGACACATCCA-
C
AGCAGATACAGAGGCAGCTACTGGAGAACCGTGAGAGCCTGCCTGGGTTGCCCACTGAGAAGAGGAGCTCTGC
TGCTGCTGAGCATCTACTTCTACTACTCGCTGCCCAACGCTGTGGGCCCCCCCTTCACCTGGATGCTGGCCCT-
GCT
GGGTCTGAGCCAGGCCCTGAACATCCTCCTGGGCCTGAAGGGCCTGGCCCCCGCCGAGATAAGCGCCGTTTGC-
G
AGAAGGGCAACTTCAACGTGGCCCATGGCCTGGCCTGGAGCTACTACATCGGCTACTTACGCCTGATCCTGCC-
C
GAGCTGCAGGCCAGAATCAGAACCTACAACCAGCATTACAACAACCTGCTGAGAGGCGCCGTGAGCCAGAGAC
TGTATATCCTGCTGCCCCTGGACTGCGGCGTGCCCGACAACCTGAGCATGGCCGACCCCAACATCAGATTCCT-
GG
ACAAGCTCCCCCAGCAGACCGGCGACCACGCCGGAATCAAAGACAGAGTGTATAGCAACAGCATCTACGAGCT
GCTGGAGAACGGCCAGAGAGCCGGCACCTGCGTACTGGAGTACGCCACCCCCTTGCAGACCCTGTTTGCCATG-
A
GCCAGTACAGCCAGGCCGGCTTCAGCAGAGAGGACATGCTGGAGCAGGCCAAGCTGTTCTGCAGAACCCTGGA
GGACATCCTGGCCGACGCCCCCGAGAGCCAGAACAACTGCAGACTGATCGCCTACCAAGAGCCCGCCGACGAC
AGCAGCTTCAGCTTAAGCCAGGAGGTGCTGAGACATCTGAGACAGGAGGAGAAGGAGGAGGTGACCGTGGGC
AGCCTCAAGACCAGCGCTGTGCCCTCTACCAGCACCATGAGCCAGGAGCCCGAGCTGCTGATCAGCGGCATGG-
A GAAGCCCCTGCCCCTGAGAACAGACTTCAGC (hu STING (R284M); no epitope
tag; nucleotide sequence) 142
ATGCCCCATAGCAGCCTGCACCCCAGCATCCCCTGCCCCAGAGGCCACGGCGCCCAGAAGGCCGCCCTGG-
TCCT
GCTGAGCGCATGCCTGGTCACCCTGTGGGGCCTGGGCGAGCCCCCCGAGCACACCCTGAGATACCTGGTGCTG-
C
ACCTCGCCAGCCTGCAGCTGGGCCTGCTGCTGAACGGCGTGTGCAGCCTGGCCGAGGAGCTGAGACACATCCA-
C
AGCAGATATAGAGGCAGCTACTGGAGAACCGTGAGAGCTTGCCTCGGCTGCCCCCTGAGAAGAGGCGCCCTGC
TGCTGCTGAGCATCTACTTTTACTACAGCCTGCCCAACGCTGTGGGCCCCCCTTTCACGTGGATGCTCGCCCT-
GCT
GGGACTGAGCCAGGCCCTGAACATCCTGCTGGGCCTTAAGGGCCTAGCCCCCGCCGAGATCAGCGCCGTGTGC
GAGAAGGGCAACTTCAATGTGGCCCACGGCCTGGCCTGGAGCTACTACATCGGCTACCTGAGACTGATCCTGC-
C
CGAGCTGCAGGCCAGAATCAGAACCTACAATCAGCACTACAACAACCTGCTGAGAGGCGCCGTGAGCCAGAGA
CTGTACATCCTGCTGCCCCTGGACTGCGGCGTGCCCGACAACCTCAGCATGGCCGACCCCAACATCAGATTCC-
TG
GACAAGCTGCCCCAGCAGACCGGCGACCACGCCGGCATCAAGGATCGCGTGTACAGCAACAGCATCTACGAGC
TGCTGGAAAACGGCCAGAGAGCCGGAACCTGCGTGCTGGAGTACGCCACACCCCTGCAGACCCTGTTCGCCAT-
G
AGCCAGTACAGCCAGGCCGGCTTCAGCAGAGAGGACAAGCTGGAGCAGGCCAAGCTGTTCTGCAGAACCCTGG
AGGATATCCTCGCCGACGCCCCCGAGAGCCAGAACAACTGCAGGCTGATCGCGTACCAGGAGCCCGCTGACGA
CAGCAGCTTTAGCCTGAGCCAGGAGGTGCTGAGACATCTGCGTCAAGAGGAAAAGGAGGAGGTGACCGTGGG
CTCCCTGAAGACCAGCGCCGTGCCCAGCACCAGCACCATGAGCCAGGAGCCCGAGCTGCTGATCAGCGGCATG
GAGAAGCCACTGCCCCTCAGAACCGACTTCAGC (Hu STING (R284K); no epitope
tag; nucleotide sequence) 143
ATGCCTCACAGCAGCCTGCACCCTAGCATCCCTTGCCCTAGAGGCCACGGCGCCCAGAAGGCCGCCCTGG-
TGCT
GCTGAGCGCCTGCCTGGTGACCCTGTGGGGCCTGGGCGAGCCTCCTGAGCACACCCTGAGATACCTGGTGCTG-
C
ACCTGGCCAGCCTGCAGCTGGGCCTGCTGCTGAACGGCGTGTGCAGCCTGGCCGAGGAGCTGAGACACATCCA
CAGCAGATACAGAGGCAGCTACTGGAGAACCGTGAGAGCCTGCCTGGGCTGCCCTCTGAGAAGAGGCGCCCTG
CTGCTGCTGAGCATCTACTTCTACTACAGCCTGCCTAACGCCGTGGGCCCTCCTTTCACCTGGATGCTGGCCC-
TGC
TGGGCCTGAGCCAGGCCCTGAACATCCTGCTGGGCCTGAAGGGCCTGGCCCCTGCCGAGATCAGCGCCGTGTG
CGAGAAGGGCAACTTCAGCGTGGCCCACGGCCTGGCCTGGAGCTACTACATCGGCTACCTGAGACTGATCCTG-
C
CTGAGCTGCAGGCCAGAATCAGAACCTACAACCAGCACTACAACAACCTGCTGAGAGGCGCCGTGAGCCAGAG
ACTGTACATCCTGCTGCCTCTGGACTGCGGCGTGCCTGACAACCTGAGCATGGCCGACCCTAACATCAGATTC-
CT
GGACAAGCTGCCTCAGCAGACCGGCGACCACGCCGGCATCAAGGACAGAGTGTACAGCAACAGCATCTACGAG
CTGCTGGAGAACGGCCAGAGAGCCGGCACCTGCGTGCTGGAGTACGCCACCCCTCTGCAGACCCTGTTCGCCA-
T
GAGCCAGTACAGCCAGGCCGGCTTCAGCAGAGAGGACAGACTGGAGCAGGCCAAGCTGTTCTGCAGAACCCTG
GAGGACATCCTGGCCGACGCCCCTGAGAGCCAGAACAACTGCAGACTGATCGCCTACCAGGAGCCTGCCGACG
ACAGCAGCTTCAGCCTGAGCCAGGAGGTGCTGAGACACCTGAGACAGGAGGAGAAGGAGGAGGTGACCGTGG
GCAGCCTGAAGACCAGCGCCGTGCCTAGCACCAGCACCATGAGCCAGGAGCCTGAGCTGCTGATCAGCGGCAT
GGAGAAGCCTCTGCCTCTGAGAACCGACTTCAGC (Hu STING(N154S); no epitope
tag; nucleotide sequence) 144
ATGCCTCACAGCAGCCTGCACCCTAGCATCCCTTGCCCTAGAGGCCACGGCGCCCAGAAGGCCGCCCTGG-
TGCT
GCTGAGCGCCTGCCTGGTGACCCTGTGGGGCCTGGGCGAGCCTCCTGAGCACACCCTGAGATACCTGGTGCTG-
C
ACCTGGCCAGCCTGCAGCTGGGCCTGCTGCTGAACGGCGTGTGCAGCCTGGCCGAGGAGCTGAGACACATCCA
CAGCAGATACAGAGGCAGCTACTGGAGAACCGTGAGAGCCTGCCTGGGCTGCCCTCTGAGAAGAGGCGCCCTG
CTGCTGCTGAGCATCTACTTCTACTACAGCCTGCCTAACGCCGTGGGCCCTCCTTTCACCTGGATGCTGGCCC-
TGC
TGGGCCTGAGCCAGGCCCTGAACATCCTGCTGGGCCTGAAGGGCCTGGCCCCTGCCGAGATCAGCGCCCTGTG-
C
GAGAAGGGCAACTTCAACGTGGCCCACGGCCTGGCCTGGAGCTACTACATCGGCTACCTGAGACTGATCCTGC-
C
TGAGCTGCAGGCCAGAATCAGAACCTACAACCAGCACTACAACAACCTGCTGAGAGGCGCCGTGAGCCAGAGA
CTGTACATCCTGCTGCCTCTGGACTGCGGCGTGCCTGACAACCTGAGCATGGCCGACCCTAACATCAGATTCC-
TG
GACAAGCTGCCTCAGCAGACCGGCGACCACGCCGGCATCAAGGACAGAGTGTACAGCAACAGCATCTACGAGC
TGCTGGAGAACGGCCAGAGAGCCGGCACCTGCGTGCTGGAGTACGCCACCCCTCTGCAGACCCTGTTCGCCAT-
G
AGCCAGTACAGCCAGGCCGGCTTCAGCAGAGAGGACAGACTGGAGCAGGCCAAGCTGTTCTGCAGAACCCTGG
AGGACATCCTGGCCGACGCCCCTGAGAGCCAGAACAACTGCAGACTGATCGCCTACCAGGAGCCTGCCGACGA
CAGCAGCTTCAGCCTGAGCCAGGAGGTGCTGAGACACCTGAGACAGGAGGAGAAGGAGGAGGTGACCGTGGG
CAGCCTGAAGACCAGCGCCGTGCCTAGCACCAGCACCATGAGCCAGGAGCCTGAGCTGCTGATCAGCGGCATG
GAGAAGCCTCTGCCTCTGAGAACCGACTTCAGC (Hu STING(V147L); no epitope tag;
nucleotide sequence) 145
ATGCCTCACAGCAGCCTGCACCCTAGCATCCCTTGCCCTAGAGGCCACGGCGCCCAGAAGGCCGCCCTGG-
TGCT
GCTGAGCGCCTGCCTGGTGACCCTGTGGGGCCTGGGCGAGCCTCCTGAGCACACCCTGAGATACCTGGTGCTG-
C
ACCTGGCCAGCCTGCAGCTGGGCCTGCTGCTGAACGGCGTGTGCAGCCTGGCCGAGGAGCTGAGACACATCCA
CAGCAGATACAGAGGCAGCTACTGGAGAACCGTGAGAGCCTGCCTGGGCTGCCCTCTGAGAAGAGGCGCCCTG
CTGCTGCTGAGCATCTACTTCTACTACAGCCTGCCTAACGCCGTGGGCCCTCCTTTCACCTGGATGCTGGCCC-
TGC
TGGGCCTGAGCCAGGCCCTGAACATCCTGCTGGGCCTGAAGGGCCTGGCCCCTGCCGAGATCAGCGCCGTGTG
CGAGAAGGGCAACTTCAACGTGGCCCACGGCCTGGCCTGGAGCTACTACATCGGCTACCTGAGACTGATCCTG-
C
CTGAGCTGCAGGCCAGAATCAGAACCTACAACCAGCACTACAACAACCTGCTGAGAGGCGCCGTGAGCCAGAG
ACTGTACATCCTGCTGCCTCTGGACTGCGGCGTGCCTGACAACCTGAGCATGGCCGACCCTAACATCAGATTC-
CT
GGACAAGCTGCCTCAGCAGACCGGCGACCACGCCGGCATCAAGGACAGAGTGTACAGCAACAGCATCTACGAG
CTGCTGGAGAACGGCCAGAGAGCCGGCACCTGCGTGCTGGAGTACGCCACCCCTCTGCAGACCCTGTTCGCCA-
T
GAGCCAGTACAGCCAGGCCGGCTTCAGCAGAGAGGACAGACTGGAGCAGGCCAAGCTGTTCTGCAGAACCCTG
GAGGACATCCTGGCCGACGCCCCTGAGAGCCAGAACAACTGCAGACTGATCGCCTACCAGCAGCCTGCCGACG
ACAGCAGCTTCAGCCTGAGCCAGGAGGTGCTGAGACACCTGAGACAGGAGGAGAAGGAGGAGGTGACCGTGG
GCAGCCTGAAGACCAGCGCCGTGCCTAGCACCAGCACCATGAGCCAGGAGCCTGAGCTGCTGATCAGCGGCAT
GGAGAAGCCTCTGCCTCTGAGAACCGACTTCAGC (Hu STING (E315Q); no epitope
tag; nucleotide sequence) 146
ATGCCTCACAGCAGCCTGCACCCTAGCATCCCTTGCCCTAGAGGCCACGGCGCCCAGAAGGCCGCCCTGG-
TGCT
GCTGAGCGCCTGCCTGGTGACCCTGTGGGGCCTGGGCGAGCCTCCTGAGCACACCCTGAGATACCTGGTGCTG-
C
ACCTGGCCAGCCTGCAGCTGGGCCTGCTGCTGAACGGCGTGTGCAGCCTGGCCGAGGAGCTGAGACACATCCA
CAGCAGATACAGAGGCAGCTACTGGAGAACCGTGAGAGCCTGCCTGGGCTGCCCTCTGAGAAGAGGCGCCCTG
CTGCTGCTGAGCATCTACTTCTACTACAGCCTGCCTAACGCCGTGGGCCCTCCTTTCACCTGGATGCTGGCCC-
TGC
TGGGCCTGAGCCAGGCCCTGAACATCCTGCTGGGCCTGAAGGGCCTGGCCCCTGCCGAGATCAGCGCCGTGTG
CGAGAAGGGCAACTTCAACGTGGCCCACGGCCTGGCCTGGAGCTACTACATCGGCTACCTGAGACTGATCCTG-
C
CTGAGCTGCAGGCCAGAATCAGAACCTACAACCAGCACTACAACAACCTGCTGAGAGGCGCCGTGAGCCAGAG
ACTGTACATCCTGCTGCCTCTGGACTGCGGCGTGCCTGACAACCTGAGCATGGCCGACCCTAACATCAGATTC-
CT
GGACAAGCTGCCTCAGCAGACCGGCGACCACGCCGGCATCAAGGACAGAGTGTACAGCAACAGCATCTACGAG
CTGCTGGAGAACGGCCAGAGAGCCGGCACCTGCGTGCTGGAGTACGCCACCCCTCTGCAGACCCTGTTCGCCA-
T
GAGCCAGTACAGCCAGGCCGGCTTCAGCAGAGAGGACAGACTGGAGCAGGCCAAGCTGTTCTGCAGAACCCTG
GAGGACATCCTGGCCGACGCCCCTGAGAGCCAGAACAACTGCAGACTGATCGCCTACCAGGAGCCTGCCGACG
ACAGCAGCTTCAGCCTGAGCCAGGAGGTGCTGAGACACCTGAGACAGGAGGAGAAGGAGGAGGTGACCGTGG
GCAGCCTGAAGACCAGCGCCGTGCCTAGCACCAGCACCATGAGCCAGGAGCCTGAGCTGCTGATCAGCGGCAT
GGAGAAGCCTCTGCCTCTGGCCACCGACTTCAGC (Hu STING (R375A); no epitope
tag; nucleotide sequence) 147
ATGCCTCACAGCAGCCTGCACCCTAGCATCCCTTGCCCTAGAGGCCACGGCGCCCAGAAGGCCGCCCTGG-
TGCT
GCTGAGCGCCTGCCTGGTGACCCTGTGGGGCCTGGGCGAGCCTCCTGAGCACACCCTGAGATACCTGGTGCTG-
C
ACCTGGCCAGCCTGCAGCTGGGCCTGCTGCTGAACGGCGTGTGCAGCCTGGCCGAGGAGCTGAGACACATCCA
CAGCAGATACAGAGGCAGCTACTGGAGAACCGTGAGAGCCTGCCTGGGCTGCCCTCTGAGAAGAGGCGCCCTG
CTGCTGCTGAGCATCTACTTCTACTACAGCCTGCCTAACGCCGTGGGCCCTCCTTTCACCTGGATGCTGGCCC-
TGC
TGGGCCTGAGCCAGGCCCTGAACATCCTGCTGGGCCTGAAGGGCCTGGCCCCTGCCGAGATCAGCGCCCTGTG-
C
GAGAAGGGCAACTTCAGCATGGCCCACGGCCTGGCCTGGAGCTACTACATCGGCTACCTGAGACTGATCCTGC-
C
TGAGCTGCAGGCCAGAATCAGAACCTACAACCAGCACTACAACAACCTGCTGAGAGGCGCCGTGAGCCAGAGA
CTGTACATCCTGCTGCCTCTGGACTGCGGCGTGCCTGACAACCTGAGCATGGCCGACCCTAACATCAGATTCC-
TG
GACAAGCTGCCTCAGCAGACCGGCGACCACGCCGGCATCAAGGACAGAGTGTACAGCAACAGCATCTACGAGC
TGCTGGAGAACGGCCAGAGAGCCGGCACCTGCGTGCTGGAGTACGCCACCCCTCTGCAGACCCTGTTCGCCAT-
G
AGCCAGTACAGCCAGGCCGGCTTCAGCAGAGAGGACAGACTGGAGCAGGCCAAGCTGTTCTGCAGAACCCTGG
AGGACATCCTGGCCGACGCCCCTGAGAGCCAGAACAACTGCAGACTGATCGCCTACCAGGAGCCTGCCGACGA
CAGCAGCTTCAGCCTGAGCCAGGAGGTGCTGAGACACCTGAGACAGGAGGAGAAGGAGGAGGTGACCGTGGG
CAGCCTGAAGACCAGCGCCGTGCCTAGCACCAGCACCATGAGCCAGGAGCCTGAGCTGCTGATCAGCGGCATG
GAGAAGCCTCTGCCTCTGAGAACCGACTTCAGC (Hu STING(V147L/N154S/V155M); no
epitope tag; nucleotide sequence) 148
ATGCCTCACAGCAGCCTGCACCCTAGCATCCCTTGCCCTAGAGGCCACGGCGCCCAGAAGGCCGCCCTGG-
TGCT
GCTGAGCGCCTGCCTGGTGACCCTGTGGGGCCTGGGCGAGCCTCCTGAGCACACCCTGAGATACCTGGTGCTG-
C
ACCTGGCCAGCCTGCAGCTGGGCCTGCTGCTGAACGGCGTGTGCAGCCTGGCCGAGGAGCTGAGACACATCCA
CAGCAGATACAGAGGCAGCTACTGGAGAACCGTGAGAGCCTGCCTGGGCTGCCCTCTGAGAAGAGGCGCCCTG
CTGCTGCTGAGCATCTACTTCTACTACAGCCTGCCTAACGCCGTGGGCCCTCCTTTCACCTGGATGCTGGCCC-
TGC
TGGGCCTGAGCCAGGCCCTGAACATCCTGCTGGGCCTGAAGGGCCTGGCCCCTGCCGAGATCAGCGCCCTGTG-
C
GAGAAGGGCAACTTCAGCATGGCCCACGGCCTGGCCTGGAGCTACTACATCGGCTACCTGAGACTGATCCTGC-
C
TGAGCTGCAGGCCAGAATCAGAACCTACAACCAGCACTACAACAACCTGCTGAGAGGCGCCGTGAGCCAGAGA
CTGTACATCCTGCTGCCTCTGGACTGCGGCGTGCCTGACAACCTGAGCATGGCCGACCCTAACATCAGATTCC-
TG
GACAAGCTGCCTCAGCAGACCGGCGACCACGCCGGCATCAAGGACAGAGTGTACAGCAACAGCATCTACGAGC
TGCTGGAGAACGGCCAGAGAGCCGGCACCTGCGTGCTGGAGTACGCCACCCCTCTGCAGACCCTGTTCGCCAT-
G
AGCCAGTACAGCCAGGCCGGCTTCAGCAGAGAGGACATGCTGGAGCAGGCCAAGCTGTTCTGCAGAACCCTGG
AGGACATCCTGGCCGACGCCCCTGAGAGCCAGAACAACTGCAGACTGATCGCCTACCAGGAGCCTGCCGACGA
CAGCAGCTTCAGCCTGAGCCAGGAGGTGCTGAGACACCTGAGACAGGAGGAGAAGGAGGAGGTGACCGTGGG
CAGCCTGAAGACCAGCGCCGTGCCTAGCACCAGCACCATGAGCCAGGAGCCTGAGCTGCTGATCAGCGGCATG
GAGAAGCCTCTGCCTCTGAGAACCGACTTCAGC (Hu
STING(R284M/V147L/N154S/V155M); no epitope tag; nucleotide
sequence) 149
TGATAATAGGCTGGAGCCTCGGTGGCCTAGCTTCTTGCCCCTTGGGCCTCCCCCCAGCCCCTCCTCCCCT-
TCCTGC
ACCCGTACCCCCCAAACACCATTGTCACACTCCAGTGGTCTTTGAATAAAGTCTGAGTGGGCGGC
(3' UTR used in STING V155M construct, containing miR122 binding
site) 150
ATGGAGACCCCCAAGCCTAGAATCCTGCCCTGGCTGGTGAGCCAGCTGGACCTGGGCCAGCTGGAGGGCG-
TAG
CCTGGCTGGACGAGAGCAGAACCAGATTCAGAATCCCCTGGAAGCACGGCCTGAGACAAGACGCCCAGATGGC
CGACTTCGGCATCTTCCAGGCCTGGGCCGAGGCCAGCGGCGCCTACACCCCTGGCAAGGATAAGCCCGATGTG-
A
GCACCTGGAAGAGAAACTTCAGAAGCGCCCTGAACAGAAAGGAGGTGCTGAGACTGGCCGCCGACAATAGCAA
GGACCCCTACGACCCCCACAAGGTGTACGAGTTCGTTACCCCCGGCGCCAGGGACTTCGTGCACCTGGGCGCC-
A
GCCCCGACACCAACGGCAAGAGCAGCCTGCCCCACAGCCAGGAGAACCTGCCCAAGCTGTTCGATGGCCTGAT-
C
CTGGGCCCCCTGAAGGACGAGGGCAGCAGCGACCTGGCCATCGTGAGCGACCCTAGCCAGCAGCTGCCCTCCC
CCAACGTGAACAACTTCCTGAACCCCGCCCCCCAGGAGAACCCCCTGAAGCAACTGCTGGCCGAGGAGCAGTG-
G
GAGTTCGAGGTGACCGCCTTCTACAGAGGCAGACAGGTGTTCCAGCAGACCCTGTTCTGCCCCGGCGGCCTGA-
G
ACTGGTAGGCAGCACCGCTGACATGACCCTGCCCTGGCAGCCCGTGACCCTGCCCGACCCCGAAGGCTTTCTG-
A
CCGACAAGCTGGTGAAGGAGTACGTCGGCCAAGTGCTGAAGGGCCTGGGCAACGGCCTGGCCCTGTGGCAGG
CCGGCCAGTGCCTGTGGGCCCAGAGACTCGGCCACAGCCACGCCTTCTGGGCCCTGGGCGAGGAACTCCTGCC-
C
GATAGCGGCAGAGGCCCCGACGGCGAGGTGCACAAGGACAAGGACGGCGCCGTGTTCGACCTGCGCCCCTTCG
TGGCCGACCTGATCGCCTTCATGGAGGGCAGCGGCCACAGCCCCAGATATACCCTGTGGTTCTGCATGGGCGA-
G
ATGTGGCCCCAGGACCAGCCCTGGGTGAAGAGACTGGTGATGGTGAAGGTGGTGCCCACCTGCCTGAAAGAGC
TGCTGGAGATGGCCAGAGAGGGCGGCGCCAGCTCCCTGAAAACCGTGGACCTGCACATTGACAACAGCCAGCC
CATCAGCCTGACCAGCGACCAGTACAAGGCCTACCTGCAGGACCTGGTGGAGGACATGGACTTCCAGGCCACC-
G GCAACATC (super mouse IRF3 S396D; no epitope tag) 151
ATGGGCACCCCCAAGCCCAGAATCCTGCCCTGGCTGGTGAGCCAGCTGGACCTGGGCCAGCTGGAGGGAG-
TGG
CCTGGGTGAACAAGAGCAGAACCAGATTCAGAATCCCCTGGAAGCACGGCCTCAGACAGGACGCCCAGCAGGA
GGACTTCGGCATTTTTCAGGCTTGGGCCGAGGCCACCGGCGCCTACGTGCCCGGCAGAGACAAGCCCGACCTG-
C
CCACCTGGAAAAGAAACTTCAGAAGCGCCTTGAATAGAAAGGAGGGCCTGAGACTGGCCGAGGACAGAAGCA
AGGACCCCCACGACCCTCACAAGATCTACGAGTTCGTGAATAGCGGCGTGGGCGACTTTAGCCAGCCCGACAC-
C
AGCCCCGACACCAACGGCGGCGGCAGCACCAGCGACACGCAGGAGGACATCCTGGATGAACTGCTGGGCAACA
TGGTGCTGGCCCCCCTGCCCGATCCCGGCCCCCCTTCGCTTGCCGTGGCCCCCGAGCCCTGCCCCCAGCCCCT-
GA
GAAGCCCCTCTCTGGATAACCCCACCCCCTTCCCCAACCTGGGCCCCAGCGAGAATCCACTGAAGAGACTTCT-
GG
TCCCCGGCGAGGAGTGGGAGTTCGAGGTGACCGCCTTCTACAGAGGCAGACAGGTGTTCCAGCAGACCATCAG
CTGCCCCGAAGGCCTGAGATTAGTGGGCAGCGAAGTGGGCGACAGGACCCTGCCCGGGTGGCCCGTGACCCTG
CCCGATCCCGGCATGAGCCTGACCGACAGAGGTGTGATGAGCTACGTGAGACACGTGCTGAGCTGCCTGGGCG
GCGGCCTGGCACTGTGGAGAGCCGGCCAGTGGCTGTGGGCCCAGAGACTGGGCCACTGCCACACCTACTGGGC
CGTGAGCGAGGAGCTGCTGCCCAACAGCGGCCACGGCCCCGACGGCGAGGTGCCCAAGGACAAGGAAGGGGG
CGTGTTCGACCTGGGCCCCTTCATCGTAGACCTGATCACCTTTACCGAGGGCAGCGGCAGGAGCCCCAGATAC-
G
CCCTGTGGTTCTGCGTGGGCGAAAGCTGGCCCCAGGACCAGCCCTGGACCAAGAGACTGGTGATGGTGAAGGT
AGTGCCCACCTGCCTGAGAGCCTTAGTGGAGATGGCCAGAGTGGGCGGGGCCAGCAGCCTGGAGAACACCGTG
GATCTTCACATCGACAACAGCCACCCCCTGAGCCTGACCAGCGACCAGTACAAGGCCTACCTGCAGGACCTGG-
T GGAGGGCATGGACTTCCAGGGCCCCGGCGAGACC (super human IRF3 S396D; no
epitope tag) 152
ATGGCGCTGGCCCCCGAAAGAGCCGCCCCCAGAGTCCTCTTCGGCGAATGGCTCCTTGGCGAAATTTCGT-
CGGG
CTGCTACGAGGGCTTACAATGGCTGGATGAGGCGAGAACCTGTTTCAGGGTGCCCTGGAAACACTTCGCCAGA-
A
AGGATCTAAGCGAAGCAGATGCTAGAATTTTTAAGGCTTGGGCCGTGGCCAGGGGAAGATGGCCCCCCTCGAG
CAGAGGCGGCGGCCCTCCCCCCGAGGCAGAAACGGCCGAGAGAGCCGGATGGAAAACCAATTTCAGATGCGCC
CTGAGATCTACAAGAAGATTCGTGATGCTTAGAGACAACAGCGGAGATCCCGCCGATCCCCATAAGGTGTATG-
C
CCTGTCCCGGGAGCTGTGCTGGAGGGAAGGGCCTGGCACTGACCAGACCGAAGCCGAAGCCCCCGCGGCCGTG
CCGCCGCCCCAAGGAGGCCCACCAGGCCCTTTCCTCGCTCACACCCACGCCGGTCTGCAAGCCCCGGGACCTC-
TA
CCTGCCCCTGCCGGCGATAAAGGCGACCTGTTGCTGCAGGCCGTCCAACAGAGCTGCCTGGCCGATCATCTGC-
T
CACAGCCAGCTGGGGCGCTGACCCCGTCCCAACAAAGGCCCCCGGTGAGGGCCAAGAAGGCCTGCCTCTGACC
GGCGCCTGTGCCGGCGGCCCTGGCCTGCCTGCTGGCGAGCTGTACGGATGGGCTGTCGAAACCACTCCCTCCC-
C
CGGCCCCCAACCTGCGGCCCTGACAACCGGCGAGGCAGCCGCACCCGAAAGCCCCCACCAGGCCGAACCCTAC-
C
TCAGTCCCAGCCCCTCCGCCTGCACCGCTGTGCAGGAGCCCAGCCCCGGTGCTCTGGACGTAACAATCATGTA-
CA
AAGGCAGAACCGTGCTTCAGAAGGTGGTTGGACACCCCTCCTGTACTTTTCTCTACGGCCCCCCCGACCCTGC-
CG
TGAGAGCTACCGACCCGCAACAGGTGGCCTTTCCCTCGCCCGCCGAACTGCCCGATCAAAAACAGCTGAGATA-
C
ACCGAGGAGCTGCTGAGACACGTGGCGCCGGGCTTACACCTAGAGTTGAGAGGCCCCCAACTCTGGGCCAGAC
GCATGGGCAAGTGTAAGGTGTACTGGGAGGTCGGGGGCCCTCCCGGCTCTGCCAGCCCCAGCACCCCTGCTTG-
T
CTCTTGCCCAGAAACTGTGATACCCCCATCTTCGACTTCCGTGTATTTTTCCAGGAACTGGTCGAGTTTAGAG-
CCA
GACAGAGACGAGGCAGCCCCAGATATACAATCTACCTCGGCTTCGGCCAGGACCTGAGTGCCGGCAGACCTAA
GGAGAAGTCGCTGGTCCTAGTGAAGTTAGAGCCCTGGCTATGTAGAGTGCACCTGGAGGGCACCCAGAGAGAA
GGAGTGAGCAGCCTGGACAGCAGCAGCCTGAGTCTGTGCCTGAGCTCCGCCAACTCGCTGTATGATGACATCG-
A GTGTTTCCTCATGGAGCTGGAGCAGCCCGCC (Wild-type Hu IRF7 isoform A;
P037 without epitope tag) 153
ATGGCCCTTGCCCCTGAGCGGGCCGCCCCCAGAGTGTTATTCGGCGAGTGGCTGCTGGGCGAGATCAGCA-
GCG
GCTGCTACGAGGGACTGCAGTGGCTGGACGAGGCTAGAACCTGCTTCAGAGTGCCCTGGAAGCATTTCGCCAG
AAAAGACCTGAGCGAGGCTGATGCTAGAATCTTCAAAGCCTGGGCTGTGGCCCGAGGAAGATGGCCCCCCAGC
AGCAGAGGAGGCGGCCCTCCTCCCGAGGCCGAAACCGCAGAGCGTGCTGGCTGGAAAACCAACTTTAGGTGTG
CCCTGAGGAGCACCAGAAGATTCGTTATGCTCAGAGACAACAGCGGGGACCCCGCCGACCCGCACAAGGTGTA
CGCCTTAAGTAGGGAGCTGTGCTGGAGAGAGGGACCGGGGACCGACCAAACCGAGGCTGAGGCGCCCGCCGC
CGTTCCACCTCCCCAGGGTGGTCCCCCAGGGCCCTTTCTGGCACACACCCACGCCGGATTACAGGCGCCAGGG-
C
CCTTACCCGCCCCCGCCGGAGACAAAGGCGACCTCCTGCTGCAAGCCGTGCAACAAAGCTGCCTGGCCGATCA-
C
TTACTAACCGCTAGCTGGGGCGCCGATCCTGTTCCCACCAAGGCCCCCGGTGAAGGGCAAGAAGGACTGCCCT-
T
AACCGGCGCCTGTGCCGGAGGCCCTGGTCTGCCAGCCGGCGAGCTGTACGGTTGGGCTGTCGAAACAACACCC
AGTCCGGGCCCACAGCCTGCCGCTCTGACCACCGGCGAAGCCGCCGCCCCCGAGAGCCCACACCAGGCTGAAC-
C
CTACCTGAGCCCCAGCCCCAGCGCCTGCACCGCTGTGCAGGAGCCTAGCCCCGGCGCTCTTGATGTGACAATA-
AT
GTACAAGGGCAGGACCGTGCTGCAAAAGGTCGTGGGCCATCCGTCGTGTACCTTTCTGTACGGCCCTCCAGAC-
C
CCGCGGTTAGAGCCACCGACCCCCAGCAAGTCGCCTTCCCCTCCCCCGCCGAACTGCCCGACCAAAAGCAGCT-
GC
GGTACACAGAAGAACTACTTAGACACGTGGCCCCCGGTCTGCACTTGGAGCTGAGAGGCCCCCAGCTCTGGGC-
C
AGAAGAATGGGCAAGTGCAAAGTGTACTGGGAGGTGGGCGGCCCACCCGGCTCAGCTTCGCCCTCCACACCCG
CATGCCTGCTGCCCAGAAATTGCGACACGCCCATCTTCGATTTTAGAGTGTTCTTTCAGGAGTTGGTGGAGTT-
CA
GAGCCAGACAAAGACGCGGCAGCCCCAGATACACCATTTACCTCGGCTTCGGCCAGGACCTCAGCGCTGGCAG-
A
CCCAAGGAGAAGAGTCTGGTCCTCGTGAAGCTGGAGCCCTGGCTGTGCAGAGTGCACCTGGAGGGCACCCAGC
GTGAAGGCGTGAGCAGCCTGGATTCAAGCGACCTGGACCTATGCCTAAGCAGCGCTAACTCACTGTACGACGA-
T ATCGAATGCTTCCTGATGGAACTGGAGCAGCCTGCC (constitutively active Hu
IRF7 S477D/S479D; P033 without epitope tag) 154
ATGGCCCTGGCACCCGAGAGGGCCGCCCCCAGGGTGCTCTTCGGCGAGTGGTTACTAGGCGAAATTAGCA-
GCG
GCTGCTATGAAGGCCTTCAGTGGCTGGACGAGGCCAGAACCTGCTTTAGAGTTCCCTGGAAGCACTTCGCCCG-
G
AAAGATCTCTCTGAAGCCGACGCCAGAATATTCAAGGCCTGGGCTGTCGCCAGGGGCAGGTGGCCACCCTCCA-
G
CCGAGGTGGCGGCCCTCCCCCTGAGGCTGAGACTGCGGAAAGGGCGGGCTGGAAGACCAATTTCAGATGCGCT
CTGAGAAGCACCAGACGTTTTGTGATGCTAAGAGACAATAGCGGCGATCCCGCCGACCCCCATAAGGTATACG-
C
ACTGAGCCGAGAGCTCTGTTGGAGAGAAGGCCCCGGCACCGACCAGACCGAGGCTGAAGCCCCTGCAGCCGTG
CCCCCCCCTCAAGGCGGGCCCCCCGGCCCCTTCCTGGCCCATACCCATGCAGGGTTACAAGCACCCGGGCCCT-
TG
CCCGCCCCAGCGGGAGACAAGGGCGACCTCTTACTGCAGGCCGTGCAACAAAGTTGTCTGGCGGACCACCTGC-
T
GACCGCATCATGGGGCGCGGATCCTGTGCCCACCAAGGCACCCGGCGAAGGCCAGGAGGGCCTGCCCTTGACC
GGCGCCTGCGCTGGCGGACCCGGCCTACCTGCTGGCGAACTGTATGGCTGGGCCGTAGAGACGACTCCCAGCC
CTGGCCCACAACCCGCGGCTTTGACCACCGGCGAAGCCGCCGCCCCCGAGTCTCCGCACCAGGCCGAGCCTTA-
C
CTCAGCCCAAGCCCTAGCGCCTGCACCGCCGTGCAAGAACCTAGCCCCGGAGCCCTGGATGTGACAATCATGT-
A
CAAGGGTAGAACCGTACTGCAAAAGGTGGTGGGTCATCCCAGCTGCACCTTTCTTTACGGCCCACCCGACCCT-
GC
CGTGCGAGCCACAGACCCACAACAGGTCGCCTTCCCAAGCCCCGCCGAACTGCCCGATCAGAAACAGCTGAGA-
T
ATACAGAGGAGCTTCTGCGGCACGTAGCTCCCGGCCTACATCTCGAGCTGAGGGGCCCACAACTGTGGGCCAG-
A
CGCATGGGCAAATGCAAGGTCTACTGGGAAGTGGGAGGCCCCCCCGGCAGCGCATCTCCCAGCACGCCCGCGT
GCCTGCTGCCTAGAAATTGCGACACCCCCATCTTTGACTTCCGGGTATTCTTTCAGGAGCTGGTAGAGTTCAG-
AG
CCAGGCAGCGGAGGGGCTCCCCCAGATACACAATCTACCTGGGCTTCGGACAGGACCTGTCCGCCGGCCGCCC-
C
AAGGAAAAGAGCCTGGTGCTGGTGAAGCTGGAGCCCTGGCTGTGTAGGGTACACCTCGAAGGCACCCAGAGA
GAAGGAGTGAGCTCGCTTGATGACAGCGATCTGTCGGATTGCCTTAGCAGCGCCAACAGCCTGTATGATGATA-
T CGAGTGCTTCCTTATGGAACTGGAGCAGCCCGCC (constitutively active Hu IRF7
S475D/S477D/L480D; P034 without epitope tag) 155
ATGGCCCTAGCCCCCGAAAGAGCAGCTCCCAGAGTGCTGTTCGGCGAATGGCTGCTTGGCGAGATCAGCA-
GCG
GCTGCTACGAAGGCCTGCAGTGGCTGGACGAAGCCCGCACCTGTTTCAGAGTGCCCTGGAAGCACTTCGCTAG-
A
AAGGATTTGAGCGAGGCTGATGCTAGAATCTTTAAGGCTTGGGCTGTGGCAAGAGGCAGATGGCCGCCTAGTA
GCAGAGGGGGCGGACCTCCCCCCGAGGCTGAGACCGCTGAGAGAGCAGGGTGGAAAACCAACTTCAGATGCG
CGCTGAGAAGCACCCGAAGATTCGTGATGCTACGTGACAATAGCGGCGACCCCGCCGACCCCCACAAAGTGTA-
C
GCCCTGTCCCGAGAACTTTGCTGGAGAGAGGGACCCGGCACCGATCAAACAGAGGCTGAGGCCCCGGCCGCTG
TACCCCCGCCCCAAGGAGGCCCCCCAGGCCCCTTTCTGGCTCATACACATGCCGGCCTGCAGGCACCCGGGCC-
CC
TCCCGGCTCCTGCCGGCGACAAGGGCGATCTCCTTCTCCAGGCCGTGCAGCAGAGCTGCCTGGCCGATCACCT-
G
CTGACCGCCTCGTGGGGCGCCGACCCCGTGCCCACCAAAGCCCCGGGTGAAGGCCAAGAGGGGCTCCCTTTAA-
C
CGGAGCATGCGCCGGAGGCCCCGGCCTGCCAGCCGGCGAGTTATATGGCTGGGCTGTGGAGACCACACCCTCC
CCCGGCCCTCAACCCGCTGCCCTGACCACCGGTGAGGCCGCCGCCCCCGAGAGCCCACACCAGGCCGAACCCT-
A
CCTGAGCCCTAGCCCTAGCGCCTGCACCGCCGTGCAAGAACCCAGCCCCGGAGCCCTGGATGTGACCATTATG-
T
ACAAGGGCCGGACAGTGCTGCAAAAGGTTGTGGGACACCCGAGCTGCACCTTTCTGTACGGTCCGCCTGACCC-
C
GCCGTGAGAGCCACGGACCCGCAGCAGGTGGCCTTCCCCTCACCCGCGGAGCTGCCCGACCAAAAGCAACTCA
GATACACAGAAGAACTATTGCGTCACGTCGCGCCCGGCCTGCATCTGGAGCTGAGAGGCCCCCAGCTCTGGGC-
C
AGAAGGATGGGCAAATGCAAGGTGTACTGGGAGGTGGGAGGCCCCCCCGGCAGCGCCAGCCCCAGCACTCCC
GCGTGCCTGCTGCCCAGAAATTGCGACACTCCCATCTTCGATTTCAGGGTGTTCTTCCAGGAGCTGGTGGAGT-
TC
AGAGCCAGGCAGAGAAGGGGTAGCCCCAGATACACAATCTATCTAGGCTTTGGACAAGATCTGAGCGCCGGCC
GGCCTAAGGAAAAAAGCCTGGTGCTGGTAAAGCTGGAGCCGTGGCTTTGTAGAGTGCACCTGGAGGGGACGCA
GCGAGAGGGCGTGAGCAGCTTAGACGACGATGACTTGGATCTGTGTCTCGACAGCGCCAACGACTTGTACGAC
GACATCGAGTGCTTCCTGATGGAACTGGAGCAGCCCGCC (constitutively active Hu
IRF7 S475D/S476D/S477D/S479D/S483D/S487D; P035 without epitope tag)
156
ATGGCCCTGGCCCCCGAGAGAGCCGCCCCCAGAGTGCTCTTCGGCGAGTGGCTGCTGGGCGAGATAAGCA-
GCG
GCTGCTACGAAGGTCTGCAGTGGCTAGACGAGGCCAGAACCTGCTTTAGAGTGCCCTGGAAGCACTTCGCTCG-
A
AAGGACCTGTCCGAGGCCGATGCTAGAATTTTTAAGGCTTGGGCCGTCGCTAGGGGAAGATGGCCCCCTAGCA
GTAGAGGCGGCGGCCCCCCTCCCGAAGCCGAGACGGCCGAGAGGGCCGGCTGGAAAACCAATTTCAGATGCGC
CCTGAGGAGCACCCGCAGGTTCGTAATGCTGCGAGACAATAGCGGCGATCCTGCGGATCCTCACAAGGTTTAC-
G
CCTTGAGTAGAGAACTGTGCTGGCGGGAGGGCCCCGGAACCGACCAGACGGAGGCAGAGGCACCCGCTGCCG
TGCCCCCCCCTCAAGGAGGACCCCCTGGACCCTTTCTGGCCCACACCCACGCTGGTCTGCAGGCCCCAGGCCC-
AC
TGCCCGCCCCAGCGGGCGATAAGGGTGACCTGCTCCTACAGGCGGTGCAACAGAGCTGTCTGGCCGACCACCT-
G
TTGACCGCCAGCTGGGGGGCCGACCCGGTGCCCACCAAAGCTCCCGGAGAGGGCCAAGAAGGCCTCCCACTAA
CTGGCGCCTGCGCCGGGGGCCCGGGATTACCCGCCGGCGAGCTGTATGGCTGGGCCGTGGAGACCACGCCCAG
CCCCGAGGGCGTGTCGTCCCTGGACAGCAGCAGCCTGAGCCTGTGCCTGAGCTCCGCCAACAGCCTGTATGAC-
G ACATCGAGTGCTTCCTGATGGAGCTGGAACAACCCGCC (constitutively active
truncated Hu IRF7 1-246 + 468-503; P032 without epitope tag) 157
ATGGCACTGGCGCCTGAAAGAGCCGCTCCGCGTGTGCTCTTCGGCGAGTGGCTGCTGGGCGAGATCAGCT-
CCG
GCTGCTACGAGGGTCTACAGTGGCTGGACGAGGCCAGAACCTGTTTTAGAGTGCCCTGGAAGCACTTCGCGAG
AAAGGACCTGAGCGAGGCCGACGCCAGAATCTTCAAAGCCTGGGCAGTGGCTAGGGGCAGATGGCCTCCCAGC
AGCCGGGGCGGCGGCCCACCCCCCGAGGCCGAAACCGCCGAAAGAGCTGGCTGGAAGACCAACTTCAGATGC
GCCCTGAGAAGCACCAGAAGATTTGTCATGCTGAGAGATAATTCAGGAGACCCCGCCGACCCTCACAAGGTGT-
A
CGCCCTGTCCAGAGAGCTGTGTTGGAGAGAGGGCCCCGGAACCGACCAGACCGAGGCCGAGGCTCCAGCTGCC
GTGCCACCCCCCCAAGGCGGACCACCCGGCCCCTTCTTGGCACATACGCACGCCGGCCTCCAGGCTCCCGGCC-
CT
CTGCCCGCCCCTGCTGGTGACAAAGGCGATCTGCTGCTGCAAGCCGTCCAGCAATCCTGCTTGGCTGACCACC-
TG
CTGACCGCTAGCTGGGGAGCCGACCCCGTTCCCACCAAGGCTCCCGGAGAAGGACAGGAGGGCCTGCCCCTTA
CCGGCGCTTGCGCGGGGGGCCCTGGCTTGCCTGCCGGCGAACTGTACGGCTGGGCCGTGGAGACCACGCCTTC
CCCCGAGGGCGTGTCCAGCCTGGACGATGATGACCTGGATCTGTGCCTGGACAGCGCCAACGACCTGTACGAT-
G ACATCGAGTGCTTTTTGATGGAGCTGGAGCAGCCCGCC (constitutively active
truncated Hu IRF7 1-246 + 468-503 plus
S475D/S476D/S477D/S479D/S483D/S487D; P036 without epitope tag) 158
ATGGCCCTGGCCCCCGAGAGAGCCGCGCCCAGAGTGCTGTTCGGCGAATGGCTGCTGGGCGAGATCAGCA-
GCG
GCTGCTATGAGGGCCTGCAGTGGCTCGACGAAGCCAGGACGTGCTTCAGAGTCCCCTGGAAGCACTTCGCCAG-
A
AAGGATCTGAGCGAGGCTGACGCCAGAATCTTCAAGGCCTGGGCAGTTGCGCGTGGGAGATGGCCCCCCAGCT
CGCGGGGCGGCGGTCCCCCCCCTGAGGCCGAGACCGCCGAAAGAGCCGGATGGAAAACCAACTTTCGATGCGC
CCTCAGAAGCACCAGACGGTTTGTGATGCTGAGAGATAACAGCGGCGACCCTGCAGACCCCCATAAAGTGTAT-
G
CCCTGAGCAGAGAGCTGTGTTGGCGAGAGGGCCCCGGAACCGACCAAACCGAGGCCGAGGCCCCCGCCGCCGT
ACCCCCCCCTCAAGGCCCCCAGCCTGCTGCTCTGACCACGGGAGAAGCCGCCGCTCCTGAGAGCCCCCACCAA-
G
CCGAGCCCTATCTGAGCCCTAGCCCCAGCGCCTGCACCGCCGTGCAGGAGCCCTCACCGGGCGCCCTAGACGT-
G
ACCATCATGTACAAGGGGCGCACGGTGCTGCAAAAGGTGGTGGGCCACCCCAGCTGCACCTTCCTGTACGGCC-
C
CCCCGACCCTGCCGTGAGAGCCACCGACCCCCAGCAAGTCGCCTTCCCCAGCCCCGCCGAGCTGCCCGACCAG-
A
AGCAGCTGAGGTACACCGAGGAGTTGCTGAGACATGTGGCCCCCGGCTTGCACCTCGAGCTGAGAGGCCCGCA
GCTCTGGGCCAGAAGAATGGGCAAGTGCAAGGTGTACTGGGAGGTGGGCGGCCCCCCCGGCAGCGCGAGCCC
AAGCACCCCGGCCTGCCTGCTGCCTAGAAACTGCGACACCCCTATCTTCGACTTCAGAGTATTTTTCCAGGAG-
CT
GGTCGAGTTCAGGGCCAGACAGCGTAGAGGCAGCCCCAGATACACCATCTACCTTGGATTCGGCCAGGACCTG-
A
GCGCCGGCAGACCCAAAGAGAAGTCCCTGGTACTGGTGAAGCTAGAGCCCTGGCTGTGTAGGGTGCATCTGGA
AGGCACCCAAAGAGAGGGCGTAAGCTCGCTTGACAGCAGCAGCCTCAGCCTGTGCCTGAGCAGCGCTAACAGC
TTATACGACGACATCGAGTGCTTCCTGATGGAGCTGGAACAACCCGCC (truncated Hu IRF7
1-151 + 247-503; P038 without epitope tag; null mutation) 159
ATGGGCGGCCCTCCCGGGCCTTTCCTGGCCCATACACACGCCGGCCTACAGGCTCCTGGCCCTCTGCCCG-
CCCCG
GCCGGCGACAAGGGCGACCTCCTGCTGCAGGCCGTGCAGCAGTCCTGTCTGGCCGACCACCTGCTGACTGCTA-
G
CTGGGGCGCCGATCCCGTGCCCACCAAGGCCCCAGGAGAGGGGCAAGAGGGCCTGCCTCTAACCGGCGCATGC
GCAGGTGGACCAGGCCTCCCCGCCGGCGAGCTGTATGGTTGGGCCGTGGAGACAACCCCCAGCCCCGGCCCGC
AGCCTGCTGCGCTGACCACAGGCGAGGCCGCTGCCCCTGAGAGCCCCCACCAAGCTGAACCCTACCTGAGCCC-
C
AGCCCCTCTGCCTGCACAGCGGTGCAGGAGCCCAGTCCCGGCGCCTTGGACGTGACCATCATGTATAAGGGCA-
G
GACTGTGTTACAAAAGGTAGTGGGCCACCCAAGTTGTACCTTTCTGTACGGGCCCCCCGACCCAGCCGTGCGC-
G
CCACCGACCCCCAGCAGGTGGCCTTCCCCAGCCCCGCTGAGTTGCCCGATCAGAAACAACTCCGGTACACCGA-
G
GAATTACTTAGACATGTGGCTCCCGGCCTGCATCTGGAGCTTAGAGGTCCACAGTTGTGGGCCAGAAGAATGG-
G
CAAGTGCAAGGTTTATTGGGAGGTCGGAGGCCCCCCGGGCAGCGCCAGCCCCAGCACCCCCGCCTGTCTTCTG-
C
CCAGAAACTGCGACACCCCAATCTTCGATTTCAGAGTGTTTTTCCAGGAACTGGTGGAGTTCAGAGCAAGGCA-
A
AGAAGAGGCAGCCCTAGATACACCATCTACCTGGGCTTTGGCCAAGACCTGAGCGCCGGCAGACCCAAGGAAA
AATCCCTGGTCCTGGTGAAACTGGAGCCCTGGCTGTGCAGAGTCCACCTGGAGGGCACCCAGAGAGAGGGCGT
GAGCAGCCTGGACTCGAGCAGCCTGTCCCTGTGTCTGAGCAGCGCGAATTCGCTATATGACGACATCGAATGC-
T TTCTGATGGAGCTGGAACAGCCCGCC (truncated Hu IRF7 152-503; P039
without epitope tag; null mutation) 160
ATGCCTCACAGCAGCCTCCACCCTAGCATCCCTTGCCCTAGAGGCCACGGCGCCCAGAAGGCCGCCCTCG-
TGCTT
TTAAGCGCCTGCTTGGTGACCCTTTGGGGCTTGGGCGAGCCTCCAGAGCACACCTTGAGATATTTGGTGCTCC-
AC
CTGGCCAGCCTTCAGCTGGGCTTGTTACTCAACGGCGTGTGCAGCCTGGCCGAGGAGCTGAGACACATCCACA-
G
CAGATACAGAGGCAGCTACTGGAGAACCGTGAGAGCGTGTCTGGGCTGCCCTCTGAGAAGAGGCGCCTTGCTT
CTTCTCAGTATCTACTTCTACTACTCCCTGCCTAACGCCGTGGGCCCTCCTTTCACCTGGATGCTGGCACTGC-
TCG
GCCTCAGCCAGGCCCTGAACATCTTGTTGGGCTTGAAGGGCCTGGCCCCTGCCGAGATCAGCGCCGTGTGCGA-
G
AAGGGCAACTTCAACATGGCCCACGGATTGGCTTGGAGCTACTACATCGGCTACCTGAGACTGATCCTGCCTG-
A
GCTGCAGGCCAGAATCAGAACCTACAACCAGCACTACAACAACCTGCTGCGCGGCGCAGTGAGCCAGAGACTG
TATATTCTGCTGCCTCTGGACTGCGGCGTGCCTGACAACCTGAGCATGGCCGACCCTAACATCAGATTCCTGG-
AC
AAGCTGCCTCAGCAGACCGGCGACCACGCCGGCATCAAGGACAGAGTGTACAGCAACAGCATCTATGAGCTGC
TCGAGAATGGCCAGAGAGCCGGCACCTGCGTGCTGGAGTACGCCACCCCTCTGCAGACCCTGTTCGCCATGAG-
C
CAGTATAGTCAAGCTGGCTTCAGCAGAGAGGACAGACTGGAGCAGGCCAAGCTGTTCTGCAGAACCCTGGAGG
ACATTCTGGCTGACGCCCCTGAGAGCCAGAACAACTGCCGACTGATCGCCTACCAGGAACCAGCCGACGACAG-
C
AGCTTCAGTCTTTCTCAGGAGGTTCTTCGCCACTTGCGCCAGGAGGAGAAGGAGGAGGTGACCGTGGGCAGCC
TGAAGACCTCCGCAGTCCCTAGCACCAGCACCATGAGTCAGGAGCCGGAGCTATTAATCAGCGGCATGGAGAA
GCCTCTTCCACTCCGAACCGACTTCAGCGCCACCAACTTCAGCCTGCTGAAGCAGGCAGGTGACGTTGAGGAG-
A
ATCCGGGACCTATGACCGAGTACAAGCTGGTGGTTGTGGGCGCCGACGGCGTGGGCAAGAGCGCCCTGACCAT
CCAGCTGATCCAG (KRAS(G12D)25mer_nt.STING(V155M)) 161
ATGACCGAGTACAAGCTAGTAGTCGTGGGCGCCGACGGCGTGGGCAAGAGCGCCCTCACCATCCAGCTAA-
TCC
AGGCCACCAACTTCAGCTTGCTCAAGCAGGCCGGCGACGTGGAGGAGAACCCAGGCCCTATGCCTCACAGCAG
CCTTCACCCTAGCATCCCTTGCCCTAGAGGCCACGGCGCCCAGAAGGCCGCCCTGGTGCTGCTGAGCGCCTGC-
CT
GGTGACCCTGTGGGGCCTGGGCGAGCCTCCTGAGCACACCCTGAGATATCTGGTGCTTCACCTGGCCAGTTTA-
C
AGCTGGGCCTGCTTCTTAACGGCGTGTGCAGCCTGGCCGAGGAGCTGAGACACATCCACAGCAGATACAGAGG
CAGCTACTGGAGAACCGTGAGAGCCTGCCTAGGCTGCCCTCTGAGAAGAGGCGCTCTGTTGCTACTTTCCATC-
TA
CTTCTACTACTCCCTGCCTAACGCCGTGGGCCCTCCTTTCACTTGGATGCTGGCGTTGCTGGGTCTGAGCCAG-
GCC
CTGAACATCCTTCTCGGTCTGAAGGGCCTGGCCCCTGCCGAGATCAGCGCCGTGTGCGAGAAGGGCAACTTCA-
A
CATGGCCCACGGACTCGCCTGGAGCTACTACATCGGCTACCTGAGACTGATCCTGCCTGAGCTGCAGGCCAGA-
A
TCAGAACCTACAACCAGCACTACAACAACCTGCTGCGGGGCGCCGTGAGCCAGAGACTGTATATACTTCTTCC-
TC
TGGACTGCGGCGTGCCTGACAACCTGAGCATGGCCGACCCTAACATCAGATTCCTGGACAAGCTGCCTCAGCA-
G
ACCGGCGACCACGCCGGCATCAAGGACAGAGTGTACAGCAACTCCATTTATGAGCTGCTCGAGAATGGCCAGA
GAGCCGGCACCTGCGTGCTGGAGTACGCCACCCCTCTGCAGACCCTGTTCGCCATGAGCCAGTACAGTCAGGC-
T
GGATTCAGCAGAGAGGACAGACTGGAGCAGGCCAAGCTGTTCTGCAGGACACTGGAGGACATACTAGCAGAC
GCCCCTGAGAGCCAGAACAACTGCAGACTGATTGCCTACCAGGAGCCTGCGGACGACAGCTCCTTCAGTCTGA-
G
TCAGGAGGTGTTGCGGCACTTACGCCAAGAAGAGAAGGAGGAGGTGACCGTGGGCAGCCTGAAGACTAGCGC
TGTGCCTAGCACCAGCACAATGTCACAGGAGCCGGAATTGCTAATCAGCGGCATGGAGAAGCCTCTCCCATTA-
C GTACCGACTTCAGC (KRAS(G12D)25mer_ct.STING(V155M)) 162
ATGCCTCACAGCAGCCTTCACCCTAGCATCCCTTGCCCTAGAGGCCACGGCGCCCAGAAGGCCGCCCTAG-
TGCTC
CTTAGCGCCTGCCTCGTGACCCTATGGGGCTTAGGCGAGCCTCCAGAGCACACCTTGAGATACCTCGTCCTCC-
AC
CTGGCTAGTCTACAGCTGGGCCTTCTCCTCAACGGCGTGTGCAGCCTGGCCGAGGAGCTGAGACACATCCACA-
G
CAGATACAGAGGCAGCTACTGGAGAACCGTGAGAGCGTGCCTGGGCTGCCCTCTGAGAAGAGGCGCACTGCTG
TTACTCAGCATCTACTTCTACTACTCACTGCCAAACGCCGTGGGCCCTCCTTTCACCTGGATGCTGGCCTTGC-
TCG
GATTGAGCCAGGCCCTGAACATTTTACTGGGATTGAAGGGCCTGGCCCCTGCCGAGATCAGCGCCGTGTGCGA-
G
AAGGGCAACTTCAACATGGCCCACGGCCTAGCTTGGAGCTACTACATCGGCTACCTGAGACTGATCCTGCCTG-
A
GCTGCAGGCCAGAATCAGAACCTACAACCAGCACTACAACAACCTGCTGCGTGGAGCGGTGAGCCAGAGACTG
TATATCCTCCTGCCTCTGGACTGCGGAGTGCCTGACAACCTGAGCATGGCCGACCCTAACATCAGATTCCTGG-
AC
AAGCTGCCTCAGCAGACCGGCGACCACGCCGGCATCAAGGACAGAGTGTACAGCAACTCAATCTACGAGCTGT-
T
GGAGAATGGCCAGAGAGCCGGCACCTGCGTGCTGGAGTACGCCACCCCTCTGCAGACCCTGTTCGCCATGAGC-
C
AGTACTCTCAGGCAGGCTTCAGCAGAGAGGACAGACTGGAGCAGGCCAAGCTGTTCTGCAGAACCCTGGAGGA
CATCCTGGCGGACGCCCCTGAGAGCCAGAACAACTGCCGGCTTATCGCCTACCAGGAGCCAGCAGACGACAGC
AGCTTCTCTCTCTCACAAGAGGTACTGCGCCATCTTCGCCAGGAGGAGAAGGAGGAGGTGACCGTGGGCAGCC-
T
GAAGACATCCGCCGTACCTAGCACCAGCACCATGTCTCAGGAACCGGAACTGTTGATCAGCGGCATGGAGAAG-
C
CTCTGCCACTGCGCACCGACTTCAGCGCCACCAACTTCTCCCTACTGAAGCAAGCCGGTGACGTTGAAGAGAA-
CC
CTGGCCCTATGACCGAGTACAAGCTGGTAGTAGTAGGCGCCGACGGCGTGGGCAAGAGCGCCCTGACCATCCA
GCTGATCCAGATGACTGAATATAAGCTTGTCGTCGTGGGCGCAGATGGCGTTGGTAAGAGCGCACTTACAATT-
C
AACTCATTCAGATGACGGAGTATAAGCTGGTGGTGGTCGGAGCTGACGGCGTAGGCAAGAGTGCCCTTACTAT-
T CAGCTAATTCAG (KRAS(G12D)25mer^3_nt.STING(V155M)) 163
ATGACCGAGTACAAGCTTGTGGTGGTTGGCGCCGACGGCGTGGGCAAGAGCGCCTTAACCATCCAGCTTA-
TCCA
GATGACAGAGTATAAGCTAGTGGTGGTCGGCGCAGACGGAGTGGGAAAGAGTGCATTAACTATTCAACTCATC
CAAATGACCGAATACAAGCTAGTAGTTGTGGGTGCAGATGGCGTCGGCAAGTCTGCACTGACAATTCAGCTCA-
T
CCAGGCCACCAACTTCAGCCTGCTGAAGCAGGCCGGCGACGTGGAGGAGAACCCTGGCCCTATGCCTCACAGC-
A
GCCTGCACCCTAGCATCCCTTGCCCTAGAGGCCACGGCGCCCAGAAGGCCGCCCTGGTGCTGCTGAGCGCCTG-
C
CTGGTGACCCTGTGGGGCCTGGGCGAGCCTCCTGAGCACACCCTGAGATACCTAGTTTTGCACCTGGCTTCTC-
TG
CAGCTGGGCCTACTGCTCAACGGCGTGTGCAGCCTGGCCGAGGAGCTGAGACACATCCACAGCAGATACAGAG
GCAGCTACTGGAGAACCGTGAGAGCATGCTTAGGCTGCCCTCTGAGAAGAGGCGCTCTGCTCCTCTTGTCCAT-
CT
ACTTCTACTACTCGCTACCTAACGCCGTGGGCCCTCCTTTCACCTGGATGCTGGCCCTCTTGGGATTAAGCCA-
GGC
CCTGAACATCTTGCTGGGACTGAAGGGCCTGGCCCCTGCCGAGATCAGCGCCGTGTGCGAGAAGGGCAACTTC-
A
ACATGGCCCACGGACTCGCTTGGAGCTACTACATCGGCTACCTGAGACTGATCCTGCCTGAGCTGCAGGCCAG-
A
ATCAGAACCTACAACCAGCACTACAACAACCTGCTGCGGGGAGCAGTGAGCCAGAGACTGTATATTCTGCTCC-
C
TCTGGACTGCGGCGTGCCTGACAACCTGAGCATGGCCGACCCTAACATCAGATTCCTGGACAAGCTGCCTCAG-
C
AGACCGGCGACCACGCCGGCATCAAGGACAGAGTGTACAGCAACAGCATTTACGAGCTGCTGGAGAACGGCCA
GAGAGCCGGCACCTGCGTGCTGGAGTACGCCACCCCTCTGCAGACCCTGTTCGCCATGAGCCAGTACTCCCAG-
G
CAGGATTCAGCAGAGAGGACAGACTGGAGCAGGCCAAGCTGTTCTGCCGTACTCTTGAGGACATCCTTGCAGA-
C
GCCCCTGAGAGCCAGAACAACTGCCGGTTGATTGCCTACCAGGAACCGGCAGACGACAGCTCATTCTCCTTGT-
CT
CAGGAGGTCCTTAGACACCTGCGGCAGGAGGAGAAGGAGGAGGTGACCGTGGGCAGCCTGAAGACATCCGCC
GTGCCTAGCACGTCTACCATGTCCCAGGAGCCGGAACTGCTAATCAGCGGCATGGAGAAGCCTCTGCCTCTCA-
G GACCGACTTCAGC
(KRAS(G12D)25mer^3_ct.STING(V155M)) 164
MPHSSLHPSIPCPRGHGAQKAALVLLSACLVTLWGLGEPPEHTLRYLVLHLASLQLGLLLNGVCSLAEEL-
RHIHSRYRGS
YWRTVRACLGCPLRRGALLLLSIYFYYSLPNAVGPPFTWMLALLGLSQALNILLGLKGLAPAEISAVCEKGNF-
NVAHGL
AWSYYIGYLRLILPELQARIRTYNQHYNNLLRGAVSQRLYILLPLDCGVPDNLSMADPNIRFLDKLPQQTGDH-
AGIKDR
VYSNSIYELLENGQRAGTCVLEYATPLQTLFAMSQYSQAGFSREDkLEQAKLFCRTLEDILADAPESQNNCRL-
IAYQEP
ADDSSFSLSQEVLRHLRQEEKEEVTVGSLKTSAVPSTSTMSQEPELLISGMEKPLPLRTDFST (Hu
STING (R284K) var; no epitope tag) 165
ATGCCCCATAGCAGCCTGCACCCCAGCATCCCCTGCCCCAGAGGCCACGGCGCCCAGAAGGCCGCCCTGG-
TCCT
GCTGAGCGCATGCCTGGTCACCCTGTGGGGCCTGGGCGAGCCCCCCGAGCACACCCTGAGATACCTGGTGCTG-
C
ACCTCGCCAGCCTGCAGCTGGGCCTGCTGCTGAACGGCGTGTGCAGCCTGGCCGAGGAGCTGAGACACATCCA-
C
AGCAGATATAGAGGCAGCTACTGGAGAACCGTGAGAGCTTGCCTCGGCTGCCCCCTGAGAAGAGGCGCCCTGC
TGCTGCTGAGCATCTACTTTTACTACAGCCTGCCCAACGCTGTGGGCCCCCCTTTCACGTGGATGCTCGCCCT-
GCT
GGGACTGAGCCAGGCCCTGAACATCCTGCTGGGCCTTAAGGGCCTAGCCCCCGCCGAGATCAGCGCCGTGTGC
GAGAAGGGCAACTTCAATGTGGCCCACGGCCTGGCCTGGAGCTACTACATCGGCTACCTGAGACTGATCCTGC-
C
CGAGCTGCAGGCCAGAATCAGAACCTACAATCAGCACTACAACAACCTGCTGAGAGGCGCCGTGAGCCAGAGA
CTGTACATCCTGCTGCCCCTGGACTGCGGCGTGCCCGACAACCTCAGCATGGCCGACCCCAACATCAGATTCC-
TG
GACAAGCTGCCCCAGCAGACCGGCGACCACGCCGGCATCAAGGATCGCGTGTACAGCAACAGCATCTACGAGC
TGCTGGAAAACGGCCAGAGAGCCGGAACCTGCGTGCTGGAGTACGCCACACCCCTGCAGACCCTGTTCGCCAT-
G
AGCCAGTACAGCCAGGCCGGCTTCAGCAGAGAGGACAAGCTGGAGCAGGCCAAGCTGTTCTGCAGAACCCTGG
AGGATATCCTCGCCGACGCCCCCGAGAGCCAGAACAACTGCAGGCTGATCGCGTACCAGGAGCCCGCTGACGA
CAGCAGCTTTAGCCTGAGCCAGGAGGTGCTGAGACATCTGCGTCAAGAGGAAAAGGAGGAGGTGACCGTGGG
CTCCCTGAAGACCAGCGCCGTGCCCAGCACCAGCACCATGAGCCAGGAGCCCGAGCTGCTGATCAGCGGCATG
GAGAAGCCACTGCCCCTCAGAACCGACTTCAGCACC (Hu STING (R284K) var; no
epitope tag) 166
MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQ-
YMRTGEG
FLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQ-
RVEDAF YTLVREIRQYRLKKISKEEKTPGCVKIKKC Human KRAS sp/P01116[1-186]
167
5'.sup.7MeG.sub.pppG.sub.2'OMeGGAAAUAAGAGAGAAAAGAAGAGUAAGAAGAAAUAUAAGA-
GCCACCAUG
ACCGAGUACAAGCUCGUGGUCGUCGGCGCCGACGGGGUAGGCAAGUCCGCUCUGACCAU
UCAGCUCAUCCAGAUGACGGAGUACAAACUCGUGGUAGUGGGAGCCGUGGGUGUGGGC
AAGAGCGCGCUCACCAUCCAACUCAUCCAAAUGACCGAAUAUAAACUCGUCGUGGUGGG
AGCCGGCGACGUGGGAAAGAGCGCCCUUACCAUCCAGUUAAUCCAGAUGACAGAAUACA
AGCUGGUGGUGGUCGGUGCCUGCGGCGUGGGUAAGUCCGCCCUGACAAUCCAGCUGAUC
CAGUGAUAAUAGGCUGGAGCCUCGGUGGCCAUGCUUCUUGCCCCUUGGGCCUCCCCCCA
GCCCCUCCUCCCCUUCCUGCACCCGUACCCCCGUGGUCUUUGAAUAAAGUCUGAGUGGG
CGGCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAUCUAG.sub.OH3' Where:
A, C G & U = AMP, CMP, GMP & N1-.psi.UMP, respectively; Me
= methyl; p = inorganic phosphate (KRAS concatemer mRNA sequence;
CX-012908) 168
5'.sup.7MeG.sub.pppG.sub.2'OMeGGAAAUAAGAGAGAAAAGAAGAGUAAGAAGAAAUAUAAGA-
GCCACCAUG
CCCCACAGUAGCCUCCACCCCAGCAUCCCCUGCCCCAGAGGCCACGGCGCACAGAAGGCC
GCCCUGGUGCUGCUGAGCGCCUGUCUGGUGACCCUGUGGGGUCUGGGCGAGCCCCCCGA
GCACACCCUGCGGUACCUCGUGCUGCAUCUGGCCAGCCUGCAGCUGGGCCUGCUGCUGA
ACGGCGUGUGCAGCCUGGCCGAAGAGCUGAGACACAUCCACAGCAGAUACAGAGGCUCC
UACUGGAGAACCGUCAGAGCCUGCCUCGGCUGUCCCCUGAGAAGAGGCGCCCUGCUGCU
CCUGAGCAUCUACUUCUACUACAGCCUGCCCAACGCCGUGGGCCCCCCCUUCACCUGGA
UGCUGGCCCUGCUGGGCCUGAGCCAGGCCCUGAACAUCCUGCUGGGCCUGAAGGGCUUG
GCCCCCGCCGAGAUCUCCGCCGUGUGCGAGAAGGGCAACUUCAACAUGGCCCAUGGCCU
UGCCUGGUCCUACUACAUCGGCUACCUGAGACUGAUCCUGCCCGAGCUGCAGGCCAGAA
UCAGAACCUACAACCAGCACUACAACAACCUGCUGAGAGGCGCCGUGAGCCAAAGACUG
UACAUCCUGCUGCCCCUGGACUGCGGCGUGCCCGACAACCUUAGCAUGGCCGACCCCAA
CAUCAGAUUCCUGGACAAGCUGCCCCAGCAGACCGGCGACCACGCCGGCAUCAAGGACA
GAGUGUACAGCAACAGCAUCUACGAGCUGCUGGAGAACGGCCAGAGAGCCGGCACCUGC
GUGCUGGAGUACGCCACCCCCCUGCAGACCCUGUUCGCCAUGAGCCAGUACAGCCAGGC
CGGCUUCAGCAGAGAGGACAGACUGGAGCAAGCCAAGCUGUUCUGCAGAACCCUGGAGG
ACAUCCUGGCGGACGCCCCCGAGAGCCAAAACAACUGCAGACUGAUCGCCUACCAGGAG
CCCGCCGACGACAGCAGCUUCAGCCUGAGCCAGGAAGUGCUGAGACACCUGAGACAGGA
AGAGAAGGAGGAGGUGACCGUGGGAAGCCUGAAGACCAGCGCCGUGCCCAGCACCAGCA
CCAUGAGCCAGGAGCCCGAGCUGCUGAUCAGCGGCAUGGAGAAGCCCCUGCCCCUGAGA
ACCGACUUCAGCUGAUAAUAGGCUGGAGCCUCGGUGGCCUAGCUUCUUGCCCCUUGGGC
CUCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACCCCCCAAACACCAUUGUCACACU
CCAGUGGUCUUUGAAUAAAGUCUGAGUGGGCGGCAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAUCUAG.sub.OH3' Where: A, C G & U = AMP, CMP,
GMP & N1-.psi.UMP, respectively; Me = methyl; p = inorganic
phosphate; underline = miR-122 binding site (STING mRNA sequence;
CX-012871) 169
AUGACCGAGUACAAGCUCGUGGUCGUCGGCGCCGACGGGGUAGGCAAGUCCGCUCUGACCAUUCAGCUCA
UCCAGAUGACGGAGUACAAACUCGUGGUAGUGGGAGCCGUGGGUGUGGGCAAGAGCGCGCUCACCAUCCA
ACUCAUCCAAAUGACCGAAUAUAAACUCGUCGUGGUGGGAGCCGGCGACGUGGGAAAGAGCGCCCUUACC
AUCCAGUUAAUCCAGAUGACAGAAUACAAGCUGGUGGUGGUCGGUGCCUGCGGCGUGGGUAAGUCCGCCC
UGACAAUCCAGCUGAUCCAG (KRAS(G12D G12V G13D G12C) 100mer "4MUT" nt.
seq) 170
AUGCCCCACAGUAGCCUCCACCCCAGCAUCCCCUGCCCCAGAGGCCACGGCGCACAGAAGGCCGCCCUGG-
UG
CUGCUGAGCGCCUGUCUGGUGACCCUGUGGGGUCUGGGCGAGCCCCCCGAGCACACCCUGCGGUACCUCG
UGCUGCAUCUGGCCAGCCUGCAGCUGGGCCUGCUGCUGAACGGCGUGUGCAGCCUGGCCGAAGAGCUGAG
ACACAUCCACAGCAGAUACAGAGGCUCCUACUGGAGAACCGUCAGAGCCUGCCUCGGCUGUCCCCUGAGAA
GAGGCGCCCUGCUGCUCCUGAGCAUCUACUUCUACUACAGCCUGCCCAACGCCGUGGGCCCCCCCUUCACC
UGGAUGCUGGCCCUGCUGGGCCUGAGCCAGGCCCUGAACAUCCUGCUGGGCCUGAAGGGCUUGGCCCCCG
CCGAGAUCUCCGCCGUGUGCGAGAAGGGCAACUUCAACAUGGCCCAUGGCCUUGCCUGGUCCUACUACAUC
GGCUACCUGAGACUGAUCCUGCCCGAGCUGCAGGCCAGAAUCAGAACCUACAACCAGCACUACAACAACCU
GCUGAGAGGCGCCGUGAGCCAAAGACUGUACAUCCUGCUGCCCCUGGACUGCGGCGUGCCCGACAACCUUA
GCAUGGCCGACCCCAACAUCAGAUUCCUGGACAAGCUGCCCCAGCAGACCGGCGACCACGCCGGCAUCAAGG
ACAGAGUGUACAGCAACAGCAUCUACGAGCUGCUGGAGAACGGCCAGAGAGCCGGCACCUGCGUGCUGGA
GUACGCCACCCCCCUGCAGACCCUGUUCGCCAUGAGCCAGUACAGCCAGGCCGGCUUCAGCAGAGAGGACA
GACUGGAGCAAGCCAAGCUGUUCUGCAGAACCCUGGAGGACAUCCUGGCGGACGCCCCCGAGAGCCAAAAC
AACUGCAGACUGAUCGCCUACCAGGAGCCCGCCGACGACAGCAGCUUCAGCCUGAGCCAGGAAGUGCUGAG
ACACCUGAGACAGGAAGAGAAGGAGGAGGUGACCGUGGGAAGCCUGAAGACCAGCGCCGUGCCCAGCACCA
GCACCAUGAGCCAGGAGCCCGAGCUGCUGAUCAGCGGCAUGGAGAAGCCCCUGCCCCUGAGAACCGACUUC
AGC (huSTING(V155M); no epitope tag; nucleotide sequence) 171
CCUUAGCAGAGCUGUGGAGUGUGACAAUGGUGUUUGUGUCUAAACUAUCAAACGCCAUUAUCACACUAA
AUAGCUACUGCUAGGC (mir-122) 172 AACGCCAUUAUCACACUAAAUA
(mir-122-3p.sub.-- 173 UAUUUAGUGUGAUAAUGGCGUU (mir-122-3p binding
site) 174 UGGAGUGUGACAAUGGUGUUUG (mir-122-5p) 175
CAAACACCAUUGUCACACUCCA (mir-122-5p binding site) 176
GGAAAUAAGAGAGAAAAGAAGAGUAAGAAGAAAUAUAAGAGCCACC (5' UTR) 177
CCGCCGCCGCCG 178 CCGCCGCCGCCGCCG 179 CCCCGGCGCC (V1) 180
GGGAAATAAGAGAGAAAAGAAGAGTAAGAAGAAATATAAGA (5'UTR) 181
GGGAAATAAGAGAGAAAAGAAGAGTAAGAAGAAATATAAGACCCCGGCGCCGCCACC (V1-UTR)
182 GGGAAATAAGAGAGAAAAGAAGAGTAAGAAGAAATATAAGACCCCGGCGCCACC (V2-UTR)
183 MKLVVVGACGVGKSAMKLVVVGACGVGKSAMKLVVVGACGVGKSA (KRAS G12C
15mer^3) 184
ATGACCGAGTACAAGCTCGTGGTTGTTGGCGCCTGCGGCGTGGGCAAGAGCGCCCTCACCATCCAGCTCA-
TCCA
GATGACAGAGTATAAGTTAGTCGTTGTCGGAGCTTGCGGAGTTGGAAAGTCGGCGCTCACCATTCAACTCATA-
C
AAATGACAGAATATAAGTTAGTGGTGGTGGGTGCGTGTGGCGTTGGCAAGAGTGCGCTTACTATCCAGCTCAT-
T CAG (KRAS G12C 25mer^3 nucleotide sequence) 185
UCAAGCUUUUGGACCCUCGUACAGAAGCUAAUACGACUCACUAUAGGGAAAUAAGAGAGAAAAGAAGAGU
AAGAAGAAAUAUAAGAGCCACC (5' UTR) 186
UGAUAAUAGGCUGGAGCCUCGGUGGCCAUGCUUCUUGCCCCUUGGGCCUCCCCCCAGCCCCUCCUCCCCU-
U CCUGCACCCGUACCCCCGUGGUCUUUGAAUAAAGUCUGAGUGGGCGGC (3' UTR) 187
UGAUAAUAGGCUGGAGCCUCGGUGGCCAUGCUUCUUGCCCCUUGGGCCCAAACACCAUUGUCACACUCCA
UCCCCCCAGCCCCUCCUCCCCUUCCUCCAUAAAGUAGGAAACACUACAUGCACCCGUACCCCCGUGGUCUUU
GAAUAAAGUCUGAGUGGGCGGC (3' UTR with mi-122 and mi-142.3p sites) 188
GGAAGCGGAGCUACUAACUUCAGCCUGCUGAAGCAGGCUGGAGACGUGGAGGAGAACCCUGGACCU
(Nucleotide sequence encoding 2A peptide) 189
UCCGGACUCAGAUCCGGGGAUCUCAAAAUUGUCGCUCCUGUCAAACAAACUCUUAACUUUGAUUUACUCA
AACUGGCUGGGGAUGUAGAAAGCAAUCCAGGUCCACUC (Nucleotide sequence
encoding 2A peptide) 190
AUGACCGAGUACAAGCUGGUGGUGGUGGGCGCCGACGGCGUGGGCAAGAGCGCCCUGACCAUCCAGCUGA
UCCAG (KRAS G12D 25mer nucleotide sequence) 191
AUGACCGAGUACAAGCUGGUGGUGGUGGGCGCCGUGGGCGUGGGCAAGAGCGCCCUGACCAUCCAGCUGA
UCCAG (KRAS G12V 25mer nucleotide sequence) 192
AUGACCGAGUACAAGCUGGUGGUGGUGGGCGCCGGCGACGUGGGCAAGAGCGCCCUGACCAUCCAGCUGA
UCCAG (KRAS G13D 25mer nucleotide sequence) 193
AUGACCGAGUACAAGUUAGUGGUUGUGGGCGCCGACGGCGUGGGCAAGAGCGCCCUCACCAUCCAGCUUA
UCCAGAUGACGGAAUAUAAGUUAGUAGUAGUGGGAGCCGACGGUGUCGGCAAGUCCGCUUUGACCAUUC
AACUUAUUCAGAUGACAGAGUAUAAGCUGGUCGUUGUAGGCGCAGACGGCGUUGGAAAGUCGGCACUGA
CGAUCCAGUUGAUCCAG (KRAS G12D 25mer^3 nucleotide sequence) 194
AUGACCGAGUACAAGCUCGUCGUGGUGGGCGCCGUGGGCGUGGGCAAGAGCGCCCUAACCAUCCAGUUGA
UCCAGAUGACCGAAUAUAAGCUCGUGGUAGUCGGAGCGGUGGGCGUUGGCAAGUCAGCGCUAACAAUACA
ACUAAUCCAAAUGACCGAAUACAAGCUAGUUGUAGUCGGUGCCGUCGGCGUUGGAAAGUCAGCCCUUACA
AUUCAGCUCAUUCAG (KRAS G12V 25mer^3 nucleotide sequence) 195
AUGACCGAGUACAAGCUCGUAGUGGUUGGCGCCGGCGACGUGGGCAAGAGCGCCCUAACCAUCCAGCUCA
UCCAGAUGACAGAAUAUAAGCUUGUGGUUGUGGGAGCAGGAGACGUGGGAAAGAGUGCGUUGACGAUUC
AACUCAUACAGAUGACCGAAUACAAGUUGGUGGUGGUCGGCGCAGGUGACGUUGGUAAGUCUGCACUAA
CUAUACAACUGAUCCAG (KRAS G13D 25mer^3 nucleotide sequence) 196
AUGACCGAGUACAAGCUGGUGGUGGUGGGCGCCUGCGGCGUGGGCAAGAGCGCCCUGACCAUCCAGCUGA
UCCAG (KRAS G12C 25mer nucleotide sequence) 197
AUGACCGAGUACAAGCUCGUGGUUGUUGGCGCCUGCGGCGUGGGCAAGAGCGCCCUCACCAUCCAGCUCA
UCCAGAUGACAGAGUAUAAGUUAGUCGUUGUCGGAGCUUGCGGAGUUGGAAAGUCGGCGCUCACCAUUC
AACUCAUACAAAUGACAGAAUAUAAGUUAGUGGUGGUGGGUGCGUGUGGCGUUGGCAAGAGUGCGCUUA
CUAUCCAGCUCAUUCAG (KRAS G12C 25mer^3 nucleotide sequence) 198
AUGACCGAGUACAAGCUGGUGGUGGUGGGCGCCGGCGGCGUGGGCAAGAGCGCCCUGACCAUCCAGCUGA
UCCAG (KRAS WT 25mer nucleotide sequence) 199
GGGAAAUAAGAGAGAAAAGAAGAGUAAGAAGAAAUAUAAGAGCCACC (5' UTR sequence;
no promoter) 200
AUGACCGAGUACAAGCUCGUUGUAGUCGGCGCCGACGGCGUGGGCAAGAGCGCCUUGACCAUCCAGUUGA
UCCAGAUGACCGAAUAUAAGUUGGUGGUGGUAGGCGCAGUGGGAGUUGGCAAGUCAGCACUCACAAUUC
AGCUCAUUCAAAUGACAGAAUACAAGUUAGUCGUUGUAGGAGCAGGCGACGUCGGCAAGAGUGCCUUAAC
CAUUCAACUAAUCCAG
(KRAS(G12D G12V G13D) 75mer "3MUT" nt. seq) 201
AUGCCUCACAGCAGCCUGCACCCUAGCAUCCCUUGCCCUAGAGGCCACGGCGCCCAGAAGGCCGCCCUGG-
U
GCUGCUGAGCGCCUGCCUGGUGACCCUGUGGGGCCUGGGCGAGCCUCCUGAGCACACCCUGAGAUACCUG
GUGCUGCACCUGGCCAGCCUGCAGCUGGGCCUGCUGCUGAACGGCGUGUGCAGCCUGGCCGAGGAGCUGA
GACACAUCCACAGCAGAUACAGAGGCAGCUACUGGAGAACCGUGAGAGCCUGCCUGGGCUGCCCUCUGAGA
AGAGGCGCCCUGCUGCUGCUGAGCAUCUACUUCUACUACAGCCUGCCUAACGCCGUGGGCCCUCCUUUCAC
CUGGAUGCUGGCCCUGCUGGGCCUGAGCCAGGCCCUGAACAUCCUGCUGGGCCUGAAGGGCCUGGCCCCU
GCCGAGAUCAGCGCCGUGUGCGAGAAGGGCAACUUCAACGUGGCCCACGGCCUGGCCUGGAGCUACUACA
UCGGCUACCUGAGACUGAUCCUGCCUGAGCUGCAGGCCAGAAUCAGAACCUACAACCAGCACUACAACAAC
CUGCUGAGAGGCGCCGUGAGCCAGAGACUGUACAUCCUGCUGCCUCUGGACUGCGGCGUGCCUGACAACC
UGAGCAUGGCCGACCCUAACAUCAGAUUCCUGGACAAGCUGCCUCAGCAGACCGGCGACCACGCCGGCAUC
AAGGACAGAGUGUACAGCAACAGCAUCUACGAGCUGCUGGAGAACGGCCAGAGAGCCGGCACCUGCGUGC
UGGAGUACGCCACCCCUCUGCAGACCCUGUUCGCCAUGAGCCAGUACAGCCAGGCCGGCUUCAGCAGAGAG
GACACCCUGGAGCAGGCCAAGCUGUUCUGCAGAACCCUGGAGGACAUCCUGGCCGACGCCCCUGAGAGCCA
GAACAACUGCAGACUGAUCGCCUACCAGGAGCCUGCCGACGACAGCAGCUUCAGCCUGAGCCAGGAGGUGC
UGAGACACCUGAGACAGGAGGAGAAGGAGGAGGUGACCGUGGGCAGCCUGAAGACCAGCGCCGUGCCUAG
CACCAGCACCAUGAGCCAGGAGCCUGAGCUGCUGAUCAGCGGCAUGGAGAAGCCUCUGCCUCUGAGAACCG
ACUUCAGC (Hu STING(R284T); no epitope tag; nucleotide sequence) 202
AUGCCCCACAGCAGCCUGCACCCCUCCAUCCCCUGUCCCAGAGGCCACGGCGCCCAGAAGGCCGCCCUGG-
UG
CUGCUGAGCGCCUGCCUGGUGACCUUAUGGGGCCUGGGCGAGCCCCCCGAGCACACCCUGAGAUACCUGG
UCCUGCACCUGGCCAGCCUCCAGCUGGGCCUGCUGCUCAACGGCGUGUGUAGCCUGGCCGAGGAGCUGAG
ACACAUCCACAGCAGAUACAGAGGCAGCUACUGGAGAACCGUGAGAGCCUGCCUGGGUUGCCCACUGAGAA
GAGGAGCUCUGCUGCUGCUGAGCAUCUACUUCUACUACUCGCUGCCCAACGCUGUGGGCCCCCCCUUCACC
UGGAUGCUGGCCCUGCUGGGUCUGAGCCAGGCCCUGAACAUCCUCCUGGGCCUGAAGGGCCUGGCCCCCG
CCGAGAUAAGCGCCGUUUGCGAGAAGGGCAACUUCAACGUGGCCCAUGGCCUGGCCUGGAGCUACUACAU
CGGCUACUUACGCCUGAUCCUGCCCGAGCUGCAGGCCAGAAUCAGAACCUACAACCAGCAUUACAACAACC
UGCUGAGAGGCGCCGUGAGCCAGAGACUGUAUAUCCUGCUGCCCCUGGACUGCGGCGUGCCCGACAACCU
GAGCAUGGCCGACCCCAACAUCAGAUUCCUGGACAAGCUCCCCCAGCAGACCGGCGACCACGCCGGAAUCAA
AGACAGAGUGUAUAGCAACAGCAUCUACGAGCUGCUGGAGAACGGCCAGAGAGCCGGCACCUGCGUACUG
GAGUACGCCACCCCCUUGCAGACCCUGUUUGCCAUGAGCCAGUACAGCCAGGCCGGCUUCAGCAGAGAGGA
CAUGCUGGAGCAGGCCAAGCUGUUCUGCAGAACCCUGGAGGACAUCCUGGCCGACGCCCCCGAGAGCCAGA
ACAACUGCAGACUGAUCGCCUACCAAGAGCCCGCCGACGACAGCAGCUUCAGCUUAAGCCAGGAGGUGCUG
AGACAUCUGAGACAGGAGGAGAAGGAGGAGGUGACCGUGGGCAGCCUCAAGACCAGCGCUGUGCCCUCUA
CCAGCACCAUGAGCCAGGAGCCCGAGCUGCUGAUCAGCGGCAUGGAGAAGCCCCUGCCCCUGAGAACAGAC
UUCAGC (hu STING (R284M); no epitope tag; nucleotide sequence) 203
AUGCCCCAUAGCAGCCUGCACCCCAGCAUCCCCUGCCCCAGAGGCCACGGCGCCCAGAAGGCCGCCCUGG-
UC
CUGCUGAGCGCAUGCCUGGUCACCCUGUGGGGCCUGGGCGAGCCCCCCGAGCACACCCUGAGAUACCUGGU
GCUGCACCUCGCCAGCCUGCAGCUGGGCCUGCUGCUGAACGGCGUGUGCAGCCUGGCCGAGGAGCUGAGA
CACAUCCACAGCAGAUAUAGAGGCAGCUACUGGAGAACCGUGAGAGCUUGCCUCGGCUGCCCCCUGAGAAG
AGGCGCCCUGCUGCUGCUGAGCAUCUACUUUUACUACAGCCUGCCCAACGCUGUGGGCCCCCCUUUCACGU
GGAUGCUCGCCCUGCUGGGACUGAGCCAGGCCCUGAACAUCCUGCUGGGCCUUAAGGGCCUAGCCCCCGCC
GAGAUCAGCGCCGUGUGCGAGAAGGGCAACUUCAAUGUGGCCCACGGCCUGGCCUGGAGCUACUACAUCG
GCUACCUGAGACUGAUCCUGCCCGAGCUGCAGGCCAGAAUCAGAACCUACAAUCAGCACUACAACAACCUG
CUGAGAGGCGCCGUGAGCCAGAGACUGUACAUCCUGCUGCCCCUGGACUGCGGCGUGCCCGACAACCUCAG
CAUGGCCGACCCCAACAUCAGAUUCCUGGACAAGCUGCCCCAGCAGACCGGCGACCACGCCGGCAUCAAGGA
UCGCGUGUACAGCAACAGCAUCUACGAGCUGCUGGAAAACGGCCAGAGAGCCGGAACCUGCGUGCUGGAG
UACGCCACACCCCUGCAGACCCUGUUCGCCAUGAGCCAGUACAGCCAGGCCGGCUUCAGCAGAGAGGACAA
GCUGGAGCAGGCCAAGCUGUUCUGCAGAACCCUGGAGGAUAUCCUCGCCGACGCCCCCGAGAGCCAGAACA
ACUGCAGGCUGAUCGCGUACCAGGAGCCCGCUGACGACAGCAGCUUUAGCCUGAGCCAGGAGGUGCUGAG
ACAUCUGCGUCAAGAGGAAAAGGAGGAGGUGACCGUGGGCUCCCUGAAGACCAGCGCCGUGCCCAGCACCA
GCACCAUGAGCCAGGAGCCCGAGCUGCUGAUCAGCGGCAUGGAGAAGCCACUGCCCCUCAGAACCGACUUC
AGC (Hu STING (R284K); no epitope tag; nucleotide sequence) 204
AUGCCUCACAGCAGCCUGCACCCUAGCAUCCCUUGCCCUAGAGGCCACGGCGCCCAGAAGGCCGCCCUGG-
U
GCUGCUGAGCGCCUGCCUGGUGACCCUGUGGGGCCUGGGCGAGCCUCCUGAGCACACCCUGAGAUACCUG
GUGCUGCACCUGGCCAGCCUGCAGCUGGGCCUGCUGCUGAACGGCGUGUGCAGCCUGGCCGAGGAGCUGA
GACACAUCCACAGCAGAUACAGAGGCAGCUACUGGAGAACCGUGAGAGCCUGCCUGGGCUGCCCUCUGAGA
AGAGGCGCCCUGCUGCUGCUGAGCAUCUACUUCUACUACAGCCUGCCUAACGCCGUGGGCCCUCCUUUCAC
CUGGAUGCUGGCCCUGCUGGGCCUGAGCCAGGCCCUGAACAUCCUGCUGGGCCUGAAGGGCCUGGCCCCU
GCCGAGAUCAGCGCCGUGUGCGAGAAGGGCAACUUCAGCGUGGCCCACGGCCUGGCCUGGAGCUACUACA
UCGGCUACCUGAGACUGAUCCUGCCUGAGCUGCAGGCCAGAAUCAGAACCUACAACCAGCACUACAACAAC
CUGCUGAGAGGCGCCGUGAGCCAGAGACUGUACAUCCUGCUGCCUCUGGACUGCGGCGUGCCUGACAACC
UGAGCAUGGCCGACCCUAACAUCAGAUUCCUGGACAAGCUGCCUCAGCAGACCGGCGACCACGCCGGCAUC
AAGGACAGAGUGUACAGCAACAGCAUCUACGAGCUGCUGGAGAACGGCCAGAGAGCCGGCACCUGCGUGC
UGGAGUACGCCACCCCUCUGCAGACCCUGUUCGCCAUGAGCCAGUACAGCCAGGCCGGCUUCAGCAGAGAG
GACAGACUGGAGCAGGCCAAGCUGUUCUGCAGAACCCUGGAGGACAUCCUGGCCGACGCCCCUGAGAGCCA
GAACAACUGCAGACUGAUCGCCUACCAGGAGCCUGCCGACGACAGCAGCUUCAGCCUGAGCCAGGAGGUGC
UGAGACACCUGAGACAGGAGGAGAAGGAGGAGGUGACCGUGGGCAGCCUGAAGACCAGCGCCGUGCCUAG
CACCAGCACCAUGAGCCAGGAGCCUGAGCUGCUGAUCAGCGGCAUGGAGAAGCCUCUGCCUCUGAGAACCG
ACUUCAGC (Hu STING(N154S); no epitope tag; nucleotide sequence) 205
AUGCCUCACAGCAGCCUGCACCCUAGCAUCCCUUGCCCUAGAGGCCACGGCGCCCAGAAGGCCGCCCUGG-
U
GCUGCUGAGCGCCUGCCUGGUGACCCUGUGGGGCCUGGGCGAGCCUCCUGAGCACACCCUGAGAUACCUG
GUGCUGCACCUGGCCAGCCUGCAGCUGGGCCUGCUGCUGAACGGCGUGUGCAGCCUGGCCGAGGAGCUGA
GACACAUCCACAGCAGAUACAGAGGCAGCUACUGGAGAACCGUGAGAGCCUGCCUGGGCUGCCCUCUGAGA
AGAGGCGCCCUGCUGCUGCUGAGCAUCUACUUCUACUACAGCCUGCCUAACGCCGUGGGCCCUCCUUUCAC
CUGGAUGCUGGCCCUGCUGGGCCUGAGCCAGGCCCUGAACAUCCUGCUGGGCCUGAAGGGCCUGGCCCCU
GCCGAGAUCAGCGCCCUGUGCGAGAAGGGCAACUUCAACGUGGCCCACGGCCUGGCCUGGAGCUACUACAU
CGGCUACCUGAGACUGAUCCUGCCUGAGCUGCAGGCCAGAAUCAGAACCUACAACCAGCACUACAACAACC
UGCUGAGAGGCGCCGUGAGCCAGAGACUGUACAUCCUGCUGCCUCUGGACUGCGGCGUGCCUGACAACCU
GAGCAUGGCCGACCCUAACAUCAGAUUCCUGGACAAGCUGCCUCAGCAGACCGGCGACCACGCCGGCAUCA
AGGACAGAGUGUACAGCAACAGCAUCUACGAGCUGCUGGAGAACGGCCAGAGAGCCGGCACCUGCGUGCU
GGAGUACGCCACCCCUCUGCAGACCCUGUUCGCCAUGAGCCAGUACAGCCAGGCCGGCUUCAGCAGAGAGG
ACAGACUGGAGCAGGCCAAGCUGUUCUGCAGAACCCUGGAGGACAUCCUGGCCGACGCCCCUGAGAGCCAG
AACAACUGCAGACUGAUCGCCUACCAGGAGCCUGCCGACGACAGCAGCUUCAGCCUGAGCCAGGAGGUGCU
GAGACACCUGAGACAGGAGGAGAAGGAGGAGGUGACCGUGGGCAGCCUGAAGACCAGCGCCGUGCCUAGC
ACCAGCACCAUGAGCCAGGAGCCUGAGCUGCUGAUCAGCGGCAUGGAGAAGCCUCUGCCUCUGAGAACCGA
CUUCAGC (Hu STING(V147L); no epitope tag; nucleotide sequence) 206
AUGCCUCACAGCAGCCUGCACCCUAGCAUCCCUUGCCCUAGAGGCCACGGCGCCCAGAAGGCCGCCCUGG-
U
GCUGCUGAGCGCCUGCCUGGUGACCCUGUGGGGCCUGGGCGAGCCUCCUGAGCACACCCUGAGAUACCUG
GUGCUGCACCUGGCCAGCCUGCAGCUGGGCCUGCUGCUGAACGGCGUGUGCAGCCUGGCCGAGGAGCUGA
GACACAUCCACAGCAGAUACAGAGGCAGCUACUGGAGAACCGUGAGAGCCUGCCUGGGCUGCCCUCUGAGA
AGAGGCGCCCUGCUGCUGCUGAGCAUCUACUUCUACUACAGCCUGCCUAACGCCGUGGGCCCUCCUUUCAC
CUGGAUGCUGGCCCUGCUGGGCCUGAGCCAGGCCCUGAACAUCCUGCUGGGCCUGAAGGGCCUGGCCCCU
GCCGAGAUCAGCGCCGUGUGCGAGAAGGGCAACUUCAACGUGGCCCACGGCCUGGCCUGGAGCUACUACA
UCGGCUACCUGAGACUGAUCCUGCCUGAGCUGCAGGCCAGAAUCAGAACCUACAACCAGCACUACAACAAC
CUGCUGAGAGGCGCCGUGAGCCAGAGACUGUACAUCCUGCUGCCUCUGGACUGCGGCGUGCCUGACAACC
UGAGCAUGGCCGACCCUAACAUCAGAUUCCUGGACAAGCUGCCUCAGCAGACCGGCGACCACGCCGGCAUC
AAGGACAGAGUGUACAGCAACAGCAUCUACGAGCUGCUGGAGAACGGCCAGAGAGCCGGCACCUGCGUGC
UGGAGUACGCCACCCCUCUGCAGACCCUGUUCGCCAUGAGCCAGUACAGCCAGGCCGGCUUCAGCAGAGAG
GACAGACUGGAGCAGGCCAAGCUGUUCUGCAGAACCCUGGAGGACAUCCUGGCCGACGCCCCUGAGAGCCA
GAACAACUGCAGACUGAUCGCCUACCAGCAGCCUGCCGACGACAGCAGCUUCAGCCUGAGCCAGGAGGUGC
UGAGACACCUGAGACAGGAGGAGAAGGAGGAGGUGACCGUGGGCAGCCUGAAGACCAGCGCCGUGCCUAG
CACCAGCACCAUGAGCCAGGAGCCUGAGCUGCUGAUCAGCGGCAUGGAGAAGCCUCUGCCUCUGAGAACCG
ACUUCAGC (Hu STING (E315Q); no epitope tag; nucleotide sequence)
207
AUGCCUCACAGCAGCCUGCACCCUAGCAUCCCUUGCCCUAGAGGCCACGGCGCCCAGAAGGCCGCCCUGG-
U
GCUGCUGAGCGCCUGCCUGGUGACCCUGUGGGGCCUGGGCGAGCCUCCUGAGCACACCCUGAGAUACCUG
GUGCUGCACCUGGCCAGCCUGCAGCUGGGCCUGCUGCUGAACGGCGUGUGCAGCCUGGCCGAGGAGCUGA
GACACAUCCACAGCAGAUACAGAGGCAGCUACUGGAGAACCGUGAGAGCCUGCCUGGGCUGCCCUCUGAGA
AGAGGCGCCCUGCUGCUGCUGAGCAUCUACUUCUACUACAGCCUGCCUAACGCCGUGGGCCCUCCUUUCAC
CUGGAUGCUGGCCCUGCUGGGCCUGAGCCAGGCCCUGAACAUCCUGCUGGGCCUGAAGGGCCUGGCCCCU
GCCGAGAUCAGCGCCGUGUGCGAGAAGGGCAACUUCAACGUGGCCCACGGCCUGGCCUGGAGCUACUACA
UCGGCUACCUGAGACUGAUCCUGCCUGAGCUGCAGGCCAGAAUCAGAACCUACAACCAGCACUACAACAAC
CUGCUGAGAGGCGCCGUGAGCCAGAGACUGUACAUCCUGCUGCCUCUGGACUGCGGCGUGCCUGACAACC
UGAGCAUGGCCGACCCUAACAUCAGAUUCCUGGACAAGCUGCCUCAGCAGACCGGCGACCACGCCGGCAUC
AAGGACAGAGUGUACAGCAACAGCAUCUACGAGCUGCUGGAGAACGGCCAGAGAGCCGGCACCUGCGUGC
UGGAGUACGCCACCCCUCUGCAGACCCUGUUCGCCAUGAGCCAGUACAGCCAGGCCGGCUUCAGCAGAGAG
GACAGACUGGAGCAGGCCAAGCUGUUCUGCAGAACCCUGGAGGACAUCCUGGCCGACGCCCCUGAGAGCCA
GAACAACUGCAGACUGAUCGCCUACCAGGAGCCUGCCGACGACAGCAGCUUCAGCCUGAGCCAGGAGGUGC
UGAGACACCUGAGACAGGAGGAGAAGGAGGAGGUGACCGUGGGCAGCCUGAAGACCAGCGCCGUGCCUAG
CACCAGCACCAUGAGCCAGGAGCCUGAGCUGCUGAUCAGCGGCAUGGAGAAGCCUCUGCCUCUGGCCACCG
ACUUCAGC (Hu STING (R375A); no epitope tag; nucleotide sequence)
208
AUGCCUCACAGCAGCCUGCACCCUAGCAUCCCUUGCCCUAGAGGCCACGGCGCCCAGAAGGCCGCCCUGG-
U
GCUGCUGAGCGCCUGCCUGGUGACCCUGUGGGGCCUGGGCGAGCCUCCUGAGCACACCCUGAGAUACCUG
GUGCUGCACCUGGCCAGCCUGCAGCUGGGCCUGCUGCUGAACGGCGUGUGCAGCCUGGCCGAGGAGCUGA
GACACAUCCACAGCAGAUACAGAGGCAGCUACUGGAGAACCGUGAGAGCCUGCCUGGGCUGCCCUCUGAGA
AGAGGCGCCCUGCUGCUGCUGAGCAUCUACUUCUACUACAGCCUGCCUAACGCCGUGGGCCCUCCUUUCAC
CUGGAUGCUGGCCCUGCUGGGCCUGAGCCAGGCCCUGAACAUCCUGCUGGGCCUGAAGGGCCUGGCCCCU
GCCGAGAUCAGCGCCCUGUGCGAGAAGGGCAACUUCAGCAUGGCCCACGGCCUGGCCUGGAGCUACUACAU
CGGCUACCUGAGACUGAUCCUGCCUGAGCUGCAGGCCAGAAUCAGAACCUACAACCAGCACUACAACAACC
UGCUGAGAGGCGCCGUGAGCCAGAGACUGUACAUCCUGCUGCCUCUGGACUGCGGCGUGCCUGACAACCU
GAGCAUGGCCGACCCUAACAUCAGAUUCCUGGACAAGCUGCCUCAGCAGACCGGCGACCACGCCGGCAUCA
AGGACAGAGUGUACAGCAACAGCAUCUACGAGCUGCUGGAGAACGGCCAGAGAGCCGGCACCUGCGUGCU
GGAGUACGCCACCCCUCUGCAGACCCUGUUCGCCAUGAGCCAGUACAGCCAGGCCGGCUUCAGCAGAGAGG
ACAGACUGGAGCAGGCCAAGCUGUUCUGCAGAACCCUGGAGGACAUCCUGGCCGACGCCCCUGAGAGCCAG
AACAACUGCAGACUGAUCGCCUACCAGGAGCCUGCCGACGACAGCAGCUUCAGCCUGAGCCAGGAGGUGCU
GAGACACCUGAGACAGGAGGAGAAGGAGGAGGUGACCGUGGGCAGCCUGAAGACCAGCGCCGUGCCUAGC
ACCAGCACCAUGAGCCAGGAGCCUGAGCUGCUGAUCAGCGGCAUGGAGAAGCCUCUGCCUCUGAGAACCGA
CUUCAGC (Hu STING(V147L/N154S/V155M); no epitope tag; nucleotide
sequence) 209
AUGCCUCACAGCAGCCUGCACCCUAGCAUCCCUUGCCCUAGAGGCCACGGCGCCCAGAAGGCCGCCCUGG-
U
GCUGCUGAGCGCCUGCCUGGUGACCCUGUGGGGCCUGGGCGAGCCUCCUGAGCACACCCUGAGAUACCUG
GUGCUGCACCUGGCCAGCCUGCAGCUGGGCCUGCUGCUGAACGGCGUGUGCAGCCUGGCCGAGGAGCUGA
GACACAUCCACAGCAGAUACAGAGGCAGCUACUGGAGAACCGUGAGAGCCUGCCUGGGCUGCCCUCUGAGA
AGAGGCGCCCUGCUGCUGCUGAGCAUCUACUUCUACUACAGCCUGCCUAACGCCGUGGGCCCUCCUUUCAC
CUGGAUGCUGGCCCUGCUGGGCCUGAGCCAGGCCCUGAACAUCCUGCUGGGCCUGAAGGGCCUGGCCCCU
GCCGAGAUCAGCGCCCUGUGCGAGAAGGGCAACUUCAGCAUGGCCCACGGCCUGGCCUGGAGCUACUACAU
CGGCUACCUGAGACUGAUCCUGCCUGAGCUGCAGGCCAGAAUCAGAACCUACAACCAGCACUACAACAACC
UGCUGAGAGGCGCCGUGAGCCAGAGACUGUACAUCCUGCUGCCUCUGGACUGCGGCGUGCCUGACAACCU
GAGCAUGGCCGACCCUAACAUCAGAUUCCUGGACAAGCUGCCUCAGCAGACCGGCGACCACGCCGGCAUCA
AGGACAGAGUGUACAGCAACAGCAUCUACGAGCUGCUGGAGAACGGCCAGAGAGCCGGCACCUGCGUGCU
GGAGUACGCCACCCCUCUGCAGACCCUGUUCGCCAUGAGCCAGUACAGCCAGGCCGGCUUCAGCAGAGAGG
ACAUGCUGGAGCAGGCCAAGCUGUUCUGCAGAACCCUGGAGGACAUCCUGGCCGACGCCCCUGAGAGCCAG
AACAACUGCAGACUGAUCGCCUACCAGGAGCCUGCCGACGACAGCAGCUUCAGCCUGAGCCAGGAGGUGCU
GAGACACCUGAGACAGGAGGAGAAGGAGGAGGUGACCGUGGGCAGCCUGAAGACCAGCGCCGUGCCUAGC
ACCAGCACCAUGAGCCAGGAGCCUGAGCUGCUGAUCAGCGGCAUGGAGAAGCCUCUGCCUCUGAGAACCGA
CUUCAGC (Hu STING(R284M/V147L/N154S/V155M); no epitope tag;
nucleotide sequence) 210
UGAUAAUAGGCUGGAGCCUCGGUGGCCUAGCUUCUUGCCCCUUGGGCCUCCCCCCAGCCCCUCCUCCCCU-
U
CCUGCACCCGUACCCCCCAAACACCAUUGUCACACUCCAGUGGUCUUUGAAUAAAGUCUGAGUGGGCGGC
(3' UTR used in STING V155M construct, containing miR122 binding
site) 211
AUGGAGACCCCCAAGCCUAGAAUCCUGCCCUGGCUGGUGAGCCAGCUGGACCUGGGCCAGCUGGAGGGCG
UAGCCUGGCUGGACGAGAGCAGAACCAGAUUCAGAAUCCCCUGGAAGCACGGCCUGAGACAAGACGCCCAG
AUGGCCGACUUCGGCAUCUUCCAGGCCUGGGCCGAGGCCAGCGGCGCCUACACCCCUGGCAAGGAUAAGCC
CGAUGUGAGCACCUGGAAGAGAAACUUCAGAAGCGCCCUGAACAGAAAGGAGGUGCUGAGACUGGCCGCC
GACAAUAGCAAGGACCCCUACGACCCCCACAAGGUGUACGAGUUCGUUACCCCCGGCGCCAGGGACUUCGU
GCACCUGGGCGCCAGCCCCGACACCAACGGCAAGAGCAGCCUGCCCCACAGCCAGGAGAACCUGCCCAAGCU
GUUCGAUGGCCUGAUCCUGGGCCCCCUGAAGGACGAGGGCAGCAGCGACCUGGCCAUCGUGAGCGACCCU
AGCCAGCAGCUGCCCUCCCCCAACGUGAACAACUUCCUGAACCCCGCCCCCCAGGAGAACCCCCUGAAGCAAC
UGCUGGCCGAGGAGCAGUGGGAGUUCGAGGUGACCGCCUUCUACAGAGGCAGACAGGUGUUCCAGCAGAC
CCUGUUCUGCCCCGGCGGCCUGAGACUGGUAGGCAGCACCGCUGACAUGACCCUGCCCUGGCAGCCCGUGA
CCCUGCCCGACCCCGAAGGCUUUCUGACCGACAAGCUGGUGAAGGAGUACGUCGGCCAAGUGCUGAAGGG
CCUGGGCAACGGCCUGGCCCUGUGGCAGGCCGGCCAGUGCCUGUGGGCCCAGAGACUCGGCCACAGCCACG
CCUUCUGGGCCCUGGGCGAGGAACUCCUGCCCGAUAGCGGCAGAGGCCCCGACGGCGAGGUGCACAAGGAC
AAGGACGGCGCCGUGUUCGACCUGCGCCCCUUCGUGGCCGACCUGAUCGCCUUCAUGGAGGGCAGCGGCC
ACAGCCCCAGAUAUACCCUGUGGUUCUGCAUGGGCGAGAUGUGGCCCCAGGACCAGCCCUGGGUGAAGAG
ACUGGUGAUGGUGAAGGUGGUGCCCACCUGCCUGAAAGAGCUGCUGGAGAUGGCCAGAGAGGGCGGCGC
CAGCUCCCUGAAAACCGUGGACCUGCACAUUGACAACAGCCAGCCCAUCAGCCUGACCAGCGACCAGUACAA
GGCCUACCUGCAGGACCUGGUGGAGGACAUGGACUUCCAGGCCACCGGCAACAUC (super
mouse IRF3 S396D; no epitope tag) 212
AUGGGCACCCCCAAGCCCAGAAUCCUGCCCUGGCUGGUGAGCCAGCUGGACCUGGGCCAGCUGGAGGGAG
UGGCCUGGGUGAACAAGAGCAGAACCAGAUUCAGAAUCCCCUGGAAGCACGGCCUCAGACAGGACGCCCAG
CAGGAGGACUUCGGCAUUUUUCAGGCUUGGGCCGAGGCCACCGGCGCCUACGUGCCCGGCAGAGACAAGC
CCGACCUGCCCACCUGGAAAAGAAACUUCAGAAGCGCCUUGAAUAGAAAGGAGGGCCUGAGACUGGCCGAG
GACAGAAGCAAGGACCCCCACGACCCUCACAAGAUCUACGAGUUCGUGAAUAGCGGCGUGGGCGACUUUA
GCCAGCCCGACACCAGCCCCGACACCAACGGCGGCGGCAGCACCAGCGACACGCAGGAGGACAUCCUGGAUG
AACUGCUGGGCAACAUGGUGCUGGCCCCCCUGCCCGAUCCCGGCCCCCCUUCGCUUGCCGUGGCCCCCGAG
CCCUGCCCCCAGCCCCUGAGAAGCCCCUCUCUGGAUAACCCCACCCCCUUCCCCAACCUGGGCCCCAGCGAGA
AUCCACUGAAGAGACUUCUGGUCCCCGGCGAGGAGUGGGAGUUCGAGGUGACCGCCUUCUACAGAGGCAG
ACAGGUGUUCCAGCAGACCAUCAGCUGCCCCGAAGGCCUGAGAUUAGUGGGCAGCGAAGUGGGCGACAGG
ACCCUGCCCGGGUGGCCCGUGACCCUGCCCGAUCCCGGCAUGAGCCUGACCGACAGAGGUGUGAUGAGCUA
CGUGAGACACGUGCUGAGCUGCCUGGGCGGCGGCCUGGCACUGUGGAGAGCCGGCCAGUGGCUGUGGGC
CCAGAGACUGGGCCACUGCCACACCUACUGGGCCGUGAGCGAGGAGCUGCUGCCCAACAGCGGCCACGGCC
CCGACGGCGAGGUGCCCAAGGACAAGGAAGGGGGCGUGUUCGACCUGGGCCCCUUCAUCGUAGACCUGAU
CACCUUUACCGAGGGCAGCGGCAGGAGCCCCAGAUACGCCCUGUGGUUCUGCGUGGGCGAAAGCUGGCCC
CAGGACCAGCCCUGGACCAAGAGACUGGUGAUGGUGAAGGUAGUGCCCACCUGCCUGAGAGCCUUAGUGG
AGAUGGCCAGAGUGGGCGGGGCCAGCAGCCUGGAGAACACCGUGGAUCUUCACAUCGACAACAGCCACCCC
CUGAGCCUGACCAGCGACCAGUACAAGGCCUACCUGCAGGACCUGGUGGAGGGCAUGGACUUCCAGGGCCC
CGGCGAGACC (super human IRF3 S396D; no epitope tag) 213
AUGGCGCUGGCCCCCGAAAGAGCCGCCCCCAGAGUCCUCUUCGGCGAAUGGCUCCUUGGCGAAAUUUCGU-
C
GGGCUGCUACGAGGGCUUACAAUGGCUGGAUGAGGCGAGAACCUGUUUCAGGGUGCCCUGGAAACACUU
CGCCAGAAAGGAUCUAAGCGAAGCAGAUGCUAGAAUUUUUAAGGCUUGGGCCGUGGCCAGGGGAAGAUG
GCCCCCCUCGAGCAGAGGCGGCGGCCCUCCCCCCGAGGCAGAAACGGCCGAGAGAGCCGGAUGGAAAACCAA
UUUCAGAUGCGCCCUGAGAUCUACAAGAAGAUUCGUGAUGCUUAGAGACAACAGCGGAGAUCCCGCCGAU
CCCCAUAAGGUGUAUGCCCUGUCCCGGGAGCUGUGCUGGAGGGAAGGGCCUGGCACUGACCAGACCGAAG
CCGAAGCCCCCGCGGCCGUGCCGCCGCCCCAAGGAGGCCCACCAGGCCCUUUCCUCGCUCACACCCACGCCGG
UCUGCAAGCCCCGGGACCUCUACCUGCCCCUGCCGGCGAUAAAGGCGACCUGUUGCUGCAGGCCGUCCAAC
AGAGCUGCCUGGCCGAUCAUCUGCUCACAGCCAGCUGGGGCGCUGACCCCGUCCCAACAAAGGCCCCCGGU
GAGGGCCAAGAAGGCCUGCCUCUGACCGGCGCCUGUGCCGGCGGCCCUGGCCUGCCUGCUGGCGAGCUGU
ACGGAUGGGCUGUCGAAACCACUCCCUCCCCCGGCCCCCAACCUGCGGCCCUGACAACCGGCGAGGCAGCCG
CACCCGAAAGCCCCCACCAGGCCGAACCCUACCUCAGUCCCAGCCCCUCCGCCUGCACCGCUGUGCAGGAGCC
CAGCCCCGGUGCUCUGGACGUAACAAUCAUGUACAAAGGCAGAACCGUGCUUCAGAAGGUGGUUGGACAC
CCCUCCUGUACUUUUCUCUACGGCCCCCCCGACCCUGCCGUGAGAGCUACCGACCCGCAACAGGUGGCCUU
UCCCUCGCCCGCCGAACUGCCCGAUCAAAAACAGCUGAGAUACACCGAGGAGCUGCUGAGACACGUGGCGC
CGGGCUUACACCUAGAGUUGAGAGGCCCCCAACUCUGGGCCAGACGCAUGGGCAAGUGUAAGGUGUACUG
GGAGGUCGGGGGCCCUCCCGGCUCUGCCAGCCCCAGCACCCCUGCUUGUCUCUUGCCCAGAAACUGUGAUA
CCCCCAUCUUCGACUUCCGUGUAUUUUUCCAGGAACUGGUCGAGUUUAGAGCCAGACAGAGACGAGGCAG
CCCCAGAUAUACAAUCUACCUCGGCUUCGGCCAGGACCUGAGUGCCGGCAGACCUAAGGAGAAGUCGCUGG
UCCUAGUGAAGUUAGAGCCCUGGCUAUGUAGAGUGCACCUGGAGGGCACCCAGAGAGAAGGAGUGAGCA
GCCUGGACAGCAGCAGCCUGAGUCUGUGCCUGAGCUCCGCCAACUCGCUGUAUGAUGACAUCGAGUGUUU
CCUCAUGGAGCUGGAGCAGCCCGCC (Wild-type Hu IRF7 isoform A; P037
without epitope tag) 214
AUGGCCCUUGCCCCUGAGCGGGCCGCCCCCAGAGUGUUAUUCGGCGAGUGGCUGCUGGGCGAGAUCAGCA
GCGGCUGCUACGAGGGACUGCAGUGGCUGGACGAGGCUAGAACCUGCUUCAGAGUGCCCUGGAAGCAUU
UCGCCAGAAAAGACCUGAGCGAGGCUGAUGCUAGAAUCUUCAAAGCCUGGGCUGUGGCCCGAGGAAGAUG
GCCCCCCAGCAGCAGAGGAGGCGGCCCUCCUCCCGAGGCCGAAACCGCAGAGCGUGCUGGCUGGAAAACCA
ACUUUAGGUGUGCCCUGAGGAGCACCAGAAGAUUCGUUAUGCUCAGAGACAACAGCGGGGACCCCGCCGA
CCCGCACAAGGUGUACGCCUUAAGUAGGGAGCUGUGCUGGAGAGAGGGACCGGGGACCGACCAAACCGAG
GCUGAGGCGCCCGCCGCCGUUCCACCUCCCCAGGGUGGUCCCCCAGGGCCCUUUCUGGCACACACCCACGCC
GGAUUACAGGCGCCAGGGCCCUUACCCGCCCCCGCCGGAGACAAAGGCGACCUCCUGCUGCAAGCCGUGCA
ACAAAGCUGCCUGGCCGAUCACUUACUAACCGCUAGCUGGGGCGCCGAUCCUGUUCCCACCAAGGCCCCCG
GUGAAGGGCAAGAAGGACUGCCCUUAACCGGCGCCUGUGCCGGAGGCCCUGGUCUGCCAGCCGGCGAGCU
GUACGGUUGGGCUGUCGAAACAACACCCAGUCCGGGCCCACAGCCUGCCGCUCUGACCACCGGCGAAGCCG
CCGCCCCCGAGAGCCCACACCAGGCUGAACCCUACCUGAGCCCCAGCCCCAGCGCCUGCACCGCUGUGCAGG
AGCCUAGCCCCGGCGCUCUUGAUGUGACAAUAAUGUACAAGGGCAGGACCGUGCUGCAAAAGGUCGUGGG
CCAUCCGUCGUGUACCUUUCUGUACGGCCCUCCAGACCCCGCGGUUAGAGCCACCGACCCCCAGCAAGUCG
CCUUCCCCUCCCCCGCCGAACUGCCCGACCAAAAGCAGCUGCGGUACACAGAAGAACUACUUAGACACGUGG
CCCCCGGUCUGCACUUGGAGCUGAGAGGCCCCCAGCUCUGGGCCAGAAGAAUGGGCAAGUGCAAAGUGUA
CUGGGAGGUGGGCGGCCCACCCGGCUCAGCUUCGCCCUCCACACCCGCAUGCCUGCUGCCCAGAAAUUGCG
ACACGCCCAUCUUCGAUUUUAGAGUGUUCUUUCAGGAGUUGGUGGAGUUCAGAGCCAGACAAAGACGCG
GCAGCCCCAGAUACACCAUUUACCUCGGCUUCGGCCAGGACCUCAGCGCUGGCAGACCCAAGGAGAAGAGU
CUGGUCCUCGUGAAGCUGGAGCCCUGGCUGUGCAGAGUGCACCUGGAGGGCACCCAGCGUGAAGGCGUGA
GCAGCCUGGAUUCAAGCGACCUGGACCUAUGCCUAAGCAGCGCUAACUCACUGUACGACGAUAUCGAAUG
CUUCCUGAUGGAACUGGAGCAGCCUGCC (constitutively active Hu IRF7
S477D/S479D; P033 without epitope tag) 215
AUGGCCCUGGCACCCGAGAGGGCCGCCCCCAGGGUGCUCUUCGGCGAGUGGUUACUAGGCGAAAUUAGCA
GCGGCUGCUAUGAAGGCCUUCAGUGGCUGGACGAGGCCAGAACCUGCUUUAGAGUUCCCUGGAAGCACUU
CGCCCGGAAAGAUCUCUCUGAAGCCGACGCCAGAAUAUUCAAGGCCUGGGCUGUCGCCAGGGGCAGGUGG
CCACCCUCCAGCCGAGGUGGCGGCCCUCCCCCUGAGGCUGAGACUGCGGAAAGGGCGGGCUGGAAGACCAA
UUUCAGAUGCGCUCUGAGAAGCACCAGACGUUUUGUGAUGCUAAGAGACAAUAGCGGCGAUCCCGCCGAC
CCCCAUAAGGUAUACGCACUGAGCCGAGAGCUCUGUUGGAGAGAAGGCCCCGGCACCGACCAGACCGAGGC
UGAAGCCCCUGCAGCCGUGCCCCCCCCUCAAGGCGGGCCCCCCGGCCCCUUCCUGGCCCAUACCCAUGCAGG
GUUACAAGCACCCGGGCCCUUGCCCGCCCCAGCGGGAGACAAGGGCGACCUCUUACUGCAGGCCGUGCAAC
AAAGUUGUCUGGCGGACCACCUGCUGACCGCAUCAUGGGGCGCGGAUCCUGUGCCCACCAAGGCACCCGGC
GAAGGCCAGGAGGGCCUGCCCUUGACCGGCGCCUGCGCUGGCGGACCCGGCCUACCUGCUGGCGAACUGU
AUGGCUGGGCCGUAGAGACGACUCCCAGCCCUGGCCCACAACCCGCGGCUUUGACCACCGGCGAAGCCGCC
GCCCCCGAGUCUCCGCACCAGGCCGAGCCUUACCUCAGCCCAAGCCCUAGCGCCUGCACCGCCGUGCAAGAA
CCUAGCCCCGGAGCCCUGGAUGUGACAAUCAUGUACAAGGGUAGAACCGUACUGCAAAAGGUGGUGGGUC
AUCCCAGCUGCACCUUUCUUUACGGCCCACCCGACCCUGCCGUGCGAGCCACAGACCCACAACAGGUCGCCU
UCCCAAGCCCCGCCGAACUGCCCGAUCAGAAACAGCUGAGAUAUACAGAGGAGCUUCUGCGGCACGUAGCU
CCCGGCCUACAUCUCGAGCUGAGGGGCCCACAACUGUGGGCCAGACGCAUGGGCAAAUGCAAGGUCUACU
GGGAAGUGGGAGGCCCCCCCGGCAGCGCAUCUCCCAGCACGCCCGCGUGCCUGCUGCCUAGAAAUUGCGAC
ACCCCCAUCUUUGACUUCCGGGUAUUCUUUCAGGAGCUGGUAGAGUUCAGAGCCAGGCAGCGGAGGGGC
UCCCCCAGAUACACAAUCUACCUGGGCUUCGGACAGGACCUGUCCGCCGGCCGCCCCAAGGAAAAGAGCCU
GGUGCUGGUGAAGCUGGAGCCCUGGCUGUGUAGGGUACACCUCGAAGGCACCCAGAGAGAAGGAGUGAG
CUCGCUUGAUGACAGCGAUCUGUCGGAUUGCCUUAGCAGCGCCAACAGCCUGUAUGAUGAUAUCGAGUGC
UUCCUUAUGGAACUGGAGCAGCCCGCC (constitutively active Hu IRF7
S475D/S477D/L480D; P034 without epitope tag) 216
AUGGCCCUAGCCCCCGAAAGAGCAGCUCCCAGAGUGCUGUUCGGCGAAUGGCUGCUUGGCGAGAUCAGCA
GCGGCUGCUACGAAGGCCUGCAGUGGCUGGACGAAGCCCGCACCUGUUUCAGAGUGCCCUGGAAGCACUU
CGCUAGAAAGGAUUUGAGCGAGGCUGAUGCUAGAAUCUUUAAGGCUUGGGCUGUGGCAAGAGGCAGAUG
GCCGCCUAGUAGCAGAGGGGGCGGACCUCCCCCCGAGGCUGAGACCGCUGAGAGAGCAGGGUGGAAAACC
AACUUCAGAUGCGCGCUGAGAAGCACCCGAAGAUUCGUGAUGCUACGUGACAAUAGCGGCGACCCCGCCGA
CCCCCACAAAGUGUACGCCCUGUCCCGAGAACUUUGCUGGAGAGAGGGACCCGGCACCGAUCAAACAGAGG
CUGAGGCCCCGGCCGCUGUACCCCCGCCCCAAGGAGGCCCCCCAGGCCCCUUUCUGGCUCAUACACAUGCCG
GCCUGCAGGCACCCGGGCCCCUCCCGGCUCCUGCCGGCGACAAGGGCGAUCUCCUUCUCCAGGCCGUGCAG
CAGAGCUGCCUGGCCGAUCACCUGCUGACCGCCUCGUGGGGCGCCGACCCCGUGCCCACCAAAGCCCCGGG
UGAAGGCCAAGAGGGGCUCCCUUUAACCGGAGCAUGCGCCGGAGGCCCCGGCCUGCCAGCCGGCGAGUUA
UAUGGCUGGGCUGUGGAGACCACACCCUCCCCCGGCCCUCAACCCGCUGCCCUGACCACCGGUGAGGCCGCC
GCCCCCGAGAGCCCACACCAGGCCGAACCCUACCUGAGCCCUAGCCCUAGCGCCUGCACCGCCGUGCAAGAA
CCCAGCCCCGGAGCCCUGGAUGUGACCAUUAUGUACAAGGGCCGGACAGUGCUGCAAAAGGUUGUGGGAC
ACCCGAGCUGCACCUUUCUGUACGGUCCGCCUGACCCCGCCGUGAGAGCCACGGACCCGCAGCAGGUGGCC
UUCCCCUCACCCGCGGAGCUGCCCGACCAAAAGCAACUCAGAUACACAGAAGAACUAUUGCGUCACGUCGC
GCCCGGCCUGCAUCUGGAGCUGAGAGGCCCCCAGCUCUGGGCCAGAAGGAUGGGCAAAUGCAAGGUGUAC
UGGGAGGUGGGAGGCCCCCCCGGCAGCGCCAGCCCCAGCACUCCCGCGUGCCUGCUGCCCAGAAAUUGCGA
CACUCCCAUCUUCGAUUUCAGGGUGUUCUUCCAGGAGCUGGUGGAGUUCAGAGCCAGGCAGAGAAGGGG
UAGCCCCAGAUACACAAUCUAUCUAGGCUUUGGACAAGAUCUGAGCGCCGGCCGGCCUAAGGAAAAAAGCC
UGGUGCUGGUAAAGCUGGAGCCGUGGCUUUGUAGAGUGCACCUGGAGGGGACGCAGCGAGAGGGCGUGA
GCAGCUUAGACGACGAUGACUUGGAUCUGUGUCUCGACAGCGCCAACGACUUGUACGACGACAUCGAGUG
CUUCCUGAUGGAACUGGAGCAGCCCGCC (constitutively active Hu IRF7
S475D/S476D/S477D/S479D/S483D/S487D; P035 without epitope tag) 217
AUGGCCCUGGCCCCCGAGAGAGCCGCCCCCAGAGUGCUCUUCGGCGAGUGGCUGCUGGGCGAGAUAAGCA
GCGGCUGCUACGAAGGUCUGCAGUGGCUAGACGAGGCCAGAACCUGCUUUAGAGUGCCCUGGAAGCACUU
CGCUCGAAAGGACCUGUCCGAGGCCGAUGCUAGAAUUUUUAAGGCUUGGGCCGUCGCUAGGGGAAGAUG
GCCCCCUAGCAGUAGAGGCGGCGGCCCCCCUCCCGAAGCCGAGACGGCCGAGAGGGCCGGCUGGAAAACCA
AUUUCAGAUGCGCCCUGAGGAGCACCCGCAGGUUCGUAAUGCUGCGAGACAAUAGCGGCGAUCCUGCGGA
UCCUCACAAGGUUUACGCCUUGAGUAGAGAACUGUGCUGGCGGGAGGGCCCCGGAACCGACCAGACGGAG
GCAGAGGCACCCGCUGCCGUGCCCCCCCCUCAAGGAGGACCCCCUGGACCCUUUCUGGCCCACACCCACGCU
GGUCUGCAGGCCCCAGGCCCACUGCCCGCCCCAGCGGGCGAUAAGGGUGACCUGCUCCUACAGGCGGUGCA
ACAGAGCUGUCUGGCCGACCACCUGUUGACCGCCAGCUGGGGGGCCGACCCGGUGCCCACCAAAGCUCCCG
GAGAGGGCCAAGAAGGCCUCCCACUAACUGGCGCCUGCGCCGGGGGCCCGGGAUUACCCGCCGGCGAGCUG
UAUGGCUGGGCCGUGGAGACCACGCCCAGCCCCGAGGGCGUGUCGUCCCUGGACAGCAGCAGCCUGAGCCU
GUGCCUGAGCUCCGCCAACAGCCUGUAUGACGACAUCGAGUGCUUCCUGAUGGAGCUGGAACAACCCGCC
(constitutively active truncated Hu IRF7 1-246 + 468-503; P032
without epitope tag) 218
AUGGCACUGGCGCCUGAAAGAGCCGCUCCGCGUGUGCUCUUCGGCGAGUGGCUGCUGGGCGAGAUCAGCU
CCGGCUGCUACGAGGGUCUACAGUGGCUGGACGAGGCCAGAACCUGUUUUAGAGUGCCCUGGAAGCACUU
CGCGAGAAAGGACCUGAGCGAGGCCGACGCCAGAAUCUUCAAAGCCUGGGCAGUGGCUAGGGGCAGAUGG
CCUCCCAGCAGCCGGGGCGGCGGCCCACCCCCCGAGGCCGAAACCGCCGAAAGAGCUGGCUGGAAGACCAAC
UUCAGAUGCGCCCUGAGAAGCACCAGAAGAUUUGUCAUGCUGAGAGAUAAUUCAGGAGACCCCGCCGACC
CUCACAAGGUGUACGCCCUGUCCAGAGAGCUGUGUUGGAGAGAGGGCCCCGGAACCGACCAGACCGAGGC
CGAGGCUCCAGCUGCCGUGCCACCCCCCCAAGGCGGACCACCCGGCCCCUUCUUGGCACAUACGCACGCCGG
CCUCCAGGCUCCCGGCCCUCUGCCCGCCCCUGCUGGUGACAAAGGCGAUCUGCUGCUGCAAGCCGUCCAGC
AAUCCUGCUUGGCUGACCACCUGCUGACCGCUAGCUGGGGAGCCGACCCCGUUCCCACCAAGGCUCCCGGA
GAAGGACAGGAGGGCCUGCCCCUUACCGGCGCUUGCGCGGGGGGCCCUGGCUUGCCUGCCGGCGAACUGU
ACGGCUGGGCCGUGGAGACCACGCCUUCCCCCGAGGGCGUGUCCAGCCUGGACGAUGAUGACCUGGAUCU
GUGCCUGGACAGCGCCAACGACCUGUACGAUGACAUCGAGUGCUUUUUGAUGGAGCUGGAGCAGCCCGCC
(constitutively active truncated Hu IRF7 1-246 + 468-503 plus
S475D/S476D/S477D/S479D/S483D/S487D; P036 without epitope tag) 219
AUGGCCCUGGCCCCCGAGAGAGCCGCGCCCAGAGUGCUGUUCGGCGAAUGGCUGCUGGGCGAGAUCAGCA
GCGGCUGCUAUGAGGGCCUGCAGUGGCUCGACGAAGCCAGGACGUGCUUCAGAGUCCCCUGGAAGCACUU
CGCCAGAAAGGAUCUGAGCGAGGCUGACGCCAGAAUCUUCAAGGCCUGGGCAGUUGCGCGUGGGAGAUGG
CCCCCCAGCUCGCGGGGCGGCGGUCCCCCCCCUGAGGCCGAGACCGCCGAAAGAGCCGGAUGGAAAACCAAC
UUUCGAUGCGCCCUCAGAAGCACCAGACGGUUUGUGAUGCUGAGAGAUAACAGCGGCGACCCUGCAGACC
CCCAUAAAGUGUAUGCCCUGAGCAGAGAGCUGUGUUGGCGAGAGGGCCCCGGAACCGACCAAACCGAGGC
CGAGGCCCCCGCCGCCGUACCCCCCCCUCAAGGCCCCCAGCCUGCUGCUCUGACCACGGGAGAAGCCGCCGC
UCCUGAGAGCCCCCACCAAGCCGAGCCCUAUCUGAGCCCUAGCCCCAGCGCCUGCACCGCCGUGCAGGAGCC
CUCACCGGGCGCCCUAGACGUGACCAUCAUGUACAAGGGGCGCACGGUGCUGCAAAAGGUGGUGGGCCAC
CCCAGCUGCACCUUCCUGUACGGCCCCCCCGACCCUGCCGUGAGAGCCACCGACCCCCAGCAAGUCGCCUUC
CCCAGCCCCGCCGAGCUGCCCGACCAGAAGCAGCUGAGGUACACCGAGGAGUUGCUGAGACAUGUGGCCCC
CGGCUUGCACCUCGAGCUGAGAGGCCCGCAGCUCUGGGCCAGAAGAAUGGGCAAGUGCAAGGUGUACUGG
GAGGUGGGCGGCCCCCCCGGCAGCGCGAGCCCAAGCACCCCGGCCUGCCUGCUGCCUAGAAACUGCGACACC
CCUAUCUUCGACUUCAGAGUAUUUUUCCAGGAGCUGGUCGAGUUCAGGGCCAGACAGCGUAGAGGCAGCC
CCAGAUACACCAUCUACCUUGGAUUCGGCCAGGACCUGAGCGCCGGCAGACCCAAAGAGAAGUCCCUGGUA
CUGGUGAAGCUAGAGCCCUGGCUGUGUAGGGUGCAUCUGGAAGGCACCCAAAGAGAGGGCGUAAGCUCGC
UUGACAGCAGCAGCCUCAGCCUGUGCCUGAGCAGCGCUAACAGCUUAUACGACGACAUCGAGUGCUUCCU
GAUGGAGCUGGAACAACCCGCC (truncated Hu IRF7 1-151 + 247-503; P038
without epitope tag; null mutation) 220
AUGGGCGGCCCUCCCGGGCCUUUCCUGGCCCAUACACACGCCGGCCUACAGGCUCCUGGCCCUCUGCCCG-
CC
CCGGCCGGCGACAAGGGCGACCUCCUGCUGCAGGCCGUGCAGCAGUCCUGUCUGGCCGACCACCUGCUGAC
UGCUAGCUGGGGCGCCGAUCCCGUGCCCACCAAGGCCCCAGGAGAGGGGCAAGAGGGCCUGCCUCUAACCG
GCGCAUGCGCAGGUGGACCAGGCCUCCCCGCCGGCGAGCUGUAUGGUUGGGCCGUGGAGACAACCCCCAGC
CCCGGCCCGCAGCCUGCUGCGCUGACCACAGGCGAGGCCGCUGCCCCUGAGAGCCCCCACCAAGCUGAACCC
UACCUGAGCCCCAGCCCCUCUGCCUGCACAGCGGUGCAGGAGCCCAGUCCCGGCGCCUUGGACGUGACCAU
CAUGUAUAAGGGCAGGACUGUGUUACAAAAGGUAGUGGGCCACCCAAGUUGUACCUUUCUGUACGGGCCC
CCCGACCCAGCCGUGCGCGCCACCGACCCCCAGCAGGUGGCCUUCCCCAGCCCCGCUGAGUUGCCCGAUCAG
AAACAACUCCGGUACACCGAGGAAUUACUUAGACAUGUGGCUCCCGGCCUGCAUCUGGAGCUUAGAGGUC
CACAGUUGUGGGCCAGAAGAAUGGGCAAGUGCAAGGUUUAUUGGGAGGUCGGAGGCCCCCCGGGCAGCG
CCAGCCCCAGCACCCCCGCCUGUCUUCUGCCCAGAAACUGCGACACCCCAAUCUUCGAUUUCAGAGUGUUU
UUCCAGGAACUGGUGGAGUUCAGAGCAAGGCAAAGAAGAGGCAGCCCUAGAUACACCAUCUACCUGGGCU
UUGGCCAAGACCUGAGCGCCGGCAGACCCAAGGAAAAAUCCCUGGUCCUGGUGAAACUGGAGCCCUGGCU
GUGCAGAGUCCACCUGGAGGGCACCCAGAGAGAGGGCGUGAGCAGCCUGGACUCGAGCAGCCUGUCCCUG
UGUCUGAGCAGCGCGAAUUCGCUAUAUGACGACAUCGAAUGCUUUCUGAUGGAGCUGGAACAGCCCGCC
(truncated Hu IRF7 152-503; P039 without epitope tag; null
mutation) 221
AUGCCUCACAGCAGCCUCCACCCUAGCAUCCCUUGCCCUAGAGGCCACGGCGCCCAGAAGGCCGCCCUCG-
UG
CUUUUAAGCGCCUGCUUGGUGACCCUUUGGGGCUUGGGCGAGCCUCCAGAGCACACCUUGAGAUAUUUG
GUGCUCCACCUGGCCAGCCUUCAGCUGGGCUUGUUACUCAACGGCGUGUGCAGCCUGGCCGAGGAGCUGA
GACACAUCCACAGCAGAUACAGAGGCAGCUACUGGAGAACCGUGAGAGCGUGUCUGGGCUGCCCUCUGAG
AAGAGGCGCCUUGCUUCUUCUCAGUAUCUACUUCUACUACUCCCUGCCUAACGCCGUGGGCCCUCCUUUC
ACCUGGAUGCUGGCACUGCUCGGCCUCAGCCAGGCCCUGAACAUCUUGUUGGGCUUGAAGGGCCUGGCCC
CUGCCGAGAUCAGCGCCGUGUGCGAGAAGGGCAACUUCAACAUGGCCCACGGAUUGGCUUGGAGCUACUA
CAUCGGCUACCUGAGACUGAUCCUGCCUGAGCUGCAGGCCAGAAUCAGAACCUACAACCAGCACUACAACA
ACCUGCUGCGCGGCGCAGUGAGCCAGAGACUGUAUAUUCUGCUGCCUCUGGACUGCGGCGUGCCUGACAA
CCUGAGCAUGGCCGACCCUAACAUCAGAUUCCUGGACAAGCUGCCUCAGCAGACCGGCGACCACGCCGGCA
UCAAGGACAGAGUGUACAGCAACAGCAUCUAUGAGCUGCUCGAGAAUGGCCAGAGAGCCGGCACCUGCGU
GCUGGAGUACGCCACCCCUCUGCAGACCCUGUUCGCCAUGAGCCAGUAUAGUCAAGCUGGCUUCAGCAGA
GAGGACAGACUGGAGCAGGCCAAGCUGUUCUGCAGAACCCUGGAGGACAUUCUGGCUGACGCCCCUGAGA
GCCAGAACAACUGCCGACUGAUCGCCUACCAGGAACCAGCCGACGACAGCAGCUUCAGUCUUUCUCAGGAG
GUUCUUCGCCACUUGCGCCAGGAGGAGAAGGAGGAGGUGACCGUGGGCAGCCUGAAGACCUCCGCAGUCC
CUAGCACCAGCACCAUGAGUCAGGAGCCGGAGCUAUUAAUCAGCGGCAUGGAGAAGCCUCUUCCACUCCGA
ACCGACUUCAGCGCCACCAACUUCAGCCUGCUGAAGCAGGCAGGUGACGUUGAGGAGAAUCCGGGACCUA
UGACCGAGUACAAGCUGGUGGUUGUGGGCGCCGACGGCGUGGGCAAGAGCGCCCUGACCAUCCAGCUGAU
CCAG (KRAS(G12D)25mer_nt.STING(V155M)) 222
AUGACCGAGUACAAGCUAGUAGUCGUGGGCGCCGACGGCGUGGGCAAGAGCGCCCUCACCAUCCAGCUAA
UCCAGGCCACCAACUUCAGCUUGCUCAAGCAGGCCGGCGACGUGGAGGAGAACCCAGGCCCUAUGCCUCAC
AGCAGCCUUCACCCUAGCAUCCCUUGCCCUAGAGGCCACGGCGCCCAGAAGGCCGCCCUGGUGCUGCUGAG
CGCCUGCCUGGUGACCCUGUGGGGCCUGGGCGAGCCUCCUGAGCACACCCUGAGAUAUCUGGUGCUUCAC
CUGGCCAGUUUACAGCUGGGCCUGCUUCUUAACGGCGUGUGCAGCCUGGCCGAGGAGCUGAGACACAUCC
ACAGCAGAUACAGAGGCAGCUACUGGAGAACCGUGAGAGCCUGCCUAGGCUGCCCUCUGAGAAGAGGCGC
UCUGUUGCUACUUUCCAUCUACUUCUACUACUCCCUGCCUAACGCCGUGGGCCCUCCUUUCACUUGGAUG
CUGGCGUUGCUGGGUCUGAGCCAGGCCCUGAACAUCCUUCUCGGUCUGAAGGGCCUGGCCCCUGCCGAGA
UCAGCGCCGUGUGCGAGAAGGGCAACUUCAACAUGGCCCACGGACUCGCCUGGAGCUACUACAUCGGCUAC
CUGAGACUGAUCCUGCCUGAGCUGCAGGCCAGAAUCAGAACCUACAACCAGCACUACAACAACCUGCUGCG
GGGCGCCGUGAGCCAGAGACUGUAUAUACUUCUUCCUCUGGACUGCGGCGUGCCUGACAACCUGAGCAUG
GCCGACCCUAACAUCAGAUUCCUGGACAAGCUGCCUCAGCAGACCGGCGACCACGCCGGCAUCAAGGACAG
AGUGUACAGCAACUCCAUUUAUGAGCUGCUCGAGAAUGGCCAGAGAGCCGGCACCUGCGUGCUGGAGUAC
GCCACCCCUCUGCAGACCCUGUUCGCCAUGAGCCAGUACAGUCAGGCUGGAUUCAGCAGAGAGGACAGACU
GGAGCAGGCCAAGCUGUUCUGCAGGACACUGGAGGACAUACUAGCAGACGCCCCUGAGAGCCAGAACAACU
GCAGACUGAUUGCCUACCAGGAGCCUGCGGACGACAGCUCCUUCAGUCUGAGUCAGGAGGUGUUGCGGCA
CUUACGCCAAGAAGAGAAGGAGGAGGUGACCGUGGGCAGCCUGAAGACUAGCGCUGUGCCUAGCACCAGC
ACAAUGUCACAGGAGCCGGAAUUGCUAAUCAGCGGCAUGGAGAAGCCUCUCCCAUUACGUACCGACUUCA
GC (KRAS(G12D)25mer_ct.STING(V155M)) 223
AUGCCUCACAGCAGCCUUCACCCUAGCAUCCCUUGCCCUAGAGGCCACGGCGCCCAGAAGGCCGCCCUAG-
UG
CUCCUUAGCGCCUGCCUCGUGACCCUAUGGGGCUUAGGCGAGCCUCCAGAGCACACCUUGAGAUACCUCGU
CCUCCACCUGGCUAGUCUACAGCUGGGCCUUCUCCUCAACGGCGUGUGCAGCCUGGCCGAGGAGCUGAGA
CACAUCCACAGCAGAUACAGAGGCAGCUACUGGAGAACCGUGAGAGCGUGCCUGGGCUGCCCUCUGAGAA
GAGGCGCACUGCUGUUACUCAGCAUCUACUUCUACUACUCACUGCCAAACGCCGUGGGCCCUCCUUUCACC
UGGAUGCUGGCCUUGCUCGGAUUGAGCCAGGCCCUGAACAUUUUACUGGGAUUGAAGGGCCUGGCCCCU
GCCGAGAUCAGCGCCGUGUGCGAGAAGGGCAACUUCAACAUGGCCCACGGCCUAGCUUGGAGCUACUACA
UCGGCUACCUGAGACUGAUCCUGCCUGAGCUGCAGGCCAGAAUCAGAACCUACAACCAGCACUACAACAAC
CUGCUGCGUGGAGCGGUGAGCCAGAGACUGUAUAUCCUCCUGCCUCUGGACUGCGGAGUGCCUGACAACC
UGAGCAUGGCCGACCCUAACAUCAGAUUCCUGGACAAGCUGCCUCAGCAGACCGGCGACCACGCCGGCAUC
AAGGACAGAGUGUACAGCAACUCAAUCUACGAGCUGUUGGAGAAUGGCCAGAGAGCCGGCACCUGCGUGC
UGGAGUACGCCACCCCUCUGCAGACCCUGUUCGCCAUGAGCCAGUACUCUCAGGCAGGCUUCAGCAGAGAG
GACAGACUGGAGCAGGCCAAGCUGUUCUGCAGAACCCUGGAGGACAUCCUGGCGGACGCCCCUGAGAGCCA
GAACAACUGCCGGCUUAUCGCCUACCAGGAGCCAGCAGACGACAGCAGCUUCUCUCUCUCACAAGAGGUAC
UGCGCCAUCUUCGCCAGGAGGAGAAGGAGGAGGUGACCGUGGGCAGCCUGAAGACAUCCGCCGUACCUAG
CACCAGCACCAUGUCUCAGGAACCGGAACUGUUGAUCAGCGGCAUGGAGAAGCCUCUGCCACUGCGCACCG
ACUUCAGCGCCACCAACUUCUCCCUACUGAAGCAAGCCGGUGACGUUGAAGAGAACCCUGGCCCUAUGACC
GAGUACAAGCUGGUAGUAGUAGGCGCCGACGGCGUGGGCAAGAGCGCCCUGACCAUCCAGCUGAUCCAGA
UGACUGAAUAUAAGCUUGUCGUCGUGGGCGCAGAUGGCGUUGGUAAGAGCGCACUUACAAUUCAACUCA
UUCAGAUGACGGAGUAUAAGCUGGUGGUGGUCGGAGCUGACGGCGUAGGCAAGAGUGCCCUUACUAUUC
AGCUAAUUCAG (KRAS(G12D)25mer^3_nt.STING(V155M)) 224
AUGACCGAGUACAAGCUUGUGGUGGUUGGCGCCGACGGCGUGGGCAAGAGCGCCUUAACCAUCCAGCUUA
UCCAGAUGACAGAGUAUAAGCUAGUGGUGGUCGGCGCAGACGGAGUGGGAAAGAGUGCAUUAACUAUUC
AACUCAUCCAAAUGACCGAAUACAAGCUAGUAGUUGUGGGUGCAGAUGGCGUCGGCAAGUCUGCACUGAC
AAUUCAGCUCAUCCAGGCCACCAACUUCAGCCUGCUGAAGCAGGCCGGCGACGUGGAGGAGAACCCUGGCC
CUAUGCCUCACAGCAGCCUGCACCCUAGCAUCCCUUGCCCUAGAGGCCACGGCGCCCAGAAGGCCGCCCUGG
UGCUGCUGAGCGCCUGCCUGGUGACCCUGUGGGGCCUGGGCGAGCCUCCUGAGCACACCCUGAGAUACCU
AGUUUUGCACCUGGCUUCUCUGCAGCUGGGCCUACUGCUCAACGGCGUGUGCAGCCUGGCCGAGGAGCUG
AGACACAUCCACAGCAGAUACAGAGGCAGCUACUGGAGAACCGUGAGAGCAUGCUUAGGCUGCCCUCUGA
GAAGAGGCGCUCUGCUCCUCUUGUCCAUCUACUUCUACUACUCGCUACCUAACGCCGUGGGCCCUCCUUUC
ACCUGGAUGCUGGCCCUCUUGGGAUUAAGCCAGGCCCUGAACAUCUUGCUGGGACUGAAGGGCCUGGCCC
CUGCCGAGAUCAGCGCCGUGUGCGAGAAGGGCAACUUCAACAUGGCCCACGGACUCGCUUGGAGCUACUA
CAUCGGCUACCUGAGACUGAUCCUGCCUGAGCUGCAGGCCAGAAUCAGAACCUACAACCAGCACUACAACA
ACCUGCUGCGGGGAGCAGUGAGCCAGAGACUGUAUAUUCUGCUCCCUCUGGACUGCGGCGUGCCUGACAA
CCUGAGCAUGGCCGACCCUAACAUCAGAUUCCUGGACAAGCUGCCUCAGCAGACCGGCGACCACGCCGGCA
UCAAGGACAGAGUGUACAGCAACAGCAUUUACGAGCUGCUGGAGAACGGCCAGAGAGCCGGCACCUGCGU
GCUGGAGUACGCCACCCCUCUGCAGACCCUGUUCGCCAUGAGCCAGUACUCCCAGGCAGGAUUCAGCAGAG
AGGACAGACUGGAGCAGGCCAAGCUGUUCUGCCGUACUCUUGAGGACAUCCUUGCAGACGCCCCUGAGAG
CCAGAACAACUGCCGGUUGAUUGCCUACCAGGAACCGGCAGACGACAGCUCAUUCUCCUUGUCUCAGGAG
GUCCUUAGACACCUGCGGCAGGAGGAGAAGGAGGAGGUGACCGUGGGCAGCCUGAAGACAUCCGCCGUGC
CUAGCACGUCUACCAUGUCCCAGGAGCCGGAACUGCUAAUCAGCGGCAUGGAGAAGCCUCUGCCUCUCAGG
ACCGACUUCAGC (KRAS(G12D)25mer^3_ct.STING(V155M)) 225
AUGCCCCAUAGCAGCCUGCACCCCAGCAUCCCCUGCCCCAGAGGCCACGGCGCCCAGAAGGCCGCCCUGG-
UC
CUGCUGAGCGCAUGCCUGGUCACCCUGUGGGGCCUGGGCGAGCCCCCCGAGCACACCCUGAGAUACCUGGU
GCUGCACCUCGCCAGCCUGCAGCUGGGCCUGCUGCUGAACGGCGUGUGCAGCCUGGCCGAGGAGCUGAGA
CACAUCCACAGCAGAUAUAGAGGCAGCUACUGGAGAACCGUGAGAGCUUGCCUCGGCUGCCCCCUGAGAAG
AGGCGCCCUGCUGCUGCUGAGCAUCUACUUUUACUACAGCCUGCCCAACGCUGUGGGCCCCCCUUUCACGU
GGAUGCUCGCCCUGCUGGGACUGAGCCAGGCCCUGAACAUCCUGCUGGGCCUUAAGGGCCUAGCCCCCGCC
GAGAUCAGCGCCGUGUGCGAGAAGGGCAACUUCAAUGUGGCCCACGGCCUGGCCUGGAGCUACUACAUCG
GCUACCUGAGACUGAUCCUGCCCGAGCUGCAGGCCAGAAUCAGAACCUACAAUCAGCACUACAACAACCUG
CUGAGAGGCGCCGUGAGCCAGAGACUGUACAUCCUGCUGCCCCUGGACUGCGGCGUGCCCGACAACCUCAG
CAUGGCCGACCCCAACAUCAGAUUCCUGGACAAGCUGCCCCAGCAGACCGGCGACCACGCCGGCAUCAAGGA
UCGCGUGUACAGCAACAGCAUCUACGAGCUGCUGGAAAACGGCCAGAGAGCCGGAACCUGCGUGCUGGAG
UACGCCACACCCCUGCAGACCCUGUUCGCCAUGAGCCAGUACAGCCAGGCCGGCUUCAGCAGAGAGGACAA
GCUGGAGCAGGCCAAGCUGUUCUGCAGAACCCUGGAGGAUAUCCUCGCCGACGCCCCCGAGAGCCAGAACA
ACUGCAGGCUGAUCGCGUACCAGGAGCCCGCUGACGACAGCAGCUUUAGCCUGAGCCAGGAGGUGCUGAG
ACAUCUGCGUCAAGAGGAAAAGGAGGAGGUGACCGUGGGCUCCCUGAAGACCAGCGCCGUGCCCAGCACCA
GCACCAUGAGCCAGGAGCCCGAGCUGCUGAUCAGCGGCAUGGAGAAGCCACUGCCCCUCAGAACCGACUUC
AGCACC (Hu STING (R284K) var; no epitope tag) 226 ATIGTAMYK (EBV
BRLF1 peptide) 227 SIIPSGPLK (FLU peptide) 228 AVDLSHFLK (HIV NEF
peptide) 229 AVFDRKSDAK (EBV peptide) 230 YVNVNMGLK (HBV core
antigen peptide) 231 RVCEKMALY (HC peptide) 232 KLGGALQAK (CMV
peptide)
Sequence CWU 1
1
2321379PRTArtificial SequenceSynthetic huSTING(V155M); no epitope
tag 1Met Pro His Ser Ser Leu His Pro Ser Ile Pro Cys Pro Arg Gly
His1 5 10 15Gly Ala Gln Lys Ala Ala Leu Val Leu Leu Ser Ala Cys Leu
Val Thr 20 25 30Leu Trp Gly Leu Gly Glu Pro Pro Glu His Thr Leu Arg
Tyr Leu Val 35 40 45Leu His Leu Ala Ser Leu Gln Leu Gly Leu Leu Leu
Asn Gly Val Cys 50 55 60Ser Leu Ala Glu Glu Leu Arg His Ile His Ser
Arg Tyr Arg Gly Ser65 70 75 80Tyr Trp Arg Thr Val Arg Ala Cys Leu
Gly Cys Pro Leu Arg Arg Gly 85 90 95Ala Leu Leu Leu Leu Ser Ile Tyr
Phe Tyr Tyr Ser Leu Pro Asn Ala 100 105 110Val Gly Pro Pro Phe Thr
Trp Met Leu Ala Leu Leu Gly Leu Ser Gln 115 120 125Ala Leu Asn Ile
Leu Leu Gly Leu Lys Gly Leu Ala Pro Ala Glu Ile 130 135 140Ser Ala
Val Cys Glu Lys Gly Asn Phe Asn Met Ala His Gly Leu Ala145 150 155
160Trp Ser Tyr Tyr Ile Gly Tyr Leu Arg Leu Ile Leu Pro Glu Leu Gln
165 170 175Ala Arg Ile Arg Thr Tyr Asn Gln His Tyr Asn Asn Leu Leu
Arg Gly 180 185 190Ala Val Ser Gln Arg Leu Tyr Ile Leu Leu Pro Leu
Asp Cys Gly Val 195 200 205Pro Asp Asn Leu Ser Met Ala Asp Pro Asn
Ile Arg Phe Leu Asp Lys 210 215 220Leu Pro Gln Gln Thr Gly Asp His
Ala Gly Ile Lys Asp Arg Val Tyr225 230 235 240Ser Asn Ser Ile Tyr
Glu Leu Leu Glu Asn Gly Gln Arg Ala Gly Thr 245 250 255Cys Val Leu
Glu Tyr Ala Thr Pro Leu Gln Thr Leu Phe Ala Met Ser 260 265 270Gln
Tyr Ser Gln Ala Gly Phe Ser Arg Glu Asp Arg Leu Glu Gln Ala 275 280
285Lys Leu Phe Cys Arg Thr Leu Glu Asp Ile Leu Ala Asp Ala Pro Glu
290 295 300Ser Gln Asn Asn Cys Arg Leu Ile Ala Tyr Gln Glu Pro Ala
Asp Asp305 310 315 320Ser Ser Phe Ser Leu Ser Gln Glu Val Leu Arg
His Leu Arg Gln Glu 325 330 335Glu Lys Glu Glu Val Thr Val Gly Ser
Leu Lys Thr Ser Ala Val Pro 340 345 350Ser Thr Ser Thr Met Ser Gln
Glu Pro Glu Leu Leu Ile Ser Gly Met 355 360 365Glu Lys Pro Leu Pro
Leu Arg Thr Asp Phe Ser 370 3752379PRTArtificial SequenceSynthetic
Hu STING(R284T); no epitope tag 2Met Pro His Ser Ser Leu His Pro
Ser Ile Pro Cys Pro Arg Gly His1 5 10 15Gly Ala Gln Lys Ala Ala Leu
Val Leu Leu Ser Ala Cys Leu Val Thr 20 25 30Leu Trp Gly Leu Gly Glu
Pro Pro Glu His Thr Leu Arg Tyr Leu Val 35 40 45Leu His Leu Ala Ser
Leu Gln Leu Gly Leu Leu Leu Asn Gly Val Cys 50 55 60Ser Leu Ala Glu
Glu Leu Arg His Ile His Ser Arg Tyr Arg Gly Ser65 70 75 80Tyr Trp
Arg Thr Val Arg Ala Cys Leu Gly Cys Pro Leu Arg Arg Gly 85 90 95Ala
Leu Leu Leu Leu Ser Ile Tyr Phe Tyr Tyr Ser Leu Pro Asn Ala 100 105
110Val Gly Pro Pro Phe Thr Trp Met Leu Ala Leu Leu Gly Leu Ser Gln
115 120 125Ala Leu Asn Ile Leu Leu Gly Leu Lys Gly Leu Ala Pro Ala
Glu Ile 130 135 140Ser Ala Val Cys Glu Lys Gly Asn Phe Asn Val Ala
His Gly Leu Ala145 150 155 160Trp Ser Tyr Tyr Ile Gly Tyr Leu Arg
Leu Ile Leu Pro Glu Leu Gln 165 170 175Ala Arg Ile Arg Thr Tyr Asn
Gln His Tyr Asn Asn Leu Leu Arg Gly 180 185 190Ala Val Ser Gln Arg
Leu Tyr Ile Leu Leu Pro Leu Asp Cys Gly Val 195 200 205Pro Asp Asn
Leu Ser Met Ala Asp Pro Asn Ile Arg Phe Leu Asp Lys 210 215 220Leu
Pro Gln Gln Thr Gly Asp His Ala Gly Ile Lys Asp Arg Val Tyr225 230
235 240Ser Asn Ser Ile Tyr Glu Leu Leu Glu Asn Gly Gln Arg Ala Gly
Thr 245 250 255Cys Val Leu Glu Tyr Ala Thr Pro Leu Gln Thr Leu Phe
Ala Met Ser 260 265 270Gln Tyr Ser Gln Ala Gly Phe Ser Arg Glu Asp
Thr Leu Glu Gln Ala 275 280 285Lys Leu Phe Cys Arg Thr Leu Glu Asp
Ile Leu Ala Asp Ala Pro Glu 290 295 300Ser Gln Asn Asn Cys Arg Leu
Ile Ala Tyr Gln Glu Pro Ala Asp Asp305 310 315 320Ser Ser Phe Ser
Leu Ser Gln Glu Val Leu Arg His Leu Arg Gln Glu 325 330 335Glu Lys
Glu Glu Val Thr Val Gly Ser Leu Lys Thr Ser Ala Val Pro 340 345
350Ser Thr Ser Thr Met Ser Gln Glu Pro Glu Leu Leu Ile Ser Gly Met
355 360 365Glu Lys Pro Leu Pro Leu Arg Thr Asp Phe Ser 370
3753379PRTArtificial SequenceSynthetic hu STING (R284M); no epitope
tag 3Met Pro His Ser Ser Leu His Pro Ser Ile Pro Cys Pro Arg Gly
His1 5 10 15Gly Ala Gln Lys Ala Ala Leu Val Leu Leu Ser Ala Cys Leu
Val Thr 20 25 30Leu Trp Gly Leu Gly Glu Pro Pro Glu His Thr Leu Arg
Tyr Leu Val 35 40 45Leu His Leu Ala Ser Leu Gln Leu Gly Leu Leu Leu
Asn Gly Val Cys 50 55 60Ser Leu Ala Glu Glu Leu Arg His Ile His Ser
Arg Tyr Arg Gly Ser65 70 75 80Tyr Trp Arg Thr Val Arg Ala Cys Leu
Gly Cys Pro Leu Arg Arg Gly 85 90 95Ala Leu Leu Leu Leu Ser Ile Tyr
Phe Tyr Tyr Ser Leu Pro Asn Ala 100 105 110Val Gly Pro Pro Phe Thr
Trp Met Leu Ala Leu Leu Gly Leu Ser Gln 115 120 125Ala Leu Asn Ile
Leu Leu Gly Leu Lys Gly Leu Ala Pro Ala Glu Ile 130 135 140Ser Ala
Val Cys Glu Lys Gly Asn Phe Asn Val Ala His Gly Leu Ala145 150 155
160Trp Ser Tyr Tyr Ile Gly Tyr Leu Arg Leu Ile Leu Pro Glu Leu Gln
165 170 175Ala Arg Ile Arg Thr Tyr Asn Gln His Tyr Asn Asn Leu Leu
Arg Gly 180 185 190Ala Val Ser Gln Arg Leu Tyr Ile Leu Leu Pro Leu
Asp Cys Gly Val 195 200 205Pro Asp Asn Leu Ser Met Ala Asp Pro Asn
Ile Arg Phe Leu Asp Lys 210 215 220Leu Pro Gln Gln Thr Gly Asp His
Ala Gly Ile Lys Asp Arg Val Tyr225 230 235 240Ser Asn Ser Ile Tyr
Glu Leu Leu Glu Asn Gly Gln Arg Ala Gly Thr 245 250 255Cys Val Leu
Glu Tyr Ala Thr Pro Leu Gln Thr Leu Phe Ala Met Ser 260 265 270Gln
Tyr Ser Gln Ala Gly Phe Ser Arg Glu Asp Met Leu Glu Gln Ala 275 280
285Lys Leu Phe Cys Arg Thr Leu Glu Asp Ile Leu Ala Asp Ala Pro Glu
290 295 300Ser Gln Asn Asn Cys Arg Leu Ile Ala Tyr Gln Glu Pro Ala
Asp Asp305 310 315 320Ser Ser Phe Ser Leu Ser Gln Glu Val Leu Arg
His Leu Arg Gln Glu 325 330 335Glu Lys Glu Glu Val Thr Val Gly Ser
Leu Lys Thr Ser Ala Val Pro 340 345 350Ser Thr Ser Thr Met Ser Gln
Glu Pro Glu Leu Leu Ile Ser Gly Met 355 360 365Glu Lys Pro Leu Pro
Leu Arg Thr Asp Phe Ser 370 3754379PRTArtificial SequenceSynthetic
Hu STING (R284K); no epitope tag 4Met Pro His Ser Ser Leu His Pro
Ser Ile Pro Cys Pro Arg Gly His1 5 10 15Gly Ala Gln Lys Ala Ala Leu
Val Leu Leu Ser Ala Cys Leu Val Thr 20 25 30Leu Trp Gly Leu Gly Glu
Pro Pro Glu His Thr Leu Arg Tyr Leu Val 35 40 45Leu His Leu Ala Ser
Leu Gln Leu Gly Leu Leu Leu Asn Gly Val Cys 50 55 60Ser Leu Ala Glu
Glu Leu Arg His Ile His Ser Arg Tyr Arg Gly Ser65 70 75 80Tyr Trp
Arg Thr Val Arg Ala Cys Leu Gly Cys Pro Leu Arg Arg Gly 85 90 95Ala
Leu Leu Leu Leu Ser Ile Tyr Phe Tyr Tyr Ser Leu Pro Asn Ala 100 105
110Val Gly Pro Pro Phe Thr Trp Met Leu Ala Leu Leu Gly Leu Ser Gln
115 120 125Ala Leu Asn Ile Leu Leu Gly Leu Lys Gly Leu Ala Pro Ala
Glu Ile 130 135 140Ser Ala Val Cys Glu Lys Gly Asn Phe Asn Val Ala
His Gly Leu Ala145 150 155 160Trp Ser Tyr Tyr Ile Gly Tyr Leu Arg
Leu Ile Leu Pro Glu Leu Gln 165 170 175Ala Arg Ile Arg Thr Tyr Asn
Gln His Tyr Asn Asn Leu Leu Arg Gly 180 185 190Ala Val Ser Gln Arg
Leu Tyr Ile Leu Leu Pro Leu Asp Cys Gly Val 195 200 205Pro Asp Asn
Leu Ser Met Ala Asp Pro Asn Ile Arg Phe Leu Asp Lys 210 215 220Leu
Pro Gln Gln Thr Gly Asp His Ala Gly Ile Lys Asp Arg Val Tyr225 230
235 240Ser Asn Ser Ile Tyr Glu Leu Leu Glu Asn Gly Gln Arg Ala Gly
Thr 245 250 255Cys Val Leu Glu Tyr Ala Thr Pro Leu Gln Thr Leu Phe
Ala Met Ser 260 265 270Gln Tyr Ser Gln Ala Gly Phe Ser Arg Glu Asp
Lys Leu Glu Gln Ala 275 280 285Lys Leu Phe Cys Arg Thr Leu Glu Asp
Ile Leu Ala Asp Ala Pro Glu 290 295 300Ser Gln Asn Asn Cys Arg Leu
Ile Ala Tyr Gln Glu Pro Ala Asp Asp305 310 315 320Ser Ser Phe Ser
Leu Ser Gln Glu Val Leu Arg His Leu Arg Gln Glu 325 330 335Glu Lys
Glu Glu Val Thr Val Gly Ser Leu Lys Thr Ser Ala Val Pro 340 345
350Ser Thr Ser Thr Met Ser Gln Glu Pro Glu Leu Leu Ile Ser Gly Met
355 360 365Glu Lys Pro Leu Pro Leu Arg Thr Asp Phe Ser 370
3755379PRTArtificial SequenceSynthetic Hu STING(N154S); no epitope
tag 5Met Pro His Ser Ser Leu His Pro Ser Ile Pro Cys Pro Arg Gly
His1 5 10 15Gly Ala Gln Lys Ala Ala Leu Val Leu Leu Ser Ala Cys Leu
Val Thr 20 25 30Leu Trp Gly Leu Gly Glu Pro Pro Glu His Thr Leu Arg
Tyr Leu Val 35 40 45Leu His Leu Ala Ser Leu Gln Leu Gly Leu Leu Leu
Asn Gly Val Cys 50 55 60Ser Leu Ala Glu Glu Leu Arg His Ile His Ser
Arg Tyr Arg Gly Ser65 70 75 80Tyr Trp Arg Thr Val Arg Ala Cys Leu
Gly Cys Pro Leu Arg Arg Gly 85 90 95Ala Leu Leu Leu Leu Ser Ile Tyr
Phe Tyr Tyr Ser Leu Pro Asn Ala 100 105 110Val Gly Pro Pro Phe Thr
Trp Met Leu Ala Leu Leu Gly Leu Ser Gln 115 120 125Ala Leu Asn Ile
Leu Leu Gly Leu Lys Gly Leu Ala Pro Ala Glu Ile 130 135 140Ser Ala
Val Cys Glu Lys Gly Asn Phe Ser Val Ala His Gly Leu Ala145 150 155
160Trp Ser Tyr Tyr Ile Gly Tyr Leu Arg Leu Ile Leu Pro Glu Leu Gln
165 170 175Ala Arg Ile Arg Thr Tyr Asn Gln His Tyr Asn Asn Leu Leu
Arg Gly 180 185 190Ala Val Ser Gln Arg Leu Tyr Ile Leu Leu Pro Leu
Asp Cys Gly Val 195 200 205Pro Asp Asn Leu Ser Met Ala Asp Pro Asn
Ile Arg Phe Leu Asp Lys 210 215 220Leu Pro Gln Gln Thr Gly Asp His
Ala Gly Ile Lys Asp Arg Val Tyr225 230 235 240Ser Asn Ser Ile Tyr
Glu Leu Leu Glu Asn Gly Gln Arg Ala Gly Thr 245 250 255Cys Val Leu
Glu Tyr Ala Thr Pro Leu Gln Thr Leu Phe Ala Met Ser 260 265 270Gln
Tyr Ser Gln Ala Gly Phe Ser Arg Glu Asp Arg Leu Glu Gln Ala 275 280
285Lys Leu Phe Cys Arg Thr Leu Glu Asp Ile Leu Ala Asp Ala Pro Glu
290 295 300Ser Gln Asn Asn Cys Arg Leu Ile Ala Tyr Gln Glu Pro Ala
Asp Asp305 310 315 320Ser Ser Phe Ser Leu Ser Gln Glu Val Leu Arg
His Leu Arg Gln Glu 325 330 335Glu Lys Glu Glu Val Thr Val Gly Ser
Leu Lys Thr Ser Ala Val Pro 340 345 350Ser Thr Ser Thr Met Ser Gln
Glu Pro Glu Leu Leu Ile Ser Gly Met 355 360 365Glu Lys Pro Leu Pro
Leu Arg Thr Asp Phe Ser 370 3756379PRTArtificial SequenceSynthetic
Hu STING(V147L); no epitope tag 6Met Pro His Ser Ser Leu His Pro
Ser Ile Pro Cys Pro Arg Gly His1 5 10 15Gly Ala Gln Lys Ala Ala Leu
Val Leu Leu Ser Ala Cys Leu Val Thr 20 25 30Leu Trp Gly Leu Gly Glu
Pro Pro Glu His Thr Leu Arg Tyr Leu Val 35 40 45Leu His Leu Ala Ser
Leu Gln Leu Gly Leu Leu Leu Asn Gly Val Cys 50 55 60Ser Leu Ala Glu
Glu Leu Arg His Ile His Ser Arg Tyr Arg Gly Ser65 70 75 80Tyr Trp
Arg Thr Val Arg Ala Cys Leu Gly Cys Pro Leu Arg Arg Gly 85 90 95Ala
Leu Leu Leu Leu Ser Ile Tyr Phe Tyr Tyr Ser Leu Pro Asn Ala 100 105
110Val Gly Pro Pro Phe Thr Trp Met Leu Ala Leu Leu Gly Leu Ser Gln
115 120 125Ala Leu Asn Ile Leu Leu Gly Leu Lys Gly Leu Ala Pro Ala
Glu Ile 130 135 140Ser Ala Leu Cys Glu Lys Gly Asn Phe Asn Val Ala
His Gly Leu Ala145 150 155 160Trp Ser Tyr Tyr Ile Gly Tyr Leu Arg
Leu Ile Leu Pro Glu Leu Gln 165 170 175Ala Arg Ile Arg Thr Tyr Asn
Gln His Tyr Asn Asn Leu Leu Arg Gly 180 185 190Ala Val Ser Gln Arg
Leu Tyr Ile Leu Leu Pro Leu Asp Cys Gly Val 195 200 205Pro Asp Asn
Leu Ser Met Ala Asp Pro Asn Ile Arg Phe Leu Asp Lys 210 215 220Leu
Pro Gln Gln Thr Gly Asp His Ala Gly Ile Lys Asp Arg Val Tyr225 230
235 240Ser Asn Ser Ile Tyr Glu Leu Leu Glu Asn Gly Gln Arg Ala Gly
Thr 245 250 255Cys Val Leu Glu Tyr Ala Thr Pro Leu Gln Thr Leu Phe
Ala Met Ser 260 265 270Gln Tyr Ser Gln Ala Gly Phe Ser Arg Glu Asp
Arg Leu Glu Gln Ala 275 280 285Lys Leu Phe Cys Arg Thr Leu Glu Asp
Ile Leu Ala Asp Ala Pro Glu 290 295 300Ser Gln Asn Asn Cys Arg Leu
Ile Ala Tyr Gln Glu Pro Ala Asp Asp305 310 315 320Ser Ser Phe Ser
Leu Ser Gln Glu Val Leu Arg His Leu Arg Gln Glu 325 330 335Glu Lys
Glu Glu Val Thr Val Gly Ser Leu Lys Thr Ser Ala Val Pro 340 345
350Ser Thr Ser Thr Met Ser Gln Glu Pro Glu Leu Leu Ile Ser Gly Met
355 360 365Glu Lys Pro Leu Pro Leu Arg Thr Asp Phe Ser 370
3757379PRTArtificial SequenceSynthetic Hu STING (E315Q); no epitope
tag 7Met Pro His Ser Ser Leu His Pro Ser Ile Pro Cys Pro Arg Gly
His1 5 10 15Gly Ala Gln Lys Ala Ala Leu Val Leu Leu Ser Ala Cys Leu
Val Thr 20 25 30Leu Trp Gly Leu Gly Glu Pro Pro Glu His Thr Leu Arg
Tyr Leu Val 35 40 45Leu His Leu Ala Ser Leu Gln Leu Gly Leu Leu Leu
Asn Gly Val Cys 50 55 60Ser Leu Ala Glu Glu Leu Arg His Ile His Ser
Arg Tyr Arg Gly Ser65 70 75 80Tyr Trp Arg Thr Val Arg Ala Cys Leu
Gly Cys Pro Leu Arg Arg Gly 85 90 95Ala Leu Leu Leu Leu Ser Ile Tyr
Phe Tyr Tyr Ser Leu Pro Asn Ala 100 105 110Val Gly Pro Pro Phe Thr
Trp Met Leu Ala Leu Leu Gly Leu Ser Gln 115 120 125Ala Leu Asn Ile
Leu Leu Gly Leu Lys Gly Leu Ala Pro Ala Glu Ile 130 135 140Ser Ala
Val
Cys Glu Lys Gly Asn Phe Asn Val Ala His Gly Leu Ala145 150 155
160Trp Ser Tyr Tyr Ile Gly Tyr Leu Arg Leu Ile Leu Pro Glu Leu Gln
165 170 175Ala Arg Ile Arg Thr Tyr Asn Gln His Tyr Asn Asn Leu Leu
Arg Gly 180 185 190Ala Val Ser Gln Arg Leu Tyr Ile Leu Leu Pro Leu
Asp Cys Gly Val 195 200 205Pro Asp Asn Leu Ser Met Ala Asp Pro Asn
Ile Arg Phe Leu Asp Lys 210 215 220Leu Pro Gln Gln Thr Gly Asp His
Ala Gly Ile Lys Asp Arg Val Tyr225 230 235 240Ser Asn Ser Ile Tyr
Glu Leu Leu Glu Asn Gly Gln Arg Ala Gly Thr 245 250 255Cys Val Leu
Glu Tyr Ala Thr Pro Leu Gln Thr Leu Phe Ala Met Ser 260 265 270Gln
Tyr Ser Gln Ala Gly Phe Ser Arg Glu Asp Arg Leu Glu Gln Ala 275 280
285Lys Leu Phe Cys Arg Thr Leu Glu Asp Ile Leu Ala Asp Ala Pro Glu
290 295 300Ser Gln Asn Asn Cys Arg Leu Ile Ala Tyr Gln Gln Pro Ala
Asp Asp305 310 315 320Ser Ser Phe Ser Leu Ser Gln Glu Val Leu Arg
His Leu Arg Gln Glu 325 330 335Glu Lys Glu Glu Val Thr Val Gly Ser
Leu Lys Thr Ser Ala Val Pro 340 345 350Ser Thr Ser Thr Met Ser Gln
Glu Pro Glu Leu Leu Ile Ser Gly Met 355 360 365Glu Lys Pro Leu Pro
Leu Arg Thr Asp Phe Ser 370 3758379PRTArtificial SequenceSynthetic
Hu STING (R375A); no epitope tag 8Met Pro His Ser Ser Leu His Pro
Ser Ile Pro Cys Pro Arg Gly His1 5 10 15Gly Ala Gln Lys Ala Ala Leu
Val Leu Leu Ser Ala Cys Leu Val Thr 20 25 30Leu Trp Gly Leu Gly Glu
Pro Pro Glu His Thr Leu Arg Tyr Leu Val 35 40 45Leu His Leu Ala Ser
Leu Gln Leu Gly Leu Leu Leu Asn Gly Val Cys 50 55 60Ser Leu Ala Glu
Glu Leu Arg His Ile His Ser Arg Tyr Arg Gly Ser65 70 75 80Tyr Trp
Arg Thr Val Arg Ala Cys Leu Gly Cys Pro Leu Arg Arg Gly 85 90 95Ala
Leu Leu Leu Leu Ser Ile Tyr Phe Tyr Tyr Ser Leu Pro Asn Ala 100 105
110Val Gly Pro Pro Phe Thr Trp Met Leu Ala Leu Leu Gly Leu Ser Gln
115 120 125Ala Leu Asn Ile Leu Leu Gly Leu Lys Gly Leu Ala Pro Ala
Glu Ile 130 135 140Ser Ala Val Cys Glu Lys Gly Asn Phe Asn Val Ala
His Gly Leu Ala145 150 155 160Trp Ser Tyr Tyr Ile Gly Tyr Leu Arg
Leu Ile Leu Pro Glu Leu Gln 165 170 175Ala Arg Ile Arg Thr Tyr Asn
Gln His Tyr Asn Asn Leu Leu Arg Gly 180 185 190Ala Val Ser Gln Arg
Leu Tyr Ile Leu Leu Pro Leu Asp Cys Gly Val 195 200 205Pro Asp Asn
Leu Ser Met Ala Asp Pro Asn Ile Arg Phe Leu Asp Lys 210 215 220Leu
Pro Gln Gln Thr Gly Asp His Ala Gly Ile Lys Asp Arg Val Tyr225 230
235 240Ser Asn Ser Ile Tyr Glu Leu Leu Glu Asn Gly Gln Arg Ala Gly
Thr 245 250 255Cys Val Leu Glu Tyr Ala Thr Pro Leu Gln Thr Leu Phe
Ala Met Ser 260 265 270Gln Tyr Ser Gln Ala Gly Phe Ser Arg Glu Asp
Arg Leu Glu Gln Ala 275 280 285Lys Leu Phe Cys Arg Thr Leu Glu Asp
Ile Leu Ala Asp Ala Pro Glu 290 295 300Ser Gln Asn Asn Cys Arg Leu
Ile Ala Tyr Gln Glu Pro Ala Asp Asp305 310 315 320Ser Ser Phe Ser
Leu Ser Gln Glu Val Leu Arg His Leu Arg Gln Glu 325 330 335Glu Lys
Glu Glu Val Thr Val Gly Ser Leu Lys Thr Ser Ala Val Pro 340 345
350Ser Thr Ser Thr Met Ser Gln Glu Pro Glu Leu Leu Ile Ser Gly Met
355 360 365Glu Lys Pro Leu Pro Leu Ala Thr Asp Phe Ser 370
3759379PRTArtificial SequenceSynthetic Hu STING(V147L/N154S/V155M);
no epitope tag 9Met Pro His Ser Ser Leu His Pro Ser Ile Pro Cys Pro
Arg Gly His1 5 10 15Gly Ala Gln Lys Ala Ala Leu Val Leu Leu Ser Ala
Cys Leu Val Thr 20 25 30Leu Trp Gly Leu Gly Glu Pro Pro Glu His Thr
Leu Arg Tyr Leu Val 35 40 45Leu His Leu Ala Ser Leu Gln Leu Gly Leu
Leu Leu Asn Gly Val Cys 50 55 60Ser Leu Ala Glu Glu Leu Arg His Ile
His Ser Arg Tyr Arg Gly Ser65 70 75 80Tyr Trp Arg Thr Val Arg Ala
Cys Leu Gly Cys Pro Leu Arg Arg Gly 85 90 95Ala Leu Leu Leu Leu Ser
Ile Tyr Phe Tyr Tyr Ser Leu Pro Asn Ala 100 105 110Val Gly Pro Pro
Phe Thr Trp Met Leu Ala Leu Leu Gly Leu Ser Gln 115 120 125Ala Leu
Asn Ile Leu Leu Gly Leu Lys Gly Leu Ala Pro Ala Glu Ile 130 135
140Ser Ala Leu Cys Glu Lys Gly Asn Phe Ser Met Ala His Gly Leu
Ala145 150 155 160Trp Ser Tyr Tyr Ile Gly Tyr Leu Arg Leu Ile Leu
Pro Glu Leu Gln 165 170 175Ala Arg Ile Arg Thr Tyr Asn Gln His Tyr
Asn Asn Leu Leu Arg Gly 180 185 190Ala Val Ser Gln Arg Leu Tyr Ile
Leu Leu Pro Leu Asp Cys Gly Val 195 200 205Pro Asp Asn Leu Ser Met
Ala Asp Pro Asn Ile Arg Phe Leu Asp Lys 210 215 220Leu Pro Gln Gln
Thr Gly Asp His Ala Gly Ile Lys Asp Arg Val Tyr225 230 235 240Ser
Asn Ser Ile Tyr Glu Leu Leu Glu Asn Gly Gln Arg Ala Gly Thr 245 250
255Cys Val Leu Glu Tyr Ala Thr Pro Leu Gln Thr Leu Phe Ala Met Ser
260 265 270Gln Tyr Ser Gln Ala Gly Phe Ser Arg Glu Asp Arg Leu Glu
Gln Ala 275 280 285Lys Leu Phe Cys Arg Thr Leu Glu Asp Ile Leu Ala
Asp Ala Pro Glu 290 295 300Ser Gln Asn Asn Cys Arg Leu Ile Ala Tyr
Gln Glu Pro Ala Asp Asp305 310 315 320Ser Ser Phe Ser Leu Ser Gln
Glu Val Leu Arg His Leu Arg Gln Glu 325 330 335Glu Lys Glu Glu Val
Thr Val Gly Ser Leu Lys Thr Ser Ala Val Pro 340 345 350Ser Thr Ser
Thr Met Ser Gln Glu Pro Glu Leu Leu Ile Ser Gly Met 355 360 365Glu
Lys Pro Leu Pro Leu Arg Thr Asp Phe Ser 370 37510379PRTArtificial
SequenceSynthetic Hu STING(R284M/V147L/N154S/V155M); no epitope tag
10Met Pro His Ser Ser Leu His Pro Ser Ile Pro Cys Pro Arg Gly His1
5 10 15Gly Ala Gln Lys Ala Ala Leu Val Leu Leu Ser Ala Cys Leu Val
Thr 20 25 30Leu Trp Gly Leu Gly Glu Pro Pro Glu His Thr Leu Arg Tyr
Leu Val 35 40 45Leu His Leu Ala Ser Leu Gln Leu Gly Leu Leu Leu Asn
Gly Val Cys 50 55 60Ser Leu Ala Glu Glu Leu Arg His Ile His Ser Arg
Tyr Arg Gly Ser65 70 75 80Tyr Trp Arg Thr Val Arg Ala Cys Leu Gly
Cys Pro Leu Arg Arg Gly 85 90 95Ala Leu Leu Leu Leu Ser Ile Tyr Phe
Tyr Tyr Ser Leu Pro Asn Ala 100 105 110Val Gly Pro Pro Phe Thr Trp
Met Leu Ala Leu Leu Gly Leu Ser Gln 115 120 125Ala Leu Asn Ile Leu
Leu Gly Leu Lys Gly Leu Ala Pro Ala Glu Ile 130 135 140Ser Ala Leu
Cys Glu Lys Gly Asn Phe Ser Met Ala His Gly Leu Ala145 150 155
160Trp Ser Tyr Tyr Ile Gly Tyr Leu Arg Leu Ile Leu Pro Glu Leu Gln
165 170 175Ala Arg Ile Arg Thr Tyr Asn Gln His Tyr Asn Asn Leu Leu
Arg Gly 180 185 190Ala Val Ser Gln Arg Leu Tyr Ile Leu Leu Pro Leu
Asp Cys Gly Val 195 200 205Pro Asp Asn Leu Ser Met Ala Asp Pro Asn
Ile Arg Phe Leu Asp Lys 210 215 220Leu Pro Gln Gln Thr Gly Asp His
Ala Gly Ile Lys Asp Arg Val Tyr225 230 235 240Ser Asn Ser Ile Tyr
Glu Leu Leu Glu Asn Gly Gln Arg Ala Gly Thr 245 250 255Cys Val Leu
Glu Tyr Ala Thr Pro Leu Gln Thr Leu Phe Ala Met Ser 260 265 270Gln
Tyr Ser Gln Ala Gly Phe Ser Arg Glu Asp Met Leu Glu Gln Ala 275 280
285Lys Leu Phe Cys Arg Thr Leu Glu Asp Ile Leu Ala Asp Ala Pro Glu
290 295 300Ser Gln Asn Asn Cys Arg Leu Ile Ala Tyr Gln Glu Pro Ala
Asp Asp305 310 315 320Ser Ser Phe Ser Leu Ser Gln Glu Val Leu Arg
His Leu Arg Gln Glu 325 330 335Glu Lys Glu Glu Val Thr Val Gly Ser
Leu Lys Thr Ser Ala Val Pro 340 345 350Ser Thr Ser Thr Met Ser Gln
Glu Pro Glu Leu Leu Ile Ser Gly Met 355 360 365Glu Lys Pro Leu Pro
Leu Arg Thr Asp Phe Ser 370 37511419PRTMus
musculusmisc_feature(1)..(419)super mouse IRF3 S396D; no epitope
tag 11Met Glu Thr Pro Lys Pro Arg Ile Leu Pro Trp Leu Val Ser Gln
Leu1 5 10 15Asp Leu Gly Gln Leu Glu Gly Val Ala Trp Leu Asp Glu Ser
Arg Thr 20 25 30Arg Phe Arg Ile Pro Trp Lys His Gly Leu Arg Gln Asp
Ala Gln Met 35 40 45Ala Asp Phe Gly Ile Phe Gln Ala Trp Ala Glu Ala
Ser Gly Ala Tyr 50 55 60Thr Pro Gly Lys Asp Lys Pro Asp Val Ser Thr
Trp Lys Arg Asn Phe65 70 75 80Arg Ser Ala Leu Asn Arg Lys Glu Val
Leu Arg Leu Ala Ala Asp Asn 85 90 95Ser Lys Asp Pro Tyr Asp Pro His
Lys Val Tyr Glu Phe Val Thr Pro 100 105 110Gly Ala Arg Asp Phe Val
His Leu Gly Ala Ser Pro Asp Thr Asn Gly 115 120 125Lys Ser Ser Leu
Pro His Ser Gln Glu Asn Leu Pro Lys Leu Phe Asp 130 135 140Gly Leu
Ile Leu Gly Pro Leu Lys Asp Glu Gly Ser Ser Asp Leu Ala145 150 155
160Ile Val Ser Asp Pro Ser Gln Gln Leu Pro Ser Pro Asn Val Asn Asn
165 170 175Phe Leu Asn Pro Ala Pro Gln Glu Asn Pro Leu Lys Gln Leu
Leu Ala 180 185 190Glu Glu Gln Trp Glu Phe Glu Val Thr Ala Phe Tyr
Arg Gly Arg Gln 195 200 205Val Phe Gln Gln Thr Leu Phe Cys Pro Gly
Gly Leu Arg Leu Val Gly 210 215 220Ser Thr Ala Asp Met Thr Leu Pro
Trp Gln Pro Val Thr Leu Pro Asp225 230 235 240Pro Glu Gly Phe Leu
Thr Asp Lys Leu Val Lys Glu Tyr Val Gly Gln 245 250 255Val Leu Lys
Gly Leu Gly Asn Gly Leu Ala Leu Trp Gln Ala Gly Gln 260 265 270Cys
Leu Trp Ala Gln Arg Leu Gly His Ser His Ala Phe Trp Ala Leu 275 280
285Gly Glu Glu Leu Leu Pro Asp Ser Gly Arg Gly Pro Asp Gly Glu Val
290 295 300His Lys Asp Lys Asp Gly Ala Val Phe Asp Leu Arg Pro Phe
Val Ala305 310 315 320Asp Leu Ile Ala Phe Met Glu Gly Ser Gly His
Ser Pro Arg Tyr Thr 325 330 335Leu Trp Phe Cys Met Gly Glu Met Trp
Pro Gln Asp Gln Pro Trp Val 340 345 350Lys Arg Leu Val Met Val Lys
Val Val Pro Thr Cys Leu Lys Glu Leu 355 360 365Leu Glu Met Ala Arg
Glu Gly Gly Ala Ser Ser Leu Lys Thr Val Asp 370 375 380Leu His Ile
Asp Asn Ser Gln Pro Ile Ser Leu Thr Ser Asp Gln Tyr385 390 395
400Lys Ala Tyr Leu Gln Asp Leu Val Glu Asp Met Asp Phe Gln Ala Thr
405 410 415Gly Asn Ile12427PRTHomo
sapiensmisc_feature(1)..(427)super human IRF3 S396D; no epitope tag
12Met Gly Thr Pro Lys Pro Arg Ile Leu Pro Trp Leu Val Ser Gln Leu1
5 10 15Asp Leu Gly Gln Leu Glu Gly Val Ala Trp Val Asn Lys Ser Arg
Thr 20 25 30Arg Phe Arg Ile Pro Trp Lys His Gly Leu Arg Gln Asp Ala
Gln Gln 35 40 45Glu Asp Phe Gly Ile Phe Gln Ala Trp Ala Glu Ala Thr
Gly Ala Tyr 50 55 60Val Pro Gly Arg Asp Lys Pro Asp Leu Pro Thr Trp
Lys Arg Asn Phe65 70 75 80Arg Ser Ala Leu Asn Arg Lys Glu Gly Leu
Arg Leu Ala Glu Asp Arg 85 90 95Ser Lys Asp Pro His Asp Pro His Lys
Ile Tyr Glu Phe Val Asn Ser 100 105 110Gly Val Gly Asp Phe Ser Gln
Pro Asp Thr Ser Pro Asp Thr Asn Gly 115 120 125Gly Gly Ser Thr Ser
Asp Thr Gln Glu Asp Ile Leu Asp Glu Leu Leu 130 135 140Gly Asn Met
Val Leu Ala Pro Leu Pro Asp Pro Gly Pro Pro Ser Leu145 150 155
160Ala Val Ala Pro Glu Pro Cys Pro Gln Pro Leu Arg Ser Pro Ser Leu
165 170 175Asp Asn Pro Thr Pro Phe Pro Asn Leu Gly Pro Ser Glu Asn
Pro Leu 180 185 190Lys Arg Leu Leu Val Pro Gly Glu Glu Trp Glu Phe
Glu Val Thr Ala 195 200 205Phe Tyr Arg Gly Arg Gln Val Phe Gln Gln
Thr Ile Ser Cys Pro Glu 210 215 220Gly Leu Arg Leu Val Gly Ser Glu
Val Gly Asp Arg Thr Leu Pro Gly225 230 235 240Trp Pro Val Thr Leu
Pro Asp Pro Gly Met Ser Leu Thr Asp Arg Gly 245 250 255Val Met Ser
Tyr Val Arg His Val Leu Ser Cys Leu Gly Gly Gly Leu 260 265 270Ala
Leu Trp Arg Ala Gly Gln Trp Leu Trp Ala Gln Arg Leu Gly His 275 280
285Cys His Thr Tyr Trp Ala Val Ser Glu Glu Leu Leu Pro Asn Ser Gly
290 295 300His Gly Pro Asp Gly Glu Val Pro Lys Asp Lys Glu Gly Gly
Val Phe305 310 315 320Asp Leu Gly Pro Phe Ile Val Asp Leu Ile Thr
Phe Thr Glu Gly Ser 325 330 335Gly Arg Ser Pro Arg Tyr Ala Leu Trp
Phe Cys Val Gly Glu Ser Trp 340 345 350Pro Gln Asp Gln Pro Trp Thr
Lys Arg Leu Val Met Val Lys Val Val 355 360 365Pro Thr Cys Leu Arg
Ala Leu Val Glu Met Ala Arg Val Gly Gly Ala 370 375 380Ser Ser Leu
Glu Asn Thr Val Asp Leu His Ile Asp Asn Ser His Pro385 390 395
400Leu Ser Leu Thr Ser Asp Gln Tyr Lys Ala Tyr Leu Gln Asp Leu Val
405 410 415Glu Gly Met Asp Phe Gln Gly Pro Gly Glu Thr 420
42513503PRTArtificial SequenceSynthetic Wild-type Hu IRF7 isoform
A; P037 without epitope tag 13Met Ala Leu Ala Pro Glu Arg Ala Ala
Pro Arg Val Leu Phe Gly Glu1 5 10 15Trp Leu Leu Gly Glu Ile Ser Ser
Gly Cys Tyr Glu Gly Leu Gln Trp 20 25 30Leu Asp Glu Ala Arg Thr Cys
Phe Arg Val Pro Trp Lys His Phe Ala 35 40 45Arg Lys Asp Leu Ser Glu
Ala Asp Ala Arg Ile Phe Lys Ala Trp Ala 50 55 60Val Ala Arg Gly Arg
Trp Pro Pro Ser Ser Arg Gly Gly Gly Pro Pro65 70 75 80Pro Glu Ala
Glu Thr Ala Glu Arg Ala Gly Trp Lys Thr Asn Phe Arg 85 90 95Cys Ala
Leu Arg Ser Thr Arg Arg Phe Val Met Leu Arg Asp Asn Ser 100 105
110Gly Asp Pro Ala Asp Pro His Lys Val Tyr Ala Leu Ser Arg Glu Leu
115 120 125Cys Trp Arg Glu Gly Pro Gly Thr Asp Gln Thr Glu Ala Glu
Ala Pro 130 135 140Ala Ala Val Pro Pro Pro Gln Gly Gly Pro Pro Gly
Pro Phe Leu Ala145 150 155 160His Thr His Ala Gly Leu Gln Ala Pro
Gly Pro Leu Pro Ala Pro Ala 165 170 175Gly Asp Lys Gly Asp Leu Leu
Leu Gln Ala Val Gln Gln Ser Cys Leu 180 185
190Ala Asp His Leu Leu Thr Ala Ser Trp Gly Ala Asp Pro Val Pro Thr
195 200 205Lys Ala Pro Gly Glu Gly Gln Glu Gly Leu Pro Leu Thr Gly
Ala Cys 210 215 220Ala Gly Gly Pro Gly Leu Pro Ala Gly Glu Leu Tyr
Gly Trp Ala Val225 230 235 240Glu Thr Thr Pro Ser Pro Gly Pro Gln
Pro Ala Ala Leu Thr Thr Gly 245 250 255Glu Ala Ala Ala Pro Glu Ser
Pro His Gln Ala Glu Pro Tyr Leu Ser 260 265 270Pro Ser Pro Ser Ala
Cys Thr Ala Val Gln Glu Pro Ser Pro Gly Ala 275 280 285Leu Asp Val
Thr Ile Met Tyr Lys Gly Arg Thr Val Leu Gln Lys Val 290 295 300Val
Gly His Pro Ser Cys Thr Phe Leu Tyr Gly Pro Pro Asp Pro Ala305 310
315 320Val Arg Ala Thr Asp Pro Gln Gln Val Ala Phe Pro Ser Pro Ala
Glu 325 330 335Leu Pro Asp Gln Lys Gln Leu Arg Tyr Thr Glu Glu Leu
Leu Arg His 340 345 350Val Ala Pro Gly Leu His Leu Glu Leu Arg Gly
Pro Gln Leu Trp Ala 355 360 365Arg Arg Met Gly Lys Cys Lys Val Tyr
Trp Glu Val Gly Gly Pro Pro 370 375 380Gly Ser Ala Ser Pro Ser Thr
Pro Ala Cys Leu Leu Pro Arg Asn Cys385 390 395 400Asp Thr Pro Ile
Phe Asp Phe Arg Val Phe Phe Gln Glu Leu Val Glu 405 410 415Phe Arg
Ala Arg Gln Arg Arg Gly Ser Pro Arg Tyr Thr Ile Tyr Leu 420 425
430Gly Phe Gly Gln Asp Leu Ser Ala Gly Arg Pro Lys Glu Lys Ser Leu
435 440 445Val Leu Val Lys Leu Glu Pro Trp Leu Cys Arg Val His Leu
Glu Gly 450 455 460Thr Gln Arg Glu Gly Val Ser Ser Leu Asp Ser Ser
Ser Leu Ser Leu465 470 475 480Cys Leu Ser Ser Ala Asn Ser Leu Tyr
Asp Asp Ile Glu Cys Phe Leu 485 490 495Met Glu Leu Glu Gln Pro Ala
50014503PRTArtificial SequenceSynthetic constitutively active Hu
IRF7 S477D/S479D; P033 without epitope tag 14Met Ala Leu Ala Pro
Glu Arg Ala Ala Pro Arg Val Leu Phe Gly Glu1 5 10 15Trp Leu Leu Gly
Glu Ile Ser Ser Gly Cys Tyr Glu Gly Leu Gln Trp 20 25 30Leu Asp Glu
Ala Arg Thr Cys Phe Arg Val Pro Trp Lys His Phe Ala 35 40 45Arg Lys
Asp Leu Ser Glu Ala Asp Ala Arg Ile Phe Lys Ala Trp Ala 50 55 60Val
Ala Arg Gly Arg Trp Pro Pro Ser Ser Arg Gly Gly Gly Pro Pro65 70 75
80Pro Glu Ala Glu Thr Ala Glu Arg Ala Gly Trp Lys Thr Asn Phe Arg
85 90 95Cys Ala Leu Arg Ser Thr Arg Arg Phe Val Met Leu Arg Asp Asn
Ser 100 105 110Gly Asp Pro Ala Asp Pro His Lys Val Tyr Ala Leu Ser
Arg Glu Leu 115 120 125Cys Trp Arg Glu Gly Pro Gly Thr Asp Gln Thr
Glu Ala Glu Ala Pro 130 135 140Ala Ala Val Pro Pro Pro Gln Gly Gly
Pro Pro Gly Pro Phe Leu Ala145 150 155 160His Thr His Ala Gly Leu
Gln Ala Pro Gly Pro Leu Pro Ala Pro Ala 165 170 175Gly Asp Lys Gly
Asp Leu Leu Leu Gln Ala Val Gln Gln Ser Cys Leu 180 185 190Ala Asp
His Leu Leu Thr Ala Ser Trp Gly Ala Asp Pro Val Pro Thr 195 200
205Lys Ala Pro Gly Glu Gly Gln Glu Gly Leu Pro Leu Thr Gly Ala Cys
210 215 220Ala Gly Gly Pro Gly Leu Pro Ala Gly Glu Leu Tyr Gly Trp
Ala Val225 230 235 240Glu Thr Thr Pro Ser Pro Gly Pro Gln Pro Ala
Ala Leu Thr Thr Gly 245 250 255Glu Ala Ala Ala Pro Glu Ser Pro His
Gln Ala Glu Pro Tyr Leu Ser 260 265 270Pro Ser Pro Ser Ala Cys Thr
Ala Val Gln Glu Pro Ser Pro Gly Ala 275 280 285Leu Asp Val Thr Ile
Met Tyr Lys Gly Arg Thr Val Leu Gln Lys Val 290 295 300Val Gly His
Pro Ser Cys Thr Phe Leu Tyr Gly Pro Pro Asp Pro Ala305 310 315
320Val Arg Ala Thr Asp Pro Gln Gln Val Ala Phe Pro Ser Pro Ala Glu
325 330 335Leu Pro Asp Gln Lys Gln Leu Arg Tyr Thr Glu Glu Leu Leu
Arg His 340 345 350Val Ala Pro Gly Leu His Leu Glu Leu Arg Gly Pro
Gln Leu Trp Ala 355 360 365Arg Arg Met Gly Lys Cys Lys Val Tyr Trp
Glu Val Gly Gly Pro Pro 370 375 380Gly Ser Ala Ser Pro Ser Thr Pro
Ala Cys Leu Leu Pro Arg Asn Cys385 390 395 400Asp Thr Pro Ile Phe
Asp Phe Arg Val Phe Phe Gln Glu Leu Val Glu 405 410 415Phe Arg Ala
Arg Gln Arg Arg Gly Ser Pro Arg Tyr Thr Ile Tyr Leu 420 425 430Gly
Phe Gly Gln Asp Leu Ser Ala Gly Arg Pro Lys Glu Lys Ser Leu 435 440
445Val Leu Val Lys Leu Glu Pro Trp Leu Cys Arg Val His Leu Glu Gly
450 455 460Thr Gln Arg Glu Gly Val Ser Ser Leu Asp Ser Ser Asp Leu
Asp Leu465 470 475 480Cys Leu Ser Ser Ala Asn Ser Leu Tyr Asp Asp
Ile Glu Cys Phe Leu 485 490 495Met Glu Leu Glu Gln Pro Ala
50015503PRTArtificial SequenceSynthetic constitutively active Hu
IRF7 S475D/S477D/L480D; P034 without epitope tag 15Met Ala Leu Ala
Pro Glu Arg Ala Ala Pro Arg Val Leu Phe Gly Glu1 5 10 15Trp Leu Leu
Gly Glu Ile Ser Ser Gly Cys Tyr Glu Gly Leu Gln Trp 20 25 30Leu Asp
Glu Ala Arg Thr Cys Phe Arg Val Pro Trp Lys His Phe Ala 35 40 45Arg
Lys Asp Leu Ser Glu Ala Asp Ala Arg Ile Phe Lys Ala Trp Ala 50 55
60Val Ala Arg Gly Arg Trp Pro Pro Ser Ser Arg Gly Gly Gly Pro Pro65
70 75 80Pro Glu Ala Glu Thr Ala Glu Arg Ala Gly Trp Lys Thr Asn Phe
Arg 85 90 95Cys Ala Leu Arg Ser Thr Arg Arg Phe Val Met Leu Arg Asp
Asn Ser 100 105 110Gly Asp Pro Ala Asp Pro His Lys Val Tyr Ala Leu
Ser Arg Glu Leu 115 120 125Cys Trp Arg Glu Gly Pro Gly Thr Asp Gln
Thr Glu Ala Glu Ala Pro 130 135 140Ala Ala Val Pro Pro Pro Gln Gly
Gly Pro Pro Gly Pro Phe Leu Ala145 150 155 160His Thr His Ala Gly
Leu Gln Ala Pro Gly Pro Leu Pro Ala Pro Ala 165 170 175Gly Asp Lys
Gly Asp Leu Leu Leu Gln Ala Val Gln Gln Ser Cys Leu 180 185 190Ala
Asp His Leu Leu Thr Ala Ser Trp Gly Ala Asp Pro Val Pro Thr 195 200
205Lys Ala Pro Gly Glu Gly Gln Glu Gly Leu Pro Leu Thr Gly Ala Cys
210 215 220Ala Gly Gly Pro Gly Leu Pro Ala Gly Glu Leu Tyr Gly Trp
Ala Val225 230 235 240Glu Thr Thr Pro Ser Pro Gly Pro Gln Pro Ala
Ala Leu Thr Thr Gly 245 250 255Glu Ala Ala Ala Pro Glu Ser Pro His
Gln Ala Glu Pro Tyr Leu Ser 260 265 270Pro Ser Pro Ser Ala Cys Thr
Ala Val Gln Glu Pro Ser Pro Gly Ala 275 280 285Leu Asp Val Thr Ile
Met Tyr Lys Gly Arg Thr Val Leu Gln Lys Val 290 295 300Val Gly His
Pro Ser Cys Thr Phe Leu Tyr Gly Pro Pro Asp Pro Ala305 310 315
320Val Arg Ala Thr Asp Pro Gln Gln Val Ala Phe Pro Ser Pro Ala Glu
325 330 335Leu Pro Asp Gln Lys Gln Leu Arg Tyr Thr Glu Glu Leu Leu
Arg His 340 345 350Val Ala Pro Gly Leu His Leu Glu Leu Arg Gly Pro
Gln Leu Trp Ala 355 360 365Arg Arg Met Gly Lys Cys Lys Val Tyr Trp
Glu Val Gly Gly Pro Pro 370 375 380Gly Ser Ala Ser Pro Ser Thr Pro
Ala Cys Leu Leu Pro Arg Asn Cys385 390 395 400Asp Thr Pro Ile Phe
Asp Phe Arg Val Phe Phe Gln Glu Leu Val Glu 405 410 415Phe Arg Ala
Arg Gln Arg Arg Gly Ser Pro Arg Tyr Thr Ile Tyr Leu 420 425 430Gly
Phe Gly Gln Asp Leu Ser Ala Gly Arg Pro Lys Glu Lys Ser Leu 435 440
445Val Leu Val Lys Leu Glu Pro Trp Leu Cys Arg Val His Leu Glu Gly
450 455 460Thr Gln Arg Glu Gly Val Ser Ser Leu Asp Asp Ser Asp Leu
Ser Asp465 470 475 480Cys Leu Ser Ser Ala Asn Ser Leu Tyr Asp Asp
Ile Glu Cys Phe Leu 485 490 495Met Glu Leu Glu Gln Pro Ala
50016503PRTArtificial SequenceSynthetic constitutively active Hu
IRF7 S475D/S476D/S477D/S479D/S483D/S487D; P035 without epitope tag
16Met Ala Leu Ala Pro Glu Arg Ala Ala Pro Arg Val Leu Phe Gly Glu1
5 10 15Trp Leu Leu Gly Glu Ile Ser Ser Gly Cys Tyr Glu Gly Leu Gln
Trp 20 25 30Leu Asp Glu Ala Arg Thr Cys Phe Arg Val Pro Trp Lys His
Phe Ala 35 40 45Arg Lys Asp Leu Ser Glu Ala Asp Ala Arg Ile Phe Lys
Ala Trp Ala 50 55 60Val Ala Arg Gly Arg Trp Pro Pro Ser Ser Arg Gly
Gly Gly Pro Pro65 70 75 80Pro Glu Ala Glu Thr Ala Glu Arg Ala Gly
Trp Lys Thr Asn Phe Arg 85 90 95Cys Ala Leu Arg Ser Thr Arg Arg Phe
Val Met Leu Arg Asp Asn Ser 100 105 110Gly Asp Pro Ala Asp Pro His
Lys Val Tyr Ala Leu Ser Arg Glu Leu 115 120 125Cys Trp Arg Glu Gly
Pro Gly Thr Asp Gln Thr Glu Ala Glu Ala Pro 130 135 140Ala Ala Val
Pro Pro Pro Gln Gly Gly Pro Pro Gly Pro Phe Leu Ala145 150 155
160His Thr His Ala Gly Leu Gln Ala Pro Gly Pro Leu Pro Ala Pro Ala
165 170 175Gly Asp Lys Gly Asp Leu Leu Leu Gln Ala Val Gln Gln Ser
Cys Leu 180 185 190Ala Asp His Leu Leu Thr Ala Ser Trp Gly Ala Asp
Pro Val Pro Thr 195 200 205Lys Ala Pro Gly Glu Gly Gln Glu Gly Leu
Pro Leu Thr Gly Ala Cys 210 215 220Ala Gly Gly Pro Gly Leu Pro Ala
Gly Glu Leu Tyr Gly Trp Ala Val225 230 235 240Glu Thr Thr Pro Ser
Pro Gly Pro Gln Pro Ala Ala Leu Thr Thr Gly 245 250 255Glu Ala Ala
Ala Pro Glu Ser Pro His Gln Ala Glu Pro Tyr Leu Ser 260 265 270Pro
Ser Pro Ser Ala Cys Thr Ala Val Gln Glu Pro Ser Pro Gly Ala 275 280
285Leu Asp Val Thr Ile Met Tyr Lys Gly Arg Thr Val Leu Gln Lys Val
290 295 300Val Gly His Pro Ser Cys Thr Phe Leu Tyr Gly Pro Pro Asp
Pro Ala305 310 315 320Val Arg Ala Thr Asp Pro Gln Gln Val Ala Phe
Pro Ser Pro Ala Glu 325 330 335Leu Pro Asp Gln Lys Gln Leu Arg Tyr
Thr Glu Glu Leu Leu Arg His 340 345 350Val Ala Pro Gly Leu His Leu
Glu Leu Arg Gly Pro Gln Leu Trp Ala 355 360 365Arg Arg Met Gly Lys
Cys Lys Val Tyr Trp Glu Val Gly Gly Pro Pro 370 375 380Gly Ser Ala
Ser Pro Ser Thr Pro Ala Cys Leu Leu Pro Arg Asn Cys385 390 395
400Asp Thr Pro Ile Phe Asp Phe Arg Val Phe Phe Gln Glu Leu Val Glu
405 410 415Phe Arg Ala Arg Gln Arg Arg Gly Ser Pro Arg Tyr Thr Ile
Tyr Leu 420 425 430Gly Phe Gly Gln Asp Leu Ser Ala Gly Arg Pro Lys
Glu Lys Ser Leu 435 440 445Val Leu Val Lys Leu Glu Pro Trp Leu Cys
Arg Val His Leu Glu Gly 450 455 460Thr Gln Arg Glu Gly Val Ser Ser
Leu Asp Asp Asp Asp Leu Asp Leu465 470 475 480Cys Leu Asp Ser Ala
Asn Asp Leu Tyr Asp Asp Ile Glu Cys Phe Leu 485 490 495Met Glu Leu
Glu Gln Pro Ala 50017282PRTArtificial SequenceSynthetic
constitutively active truncated Hu IRF7 1-246 + 468-503; P032
without epitope tag 17Met Ala Leu Ala Pro Glu Arg Ala Ala Pro Arg
Val Leu Phe Gly Glu1 5 10 15Trp Leu Leu Gly Glu Ile Ser Ser Gly Cys
Tyr Glu Gly Leu Gln Trp 20 25 30Leu Asp Glu Ala Arg Thr Cys Phe Arg
Val Pro Trp Lys His Phe Ala 35 40 45Arg Lys Asp Leu Ser Glu Ala Asp
Ala Arg Ile Phe Lys Ala Trp Ala 50 55 60Val Ala Arg Gly Arg Trp Pro
Pro Ser Ser Arg Gly Gly Gly Pro Pro65 70 75 80Pro Glu Ala Glu Thr
Ala Glu Arg Ala Gly Trp Lys Thr Asn Phe Arg 85 90 95Cys Ala Leu Arg
Ser Thr Arg Arg Phe Val Met Leu Arg Asp Asn Ser 100 105 110Gly Asp
Pro Ala Asp Pro His Lys Val Tyr Ala Leu Ser Arg Glu Leu 115 120
125Cys Trp Arg Glu Gly Pro Gly Thr Asp Gln Thr Glu Ala Glu Ala Pro
130 135 140Ala Ala Val Pro Pro Pro Gln Gly Gly Pro Pro Gly Pro Phe
Leu Ala145 150 155 160His Thr His Ala Gly Leu Gln Ala Pro Gly Pro
Leu Pro Ala Pro Ala 165 170 175Gly Asp Lys Gly Asp Leu Leu Leu Gln
Ala Val Gln Gln Ser Cys Leu 180 185 190Ala Asp His Leu Leu Thr Ala
Ser Trp Gly Ala Asp Pro Val Pro Thr 195 200 205Lys Ala Pro Gly Glu
Gly Gln Glu Gly Leu Pro Leu Thr Gly Ala Cys 210 215 220Ala Gly Gly
Pro Gly Leu Pro Ala Gly Glu Leu Tyr Gly Trp Ala Val225 230 235
240Glu Thr Thr Pro Ser Pro Glu Gly Val Ser Ser Leu Asp Ser Ser Ser
245 250 255Leu Ser Leu Cys Leu Ser Ser Ala Asn Ser Leu Tyr Asp Asp
Ile Glu 260 265 270Cys Phe Leu Met Glu Leu Glu Gln Pro Ala 275
28018282PRTArtificial SequenceSynthetic constitutively active
truncated Hu IRF7 1-246 + 468-503 plus
S475D/S476D/S477D/S479D/S483D/S487D; P036 without epitope tag 18Met
Ala Leu Ala Pro Glu Arg Ala Ala Pro Arg Val Leu Phe Gly Glu1 5 10
15Trp Leu Leu Gly Glu Ile Ser Ser Gly Cys Tyr Glu Gly Leu Gln Trp
20 25 30Leu Asp Glu Ala Arg Thr Cys Phe Arg Val Pro Trp Lys His Phe
Ala 35 40 45Arg Lys Asp Leu Ser Glu Ala Asp Ala Arg Ile Phe Lys Ala
Trp Ala 50 55 60Val Ala Arg Gly Arg Trp Pro Pro Ser Ser Arg Gly Gly
Gly Pro Pro65 70 75 80Pro Glu Ala Glu Thr Ala Glu Arg Ala Gly Trp
Lys Thr Asn Phe Arg 85 90 95Cys Ala Leu Arg Ser Thr Arg Arg Phe Val
Met Leu Arg Asp Asn Ser 100 105 110Gly Asp Pro Ala Asp Pro His Lys
Val Tyr Ala Leu Ser Arg Glu Leu 115 120 125Cys Trp Arg Glu Gly Pro
Gly Thr Asp Gln Thr Glu Ala Glu Ala Pro 130 135 140Ala Ala Val Pro
Pro Pro Gln Gly Gly Pro Pro Gly Pro Phe Leu Ala145 150 155 160His
Thr His Ala Gly Leu Gln Ala Pro Gly Pro Leu Pro Ala Pro Ala 165 170
175Gly Asp Lys Gly Asp Leu Leu Leu Gln Ala Val Gln Gln Ser Cys Leu
180 185 190Ala Asp His Leu Leu Thr Ala Ser Trp Gly Ala Asp Pro Val
Pro Thr 195 200 205Lys Ala Pro Gly Glu Gly Gln Glu Gly Leu Pro Leu
Thr Gly Ala Cys 210 215 220Ala Gly Gly Pro Gly Leu Pro Ala Gly Glu
Leu Tyr Gly Trp Ala Val225 230 235 240Glu Thr Thr Pro Ser Pro Glu
Gly Val Ser Ser Leu Asp Asp Asp Asp 245 250 255Leu Asp Leu Cys Leu
Asp Ser Ala Asn Asp Leu Tyr Asp Asp Ile Glu 260 265 270Cys Phe Leu
Met Glu Leu Glu Gln Pro Ala 275
28019408PRTArtificial SequenceSynthetic truncated Hu IRF7 1-151 +
247-503; P038 without epitope tag; null mutation 19Met Ala Leu Ala
Pro Glu Arg Ala Ala Pro Arg Val Leu Phe Gly Glu1 5 10 15Trp Leu Leu
Gly Glu Ile Ser Ser Gly Cys Tyr Glu Gly Leu Gln Trp 20 25 30Leu Asp
Glu Ala Arg Thr Cys Phe Arg Val Pro Trp Lys His Phe Ala 35 40 45Arg
Lys Asp Leu Ser Glu Ala Asp Ala Arg Ile Phe Lys Ala Trp Ala 50 55
60Val Ala Arg Gly Arg Trp Pro Pro Ser Ser Arg Gly Gly Gly Pro Pro65
70 75 80Pro Glu Ala Glu Thr Ala Glu Arg Ala Gly Trp Lys Thr Asn Phe
Arg 85 90 95Cys Ala Leu Arg Ser Thr Arg Arg Phe Val Met Leu Arg Asp
Asn Ser 100 105 110Gly Asp Pro Ala Asp Pro His Lys Val Tyr Ala Leu
Ser Arg Glu Leu 115 120 125Cys Trp Arg Glu Gly Pro Gly Thr Asp Gln
Thr Glu Ala Glu Ala Pro 130 135 140Ala Ala Val Pro Pro Pro Gln Gly
Pro Gln Pro Ala Ala Leu Thr Thr145 150 155 160Gly Glu Ala Ala Ala
Pro Glu Ser Pro His Gln Ala Glu Pro Tyr Leu 165 170 175Ser Pro Ser
Pro Ser Ala Cys Thr Ala Val Gln Glu Pro Ser Pro Gly 180 185 190Ala
Leu Asp Val Thr Ile Met Tyr Lys Gly Arg Thr Val Leu Gln Lys 195 200
205Val Val Gly His Pro Ser Cys Thr Phe Leu Tyr Gly Pro Pro Asp Pro
210 215 220Ala Val Arg Ala Thr Asp Pro Gln Gln Val Ala Phe Pro Ser
Pro Ala225 230 235 240Glu Leu Pro Asp Gln Lys Gln Leu Arg Tyr Thr
Glu Glu Leu Leu Arg 245 250 255His Val Ala Pro Gly Leu His Leu Glu
Leu Arg Gly Pro Gln Leu Trp 260 265 270Ala Arg Arg Met Gly Lys Cys
Lys Val Tyr Trp Glu Val Gly Gly Pro 275 280 285Pro Gly Ser Ala Ser
Pro Ser Thr Pro Ala Cys Leu Leu Pro Arg Asn 290 295 300Cys Asp Thr
Pro Ile Phe Asp Phe Arg Val Phe Phe Gln Glu Leu Val305 310 315
320Glu Phe Arg Ala Arg Gln Arg Arg Gly Ser Pro Arg Tyr Thr Ile Tyr
325 330 335Leu Gly Phe Gly Gln Asp Leu Ser Ala Gly Arg Pro Lys Glu
Lys Ser 340 345 350Leu Val Leu Val Lys Leu Glu Pro Trp Leu Cys Arg
Val His Leu Glu 355 360 365Gly Thr Gln Arg Glu Gly Val Ser Ser Leu
Asp Ser Ser Ser Leu Ser 370 375 380Leu Cys Leu Ser Ser Ala Asn Ser
Leu Tyr Asp Asp Ile Glu Cys Phe385 390 395 400Leu Met Glu Leu Glu
Gln Pro Ala 40520353PRTArtificial SequenceSynthetic truncated Hu
IRF7 152-503; P039 without epitope tag; null mutation 20Met Gly Gly
Pro Pro Gly Pro Phe Leu Ala His Thr His Ala Gly Leu1 5 10 15Gln Ala
Pro Gly Pro Leu Pro Ala Pro Ala Gly Asp Lys Gly Asp Leu 20 25 30Leu
Leu Gln Ala Val Gln Gln Ser Cys Leu Ala Asp His Leu Leu Thr 35 40
45Ala Ser Trp Gly Ala Asp Pro Val Pro Thr Lys Ala Pro Gly Glu Gly
50 55 60Gln Glu Gly Leu Pro Leu Thr Gly Ala Cys Ala Gly Gly Pro Gly
Leu65 70 75 80Pro Ala Gly Glu Leu Tyr Gly Trp Ala Val Glu Thr Thr
Pro Ser Pro 85 90 95Gly Pro Gln Pro Ala Ala Leu Thr Thr Gly Glu Ala
Ala Ala Pro Glu 100 105 110Ser Pro His Gln Ala Glu Pro Tyr Leu Ser
Pro Ser Pro Ser Ala Cys 115 120 125Thr Ala Val Gln Glu Pro Ser Pro
Gly Ala Leu Asp Val Thr Ile Met 130 135 140Tyr Lys Gly Arg Thr Val
Leu Gln Lys Val Val Gly His Pro Ser Cys145 150 155 160Thr Phe Leu
Tyr Gly Pro Pro Asp Pro Ala Val Arg Ala Thr Asp Pro 165 170 175Gln
Gln Val Ala Phe Pro Ser Pro Ala Glu Leu Pro Asp Gln Lys Gln 180 185
190Leu Arg Tyr Thr Glu Glu Leu Leu Arg His Val Ala Pro Gly Leu His
195 200 205Leu Glu Leu Arg Gly Pro Gln Leu Trp Ala Arg Arg Met Gly
Lys Cys 210 215 220Lys Val Tyr Trp Glu Val Gly Gly Pro Pro Gly Ser
Ala Ser Pro Ser225 230 235 240Thr Pro Ala Cys Leu Leu Pro Arg Asn
Cys Asp Thr Pro Ile Phe Asp 245 250 255Phe Arg Val Phe Phe Gln Glu
Leu Val Glu Phe Arg Ala Arg Gln Arg 260 265 270Arg Gly Ser Pro Arg
Tyr Thr Ile Tyr Leu Gly Phe Gly Gln Asp Leu 275 280 285Ser Ala Gly
Arg Pro Lys Glu Lys Ser Leu Val Leu Val Lys Leu Glu 290 295 300Pro
Trp Leu Cys Arg Val His Leu Glu Gly Thr Gln Arg Glu Gly Val305 310
315 320Ser Ser Leu Asp Ser Ser Ser Leu Ser Leu Cys Leu Ser Ser Ala
Asn 325 330 335Ser Leu Tyr Asp Asp Ile Glu Cys Phe Leu Met Glu Leu
Glu Gln Pro 340 345 350Ala2192DNAArtificial SequenceSynthetic 5 UTR
21tcaagctttt ggaccctcgt acagaagcta atacgactca ctatagggaa ataagagaga
60aaagaagagt aagaagaaat ataagagcca cc 9222119DNAArtificial
SequenceSynthetic 3 UTR 22tgataatagg ctggagcctc ggtggccatg
cttcttgccc cttgggcctc cccccagccc 60ctcctcccct tcctgcaccc gtacccccgt
ggtctttgaa taaagtctga gtgggcggc 11923164DNAArtificial
SequenceSynthetic 3 UTR with mi-122 and mi-142.3p sites
23tgataatagg ctggagcctc ggtggccatg cttcttgccc cttgggccca aacaccattg
60tcacactcca tccccccagc ccctcctccc cttcctccat aaagtaggaa acactacatg
120cacccgtacc cccgtggtct ttgaataaag tctgagtggg cggc
1642422PRTArtificial SequenceSynthetic 2A peptide amino acid
sequence 24Gly Ser Gly Ala Thr Asn Phe Ser Leu Leu Lys Gln Ala Gly
Asp Val1 5 10 15Glu Glu Asn Pro Gly Pro 202566DNAArtificial
SequenceSynthetic Nucleotide sequence encoding 2A peptide
25ggaagcggag ctactaactt cagcctgctg aagcaggctg gagacgtgga ggagaaccct
60ggacct 6626108DNAArtificial SequenceSynthetic Nucleotide sequence
encoding 2A peptide 26tccggactca gatccgggga tctcaaaatt gtcgctcctg
tcaaacaaac tcttaacttt 60gatttactca aactggctgg ggatgtagaa agcaatccag
gtccactc 1082787RNAArtificial SequenceSynthetic miR-142
27gacagugcag ucacccauaa aguagaaagc acuacuaaca gcacuggagg guguaguguu
60uccuacuuua uggaugagug uacugug 872823RNAArtificial
SequenceSynthetic miR-142-3p 28uguaguguuu ccuacuuuau gga
232923RNAArtificial SequenceSynthetic miR-142-3p binding site
29uccauaaagu aggaaacacu aca 233021RNAArtificial SequenceSynthetic
miR-142-5p 30cauaaaguag aaagcacuac u 213121RNAArtificial
SequenceSynthetic miR-142-5p binding site 31aguagugcuu ucuacuuuau g
213222RNAArtificial SequenceSynthetic miR-122-3p 32aacgccauua
ucacacuaaa ua 223322RNAArtificial SequenceSynthetic miR-122-5p
33uggaguguga caaugguguu ug 223422RNAArtificial SequenceSynthetic
miR-21-5p 34uagcuuauca gacugauguu ga 223521RNAArtificial
SequenceSynthetic miR-21-3p 35caacaccagu cgaugggcug u
213616PRTArtificial SequenceSynthetic KRAS(G12D)15mer 36Met Lys Leu
Val Val Val Gly Ala Asp Gly Val Gly Lys Ser Ala Leu1 5 10
153716PRTArtificial SequenceSynthetic KRAS(G12V)15mer 37Met Lys Leu
Val Val Val Gly Ala Val Gly Val Gly Lys Ser Ala Leu1 5 10
153816PRTArtificial SequenceSynthetic KRAS(G13D)15mer 38Met Leu Val
Val Val Gly Ala Gly Asp Val Gly Lys Ser Ala Leu Thr1 5 10
153925PRTArtificial SequenceSynthetic KRAS(G12D)25mer 39Met Thr Glu
Tyr Lys Leu Val Val Val Gly Ala Asp Gly Val Gly Lys1 5 10 15Ser Ala
Leu Thr Ile Gln Leu Ile Gln 20 254025PRTArtificial
SequenceSynthetic KRAS(G12V)25mer 40Met Thr Glu Tyr Lys Leu Val Val
Val Gly Ala Val Gly Val Gly Lys1 5 10 15Ser Ala Leu Thr Ile Gln Leu
Ile Gln 20 254125PRTArtificial SequenceSynthetic KRAS(G13D)25mer
41Met Thr Glu Tyr Lys Leu Val Val Val Gly Ala Gly Asp Val Gly Lys1
5 10 15Ser Ala Leu Thr Ile Gln Leu Ile Gln 20 254246PRTArtificial
SequenceSynthetic KRAS(G12D)15mer^3 42Met Lys Leu Val Val Val Gly
Ala Asp Gly Val Gly Lys Ser Ala Leu1 5 10 15Lys Leu Val Val Val Gly
Ala Asp Gly Val Gly Lys Ser Ala Leu Lys 20 25 30Leu Val Val Val Gly
Ala Asp Gly Val Gly Lys Ser Ala Leu 35 40 454346PRTArtificial
SequenceSynthetic KRAS(G12V)15mer^3 43Met Lys Leu Val Val Val Gly
Ala Val Gly Val Gly Lys Ser Ala Leu1 5 10 15Lys Leu Val Val Val Gly
Ala Val Gly Val Gly Lys Ser Ala Leu Lys 20 25 30Leu Val Val Val Gly
Ala Val Gly Val Gly Lys Ser Ala Leu 35 40 454446PRTArtificial
SequenceSynthetic KRAS(G13D)15mer^3 44Met Leu Val Val Val Gly Ala
Gly Asp Val Gly Lys Ser Ala Leu Thr1 5 10 15Leu Val Val Val Gly Ala
Gly Asp Val Gly Lys Ser Ala Leu Thr Leu 20 25 30Val Val Val Gly Ala
Gly Asp Val Gly Lys Ser Ala Leu Thr 35 40 454575PRTArtificial
SequenceSynthetic KRAS(G12D)25mer^3 45Met Thr Glu Tyr Lys Leu Val
Val Val Gly Ala Asp Gly Val Gly Lys1 5 10 15Ser Ala Leu Thr Ile Gln
Leu Ile Gln Met Thr Glu Tyr Lys Leu Val 20 25 30Val Val Gly Ala Asp
Gly Val Gly Lys Ser Ala Leu Thr Ile Gln Leu 35 40 45Ile Gln Met Thr
Glu Tyr Lys Leu Val Val Val Gly Ala Asp Gly Val 50 55 60Gly Lys Ser
Ala Leu Thr Ile Gln Leu Ile Gln65 70 754675PRTArtificial
SequenceSynthetic KRAS(G12V)25mer^3 46Met Thr Glu Tyr Lys Leu Val
Val Val Gly Ala Val Gly Val Gly Lys1 5 10 15Ser Ala Leu Thr Ile Gln
Leu Ile Gln Met Thr Glu Tyr Lys Leu Val 20 25 30Val Val Gly Ala Val
Gly Val Gly Lys Ser Ala Leu Thr Ile Gln Leu 35 40 45Ile Gln Met Thr
Glu Tyr Lys Leu Val Val Val Gly Ala Val Gly Val 50 55 60Gly Lys Ser
Ala Leu Thr Ile Gln Leu Ile Gln65 70 754775PRTArtificial
SequenceSynthetic KRAS(G13D)25mer^3 47Met Thr Glu Tyr Lys Leu Val
Val Val Gly Ala Gly Asp Val Gly Lys1 5 10 15Ser Ala Leu Thr Ile Gln
Leu Ile Gln Met Thr Glu Tyr Lys Leu Val 20 25 30Val Val Gly Ala Gly
Asp Val Gly Lys Ser Ala Leu Thr Ile Gln Leu 35 40 45Ile Gln Met Thr
Glu Tyr Lys Leu Val Val Val Gly Ala Gly Asp Val 50 55 60Gly Lys Ser
Ala Leu Thr Ile Gln Leu Ile Gln65 70 7548414PRTArtificial
SequenceSynthetic KRAS(G12D)15mer_nt.STING(V155M) 48Met Pro His Ser
Ser Leu His Pro Ser Ile Pro Cys Pro Arg Gly His1 5 10 15Gly Ala Gln
Lys Ala Ala Leu Val Leu Leu Ser Ala Cys Leu Val Thr 20 25 30Leu Trp
Gly Leu Gly Glu Pro Pro Glu His Thr Leu Arg Tyr Leu Val 35 40 45Leu
His Leu Ala Ser Leu Gln Leu Gly Leu Leu Leu Asn Gly Val Cys 50 55
60Ser Leu Ala Glu Glu Leu Arg His Ile His Ser Arg Tyr Arg Gly Ser65
70 75 80Tyr Trp Arg Thr Val Arg Ala Cys Leu Gly Cys Pro Leu Arg Arg
Gly 85 90 95Ala Leu Leu Leu Leu Ser Ile Tyr Phe Tyr Tyr Ser Leu Pro
Asn Ala 100 105 110Val Gly Pro Pro Phe Thr Trp Met Leu Ala Leu Leu
Gly Leu Ser Gln 115 120 125Ala Leu Asn Ile Leu Leu Gly Leu Lys Gly
Leu Ala Pro Ala Glu Ile 130 135 140Ser Ala Val Cys Glu Lys Gly Asn
Phe Asn Met Ala His Gly Leu Ala145 150 155 160Trp Ser Tyr Tyr Ile
Gly Tyr Leu Arg Leu Ile Leu Pro Glu Leu Gln 165 170 175Ala Arg Ile
Arg Thr Tyr Asn Gln His Tyr Asn Asn Leu Leu Arg Gly 180 185 190Ala
Val Ser Gln Arg Leu Tyr Ile Leu Leu Pro Leu Asp Cys Gly Val 195 200
205Pro Asp Asn Leu Ser Met Ala Asp Pro Asn Ile Arg Phe Leu Asp Lys
210 215 220Leu Pro Gln Gln Thr Gly Asp His Ala Gly Ile Lys Asp Arg
Val Tyr225 230 235 240Ser Asn Ser Ile Tyr Glu Leu Leu Glu Asn Gly
Gln Arg Ala Gly Thr 245 250 255Cys Val Leu Glu Tyr Ala Thr Pro Leu
Gln Thr Leu Phe Ala Met Ser 260 265 270Gln Tyr Ser Gln Ala Gly Phe
Ser Arg Glu Asp Arg Leu Glu Gln Ala 275 280 285Lys Leu Phe Cys Arg
Thr Leu Glu Asp Ile Leu Ala Asp Ala Pro Glu 290 295 300Ser Gln Asn
Asn Cys Arg Leu Ile Ala Tyr Gln Glu Pro Ala Asp Asp305 310 315
320Ser Ser Phe Ser Leu Ser Gln Glu Val Leu Arg His Leu Arg Gln Glu
325 330 335Glu Lys Glu Glu Val Thr Val Gly Ser Leu Lys Thr Ser Ala
Val Pro 340 345 350Ser Thr Ser Thr Met Ser Gln Glu Pro Glu Leu Leu
Ile Ser Gly Met 355 360 365Glu Lys Pro Leu Pro Leu Arg Thr Asp Phe
Ser Ala Thr Asn Phe Ser 370 375 380Leu Leu Lys Gln Ala Gly Asp Val
Glu Glu Asn Pro Gly Pro Met Lys385 390 395 400Leu Val Val Val Gly
Ala Asp Gly Val Gly Lys Ser Ala Leu 405 41049414PRTArtificial
SequenceSynthetic KRAS(G12V)15mer_nt.STING(V155M 49Met Pro His Ser
Ser Leu His Pro Ser Ile Pro Cys Pro Arg Gly His1 5 10 15Gly Ala Gln
Lys Ala Ala Leu Val Leu Leu Ser Ala Cys Leu Val Thr 20 25 30Leu Trp
Gly Leu Gly Glu Pro Pro Glu His Thr Leu Arg Tyr Leu Val 35 40 45Leu
His Leu Ala Ser Leu Gln Leu Gly Leu Leu Leu Asn Gly Val Cys 50 55
60Ser Leu Ala Glu Glu Leu Arg His Ile His Ser Arg Tyr Arg Gly Ser65
70 75 80Tyr Trp Arg Thr Val Arg Ala Cys Leu Gly Cys Pro Leu Arg Arg
Gly 85 90 95Ala Leu Leu Leu Leu Ser Ile Tyr Phe Tyr Tyr Ser Leu Pro
Asn Ala 100 105 110Val Gly Pro Pro Phe Thr Trp Met Leu Ala Leu Leu
Gly Leu Ser Gln 115 120 125Ala Leu Asn Ile Leu Leu Gly Leu Lys Gly
Leu Ala Pro Ala Glu Ile 130 135 140Ser Ala Val Cys Glu Lys Gly Asn
Phe Asn Met Ala His Gly Leu Ala145 150 155 160Trp Ser Tyr Tyr Ile
Gly Tyr Leu Arg Leu Ile Leu Pro Glu Leu Gln 165 170 175Ala Arg Ile
Arg Thr Tyr Asn Gln His Tyr Asn Asn Leu Leu Arg Gly 180 185 190Ala
Val Ser Gln Arg Leu Tyr Ile Leu Leu Pro Leu Asp Cys Gly Val 195 200
205Pro Asp Asn Leu Ser Met Ala Asp Pro Asn Ile Arg Phe Leu Asp Lys
210 215 220Leu Pro Gln Gln Thr Gly Asp His Ala Gly Ile Lys Asp Arg
Val Tyr225 230 235 240Ser Asn Ser Ile Tyr Glu Leu Leu Glu Asn Gly
Gln Arg Ala Gly Thr 245 250 255Cys Val Leu Glu Tyr Ala Thr Pro Leu
Gln Thr Leu Phe Ala Met Ser 260 265 270Gln Tyr Ser Gln Ala Gly Phe
Ser Arg Glu Asp Arg Leu Glu Gln Ala 275 280 285Lys Leu Phe Cys Arg
Thr Leu Glu Asp Ile Leu Ala Asp Ala Pro Glu 290 295 300Ser Gln Asn
Asn Cys Arg Leu Ile Ala Tyr Gln Glu Pro Ala Asp
Asp305 310 315 320Ser Ser Phe Ser Leu Ser Gln Glu Val Leu Arg His
Leu Arg Gln Glu 325 330 335Glu Lys Glu Glu Val Thr Val Gly Ser Leu
Lys Thr Ser Ala Val Pro 340 345 350Ser Thr Ser Thr Met Ser Gln Glu
Pro Glu Leu Leu Ile Ser Gly Met 355 360 365Glu Lys Pro Leu Pro Leu
Arg Thr Asp Phe Ser Ala Thr Asn Phe Ser 370 375 380Leu Leu Lys Gln
Ala Gly Asp Val Glu Glu Asn Pro Gly Pro Met Lys385 390 395 400Leu
Val Val Val Gly Ala Val Gly Val Gly Lys Ser Ala Leu 405
41050414PRTArtificial SequenceSynthetic
KRAS(G13D)15mer_nt.STING(V155M 50Met Pro His Ser Ser Leu His Pro
Ser Ile Pro Cys Pro Arg Gly His1 5 10 15Gly Ala Gln Lys Ala Ala Leu
Val Leu Leu Ser Ala Cys Leu Val Thr 20 25 30Leu Trp Gly Leu Gly Glu
Pro Pro Glu His Thr Leu Arg Tyr Leu Val 35 40 45Leu His Leu Ala Ser
Leu Gln Leu Gly Leu Leu Leu Asn Gly Val Cys 50 55 60Ser Leu Ala Glu
Glu Leu Arg His Ile His Ser Arg Tyr Arg Gly Ser65 70 75 80Tyr Trp
Arg Thr Val Arg Ala Cys Leu Gly Cys Pro Leu Arg Arg Gly 85 90 95Ala
Leu Leu Leu Leu Ser Ile Tyr Phe Tyr Tyr Ser Leu Pro Asn Ala 100 105
110Val Gly Pro Pro Phe Thr Trp Met Leu Ala Leu Leu Gly Leu Ser Gln
115 120 125Ala Leu Asn Ile Leu Leu Gly Leu Lys Gly Leu Ala Pro Ala
Glu Ile 130 135 140Ser Ala Val Cys Glu Lys Gly Asn Phe Asn Met Ala
His Gly Leu Ala145 150 155 160Trp Ser Tyr Tyr Ile Gly Tyr Leu Arg
Leu Ile Leu Pro Glu Leu Gln 165 170 175Ala Arg Ile Arg Thr Tyr Asn
Gln His Tyr Asn Asn Leu Leu Arg Gly 180 185 190Ala Val Ser Gln Arg
Leu Tyr Ile Leu Leu Pro Leu Asp Cys Gly Val 195 200 205Pro Asp Asn
Leu Ser Met Ala Asp Pro Asn Ile Arg Phe Leu Asp Lys 210 215 220Leu
Pro Gln Gln Thr Gly Asp His Ala Gly Ile Lys Asp Arg Val Tyr225 230
235 240Ser Asn Ser Ile Tyr Glu Leu Leu Glu Asn Gly Gln Arg Ala Gly
Thr 245 250 255Cys Val Leu Glu Tyr Ala Thr Pro Leu Gln Thr Leu Phe
Ala Met Ser 260 265 270Gln Tyr Ser Gln Ala Gly Phe Ser Arg Glu Asp
Arg Leu Glu Gln Ala 275 280 285Lys Leu Phe Cys Arg Thr Leu Glu Asp
Ile Leu Ala Asp Ala Pro Glu 290 295 300Ser Gln Asn Asn Cys Arg Leu
Ile Ala Tyr Gln Glu Pro Ala Asp Asp305 310 315 320Ser Ser Phe Ser
Leu Ser Gln Glu Val Leu Arg His Leu Arg Gln Glu 325 330 335Glu Lys
Glu Glu Val Thr Val Gly Ser Leu Lys Thr Ser Ala Val Pro 340 345
350Ser Thr Ser Thr Met Ser Gln Glu Pro Glu Leu Leu Ile Ser Gly Met
355 360 365Glu Lys Pro Leu Pro Leu Arg Thr Asp Phe Ser Ala Thr Asn
Phe Ser 370 375 380Leu Leu Lys Gln Ala Gly Asp Val Glu Glu Asn Pro
Gly Pro Met Leu385 390 395 400Val Val Val Gly Ala Gly Asp Val Gly
Lys Ser Ala Leu Thr 405 41051423PRTArtificial SequenceSynthetic
KRAS(G12D)25mer_nt.STING(V155M) 51Met Pro His Ser Ser Leu His Pro
Ser Ile Pro Cys Pro Arg Gly His1 5 10 15Gly Ala Gln Lys Ala Ala Leu
Val Leu Leu Ser Ala Cys Leu Val Thr 20 25 30Leu Trp Gly Leu Gly Glu
Pro Pro Glu His Thr Leu Arg Tyr Leu Val 35 40 45Leu His Leu Ala Ser
Leu Gln Leu Gly Leu Leu Leu Asn Gly Val Cys 50 55 60Ser Leu Ala Glu
Glu Leu Arg His Ile His Ser Arg Tyr Arg Gly Ser65 70 75 80Tyr Trp
Arg Thr Val Arg Ala Cys Leu Gly Cys Pro Leu Arg Arg Gly 85 90 95Ala
Leu Leu Leu Leu Ser Ile Tyr Phe Tyr Tyr Ser Leu Pro Asn Ala 100 105
110Val Gly Pro Pro Phe Thr Trp Met Leu Ala Leu Leu Gly Leu Ser Gln
115 120 125Ala Leu Asn Ile Leu Leu Gly Leu Lys Gly Leu Ala Pro Ala
Glu Ile 130 135 140Ser Ala Val Cys Glu Lys Gly Asn Phe Asn Met Ala
His Gly Leu Ala145 150 155 160Trp Ser Tyr Tyr Ile Gly Tyr Leu Arg
Leu Ile Leu Pro Glu Leu Gln 165 170 175Ala Arg Ile Arg Thr Tyr Asn
Gln His Tyr Asn Asn Leu Leu Arg Gly 180 185 190Ala Val Ser Gln Arg
Leu Tyr Ile Leu Leu Pro Leu Asp Cys Gly Val 195 200 205Pro Asp Asn
Leu Ser Met Ala Asp Pro Asn Ile Arg Phe Leu Asp Lys 210 215 220Leu
Pro Gln Gln Thr Gly Asp His Ala Gly Ile Lys Asp Arg Val Tyr225 230
235 240Ser Asn Ser Ile Tyr Glu Leu Leu Glu Asn Gly Gln Arg Ala Gly
Thr 245 250 255Cys Val Leu Glu Tyr Ala Thr Pro Leu Gln Thr Leu Phe
Ala Met Ser 260 265 270Gln Tyr Ser Gln Ala Gly Phe Ser Arg Glu Asp
Arg Leu Glu Gln Ala 275 280 285Lys Leu Phe Cys Arg Thr Leu Glu Asp
Ile Leu Ala Asp Ala Pro Glu 290 295 300Ser Gln Asn Asn Cys Arg Leu
Ile Ala Tyr Gln Glu Pro Ala Asp Asp305 310 315 320Ser Ser Phe Ser
Leu Ser Gln Glu Val Leu Arg His Leu Arg Gln Glu 325 330 335Glu Lys
Glu Glu Val Thr Val Gly Ser Leu Lys Thr Ser Ala Val Pro 340 345
350Ser Thr Ser Thr Met Ser Gln Glu Pro Glu Leu Leu Ile Ser Gly Met
355 360 365Glu Lys Pro Leu Pro Leu Arg Thr Asp Phe Ser Ala Thr Asn
Phe Ser 370 375 380Leu Leu Lys Gln Ala Gly Asp Val Glu Glu Asn Pro
Gly Pro Met Thr385 390 395 400Glu Tyr Lys Leu Val Val Val Gly Ala
Asp Gly Val Gly Lys Ser Ala 405 410 415Leu Thr Ile Gln Leu Ile Gln
42052423PRTArtificial SequenceSynthetic
KRAS(G12V)25mer_nt.STING(V155M 52Met Pro His Ser Ser Leu His Pro
Ser Ile Pro Cys Pro Arg Gly His1 5 10 15Gly Ala Gln Lys Ala Ala Leu
Val Leu Leu Ser Ala Cys Leu Val Thr 20 25 30Leu Trp Gly Leu Gly Glu
Pro Pro Glu His Thr Leu Arg Tyr Leu Val 35 40 45Leu His Leu Ala Ser
Leu Gln Leu Gly Leu Leu Leu Asn Gly Val Cys 50 55 60Ser Leu Ala Glu
Glu Leu Arg His Ile His Ser Arg Tyr Arg Gly Ser65 70 75 80Tyr Trp
Arg Thr Val Arg Ala Cys Leu Gly Cys Pro Leu Arg Arg Gly 85 90 95Ala
Leu Leu Leu Leu Ser Ile Tyr Phe Tyr Tyr Ser Leu Pro Asn Ala 100 105
110Val Gly Pro Pro Phe Thr Trp Met Leu Ala Leu Leu Gly Leu Ser Gln
115 120 125Ala Leu Asn Ile Leu Leu Gly Leu Lys Gly Leu Ala Pro Ala
Glu Ile 130 135 140Ser Ala Val Cys Glu Lys Gly Asn Phe Asn Met Ala
His Gly Leu Ala145 150 155 160Trp Ser Tyr Tyr Ile Gly Tyr Leu Arg
Leu Ile Leu Pro Glu Leu Gln 165 170 175Ala Arg Ile Arg Thr Tyr Asn
Gln His Tyr Asn Asn Leu Leu Arg Gly 180 185 190Ala Val Ser Gln Arg
Leu Tyr Ile Leu Leu Pro Leu Asp Cys Gly Val 195 200 205Pro Asp Asn
Leu Ser Met Ala Asp Pro Asn Ile Arg Phe Leu Asp Lys 210 215 220Leu
Pro Gln Gln Thr Gly Asp His Ala Gly Ile Lys Asp Arg Val Tyr225 230
235 240Ser Asn Ser Ile Tyr Glu Leu Leu Glu Asn Gly Gln Arg Ala Gly
Thr 245 250 255Cys Val Leu Glu Tyr Ala Thr Pro Leu Gln Thr Leu Phe
Ala Met Ser 260 265 270Gln Tyr Ser Gln Ala Gly Phe Ser Arg Glu Asp
Arg Leu Glu Gln Ala 275 280 285Lys Leu Phe Cys Arg Thr Leu Glu Asp
Ile Leu Ala Asp Ala Pro Glu 290 295 300Ser Gln Asn Asn Cys Arg Leu
Ile Ala Tyr Gln Glu Pro Ala Asp Asp305 310 315 320Ser Ser Phe Ser
Leu Ser Gln Glu Val Leu Arg His Leu Arg Gln Glu 325 330 335Glu Lys
Glu Glu Val Thr Val Gly Ser Leu Lys Thr Ser Ala Val Pro 340 345
350Ser Thr Ser Thr Met Ser Gln Glu Pro Glu Leu Leu Ile Ser Gly Met
355 360 365Glu Lys Pro Leu Pro Leu Arg Thr Asp Phe Ser Ala Thr Asn
Phe Ser 370 375 380Leu Leu Lys Gln Ala Gly Asp Val Glu Glu Asn Pro
Gly Pro Met Thr385 390 395 400Glu Tyr Lys Leu Val Val Val Gly Ala
Val Gly Val Gly Lys Ser Ala 405 410 415Leu Thr Ile Gln Leu Ile Gln
42053423PRTArtificial SequenceSynthetic
KRAS(G13D)25mer_nt.STING(V155M 53Met Pro His Ser Ser Leu His Pro
Ser Ile Pro Cys Pro Arg Gly His1 5 10 15Gly Ala Gln Lys Ala Ala Leu
Val Leu Leu Ser Ala Cys Leu Val Thr 20 25 30Leu Trp Gly Leu Gly Glu
Pro Pro Glu His Thr Leu Arg Tyr Leu Val 35 40 45Leu His Leu Ala Ser
Leu Gln Leu Gly Leu Leu Leu Asn Gly Val Cys 50 55 60Ser Leu Ala Glu
Glu Leu Arg His Ile His Ser Arg Tyr Arg Gly Ser65 70 75 80Tyr Trp
Arg Thr Val Arg Ala Cys Leu Gly Cys Pro Leu Arg Arg Gly 85 90 95Ala
Leu Leu Leu Leu Ser Ile Tyr Phe Tyr Tyr Ser Leu Pro Asn Ala 100 105
110Val Gly Pro Pro Phe Thr Trp Met Leu Ala Leu Leu Gly Leu Ser Gln
115 120 125Ala Leu Asn Ile Leu Leu Gly Leu Lys Gly Leu Ala Pro Ala
Glu Ile 130 135 140Ser Ala Val Cys Glu Lys Gly Asn Phe Asn Met Ala
His Gly Leu Ala145 150 155 160Trp Ser Tyr Tyr Ile Gly Tyr Leu Arg
Leu Ile Leu Pro Glu Leu Gln 165 170 175Ala Arg Ile Arg Thr Tyr Asn
Gln His Tyr Asn Asn Leu Leu Arg Gly 180 185 190Ala Val Ser Gln Arg
Leu Tyr Ile Leu Leu Pro Leu Asp Cys Gly Val 195 200 205Pro Asp Asn
Leu Ser Met Ala Asp Pro Asn Ile Arg Phe Leu Asp Lys 210 215 220Leu
Pro Gln Gln Thr Gly Asp His Ala Gly Ile Lys Asp Arg Val Tyr225 230
235 240Ser Asn Ser Ile Tyr Glu Leu Leu Glu Asn Gly Gln Arg Ala Gly
Thr 245 250 255Cys Val Leu Glu Tyr Ala Thr Pro Leu Gln Thr Leu Phe
Ala Met Ser 260 265 270Gln Tyr Ser Gln Ala Gly Phe Ser Arg Glu Asp
Arg Leu Glu Gln Ala 275 280 285Lys Leu Phe Cys Arg Thr Leu Glu Asp
Ile Leu Ala Asp Ala Pro Glu 290 295 300Ser Gln Asn Asn Cys Arg Leu
Ile Ala Tyr Gln Glu Pro Ala Asp Asp305 310 315 320Ser Ser Phe Ser
Leu Ser Gln Glu Val Leu Arg His Leu Arg Gln Glu 325 330 335Glu Lys
Glu Glu Val Thr Val Gly Ser Leu Lys Thr Ser Ala Val Pro 340 345
350Ser Thr Ser Thr Met Ser Gln Glu Pro Glu Leu Leu Ile Ser Gly Met
355 360 365Glu Lys Pro Leu Pro Leu Arg Thr Asp Phe Ser Ala Thr Asn
Phe Ser 370 375 380Leu Leu Lys Gln Ala Gly Asp Val Glu Glu Asn Pro
Gly Pro Met Thr385 390 395 400Glu Tyr Lys Leu Val Val Val Gly Ala
Gly Asp Val Gly Lys Ser Ala 405 410 415Leu Thr Ile Gln Leu Ile Gln
42054444PRTArtificial SequenceSynthetic
KRAS(G12D)15mer^3_nt.STING(V155M) 54Met Pro His Ser Ser Leu His Pro
Ser Ile Pro Cys Pro Arg Gly His1 5 10 15Gly Ala Gln Lys Ala Ala Leu
Val Leu Leu Ser Ala Cys Leu Val Thr 20 25 30Leu Trp Gly Leu Gly Glu
Pro Pro Glu His Thr Leu Arg Tyr Leu Val 35 40 45Leu His Leu Ala Ser
Leu Gln Leu Gly Leu Leu Leu Asn Gly Val Cys 50 55 60Ser Leu Ala Glu
Glu Leu Arg His Ile His Ser Arg Tyr Arg Gly Ser65 70 75 80Tyr Trp
Arg Thr Val Arg Ala Cys Leu Gly Cys Pro Leu Arg Arg Gly 85 90 95Ala
Leu Leu Leu Leu Ser Ile Tyr Phe Tyr Tyr Ser Leu Pro Asn Ala 100 105
110Val Gly Pro Pro Phe Thr Trp Met Leu Ala Leu Leu Gly Leu Ser Gln
115 120 125Ala Leu Asn Ile Leu Leu Gly Leu Lys Gly Leu Ala Pro Ala
Glu Ile 130 135 140Ser Ala Val Cys Glu Lys Gly Asn Phe Asn Met Ala
His Gly Leu Ala145 150 155 160Trp Ser Tyr Tyr Ile Gly Tyr Leu Arg
Leu Ile Leu Pro Glu Leu Gln 165 170 175Ala Arg Ile Arg Thr Tyr Asn
Gln His Tyr Asn Asn Leu Leu Arg Gly 180 185 190Ala Val Ser Gln Arg
Leu Tyr Ile Leu Leu Pro Leu Asp Cys Gly Val 195 200 205Pro Asp Asn
Leu Ser Met Ala Asp Pro Asn Ile Arg Phe Leu Asp Lys 210 215 220Leu
Pro Gln Gln Thr Gly Asp His Ala Gly Ile Lys Asp Arg Val Tyr225 230
235 240Ser Asn Ser Ile Tyr Glu Leu Leu Glu Asn Gly Gln Arg Ala Gly
Thr 245 250 255Cys Val Leu Glu Tyr Ala Thr Pro Leu Gln Thr Leu Phe
Ala Met Ser 260 265 270Gln Tyr Ser Gln Ala Gly Phe Ser Arg Glu Asp
Arg Leu Glu Gln Ala 275 280 285Lys Leu Phe Cys Arg Thr Leu Glu Asp
Ile Leu Ala Asp Ala Pro Glu 290 295 300Ser Gln Asn Asn Cys Arg Leu
Ile Ala Tyr Gln Glu Pro Ala Asp Asp305 310 315 320Ser Ser Phe Ser
Leu Ser Gln Glu Val Leu Arg His Leu Arg Gln Glu 325 330 335Glu Lys
Glu Glu Val Thr Val Gly Ser Leu Lys Thr Ser Ala Val Pro 340 345
350Ser Thr Ser Thr Met Ser Gln Glu Pro Glu Leu Leu Ile Ser Gly Met
355 360 365Glu Lys Pro Leu Pro Leu Arg Thr Asp Phe Ser Ala Thr Asn
Phe Ser 370 375 380Leu Leu Lys Gln Ala Gly Asp Val Glu Glu Asn Pro
Gly Pro Met Lys385 390 395 400Leu Val Val Val Gly Ala Asp Gly Val
Gly Lys Ser Ala Leu Lys Leu 405 410 415Val Val Val Gly Ala Asp Gly
Val Gly Lys Ser Ala Leu Lys Leu Val 420 425 430Val Val Gly Ala Asp
Gly Val Gly Lys Ser Ala Leu 435 44055444PRTArtificial
SequenceSynthetic KRAS(G12V)15mer^3_nt.STING(V155M 55Met Pro His
Ser Ser Leu His Pro Ser Ile Pro Cys Pro Arg Gly His1 5 10 15Gly Ala
Gln Lys Ala Ala Leu Val Leu Leu Ser Ala Cys Leu Val Thr 20 25 30Leu
Trp Gly Leu Gly Glu Pro Pro Glu His Thr Leu Arg Tyr Leu Val 35 40
45Leu His Leu Ala Ser Leu Gln Leu Gly Leu Leu Leu Asn Gly Val Cys
50 55 60Ser Leu Ala Glu Glu Leu Arg His Ile His Ser Arg Tyr Arg Gly
Ser65 70 75 80Tyr Trp Arg Thr Val Arg Ala Cys Leu Gly Cys Pro Leu
Arg Arg Gly 85 90 95Ala Leu Leu Leu Leu Ser Ile Tyr Phe Tyr Tyr Ser
Leu Pro Asn Ala 100 105 110Val Gly Pro Pro Phe Thr Trp Met Leu Ala
Leu Leu Gly Leu Ser Gln 115 120 125Ala Leu Asn Ile Leu Leu Gly Leu
Lys Gly Leu Ala Pro Ala Glu Ile 130 135 140Ser Ala Val Cys Glu Lys
Gly Asn Phe Asn Met Ala His Gly Leu Ala145 150 155 160Trp Ser Tyr
Tyr Ile Gly Tyr Leu Arg Leu Ile Leu Pro Glu Leu Gln 165 170 175Ala
Arg Ile Arg Thr Tyr Asn Gln His Tyr Asn Asn
Leu Leu Arg Gly 180 185 190Ala Val Ser Gln Arg Leu Tyr Ile Leu Leu
Pro Leu Asp Cys Gly Val 195 200 205Pro Asp Asn Leu Ser Met Ala Asp
Pro Asn Ile Arg Phe Leu Asp Lys 210 215 220Leu Pro Gln Gln Thr Gly
Asp His Ala Gly Ile Lys Asp Arg Val Tyr225 230 235 240Ser Asn Ser
Ile Tyr Glu Leu Leu Glu Asn Gly Gln Arg Ala Gly Thr 245 250 255Cys
Val Leu Glu Tyr Ala Thr Pro Leu Gln Thr Leu Phe Ala Met Ser 260 265
270Gln Tyr Ser Gln Ala Gly Phe Ser Arg Glu Asp Arg Leu Glu Gln Ala
275 280 285Lys Leu Phe Cys Arg Thr Leu Glu Asp Ile Leu Ala Asp Ala
Pro Glu 290 295 300Ser Gln Asn Asn Cys Arg Leu Ile Ala Tyr Gln Glu
Pro Ala Asp Asp305 310 315 320Ser Ser Phe Ser Leu Ser Gln Glu Val
Leu Arg His Leu Arg Gln Glu 325 330 335Glu Lys Glu Glu Val Thr Val
Gly Ser Leu Lys Thr Ser Ala Val Pro 340 345 350Ser Thr Ser Thr Met
Ser Gln Glu Pro Glu Leu Leu Ile Ser Gly Met 355 360 365Glu Lys Pro
Leu Pro Leu Arg Thr Asp Phe Ser Ala Thr Asn Phe Ser 370 375 380Leu
Leu Lys Gln Ala Gly Asp Val Glu Glu Asn Pro Gly Pro Met Lys385 390
395 400Leu Val Val Val Gly Ala Val Gly Val Gly Lys Ser Ala Leu Lys
Leu 405 410 415Val Val Val Gly Ala Val Gly Val Gly Lys Ser Ala Leu
Lys Leu Val 420 425 430Val Val Gly Ala Val Gly Val Gly Lys Ser Ala
Leu 435 44056444PRTArtificial SequenceSynthetic
KRAS(G13D)15mer^3_nt.STING(V155M 56Met Pro His Ser Ser Leu His Pro
Ser Ile Pro Cys Pro Arg Gly His1 5 10 15Gly Ala Gln Lys Ala Ala Leu
Val Leu Leu Ser Ala Cys Leu Val Thr 20 25 30Leu Trp Gly Leu Gly Glu
Pro Pro Glu His Thr Leu Arg Tyr Leu Val 35 40 45Leu His Leu Ala Ser
Leu Gln Leu Gly Leu Leu Leu Asn Gly Val Cys 50 55 60Ser Leu Ala Glu
Glu Leu Arg His Ile His Ser Arg Tyr Arg Gly Ser65 70 75 80Tyr Trp
Arg Thr Val Arg Ala Cys Leu Gly Cys Pro Leu Arg Arg Gly 85 90 95Ala
Leu Leu Leu Leu Ser Ile Tyr Phe Tyr Tyr Ser Leu Pro Asn Ala 100 105
110Val Gly Pro Pro Phe Thr Trp Met Leu Ala Leu Leu Gly Leu Ser Gln
115 120 125Ala Leu Asn Ile Leu Leu Gly Leu Lys Gly Leu Ala Pro Ala
Glu Ile 130 135 140Ser Ala Val Cys Glu Lys Gly Asn Phe Asn Met Ala
His Gly Leu Ala145 150 155 160Trp Ser Tyr Tyr Ile Gly Tyr Leu Arg
Leu Ile Leu Pro Glu Leu Gln 165 170 175Ala Arg Ile Arg Thr Tyr Asn
Gln His Tyr Asn Asn Leu Leu Arg Gly 180 185 190Ala Val Ser Gln Arg
Leu Tyr Ile Leu Leu Pro Leu Asp Cys Gly Val 195 200 205Pro Asp Asn
Leu Ser Met Ala Asp Pro Asn Ile Arg Phe Leu Asp Lys 210 215 220Leu
Pro Gln Gln Thr Gly Asp His Ala Gly Ile Lys Asp Arg Val Tyr225 230
235 240Ser Asn Ser Ile Tyr Glu Leu Leu Glu Asn Gly Gln Arg Ala Gly
Thr 245 250 255Cys Val Leu Glu Tyr Ala Thr Pro Leu Gln Thr Leu Phe
Ala Met Ser 260 265 270Gln Tyr Ser Gln Ala Gly Phe Ser Arg Glu Asp
Arg Leu Glu Gln Ala 275 280 285Lys Leu Phe Cys Arg Thr Leu Glu Asp
Ile Leu Ala Asp Ala Pro Glu 290 295 300Ser Gln Asn Asn Cys Arg Leu
Ile Ala Tyr Gln Glu Pro Ala Asp Asp305 310 315 320Ser Ser Phe Ser
Leu Ser Gln Glu Val Leu Arg His Leu Arg Gln Glu 325 330 335Glu Lys
Glu Glu Val Thr Val Gly Ser Leu Lys Thr Ser Ala Val Pro 340 345
350Ser Thr Ser Thr Met Ser Gln Glu Pro Glu Leu Leu Ile Ser Gly Met
355 360 365Glu Lys Pro Leu Pro Leu Arg Thr Asp Phe Ser Ala Thr Asn
Phe Ser 370 375 380Leu Leu Lys Gln Ala Gly Asp Val Glu Glu Asn Pro
Gly Pro Met Leu385 390 395 400Val Val Val Gly Ala Gly Asp Val Gly
Lys Ser Ala Leu Thr Leu Val 405 410 415Val Val Gly Ala Gly Asp Val
Gly Lys Ser Ala Leu Thr Leu Val Val 420 425 430Val Gly Ala Gly Asp
Val Gly Lys Ser Ala Leu Thr 435 44057473PRTArtificial
SequenceSynthetic KRAS(G12D)25mer^3_nt.STING(V155M) 57Met Pro His
Ser Ser Leu His Pro Ser Ile Pro Cys Pro Arg Gly His1 5 10 15Gly Ala
Gln Lys Ala Ala Leu Val Leu Leu Ser Ala Cys Leu Val Thr 20 25 30Leu
Trp Gly Leu Gly Glu Pro Pro Glu His Thr Leu Arg Tyr Leu Val 35 40
45Leu His Leu Ala Ser Leu Gln Leu Gly Leu Leu Leu Asn Gly Val Cys
50 55 60Ser Leu Ala Glu Glu Leu Arg His Ile His Ser Arg Tyr Arg Gly
Ser65 70 75 80Tyr Trp Arg Thr Val Arg Ala Cys Leu Gly Cys Pro Leu
Arg Arg Gly 85 90 95Ala Leu Leu Leu Leu Ser Ile Tyr Phe Tyr Tyr Ser
Leu Pro Asn Ala 100 105 110Val Gly Pro Pro Phe Thr Trp Met Leu Ala
Leu Leu Gly Leu Ser Gln 115 120 125Ala Leu Asn Ile Leu Leu Gly Leu
Lys Gly Leu Ala Pro Ala Glu Ile 130 135 140Ser Ala Val Cys Glu Lys
Gly Asn Phe Asn Met Ala His Gly Leu Ala145 150 155 160Trp Ser Tyr
Tyr Ile Gly Tyr Leu Arg Leu Ile Leu Pro Glu Leu Gln 165 170 175Ala
Arg Ile Arg Thr Tyr Asn Gln His Tyr Asn Asn Leu Leu Arg Gly 180 185
190Ala Val Ser Gln Arg Leu Tyr Ile Leu Leu Pro Leu Asp Cys Gly Val
195 200 205Pro Asp Asn Leu Ser Met Ala Asp Pro Asn Ile Arg Phe Leu
Asp Lys 210 215 220Leu Pro Gln Gln Thr Gly Asp His Ala Gly Ile Lys
Asp Arg Val Tyr225 230 235 240Ser Asn Ser Ile Tyr Glu Leu Leu Glu
Asn Gly Gln Arg Ala Gly Thr 245 250 255Cys Val Leu Glu Tyr Ala Thr
Pro Leu Gln Thr Leu Phe Ala Met Ser 260 265 270Gln Tyr Ser Gln Ala
Gly Phe Ser Arg Glu Asp Arg Leu Glu Gln Ala 275 280 285Lys Leu Phe
Cys Arg Thr Leu Glu Asp Ile Leu Ala Asp Ala Pro Glu 290 295 300Ser
Gln Asn Asn Cys Arg Leu Ile Ala Tyr Gln Glu Pro Ala Asp Asp305 310
315 320Ser Ser Phe Ser Leu Ser Gln Glu Val Leu Arg His Leu Arg Gln
Glu 325 330 335Glu Lys Glu Glu Val Thr Val Gly Ser Leu Lys Thr Ser
Ala Val Pro 340 345 350Ser Thr Ser Thr Met Ser Gln Glu Pro Glu Leu
Leu Ile Ser Gly Met 355 360 365Glu Lys Pro Leu Pro Leu Arg Thr Asp
Phe Ser Ala Thr Asn Phe Ser 370 375 380Leu Leu Lys Gln Ala Gly Asp
Val Glu Glu Asn Pro Gly Pro Met Thr385 390 395 400Glu Tyr Lys Leu
Val Val Val Gly Ala Asp Gly Val Gly Lys Ser Ala 405 410 415Leu Thr
Ile Gln Leu Ile Gln Met Thr Glu Tyr Lys Leu Val Val Val 420 425
430Gly Ala Asp Gly Val Gly Lys Ser Ala Leu Thr Ile Gln Leu Ile Gln
435 440 445Met Thr Glu Tyr Lys Leu Val Val Val Gly Ala Asp Gly Val
Gly Lys 450 455 460Ser Ala Leu Thr Ile Gln Leu Ile Gln465
47058473PRTArtificial SequenceSynthetic
KRAS(G12V)25mer^3_nt.STING(V155M 58Met Pro His Ser Ser Leu His Pro
Ser Ile Pro Cys Pro Arg Gly His1 5 10 15Gly Ala Gln Lys Ala Ala Leu
Val Leu Leu Ser Ala Cys Leu Val Thr 20 25 30Leu Trp Gly Leu Gly Glu
Pro Pro Glu His Thr Leu Arg Tyr Leu Val 35 40 45Leu His Leu Ala Ser
Leu Gln Leu Gly Leu Leu Leu Asn Gly Val Cys 50 55 60Ser Leu Ala Glu
Glu Leu Arg His Ile His Ser Arg Tyr Arg Gly Ser65 70 75 80Tyr Trp
Arg Thr Val Arg Ala Cys Leu Gly Cys Pro Leu Arg Arg Gly 85 90 95Ala
Leu Leu Leu Leu Ser Ile Tyr Phe Tyr Tyr Ser Leu Pro Asn Ala 100 105
110Val Gly Pro Pro Phe Thr Trp Met Leu Ala Leu Leu Gly Leu Ser Gln
115 120 125Ala Leu Asn Ile Leu Leu Gly Leu Lys Gly Leu Ala Pro Ala
Glu Ile 130 135 140Ser Ala Val Cys Glu Lys Gly Asn Phe Asn Met Ala
His Gly Leu Ala145 150 155 160Trp Ser Tyr Tyr Ile Gly Tyr Leu Arg
Leu Ile Leu Pro Glu Leu Gln 165 170 175Ala Arg Ile Arg Thr Tyr Asn
Gln His Tyr Asn Asn Leu Leu Arg Gly 180 185 190Ala Val Ser Gln Arg
Leu Tyr Ile Leu Leu Pro Leu Asp Cys Gly Val 195 200 205Pro Asp Asn
Leu Ser Met Ala Asp Pro Asn Ile Arg Phe Leu Asp Lys 210 215 220Leu
Pro Gln Gln Thr Gly Asp His Ala Gly Ile Lys Asp Arg Val Tyr225 230
235 240Ser Asn Ser Ile Tyr Glu Leu Leu Glu Asn Gly Gln Arg Ala Gly
Thr 245 250 255Cys Val Leu Glu Tyr Ala Thr Pro Leu Gln Thr Leu Phe
Ala Met Ser 260 265 270Gln Tyr Ser Gln Ala Gly Phe Ser Arg Glu Asp
Arg Leu Glu Gln Ala 275 280 285Lys Leu Phe Cys Arg Thr Leu Glu Asp
Ile Leu Ala Asp Ala Pro Glu 290 295 300Ser Gln Asn Asn Cys Arg Leu
Ile Ala Tyr Gln Glu Pro Ala Asp Asp305 310 315 320Ser Ser Phe Ser
Leu Ser Gln Glu Val Leu Arg His Leu Arg Gln Glu 325 330 335Glu Lys
Glu Glu Val Thr Val Gly Ser Leu Lys Thr Ser Ala Val Pro 340 345
350Ser Thr Ser Thr Met Ser Gln Glu Pro Glu Leu Leu Ile Ser Gly Met
355 360 365Glu Lys Pro Leu Pro Leu Arg Thr Asp Phe Ser Ala Thr Asn
Phe Ser 370 375 380Leu Leu Lys Gln Ala Gly Asp Val Glu Glu Asn Pro
Gly Pro Met Thr385 390 395 400Glu Tyr Lys Leu Val Val Val Gly Ala
Val Gly Val Gly Lys Ser Ala 405 410 415Leu Thr Ile Gln Leu Ile Gln
Met Thr Glu Tyr Lys Leu Val Val Val 420 425 430Gly Ala Val Gly Val
Gly Lys Ser Ala Leu Thr Ile Gln Leu Ile Gln 435 440 445Met Thr Glu
Tyr Lys Leu Val Val Val Gly Ala Val Gly Val Gly Lys 450 455 460Ser
Ala Leu Thr Ile Gln Leu Ile Gln465 47059473PRTArtificial
SequenceSynthetic KRAS(G13D)25mer^3_nt.STING(V155M 59Met Pro His
Ser Ser Leu His Pro Ser Ile Pro Cys Pro Arg Gly His1 5 10 15Gly Ala
Gln Lys Ala Ala Leu Val Leu Leu Ser Ala Cys Leu Val Thr 20 25 30Leu
Trp Gly Leu Gly Glu Pro Pro Glu His Thr Leu Arg Tyr Leu Val 35 40
45Leu His Leu Ala Ser Leu Gln Leu Gly Leu Leu Leu Asn Gly Val Cys
50 55 60Ser Leu Ala Glu Glu Leu Arg His Ile His Ser Arg Tyr Arg Gly
Ser65 70 75 80Tyr Trp Arg Thr Val Arg Ala Cys Leu Gly Cys Pro Leu
Arg Arg Gly 85 90 95Ala Leu Leu Leu Leu Ser Ile Tyr Phe Tyr Tyr Ser
Leu Pro Asn Ala 100 105 110Val Gly Pro Pro Phe Thr Trp Met Leu Ala
Leu Leu Gly Leu Ser Gln 115 120 125Ala Leu Asn Ile Leu Leu Gly Leu
Lys Gly Leu Ala Pro Ala Glu Ile 130 135 140Ser Ala Val Cys Glu Lys
Gly Asn Phe Asn Met Ala His Gly Leu Ala145 150 155 160Trp Ser Tyr
Tyr Ile Gly Tyr Leu Arg Leu Ile Leu Pro Glu Leu Gln 165 170 175Ala
Arg Ile Arg Thr Tyr Asn Gln His Tyr Asn Asn Leu Leu Arg Gly 180 185
190Ala Val Ser Gln Arg Leu Tyr Ile Leu Leu Pro Leu Asp Cys Gly Val
195 200 205Pro Asp Asn Leu Ser Met Ala Asp Pro Asn Ile Arg Phe Leu
Asp Lys 210 215 220Leu Pro Gln Gln Thr Gly Asp His Ala Gly Ile Lys
Asp Arg Val Tyr225 230 235 240Ser Asn Ser Ile Tyr Glu Leu Leu Glu
Asn Gly Gln Arg Ala Gly Thr 245 250 255Cys Val Leu Glu Tyr Ala Thr
Pro Leu Gln Thr Leu Phe Ala Met Ser 260 265 270Gln Tyr Ser Gln Ala
Gly Phe Ser Arg Glu Asp Arg Leu Glu Gln Ala 275 280 285Lys Leu Phe
Cys Arg Thr Leu Glu Asp Ile Leu Ala Asp Ala Pro Glu 290 295 300Ser
Gln Asn Asn Cys Arg Leu Ile Ala Tyr Gln Glu Pro Ala Asp Asp305 310
315 320Ser Ser Phe Ser Leu Ser Gln Glu Val Leu Arg His Leu Arg Gln
Glu 325 330 335Glu Lys Glu Glu Val Thr Val Gly Ser Leu Lys Thr Ser
Ala Val Pro 340 345 350Ser Thr Ser Thr Met Ser Gln Glu Pro Glu Leu
Leu Ile Ser Gly Met 355 360 365Glu Lys Pro Leu Pro Leu Arg Thr Asp
Phe Ser Ala Thr Asn Phe Ser 370 375 380Leu Leu Lys Gln Ala Gly Asp
Val Glu Glu Asn Pro Gly Pro Met Thr385 390 395 400Glu Tyr Lys Leu
Val Val Val Gly Ala Gly Asp Val Gly Lys Ser Ala 405 410 415Leu Thr
Ile Gln Leu Ile Gln Met Thr Glu Tyr Lys Leu Val Val Val 420 425
430Gly Ala Gly Asp Val Gly Lys Ser Ala Leu Thr Ile Gln Leu Ile Gln
435 440 445Met Thr Glu Tyr Lys Leu Val Val Val Gly Ala Gly Asp Val
Gly Lys 450 455 460Ser Ala Leu Thr Ile Gln Leu Ile Gln465
47060414PRTArtificial SequenceSynthetic
KRAS(G12D)15mer_ct.STING(V155M) 60Met Lys Leu Val Val Val Gly Ala
Asp Gly Val Gly Lys Ser Ala Leu1 5 10 15Ala Thr Asn Phe Ser Leu Leu
Lys Gln Ala Gly Asp Val Glu Glu Asn 20 25 30Pro Gly Pro Met Pro His
Ser Ser Leu His Pro Ser Ile Pro Cys Pro 35 40 45Arg Gly His Gly Ala
Gln Lys Ala Ala Leu Val Leu Leu Ser Ala Cys 50 55 60Leu Val Thr Leu
Trp Gly Leu Gly Glu Pro Pro Glu His Thr Leu Arg65 70 75 80Tyr Leu
Val Leu His Leu Ala Ser Leu Gln Leu Gly Leu Leu Leu Asn 85 90 95Gly
Val Cys Ser Leu Ala Glu Glu Leu Arg His Ile His Ser Arg Tyr 100 105
110Arg Gly Ser Tyr Trp Arg Thr Val Arg Ala Cys Leu Gly Cys Pro Leu
115 120 125Arg Arg Gly Ala Leu Leu Leu Leu Ser Ile Tyr Phe Tyr Tyr
Ser Leu 130 135 140Pro Asn Ala Val Gly Pro Pro Phe Thr Trp Met Leu
Ala Leu Leu Gly145 150 155 160Leu Ser Gln Ala Leu Asn Ile Leu Leu
Gly Leu Lys Gly Leu Ala Pro 165 170 175Ala Glu Ile Ser Ala Val Cys
Glu Lys Gly Asn Phe Asn Met Ala His 180 185 190Gly Leu Ala Trp Ser
Tyr Tyr Ile Gly Tyr Leu Arg Leu Ile Leu Pro 195 200 205Glu Leu Gln
Ala Arg Ile Arg Thr Tyr Asn Gln His Tyr Asn Asn Leu 210 215 220Leu
Arg Gly Ala Val Ser Gln Arg Leu Tyr Ile Leu Leu Pro Leu Asp225 230
235 240Cys Gly Val Pro Asp Asn Leu Ser Met Ala Asp Pro Asn Ile Arg
Phe 245 250 255Leu Asp Lys Leu Pro Gln Gln Thr Gly Asp His Ala Gly
Ile Lys Asp 260 265 270Arg Val Tyr Ser Asn Ser Ile Tyr Glu Leu Leu
Glu Asn Gly Gln Arg 275 280 285Ala Gly Thr Cys Val Leu Glu Tyr Ala
Thr Pro Leu Gln Thr Leu Phe 290 295
300Ala Met Ser Gln Tyr Ser Gln Ala Gly Phe Ser Arg Glu Asp Arg
Leu305 310 315 320Glu Gln Ala Lys Leu Phe Cys Arg Thr Leu Glu Asp
Ile Leu Ala Asp 325 330 335Ala Pro Glu Ser Gln Asn Asn Cys Arg Leu
Ile Ala Tyr Gln Glu Pro 340 345 350Ala Asp Asp Ser Ser Phe Ser Leu
Ser Gln Glu Val Leu Arg His Leu 355 360 365Arg Gln Glu Glu Lys Glu
Glu Val Thr Val Gly Ser Leu Lys Thr Ser 370 375 380Ala Val Pro Ser
Thr Ser Thr Met Ser Gln Glu Pro Glu Leu Leu Ile385 390 395 400Ser
Gly Met Glu Lys Pro Leu Pro Leu Arg Thr Asp Phe Ser 405
41061414PRTArtificial SequenceSynthetic
KRAS(G12V)15mer_ct.STING(V155M 61Met Lys Leu Val Val Val Gly Ala
Val Gly Val Gly Lys Ser Ala Leu1 5 10 15Ala Thr Asn Phe Ser Leu Leu
Lys Gln Ala Gly Asp Val Glu Glu Asn 20 25 30Pro Gly Pro Met Pro His
Ser Ser Leu His Pro Ser Ile Pro Cys Pro 35 40 45Arg Gly His Gly Ala
Gln Lys Ala Ala Leu Val Leu Leu Ser Ala Cys 50 55 60Leu Val Thr Leu
Trp Gly Leu Gly Glu Pro Pro Glu His Thr Leu Arg65 70 75 80Tyr Leu
Val Leu His Leu Ala Ser Leu Gln Leu Gly Leu Leu Leu Asn 85 90 95Gly
Val Cys Ser Leu Ala Glu Glu Leu Arg His Ile His Ser Arg Tyr 100 105
110Arg Gly Ser Tyr Trp Arg Thr Val Arg Ala Cys Leu Gly Cys Pro Leu
115 120 125Arg Arg Gly Ala Leu Leu Leu Leu Ser Ile Tyr Phe Tyr Tyr
Ser Leu 130 135 140Pro Asn Ala Val Gly Pro Pro Phe Thr Trp Met Leu
Ala Leu Leu Gly145 150 155 160Leu Ser Gln Ala Leu Asn Ile Leu Leu
Gly Leu Lys Gly Leu Ala Pro 165 170 175Ala Glu Ile Ser Ala Val Cys
Glu Lys Gly Asn Phe Asn Met Ala His 180 185 190Gly Leu Ala Trp Ser
Tyr Tyr Ile Gly Tyr Leu Arg Leu Ile Leu Pro 195 200 205Glu Leu Gln
Ala Arg Ile Arg Thr Tyr Asn Gln His Tyr Asn Asn Leu 210 215 220Leu
Arg Gly Ala Val Ser Gln Arg Leu Tyr Ile Leu Leu Pro Leu Asp225 230
235 240Cys Gly Val Pro Asp Asn Leu Ser Met Ala Asp Pro Asn Ile Arg
Phe 245 250 255Leu Asp Lys Leu Pro Gln Gln Thr Gly Asp His Ala Gly
Ile Lys Asp 260 265 270Arg Val Tyr Ser Asn Ser Ile Tyr Glu Leu Leu
Glu Asn Gly Gln Arg 275 280 285Ala Gly Thr Cys Val Leu Glu Tyr Ala
Thr Pro Leu Gln Thr Leu Phe 290 295 300Ala Met Ser Gln Tyr Ser Gln
Ala Gly Phe Ser Arg Glu Asp Arg Leu305 310 315 320Glu Gln Ala Lys
Leu Phe Cys Arg Thr Leu Glu Asp Ile Leu Ala Asp 325 330 335Ala Pro
Glu Ser Gln Asn Asn Cys Arg Leu Ile Ala Tyr Gln Glu Pro 340 345
350Ala Asp Asp Ser Ser Phe Ser Leu Ser Gln Glu Val Leu Arg His Leu
355 360 365Arg Gln Glu Glu Lys Glu Glu Val Thr Val Gly Ser Leu Lys
Thr Ser 370 375 380Ala Val Pro Ser Thr Ser Thr Met Ser Gln Glu Pro
Glu Leu Leu Ile385 390 395 400Ser Gly Met Glu Lys Pro Leu Pro Leu
Arg Thr Asp Phe Ser 405 41062414PRTArtificial SequenceSynthetic
KRAS(G13D)15mer_ct.STING(V155M 62Met Leu Val Val Val Gly Ala Gly
Asp Val Gly Lys Ser Ala Leu Thr1 5 10 15Ala Thr Asn Phe Ser Leu Leu
Lys Gln Ala Gly Asp Val Glu Glu Asn 20 25 30Pro Gly Pro Met Pro His
Ser Ser Leu His Pro Ser Ile Pro Cys Pro 35 40 45Arg Gly His Gly Ala
Gln Lys Ala Ala Leu Val Leu Leu Ser Ala Cys 50 55 60Leu Val Thr Leu
Trp Gly Leu Gly Glu Pro Pro Glu His Thr Leu Arg65 70 75 80Tyr Leu
Val Leu His Leu Ala Ser Leu Gln Leu Gly Leu Leu Leu Asn 85 90 95Gly
Val Cys Ser Leu Ala Glu Glu Leu Arg His Ile His Ser Arg Tyr 100 105
110Arg Gly Ser Tyr Trp Arg Thr Val Arg Ala Cys Leu Gly Cys Pro Leu
115 120 125Arg Arg Gly Ala Leu Leu Leu Leu Ser Ile Tyr Phe Tyr Tyr
Ser Leu 130 135 140Pro Asn Ala Val Gly Pro Pro Phe Thr Trp Met Leu
Ala Leu Leu Gly145 150 155 160Leu Ser Gln Ala Leu Asn Ile Leu Leu
Gly Leu Lys Gly Leu Ala Pro 165 170 175Ala Glu Ile Ser Ala Val Cys
Glu Lys Gly Asn Phe Asn Met Ala His 180 185 190Gly Leu Ala Trp Ser
Tyr Tyr Ile Gly Tyr Leu Arg Leu Ile Leu Pro 195 200 205Glu Leu Gln
Ala Arg Ile Arg Thr Tyr Asn Gln His Tyr Asn Asn Leu 210 215 220Leu
Arg Gly Ala Val Ser Gln Arg Leu Tyr Ile Leu Leu Pro Leu Asp225 230
235 240Cys Gly Val Pro Asp Asn Leu Ser Met Ala Asp Pro Asn Ile Arg
Phe 245 250 255Leu Asp Lys Leu Pro Gln Gln Thr Gly Asp His Ala Gly
Ile Lys Asp 260 265 270Arg Val Tyr Ser Asn Ser Ile Tyr Glu Leu Leu
Glu Asn Gly Gln Arg 275 280 285Ala Gly Thr Cys Val Leu Glu Tyr Ala
Thr Pro Leu Gln Thr Leu Phe 290 295 300Ala Met Ser Gln Tyr Ser Gln
Ala Gly Phe Ser Arg Glu Asp Arg Leu305 310 315 320Glu Gln Ala Lys
Leu Phe Cys Arg Thr Leu Glu Asp Ile Leu Ala Asp 325 330 335Ala Pro
Glu Ser Gln Asn Asn Cys Arg Leu Ile Ala Tyr Gln Glu Pro 340 345
350Ala Asp Asp Ser Ser Phe Ser Leu Ser Gln Glu Val Leu Arg His Leu
355 360 365Arg Gln Glu Glu Lys Glu Glu Val Thr Val Gly Ser Leu Lys
Thr Ser 370 375 380Ala Val Pro Ser Thr Ser Thr Met Ser Gln Glu Pro
Glu Leu Leu Ile385 390 395 400Ser Gly Met Glu Lys Pro Leu Pro Leu
Arg Thr Asp Phe Ser 405 41063423PRTArtificial SequenceSynthetic
KRAS(G12D)25mer_ct.STING(V155M) 63Met Thr Glu Tyr Lys Leu Val Val
Val Gly Ala Asp Gly Val Gly Lys1 5 10 15Ser Ala Leu Thr Ile Gln Leu
Ile Gln Ala Thr Asn Phe Ser Leu Leu 20 25 30Lys Gln Ala Gly Asp Val
Glu Glu Asn Pro Gly Pro Met Pro His Ser 35 40 45Ser Leu His Pro Ser
Ile Pro Cys Pro Arg Gly His Gly Ala Gln Lys 50 55 60Ala Ala Leu Val
Leu Leu Ser Ala Cys Leu Val Thr Leu Trp Gly Leu65 70 75 80Gly Glu
Pro Pro Glu His Thr Leu Arg Tyr Leu Val Leu His Leu Ala 85 90 95Ser
Leu Gln Leu Gly Leu Leu Leu Asn Gly Val Cys Ser Leu Ala Glu 100 105
110Glu Leu Arg His Ile His Ser Arg Tyr Arg Gly Ser Tyr Trp Arg Thr
115 120 125Val Arg Ala Cys Leu Gly Cys Pro Leu Arg Arg Gly Ala Leu
Leu Leu 130 135 140Leu Ser Ile Tyr Phe Tyr Tyr Ser Leu Pro Asn Ala
Val Gly Pro Pro145 150 155 160Phe Thr Trp Met Leu Ala Leu Leu Gly
Leu Ser Gln Ala Leu Asn Ile 165 170 175Leu Leu Gly Leu Lys Gly Leu
Ala Pro Ala Glu Ile Ser Ala Val Cys 180 185 190Glu Lys Gly Asn Phe
Asn Met Ala His Gly Leu Ala Trp Ser Tyr Tyr 195 200 205Ile Gly Tyr
Leu Arg Leu Ile Leu Pro Glu Leu Gln Ala Arg Ile Arg 210 215 220Thr
Tyr Asn Gln His Tyr Asn Asn Leu Leu Arg Gly Ala Val Ser Gln225 230
235 240Arg Leu Tyr Ile Leu Leu Pro Leu Asp Cys Gly Val Pro Asp Asn
Leu 245 250 255Ser Met Ala Asp Pro Asn Ile Arg Phe Leu Asp Lys Leu
Pro Gln Gln 260 265 270Thr Gly Asp His Ala Gly Ile Lys Asp Arg Val
Tyr Ser Asn Ser Ile 275 280 285Tyr Glu Leu Leu Glu Asn Gly Gln Arg
Ala Gly Thr Cys Val Leu Glu 290 295 300Tyr Ala Thr Pro Leu Gln Thr
Leu Phe Ala Met Ser Gln Tyr Ser Gln305 310 315 320Ala Gly Phe Ser
Arg Glu Asp Arg Leu Glu Gln Ala Lys Leu Phe Cys 325 330 335Arg Thr
Leu Glu Asp Ile Leu Ala Asp Ala Pro Glu Ser Gln Asn Asn 340 345
350Cys Arg Leu Ile Ala Tyr Gln Glu Pro Ala Asp Asp Ser Ser Phe Ser
355 360 365Leu Ser Gln Glu Val Leu Arg His Leu Arg Gln Glu Glu Lys
Glu Glu 370 375 380Val Thr Val Gly Ser Leu Lys Thr Ser Ala Val Pro
Ser Thr Ser Thr385 390 395 400Met Ser Gln Glu Pro Glu Leu Leu Ile
Ser Gly Met Glu Lys Pro Leu 405 410 415Pro Leu Arg Thr Asp Phe Ser
42064423PRTArtificial SequenceSynthetic
KRAS(G12V)25mer_ct.STING(V155M 64Met Thr Glu Tyr Lys Leu Val Val
Val Gly Ala Val Gly Val Gly Lys1 5 10 15Ser Ala Leu Thr Ile Gln Leu
Ile Gln Ala Thr Asn Phe Ser Leu Leu 20 25 30Lys Gln Ala Gly Asp Val
Glu Glu Asn Pro Gly Pro Met Pro His Ser 35 40 45Ser Leu His Pro Ser
Ile Pro Cys Pro Arg Gly His Gly Ala Gln Lys 50 55 60Ala Ala Leu Val
Leu Leu Ser Ala Cys Leu Val Thr Leu Trp Gly Leu65 70 75 80Gly Glu
Pro Pro Glu His Thr Leu Arg Tyr Leu Val Leu His Leu Ala 85 90 95Ser
Leu Gln Leu Gly Leu Leu Leu Asn Gly Val Cys Ser Leu Ala Glu 100 105
110Glu Leu Arg His Ile His Ser Arg Tyr Arg Gly Ser Tyr Trp Arg Thr
115 120 125Val Arg Ala Cys Leu Gly Cys Pro Leu Arg Arg Gly Ala Leu
Leu Leu 130 135 140Leu Ser Ile Tyr Phe Tyr Tyr Ser Leu Pro Asn Ala
Val Gly Pro Pro145 150 155 160Phe Thr Trp Met Leu Ala Leu Leu Gly
Leu Ser Gln Ala Leu Asn Ile 165 170 175Leu Leu Gly Leu Lys Gly Leu
Ala Pro Ala Glu Ile Ser Ala Val Cys 180 185 190Glu Lys Gly Asn Phe
Asn Met Ala His Gly Leu Ala Trp Ser Tyr Tyr 195 200 205Ile Gly Tyr
Leu Arg Leu Ile Leu Pro Glu Leu Gln Ala Arg Ile Arg 210 215 220Thr
Tyr Asn Gln His Tyr Asn Asn Leu Leu Arg Gly Ala Val Ser Gln225 230
235 240Arg Leu Tyr Ile Leu Leu Pro Leu Asp Cys Gly Val Pro Asp Asn
Leu 245 250 255Ser Met Ala Asp Pro Asn Ile Arg Phe Leu Asp Lys Leu
Pro Gln Gln 260 265 270Thr Gly Asp His Ala Gly Ile Lys Asp Arg Val
Tyr Ser Asn Ser Ile 275 280 285Tyr Glu Leu Leu Glu Asn Gly Gln Arg
Ala Gly Thr Cys Val Leu Glu 290 295 300Tyr Ala Thr Pro Leu Gln Thr
Leu Phe Ala Met Ser Gln Tyr Ser Gln305 310 315 320Ala Gly Phe Ser
Arg Glu Asp Arg Leu Glu Gln Ala Lys Leu Phe Cys 325 330 335Arg Thr
Leu Glu Asp Ile Leu Ala Asp Ala Pro Glu Ser Gln Asn Asn 340 345
350Cys Arg Leu Ile Ala Tyr Gln Glu Pro Ala Asp Asp Ser Ser Phe Ser
355 360 365Leu Ser Gln Glu Val Leu Arg His Leu Arg Gln Glu Glu Lys
Glu Glu 370 375 380Val Thr Val Gly Ser Leu Lys Thr Ser Ala Val Pro
Ser Thr Ser Thr385 390 395 400Met Ser Gln Glu Pro Glu Leu Leu Ile
Ser Gly Met Glu Lys Pro Leu 405 410 415Pro Leu Arg Thr Asp Phe Ser
42065423PRTArtificial SequenceSynthetic
KRAS(G13D)25mer_ct.STING(V155M 65Met Thr Glu Tyr Lys Leu Val Val
Val Gly Ala Gly Asp Val Gly Lys1 5 10 15Ser Ala Leu Thr Ile Gln Leu
Ile Gln Ala Thr Asn Phe Ser Leu Leu 20 25 30Lys Gln Ala Gly Asp Val
Glu Glu Asn Pro Gly Pro Met Pro His Ser 35 40 45Ser Leu His Pro Ser
Ile Pro Cys Pro Arg Gly His Gly Ala Gln Lys 50 55 60Ala Ala Leu Val
Leu Leu Ser Ala Cys Leu Val Thr Leu Trp Gly Leu65 70 75 80Gly Glu
Pro Pro Glu His Thr Leu Arg Tyr Leu Val Leu His Leu Ala 85 90 95Ser
Leu Gln Leu Gly Leu Leu Leu Asn Gly Val Cys Ser Leu Ala Glu 100 105
110Glu Leu Arg His Ile His Ser Arg Tyr Arg Gly Ser Tyr Trp Arg Thr
115 120 125Val Arg Ala Cys Leu Gly Cys Pro Leu Arg Arg Gly Ala Leu
Leu Leu 130 135 140Leu Ser Ile Tyr Phe Tyr Tyr Ser Leu Pro Asn Ala
Val Gly Pro Pro145 150 155 160Phe Thr Trp Met Leu Ala Leu Leu Gly
Leu Ser Gln Ala Leu Asn Ile 165 170 175Leu Leu Gly Leu Lys Gly Leu
Ala Pro Ala Glu Ile Ser Ala Val Cys 180 185 190Glu Lys Gly Asn Phe
Asn Met Ala His Gly Leu Ala Trp Ser Tyr Tyr 195 200 205Ile Gly Tyr
Leu Arg Leu Ile Leu Pro Glu Leu Gln Ala Arg Ile Arg 210 215 220Thr
Tyr Asn Gln His Tyr Asn Asn Leu Leu Arg Gly Ala Val Ser Gln225 230
235 240Arg Leu Tyr Ile Leu Leu Pro Leu Asp Cys Gly Val Pro Asp Asn
Leu 245 250 255Ser Met Ala Asp Pro Asn Ile Arg Phe Leu Asp Lys Leu
Pro Gln Gln 260 265 270Thr Gly Asp His Ala Gly Ile Lys Asp Arg Val
Tyr Ser Asn Ser Ile 275 280 285Tyr Glu Leu Leu Glu Asn Gly Gln Arg
Ala Gly Thr Cys Val Leu Glu 290 295 300Tyr Ala Thr Pro Leu Gln Thr
Leu Phe Ala Met Ser Gln Tyr Ser Gln305 310 315 320Ala Gly Phe Ser
Arg Glu Asp Arg Leu Glu Gln Ala Lys Leu Phe Cys 325 330 335Arg Thr
Leu Glu Asp Ile Leu Ala Asp Ala Pro Glu Ser Gln Asn Asn 340 345
350Cys Arg Leu Ile Ala Tyr Gln Glu Pro Ala Asp Asp Ser Ser Phe Ser
355 360 365Leu Ser Gln Glu Val Leu Arg His Leu Arg Gln Glu Glu Lys
Glu Glu 370 375 380Val Thr Val Gly Ser Leu Lys Thr Ser Ala Val Pro
Ser Thr Ser Thr385 390 395 400Met Ser Gln Glu Pro Glu Leu Leu Ile
Ser Gly Met Glu Lys Pro Leu 405 410 415Pro Leu Arg Thr Asp Phe Ser
42066444PRTArtificial SequenceSynthetic
KRAS(G12D)15mer^3_ct.STING(V155M) 66Met Lys Leu Val Val Val Gly Ala
Asp Gly Val Gly Lys Ser Ala Leu1 5 10 15Lys Leu Val Val Val Gly Ala
Asp Gly Val Gly Lys Ser Ala Leu Lys 20 25 30Leu Val Val Val Gly Ala
Asp Gly Val Gly Lys Ser Ala Leu Ala Thr 35 40 45Asn Phe Ser Leu Leu
Lys Gln Ala Gly Asp Val Glu Glu Asn Pro Gly 50 55 60Pro Met Pro His
Ser Ser Leu His Pro Ser Ile Pro Cys Pro Arg Gly65 70 75 80His Gly
Ala Gln Lys Ala Ala Leu Val Leu Leu Ser Ala Cys Leu Val 85 90 95Thr
Leu Trp Gly Leu Gly Glu Pro Pro Glu His Thr Leu Arg Tyr Leu 100 105
110Val Leu His Leu Ala Ser Leu Gln Leu Gly Leu Leu Leu Asn Gly Val
115 120 125Cys Ser Leu Ala Glu Glu Leu Arg His Ile His Ser Arg Tyr
Arg Gly 130 135 140Ser Tyr Trp Arg Thr Val Arg Ala Cys Leu Gly Cys
Pro Leu Arg Arg145 150 155 160Gly Ala Leu Leu Leu Leu Ser Ile Tyr
Phe Tyr Tyr Ser Leu Pro Asn 165 170 175Ala Val Gly Pro Pro Phe Thr
Trp Met Leu Ala Leu Leu Gly Leu Ser 180 185 190Gln Ala Leu Asn Ile
Leu Leu Gly Leu Lys Gly Leu Ala Pro Ala Glu 195
200 205Ile Ser Ala Val Cys Glu Lys Gly Asn Phe Asn Met Ala His Gly
Leu 210 215 220Ala Trp Ser Tyr Tyr Ile Gly Tyr Leu Arg Leu Ile Leu
Pro Glu Leu225 230 235 240Gln Ala Arg Ile Arg Thr Tyr Asn Gln His
Tyr Asn Asn Leu Leu Arg 245 250 255Gly Ala Val Ser Gln Arg Leu Tyr
Ile Leu Leu Pro Leu Asp Cys Gly 260 265 270Val Pro Asp Asn Leu Ser
Met Ala Asp Pro Asn Ile Arg Phe Leu Asp 275 280 285Lys Leu Pro Gln
Gln Thr Gly Asp His Ala Gly Ile Lys Asp Arg Val 290 295 300Tyr Ser
Asn Ser Ile Tyr Glu Leu Leu Glu Asn Gly Gln Arg Ala Gly305 310 315
320Thr Cys Val Leu Glu Tyr Ala Thr Pro Leu Gln Thr Leu Phe Ala Met
325 330 335Ser Gln Tyr Ser Gln Ala Gly Phe Ser Arg Glu Asp Arg Leu
Glu Gln 340 345 350Ala Lys Leu Phe Cys Arg Thr Leu Glu Asp Ile Leu
Ala Asp Ala Pro 355 360 365Glu Ser Gln Asn Asn Cys Arg Leu Ile Ala
Tyr Gln Glu Pro Ala Asp 370 375 380Asp Ser Ser Phe Ser Leu Ser Gln
Glu Val Leu Arg His Leu Arg Gln385 390 395 400Glu Glu Lys Glu Glu
Val Thr Val Gly Ser Leu Lys Thr Ser Ala Val 405 410 415Pro Ser Thr
Ser Thr Met Ser Gln Glu Pro Glu Leu Leu Ile Ser Gly 420 425 430Met
Glu Lys Pro Leu Pro Leu Arg Thr Asp Phe Ser 435
44067444PRTArtificial SequenceSynthetic
KRAS(G12V)15mer^3_ct.STING(V155M 67Met Lys Leu Val Val Val Gly Ala
Val Gly Val Gly Lys Ser Ala Leu1 5 10 15Lys Leu Val Val Val Gly Ala
Val Gly Val Gly Lys Ser Ala Leu Lys 20 25 30Leu Val Val Val Gly Ala
Val Gly Val Gly Lys Ser Ala Leu Ala Thr 35 40 45Asn Phe Ser Leu Leu
Lys Gln Ala Gly Asp Val Glu Glu Asn Pro Gly 50 55 60Pro Met Pro His
Ser Ser Leu His Pro Ser Ile Pro Cys Pro Arg Gly65 70 75 80His Gly
Ala Gln Lys Ala Ala Leu Val Leu Leu Ser Ala Cys Leu Val 85 90 95Thr
Leu Trp Gly Leu Gly Glu Pro Pro Glu His Thr Leu Arg Tyr Leu 100 105
110Val Leu His Leu Ala Ser Leu Gln Leu Gly Leu Leu Leu Asn Gly Val
115 120 125Cys Ser Leu Ala Glu Glu Leu Arg His Ile His Ser Arg Tyr
Arg Gly 130 135 140Ser Tyr Trp Arg Thr Val Arg Ala Cys Leu Gly Cys
Pro Leu Arg Arg145 150 155 160Gly Ala Leu Leu Leu Leu Ser Ile Tyr
Phe Tyr Tyr Ser Leu Pro Asn 165 170 175Ala Val Gly Pro Pro Phe Thr
Trp Met Leu Ala Leu Leu Gly Leu Ser 180 185 190Gln Ala Leu Asn Ile
Leu Leu Gly Leu Lys Gly Leu Ala Pro Ala Glu 195 200 205Ile Ser Ala
Val Cys Glu Lys Gly Asn Phe Asn Met Ala His Gly Leu 210 215 220Ala
Trp Ser Tyr Tyr Ile Gly Tyr Leu Arg Leu Ile Leu Pro Glu Leu225 230
235 240Gln Ala Arg Ile Arg Thr Tyr Asn Gln His Tyr Asn Asn Leu Leu
Arg 245 250 255Gly Ala Val Ser Gln Arg Leu Tyr Ile Leu Leu Pro Leu
Asp Cys Gly 260 265 270Val Pro Asp Asn Leu Ser Met Ala Asp Pro Asn
Ile Arg Phe Leu Asp 275 280 285Lys Leu Pro Gln Gln Thr Gly Asp His
Ala Gly Ile Lys Asp Arg Val 290 295 300Tyr Ser Asn Ser Ile Tyr Glu
Leu Leu Glu Asn Gly Gln Arg Ala Gly305 310 315 320Thr Cys Val Leu
Glu Tyr Ala Thr Pro Leu Gln Thr Leu Phe Ala Met 325 330 335Ser Gln
Tyr Ser Gln Ala Gly Phe Ser Arg Glu Asp Arg Leu Glu Gln 340 345
350Ala Lys Leu Phe Cys Arg Thr Leu Glu Asp Ile Leu Ala Asp Ala Pro
355 360 365Glu Ser Gln Asn Asn Cys Arg Leu Ile Ala Tyr Gln Glu Pro
Ala Asp 370 375 380Asp Ser Ser Phe Ser Leu Ser Gln Glu Val Leu Arg
His Leu Arg Gln385 390 395 400Glu Glu Lys Glu Glu Val Thr Val Gly
Ser Leu Lys Thr Ser Ala Val 405 410 415Pro Ser Thr Ser Thr Met Ser
Gln Glu Pro Glu Leu Leu Ile Ser Gly 420 425 430Met Glu Lys Pro Leu
Pro Leu Arg Thr Asp Phe Ser 435 44068444PRTArtificial
SequenceSynthetic KRAS(G13D)15mer^3_ct.STING(V155M 68Met Leu Val
Val Val Gly Ala Gly Asp Val Gly Lys Ser Ala Leu Thr1 5 10 15Leu Val
Val Val Gly Ala Gly Asp Val Gly Lys Ser Ala Leu Thr Leu 20 25 30Val
Val Val Gly Ala Gly Asp Val Gly Lys Ser Ala Leu Thr Ala Thr 35 40
45Asn Phe Ser Leu Leu Lys Gln Ala Gly Asp Val Glu Glu Asn Pro Gly
50 55 60Pro Met Pro His Ser Ser Leu His Pro Ser Ile Pro Cys Pro Arg
Gly65 70 75 80His Gly Ala Gln Lys Ala Ala Leu Val Leu Leu Ser Ala
Cys Leu Val 85 90 95Thr Leu Trp Gly Leu Gly Glu Pro Pro Glu His Thr
Leu Arg Tyr Leu 100 105 110Val Leu His Leu Ala Ser Leu Gln Leu Gly
Leu Leu Leu Asn Gly Val 115 120 125Cys Ser Leu Ala Glu Glu Leu Arg
His Ile His Ser Arg Tyr Arg Gly 130 135 140Ser Tyr Trp Arg Thr Val
Arg Ala Cys Leu Gly Cys Pro Leu Arg Arg145 150 155 160Gly Ala Leu
Leu Leu Leu Ser Ile Tyr Phe Tyr Tyr Ser Leu Pro Asn 165 170 175Ala
Val Gly Pro Pro Phe Thr Trp Met Leu Ala Leu Leu Gly Leu Ser 180 185
190Gln Ala Leu Asn Ile Leu Leu Gly Leu Lys Gly Leu Ala Pro Ala Glu
195 200 205Ile Ser Ala Val Cys Glu Lys Gly Asn Phe Asn Met Ala His
Gly Leu 210 215 220Ala Trp Ser Tyr Tyr Ile Gly Tyr Leu Arg Leu Ile
Leu Pro Glu Leu225 230 235 240Gln Ala Arg Ile Arg Thr Tyr Asn Gln
His Tyr Asn Asn Leu Leu Arg 245 250 255Gly Ala Val Ser Gln Arg Leu
Tyr Ile Leu Leu Pro Leu Asp Cys Gly 260 265 270Val Pro Asp Asn Leu
Ser Met Ala Asp Pro Asn Ile Arg Phe Leu Asp 275 280 285Lys Leu Pro
Gln Gln Thr Gly Asp His Ala Gly Ile Lys Asp Arg Val 290 295 300Tyr
Ser Asn Ser Ile Tyr Glu Leu Leu Glu Asn Gly Gln Arg Ala Gly305 310
315 320Thr Cys Val Leu Glu Tyr Ala Thr Pro Leu Gln Thr Leu Phe Ala
Met 325 330 335Ser Gln Tyr Ser Gln Ala Gly Phe Ser Arg Glu Asp Arg
Leu Glu Gln 340 345 350Ala Lys Leu Phe Cys Arg Thr Leu Glu Asp Ile
Leu Ala Asp Ala Pro 355 360 365Glu Ser Gln Asn Asn Cys Arg Leu Ile
Ala Tyr Gln Glu Pro Ala Asp 370 375 380Asp Ser Ser Phe Ser Leu Ser
Gln Glu Val Leu Arg His Leu Arg Gln385 390 395 400Glu Glu Lys Glu
Glu Val Thr Val Gly Ser Leu Lys Thr Ser Ala Val 405 410 415Pro Ser
Thr Ser Thr Met Ser Gln Glu Pro Glu Leu Leu Ile Ser Gly 420 425
430Met Glu Lys Pro Leu Pro Leu Arg Thr Asp Phe Ser 435
44069473PRTArtificial SequenceSynthetic
KRAS(G12D)25mer^3_ct.STING(V155M) 69Met Thr Glu Tyr Lys Leu Val Val
Val Gly Ala Asp Gly Val Gly Lys1 5 10 15Ser Ala Leu Thr Ile Gln Leu
Ile Gln Met Thr Glu Tyr Lys Leu Val 20 25 30Val Val Gly Ala Asp Gly
Val Gly Lys Ser Ala Leu Thr Ile Gln Leu 35 40 45Ile Gln Met Thr Glu
Tyr Lys Leu Val Val Val Gly Ala Asp Gly Val 50 55 60Gly Lys Ser Ala
Leu Thr Ile Gln Leu Ile Gln Ala Thr Asn Phe Ser65 70 75 80Leu Leu
Lys Gln Ala Gly Asp Val Glu Glu Asn Pro Gly Pro Met Pro 85 90 95His
Ser Ser Leu His Pro Ser Ile Pro Cys Pro Arg Gly His Gly Ala 100 105
110Gln Lys Ala Ala Leu Val Leu Leu Ser Ala Cys Leu Val Thr Leu Trp
115 120 125Gly Leu Gly Glu Pro Pro Glu His Thr Leu Arg Tyr Leu Val
Leu His 130 135 140Leu Ala Ser Leu Gln Leu Gly Leu Leu Leu Asn Gly
Val Cys Ser Leu145 150 155 160Ala Glu Glu Leu Arg His Ile His Ser
Arg Tyr Arg Gly Ser Tyr Trp 165 170 175Arg Thr Val Arg Ala Cys Leu
Gly Cys Pro Leu Arg Arg Gly Ala Leu 180 185 190Leu Leu Leu Ser Ile
Tyr Phe Tyr Tyr Ser Leu Pro Asn Ala Val Gly 195 200 205Pro Pro Phe
Thr Trp Met Leu Ala Leu Leu Gly Leu Ser Gln Ala Leu 210 215 220Asn
Ile Leu Leu Gly Leu Lys Gly Leu Ala Pro Ala Glu Ile Ser Ala225 230
235 240Val Cys Glu Lys Gly Asn Phe Asn Met Ala His Gly Leu Ala Trp
Ser 245 250 255Tyr Tyr Ile Gly Tyr Leu Arg Leu Ile Leu Pro Glu Leu
Gln Ala Arg 260 265 270Ile Arg Thr Tyr Asn Gln His Tyr Asn Asn Leu
Leu Arg Gly Ala Val 275 280 285Ser Gln Arg Leu Tyr Ile Leu Leu Pro
Leu Asp Cys Gly Val Pro Asp 290 295 300Asn Leu Ser Met Ala Asp Pro
Asn Ile Arg Phe Leu Asp Lys Leu Pro305 310 315 320Gln Gln Thr Gly
Asp His Ala Gly Ile Lys Asp Arg Val Tyr Ser Asn 325 330 335Ser Ile
Tyr Glu Leu Leu Glu Asn Gly Gln Arg Ala Gly Thr Cys Val 340 345
350Leu Glu Tyr Ala Thr Pro Leu Gln Thr Leu Phe Ala Met Ser Gln Tyr
355 360 365Ser Gln Ala Gly Phe Ser Arg Glu Asp Arg Leu Glu Gln Ala
Lys Leu 370 375 380Phe Cys Arg Thr Leu Glu Asp Ile Leu Ala Asp Ala
Pro Glu Ser Gln385 390 395 400Asn Asn Cys Arg Leu Ile Ala Tyr Gln
Glu Pro Ala Asp Asp Ser Ser 405 410 415Phe Ser Leu Ser Gln Glu Val
Leu Arg His Leu Arg Gln Glu Glu Lys 420 425 430Glu Glu Val Thr Val
Gly Ser Leu Lys Thr Ser Ala Val Pro Ser Thr 435 440 445Ser Thr Met
Ser Gln Glu Pro Glu Leu Leu Ile Ser Gly Met Glu Lys 450 455 460Pro
Leu Pro Leu Arg Thr Asp Phe Ser465 47070473PRTArtificial
SequenceSynthetic KRAS(G12V)25mer^3_ct.STING(V155M 70Met Thr Glu
Tyr Lys Leu Val Val Val Gly Ala Val Gly Val Gly Lys1 5 10 15Ser Ala
Leu Thr Ile Gln Leu Ile Gln Met Thr Glu Tyr Lys Leu Val 20 25 30Val
Val Gly Ala Val Gly Val Gly Lys Ser Ala Leu Thr Ile Gln Leu 35 40
45Ile Gln Met Thr Glu Tyr Lys Leu Val Val Val Gly Ala Val Gly Val
50 55 60Gly Lys Ser Ala Leu Thr Ile Gln Leu Ile Gln Ala Thr Asn Phe
Ser65 70 75 80Leu Leu Lys Gln Ala Gly Asp Val Glu Glu Asn Pro Gly
Pro Met Pro 85 90 95His Ser Ser Leu His Pro Ser Ile Pro Cys Pro Arg
Gly His Gly Ala 100 105 110Gln Lys Ala Ala Leu Val Leu Leu Ser Ala
Cys Leu Val Thr Leu Trp 115 120 125Gly Leu Gly Glu Pro Pro Glu His
Thr Leu Arg Tyr Leu Val Leu His 130 135 140Leu Ala Ser Leu Gln Leu
Gly Leu Leu Leu Asn Gly Val Cys Ser Leu145 150 155 160Ala Glu Glu
Leu Arg His Ile His Ser Arg Tyr Arg Gly Ser Tyr Trp 165 170 175Arg
Thr Val Arg Ala Cys Leu Gly Cys Pro Leu Arg Arg Gly Ala Leu 180 185
190Leu Leu Leu Ser Ile Tyr Phe Tyr Tyr Ser Leu Pro Asn Ala Val Gly
195 200 205Pro Pro Phe Thr Trp Met Leu Ala Leu Leu Gly Leu Ser Gln
Ala Leu 210 215 220Asn Ile Leu Leu Gly Leu Lys Gly Leu Ala Pro Ala
Glu Ile Ser Ala225 230 235 240Val Cys Glu Lys Gly Asn Phe Asn Met
Ala His Gly Leu Ala Trp Ser 245 250 255Tyr Tyr Ile Gly Tyr Leu Arg
Leu Ile Leu Pro Glu Leu Gln Ala Arg 260 265 270Ile Arg Thr Tyr Asn
Gln His Tyr Asn Asn Leu Leu Arg Gly Ala Val 275 280 285Ser Gln Arg
Leu Tyr Ile Leu Leu Pro Leu Asp Cys Gly Val Pro Asp 290 295 300Asn
Leu Ser Met Ala Asp Pro Asn Ile Arg Phe Leu Asp Lys Leu Pro305 310
315 320Gln Gln Thr Gly Asp His Ala Gly Ile Lys Asp Arg Val Tyr Ser
Asn 325 330 335Ser Ile Tyr Glu Leu Leu Glu Asn Gly Gln Arg Ala Gly
Thr Cys Val 340 345 350Leu Glu Tyr Ala Thr Pro Leu Gln Thr Leu Phe
Ala Met Ser Gln Tyr 355 360 365Ser Gln Ala Gly Phe Ser Arg Glu Asp
Arg Leu Glu Gln Ala Lys Leu 370 375 380Phe Cys Arg Thr Leu Glu Asp
Ile Leu Ala Asp Ala Pro Glu Ser Gln385 390 395 400Asn Asn Cys Arg
Leu Ile Ala Tyr Gln Glu Pro Ala Asp Asp Ser Ser 405 410 415Phe Ser
Leu Ser Gln Glu Val Leu Arg His Leu Arg Gln Glu Glu Lys 420 425
430Glu Glu Val Thr Val Gly Ser Leu Lys Thr Ser Ala Val Pro Ser Thr
435 440 445Ser Thr Met Ser Gln Glu Pro Glu Leu Leu Ile Ser Gly Met
Glu Lys 450 455 460Pro Leu Pro Leu Arg Thr Asp Phe Ser465
47071473PRTArtificial SequenceSynthetic
KRAS(G13D)25mer^3_ct.STING(V155M 71Met Thr Glu Tyr Lys Leu Val Val
Val Gly Ala Gly Asp Val Gly Lys1 5 10 15Ser Ala Leu Thr Ile Gln Leu
Ile Gln Met Thr Glu Tyr Lys Leu Val 20 25 30Val Val Gly Ala Gly Asp
Val Gly Lys Ser Ala Leu Thr Ile Gln Leu 35 40 45Ile Gln Met Thr Glu
Tyr Lys Leu Val Val Val Gly Ala Gly Asp Val 50 55 60Gly Lys Ser Ala
Leu Thr Ile Gln Leu Ile Gln Ala Thr Asn Phe Ser65 70 75 80Leu Leu
Lys Gln Ala Gly Asp Val Glu Glu Asn Pro Gly Pro Met Pro 85 90 95His
Ser Ser Leu His Pro Ser Ile Pro Cys Pro Arg Gly His Gly Ala 100 105
110Gln Lys Ala Ala Leu Val Leu Leu Ser Ala Cys Leu Val Thr Leu Trp
115 120 125Gly Leu Gly Glu Pro Pro Glu His Thr Leu Arg Tyr Leu Val
Leu His 130 135 140Leu Ala Ser Leu Gln Leu Gly Leu Leu Leu Asn Gly
Val Cys Ser Leu145 150 155 160Ala Glu Glu Leu Arg His Ile His Ser
Arg Tyr Arg Gly Ser Tyr Trp 165 170 175Arg Thr Val Arg Ala Cys Leu
Gly Cys Pro Leu Arg Arg Gly Ala Leu 180 185 190Leu Leu Leu Ser Ile
Tyr Phe Tyr Tyr Ser Leu Pro Asn Ala Val Gly 195 200 205Pro Pro Phe
Thr Trp Met Leu Ala Leu Leu Gly Leu Ser Gln Ala Leu 210 215 220Asn
Ile Leu Leu Gly Leu Lys Gly Leu Ala Pro Ala Glu Ile Ser Ala225 230
235 240Val Cys Glu Lys Gly Asn Phe Asn Met Ala His Gly Leu Ala Trp
Ser 245 250 255Tyr Tyr Ile Gly Tyr Leu Arg Leu Ile Leu Pro Glu Leu
Gln Ala Arg 260 265 270Ile Arg Thr Tyr Asn Gln His Tyr Asn Asn Leu
Leu Arg Gly Ala Val 275 280 285Ser Gln Arg Leu Tyr Ile Leu Leu Pro
Leu Asp Cys Gly Val Pro Asp 290 295 300Asn Leu Ser Met Ala Asp Pro
Asn Ile Arg Phe Leu Asp Lys Leu Pro305 310 315 320Gln Gln Thr Gly
Asp His Ala Gly Ile Lys Asp Arg Val Tyr Ser Asn 325 330 335Ser Ile
Tyr Glu Leu Leu Glu Asn Gly Gln Arg Ala Gly Thr Cys Val 340 345
350Leu Glu Tyr Ala Thr Pro Leu Gln Thr Leu Phe Ala Met Ser Gln Tyr
355 360 365Ser Gln Ala Gly Phe Ser Arg Glu Asp Arg Leu Glu Gln Ala
Lys Leu 370 375 380Phe Cys Arg Thr Leu Glu Asp Ile Leu Ala Asp Ala
Pro Glu Ser Gln385 390 395 400Asn Asn Cys Arg Leu Ile Ala Tyr Gln
Glu Pro Ala Asp Asp Ser Ser 405 410 415Phe Ser Leu Ser Gln Glu Val
Leu Arg His Leu Arg Gln Glu Glu Lys 420 425 430Glu Glu Val Thr Val
Gly Ser Leu Lys Thr Ser Ala Val Pro Ser Thr 435 440 445Ser Thr Met
Ser Gln Glu Pro Glu Leu Leu Ile Ser Gly Met Glu Lys 450 455 460Pro
Leu Pro Leu Arg Thr Asp Phe Ser465 4707225PRTArtificial
SequenceSynthetic KRAS(G12C)25mer 72Met Thr Glu Tyr Lys Leu Val Val
Val Gly Ala Cys Gly Val Gly Lys1 5 10 15Ser Ala Leu Thr Ile Gln Leu
Ile Gln 20 257375PRTArtificial SequenceSynthetic KRAS(G12C)25mer^3
73Met Thr Glu Tyr Lys Leu Val Val Val Gly Ala Cys Gly Val Gly Lys1
5 10 15Ser Ala Leu Thr Ile Gln Leu Ile Gln Met Thr Glu Tyr Lys Leu
Val 20 25 30Val Val Gly Ala Cys Gly Val Gly Lys Ser Ala Leu Thr Ile
Gln Leu 35 40 45Ile Gln Met Thr Glu Tyr Lys Leu Val Val Val Gly Ala
Cys Gly Val 50 55 60Gly Lys Ser Ala Leu Thr Ile Gln Leu Ile Gln65
70 757425PRTArtificial SequenceSynthetic KRAS(WT)25mer 74Met Thr
Glu Tyr Lys Leu Val Val Val Gly Ala Gly Gly Val Gly Lys1 5 10 15Ser
Ala Leu Thr Ile Gln Leu Ile Gln 20 2575296PRTHomo
sapiensmisc_feature(1)..(296)human myd88(L265P); P4027 without
epitope tag 75Met Ser Ala Gly Asp Pro Arg Val Gly Ser Gly Ser Leu
Asp Ser Phe1 5 10 15Met Phe Ser Ile Pro Leu Val Ala Leu Asn Val Gly
Val Arg Arg Arg 20 25 30Leu Ser Leu Phe Leu Asn Pro Arg Thr Pro Val
Ala Ala Asp Trp Thr 35 40 45Leu Leu Ala Glu Glu Met Gly Phe Glu Tyr
Leu Glu Ile Arg Glu Leu 50 55 60Glu Thr Arg Pro Asp Pro Thr Arg Ser
Leu Leu Asp Ala Trp Gln Gly65 70 75 80Arg Ser Gly Ala Ser Val Gly
Arg Leu Leu Glu Leu Leu Ala Leu Leu 85 90 95Asp Arg Glu Asp Ile Leu
Lys Glu Leu Lys Ser Arg Ile Glu Glu Asp 100 105 110Cys Gln Lys Tyr
Leu Gly Lys Gln Gln Asn Gln Glu Ser Glu Lys Pro 115 120 125Leu Gln
Val Ala Arg Val Glu Ser Ser Val Pro Gln Thr Lys Glu Leu 130 135
140Gly Gly Ile Thr Thr Leu Asp Asp Pro Leu Gly Gln Thr Pro Glu
Leu145 150 155 160Phe Asp Ala Phe Ile Cys Tyr Cys Pro Asn Asp Ile
Glu Phe Val Gln 165 170 175Glu Met Ile Arg Gln Leu Glu Gln Thr Asp
Tyr Arg Leu Lys Leu Cys 180 185 190Val Ser Asp Arg Asp Val Leu Pro
Gly Thr Cys Val Trp Ser Ile Ala 195 200 205Ser Glu Leu Ile Glu Lys
Arg Cys Arg Arg Met Val Val Val Val Ser 210 215 220Asp Asp Tyr Leu
Gln Ser Lys Glu Cys Asp Phe Gln Thr Lys Phe Ala225 230 235 240Leu
Ser Leu Ser Pro Gly Val Gln Gln Lys Arg Pro Ile Pro Ile Lys 245 250
255Tyr Lys Ala Met Lys Lys Asp Phe Pro Ser Ile Leu Arg Phe Ile Thr
260 265 270Ile Cys Asp Tyr Thr Asn Pro Cys Thr Lys Ser Trp Phe Trp
Thr Arg 275 280 285Leu Ala Lys Ala Leu Ser Leu Pro 290
29576296PRTMus musculusmisc_feature(1)..(296)mouse myd88(L265P);
P4028 without epitope tag 76Met Ala Ala Gly Gly Pro Gly Ala Gly Ser
Ala Ala Pro Val Ser Ser1 5 10 15Thr Ser Ser Leu Pro Leu Ala Ala Leu
Asn Met Arg Val Arg Arg Arg 20 25 30Leu Ser Leu Phe Leu Asn Val Arg
Thr Gln Val Ala Ala Asp Trp Thr 35 40 45Ala Leu Ala Glu Glu Met Asp
Phe Glu Tyr Leu Glu Ile Arg Gln Leu 50 55 60Glu Thr Gln Ala Asp Pro
Thr Gly Arg Leu Leu Asp Ala Trp Gln Gly65 70 75 80Arg Pro Gly Ala
Ser Val Gly Arg Leu Leu Glu Leu Leu Thr Lys Leu 85 90 95Gly Arg Asp
Asp Val Leu Leu Glu Leu Gly Pro Ser Ile Glu Glu Asp 100 105 110Cys
Gln Lys Tyr Ile Leu Lys Gln Gln Gln Glu Glu Ala Glu Lys Pro 115 120
125Leu Gln Val Ala Ala Val Asp Ser Ser Val Pro Arg Thr Ala Glu Leu
130 135 140Ala Gly Ile Thr Thr Leu Asp Asp Pro Leu Gly His Met Pro
Glu Arg145 150 155 160Phe Asp Ala Phe Ile Cys Tyr Cys Pro Ser Asp
Ile Gln Phe Val Gln 165 170 175Glu Met Ile Arg Gln Leu Glu Gln Thr
Asn Tyr Arg Leu Lys Leu Cys 180 185 190Val Ser Asp Arg Asp Val Leu
Pro Gly Thr Cys Val Trp Ser Ile Ala 195 200 205Ser Glu Leu Ile Glu
Lys Arg Cys Arg Arg Met Val Val Val Val Ser 210 215 220Asp Asp Tyr
Leu Gln Ser Lys Glu Cys Asp Phe Gln Thr Lys Phe Ala225 230 235
240Leu Ser Leu Ser Pro Gly Ala His Gln Lys Arg Pro Ile Pro Ile Lys
245 250 255Tyr Lys Ala Met Lys Lys Glu Phe Pro Ser Ile Leu Arg Phe
Ile Thr 260 265 270Val Cys Asp Tyr Thr Asn Pro Cys Thr Lys Ser Trp
Phe Trp Thr Arg 275 280 285Leu Ala Lys Ala Leu Ser Leu Pro 290
29577232PRTMus musculusmisc_feature(1)..(232)Mouse TRAM (TICAM2);
P4033 without epitope tag 77Met Gly Val Gly Lys Ser Lys Leu Asp Lys
Cys Pro Leu Ser Trp His1 5 10 15Lys Lys Asp Ser Val Asp Ala Asp Gln
Asp Gly His Glu Ser Asp Ser 20 25 30Lys Asn Ser Glu Glu Ala Cys Leu
Arg Gly Phe Val Glu Gln Ser Ser 35 40 45Gly Ser Glu Pro Pro Thr Gly
Glu Gln Asp Gln Pro Glu Ala Lys Gly 50 55 60Ala Gly Pro Glu Glu Gln
Asp Glu Glu Glu Phe Leu Lys Phe Val Ile65 70 75 80Leu His Ala Glu
Asp Asp Thr Asp Glu Ala Leu Arg Val Gln Asp Leu 85 90 95Leu Gln Asn
Asp Phe Gly Ile Arg Pro Gly Ile Val Phe Ala Glu Met 100 105 110Pro
Cys Gly Arg Leu His Leu Gln Asn Leu Asp Asp Ala Val Asn Gly 115 120
125Ser Ala Trp Thr Ile Leu Leu Leu Thr Glu Asn Phe Leu Arg Asp Thr
130 135 140Trp Cys Asn Phe Gln Phe Tyr Thr Ser Leu Met Asn Ser Val
Ser Arg145 150 155 160Gln His Lys Tyr Asn Ser Val Ile Pro Met Arg
Pro Leu Asn Ser Pro 165 170 175Leu Pro Arg Glu Arg Thr Pro Leu Ala
Leu Gln Thr Ile Asn Ala Leu 180 185 190Glu Glu Glu Ser Gln Gly Phe
Ser Thr Gln Val Glu Arg Ile Phe Arg 195 200 205Glu Ser Val Phe Glu
Arg Gln Gln Ser Ile Trp Lys Glu Thr Arg Ser 210 215 220Val Ser Gln
Lys Gln Phe Ile Ala225 23078847PRTArtificial SequenceSynthetic
STAT6 V547A/T548A); P008 with no epitope tag 78Met Ser Leu Trp Gly
Leu Val Ser Lys Met Pro Pro Glu Lys Val Gln1 5 10 15Arg Leu Tyr Val
Asp Phe Pro Gln His Leu Arg His Leu Leu Gly Asp 20 25 30Trp Leu Glu
Ser Gln Pro Trp Glu Phe Leu Val Gly Ser Asp Ala Phe 35 40 45Cys Cys
Asn Leu Ala Ser Ala Leu Leu Ser Asp Thr Val Gln His Leu 50 55 60Gln
Ala Ser Val Gly Glu Gln Gly Glu Gly Ser Thr Ile Leu Gln His65 70 75
80Ile Ser Thr Leu Glu Ser Ile Tyr Gln Arg Asp Pro Leu Lys Leu Val
85 90 95Ala Thr Phe Arg Gln Ile Leu Gln Gly Glu Lys Lys Ala Val Met
Glu 100 105 110Gln Phe Arg His Leu Pro Met Pro Phe His Trp Lys Gln
Glu Glu Leu 115 120 125Lys Phe Lys Thr Gly Leu Arg Arg Leu Gln His
Arg Val Gly Glu Ile 130 135 140His Leu Leu Arg Glu Ala Leu Gln Lys
Gly Ala Glu Ala Gly Gln Val145 150 155 160Ser Leu His Ser Leu Ile
Glu Thr Pro Ala Asn Gly Thr Gly Pro Ser 165 170 175Glu Ala Leu Ala
Met Leu Leu Gln Glu Thr Thr Gly Glu Leu Glu Ala 180 185 190Ala Lys
Ala Leu Val Leu Lys Arg Ile Gln Ile Trp Lys Arg Gln Gln 195 200
205Gln Leu Ala Gly Asn Gly Ala Pro Phe Glu Glu Ser Leu Ala Pro Leu
210 215 220Gln Glu Arg Cys Glu Ser Leu Val Asp Ile Tyr Ser Gln Leu
Gln Gln225 230 235 240Glu Val Gly Ala Ala Gly Gly Glu Leu Glu Pro
Lys Thr Arg Ala Ser 245 250 255Leu Thr Gly Arg Leu Asp Glu Val Leu
Arg Thr Leu Val Thr Ser Cys 260 265 270Phe Leu Val Glu Lys Gln Pro
Pro Gln Val Leu Lys Thr Gln Thr Lys 275 280 285Phe Gln Ala Gly Val
Arg Phe Leu Leu Gly Leu Arg Phe Leu Gly Ala 290 295 300Pro Ala Lys
Pro Pro Leu Val Arg Ala Asp Met Val Thr Glu Lys Gln305 310 315
320Ala Arg Glu Leu Ser Val Pro Gln Gly Pro Gly Ala Gly Ala Glu Ser
325 330 335Thr Gly Glu Ile Ile Asn Asn Thr Val Pro Leu Glu Asn Ser
Ile Pro 340 345 350Gly Asn Cys Cys Ser Ala Leu Phe Lys Asn Leu Leu
Leu Lys Lys Ile 355 360 365Lys Arg Cys Glu Arg Lys Gly Thr Glu Ser
Val Thr Glu Glu Lys Cys 370 375 380Ala Val Leu Phe Ser Ala Ser Phe
Thr Leu Gly Pro Gly Lys Leu Pro385 390 395 400Ile Gln Leu Gln Ala
Leu Ser Leu Pro Leu Val Val Ile Val His Gly 405 410 415Asn Gln Asp
Asn Asn Ala Lys Ala Thr Ile Leu Trp Asp Asn Ala Phe 420 425 430Ser
Glu Met Asp Arg Val Pro Phe Val Val Ala Glu Arg Val Pro Trp 435 440
445Glu Lys Met Cys Glu Thr Leu Asn Leu Lys Phe Met Ala Glu Val Gly
450 455 460Thr Asn Arg Gly Leu Leu Pro Glu His Phe Leu Phe Leu Ala
Gln Lys465 470 475 480Ile Phe Asn Asp Asn Ser Leu Ser Met Glu Ala
Phe Gln His Arg Ser 485 490 495Val Ser Trp Ser Gln Phe Asn Lys Glu
Ile Leu Leu Gly Arg Gly Phe 500 505 510Thr Phe Trp Gln Trp Phe Asp
Gly Val Leu Asp Leu Thr Lys Arg Cys 515 520 525Leu Arg Ser Tyr Trp
Ser Asp Arg Leu Ile Ile Gly Phe Ile Ser Lys 530 535 540Gln Tyr Ala
Ala Ser Leu Leu Leu Asn Glu Pro Asp Gly Thr Phe Leu545 550 555
560Leu Arg Phe Ser Asp Ser Glu Ile Gly Gly Ile Thr Ile Ala His Val
565 570 575Ile Arg Gly Gln Asp Gly Ser Pro Gln Ile Glu Asn Ile Gln
Pro Phe 580 585 590Ser Ala Lys Asp Leu Ser Ile Arg Ser Leu Gly Asp
Arg Ile Arg Asp 595 600 605Leu Ala Gln Leu Lys Asn Leu Tyr Pro Lys
Lys Pro Lys Asp Glu Ala 610 615 620Phe Arg Ser His Tyr Lys Pro Glu
Gln Met Gly Lys Asp Gly Arg Gly625 630 635 640Tyr Val Pro Ala Thr
Ile Lys Met Thr Val Glu Arg Asp Gln Pro Leu 645 650 655Pro Thr Pro
Glu Leu Gln Met Pro Thr Met Val Pro Ser Tyr Asp Leu 660 665 670Gly
Met Ala Pro Asp Ser Ser Met Ser Met Gln Leu Gly Pro Asp Met 675 680
685Val Pro Gln Val Tyr Pro Pro His Ser His Ser Ile Pro Pro Tyr Gln
690 695 700Gly Leu Ser Pro Glu Glu Ser Val Asn Val Leu Ser Ala Phe
Gln Glu705 710 715 720Pro His Leu Gln Met Pro Pro Ser Leu Gly Gln
Met Ser Leu Pro Phe 725 730 735Asp Gln Pro His Pro Gln Gly Leu Leu
Pro Cys Gln Pro Gln Glu His 740 745 750Ala Val Ser Ser Pro Asp Pro
Leu Leu Cys Ser Asp Val Thr Met Val 755 760 765Glu Asp Ser Cys Leu
Ser Gln Pro Val Thr Ala Phe Pro Gln Gly Thr 770 775 780Trp Ile Gly
Glu Asp Ile Phe Pro Pro Leu Leu Pro Pro Thr Glu Gln785 790 795
800Asp Leu Thr Lys Leu Leu Leu Glu Gly Gln Gly Glu Ser Gly Gly Gly
805 810 815Ser Leu Gly Ala Gln Pro Leu Leu Gln Pro Ser His Tyr Gly
Gln Ser 820 825 830Gly Ile Ser Met Ser His Met Asp Leu Arg Ala Asn
Pro Ser Trp 835 840 84579847PRTArtificial SequenceSynthetic STAT6
(S407D); P009 with no epitope tag 79Met Ser Leu Trp Gly Leu Val Ser
Lys Met Pro Pro Glu Lys Val Gln1 5 10 15Arg Leu Tyr Val Asp Phe Pro
Gln His Leu Arg His Leu Leu Gly Asp 20 25 30Trp Leu Glu Ser Gln Pro
Trp Glu Phe Leu Val Gly Ser Asp Ala Phe 35 40 45Cys Cys Asn Leu Ala
Ser Ala Leu Leu Ser Asp Thr Val Gln His Leu 50 55 60Gln Ala Ser Val
Gly Glu Gln Gly Glu Gly Ser Thr Ile Leu Gln His65 70 75 80Ile Ser
Thr Leu Glu Ser Ile Tyr Gln Arg Asp Pro Leu Lys Leu Val 85 90 95Ala
Thr Phe Arg Gln Ile Leu Gln Gly Glu Lys Lys Ala Val Met Glu 100 105
110Gln Phe Arg His Leu Pro Met Pro Phe His Trp Lys Gln Glu Glu Leu
115 120 125Lys Phe Lys Thr Gly Leu Arg Arg Leu Gln His Arg Val Gly
Glu Ile 130 135 140His Leu Leu Arg Glu Ala Leu Gln Lys Gly Ala Glu
Ala Gly Gln Val145 150 155 160Ser Leu His Ser Leu Ile Glu Thr Pro
Ala Asn Gly Thr Gly Pro Ser 165 170 175Glu Ala Leu Ala Met Leu Leu
Gln Glu Thr Thr Gly Glu Leu Glu Ala 180 185 190Ala Lys Ala Leu Val
Leu Lys Arg Ile Gln Ile Trp Lys Arg Gln Gln 195 200 205Gln Leu Ala
Gly Asn Gly Ala Pro Phe Glu Glu Ser Leu Ala Pro Leu 210 215 220Gln
Glu Arg Cys Glu Ser Leu Val Asp Ile Tyr Ser Gln Leu Gln Gln225 230
235 240Glu Val Gly Ala Ala Gly Gly Glu Leu Glu Pro Lys Thr Arg Ala
Ser 245 250 255Leu Thr Gly Arg Leu Asp Glu Val Leu Arg Thr Leu Val
Thr Ser Cys 260 265 270Phe Leu Val Glu Lys Gln Pro Pro Gln Val Leu
Lys Thr Gln Thr Lys 275 280 285Phe Gln Ala Gly Val Arg Phe Leu Leu
Gly Leu Arg Phe Leu Gly Ala 290 295 300Pro Ala Lys Pro Pro Leu Val
Arg Ala Asp Met Val Thr Glu Lys Gln305 310 315 320Ala Arg Glu Leu
Ser Val Pro Gln Gly Pro Gly Ala Gly Ala Glu Ser 325 330 335Thr Gly
Glu Ile Ile Asn Asn Thr Val Pro Leu Glu Asn Ser Ile Pro 340 345
350Gly Asn Cys Cys Ser Ala Leu Phe Lys Asn Leu Leu Leu Lys Lys Ile
355 360 365Lys Arg Cys Glu Arg Lys Gly Thr Glu Ser Val Thr Glu Glu
Lys Cys 370 375 380Ala Val Leu Phe Ser Ala Ser Phe Thr Leu Gly Pro
Gly Lys Leu Pro385 390 395 400Ile Gln Leu Gln Ala Leu Asp Leu Pro
Leu Val Val Ile Val His Gly 405 410 415Asn Gln Asp Asn Asn Ala Lys
Ala Thr Ile Leu Trp Asp Asn Ala Phe 420 425 430Ser Glu Met Asp Arg
Val Pro Phe Val Val Ala Glu Arg Val Pro Trp 435 440 445Glu Lys Met
Cys Glu Thr Leu Asn Leu Lys Phe Met Ala Glu Val Gly 450 455 460Thr
Asn Arg Gly Leu Leu Pro Glu His Phe Leu Phe Leu Ala Gln Lys465 470
475 480Ile Phe
Asn Asp Asn Ser Leu Ser Met Glu Ala Phe Gln His Arg Ser 485 490
495Val Ser Trp Ser Gln Phe Asn Lys Glu Ile Leu Leu Gly Arg Gly Phe
500 505 510Thr Phe Trp Gln Trp Phe Asp Gly Val Leu Asp Leu Thr Lys
Arg Cys 515 520 525Leu Arg Ser Tyr Trp Ser Asp Arg Leu Ile Ile Gly
Phe Ile Ser Lys 530 535 540Gln Tyr Val Thr Ser Leu Leu Leu Asn Glu
Pro Asp Gly Thr Phe Leu545 550 555 560Leu Arg Phe Ser Asp Ser Glu
Ile Gly Gly Ile Thr Ile Ala His Val 565 570 575Ile Arg Gly Gln Asp
Gly Ser Pro Gln Ile Glu Asn Ile Gln Pro Phe 580 585 590Ser Ala Lys
Asp Leu Ser Ile Arg Ser Leu Gly Asp Arg Ile Arg Asp 595 600 605Leu
Ala Gln Leu Lys Asn Leu Tyr Pro Lys Lys Pro Lys Asp Glu Ala 610 615
620Phe Arg Ser His Tyr Lys Pro Glu Gln Met Gly Lys Asp Gly Arg
Gly625 630 635 640Tyr Val Pro Ala Thr Ile Lys Met Thr Val Glu Arg
Asp Gln Pro Leu 645 650 655Pro Thr Pro Glu Leu Gln Met Pro Thr Met
Val Pro Ser Tyr Asp Leu 660 665 670Gly Met Ala Pro Asp Ser Ser Met
Ser Met Gln Leu Gly Pro Asp Met 675 680 685Val Pro Gln Val Tyr Pro
Pro His Ser His Ser Ile Pro Pro Tyr Gln 690 695 700Gly Leu Ser Pro
Glu Glu Ser Val Asn Val Leu Ser Ala Phe Gln Glu705 710 715 720Pro
His Leu Gln Met Pro Pro Ser Leu Gly Gln Met Ser Leu Pro Phe 725 730
735Asp Gln Pro His Pro Gln Gly Leu Leu Pro Cys Gln Pro Gln Glu His
740 745 750Ala Val Ser Ser Pro Asp Pro Leu Leu Cys Ser Asp Val Thr
Met Val 755 760 765Glu Asp Ser Cys Leu Ser Gln Pro Val Thr Ala Phe
Pro Gln Gly Thr 770 775 780Trp Ile Gly Glu Asp Ile Phe Pro Pro Leu
Leu Pro Pro Thr Glu Gln785 790 795 800Asp Leu Thr Lys Leu Leu Leu
Glu Gly Gln Gly Glu Ser Gly Gly Gly 805 810 815Ser Leu Gly Ala Gln
Pro Leu Leu Gln Pro Ser His Tyr Gly Gln Ser 820 825 830Gly Ile Ser
Met Ser His Met Asp Leu Arg Ala Asn Pro Ser Trp 835 840
84580847PRTArtificial SequenceSynthetic STAT6 (S407D/V547A/T548A);
P010 with no epitope tag 80Met Ser Leu Trp Gly Leu Val Ser Lys Met
Pro Pro Glu Lys Val Gln1 5 10 15Arg Leu Tyr Val Asp Phe Pro Gln His
Leu Arg His Leu Leu Gly Asp 20 25 30Trp Leu Glu Ser Gln Pro Trp Glu
Phe Leu Val Gly Ser Asp Ala Phe 35 40 45Cys Cys Asn Leu Ala Ser Ala
Leu Leu Ser Asp Thr Val Gln His Leu 50 55 60Gln Ala Ser Val Gly Glu
Gln Gly Glu Gly Ser Thr Ile Leu Gln His65 70 75 80Ile Ser Thr Leu
Glu Ser Ile Tyr Gln Arg Asp Pro Leu Lys Leu Val 85 90 95Ala Thr Phe
Arg Gln Ile Leu Gln Gly Glu Lys Lys Ala Val Met Glu 100 105 110Gln
Phe Arg His Leu Pro Met Pro Phe His Trp Lys Gln Glu Glu Leu 115 120
125Lys Phe Lys Thr Gly Leu Arg Arg Leu Gln His Arg Val Gly Glu Ile
130 135 140His Leu Leu Arg Glu Ala Leu Gln Lys Gly Ala Glu Ala Gly
Gln Val145 150 155 160Ser Leu His Ser Leu Ile Glu Thr Pro Ala Asn
Gly Thr Gly Pro Ser 165 170 175Glu Ala Leu Ala Met Leu Leu Gln Glu
Thr Thr Gly Glu Leu Glu Ala 180 185 190Ala Lys Ala Leu Val Leu Lys
Arg Ile Gln Ile Trp Lys Arg Gln Gln 195 200 205Gln Leu Ala Gly Asn
Gly Ala Pro Phe Glu Glu Ser Leu Ala Pro Leu 210 215 220Gln Glu Arg
Cys Glu Ser Leu Val Asp Ile Tyr Ser Gln Leu Gln Gln225 230 235
240Glu Val Gly Ala Ala Gly Gly Glu Leu Glu Pro Lys Thr Arg Ala Ser
245 250 255Leu Thr Gly Arg Leu Asp Glu Val Leu Arg Thr Leu Val Thr
Ser Cys 260 265 270Phe Leu Val Glu Lys Gln Pro Pro Gln Val Leu Lys
Thr Gln Thr Lys 275 280 285Phe Gln Ala Gly Val Arg Phe Leu Leu Gly
Leu Arg Phe Leu Gly Ala 290 295 300Pro Ala Lys Pro Pro Leu Val Arg
Ala Asp Met Val Thr Glu Lys Gln305 310 315 320Ala Arg Glu Leu Ser
Val Pro Gln Gly Pro Gly Ala Gly Ala Glu Ser 325 330 335Thr Gly Glu
Ile Ile Asn Asn Thr Val Pro Leu Glu Asn Ser Ile Pro 340 345 350Gly
Asn Cys Cys Ser Ala Leu Phe Lys Asn Leu Leu Leu Lys Lys Ile 355 360
365Lys Arg Cys Glu Arg Lys Gly Thr Glu Ser Val Thr Glu Glu Lys Cys
370 375 380Ala Val Leu Phe Ser Ala Ser Phe Thr Leu Gly Pro Gly Lys
Leu Pro385 390 395 400Ile Gln Leu Gln Ala Leu Asp Leu Pro Leu Val
Val Ile Val His Gly 405 410 415Asn Gln Asp Asn Asn Ala Lys Ala Thr
Ile Leu Trp Asp Asn Ala Phe 420 425 430Ser Glu Met Asp Arg Val Pro
Phe Val Val Ala Glu Arg Val Pro Trp 435 440 445Glu Lys Met Cys Glu
Thr Leu Asn Leu Lys Phe Met Ala Glu Val Gly 450 455 460Thr Asn Arg
Gly Leu Leu Pro Glu His Phe Leu Phe Leu Ala Gln Lys465 470 475
480Ile Phe Asn Asp Asn Ser Leu Ser Met Glu Ala Phe Gln His Arg Ser
485 490 495Val Ser Trp Ser Gln Phe Asn Lys Glu Ile Leu Leu Gly Arg
Gly Phe 500 505 510Thr Phe Trp Gln Trp Phe Asp Gly Val Leu Asp Leu
Thr Lys Arg Cys 515 520 525Leu Arg Ser Tyr Trp Ser Asp Arg Leu Ile
Ile Gly Phe Ile Ser Lys 530 535 540Gln Tyr Ala Ala Ser Leu Leu Leu
Asn Glu Pro Asp Gly Thr Phe Leu545 550 555 560Leu Arg Phe Ser Asp
Ser Glu Ile Gly Gly Ile Thr Ile Ala His Val 565 570 575Ile Arg Gly
Gln Asp Gly Ser Pro Gln Ile Glu Asn Ile Gln Pro Phe 580 585 590Ser
Ala Lys Asp Leu Ser Ile Arg Ser Leu Gly Asp Arg Ile Arg Asp 595 600
605Leu Ala Gln Leu Lys Asn Leu Tyr Pro Lys Lys Pro Lys Asp Glu Ala
610 615 620Phe Arg Ser His Tyr Lys Pro Glu Gln Met Gly Lys Asp Gly
Arg Gly625 630 635 640Tyr Val Pro Ala Thr Ile Lys Met Thr Val Glu
Arg Asp Gln Pro Leu 645 650 655Pro Thr Pro Glu Leu Gln Met Pro Thr
Met Val Pro Ser Tyr Asp Leu 660 665 670Gly Met Ala Pro Asp Ser Ser
Met Ser Met Gln Leu Gly Pro Asp Met 675 680 685Val Pro Gln Val Tyr
Pro Pro His Ser His Ser Ile Pro Pro Tyr Gln 690 695 700Gly Leu Ser
Pro Glu Glu Ser Val Asn Val Leu Ser Ala Phe Gln Glu705 710 715
720Pro His Leu Gln Met Pro Pro Ser Leu Gly Gln Met Ser Leu Pro Phe
725 730 735Asp Gln Pro His Pro Gln Gly Leu Leu Pro Cys Gln Pro Gln
Glu His 740 745 750Ala Val Ser Ser Pro Asp Pro Leu Leu Cys Ser Asp
Val Thr Met Val 755 760 765Glu Asp Ser Cys Leu Ser Gln Pro Val Thr
Ala Phe Pro Gln Gly Thr 770 775 780Trp Ile Gly Glu Asp Ile Phe Pro
Pro Leu Leu Pro Pro Thr Glu Gln785 790 795 800Asp Leu Thr Lys Leu
Leu Leu Glu Gly Gln Gly Glu Ser Gly Gly Gly 805 810 815Ser Leu Gly
Ala Gln Pro Leu Leu Gln Pro Ser His Tyr Gly Gln Ser 820 825 830Gly
Ile Ser Met Ser His Met Asp Leu Arg Ala Asn Pro Ser Trp 835 840
84581847PRTArtificial SequenceSynthetic STAT6 (V547A/T548A/Y641F);
P011 with no epitope tag 81Met Ser Leu Trp Gly Leu Val Ser Lys Met
Pro Pro Glu Lys Val Gln1 5 10 15Arg Leu Tyr Val Asp Phe Pro Gln His
Leu Arg His Leu Leu Gly Asp 20 25 30Trp Leu Glu Ser Gln Pro Trp Glu
Phe Leu Val Gly Ser Asp Ala Phe 35 40 45Cys Cys Asn Leu Ala Ser Ala
Leu Leu Ser Asp Thr Val Gln His Leu 50 55 60Gln Ala Ser Val Gly Glu
Gln Gly Glu Gly Ser Thr Ile Leu Gln His65 70 75 80Ile Ser Thr Leu
Glu Ser Ile Tyr Gln Arg Asp Pro Leu Lys Leu Val 85 90 95Ala Thr Phe
Arg Gln Ile Leu Gln Gly Glu Lys Lys Ala Val Met Glu 100 105 110Gln
Phe Arg His Leu Pro Met Pro Phe His Trp Lys Gln Glu Glu Leu 115 120
125Lys Phe Lys Thr Gly Leu Arg Arg Leu Gln His Arg Val Gly Glu Ile
130 135 140His Leu Leu Arg Glu Ala Leu Gln Lys Gly Ala Glu Ala Gly
Gln Val145 150 155 160Ser Leu His Ser Leu Ile Glu Thr Pro Ala Asn
Gly Thr Gly Pro Ser 165 170 175Glu Ala Leu Ala Met Leu Leu Gln Glu
Thr Thr Gly Glu Leu Glu Ala 180 185 190Ala Lys Ala Leu Val Leu Lys
Arg Ile Gln Ile Trp Lys Arg Gln Gln 195 200 205Gln Leu Ala Gly Asn
Gly Ala Pro Phe Glu Glu Ser Leu Ala Pro Leu 210 215 220Gln Glu Arg
Cys Glu Ser Leu Val Asp Ile Tyr Ser Gln Leu Gln Gln225 230 235
240Glu Val Gly Ala Ala Gly Gly Glu Leu Glu Pro Lys Thr Arg Ala Ser
245 250 255Leu Thr Gly Arg Leu Asp Glu Val Leu Arg Thr Leu Val Thr
Ser Cys 260 265 270Phe Leu Val Glu Lys Gln Pro Pro Gln Val Leu Lys
Thr Gln Thr Lys 275 280 285Phe Gln Ala Gly Val Arg Phe Leu Leu Gly
Leu Arg Phe Leu Gly Ala 290 295 300Pro Ala Lys Pro Pro Leu Val Arg
Ala Asp Met Val Thr Glu Lys Gln305 310 315 320Ala Arg Glu Leu Ser
Val Pro Gln Gly Pro Gly Ala Gly Ala Glu Ser 325 330 335Thr Gly Glu
Ile Ile Asn Asn Thr Val Pro Leu Glu Asn Ser Ile Pro 340 345 350Gly
Asn Cys Cys Ser Ala Leu Phe Lys Asn Leu Leu Leu Lys Lys Ile 355 360
365Lys Arg Cys Glu Arg Lys Gly Thr Glu Ser Val Thr Glu Glu Lys Cys
370 375 380Ala Val Leu Phe Ser Ala Ser Phe Thr Leu Gly Pro Gly Lys
Leu Pro385 390 395 400Ile Gln Leu Gln Ala Leu Ser Leu Pro Leu Val
Val Ile Val His Gly 405 410 415Asn Gln Asp Asn Asn Ala Lys Ala Thr
Ile Leu Trp Asp Asn Ala Phe 420 425 430Ser Glu Met Asp Arg Val Pro
Phe Val Val Ala Glu Arg Val Pro Trp 435 440 445Glu Lys Met Cys Glu
Thr Leu Asn Leu Lys Phe Met Ala Glu Val Gly 450 455 460Thr Asn Arg
Gly Leu Leu Pro Glu His Phe Leu Phe Leu Ala Gln Lys465 470 475
480Ile Phe Asn Asp Asn Ser Leu Ser Met Glu Ala Phe Gln His Arg Ser
485 490 495Val Ser Trp Ser Gln Phe Asn Lys Glu Ile Leu Leu Gly Arg
Gly Phe 500 505 510Thr Phe Trp Gln Trp Phe Asp Gly Val Leu Asp Leu
Thr Lys Arg Cys 515 520 525Leu Arg Ser Tyr Trp Ser Asp Arg Leu Ile
Ile Gly Phe Ile Ser Lys 530 535 540Gln Tyr Ala Ala Ser Leu Leu Leu
Asn Glu Pro Asp Gly Thr Phe Leu545 550 555 560Leu Arg Phe Ser Asp
Ser Glu Ile Gly Gly Ile Thr Ile Ala His Val 565 570 575Ile Arg Gly
Gln Asp Gly Ser Pro Gln Ile Glu Asn Ile Gln Pro Phe 580 585 590Ser
Ala Lys Asp Leu Ser Ile Arg Ser Leu Gly Asp Arg Ile Arg Asp 595 600
605Leu Ala Gln Leu Lys Asn Leu Tyr Pro Lys Lys Pro Lys Asp Glu Ala
610 615 620Phe Arg Ser His Tyr Lys Pro Glu Gln Met Gly Lys Asp Gly
Arg Gly625 630 635 640Phe Val Pro Ala Thr Ile Lys Met Thr Val Glu
Arg Asp Gln Pro Leu 645 650 655Pro Thr Pro Glu Leu Gln Met Pro Thr
Met Val Pro Ser Tyr Asp Leu 660 665 670Gly Met Ala Pro Asp Ser Ser
Met Ser Met Gln Leu Gly Pro Asp Met 675 680 685Val Pro Gln Val Tyr
Pro Pro His Ser His Ser Ile Pro Pro Tyr Gln 690 695 700Gly Leu Ser
Pro Glu Glu Ser Val Asn Val Leu Ser Ala Phe Gln Glu705 710 715
720Pro His Leu Gln Met Pro Pro Ser Leu Gly Gln Met Ser Leu Pro Phe
725 730 735Asp Gln Pro His Pro Gln Gly Leu Leu Pro Cys Gln Pro Gln
Glu His 740 745 750Ala Val Ser Ser Pro Asp Pro Leu Leu Cys Ser Asp
Val Thr Met Val 755 760 765Glu Asp Ser Cys Leu Ser Gln Pro Val Thr
Ala Phe Pro Gln Gly Thr 770 775 780Trp Ile Gly Glu Asp Ile Phe Pro
Pro Leu Leu Pro Pro Thr Glu Gln785 790 795 800Asp Leu Thr Lys Leu
Leu Leu Glu Gly Gln Gly Glu Ser Gly Gly Gly 805 810 815Ser Leu Gly
Ala Gln Pro Leu Leu Gln Pro Ser His Tyr Gly Gln Ser 820 825 830Gly
Ile Ser Met Ser His Met Asp Leu Arg Ala Asn Pro Ser Trp 835 840
84582479PRTArtificial SequenceSynthetic hu-cFLIP-L; P1006 without
epitope tag 82Ser Ala Glu Val Ile His Gln Val Glu Glu Ala Leu Asp
Thr Asp Glu1 5 10 15Lys Glu Met Leu Leu Phe Leu Cys Arg Asp Val Ala
Ile Asp Val Val 20 25 30Pro Pro Asn Val Arg Asp Leu Leu Asp Ile Leu
Arg Glu Arg Gly Lys 35 40 45Leu Ser Val Gly Asp Leu Ala Glu Leu Leu
Tyr Arg Val Arg Arg Phe 50 55 60Asp Leu Leu Lys Arg Ile Leu Lys Met
Asp Arg Lys Ala Val Glu Thr65 70 75 80His Leu Leu Arg Asn Pro His
Leu Val Ser Asp Tyr Arg Val Leu Met 85 90 95Ala Glu Ile Gly Glu Asp
Leu Asp Lys Ser Asp Val Ser Ser Leu Ile 100 105 110Phe Leu Met Lys
Asp Tyr Met Gly Arg Gly Lys Ile Ser Lys Glu Lys 115 120 125Ser Phe
Leu Asp Leu Val Val Glu Leu Glu Lys Leu Asn Leu Val Ala 130 135
140Pro Asp Gln Leu Asp Leu Leu Glu Lys Cys Leu Lys Asn Ile His
Arg145 150 155 160Ile Asp Leu Lys Thr Lys Ile Gln Lys Tyr Lys Gln
Ser Val Gln Gly 165 170 175Ala Gly Thr Ser Tyr Arg Asn Val Leu Gln
Ala Ala Ile Gln Lys Ser 180 185 190Leu Lys Asp Pro Ser Asn Asn Phe
Arg Leu His Asn Gly Arg Ser Lys 195 200 205Glu Gln Arg Leu Lys Glu
Gln Leu Gly Ala Gln Gln Glu Pro Val Lys 210 215 220Lys Ser Ile Gln
Glu Ser Glu Ala Phe Leu Pro Gln Ser Ile Pro Glu225 230 235 240Glu
Arg Tyr Lys Met Lys Ser Lys Pro Leu Gly Ile Cys Leu Ile Ile 245 250
255Asp Cys Ile Gly Asn Glu Thr Glu Leu Leu Arg Asp Thr Phe Thr Ser
260 265 270Leu Gly Tyr Glu Val Gln Lys Phe Leu His Leu Ser Met His
Gly Ile 275 280 285Ser Gln Ile Leu Gly Gln Phe Ala Cys Met Pro Glu
His Arg Asp Tyr 290 295 300Asp Ser Phe Val Cys Val Leu Val Ser Arg
Gly Gly Ser Gln Ser Val305 310 315 320Tyr Gly Val Asp Gln Thr His
Ser Gly Leu Pro Leu His His Ile Arg 325 330 335Arg Met Phe Met Gly
Asp Ser Cys Pro Tyr Leu Ala Gly Lys Pro Lys 340 345 350Met Phe Phe
Ile Gln Asn Tyr Val Val Ser Glu Gly Gln Leu Glu Asp 355 360 365Ser
Ser Leu Leu Glu Val Asp Gly Pro
Ala Met Lys Asn Val Glu Phe 370 375 380Lys Ala Gln Lys Arg Gly Leu
Cys Thr Val His Arg Glu Ala Asp Phe385 390 395 400Phe Trp Ser Leu
Cys Thr Ala Asp Met Ser Leu Leu Glu Gln Ser His 405 410 415Ser Ser
Pro Ser Leu Tyr Leu Gln Cys Leu Ser Gln Lys Leu Arg Gln 420 425
430Glu Arg Lys Arg Pro Leu Leu Asp Leu His Ile Glu Leu Asn Gly Tyr
435 440 445Met Tyr Asp Trp Asn Ser Arg Val Ser Ala Lys Glu Lys Tyr
Tyr Val 450 455 460Trp Leu Gln His Thr Leu Arg Lys Lys Leu Ile Leu
Ser Tyr Thr465 470 47583226PRTArtificial SequenceSynthetic
hu-cFLIP-S(1-227); P1007 without epitope tag 83Ser Ala Glu Val Ile
His Gln Val Glu Glu Ala Leu Asp Thr Asp Glu1 5 10 15Lys Glu Met Leu
Leu Phe Leu Cys Arg Asp Val Ala Ile Asp Val Val 20 25 30Pro Pro Asn
Val Arg Asp Leu Leu Asp Ile Leu Arg Glu Arg Gly Lys 35 40 45Leu Ser
Val Gly Asp Leu Ala Glu Leu Leu Tyr Arg Val Arg Arg Phe 50 55 60Asp
Leu Leu Lys Arg Ile Leu Lys Met Asp Arg Lys Ala Val Glu Thr65 70 75
80His Leu Leu Arg Asn Pro His Leu Val Ser Asp Tyr Arg Val Leu Met
85 90 95Ala Glu Ile Gly Glu Asp Leu Asp Lys Ser Asp Val Ser Ser Leu
Ile 100 105 110Phe Leu Met Lys Asp Tyr Met Gly Arg Gly Lys Ile Ser
Lys Glu Lys 115 120 125Ser Phe Leu Asp Leu Val Val Glu Leu Glu Lys
Leu Asn Leu Val Ala 130 135 140Pro Asp Gln Leu Asp Leu Leu Glu Lys
Cys Leu Lys Asn Ile His Arg145 150 155 160Ile Asp Leu Lys Thr Lys
Ile Gln Lys Tyr Lys Gln Ser Val Gln Gly 165 170 175Ala Gly Thr Ser
Tyr Arg Asn Val Leu Gln Ala Ala Ile Gln Lys Ser 180 185 190Leu Lys
Asp Pro Ser Asn Asn Phe Arg Leu His Asn Gly Arg Ser Lys 195 200
205Glu Gln Arg Leu Lys Glu Gln Leu Gly Ala Gln Gln Glu Pro Val Lys
210 215 220Lys Ser22584195PRTArtificial SequenceSynthetic
hu-cFLIP-p22(1-198); P1008 without epitope tag 84Ser Ala Glu Val
Ile His Gln Val Glu Glu Ala Leu Asp Thr Asp Glu1 5 10 15Lys Glu Met
Leu Leu Phe Leu Cys Arg Asp Val Ala Ile Asp Val Val 20 25 30Pro Pro
Asn Val Arg Asp Leu Leu Asp Ile Leu Arg Glu Arg Gly Lys 35 40 45Leu
Ser Val Gly Asp Leu Ala Glu Leu Leu Tyr Arg Val Arg Arg Phe 50 55
60Asp Leu Leu Lys Arg Ile Leu Lys Met Asp Arg Lys Ala Val Glu Thr65
70 75 80His Leu Leu Arg Asn Pro His Leu Val Ser Asp Tyr Arg Val Leu
Met 85 90 95Ala Glu Ile Gly Glu Asp Leu Asp Lys Ser Asp Val Ser Ser
Leu Ile 100 105 110Phe Leu Met Lys Asp Tyr Met Gly Arg Gly Lys Ile
Ser Lys Glu Lys 115 120 125Ser Phe Leu Asp Leu Val Val Glu Leu Glu
Lys Leu Asn Leu Val Ala 130 135 140Pro Asp Gln Leu Asp Leu Leu Glu
Lys Cys Leu Lys Asn Ile His Arg145 150 155 160Ile Asp Leu Lys Thr
Lys Ile Gln Lys Tyr Lys Gln Ser Val Gln Gly 165 170 175Ala Gly Thr
Ser Tyr Arg Asn Val Leu Gln Ala Ala Ile Gln Lys Ser 180 185 190Leu
Lys Asp 19585375PRTArtificial SequenceSynthetic
hu-cFLIP-p43(1-376); P1009 without epitope tag 85Ser Ala Glu Val
Ile His Gln Val Glu Glu Ala Leu Asp Thr Asp Glu1 5 10 15Lys Glu Met
Leu Leu Phe Leu Cys Arg Asp Val Ala Ile Asp Val Val 20 25 30Pro Pro
Asn Val Arg Asp Leu Leu Asp Ile Leu Arg Glu Arg Gly Lys 35 40 45Leu
Ser Val Gly Asp Leu Ala Glu Leu Leu Tyr Arg Val Arg Arg Phe 50 55
60Asp Leu Leu Lys Arg Ile Leu Lys Met Asp Arg Lys Ala Val Glu Thr65
70 75 80His Leu Leu Arg Asn Pro His Leu Val Ser Asp Tyr Arg Val Leu
Met 85 90 95Ala Glu Ile Gly Glu Asp Leu Asp Lys Ser Asp Val Ser Ser
Leu Ile 100 105 110Phe Leu Met Lys Asp Tyr Met Gly Arg Gly Lys Ile
Ser Lys Glu Lys 115 120 125Ser Phe Leu Asp Leu Val Val Glu Leu Glu
Lys Leu Asn Leu Val Ala 130 135 140Pro Asp Gln Leu Asp Leu Leu Glu
Lys Cys Leu Lys Asn Ile His Arg145 150 155 160Ile Asp Leu Lys Thr
Lys Ile Gln Lys Tyr Lys Gln Ser Val Gln Gly 165 170 175Ala Gly Thr
Ser Tyr Arg Asn Val Leu Gln Ala Ala Ile Gln Lys Ser 180 185 190Leu
Lys Asp Pro Ser Asn Asn Phe Arg Leu His Asn Gly Arg Ser Lys 195 200
205Glu Gln Arg Leu Lys Glu Gln Leu Gly Ala Gln Gln Glu Pro Val Lys
210 215 220Lys Ser Ile Gln Glu Ser Glu Ala Phe Leu Pro Gln Ser Ile
Pro Glu225 230 235 240Glu Arg Tyr Lys Met Lys Ser Lys Pro Leu Gly
Ile Cys Leu Ile Ile 245 250 255Asp Cys Ile Gly Asn Glu Thr Glu Leu
Leu Arg Asp Thr Phe Thr Ser 260 265 270Leu Gly Tyr Glu Val Gln Lys
Phe Leu His Leu Ser Met His Gly Ile 275 280 285Ser Gln Ile Leu Gly
Gln Phe Ala Cys Met Pro Glu His Arg Asp Tyr 290 295 300Asp Ser Phe
Val Cys Val Leu Val Ser Arg Gly Gly Ser Gln Ser Val305 310 315
320Tyr Gly Val Asp Gln Thr His Ser Gly Leu Pro Leu His His Ile Arg
325 330 335Arg Met Phe Met Gly Asp Ser Cys Pro Tyr Leu Ala Gly Lys
Pro Lys 340 345 350Met Phe Phe Ile Gln Asn Tyr Val Val Ser Glu Gly
Gln Leu Glu Asp 355 360 365Ser Ser Leu Leu Glu Val Asp 370
37586104PRTArtificial SequenceSynthetic hu-cFLIP-p12(377-480);
P1010 without epitope tag 86Gly Pro Ala Met Lys Asn Val Glu Phe Lys
Ala Gln Lys Arg Gly Leu1 5 10 15Cys Thr Val His Arg Glu Ala Asp Phe
Phe Trp Ser Leu Cys Thr Ala 20 25 30Asp Met Ser Leu Leu Glu Gln Ser
His Ser Ser Pro Ser Leu Tyr Leu 35 40 45Gln Cys Leu Ser Gln Lys Leu
Arg Gln Glu Arg Lys Arg Pro Leu Leu 50 55 60Asp Leu His Ile Glu Leu
Asn Gly Tyr Met Tyr Asp Trp Asn Ser Arg65 70 75 80Val Ser Ala Lys
Glu Lys Tyr Tyr Val Trp Leu Gln His Thr Leu Arg 85 90 95Lys Lys Leu
Ile Leu Ser Tyr Thr 10087756PRTArtificial SequenceSynthetic
huIKK2ca(S177E/S181E); P4005 without epitope tag 87Met Ser Trp Ser
Pro Ser Leu Thr Thr Gln Thr Cys Gly Ala Trp Glu1 5 10 15Met Lys Glu
Arg Leu Gly Thr Gly Gly Phe Gly Asn Val Ile Arg Trp 20 25 30His Asn
Gln Glu Thr Gly Glu Gln Ile Ala Ile Lys Gln Cys Arg Gln 35 40 45Glu
Leu Ser Pro Arg Asn Arg Glu Arg Trp Cys Leu Glu Ile Gln Ile 50 55
60Met Arg Arg Leu Thr His Pro Asn Val Val Ala Ala Arg Asp Val Pro65
70 75 80Glu Gly Met Gln Asn Leu Ala Pro Asn Asp Leu Pro Leu Leu Ala
Met 85 90 95Glu Tyr Cys Gln Gly Gly Asp Leu Arg Lys Tyr Leu Asn Gln
Phe Glu 100 105 110Asn Cys Cys Gly Leu Arg Glu Gly Ala Ile Leu Thr
Leu Leu Ser Asp 115 120 125Ile Ala Ser Ala Leu Arg Tyr Leu His Glu
Asn Arg Ile Ile His Arg 130 135 140Asp Leu Lys Pro Glu Asn Ile Val
Leu Gln Gln Gly Glu Gln Arg Leu145 150 155 160Ile His Lys Ile Ile
Asp Leu Gly Tyr Ala Lys Glu Leu Asp Gln Gly 165 170 175Glu Leu Cys
Thr Glu Phe Val Gly Thr Leu Gln Tyr Leu Ala Pro Glu 180 185 190Leu
Leu Glu Gln Gln Lys Tyr Thr Val Thr Val Asp Tyr Trp Ser Phe 195 200
205Gly Thr Leu Ala Phe Glu Cys Ile Thr Gly Phe Arg Pro Phe Leu Pro
210 215 220Asn Trp Gln Pro Val Gln Trp His Ser Lys Val Arg Gln Lys
Ser Glu225 230 235 240Val Asp Ile Val Val Ser Glu Asp Leu Asn Gly
Thr Val Lys Phe Ser 245 250 255Ser Ser Leu Pro Tyr Pro Asn Asn Leu
Asn Ser Val Leu Ala Glu Arg 260 265 270Leu Glu Lys Trp Leu Gln Leu
Met Leu Met Trp His Pro Arg Gln Arg 275 280 285Gly Thr Asp Pro Thr
Tyr Gly Pro Asn Gly Cys Phe Lys Ala Leu Asp 290 295 300Asp Ile Leu
Asn Leu Lys Leu Val His Ile Leu Asn Met Val Thr Gly305 310 315
320Thr Ile His Thr Tyr Pro Val Thr Glu Asp Glu Ser Leu Gln Ser Leu
325 330 335Lys Ala Arg Ile Gln Gln Asp Thr Gly Ile Pro Glu Glu Asp
Gln Glu 340 345 350Leu Leu Gln Glu Ala Gly Leu Ala Leu Ile Pro Asp
Lys Pro Ala Thr 355 360 365Gln Cys Ile Ser Asp Gly Lys Leu Asn Glu
Gly His Thr Leu Asp Met 370 375 380Asp Leu Val Phe Leu Phe Asp Asn
Ser Lys Ile Thr Tyr Glu Thr Gln385 390 395 400Ile Ser Pro Arg Pro
Gln Pro Glu Ser Val Ser Cys Ile Leu Gln Glu 405 410 415Pro Lys Arg
Asn Leu Ala Phe Phe Gln Leu Arg Lys Val Trp Gly Gln 420 425 430Val
Trp His Ser Ile Gln Thr Leu Lys Glu Asp Cys Asn Arg Leu Gln 435 440
445Gln Gly Gln Arg Ala Ala Met Met Asn Leu Leu Arg Asn Asn Ser Cys
450 455 460Leu Ser Lys Met Lys Asn Ser Met Ala Ser Met Ser Gln Gln
Leu Lys465 470 475 480Ala Lys Leu Asp Phe Phe Lys Thr Ser Ile Gln
Ile Asp Leu Glu Lys 485 490 495Tyr Ser Glu Gln Thr Glu Phe Gly Ile
Thr Ser Asp Lys Leu Leu Leu 500 505 510Ala Trp Arg Glu Met Glu Gln
Ala Val Glu Leu Cys Gly Arg Glu Asn 515 520 525Glu Val Lys Leu Leu
Val Glu Arg Met Met Ala Leu Gln Thr Asp Ile 530 535 540Val Asp Leu
Gln Arg Ser Pro Met Gly Arg Lys Gln Gly Gly Thr Leu545 550 555
560Asp Asp Leu Glu Glu Gln Ala Arg Glu Leu Tyr Arg Arg Leu Arg Glu
565 570 575Lys Pro Arg Asp Gln Arg Thr Glu Gly Asp Ser Gln Glu Met
Val Arg 580 585 590Leu Leu Leu Gln Ala Ile Gln Ser Phe Glu Lys Lys
Val Arg Val Ile 595 600 605Tyr Thr Gln Leu Ser Lys Thr Val Val Cys
Lys Gln Lys Ala Leu Glu 610 615 620Leu Leu Pro Lys Val Glu Glu Val
Val Ser Leu Met Asn Glu Asp Glu625 630 635 640Lys Thr Val Val Arg
Leu Gln Glu Lys Arg Gln Lys Glu Leu Trp Asn 645 650 655Leu Leu Lys
Ile Ala Cys Ser Lys Val Arg Gly Pro Val Ser Gly Ser 660 665 670Pro
Asp Ser Met Asn Ala Ser Arg Leu Ser Gln Pro Gly Gln Leu Met 675 680
685Ser Gln Pro Ser Thr Ala Ser Asn Ser Leu Pro Glu Pro Ala Lys Lys
690 695 700Ser Glu Glu Leu Val Ala Glu Ala His Asn Leu Cys Thr Leu
Leu Glu705 710 715 720Asn Ala Ile Gln Asp Thr Val Arg Glu Gln Asp
Gln Ser Phe Thr Ala 725 730 735Leu Asp Trp Ser Trp Leu Gln Thr Glu
Glu Glu Glu His Ser Cys Leu 740 745 750Glu Gln Ala Ser
75588756PRTArtificial SequenceSynthetic huIKK2null(S177A/S181A);
P4006 without epitope tag 88Met Ser Trp Ser Pro Ser Leu Thr Thr Gln
Thr Cys Gly Ala Trp Glu1 5 10 15Met Lys Glu Arg Leu Gly Thr Gly Gly
Phe Gly Asn Val Ile Arg Trp 20 25 30His Asn Gln Glu Thr Gly Glu Gln
Ile Ala Ile Lys Gln Cys Arg Gln 35 40 45Glu Leu Ser Pro Arg Asn Arg
Glu Arg Trp Cys Leu Glu Ile Gln Ile 50 55 60Met Arg Arg Leu Thr His
Pro Asn Val Val Ala Ala Arg Asp Val Pro65 70 75 80Glu Gly Met Gln
Asn Leu Ala Pro Asn Asp Leu Pro Leu Leu Ala Met 85 90 95Glu Tyr Cys
Gln Gly Gly Asp Leu Arg Lys Tyr Leu Asn Gln Phe Glu 100 105 110Asn
Cys Cys Gly Leu Arg Glu Gly Ala Ile Leu Thr Leu Leu Ser Asp 115 120
125Ile Ala Ser Ala Leu Arg Tyr Leu His Glu Asn Arg Ile Ile His Arg
130 135 140Asp Leu Lys Pro Glu Asn Ile Val Leu Gln Gln Gly Glu Gln
Arg Leu145 150 155 160Ile His Lys Ile Ile Asp Leu Gly Tyr Ala Lys
Glu Leu Asp Gln Gly 165 170 175Ala Leu Cys Thr Ala Phe Val Gly Thr
Leu Gln Tyr Leu Ala Pro Glu 180 185 190Leu Leu Glu Gln Gln Lys Tyr
Thr Val Thr Val Asp Tyr Trp Ser Phe 195 200 205Gly Thr Leu Ala Phe
Glu Cys Ile Thr Gly Phe Arg Pro Phe Leu Pro 210 215 220Asn Trp Gln
Pro Val Gln Trp His Ser Lys Val Arg Gln Lys Ser Glu225 230 235
240Val Asp Ile Val Val Ser Glu Asp Leu Asn Gly Thr Val Lys Phe Ser
245 250 255Ser Ser Leu Pro Tyr Pro Asn Asn Leu Asn Ser Val Leu Ala
Glu Arg 260 265 270Leu Glu Lys Trp Leu Gln Leu Met Leu Met Trp His
Pro Arg Gln Arg 275 280 285Gly Thr Asp Pro Thr Tyr Gly Pro Asn Gly
Cys Phe Lys Ala Leu Asp 290 295 300Asp Ile Leu Asn Leu Lys Leu Val
His Ile Leu Asn Met Val Thr Gly305 310 315 320Thr Ile His Thr Tyr
Pro Val Thr Glu Asp Glu Ser Leu Gln Ser Leu 325 330 335Lys Ala Arg
Ile Gln Gln Asp Thr Gly Ile Pro Glu Glu Asp Gln Glu 340 345 350Leu
Leu Gln Glu Ala Gly Leu Ala Leu Ile Pro Asp Lys Pro Ala Thr 355 360
365Gln Cys Ile Ser Asp Gly Lys Leu Asn Glu Gly His Thr Leu Asp Met
370 375 380Asp Leu Val Phe Leu Phe Asp Asn Ser Lys Ile Thr Tyr Glu
Thr Gln385 390 395 400Ile Ser Pro Arg Pro Gln Pro Glu Ser Val Ser
Cys Ile Leu Gln Glu 405 410 415Pro Lys Arg Asn Leu Ala Phe Phe Gln
Leu Arg Lys Val Trp Gly Gln 420 425 430Val Trp His Ser Ile Gln Thr
Leu Lys Glu Asp Cys Asn Arg Leu Gln 435 440 445Gln Gly Gln Arg Ala
Ala Met Met Asn Leu Leu Arg Asn Asn Ser Cys 450 455 460Leu Ser Lys
Met Lys Asn Ser Met Ala Ser Met Ser Gln Gln Leu Lys465 470 475
480Ala Lys Leu Asp Phe Phe Lys Thr Ser Ile Gln Ile Asp Leu Glu Lys
485 490 495Tyr Ser Glu Gln Thr Glu Phe Gly Ile Thr Ser Asp Lys Leu
Leu Leu 500 505 510Ala Trp Arg Glu Met Glu Gln Ala Val Glu Leu Cys
Gly Arg Glu Asn 515 520 525Glu Val Lys Leu Leu Val Glu Arg Met Met
Ala Leu Gln Thr Asp Ile 530 535 540Val Asp Leu Gln Arg Ser Pro Met
Gly Arg Lys Gln Gly Gly Thr Leu545 550 555 560Asp Asp Leu Glu Glu
Gln Ala Arg Glu Leu Tyr Arg Arg Leu Arg Glu 565 570 575Lys Pro Arg
Asp Gln Arg Thr Glu Gly Asp Ser Gln Glu Met Val Arg 580 585 590Leu
Leu Leu Gln Ala Ile Gln Ser Phe Glu Lys Lys Val Arg Val Ile 595 600
605Tyr Thr Gln Leu Ser Lys Thr Val Val Cys Lys Gln Lys Ala Leu Glu
610 615 620Leu Leu Pro Lys Val Glu Glu Val Val Ser Leu Met Asn Glu
Asp Glu625 630 635 640Lys Thr
Val Val Arg Leu Gln Glu Lys Arg Gln Lys Glu Leu Trp Asn 645 650
655Leu Leu Lys Ile Ala Cys Ser Lys Val Arg Gly Pro Val Ser Gly Ser
660 665 670Pro Asp Ser Met Asn Ala Ser Arg Leu Ser Gln Pro Gly Gln
Leu Met 675 680 685Ser Gln Pro Ser Thr Ala Ser Asn Ser Leu Pro Glu
Pro Ala Lys Lys 690 695 700Ser Glu Glu Leu Val Ala Glu Ala His Asn
Leu Cys Thr Leu Leu Glu705 710 715 720Asn Ala Ile Gln Asp Thr Val
Arg Glu Gln Asp Gln Ser Phe Thr Ala 725 730 735Leu Asp Trp Ser Trp
Leu Gln Thr Glu Glu Glu Glu His Ser Cys Leu 740 745 750Glu Gln Ala
Ser 75589757PRTArtificial SequenceSynthetic muIKK2ca(S177E/S181E);
P4002 without epitope tag 89Met Ser Trp Ser Pro Ser Leu Pro Thr Gln
Thr Cys Gly Ala Trp Glu1 5 10 15Met Lys Glu Arg Leu Gly Thr Gly Gly
Phe Gly Asn Val Ile Arg Trp 20 25 30His Asn Gln Ala Thr Gly Glu Gln
Ile Ala Ile Lys Gln Cys Arg Gln 35 40 45Glu Leu Ser Pro Lys Asn Arg
Asn Arg Trp Cys Leu Glu Ile Gln Ile 50 55 60Met Arg Arg Leu Asn His
Pro Asn Val Val Ala Ala Arg Asp Val Pro65 70 75 80Glu Gly Met Gln
Asn Leu Ala Pro Asn Asp Leu Pro Leu Leu Ala Met 85 90 95Glu Tyr Cys
Gln Gly Gly Asp Leu Arg Arg Tyr Leu Asn Gln Phe Glu 100 105 110Asn
Cys Cys Gly Leu Arg Glu Gly Ala Val Leu Thr Leu Leu Ser Asp 115 120
125Ile Ala Ser Ala Leu Arg Tyr Leu His Glu Asn Arg Ile Ile His Arg
130 135 140Asp Leu Lys Pro Glu Asn Ile Val Leu Gln Gln Gly Glu Lys
Arg Leu145 150 155 160Ile His Lys Ile Ile Asp Leu Gly Tyr Ala Lys
Glu Leu Asp Gln Gly 165 170 175Glu Leu Cys Thr Glu Phe Val Gly Thr
Leu Gln Tyr Leu Ala Pro Glu 180 185 190Leu Leu Glu Gln Gln Lys Tyr
Thr Val Thr Val Asp Tyr Trp Ser Phe 195 200 205Gly Thr Leu Ala Phe
Glu Cys Ile Thr Gly Phe Arg Pro Phe Leu Pro 210 215 220Asn Trp Gln
Pro Val Gln Trp His Ser Lys Val Arg Gln Lys Ser Glu225 230 235
240Val Asp Ile Val Val Ser Glu Asp Leu Asn Gly Ala Val Lys Phe Ser
245 250 255Ser Ser Leu Pro Phe Pro Asn Asn Leu Asn Ser Val Leu Ala
Glu Arg 260 265 270Leu Glu Lys Trp Leu Gln Leu Met Leu Met Trp His
Pro Arg Gln Arg 275 280 285Gly Thr Asp Pro Gln Tyr Gly Pro Asn Gly
Cys Phe Arg Ala Leu Asp 290 295 300Asp Ile Leu Asn Leu Lys Leu Val
His Val Leu Asn Met Val Thr Gly305 310 315 320Thr Val His Thr Tyr
Pro Val Thr Glu Asp Glu Ser Leu Gln Ser Leu 325 330 335Lys Thr Arg
Ile Gln Glu Asn Thr Gly Ile Leu Glu Thr Asp Gln Glu 340 345 350Leu
Leu Gln Lys Ala Gly Leu Val Leu Leu Pro Asp Lys Pro Ala Thr 355 360
365Gln Cys Ile Ser Asp Ser Lys Thr Asn Glu Gly Leu Thr Leu Asp Met
370 375 380Asp Leu Val Phe Leu Leu Asp Asn Ser Lys Ile Asn Tyr Glu
Thr Gln385 390 395 400Ile Thr Pro Arg Pro Pro Pro Glu Ser Val Ser
Cys Ile Leu Gln Glu 405 410 415Pro Lys Arg Asn Leu Ser Phe Phe Gln
Leu Arg Lys Val Trp Gly Gln 420 425 430Val Trp His Ser Ile Gln Thr
Leu Lys Glu Asp Cys Asn Arg Leu Gln 435 440 445Gln Gly Gln Arg Ala
Ala Met Met Ser Leu Leu Arg Asn Asn Ser Cys 450 455 460Leu Ser Lys
Met Lys Asn Ala Met Ala Ser Thr Ala Gln Gln Leu Lys465 470 475
480Ala Lys Leu Asp Phe Phe Lys Thr Ser Ile Gln Ile Asp Leu Glu Lys
485 490 495Tyr Lys Glu Gln Thr Glu Phe Gly Ile Thr Ser Asp Lys Leu
Leu Leu 500 505 510Ala Trp Arg Glu Met Glu Gln Ala Val Glu Gln Cys
Gly Arg Glu Asn 515 520 525Asp Val Lys His Leu Val Glu Arg Met Met
Ala Leu Gln Thr Asp Ile 530 535 540Val Asp Leu Gln Arg Ser Pro Met
Gly Arg Lys Gln Gly Gly Thr Leu545 550 555 560Asp Asp Leu Glu Glu
Gln Ala Arg Glu Leu Tyr Arg Lys Leu Arg Glu 565 570 575Lys Pro Arg
Asp Gln Arg Thr Glu Gly Asp Ser Gln Glu Met Val Arg 580 585 590Leu
Leu Leu Gln Ala Ile Gln Ser Phe Glu Lys Lys Val Arg Val Ile 595 600
605Tyr Thr Gln Leu Ser Lys Thr Val Val Cys Lys Gln Lys Ala Leu Glu
610 615 620Leu Leu Pro Lys Val Glu Glu Val Val Ser Leu Met Asn Glu
Asp Glu625 630 635 640Arg Thr Val Val Arg Leu Gln Glu Lys Arg Gln
Lys Glu Leu Trp Asn 645 650 655Leu Leu Lys Ile Ala Cys Ser Lys Val
Arg Gly Pro Val Ser Gly Ser 660 665 670Pro Asp Ser Met Asn Val Ser
Arg Leu Ser His Pro Gly Gln Leu Met 675 680 685Ser Gln Pro Ser Ser
Ala Cys Asp Ser Leu Pro Glu Ser Asp Lys Lys 690 695 700Ser Glu Glu
Leu Val Ala Glu Ala His Ala Leu Cys Ser Arg Leu Glu705 710 715
720Ser Ala Leu Gln Asp Thr Val Lys Glu Gln Asp Arg Ser Phe Thr Thr
725 730 735Leu Asp Trp Ser Trp Leu Gln Met Glu Asp Glu Glu Arg Cys
Ser Leu 740 745 750Glu Gln Ala Cys Asp 75590757PRTArtificial
SequenceSynthetic muIKK2null(S177A/S181A); P4003 without epitope
tag 90Met Ser Trp Ser Pro Ser Leu Pro Thr Gln Thr Cys Gly Ala Trp
Glu1 5 10 15Met Lys Glu Arg Leu Gly Thr Gly Gly Phe Gly Asn Val Ile
Arg Trp 20 25 30His Asn Gln Ala Thr Gly Glu Gln Ile Ala Ile Lys Gln
Cys Arg Gln 35 40 45Glu Leu Ser Pro Lys Asn Arg Asn Arg Trp Cys Leu
Glu Ile Gln Ile 50 55 60Met Arg Arg Leu Asn His Pro Asn Val Val Ala
Ala Arg Asp Val Pro65 70 75 80Glu Gly Met Gln Asn Leu Ala Pro Asn
Asp Leu Pro Leu Leu Ala Met 85 90 95Glu Tyr Cys Gln Gly Gly Asp Leu
Arg Arg Tyr Leu Asn Gln Phe Glu 100 105 110Asn Cys Cys Gly Leu Arg
Glu Gly Ala Val Leu Thr Leu Leu Ser Asp 115 120 125Ile Ala Ser Ala
Leu Arg Tyr Leu His Glu Asn Arg Ile Ile His Arg 130 135 140Asp Leu
Lys Pro Glu Asn Ile Val Leu Gln Gln Gly Glu Lys Arg Leu145 150 155
160Ile His Lys Ile Ile Asp Leu Gly Tyr Ala Lys Glu Leu Asp Gln Gly
165 170 175Ala Leu Cys Thr Ala Phe Val Gly Thr Leu Gln Tyr Leu Ala
Pro Glu 180 185 190Leu Leu Glu Gln Gln Lys Tyr Thr Val Thr Val Asp
Tyr Trp Ser Phe 195 200 205Gly Thr Leu Ala Phe Glu Cys Ile Thr Gly
Phe Arg Pro Phe Leu Pro 210 215 220Asn Trp Gln Pro Val Gln Trp His
Ser Lys Val Arg Gln Lys Ser Glu225 230 235 240Val Asp Ile Val Val
Ser Glu Asp Leu Asn Gly Ala Val Lys Phe Ser 245 250 255Ser Ser Leu
Pro Phe Pro Asn Asn Leu Asn Ser Val Leu Ala Glu Arg 260 265 270Leu
Glu Lys Trp Leu Gln Leu Met Leu Met Trp His Pro Arg Gln Arg 275 280
285Gly Thr Asp Pro Gln Tyr Gly Pro Asn Gly Cys Phe Arg Ala Leu Asp
290 295 300Asp Ile Leu Asn Leu Lys Leu Val His Val Leu Asn Met Val
Thr Gly305 310 315 320Thr Val His Thr Tyr Pro Val Thr Glu Asp Glu
Ser Leu Gln Ser Leu 325 330 335Lys Thr Arg Ile Gln Glu Asn Thr Gly
Ile Leu Glu Thr Asp Gln Glu 340 345 350Leu Leu Gln Lys Ala Gly Leu
Val Leu Leu Pro Asp Lys Pro Ala Thr 355 360 365Gln Cys Ile Ser Asp
Ser Lys Thr Asn Glu Gly Leu Thr Leu Asp Met 370 375 380Asp Leu Val
Phe Leu Leu Asp Asn Ser Lys Ile Asn Tyr Glu Thr Gln385 390 395
400Ile Thr Pro Arg Pro Pro Pro Glu Ser Val Ser Cys Ile Leu Gln Glu
405 410 415Pro Lys Arg Asn Leu Ser Phe Phe Gln Leu Arg Lys Val Trp
Gly Gln 420 425 430Val Trp His Ser Ile Gln Thr Leu Lys Glu Asp Cys
Asn Arg Leu Gln 435 440 445Gln Gly Gln Arg Ala Ala Met Met Ser Leu
Leu Arg Asn Asn Ser Cys 450 455 460Leu Ser Lys Met Lys Asn Ala Met
Ala Ser Thr Ala Gln Gln Leu Lys465 470 475 480Ala Lys Leu Asp Phe
Phe Lys Thr Ser Ile Gln Ile Asp Leu Glu Lys 485 490 495Tyr Lys Glu
Gln Thr Glu Phe Gly Ile Thr Ser Asp Lys Leu Leu Leu 500 505 510Ala
Trp Arg Glu Met Glu Gln Ala Val Glu Gln Cys Gly Arg Glu Asn 515 520
525Asp Val Lys His Leu Val Glu Arg Met Met Ala Leu Gln Thr Asp Ile
530 535 540Val Asp Leu Gln Arg Ser Pro Met Gly Arg Lys Gln Gly Gly
Thr Leu545 550 555 560Asp Asp Leu Glu Glu Gln Ala Arg Glu Leu Tyr
Arg Lys Leu Arg Glu 565 570 575Lys Pro Arg Asp Gln Arg Thr Glu Gly
Asp Ser Gln Glu Met Val Arg 580 585 590Leu Leu Leu Gln Ala Ile Gln
Ser Phe Glu Lys Lys Val Arg Val Ile 595 600 605Tyr Thr Gln Leu Ser
Lys Thr Val Val Cys Lys Gln Lys Ala Leu Glu 610 615 620Leu Leu Pro
Lys Val Glu Glu Val Val Ser Leu Met Asn Glu Asp Glu625 630 635
640Arg Thr Val Val Arg Leu Gln Glu Lys Arg Gln Lys Glu Leu Trp Asn
645 650 655Leu Leu Lys Ile Ala Cys Ser Lys Val Arg Gly Pro Val Ser
Gly Ser 660 665 670Pro Asp Ser Met Asn Val Ser Arg Leu Ser His Pro
Gly Gln Leu Met 675 680 685Ser Gln Pro Ser Ser Ala Cys Asp Ser Leu
Pro Glu Ser Asp Lys Lys 690 695 700Ser Glu Glu Leu Val Ala Glu Ala
His Ala Leu Cys Ser Arg Leu Glu705 710 715 720Ser Ala Leu Gln Asp
Thr Val Lys Glu Gln Asp Arg Ser Phe Thr Thr 725 730 735Leu Asp Trp
Ser Trp Leu Gln Met Glu Asp Glu Glu Arg Cys Ser Leu 740 745 750Glu
Gln Ala Cys Asp 75591744PRTHomo sapiensmisc_feature(1)..(744)Human
constitutively active IKK alpha (PEST mutation) P.4013 without
epitope tag 91Met Glu Arg Pro Pro Gly Leu Arg Pro Gly Ala Gly Gly
Pro Trp Glu1 5 10 15Met Arg Glu Arg Leu Gly Thr Gly Gly Phe Gly Asn
Val Cys Leu Tyr 20 25 30Gln His Arg Glu Leu Asp Leu Lys Ile Ala Ile
Lys Ser Cys Arg Leu 35 40 45Glu Leu Ser Thr Lys Asn Arg Glu Arg Trp
Cys His Glu Ile Gln Ile 50 55 60Met Lys Lys Leu Asn His Ala Asn Val
Val Lys Ala Cys Asp Val Pro65 70 75 80Glu Glu Leu Asn Ile Leu Ile
His Asp Val Pro Leu Leu Ala Met Glu 85 90 95Tyr Cys Ser Gly Gly Asp
Leu Arg Lys Leu Leu Asn Lys Pro Glu Asn 100 105 110Cys Cys Gly Leu
Lys Glu Ser Gln Ile Leu Ser Leu Leu Ser Asp Ile 115 120 125Gly Ser
Gly Ile Arg Tyr Leu His Glu Asn Lys Ile Ile His Arg Asp 130 135
140Leu Lys Pro Glu Asn Ile Val Leu Gln Asp Val Gly Gly Lys Ile
Ile145 150 155 160His Lys Ile Ile Asp Leu Gly Tyr Ala Lys Asp Val
Asp Gln Gly Glu 165 170 175Leu Cys Thr Glu Phe Val Gly Thr Leu Gln
Tyr Leu Ala Pro Glu Leu 180 185 190Phe Glu Asn Lys Pro Tyr Thr Ala
Thr Val Asp Tyr Trp Ser Phe Gly 195 200 205Thr Met Val Phe Glu Cys
Ile Ala Gly Tyr Arg Pro Phe Leu His His 210 215 220Leu Gln Pro Phe
Thr Trp His Glu Lys Ile Lys Lys Lys Asp Pro Lys225 230 235 240Cys
Ile Phe Ala Cys Glu Glu Met Ser Gly Glu Val Arg Phe Ser Ser 245 250
255His Leu Pro Gln Pro Asn Ser Leu Cys Ser Leu Val Val Glu Pro Met
260 265 270Glu Asn Trp Leu Gln Leu Met Leu Asn Trp Asp Pro Gln Gln
Arg Gly 275 280 285Gly Pro Val Asp Leu Thr Leu Lys Gln Pro Arg Cys
Phe Val Leu Met 290 295 300Asp His Ile Leu Asn Leu Lys Ile Val His
Ile Leu Asn Met Thr Ser305 310 315 320Ala Lys Ile Ile Ser Phe Leu
Leu Pro Pro Asp Glu Ser Leu His Ser 325 330 335Leu Gln Ser Arg Ile
Glu Arg Glu Thr Gly Ile Asn Thr Gly Ser Gln 340 345 350Glu Leu Leu
Ser Glu Thr Gly Ile Ser Leu Asp Pro Arg Lys Pro Ala 355 360 365Ser
Gln Cys Val Leu Asp Gly Val Arg Gly Cys Asp Ser Tyr Met Val 370 375
380Tyr Leu Phe Asp Lys Ser Lys Thr Val Tyr Glu Gly Pro Phe Ala
Ser385 390 395 400Arg Ser Leu Ser Asp Cys Val Asn Tyr Ile Val Gln
Asp Ser Lys Ile 405 410 415Gln Leu Pro Ile Ile Gln Leu Arg Lys Val
Trp Ala Glu Ala Val His 420 425 430Tyr Val Ser Gly Leu Lys Glu Asp
Tyr Ser Arg Leu Phe Gln Gly Gln 435 440 445Arg Ala Ala Met Leu Ser
Leu Leu Arg Tyr Asn Ala Asn Leu Thr Lys 450 455 460Met Lys Asn Thr
Leu Ile Ser Ala Ser Gln Gln Leu Lys Ala Lys Leu465 470 475 480Glu
Phe Phe His Lys Ser Ile Gln Leu Asp Leu Glu Arg Tyr Ser Glu 485 490
495Gln Met Thr Tyr Gly Ile Ser Ser Glu Lys Met Leu Lys Ala Trp Lys
500 505 510Glu Met Glu Glu Lys Ala Ile His Tyr Ala Glu Val Gly Val
Ile Gly 515 520 525Tyr Leu Glu Asp Gln Ile Met Ser Leu His Ala Glu
Ile Met Glu Leu 530 535 540Gln Lys Ser Pro Tyr Arg Arg Gln Gly Asp
Leu Met Glu Ser Leu Glu545 550 555 560Gln Arg Ala Ile Asp Leu Tyr
Lys Gln Leu Lys His Arg Pro Ser Asp 565 570 575His Ser Tyr Ser Asp
Ser Thr Glu Met Val Lys Ile Ile Val His Thr 580 585 590Val Gln Ser
Gln Asp Arg Val Leu Lys Glu Leu Phe Gly His Leu Ser 595 600 605Lys
Leu Leu Gly Cys Lys Gln Lys Ile Ile Asp Leu Leu Pro Lys Val 610 615
620Glu Val Ala Leu Ser Asn Ile Lys Glu Ala Asp Asn Thr Val Met
Phe625 630 635 640Met Gln Gly Lys Arg Gln Lys Glu Ile Trp His Leu
Leu Lys Ile Ala 645 650 655Cys Thr Gln Ala Ala Ala Arg Ala Leu Val
Gly Ala Ala Leu Glu Gly 660 665 670Ala Val Ala Pro Gln Ala Ala Ala
Trp Leu Pro Pro Ala Ala Ala Glu 675 680 685His Asp His Ala Leu Ala
Cys Val Val Ala Pro Gln Asp Gly Glu Ala 690 695 700Ala Ala Gln Met
Ile Glu Glu Asn Leu Asn Cys Leu Gly His Leu Ala705 710 715 720Ala
Ile Ile His Glu Ala Asn Glu Glu Gln Gly Asn Ser Met Met Asn 725 730
735Leu Asp Trp Ser Trp Leu Thr Glu 74092744PRTHomo
sapiensmisc_feature(1)..(744)Human constitutively active IKK alpha
(PEST mutation) P.4014 without epitope tag 92Met Glu Arg Pro Pro
Gly Leu Arg Pro Gly Ala Gly Gly Pro Trp Glu1 5 10 15Met Arg Glu Arg
Leu Gly Thr Gly Gly Phe Gly Asn Val Cys Leu Tyr 20 25 30Gln His Arg
Glu Leu Asp Leu Lys Ile Ala Ile Lys Ser Cys Arg Leu
35 40 45Glu Leu Ser Thr Lys Asn Arg Glu Arg Trp Cys His Glu Ile Gln
Ile 50 55 60Met Lys Lys Leu Asn His Ala Asn Val Val Lys Ala Cys Asp
Val Pro65 70 75 80Glu Glu Leu Asn Ile Leu Ile His Asp Val Pro Leu
Leu Ala Met Glu 85 90 95Tyr Cys Ser Gly Gly Asp Leu Arg Lys Leu Leu
Asn Lys Pro Glu Asn 100 105 110Cys Cys Gly Leu Lys Glu Ser Gln Ile
Leu Ser Leu Leu Ser Asp Ile 115 120 125Gly Ser Gly Ile Arg Tyr Leu
His Glu Asn Lys Ile Ile His Arg Asp 130 135 140Leu Lys Pro Glu Asn
Ile Val Leu Gln Asp Val Gly Gly Lys Ile Ile145 150 155 160His Lys
Ile Ile Asp Leu Gly Tyr Ala Lys Asp Val Asp Gln Gly Glu 165 170
175Leu Cys Thr Glu Phe Val Gly Thr Leu Gln Tyr Leu Ala Pro Glu Leu
180 185 190Phe Glu Asn Lys Pro Tyr Thr Ala Thr Val Asp Tyr Trp Ser
Phe Gly 195 200 205Thr Met Val Phe Glu Cys Ile Ala Gly Tyr Arg Pro
Phe Leu His His 210 215 220Leu Gln Pro Phe Thr Trp His Glu Lys Ile
Lys Lys Lys Asp Pro Lys225 230 235 240Cys Ile Phe Ala Cys Glu Glu
Met Ser Gly Glu Val Arg Phe Ser Ser 245 250 255His Leu Pro Gln Pro
Asn Ser Leu Cys Ser Leu Val Val Glu Pro Met 260 265 270Glu Asn Trp
Leu Gln Leu Met Leu Asn Trp Asp Pro Gln Gln Arg Gly 275 280 285Gly
Pro Val Asp Leu Thr Leu Lys Gln Pro Arg Cys Phe Val Leu Met 290 295
300Asp His Ile Leu Asn Leu Lys Ile Val His Ile Leu Asn Met Thr
Ser305 310 315 320Ala Lys Ile Ile Ser Phe Leu Leu Pro Pro Asp Glu
Ser Leu His Ser 325 330 335Leu Gln Ser Arg Ile Glu Arg Glu Thr Gly
Ile Asn Thr Gly Ser Gln 340 345 350Glu Leu Leu Ser Glu Thr Gly Ile
Ser Leu Asp Pro Arg Lys Pro Ala 355 360 365Ser Gln Cys Val Leu Asp
Gly Val Arg Gly Cys Asp Ser Tyr Met Val 370 375 380Tyr Leu Phe Asp
Lys Ser Lys Thr Val Tyr Glu Gly Pro Phe Ala Ser385 390 395 400Arg
Ser Leu Ser Asp Cys Val Asn Tyr Ile Val Gln Asp Ser Lys Ile 405 410
415Gln Leu Pro Ile Ile Gln Leu Arg Lys Val Trp Ala Glu Ala Val His
420 425 430Tyr Val Ser Gly Leu Lys Glu Asp Tyr Ser Arg Leu Phe Gln
Gly Gln 435 440 445Arg Ala Ala Met Leu Ser Leu Leu Arg Tyr Asn Ala
Asn Leu Thr Lys 450 455 460Met Lys Asn Thr Leu Ile Ser Ala Ser Gln
Gln Leu Lys Ala Lys Leu465 470 475 480Glu Phe Phe His Lys Ser Ile
Gln Leu Asp Leu Glu Arg Tyr Ser Glu 485 490 495Gln Met Thr Tyr Gly
Ile Ser Ser Glu Lys Met Leu Lys Ala Trp Lys 500 505 510Glu Met Glu
Glu Lys Ala Ile His Tyr Ala Glu Val Gly Val Ile Gly 515 520 525Tyr
Leu Glu Asp Gln Ile Met Ser Leu His Ala Glu Ile Met Glu Leu 530 535
540Gln Lys Ser Pro Tyr Arg Arg Gln Gly Asp Leu Met Glu Ser Leu
Glu545 550 555 560Gln Arg Ala Ile Asp Leu Tyr Lys Gln Leu Lys His
Arg Pro Ser Asp 565 570 575His Ser Tyr Ser Asp Ser Thr Glu Met Val
Lys Ile Ile Val His Thr 580 585 590Val Gln Ser Gln Asp Arg Val Leu
Lys Glu Leu Phe Gly His Leu Ser 595 600 605Lys Leu Leu Gly Cys Lys
Gln Lys Ile Ile Asp Leu Leu Pro Lys Val 610 615 620Glu Val Ala Leu
Ser Asn Ile Lys Glu Ala Asp Asn Thr Val Met Phe625 630 635 640Met
Gln Gly Lys Arg Gln Lys Glu Ile Trp His Leu Leu Lys Ile Ala 645 650
655Cys Thr Gln Ala Ala Ala Arg Ala Leu Val Gly Ala Ala Leu Glu Gly
660 665 670Ala Val Ala Pro Gln Ala Ala Ala Trp Leu Pro Pro Ala Ala
Ala Glu 675 680 685His Asp His Ala Leu Ala Cys Val Val Ala Pro Gln
Asp Gly Glu Ala 690 695 700Ala Ala Gln Met Ile Glu Glu Asn Leu Asn
Cys Leu Gly His Leu Ala705 710 715 720Ala Ile Ile His Glu Ala Asn
Glu Glu Gln Gly Asn Ser Met Met Asn 725 730 735Leu Asp Trp Ser Trp
Leu Thr Glu 74093756PRTHomo sapiensmisc_feature(1)..(756)Human
constitutively active IKK beta (PEST mutation) P.4015 without
epitope tag 93Met Ser Trp Ser Pro Ser Leu Thr Thr Gln Thr Cys Gly
Ala Trp Glu1 5 10 15Met Lys Glu Arg Leu Gly Thr Gly Gly Phe Gly Asn
Val Ile Arg Trp 20 25 30His Asn Gln Glu Thr Gly Glu Gln Ile Ala Ile
Lys Gln Cys Arg Gln 35 40 45Glu Leu Ser Pro Arg Asn Arg Glu Arg Trp
Cys Leu Glu Ile Gln Ile 50 55 60Met Arg Arg Leu Thr His Pro Asn Val
Val Ala Ala Arg Asp Val Pro65 70 75 80Glu Gly Met Gln Asn Leu Ala
Pro Asn Asp Leu Pro Leu Leu Ala Met 85 90 95Glu Tyr Cys Gln Gly Gly
Asp Leu Arg Lys Tyr Leu Asn Gln Phe Glu 100 105 110Asn Cys Cys Gly
Leu Arg Glu Gly Ala Ile Leu Thr Leu Leu Ser Asp 115 120 125Ile Ala
Ser Ala Leu Arg Tyr Leu His Glu Asn Arg Ile Ile His Arg 130 135
140Asp Leu Lys Pro Glu Asn Ile Val Leu Gln Gln Gly Glu Gln Arg
Leu145 150 155 160Ile His Lys Ile Ile Asp Leu Gly Tyr Ala Lys Glu
Leu Asp Gln Gly 165 170 175Glu Leu Cys Thr Glu Phe Val Gly Thr Leu
Gln Tyr Leu Ala Pro Glu 180 185 190Leu Leu Glu Gln Gln Lys Tyr Thr
Val Thr Val Asp Tyr Trp Ser Phe 195 200 205Gly Thr Leu Ala Phe Glu
Cys Ile Thr Gly Phe Arg Pro Phe Leu Pro 210 215 220Asn Trp Gln Pro
Val Gln Trp His Ser Lys Val Arg Gln Lys Ser Glu225 230 235 240Val
Asp Ile Val Val Ser Glu Asp Leu Asn Gly Thr Val Lys Phe Ser 245 250
255Ser Ser Leu Pro Tyr Pro Asn Asn Leu Asn Ser Val Leu Ala Glu Arg
260 265 270Leu Glu Lys Trp Leu Gln Leu Met Leu Met Trp His Pro Arg
Gln Arg 275 280 285Gly Thr Asp Pro Thr Tyr Gly Pro Asn Gly Cys Phe
Lys Ala Leu Asp 290 295 300Asp Ile Leu Asn Leu Lys Leu Val His Ile
Leu Asn Met Val Thr Gly305 310 315 320Thr Ile His Thr Tyr Pro Val
Thr Glu Asp Glu Ser Leu Gln Ser Leu 325 330 335Lys Ala Arg Ile Gln
Gln Asp Thr Gly Ile Pro Glu Glu Asp Gln Glu 340 345 350Leu Leu Gln
Glu Ala Gly Leu Ala Leu Ile Pro Asp Lys Pro Ala Thr 355 360 365Gln
Cys Ile Ser Asp Gly Lys Leu Asn Glu Gly His Thr Leu Asp Met 370 375
380Asp Leu Val Phe Leu Phe Asp Asn Ser Lys Ile Thr Tyr Glu Thr
Gln385 390 395 400Ile Ser Pro Arg Pro Gln Pro Glu Ser Val Ser Cys
Ile Leu Gln Glu 405 410 415Pro Lys Arg Asn Leu Ala Phe Phe Gln Leu
Arg Lys Val Trp Gly Gln 420 425 430Val Trp His Ser Ile Gln Thr Leu
Lys Glu Asp Cys Asn Arg Leu Gln 435 440 445Gln Gly Gln Arg Ala Ala
Met Met Asn Leu Leu Arg Asn Asn Ser Cys 450 455 460Leu Ser Lys Met
Lys Asn Ser Met Ala Ser Met Ser Gln Gln Leu Lys465 470 475 480Ala
Lys Leu Asp Phe Phe Lys Thr Ser Ile Gln Ile Asp Leu Glu Lys 485 490
495Tyr Ser Glu Gln Thr Glu Phe Gly Ile Thr Ser Asp Lys Leu Leu Leu
500 505 510Ala Trp Arg Glu Met Glu Gln Ala Val Glu Leu Cys Gly Arg
Glu Asn 515 520 525Glu Val Lys Leu Leu Val Glu Arg Met Met Ala Leu
Gln Thr Asp Ile 530 535 540Val Asp Leu Gln Arg Ser Pro Met Gly Arg
Lys Gln Gly Gly Thr Leu545 550 555 560Asp Asp Leu Glu Glu Gln Ala
Arg Glu Leu Tyr Arg Arg Leu Arg Glu 565 570 575Lys Pro Arg Asp Gln
Arg Thr Glu Gly Asp Ser Gln Glu Met Val Arg 580 585 590Leu Leu Leu
Gln Ala Ile Gln Ser Phe Glu Lys Lys Val Arg Val Ile 595 600 605Tyr
Thr Gln Leu Ser Lys Thr Val Val Cys Lys Gln Lys Ala Leu Glu 610 615
620Leu Leu Pro Lys Val Glu Glu Val Val Ser Leu Met Asn Glu Asp
Glu625 630 635 640Lys Thr Val Val Arg Leu Gln Glu Lys Arg Gln Lys
Glu Leu Trp Asn 645 650 655Leu Leu Lys Ile Ala Cys Ser Lys Val Arg
Gly Pro Val Ala Gly Ala 660 665 670Pro Asp Ala Met Asn Ala Ala Arg
Leu Ala Gln Pro Gly Gln Leu Met 675 680 685Ala Gln Pro Ala Thr Ala
Ala Asn Ala Leu Pro Glu Pro Ala Lys Lys 690 695 700Ala Glu Glu Leu
Val Ala Glu Ala His Asn Leu Cys Thr Leu Leu Glu705 710 715 720Asn
Ala Ile Gln Asp Thr Val Arg Glu Gln Asp Gln Ser Phe Thr Ala 725 730
735Leu Asp Trp Ser Trp Leu Gln Thr Glu Glu Glu Glu His Ser Cys Leu
740 745 750Glu Gln Ala Ser 75594756PRTHomo
sapiensmisc_feature(1)..(756)Human constitutively active IKK beta
(PEST mutation) P.4016 without epitope tag 94Met Ser Trp Ser Pro
Ser Leu Thr Thr Gln Thr Cys Gly Ala Trp Glu1 5 10 15Met Lys Glu Arg
Leu Gly Thr Gly Gly Phe Gly Asn Val Ile Arg Trp 20 25 30His Asn Gln
Glu Thr Gly Glu Gln Ile Ala Ile Lys Gln Cys Arg Gln 35 40 45Glu Leu
Ser Pro Arg Asn Arg Glu Arg Trp Cys Leu Glu Ile Gln Ile 50 55 60Met
Arg Arg Leu Thr His Pro Asn Val Val Ala Ala Arg Asp Val Pro65 70 75
80Glu Gly Met Gln Asn Leu Ala Pro Asn Asp Leu Pro Leu Leu Ala Met
85 90 95Glu Tyr Cys Gln Gly Gly Asp Leu Arg Lys Tyr Leu Asn Gln Phe
Glu 100 105 110Asn Cys Cys Gly Leu Arg Glu Gly Ala Ile Leu Thr Leu
Leu Ser Asp 115 120 125Ile Ala Ser Ala Leu Arg Tyr Leu His Glu Asn
Arg Ile Ile His Arg 130 135 140Asp Leu Lys Pro Glu Asn Ile Val Leu
Gln Gln Gly Glu Gln Arg Leu145 150 155 160Ile His Lys Ile Ile Asp
Leu Gly Tyr Ala Lys Glu Leu Asp Gln Gly 165 170 175Glu Leu Cys Thr
Glu Phe Val Gly Thr Leu Gln Tyr Leu Ala Pro Glu 180 185 190Leu Leu
Glu Gln Gln Lys Tyr Thr Val Thr Val Asp Tyr Trp Ser Phe 195 200
205Gly Thr Leu Ala Phe Glu Cys Ile Thr Gly Phe Arg Pro Phe Leu Pro
210 215 220Asn Trp Gln Pro Val Gln Trp His Ser Lys Val Arg Gln Lys
Ser Glu225 230 235 240Val Asp Ile Val Val Ser Glu Asp Leu Asn Gly
Thr Val Lys Phe Ser 245 250 255Ser Ser Leu Pro Tyr Pro Asn Asn Leu
Asn Ser Val Leu Ala Glu Arg 260 265 270Leu Glu Lys Trp Leu Gln Leu
Met Leu Met Trp His Pro Arg Gln Arg 275 280 285Gly Thr Asp Pro Thr
Tyr Gly Pro Asn Gly Cys Phe Lys Ala Leu Asp 290 295 300Asp Ile Leu
Asn Leu Lys Leu Val His Ile Leu Asn Met Val Thr Gly305 310 315
320Thr Ile His Thr Tyr Pro Val Thr Glu Asp Glu Ser Leu Gln Ser Leu
325 330 335Lys Ala Arg Ile Gln Gln Asp Thr Gly Ile Pro Glu Glu Asp
Gln Glu 340 345 350Leu Leu Gln Glu Ala Gly Leu Ala Leu Ile Pro Asp
Lys Pro Ala Thr 355 360 365Gln Cys Ile Ser Asp Gly Lys Leu Asn Glu
Gly His Thr Leu Asp Met 370 375 380Asp Leu Val Phe Leu Phe Asp Asn
Ser Lys Ile Thr Tyr Glu Thr Gln385 390 395 400Ile Ser Pro Arg Pro
Gln Pro Glu Ser Val Ser Cys Ile Leu Gln Glu 405 410 415Pro Lys Arg
Asn Leu Ala Phe Phe Gln Leu Arg Lys Val Trp Gly Gln 420 425 430Val
Trp His Ser Ile Gln Thr Leu Lys Glu Asp Cys Asn Arg Leu Gln 435 440
445Gln Gly Gln Arg Ala Ala Met Met Asn Leu Leu Arg Asn Asn Ser Cys
450 455 460Leu Ser Lys Met Lys Asn Ser Met Ala Ser Met Ser Gln Gln
Leu Lys465 470 475 480Ala Lys Leu Asp Phe Phe Lys Thr Ser Ile Gln
Ile Asp Leu Glu Lys 485 490 495Tyr Ser Glu Gln Thr Glu Phe Gly Ile
Thr Ser Asp Lys Leu Leu Leu 500 505 510Ala Trp Arg Glu Met Glu Gln
Ala Val Glu Leu Cys Gly Arg Glu Asn 515 520 525Glu Val Lys Leu Leu
Val Glu Arg Met Met Ala Leu Gln Thr Asp Ile 530 535 540Val Asp Leu
Gln Arg Ser Pro Met Gly Arg Lys Gln Gly Gly Thr Leu545 550 555
560Asp Asp Leu Glu Glu Gln Ala Arg Glu Leu Tyr Arg Arg Leu Arg Glu
565 570 575Lys Pro Arg Asp Gln Arg Thr Glu Gly Asp Ser Gln Glu Met
Val Arg 580 585 590Leu Leu Leu Gln Ala Ile Gln Ser Phe Glu Lys Lys
Val Arg Val Ile 595 600 605Tyr Thr Gln Leu Ser Lys Thr Val Val Cys
Lys Gln Lys Ala Leu Glu 610 615 620Leu Leu Pro Lys Val Glu Glu Val
Val Ser Leu Met Asn Glu Asp Glu625 630 635 640Lys Thr Val Val Arg
Leu Gln Glu Lys Arg Gln Lys Glu Leu Trp Asn 645 650 655Leu Leu Lys
Ile Ala Cys Ser Lys Val Arg Gly Pro Val Ala Gly Ala 660 665 670Pro
Asp Ala Met Asn Ala Ala Arg Leu Ala Gln Pro Gly Gln Leu Met 675 680
685Ala Gln Pro Ala Thr Ala Ala Asn Ala Leu Pro Glu Pro Ala Lys Lys
690 695 700Ala Glu Glu Leu Val Ala Glu Ala His Asn Leu Cys Thr Leu
Leu Glu705 710 715 720Asn Ala Ile Gln Asp Thr Val Arg Glu Gln Asp
Gln Ser Phe Thr Ala 725 730 735Leu Asp Trp Ser Trp Leu Gln Thr Glu
Glu Glu Glu His Ser Cys Leu 740 745 750Glu Gln Ala Ser
75595745PRTMus musculusmisc_feature(1)..(745)Mouse constitutively
active IKK alpha (PEST mutation) P.4017 without epitope tag 95Met
Glu Arg Pro Pro Gly Leu Arg Pro Gly Ala Gly Gly Pro Trp Glu1 5 10
15Met Arg Glu Arg Leu Gly Thr Gly Gly Phe Gly Asn Val Ser Leu Tyr
20 25 30Gln His Arg Glu Leu Asp Leu Lys Ile Ala Ile Lys Ser Cys Arg
Leu 35 40 45Glu Leu Ser Ser Lys Asn Arg Glu Arg Trp Cys His Glu Ile
Gln Ile 50 55 60Met Lys Lys Leu Asp His Ala Asn Val Val Lys Ala Cys
Asp Val Pro65 70 75 80Glu Glu Leu Asn Phe Leu Ile Asn Asp Val Pro
Leu Leu Ala Met Glu 85 90 95Tyr Cys Ser Gly Gly Asp Leu Arg Lys Leu
Leu Asn Lys Pro Glu Asn 100 105 110Cys Cys Gly Leu Lys Glu Ser Gln
Ile Leu Ser Leu Leu Ser Asp Ile 115 120 125Gly Ser Gly Ile Arg Tyr
Leu His Glu Asn Lys Ile Ile His Arg Asp 130 135 140Leu Lys Pro Glu
Asn Ile Val Leu Gln Asp Val Gly Gly Lys Thr Ile145 150 155 160His
Lys Ile Ile Asp Leu Gly Tyr Ala Lys Asp Val Asp Gln Gly Glu 165 170
175Leu Cys Thr Glu Phe Val Gly Thr Leu Gln Tyr Leu Ala Pro Glu Leu
180 185 190Phe Glu Asn Lys Pro Tyr Thr Ala Thr Val Asp Tyr Trp Ser
Phe Gly 195 200 205Thr Met Val Phe
Glu Cys Ile Ala Gly Tyr Arg Pro Phe Leu His His 210 215 220Leu Gln
Pro Phe Thr Trp His Glu Lys Ile Lys Lys Lys Asp Pro Lys225 230 235
240Cys Ile Phe Ala Cys Glu Glu Met Thr Gly Glu Val Arg Phe Ser Ser
245 250 255His Leu Pro Gln Pro Asn Ser Leu Cys Ser Leu Ile Val Glu
Pro Met 260 265 270Glu Ser Trp Leu Gln Leu Met Leu Asn Trp Asp Pro
Gln Gln Arg Gly 275 280 285Gly Pro Ile Asp Leu Thr Leu Lys Gln Pro
Arg Cys Phe Ala Leu Met 290 295 300Asp His Ile Leu Asn Leu Lys Ile
Val His Ile Leu Asn Met Thr Ser305 310 315 320Ala Lys Ile Ile Ser
Phe Leu Leu Pro Cys Asp Glu Ser Leu His Ser 325 330 335Leu Gln Ser
Arg Ile Glu Arg Glu Thr Gly Ile Asn Thr Gly Ser Gln 340 345 350Glu
Leu Leu Ser Glu Thr Gly Ile Ser Leu Asp Pro Arg Lys Pro Ala 355 360
365Ser Gln Cys Val Leu Asp Gly Val Arg Gly Cys Asp Ser Tyr Met Val
370 375 380Tyr Leu Phe Asp Lys Ser Lys Thr Val Tyr Glu Gly Pro Phe
Ala Ser385 390 395 400Arg Ser Leu Ser Asp Cys Val Asn Tyr Ile Val
Gln Asp Ser Lys Ile 405 410 415Gln Leu Pro Ile Ile Gln Leu Arg Lys
Val Trp Ala Glu Ala Val His 420 425 430Tyr Val Ser Gly Leu Lys Glu
Asp Tyr Ser Arg Leu Phe Gln Gly Gln 435 440 445Arg Ala Ala Met Leu
Ser Leu Leu Arg Tyr Asn Ala Asn Leu Thr Lys 450 455 460Met Lys Asn
Thr Leu Ile Ser Ala Ser Gln Gln Leu Lys Ala Lys Leu465 470 475
480Glu Phe Phe Arg Lys Ser Ile Gln Leu Asp Leu Glu Arg Tyr Ser Glu
485 490 495Gln Met Thr Tyr Gly Ile Ser Ser Glu Lys Met Leu Lys Ala
Trp Lys 500 505 510Glu Met Glu Glu Lys Ala Ile His Tyr Ser Glu Val
Gly Val Ile Gly 515 520 525Tyr Leu Glu Asp Gln Ile Met Ser Leu His
Thr Glu Ile Met Glu Leu 530 535 540Gln Lys Ser Pro Tyr Gly Arg Arg
Gln Gly Asp Leu Met Glu Ser Leu545 550 555 560Glu Gln Arg Ala Ile
Asp Leu Tyr Lys Gln Leu Lys His Arg Pro Pro 565 570 575Asp His Leu
Tyr Ser Asp Ser Thr Glu Met Val Lys Ile Ile Val His 580 585 590Thr
Val Gln Ser Gln Asp Arg Val Leu Lys Glu Leu Phe Gly His Leu 595 600
605Ser Lys Leu Leu Gly Cys Lys Gln Lys Ile Ile Asp Leu Leu Pro Lys
610 615 620Val Glu Val Ala Leu Ser Asn Ile Lys Glu Ala Asp Asn Thr
Val Met625 630 635 640Phe Met Gln Gly Lys Arg Gln Lys Glu Ile Trp
His Leu Leu Lys Ile 645 650 655Ala Cys Thr Gln Ala Ala Ala Arg Ala
Leu Val Gly Ala Ala Leu Glu 660 665 670Gly Ala Val Ala Pro Pro Val
Ala Ala Trp Leu Pro Pro Ala Leu Ala 675 680 685Asp Arg Glu His Pro
Leu Thr Cys Val Val Ala Pro Gln Asp Gly Glu 690 695 700Ala Leu Ala
Gln Met Ile Glu Glu Asn Leu Asn Cys Leu Gly His Leu705 710 715
720Ala Ala Ile Ile Arg Glu Ala Asn Glu Asp Gln Ser Ser Ser Leu Met
725 730 735Ser Leu Asp Trp Ser Trp Leu Ala Glu 740 74596745PRTMus
musculusmisc_feature(1)..(745)Mouse constitutively active IKK alpha
(PEST mutation) P.4018 without epitope tag 96Met Glu Arg Pro Pro
Gly Leu Arg Pro Gly Ala Gly Gly Pro Trp Glu1 5 10 15Met Arg Glu Arg
Leu Gly Thr Gly Gly Phe Gly Asn Val Ser Leu Tyr 20 25 30Gln His Arg
Glu Leu Asp Leu Lys Ile Ala Ile Lys Ser Cys Arg Leu 35 40 45Glu Leu
Ser Ser Lys Asn Arg Glu Arg Trp Cys His Glu Ile Gln Ile 50 55 60Met
Lys Lys Leu Asp His Ala Asn Val Val Lys Ala Cys Asp Val Pro65 70 75
80Glu Glu Leu Asn Phe Leu Ile Asn Asp Val Pro Leu Leu Ala Met Glu
85 90 95Tyr Cys Ser Gly Gly Asp Leu Arg Lys Leu Leu Asn Lys Pro Glu
Asn 100 105 110Cys Cys Gly Leu Lys Glu Ser Gln Ile Leu Ser Leu Leu
Ser Asp Ile 115 120 125Gly Ser Gly Ile Arg Tyr Leu His Glu Asn Lys
Ile Ile His Arg Asp 130 135 140Leu Lys Pro Glu Asn Ile Val Leu Gln
Asp Val Gly Gly Lys Thr Ile145 150 155 160His Lys Ile Ile Asp Leu
Gly Tyr Ala Lys Asp Val Asp Gln Gly Glu 165 170 175Leu Cys Thr Glu
Phe Val Gly Thr Leu Gln Tyr Leu Ala Pro Glu Leu 180 185 190Phe Glu
Asn Lys Pro Tyr Thr Ala Thr Val Asp Tyr Trp Ser Phe Gly 195 200
205Thr Met Val Phe Glu Cys Ile Ala Gly Tyr Arg Pro Phe Leu His His
210 215 220Leu Gln Pro Phe Thr Trp His Glu Lys Ile Lys Lys Lys Asp
Pro Lys225 230 235 240Cys Ile Phe Ala Cys Glu Glu Met Thr Gly Glu
Val Arg Phe Ser Ser 245 250 255His Leu Pro Gln Pro Asn Ser Leu Cys
Ser Leu Ile Val Glu Pro Met 260 265 270Glu Ser Trp Leu Gln Leu Met
Leu Asn Trp Asp Pro Gln Gln Arg Gly 275 280 285Gly Pro Ile Asp Leu
Thr Leu Lys Gln Pro Arg Cys Phe Ala Leu Met 290 295 300Asp His Ile
Leu Asn Leu Lys Ile Val His Ile Leu Asn Met Thr Ser305 310 315
320Ala Lys Ile Ile Ser Phe Leu Leu Pro Cys Asp Glu Ser Leu His Ser
325 330 335Leu Gln Ser Arg Ile Glu Arg Glu Thr Gly Ile Asn Thr Gly
Ser Gln 340 345 350Glu Leu Leu Ser Glu Thr Gly Ile Ser Leu Asp Pro
Arg Lys Pro Ala 355 360 365Ser Gln Cys Val Leu Asp Gly Val Arg Gly
Cys Asp Ser Tyr Met Val 370 375 380Tyr Leu Phe Asp Lys Ser Lys Thr
Val Tyr Glu Gly Pro Phe Ala Ser385 390 395 400Arg Ser Leu Ser Asp
Cys Val Asn Tyr Ile Val Gln Asp Ser Lys Ile 405 410 415Gln Leu Pro
Ile Ile Gln Leu Arg Lys Val Trp Ala Glu Ala Val His 420 425 430Tyr
Val Ser Gly Leu Lys Glu Asp Tyr Ser Arg Leu Phe Gln Gly Gln 435 440
445Arg Ala Ala Met Leu Ser Leu Leu Arg Tyr Asn Ala Asn Leu Thr Lys
450 455 460Met Lys Asn Thr Leu Ile Ser Ala Ser Gln Gln Leu Lys Ala
Lys Leu465 470 475 480Glu Phe Phe Arg Lys Ser Ile Gln Leu Asp Leu
Glu Arg Tyr Ser Glu 485 490 495Gln Met Thr Tyr Gly Ile Ser Ser Glu
Lys Met Leu Lys Ala Trp Lys 500 505 510Glu Met Glu Glu Lys Ala Ile
His Tyr Ser Glu Val Gly Val Ile Gly 515 520 525Tyr Leu Glu Asp Gln
Ile Met Ser Leu His Thr Glu Ile Met Glu Leu 530 535 540Gln Lys Ser
Pro Tyr Gly Arg Arg Gln Gly Asp Leu Met Glu Ser Leu545 550 555
560Glu Gln Arg Ala Ile Asp Leu Tyr Lys Gln Leu Lys His Arg Pro Pro
565 570 575Asp His Leu Tyr Ser Asp Ser Thr Glu Met Val Lys Ile Ile
Val His 580 585 590Thr Val Gln Ser Gln Asp Arg Val Leu Lys Glu Leu
Phe Gly His Leu 595 600 605Ser Lys Leu Leu Gly Cys Lys Gln Lys Ile
Ile Asp Leu Leu Pro Lys 610 615 620Val Glu Val Ala Leu Ser Asn Ile
Lys Glu Ala Asp Asn Thr Val Met625 630 635 640Phe Met Gln Gly Lys
Arg Gln Lys Glu Ile Trp His Leu Leu Lys Ile 645 650 655Ala Cys Thr
Gln Ala Ala Ala Arg Ala Leu Val Gly Ala Ala Leu Glu 660 665 670Gly
Ala Val Ala Pro Pro Val Ala Ala Trp Leu Pro Pro Ala Leu Ala 675 680
685Asp Arg Glu His Pro Leu Thr Cys Val Val Ala Pro Gln Asp Gly Glu
690 695 700Ala Leu Ala Gln Met Ile Glu Glu Asn Leu Asn Cys Leu Gly
His Leu705 710 715 720Ala Ala Ile Ile Arg Glu Ala Asn Glu Asp Gln
Ser Ser Ser Leu Met 725 730 735Ser Leu Asp Trp Ser Trp Leu Ala Glu
740 74597757PRTMus musculusmisc_feature(1)..(757)Mouse
constitutively active IKK beta (PEST mutation) P.4019 without
epitope tag 97Met Ser Trp Ser Pro Ser Leu Pro Thr Gln Thr Cys Gly
Ala Trp Glu1 5 10 15Met Lys Glu Arg Leu Gly Thr Gly Gly Phe Gly Asn
Val Ile Arg Trp 20 25 30His Asn Gln Ala Thr Gly Glu Gln Ile Ala Ile
Lys Gln Cys Arg Gln 35 40 45Glu Leu Ser Pro Lys Asn Arg Asn Arg Trp
Cys Leu Glu Ile Gln Ile 50 55 60Met Arg Arg Leu Asn His Pro Asn Val
Val Ala Ala Arg Asp Val Pro65 70 75 80Glu Gly Met Gln Asn Leu Ala
Pro Asn Asp Leu Pro Leu Leu Ala Met 85 90 95Glu Tyr Cys Gln Gly Gly
Asp Leu Arg Arg Tyr Leu Asn Gln Phe Glu 100 105 110Asn Cys Cys Gly
Leu Arg Glu Gly Ala Val Leu Thr Leu Leu Ser Asp 115 120 125Ile Ala
Ser Ala Leu Arg Tyr Leu His Glu Asn Arg Ile Ile His Arg 130 135
140Asp Leu Lys Pro Glu Asn Ile Val Leu Gln Gln Gly Glu Lys Arg
Leu145 150 155 160Ile His Lys Ile Ile Asp Leu Gly Tyr Ala Lys Glu
Leu Asp Gln Gly 165 170 175Glu Leu Cys Thr Glu Phe Val Gly Thr Leu
Gln Tyr Leu Ala Pro Glu 180 185 190Leu Leu Glu Gln Gln Lys Tyr Thr
Val Thr Val Asp Tyr Trp Ser Phe 195 200 205Gly Thr Leu Ala Phe Glu
Cys Ile Thr Gly Phe Arg Pro Phe Leu Pro 210 215 220Asn Trp Gln Pro
Val Gln Trp His Ser Lys Val Arg Gln Lys Ser Glu225 230 235 240Val
Asp Ile Val Val Ser Glu Asp Leu Asn Gly Ala Val Lys Phe Ser 245 250
255Ser Ser Leu Pro Phe Pro Asn Asn Leu Asn Ser Val Leu Ala Glu Arg
260 265 270Leu Glu Lys Trp Leu Gln Leu Met Leu Met Trp His Pro Arg
Gln Arg 275 280 285Gly Thr Asp Pro Gln Tyr Gly Pro Asn Gly Cys Phe
Arg Ala Leu Asp 290 295 300Asp Ile Leu Asn Leu Lys Leu Val His Val
Leu Asn Met Val Thr Gly305 310 315 320Thr Val His Thr Tyr Pro Val
Thr Glu Asp Glu Ser Leu Gln Ser Leu 325 330 335Lys Thr Arg Ile Gln
Glu Asn Thr Gly Ile Leu Glu Thr Asp Gln Glu 340 345 350Leu Leu Gln
Lys Ala Gly Leu Val Leu Leu Pro Asp Lys Pro Ala Thr 355 360 365Gln
Cys Ile Ser Asp Ser Lys Thr Asn Glu Gly Leu Thr Leu Asp Met 370 375
380Asp Leu Val Phe Leu Leu Asp Asn Ser Lys Ile Asn Tyr Glu Thr
Gln385 390 395 400Ile Thr Pro Arg Pro Pro Pro Glu Ser Val Ser Cys
Ile Leu Gln Glu 405 410 415Pro Lys Arg Asn Leu Ser Phe Phe Gln Leu
Arg Lys Val Trp Gly Gln 420 425 430Val Trp His Ser Ile Gln Thr Leu
Lys Glu Asp Cys Asn Arg Leu Gln 435 440 445Gln Gly Gln Arg Ala Ala
Met Met Ser Leu Leu Arg Asn Asn Ser Cys 450 455 460Leu Ser Lys Met
Lys Asn Ala Met Ala Ser Thr Ala Gln Gln Leu Lys465 470 475 480Ala
Lys Leu Asp Phe Phe Lys Thr Ser Ile Gln Ile Asp Leu Glu Lys 485 490
495Tyr Lys Glu Gln Thr Glu Phe Gly Ile Thr Ser Asp Lys Leu Leu Leu
500 505 510Ala Trp Arg Glu Met Glu Gln Ala Val Glu Gln Cys Gly Arg
Glu Asn 515 520 525Asp Val Lys His Leu Val Glu Arg Met Met Ala Leu
Gln Thr Asp Ile 530 535 540Val Asp Leu Gln Arg Ser Pro Met Gly Arg
Lys Gln Gly Gly Thr Leu545 550 555 560Asp Asp Leu Glu Glu Gln Ala
Arg Glu Leu Tyr Arg Lys Leu Arg Glu 565 570 575Lys Pro Arg Asp Gln
Arg Thr Glu Gly Asp Ser Gln Glu Met Val Arg 580 585 590Leu Leu Leu
Gln Ala Ile Gln Ser Phe Glu Lys Lys Val Arg Val Ile 595 600 605Tyr
Thr Gln Leu Ser Lys Thr Val Val Cys Lys Gln Lys Ala Leu Glu 610 615
620Leu Leu Pro Lys Val Glu Glu Val Val Ser Leu Met Asn Glu Asp
Glu625 630 635 640Arg Thr Val Val Arg Leu Gln Glu Lys Arg Gln Lys
Glu Leu Trp Asn 645 650 655Leu Leu Lys Ile Ala Cys Ser Lys Val Arg
Gly Pro Val Ala Gly Ala 660 665 670Pro Asp Ala Met Asn Val Ala Arg
Leu Ala His Pro Gly Gln Leu Met 675 680 685Ala Gln Pro Ala Ser Ala
Cys Asp Ala Leu Pro Glu Ser Asp Lys Lys 690 695 700Ala Glu Glu Leu
Val Ala Glu Ala His Ala Leu Cys Ser Arg Leu Glu705 710 715 720Ser
Ala Leu Gln Asp Thr Val Lys Glu Gln Asp Arg Ser Phe Thr Thr 725 730
735Leu Asp Trp Ser Trp Leu Gln Met Glu Asp Glu Glu Arg Cys Ser Leu
740 745 750Glu Gln Ala Cys Asp 75598757PRTMus
musculusmisc_feature(1)..(757)Mouse constitutively active IKK beta
(PEST mutation) P.4020 without epitope tag 98Met Ser Trp Ser Pro
Ser Leu Pro Thr Gln Thr Cys Gly Ala Trp Glu1 5 10 15Met Lys Glu Arg
Leu Gly Thr Gly Gly Phe Gly Asn Val Ile Arg Trp 20 25 30His Asn Gln
Ala Thr Gly Glu Gln Ile Ala Ile Lys Gln Cys Arg Gln 35 40 45Glu Leu
Ser Pro Lys Asn Arg Asn Arg Trp Cys Leu Glu Ile Gln Ile 50 55 60Met
Arg Arg Leu Asn His Pro Asn Val Val Ala Ala Arg Asp Val Pro65 70 75
80Glu Gly Met Gln Asn Leu Ala Pro Asn Asp Leu Pro Leu Leu Ala Met
85 90 95Glu Tyr Cys Gln Gly Gly Asp Leu Arg Arg Tyr Leu Asn Gln Phe
Glu 100 105 110Asn Cys Cys Gly Leu Arg Glu Gly Ala Val Leu Thr Leu
Leu Ser Asp 115 120 125Ile Ala Ser Ala Leu Arg Tyr Leu His Glu Asn
Arg Ile Ile His Arg 130 135 140Asp Leu Lys Pro Glu Asn Ile Val Leu
Gln Gln Gly Glu Lys Arg Leu145 150 155 160Ile His Lys Ile Ile Asp
Leu Gly Tyr Ala Lys Glu Leu Asp Gln Gly 165 170 175Glu Leu Cys Thr
Glu Phe Val Gly Thr Leu Gln Tyr Leu Ala Pro Glu 180 185 190Leu Leu
Glu Gln Gln Lys Tyr Thr Val Thr Val Asp Tyr Trp Ser Phe 195 200
205Gly Thr Leu Ala Phe Glu Cys Ile Thr Gly Phe Arg Pro Phe Leu Pro
210 215 220Asn Trp Gln Pro Val Gln Trp His Ser Lys Val Arg Gln Lys
Ser Glu225 230 235 240Val Asp Ile Val Val Ser Glu Asp Leu Asn Gly
Ala Val Lys Phe Ser 245 250 255Ser Ser Leu Pro Phe Pro Asn Asn Leu
Asn Ser Val Leu Ala Glu Arg 260 265 270Leu Glu Lys Trp Leu Gln Leu
Met Leu Met Trp His Pro Arg Gln Arg 275 280 285Gly Thr Asp Pro Gln
Tyr Gly Pro Asn Gly Cys Phe Arg Ala Leu Asp 290 295 300Asp Ile Leu
Asn Leu Lys Leu Val His Val Leu Asn Met Val Thr Gly305 310 315
320Thr Val His Thr Tyr Pro Val Thr Glu Asp Glu Ser Leu Gln Ser Leu
325 330 335Lys Thr Arg Ile Gln Glu Asn Thr Gly Ile Leu Glu Thr Asp
Gln Glu 340 345 350Leu Leu Gln Lys Ala Gly Leu Val Leu Leu Pro Asp
Lys Pro Ala Thr 355 360 365Gln Cys Ile Ser Asp Ser Lys Thr Asn Glu
Gly Leu Thr Leu Asp Met 370
375 380Asp Leu Val Phe Leu Leu Asp Asn Ser Lys Ile Asn Tyr Glu Thr
Gln385 390 395 400Ile Thr Pro Arg Pro Pro Pro Glu Ser Val Ser Cys
Ile Leu Gln Glu 405 410 415Pro Lys Arg Asn Leu Ser Phe Phe Gln Leu
Arg Lys Val Trp Gly Gln 420 425 430Val Trp His Ser Ile Gln Thr Leu
Lys Glu Asp Cys Asn Arg Leu Gln 435 440 445Gln Gly Gln Arg Ala Ala
Met Met Ser Leu Leu Arg Asn Asn Ser Cys 450 455 460Leu Ser Lys Met
Lys Asn Ala Met Ala Ser Thr Ala Gln Gln Leu Lys465 470 475 480Ala
Lys Leu Asp Phe Phe Lys Thr Ser Ile Gln Ile Asp Leu Glu Lys 485 490
495Tyr Lys Glu Gln Thr Glu Phe Gly Ile Thr Ser Asp Lys Leu Leu Leu
500 505 510Ala Trp Arg Glu Met Glu Gln Ala Val Glu Gln Cys Gly Arg
Glu Asn 515 520 525Asp Val Lys His Leu Val Glu Arg Met Met Ala Leu
Gln Thr Asp Ile 530 535 540Val Asp Leu Gln Arg Ser Pro Met Gly Arg
Lys Gln Gly Gly Thr Leu545 550 555 560Asp Asp Leu Glu Glu Gln Ala
Arg Glu Leu Tyr Arg Lys Leu Arg Glu 565 570 575Lys Pro Arg Asp Gln
Arg Thr Glu Gly Asp Ser Gln Glu Met Val Arg 580 585 590Leu Leu Leu
Gln Ala Ile Gln Ser Phe Glu Lys Lys Val Arg Val Ile 595 600 605Tyr
Thr Gln Leu Ser Lys Thr Val Val Cys Lys Gln Lys Ala Leu Glu 610 615
620Leu Leu Pro Lys Val Glu Glu Val Val Ser Leu Met Asn Glu Asp
Glu625 630 635 640Arg Thr Val Val Arg Leu Gln Glu Lys Arg Gln Lys
Glu Leu Trp Asn 645 650 655Leu Leu Lys Ile Ala Cys Ser Lys Val Arg
Gly Pro Val Ala Gly Ala 660 665 670Pro Asp Ala Met Asn Val Ala Arg
Leu Ala His Pro Gly Gln Leu Met 675 680 685Ala Gln Pro Ala Ser Ala
Cys Asp Ala Leu Pro Glu Ser Asp Lys Lys 690 695 700Ala Glu Glu Leu
Val Ala Glu Ala His Ala Leu Cys Ser Arg Leu Glu705 710 715 720Ser
Ala Leu Gln Asp Thr Val Lys Glu Gln Asp Arg Ser Phe Thr Thr 725 730
735Leu Asp Trp Ser Trp Leu Gln Met Glu Asp Glu Glu Arg Cys Ser Leu
740 745 750Glu Gln Ala Cys Asp 75599585PRTArtificial
SequenceSynthetic huRIPK1(1-555).IZ.TM; TH1021 without epitope tag
99Met Gln Pro Asp Met Ser Leu Asn Val Ile Lys Met Lys Ser Ser Asp1
5 10 15Phe Leu Glu Ser Ala Glu Leu Asp Ser Gly Gly Phe Gly Lys Val
Ser 20 25 30Leu Cys Phe His Arg Thr Gln Gly Leu Met Ile Met Lys Thr
Val Tyr 35 40 45Lys Gly Pro Asn Cys Ile Glu His Asn Glu Ala Leu Leu
Glu Glu Ala 50 55 60Lys Met Met Asn Arg Leu Arg His Ser Arg Val Val
Lys Leu Leu Gly65 70 75 80Val Ile Ile Glu Glu Gly Lys Tyr Ser Leu
Val Met Glu Tyr Met Glu 85 90 95Lys Gly Asn Leu Met His Val Leu Lys
Ala Glu Met Ser Thr Pro Leu 100 105 110Ser Val Lys Gly Arg Ile Ile
Leu Glu Ile Ile Glu Gly Met Cys Tyr 115 120 125Leu His Gly Lys Gly
Val Ile His Lys Asp Leu Lys Pro Glu Asn Ile 130 135 140Leu Val Asp
Asn Asp Phe His Ile Lys Ile Ala Asp Leu Gly Leu Ala145 150 155
160Ser Phe Lys Met Trp Ser Lys Leu Asn Asn Glu Glu His Asn Glu Leu
165 170 175Arg Glu Val Asp Gly Thr Ala Lys Lys Asn Gly Gly Thr Leu
Tyr Tyr 180 185 190Met Ala Pro Glu His Leu Asn Asp Val Asn Ala Lys
Pro Thr Glu Lys 195 200 205Ser Asp Val Tyr Ser Phe Ala Val Val Leu
Trp Ala Ile Phe Ala Asn 210 215 220Lys Glu Pro Tyr Glu Asn Ala Ile
Cys Glu Gln Gln Leu Ile Met Cys225 230 235 240Ile Lys Ser Gly Asn
Arg Pro Asp Val Asp Asp Ile Thr Glu Tyr Cys 245 250 255Pro Arg Glu
Ile Ile Ser Leu Met Lys Leu Cys Trp Glu Ala Asn Pro 260 265 270Glu
Ala Arg Pro Thr Phe Pro Gly Ile Glu Glu Lys Phe Arg Pro Phe 275 280
285Tyr Leu Ser Gln Leu Glu Glu Ser Val Glu Glu Asp Val Lys Ser Leu
290 295 300Lys Lys Glu Tyr Ser Asn Glu Asn Ala Val Val Lys Arg Met
Gln Ser305 310 315 320Leu Gln Leu Asp Cys Val Ala Val Pro Ser Ser
Arg Ser Asn Ser Ala 325 330 335Thr Glu Gln Pro Gly Ser Leu His Ser
Ser Gln Gly Leu Gly Met Gly 340 345 350Pro Val Glu Glu Ser Trp Phe
Ala Pro Ser Leu Glu His Pro Gln Glu 355 360 365Glu Asn Glu Pro Ser
Leu Gln Ser Lys Leu Gln Asp Glu Ala Asn Tyr 370 375 380His Leu Tyr
Gly Ser Arg Met Asp Arg Gln Thr Lys Gln Gln Pro Arg385 390 395
400Gln Asn Val Ala Tyr Asn Arg Glu Glu Glu Arg Arg Arg Arg Val Ser
405 410 415His Asp Pro Phe Ala Gln Gln Arg Pro Tyr Glu Asn Phe Gln
Asn Thr 420 425 430Glu Gly Lys Gly Thr Ala Tyr Ser Ser Ala Ala Ser
His Gly Asn Ala 435 440 445Val His Gln Pro Ser Gly Leu Thr Ser Gln
Pro Gln Val Leu Tyr Gln 450 455 460Asn Asn Gly Leu Tyr Ser Ser His
Gly Phe Gly Thr Arg Pro Leu Asp465 470 475 480Pro Gly Thr Ala Gly
Pro Arg Val Trp Tyr Arg Pro Ile Pro Ser His 485 490 495Met Pro Ser
Leu His Asn Ile Pro Val Pro Glu Thr Asn Tyr Leu Gly 500 505 510Asn
Thr Pro Thr Met Pro Phe Ser Ser Leu Pro Pro Thr Asp Glu Ser 515 520
525Ile Lys Tyr Thr Ile Tyr Asn Ser Thr Gly Ile Gln Ile Gly Ala Tyr
530 535 540Asn Tyr Met Glu Ile Gly Gly Thr Ser Ser Ser Gly Gly Ile
Lys Lys545 550 555 560Glu Ile Glu Ala Ile Lys Lys Glu Gln Glu Ala
Ile Lys Lys Lys Ile 565 570 575Glu Ala Ile Glu Lys Glu Ile Glu Ala
580 585100609PRTArtificial SequenceSynthetic huRIPK1(1-555).EE.DM;
TH1022 without epitope tag 100Met Gln Pro Asp Met Ser Leu Asn Val
Ile Lys Met Lys Ser Ser Asp1 5 10 15Phe Leu Glu Ser Ala Glu Leu Asp
Ser Gly Gly Phe Gly Lys Val Ser 20 25 30Leu Cys Phe His Arg Thr Gln
Gly Leu Met Ile Met Lys Thr Val Tyr 35 40 45Lys Gly Pro Asn Cys Ile
Glu His Asn Glu Ala Leu Leu Glu Glu Ala 50 55 60Lys Met Met Asn Arg
Leu Arg His Ser Arg Val Val Lys Leu Leu Gly65 70 75 80Val Ile Ile
Glu Glu Gly Lys Tyr Ser Leu Val Met Glu Tyr Met Glu 85 90 95Lys Gly
Asn Leu Met His Val Leu Lys Ala Glu Met Ser Thr Pro Leu 100 105
110Ser Val Lys Gly Arg Ile Ile Leu Glu Ile Ile Glu Gly Met Cys Tyr
115 120 125Leu His Gly Lys Gly Val Ile His Lys Asp Leu Lys Pro Glu
Asn Ile 130 135 140Leu Val Asp Asn Asp Phe His Ile Lys Ile Ala Asp
Leu Gly Leu Ala145 150 155 160Ser Phe Lys Met Trp Ser Lys Leu Asn
Asn Glu Glu His Asn Glu Leu 165 170 175Arg Glu Val Asp Gly Thr Ala
Lys Lys Asn Gly Gly Thr Leu Tyr Tyr 180 185 190Met Ala Pro Glu His
Leu Asn Asp Val Asn Ala Lys Pro Thr Glu Lys 195 200 205Ser Asp Val
Tyr Ser Phe Ala Val Val Leu Trp Ala Ile Phe Ala Asn 210 215 220Lys
Glu Pro Tyr Glu Asn Ala Ile Cys Glu Gln Gln Leu Ile Met Cys225 230
235 240Ile Lys Ser Gly Asn Arg Pro Asp Val Asp Asp Ile Thr Glu Tyr
Cys 245 250 255Pro Arg Glu Ile Ile Ser Leu Met Lys Leu Cys Trp Glu
Ala Asn Pro 260 265 270Glu Ala Arg Pro Thr Phe Pro Gly Ile Glu Glu
Lys Phe Arg Pro Phe 275 280 285Tyr Leu Ser Gln Leu Glu Glu Ser Val
Glu Glu Asp Val Lys Ser Leu 290 295 300Lys Lys Glu Tyr Ser Asn Glu
Asn Ala Val Val Lys Arg Met Gln Ser305 310 315 320Leu Gln Leu Asp
Cys Val Ala Val Pro Ser Ser Arg Ser Asn Ser Ala 325 330 335Thr Glu
Gln Pro Gly Ser Leu His Ser Ser Gln Gly Leu Gly Met Gly 340 345
350Pro Val Glu Glu Ser Trp Phe Ala Pro Ser Leu Glu His Pro Gln Glu
355 360 365Glu Asn Glu Pro Ser Leu Gln Ser Lys Leu Gln Asp Glu Ala
Asn Tyr 370 375 380His Leu Tyr Gly Ser Arg Met Asp Arg Gln Thr Lys
Gln Gln Pro Arg385 390 395 400Gln Asn Val Ala Tyr Asn Arg Glu Glu
Glu Arg Arg Arg Arg Val Ser 405 410 415His Asp Pro Phe Ala Gln Gln
Arg Pro Tyr Glu Asn Phe Gln Asn Thr 420 425 430Glu Gly Lys Gly Thr
Ala Tyr Ser Ser Ala Ala Ser His Gly Asn Ala 435 440 445Val His Gln
Pro Ser Gly Leu Thr Ser Gln Pro Gln Val Leu Tyr Gln 450 455 460Asn
Asn Gly Leu Tyr Ser Ser His Gly Phe Gly Thr Arg Pro Leu Asp465 470
475 480Pro Gly Thr Ala Gly Pro Arg Val Trp Tyr Arg Pro Ile Pro Ser
His 485 490 495Met Pro Ser Leu His Asn Ile Pro Val Pro Glu Thr Asn
Tyr Leu Gly 500 505 510Asn Thr Pro Thr Met Pro Phe Ser Ser Leu Pro
Pro Thr Asp Glu Ser 515 520 525Ile Lys Tyr Thr Ile Tyr Asn Ser Thr
Gly Ile Gln Ile Gly Ala Tyr 530 535 540Asn Tyr Met Glu Ile Gly Gly
Thr Ser Ser Ser Gly Ser Asp Gly Ser545 550 555 560Gly Ser Gly Ser
Gly Ser Ile Thr Ile Arg Ala Ala Phe Leu Glu Lys 565 570 575Glu Asn
Thr Ala Leu Arg Thr Glu Ile Ala Glu Leu Glu Lys Glu Val 580 585
590Gly Arg Cys Glu Asn Ile Val Ser Lys Tyr Glu Thr Arg Tyr Gly Pro
595 600 605Leu101609PRTArtificial SequenceSynthetic
huRIPK1(1-555).RR.DM; TH1023 without epitope tag 101Met Gln Pro Asp
Met Ser Leu Asn Val Ile Lys Met Lys Ser Ser Asp1 5 10 15Phe Leu Glu
Ser Ala Glu Leu Asp Ser Gly Gly Phe Gly Lys Val Ser 20 25 30Leu Cys
Phe His Arg Thr Gln Gly Leu Met Ile Met Lys Thr Val Tyr 35 40 45Lys
Gly Pro Asn Cys Ile Glu His Asn Glu Ala Leu Leu Glu Glu Ala 50 55
60Lys Met Met Asn Arg Leu Arg His Ser Arg Val Val Lys Leu Leu Gly65
70 75 80Val Ile Ile Glu Glu Gly Lys Tyr Ser Leu Val Met Glu Tyr Met
Glu 85 90 95Lys Gly Asn Leu Met His Val Leu Lys Ala Glu Met Ser Thr
Pro Leu 100 105 110Ser Val Lys Gly Arg Ile Ile Leu Glu Ile Ile Glu
Gly Met Cys Tyr 115 120 125Leu His Gly Lys Gly Val Ile His Lys Asp
Leu Lys Pro Glu Asn Ile 130 135 140Leu Val Asp Asn Asp Phe His Ile
Lys Ile Ala Asp Leu Gly Leu Ala145 150 155 160Ser Phe Lys Met Trp
Ser Lys Leu Asn Asn Glu Glu His Asn Glu Leu 165 170 175Arg Glu Val
Asp Gly Thr Ala Lys Lys Asn Gly Gly Thr Leu Tyr Tyr 180 185 190Met
Ala Pro Glu His Leu Asn Asp Val Asn Ala Lys Pro Thr Glu Lys 195 200
205Ser Asp Val Tyr Ser Phe Ala Val Val Leu Trp Ala Ile Phe Ala Asn
210 215 220Lys Glu Pro Tyr Glu Asn Ala Ile Cys Glu Gln Gln Leu Ile
Met Cys225 230 235 240Ile Lys Ser Gly Asn Arg Pro Asp Val Asp Asp
Ile Thr Glu Tyr Cys 245 250 255Pro Arg Glu Ile Ile Ser Leu Met Lys
Leu Cys Trp Glu Ala Asn Pro 260 265 270Glu Ala Arg Pro Thr Phe Pro
Gly Ile Glu Glu Lys Phe Arg Pro Phe 275 280 285Tyr Leu Ser Gln Leu
Glu Glu Ser Val Glu Glu Asp Val Lys Ser Leu 290 295 300Lys Lys Glu
Tyr Ser Asn Glu Asn Ala Val Val Lys Arg Met Gln Ser305 310 315
320Leu Gln Leu Asp Cys Val Ala Val Pro Ser Ser Arg Ser Asn Ser Ala
325 330 335Thr Glu Gln Pro Gly Ser Leu His Ser Ser Gln Gly Leu Gly
Met Gly 340 345 350Pro Val Glu Glu Ser Trp Phe Ala Pro Ser Leu Glu
His Pro Gln Glu 355 360 365Glu Asn Glu Pro Ser Leu Gln Ser Lys Leu
Gln Asp Glu Ala Asn Tyr 370 375 380His Leu Tyr Gly Ser Arg Met Asp
Arg Gln Thr Lys Gln Gln Pro Arg385 390 395 400Gln Asn Val Ala Tyr
Asn Arg Glu Glu Glu Arg Arg Arg Arg Val Ser 405 410 415His Asp Pro
Phe Ala Gln Gln Arg Pro Tyr Glu Asn Phe Gln Asn Thr 420 425 430Glu
Gly Lys Gly Thr Ala Tyr Ser Ser Ala Ala Ser His Gly Asn Ala 435 440
445Val His Gln Pro Ser Gly Leu Thr Ser Gln Pro Gln Val Leu Tyr Gln
450 455 460Asn Asn Gly Leu Tyr Ser Ser His Gly Phe Gly Thr Arg Pro
Leu Asp465 470 475 480Pro Gly Thr Ala Gly Pro Arg Val Trp Tyr Arg
Pro Ile Pro Ser His 485 490 495Met Pro Ser Leu His Asn Ile Pro Val
Pro Glu Thr Asn Tyr Leu Gly 500 505 510Asn Thr Pro Thr Met Pro Phe
Ser Ser Leu Pro Pro Thr Asp Glu Ser 515 520 525Ile Lys Tyr Thr Ile
Tyr Asn Ser Thr Gly Ile Gln Ile Gly Ala Tyr 530 535 540Asn Tyr Met
Glu Ile Gly Gly Thr Ser Ser Ser Gly Ser Asp Gly Ser545 550 555
560Gly Ser Gly Ser Gly Ser Leu Glu Ile Arg Ala Ala Phe Leu Glu Lys
565 570 575Glu Asn Thr Ala Leu Arg Thr Arg Ala Ala Glu Leu Arg Lys
Arg Val 580 585 590Gly Arg Cys Arg Asn Ile Val Ser Lys Tyr Glu Thr
Arg Tyr Gly Pro 595 600 605Leu102585PRTArtificial SequenceSynthetic
msRIPK1(1-555).IZ.TM; TH1024 without epitope tag 102Met Gln Pro Asp
Met Ser Leu Asp Asn Ile Lys Met Ala Ser Ser Asp1 5 10 15Leu Leu Glu
Lys Thr Asp Leu Asp Ser Gly Gly Phe Gly Lys Val Ser 20 25 30Leu Cys
Tyr His Arg Ser His Gly Phe Val Ile Leu Lys Lys Val Tyr 35 40 45Thr
Gly Pro Asn Arg Ala Glu Tyr Asn Glu Val Leu Leu Glu Glu Gly 50 55
60Lys Met Met His Arg Leu Arg His Ser Arg Val Val Lys Leu Leu Gly65
70 75 80Ile Ile Ile Glu Glu Gly Asn Tyr Ser Leu Val Met Glu Tyr Met
Glu 85 90 95Lys Gly Asn Leu Met His Val Leu Lys Thr Gln Ile Asp Val
Pro Leu 100 105 110Ser Leu Lys Gly Arg Ile Ile Val Glu Ala Ile Glu
Gly Met Cys Tyr 115 120 125Leu His Asp Lys Gly Val Ile His Lys Asp
Leu Lys Pro Glu Asn Ile 130 135 140Leu Val Asp Arg Asp Phe His Ile
Lys Ile Ala Asp Leu Gly Val Ala145 150 155 160Ser Phe Lys Thr Trp
Ser Lys Leu Thr Lys Glu Lys Asp Asn Lys Gln 165 170 175Lys Glu Val
Ser Ser Thr Thr Lys Lys Asn Asn Gly Gly Thr Leu Tyr 180 185 190Tyr
Met Ala Pro Glu His Leu Asn Asp Ile Asn Ala Lys Pro Thr Glu 195 200
205Lys Ser Asp Val Tyr Ser Phe Gly Ile Val Leu Trp Ala Ile Phe Ala
210 215 220Lys Lys Glu Pro Tyr Glu Asn Val Ile Cys Thr Glu Gln Phe
Val Ile225 230 235 240Cys Ile Lys Ser Gly Asn Arg
Pro Asn Val Glu Glu Ile Leu Glu Tyr 245 250 255Cys Pro Arg Glu Ile
Ile Ser Leu Met Glu Arg Cys Trp Gln Ala Ile 260 265 270Pro Glu Asp
Arg Pro Thr Phe Leu Gly Ile Glu Glu Glu Phe Arg Pro 275 280 285Phe
Tyr Leu Ser His Phe Glu Glu Tyr Val Glu Glu Asp Val Ala Ser 290 295
300Leu Lys Lys Glu Tyr Pro Asp Gln Ser Pro Val Leu Gln Arg Met
Phe305 310 315 320Ser Leu Gln His Asp Cys Val Pro Leu Pro Pro Ser
Arg Ser Asn Ser 325 330 335Glu Gln Pro Gly Ser Leu His Ser Ser Gln
Gly Leu Gln Met Gly Pro 340 345 350Val Glu Glu Ser Trp Phe Ser Ser
Ser Pro Glu Tyr Pro Gln Asp Glu 355 360 365Asn Asp Arg Ser Val Gln
Ala Lys Leu Gln Glu Glu Ala Ser Tyr His 370 375 380Ala Phe Gly Ile
Phe Ala Glu Lys Gln Thr Lys Pro Gln Pro Arg Gln385 390 395 400Asn
Glu Ala Tyr Asn Arg Glu Glu Glu Arg Lys Arg Arg Val Ser His 405 410
415Asp Pro Phe Ala Gln Gln Arg Ala Arg Glu Asn Ile Lys Ser Ala Gly
420 425 430Ala Arg Gly His Ser Asp Pro Ser Thr Thr Ser Arg Gly Ile
Ala Val 435 440 445Gln Gln Leu Ser Trp Pro Ala Thr Gln Thr Val Trp
Asn Asn Gly Leu 450 455 460Tyr Asn Gln His Gly Phe Gly Thr Thr Gly
Thr Gly Val Trp Tyr Pro465 470 475 480Pro Asn Leu Ser Gln Met Tyr
Ser Thr Tyr Lys Thr Pro Val Pro Glu 485 490 495Thr Asn Ile Pro Gly
Ser Thr Pro Thr Met Pro Tyr Phe Ser Gly Pro 500 505 510Val Ala Asp
Asp Leu Ile Lys Tyr Thr Ile Phe Asn Ser Ser Gly Ile 515 520 525Gln
Ile Gly Asn His Asn Tyr Met Asp Val Gly Leu Asn Ser Gln Pro 530 535
540Pro Asn Asn Thr Cys Lys Glu Glu Ser Thr Ser Gly Gly Ile Lys
Lys545 550 555 560Glu Ile Glu Ala Ile Lys Lys Glu Gln Glu Ala Ile
Lys Lys Lys Ile 565 570 575Glu Ala Ile Glu Lys Glu Ile Glu Ala 580
585103609PRTArtificial SequenceSynthetic msRIPK1(1-555).EE.DM;
TH1025 without epitope tag 103Met Gln Pro Asp Met Ser Leu Asp Asn
Ile Lys Met Ala Ser Ser Asp1 5 10 15Leu Leu Glu Lys Thr Asp Leu Asp
Ser Gly Gly Phe Gly Lys Val Ser 20 25 30Leu Cys Tyr His Arg Ser His
Gly Phe Val Ile Leu Lys Lys Val Tyr 35 40 45Thr Gly Pro Asn Arg Ala
Glu Tyr Asn Glu Val Leu Leu Glu Glu Gly 50 55 60Lys Met Met His Arg
Leu Arg His Ser Arg Val Val Lys Leu Leu Gly65 70 75 80Ile Ile Ile
Glu Glu Gly Asn Tyr Ser Leu Val Met Glu Tyr Met Glu 85 90 95Lys Gly
Asn Leu Met His Val Leu Lys Thr Gln Ile Asp Val Pro Leu 100 105
110Ser Leu Lys Gly Arg Ile Ile Val Glu Ala Ile Glu Gly Met Cys Tyr
115 120 125Leu His Asp Lys Gly Val Ile His Lys Asp Leu Lys Pro Glu
Asn Ile 130 135 140Leu Val Asp Arg Asp Phe His Ile Lys Ile Ala Asp
Leu Gly Val Ala145 150 155 160Ser Phe Lys Thr Trp Ser Lys Leu Thr
Lys Glu Lys Asp Asn Lys Gln 165 170 175Lys Glu Val Ser Ser Thr Thr
Lys Lys Asn Asn Gly Gly Thr Leu Tyr 180 185 190Tyr Met Ala Pro Glu
His Leu Asn Asp Ile Asn Ala Lys Pro Thr Glu 195 200 205Lys Ser Asp
Val Tyr Ser Phe Gly Ile Val Leu Trp Ala Ile Phe Ala 210 215 220Lys
Lys Glu Pro Tyr Glu Asn Val Ile Cys Thr Glu Gln Phe Val Ile225 230
235 240Cys Ile Lys Ser Gly Asn Arg Pro Asn Val Glu Glu Ile Leu Glu
Tyr 245 250 255Cys Pro Arg Glu Ile Ile Ser Leu Met Glu Arg Cys Trp
Gln Ala Ile 260 265 270Pro Glu Asp Arg Pro Thr Phe Leu Gly Ile Glu
Glu Glu Phe Arg Pro 275 280 285Phe Tyr Leu Ser His Phe Glu Glu Tyr
Val Glu Glu Asp Val Ala Ser 290 295 300Leu Lys Lys Glu Tyr Pro Asp
Gln Ser Pro Val Leu Gln Arg Met Phe305 310 315 320Ser Leu Gln His
Asp Cys Val Pro Leu Pro Pro Ser Arg Ser Asn Ser 325 330 335Glu Gln
Pro Gly Ser Leu His Ser Ser Gln Gly Leu Gln Met Gly Pro 340 345
350Val Glu Glu Ser Trp Phe Ser Ser Ser Pro Glu Tyr Pro Gln Asp Glu
355 360 365Asn Asp Arg Ser Val Gln Ala Lys Leu Gln Glu Glu Ala Ser
Tyr His 370 375 380Ala Phe Gly Ile Phe Ala Glu Lys Gln Thr Lys Pro
Gln Pro Arg Gln385 390 395 400Asn Glu Ala Tyr Asn Arg Glu Glu Glu
Arg Lys Arg Arg Val Ser His 405 410 415Asp Pro Phe Ala Gln Gln Arg
Ala Arg Glu Asn Ile Lys Ser Ala Gly 420 425 430Ala Arg Gly His Ser
Asp Pro Ser Thr Thr Ser Arg Gly Ile Ala Val 435 440 445Gln Gln Leu
Ser Trp Pro Ala Thr Gln Thr Val Trp Asn Asn Gly Leu 450 455 460Tyr
Asn Gln His Gly Phe Gly Thr Thr Gly Thr Gly Val Trp Tyr Pro465 470
475 480Pro Asn Leu Ser Gln Met Tyr Ser Thr Tyr Lys Thr Pro Val Pro
Glu 485 490 495Thr Asn Ile Pro Gly Ser Thr Pro Thr Met Pro Tyr Phe
Ser Gly Pro 500 505 510Val Ala Asp Asp Leu Ile Lys Tyr Thr Ile Phe
Asn Ser Ser Gly Ile 515 520 525Gln Ile Gly Asn His Asn Tyr Met Asp
Val Gly Leu Asn Ser Gln Pro 530 535 540Pro Asn Asn Thr Cys Lys Glu
Glu Ser Thr Ser Gly Ser Asp Gly Ser545 550 555 560Gly Ser Gly Ser
Gly Ser Ile Thr Ile Arg Ala Ala Phe Leu Glu Lys 565 570 575Glu Asn
Thr Ala Leu Arg Thr Glu Ile Ala Glu Leu Glu Lys Glu Val 580 585
590Gly Arg Cys Glu Asn Ile Val Ser Lys Tyr Glu Thr Arg Tyr Gly Pro
595 600 605Leu104609PRTArtificial SequenceSynthetic
msRIPK1(1-555).RR.DM; TH1026 without epitope tag 104Met Gln Pro Asp
Met Ser Leu Asp Asn Ile Lys Met Ala Ser Ser Asp1 5 10 15Leu Leu Glu
Lys Thr Asp Leu Asp Ser Gly Gly Phe Gly Lys Val Ser 20 25 30Leu Cys
Tyr His Arg Ser His Gly Phe Val Ile Leu Lys Lys Val Tyr 35 40 45Thr
Gly Pro Asn Arg Ala Glu Tyr Asn Glu Val Leu Leu Glu Glu Gly 50 55
60Lys Met Met His Arg Leu Arg His Ser Arg Val Val Lys Leu Leu Gly65
70 75 80Ile Ile Ile Glu Glu Gly Asn Tyr Ser Leu Val Met Glu Tyr Met
Glu 85 90 95Lys Gly Asn Leu Met His Val Leu Lys Thr Gln Ile Asp Val
Pro Leu 100 105 110Ser Leu Lys Gly Arg Ile Ile Val Glu Ala Ile Glu
Gly Met Cys Tyr 115 120 125Leu His Asp Lys Gly Val Ile His Lys Asp
Leu Lys Pro Glu Asn Ile 130 135 140Leu Val Asp Arg Asp Phe His Ile
Lys Ile Ala Asp Leu Gly Val Ala145 150 155 160Ser Phe Lys Thr Trp
Ser Lys Leu Thr Lys Glu Lys Asp Asn Lys Gln 165 170 175Lys Glu Val
Ser Ser Thr Thr Lys Lys Asn Asn Gly Gly Thr Leu Tyr 180 185 190Tyr
Met Ala Pro Glu His Leu Asn Asp Ile Asn Ala Lys Pro Thr Glu 195 200
205Lys Ser Asp Val Tyr Ser Phe Gly Ile Val Leu Trp Ala Ile Phe Ala
210 215 220Lys Lys Glu Pro Tyr Glu Asn Val Ile Cys Thr Glu Gln Phe
Val Ile225 230 235 240Cys Ile Lys Ser Gly Asn Arg Pro Asn Val Glu
Glu Ile Leu Glu Tyr 245 250 255Cys Pro Arg Glu Ile Ile Ser Leu Met
Glu Arg Cys Trp Gln Ala Ile 260 265 270Pro Glu Asp Arg Pro Thr Phe
Leu Gly Ile Glu Glu Glu Phe Arg Pro 275 280 285Phe Tyr Leu Ser His
Phe Glu Glu Tyr Val Glu Glu Asp Val Ala Ser 290 295 300Leu Lys Lys
Glu Tyr Pro Asp Gln Ser Pro Val Leu Gln Arg Met Phe305 310 315
320Ser Leu Gln His Asp Cys Val Pro Leu Pro Pro Ser Arg Ser Asn Ser
325 330 335Glu Gln Pro Gly Ser Leu His Ser Ser Gln Gly Leu Gln Met
Gly Pro 340 345 350Val Glu Glu Ser Trp Phe Ser Ser Ser Pro Glu Tyr
Pro Gln Asp Glu 355 360 365Asn Asp Arg Ser Val Gln Ala Lys Leu Gln
Glu Glu Ala Ser Tyr His 370 375 380Ala Phe Gly Ile Phe Ala Glu Lys
Gln Thr Lys Pro Gln Pro Arg Gln385 390 395 400Asn Glu Ala Tyr Asn
Arg Glu Glu Glu Arg Lys Arg Arg Val Ser His 405 410 415Asp Pro Phe
Ala Gln Gln Arg Ala Arg Glu Asn Ile Lys Ser Ala Gly 420 425 430Ala
Arg Gly His Ser Asp Pro Ser Thr Thr Ser Arg Gly Ile Ala Val 435 440
445Gln Gln Leu Ser Trp Pro Ala Thr Gln Thr Val Trp Asn Asn Gly Leu
450 455 460Tyr Asn Gln His Gly Phe Gly Thr Thr Gly Thr Gly Val Trp
Tyr Pro465 470 475 480Pro Asn Leu Ser Gln Met Tyr Ser Thr Tyr Lys
Thr Pro Val Pro Glu 485 490 495Thr Asn Ile Pro Gly Ser Thr Pro Thr
Met Pro Tyr Phe Ser Gly Pro 500 505 510Val Ala Asp Asp Leu Ile Lys
Tyr Thr Ile Phe Asn Ser Ser Gly Ile 515 520 525Gln Ile Gly Asn His
Asn Tyr Met Asp Val Gly Leu Asn Ser Gln Pro 530 535 540Pro Asn Asn
Thr Cys Lys Glu Glu Ser Thr Ser Gly Ser Asp Gly Ser545 550 555
560Gly Ser Gly Ser Gly Ser Leu Glu Ile Arg Ala Ala Phe Leu Glu Lys
565 570 575Glu Asn Thr Ala Leu Arg Thr Arg Ala Ala Glu Leu Arg Lys
Arg Val 580 585 590Gly Arg Cys Arg Asn Ile Val Ser Lys Tyr Glu Thr
Arg Tyr Gly Pro 595 600 605Leu105378PRTHomo
sapiensmisc_feature(1)..(378)human TAK1-TAB1; P4031 without epitope
tag 105Met Ser Thr Ala Ser Ala Ala Ser Ser Ser Ser Ser Ser Ser Ala
Gly1 5 10 15Glu Met Ile Glu Ala Pro Ser Gln Val Leu Asn Phe Glu Glu
Ile Asp 20 25 30Tyr Lys Glu Ile Glu Val Glu Glu Val Val Gly Arg Gly
Ala Phe Gly 35 40 45Val Val Cys Lys Ala Lys Trp Arg Ala Lys Asp Val
Ala Ile Lys Gln 50 55 60Ile Glu Ser Glu Ser Glu Arg Lys Ala Phe Ile
Val Glu Leu Arg Gln65 70 75 80Leu Ser Arg Val Asn His Pro Asn Ile
Val Lys Leu Tyr Gly Ala Cys 85 90 95Leu Asn Pro Val Cys Leu Val Met
Glu Tyr Ala Glu Gly Gly Ser Leu 100 105 110Tyr Asn Val Leu His Gly
Ala Glu Pro Leu Pro Tyr Tyr Thr Ala Ala 115 120 125His Ala Met Ser
Trp Cys Leu Gln Cys Ser Gln Gly Val Ala Tyr Leu 130 135 140His Ser
Met Gln Pro Lys Ala Leu Ile His Arg Asp Leu Lys Pro Pro145 150 155
160Asn Leu Leu Leu Val Ala Gly Gly Thr Val Leu Lys Ile Cys Asp Phe
165 170 175Gly Thr Ala Cys Asp Ile Gln Thr His Met Thr Asn Asn Lys
Gly Ser 180 185 190Ala Ala Trp Met Ala Pro Glu Val Phe Glu Gly Ser
Asn Tyr Ser Glu 195 200 205Lys Cys Asp Val Phe Ser Trp Gly Ile Ile
Leu Trp Glu Val Ile Thr 210 215 220Arg Arg Lys Pro Phe Asp Glu Ile
Gly Gly Pro Ala Phe Arg Ile Met225 230 235 240Trp Ala Val His Asn
Gly Thr Arg Pro Pro Leu Ile Lys Asn Leu Pro 245 250 255Lys Pro Ile
Glu Ser Leu Met Thr Arg Cys Trp Ser Lys Asp Pro Ser 260 265 270Gln
Arg Pro Ser Met Glu Glu Ile Val Lys Ile Met Thr His Leu Met 275 280
285Arg Tyr Phe Pro Gly Ala Asp Glu Pro Leu Gln Tyr Pro Cys Gln Glu
290 295 300Phe Gly Gly Gly Gly Gly Gln Ser Pro Thr Leu Thr Leu Gln
Ser Thr305 310 315 320Asn Thr His Thr Gln Ser Ser Ser Ser Ser Ser
Asp Gly Gly Leu Phe 325 330 335Arg Ser Arg Pro Ala His Ser Leu Pro
Pro Gly Glu Asp Gly Arg Val 340 345 350Glu Pro Tyr Val Asp Phe Ala
Glu Phe Tyr Arg Leu Trp Ser Val Asp 355 360 365His Gly Glu Gln Ser
Val Val Thr Ala Pro 370 375106239PRTArtificial SequenceSynthetic
Diablo.1; without epitope tag 106Met Ala Ala Leu Lys Ser Trp Leu
Ser Arg Ser Val Thr Ser Phe Phe1 5 10 15Arg Tyr Arg Gln Cys Leu Cys
Val Pro Val Val Ala Asn Phe Lys Lys 20 25 30Arg Cys Phe Ser Glu Leu
Ile Arg Pro Trp His Lys Thr Val Thr Ile 35 40 45Gly Phe Gly Val Thr
Leu Cys Ala Val Pro Ile Ala Gln Lys Ser Glu 50 55 60Pro His Ser Leu
Ser Ser Glu Ala Leu Met Arg Arg Ala Val Ser Leu65 70 75 80Val Thr
Asp Ser Thr Ser Thr Phe Leu Ser Gln Thr Thr Tyr Ala Leu 85 90 95Ile
Glu Ala Ile Thr Glu Tyr Thr Lys Ala Val Tyr Thr Leu Thr Ser 100 105
110Leu Tyr Arg Gln Tyr Thr Ser Leu Leu Gly Lys Met Asn Ser Glu Glu
115 120 125Glu Asp Glu Val Trp Gln Val Ile Ile Gly Ala Arg Ala Glu
Met Thr 130 135 140Ser Lys His Gln Glu Tyr Leu Lys Leu Glu Thr Thr
Trp Met Thr Ala145 150 155 160Val Gly Leu Ser Glu Met Ala Ala Glu
Ala Ala Tyr Gln Thr Gly Ala 165 170 175Asp Gln Ala Ser Ile Thr Ala
Arg Asn His Ile Gln Leu Val Lys Leu 180 185 190Gln Val Glu Glu Val
His Gln Leu Ser Arg Lys Ala Glu Thr Lys Leu 195 200 205Ala Glu Ala
Gln Ile Glu Glu Leu Arg Gln Lys Thr Gln Glu Glu Gly 210 215 220Glu
Glu Arg Ala Glu Ser Glu Gln Glu Ala Tyr Leu Arg Glu Asp225 230
235107239PRTArtificial SequenceSynthetic Diablo.1(S126L); without
epitope tag 107Met Ala Ala Leu Lys Ser Trp Leu Ser Arg Ser Val Thr
Ser Phe Phe1 5 10 15Arg Tyr Arg Gln Cys Leu Cys Val Pro Val Val Ala
Asn Phe Lys Lys 20 25 30Arg Cys Phe Ser Glu Leu Ile Arg Pro Trp His
Lys Thr Val Thr Ile 35 40 45Gly Phe Gly Val Thr Leu Cys Ala Val Pro
Ile Ala Gln Lys Ser Glu 50 55 60Pro His Ser Leu Ser Ser Glu Ala Leu
Met Arg Arg Ala Val Ser Leu65 70 75 80Val Thr Asp Ser Thr Ser Thr
Phe Leu Ser Gln Thr Thr Tyr Ala Leu 85 90 95Ile Glu Ala Ile Thr Glu
Tyr Thr Lys Ala Val Tyr Thr Leu Thr Ser 100 105 110Leu Tyr Arg Gln
Tyr Thr Ser Leu Leu Gly Lys Met Asn Leu Glu Glu 115 120 125Glu Asp
Glu Val Trp Gln Val Ile Ile Gly Ala Arg Ala Glu Met Thr 130 135
140Ser Lys His Gln Glu Tyr Leu Lys Leu Glu Thr Thr Trp Met Thr
Ala145 150 155 160Val Gly Leu Ser Glu Met Ala Ala Glu Ala Ala Tyr
Gln Thr Gly Ala 165 170 175Asp Gln Ala Ser Ile Thr Ala Arg Asn His
Ile Gln Leu Val Lys Leu 180 185 190Gln Val Glu Glu Val His Gln Leu
Ser Arg Lys Ala Glu Thr Lys Leu 195 200 205Ala Glu Ala Gln Ile Glu
Glu Leu Arg Gln Lys Thr Gln Glu Glu Gly 210 215 220Glu Glu Arg Ala
Glu Ser Glu Gln Glu Ala Tyr Leu Arg Glu Asp225 230
235108185PRTArtificial SequenceSynthetic Diablo.1(56-239);
without
epitope tag 108Met Ala Val Pro Ile Ala Gln Lys Ser Glu Pro His Ser
Leu Ser Ser1 5 10 15Glu Ala Leu Met Arg Arg Ala Val Ser Leu Val Thr
Asp Ser Thr Ser 20 25 30Thr Phe Leu Ser Gln Thr Thr Tyr Ala Leu Ile
Glu Ala Ile Thr Glu 35 40 45Tyr Thr Lys Ala Val Tyr Thr Leu Thr Ser
Leu Tyr Arg Gln Tyr Thr 50 55 60Ser Leu Leu Gly Lys Met Asn Ser Glu
Glu Glu Asp Glu Val Trp Gln65 70 75 80Val Ile Ile Gly Ala Arg Ala
Glu Met Thr Ser Lys His Gln Glu Tyr 85 90 95Leu Lys Leu Glu Thr Thr
Trp Met Thr Ala Val Gly Leu Ser Glu Met 100 105 110Ala Ala Glu Ala
Ala Tyr Gln Thr Gly Ala Asp Gln Ala Ser Ile Thr 115 120 125Ala Arg
Asn His Ile Gln Leu Val Lys Leu Gln Val Glu Glu Val His 130 135
140Gln Leu Ser Arg Lys Ala Glu Thr Lys Leu Ala Glu Ala Gln Ile
Glu145 150 155 160Glu Leu Arg Gln Lys Thr Gln Glu Glu Gly Glu Glu
Arg Ala Glu Ser 165 170 175Glu Gln Glu Ala Tyr Leu Arg Glu Asp 180
185109185PRTArtificial SequenceSynthetic Diablo.1(56-239/S126L);
without epitope tag 109Met Ala Val Pro Ile Ala Gln Lys Ser Glu Pro
His Ser Leu Ser Ser1 5 10 15Glu Ala Leu Met Arg Arg Ala Val Ser Leu
Val Thr Asp Ser Thr Ser 20 25 30Thr Phe Leu Ser Gln Thr Thr Tyr Ala
Leu Ile Glu Ala Ile Thr Glu 35 40 45Tyr Thr Lys Ala Val Tyr Thr Leu
Thr Ser Leu Tyr Arg Gln Tyr Thr 50 55 60Ser Leu Leu Gly Lys Met Asn
Leu Glu Glu Glu Asp Glu Val Trp Gln65 70 75 80Val Ile Ile Gly Ala
Arg Ala Glu Met Thr Ser Lys His Gln Glu Tyr 85 90 95Leu Lys Leu Glu
Thr Thr Trp Met Thr Ala Val Gly Leu Ser Glu Met 100 105 110Ala Ala
Glu Ala Ala Tyr Gln Thr Gly Ala Asp Gln Ala Ser Ile Thr 115 120
125Ala Arg Asn His Ile Gln Leu Val Lys Leu Gln Val Glu Glu Val His
130 135 140Gln Leu Ser Arg Lys Ala Glu Thr Lys Leu Ala Glu Ala Gln
Ile Glu145 150 155 160Glu Leu Arg Gln Lys Thr Gln Glu Glu Gly Glu
Glu Arg Ala Glu Ser 165 170 175Glu Gln Glu Ala Tyr Leu Arg Glu Asp
180 185110195PRTArtificial SequenceSynthetic Diablo.3; TH2003
without epitope tag 110Met Ala Ala Leu Lys Ser Trp Leu Ser Arg Ser
Val Thr Ser Phe Phe1 5 10 15Arg Tyr Arg Gln Cys Leu Cys Val Pro Val
Val Ala Asn Phe Lys Lys 20 25 30Arg Cys Phe Ser Glu Leu Ile Arg Pro
Trp His Lys Thr Val Thr Ile 35 40 45Gly Phe Gly Val Thr Leu Cys Ala
Val Pro Ile Ala Gln Ala Val Tyr 50 55 60Thr Leu Thr Ser Leu Tyr Arg
Gln Tyr Thr Ser Leu Leu Gly Lys Met65 70 75 80Asn Ser Glu Glu Glu
Asp Glu Val Trp Gln Val Ile Ile Gly Ala Arg 85 90 95Ala Glu Met Thr
Ser Lys His Gln Glu Tyr Leu Lys Leu Glu Thr Thr 100 105 110Trp Met
Thr Ala Val Gly Leu Ser Glu Met Ala Ala Glu Ala Ala Tyr 115 120
125Gln Thr Gly Ala Asp Gln Ala Ser Ile Thr Ala Arg Asn His Ile Gln
130 135 140Leu Val Lys Leu Gln Val Glu Glu Val His Gln Leu Ser Arg
Lys Ala145 150 155 160Glu Thr Lys Leu Ala Glu Ala Gln Ile Glu Glu
Leu Arg Gln Lys Thr 165 170 175Gln Glu Glu Gly Glu Glu Arg Ala Glu
Ser Glu Gln Glu Ala Tyr Leu 180 185 190Arg Glu Asp
195111195PRTArtificial SequenceSynthetic Diablo.3(S82L); TH2001
without epitope tag 111Met Ala Ala Leu Lys Ser Trp Leu Ser Arg Ser
Val Thr Ser Phe Phe1 5 10 15Arg Tyr Arg Gln Cys Leu Cys Val Pro Val
Val Ala Asn Phe Lys Lys 20 25 30Arg Cys Phe Ser Glu Leu Ile Arg Pro
Trp His Lys Thr Val Thr Ile 35 40 45Gly Phe Gly Val Thr Leu Cys Ala
Val Pro Ile Ala Gln Ala Val Tyr 50 55 60Thr Leu Thr Ser Leu Tyr Arg
Gln Tyr Thr Ser Leu Leu Gly Lys Met65 70 75 80Asn Leu Glu Glu Glu
Asp Glu Val Trp Gln Val Ile Ile Gly Ala Arg 85 90 95Ala Glu Met Thr
Ser Lys His Gln Glu Tyr Leu Lys Leu Glu Thr Thr 100 105 110Trp Met
Thr Ala Val Gly Leu Ser Glu Met Ala Ala Glu Ala Ala Tyr 115 120
125Gln Thr Gly Ala Asp Gln Ala Ser Ile Thr Ala Arg Asn His Ile Gln
130 135 140Leu Val Lys Leu Gln Val Glu Glu Val His Gln Leu Ser Arg
Lys Ala145 150 155 160Glu Thr Lys Leu Ala Glu Ala Gln Ile Glu Glu
Leu Arg Gln Lys Thr 165 170 175Gln Glu Glu Gly Glu Glu Arg Ala Glu
Ser Glu Gln Glu Ala Tyr Leu 180 185 190Arg Glu Asp
195112141PRTArtificial SequenceSynthetic Diablo.3(56-195); TH2002
without epitope tag 112Met Ala Val Pro Ile Ala Gln Ala Val Tyr Thr
Leu Thr Ser Leu Tyr1 5 10 15Arg Gln Tyr Thr Ser Leu Leu Gly Lys Met
Asn Ser Glu Glu Glu Asp 20 25 30Glu Val Trp Gln Val Ile Ile Gly Ala
Arg Ala Glu Met Thr Ser Lys 35 40 45His Gln Glu Tyr Leu Lys Leu Glu
Thr Thr Trp Met Thr Ala Val Gly 50 55 60Leu Ser Glu Met Ala Ala Glu
Ala Ala Tyr Gln Thr Gly Ala Asp Gln65 70 75 80Ala Ser Ile Thr Ala
Arg Asn His Ile Gln Leu Val Lys Leu Gln Val 85 90 95Glu Glu Val His
Gln Leu Ser Arg Lys Ala Glu Thr Lys Leu Ala Glu 100 105 110Ala Gln
Ile Glu Glu Leu Arg Gln Lys Thr Gln Glu Glu Gly Glu Glu 115 120
125Arg Ala Glu Ser Glu Gln Glu Ala Tyr Leu Arg Glu Asp 130 135
140113141PRTArtificial SequenceSynthetic Diablo.3(56-195/S82L);
without epitope tag 113Met Ala Val Pro Ile Ala Gln Ala Val Tyr Thr
Leu Thr Ser Leu Tyr1 5 10 15Arg Gln Tyr Thr Ser Leu Leu Gly Lys Met
Asn Leu Glu Glu Glu Asp 20 25 30Glu Val Trp Gln Val Ile Ile Gly Ala
Arg Ala Glu Met Thr Ser Lys 35 40 45His Gln Glu Tyr Leu Lys Leu Glu
Thr Thr Trp Met Thr Ala Val Gly 50 55 60Leu Ser Glu Met Ala Ala Glu
Ala Ala Tyr Gln Thr Gly Ala Asp Gln65 70 75 80Ala Ser Ile Thr Ala
Arg Asn His Ile Gln Leu Val Lys Leu Gln Val 85 90 95Glu Glu Val His
Gln Leu Ser Arg Lys Ala Glu Thr Lys Leu Ala Glu 100 105 110Ala Gln
Ile Glu Glu Leu Arg Gln Lys Thr Gln Glu Glu Gly Glu Glu 115 120
125Arg Ala Glu Ser Glu Gln Glu Ala Tyr Leu Arg Glu Asp 130 135
140114659PRTArtificial SequenceSynthetic Btk(E41K); P4029 without
epitope tag 114Met Ala Ala Val Ile Leu Glu Ser Ile Phe Leu Lys Arg
Ser Gln Gln1 5 10 15Lys Lys Lys Thr Ser Pro Leu Asn Phe Lys Lys Arg
Leu Phe Leu Leu 20 25 30Thr Val His Lys Leu Ser Tyr Tyr Lys Tyr Asp
Phe Glu Arg Gly Arg 35 40 45Arg Gly Ser Lys Lys Gly Ser Ile Asp Val
Glu Lys Ile Thr Cys Val 50 55 60Glu Thr Val Val Pro Glu Lys Asn Pro
Pro Pro Glu Arg Gln Ile Pro65 70 75 80Arg Arg Gly Glu Glu Ser Ser
Glu Met Glu Gln Ile Ser Ile Ile Glu 85 90 95Arg Phe Pro Tyr Pro Phe
Gln Val Val Tyr Asp Glu Gly Pro Leu Tyr 100 105 110Val Phe Ser Pro
Thr Glu Glu Leu Arg Lys Arg Trp Ile His Gln Leu 115 120 125Lys Asn
Val Ile Arg Tyr Asn Ser Asp Leu Val Gln Lys Tyr His Pro 130 135
140Cys Phe Trp Ile Asp Gly Gln Tyr Leu Cys Cys Ser Gln Thr Ala
Lys145 150 155 160Asn Ala Met Gly Cys Gln Ile Leu Glu Asn Arg Asn
Gly Ser Leu Lys 165 170 175Pro Gly Ser Ser His Arg Lys Thr Lys Lys
Pro Leu Pro Pro Thr Pro 180 185 190Glu Glu Asp Gln Ile Leu Lys Lys
Pro Leu Pro Pro Glu Pro Ala Ala 195 200 205Ala Pro Val Ser Thr Ser
Glu Leu Lys Lys Val Val Ala Leu Tyr Asp 210 215 220Tyr Met Pro Met
Asn Ala Asn Asp Leu Gln Leu Arg Lys Gly Asp Glu225 230 235 240Tyr
Phe Ile Leu Glu Glu Ser Asn Leu Pro Trp Trp Arg Ala Arg Asp 245 250
255Lys Asn Gly Gln Glu Gly Tyr Ile Pro Ser Asn Tyr Val Thr Glu Ala
260 265 270Glu Asp Ser Ile Glu Met Tyr Glu Trp Tyr Ser Lys His Met
Thr Arg 275 280 285Ser Gln Ala Glu Gln Leu Leu Lys Gln Glu Gly Lys
Glu Gly Gly Phe 290 295 300Ile Val Arg Asp Ser Ser Lys Ala Gly Lys
Tyr Thr Val Ser Val Phe305 310 315 320Ala Lys Ser Thr Gly Asp Pro
Gln Gly Val Ile Arg His Tyr Val Val 325 330 335Cys Ser Thr Pro Gln
Ser Gln Tyr Tyr Leu Ala Glu Lys His Leu Phe 340 345 350Ser Thr Ile
Pro Glu Leu Ile Asn Tyr His Gln His Asn Ser Ala Gly 355 360 365Leu
Ile Ser Arg Leu Lys Tyr Pro Val Ser Gln Gln Asn Lys Asn Ala 370 375
380Pro Ser Thr Ala Gly Leu Gly Tyr Gly Ser Trp Glu Ile Asp Pro
Lys385 390 395 400Asp Leu Thr Phe Leu Lys Glu Leu Gly Thr Gly Gln
Phe Gly Val Val 405 410 415Lys Tyr Gly Lys Trp Arg Gly Gln Tyr Asp
Val Ala Ile Lys Met Ile 420 425 430Lys Glu Gly Ser Met Ser Glu Asp
Glu Phe Ile Glu Glu Ala Lys Val 435 440 445Met Met Asn Leu Ser His
Glu Lys Leu Val Gln Leu Tyr Gly Val Cys 450 455 460Thr Lys Gln Arg
Pro Ile Phe Ile Ile Thr Glu Tyr Met Ala Asn Gly465 470 475 480Cys
Leu Leu Asn Tyr Leu Arg Glu Met Arg His Arg Phe Gln Thr Gln 485 490
495Gln Leu Leu Glu Met Cys Lys Asp Val Cys Glu Ala Met Glu Tyr Leu
500 505 510Glu Ser Lys Gln Phe Leu His Arg Asp Leu Ala Ala Arg Asn
Cys Leu 515 520 525Val Asn Asp Gln Gly Val Val Lys Val Ser Asp Phe
Gly Leu Ser Arg 530 535 540Tyr Val Leu Asp Asp Glu Tyr Thr Ser Ser
Val Gly Ser Lys Phe Pro545 550 555 560Val Arg Trp Ser Pro Pro Glu
Val Leu Met Tyr Ser Lys Phe Ser Ser 565 570 575Lys Ser Asp Ile Trp
Ala Phe Gly Val Leu Met Trp Glu Ile Tyr Ser 580 585 590Leu Gly Lys
Met Pro Tyr Glu Arg Phe Thr Asn Ser Glu Thr Ala Glu 595 600 605His
Ile Ala Gln Gly Leu Arg Leu Tyr Arg Pro His Leu Ala Ser Glu 610 615
620Lys Val Tyr Thr Ile Met Tyr Ser Cys Trp His Glu Lys Ala Asp
Glu625 630 635 640Arg Pro Thr Phe Lys Ile Leu Leu Ser Asn Ile Leu
Asp Val Met Asp 645 650 655Glu Glu Ser115225PRTArtificial
SequenceSynthetic SOCS3; P4030 without epitope tag 115Met Val Thr
His Ser Lys Phe Pro Ala Ala Gly Met Ser Arg Pro Leu1 5 10 15Asp Thr
Ser Leu Arg Leu Lys Thr Phe Ser Ser Lys Ser Glu Tyr Gln 20 25 30Leu
Val Val Asn Ala Val Arg Lys Leu Gln Glu Ser Gly Phe Tyr Trp 35 40
45Ser Ala Val Thr Gly Gly Glu Ala Asn Leu Leu Leu Ser Ala Glu Pro
50 55 60Ala Gly Thr Phe Leu Ile Arg Asp Ser Ser Asp Gln Arg His Phe
Phe65 70 75 80Thr Leu Ser Val Lys Thr Gln Ser Gly Thr Lys Asn Leu
Arg Ile Gln 85 90 95Cys Glu Gly Gly Ser Phe Ser Leu Gln Ser Asp Pro
Arg Ser Thr Gln 100 105 110Pro Val Pro Arg Phe Asp Cys Val Leu Lys
Leu Val His His Tyr Met 115 120 125Pro Pro Pro Gly Ala Pro Ser Phe
Pro Ser Pro Pro Thr Glu Pro Ser 130 135 140Ser Glu Val Pro Glu Gln
Pro Ser Ala Gln Pro Leu Pro Gly Ser Pro145 150 155 160Pro Arg Arg
Ala Tyr Tyr Ile Tyr Ser Gly Gly Glu Lys Ile Pro Leu 165 170 175Val
Leu Ser Arg Pro Leu Ser Ser Asn Val Ala Thr Leu Gln His Leu 180 185
190Cys Arg Lys Thr Val Asn Gly His Leu Asp Ser Tyr Glu Lys Val Thr
195 200 205Gln Leu Pro Gly Pro Ile Arg Glu Phe Leu Asp Gln Tyr Asp
Ala Pro 210 215 220Leu225116347PRTHomo
sapiensmisc_feature(1)..(347)IZ_hsCASP1 (self-activating human
Caspase 1); P2024 without epitope tag 116Met Arg Met Lys Gln Ile
Glu Asp Lys Ile Glu Glu Ile Leu Ser Lys1 5 10 15Ile Tyr His Ile Glu
Asn Glu Ile Ala Arg Ile Lys Lys Leu Ile Gly 20 25 30Glu Ala Asp Gln
Thr Ser Gly Asn Tyr Leu Asn Met Gln Asp Ser Gln 35 40 45Gly Val Leu
Ser Ser Phe Pro Ala Pro Gln Ala Val Gln Asp Asn Pro 50 55 60Ala Met
Pro Thr Ser Ser Gly Ser Glu Gly Asn Val Lys Leu Cys Ser65 70 75
80Leu Glu Glu Ala Gln Arg Ile Trp Lys Gln Lys Ser Ala Glu Ile Tyr
85 90 95Pro Ile Met Asp Lys Ser Ser Arg Thr Arg Leu Ala Leu Ile Ile
Cys 100 105 110Asn Glu Glu Phe Asp Ser Ile Pro Arg Arg Thr Gly Ala
Glu Val Asp 115 120 125Ile Thr Gly Met Thr Met Leu Leu Gln Asn Leu
Gly Tyr Ser Val Asp 130 135 140Val Lys Lys Asn Leu Thr Ala Ser Asp
Met Thr Thr Glu Leu Glu Ala145 150 155 160Phe Ala His Arg Pro Glu
His Lys Thr Ser Asp Ser Thr Phe Leu Val 165 170 175Phe Met Ser His
Gly Ile Arg Glu Gly Ile Cys Gly Lys Lys His Ser 180 185 190Glu Gln
Val Pro Asp Ile Leu Gln Leu Asn Ala Ile Phe Asn Met Leu 195 200
205Asn Thr Lys Asn Cys Pro Ser Leu Lys Asp Lys Pro Lys Val Ile Ile
210 215 220Ile Gln Ala Cys Arg Gly Asp Ser Pro Gly Val Val Trp Phe
Lys Asp225 230 235 240Ser Val Gly Val Ser Gly Asn Leu Ser Leu Pro
Thr Thr Glu Glu Phe 245 250 255Glu Asp Asp Ala Ile Lys Lys Ala His
Ile Glu Lys Asp Phe Ile Ala 260 265 270Phe Cys Ser Ser Thr Pro Asp
Asn Val Ser Trp Arg His Pro Thr Met 275 280 285Gly Ser Val Phe Ile
Gly Arg Leu Ile Glu His Met Gln Glu Tyr Ala 290 295 300Cys Ser Cys
Asp Val Glu Glu Ile Phe Arg Lys Val Arg Phe Ser Phe305 310 315
320Glu Gln Pro Asp Gly Arg Ala Gln Met Pro Thr Thr Glu Arg Val Thr
325 330 335Leu Thr Arg Cys Phe Tyr Leu Phe Pro Gly His 340
345117347PRTHomo sapiensmisc_feature(1)..(347)DM_hsCASP1
(self-activating human Caspase 1); P2025 without epitope tag 117Met
Arg Met Lys Gln Leu Glu Asp Lys Ile Glu Glu Leu Leu Ser Lys1 5 10
15Ile Tyr His Leu Glu Asn Glu Ile Ala Arg Leu Lys Lys Leu Ile Gly
20 25 30Glu Ala Asp Gln Thr Ser Gly Asn Tyr Leu Asn Met Gln Asp Ser
Gln 35 40 45Gly Val Leu Ser Ser Phe Pro Ala Pro Gln Ala Val Gln Asp
Asn Pro 50 55 60Ala Met Pro Thr Ser Ser Gly Ser Glu Gly Asn Val Lys
Leu Cys Ser65 70 75 80Leu Glu Glu Ala Gln Arg Ile Trp
Lys Gln Lys Ser Ala Glu Ile Tyr 85 90 95Pro Ile Met Asp Lys Ser Ser
Arg Thr Arg Leu Ala Leu Ile Ile Cys 100 105 110Asn Glu Glu Phe Asp
Ser Ile Pro Arg Arg Thr Gly Ala Glu Val Asp 115 120 125Ile Thr Gly
Met Thr Met Leu Leu Gln Asn Leu Gly Tyr Ser Val Asp 130 135 140Val
Lys Lys Asn Leu Thr Ala Ser Asp Met Thr Thr Glu Leu Glu Ala145 150
155 160Phe Ala His Arg Pro Glu His Lys Thr Ser Asp Ser Thr Phe Leu
Val 165 170 175Phe Met Ser His Gly Ile Arg Glu Gly Ile Cys Gly Lys
Lys His Ser 180 185 190Glu Gln Val Pro Asp Ile Leu Gln Leu Asn Ala
Ile Phe Asn Met Leu 195 200 205Asn Thr Lys Asn Cys Pro Ser Leu Lys
Asp Lys Pro Lys Val Ile Ile 210 215 220Ile Gln Ala Cys Arg Gly Asp
Ser Pro Gly Val Val Trp Phe Lys Asp225 230 235 240Ser Val Gly Val
Ser Gly Asn Leu Ser Leu Pro Thr Thr Glu Glu Phe 245 250 255Glu Asp
Asp Ala Ile Lys Lys Ala His Ile Glu Lys Asp Phe Ile Ala 260 265
270Phe Cys Ser Ser Thr Pro Asp Asn Val Ser Trp Arg His Pro Thr Met
275 280 285Gly Ser Val Phe Ile Gly Arg Leu Ile Glu His Met Gln Glu
Tyr Ala 290 295 300Cys Ser Cys Asp Val Glu Glu Ile Phe Arg Lys Val
Arg Phe Ser Phe305 310 315 320Glu Gln Pro Asp Gly Arg Ala Gln Met
Pro Thr Thr Glu Arg Val Thr 325 330 335Leu Thr Arg Cys Phe Tyr Leu
Phe Pro Gly His 340 345118346PRTMus
musculusmisc_feature(1)..(346)IZ_mmCASP1 (self-activating mouse
Caspase 1); P2026 without epitope tag 118Met Arg Met Lys Gln Ile
Glu Asp Lys Ile Glu Glu Ile Leu Ser Lys1 5 10 15Ile Tyr His Ile Glu
Asn Glu Ile Ala Arg Ile Lys Lys Leu Ile Gly 20 25 30Glu Arg Ser Ala
Pro Ser Ala Glu Thr Phe Val Ala Thr Glu Asp Ser 35 40 45Lys Gly Gly
His Pro Ser Ser Ser Glu Thr Lys Glu Glu Gln Asn Lys 50 55 60Glu Asp
Gly Thr Phe Pro Gly Leu Thr Gly Thr Leu Lys Phe Cys Pro65 70 75
80Leu Glu Lys Ala Gln Lys Leu Trp Lys Glu Asn Pro Ser Glu Ile Tyr
85 90 95Pro Ile Met Asn Thr Thr Thr Arg Thr Arg Leu Ala Leu Ile Ile
Cys 100 105 110Asn Thr Glu Phe Gln His Leu Ser Pro Arg Val Gly Ala
Gln Val Asp 115 120 125Leu Arg Glu Met Lys Leu Leu Leu Glu Asp Leu
Gly Tyr Thr Val Lys 130 135 140Val Lys Glu Asn Leu Thr Ala Leu Glu
Met Val Lys Glu Val Lys Glu145 150 155 160Phe Ala Ala Cys Pro Glu
His Lys Thr Ser Asp Ser Thr Phe Leu Val 165 170 175Phe Met Ser His
Gly Ile Gln Glu Gly Ile Cys Gly Thr Thr Tyr Ser 180 185 190Asn Glu
Val Ser Asp Ile Leu Lys Val Asp Thr Ile Phe Gln Met Met 195 200
205Asn Thr Leu Lys Cys Pro Ser Leu Lys Asp Lys Pro Lys Val Ile Ile
210 215 220Ile Gln Ala Cys Arg Gly Glu Lys Gln Gly Val Val Leu Leu
Lys Asp225 230 235 240Ser Val Arg Asp Ser Glu Glu Asp Phe Leu Thr
Asp Ala Ile Phe Glu 245 250 255Asp Asp Gly Ile Lys Lys Ala His Ile
Glu Lys Asp Phe Ile Ala Phe 260 265 270Cys Ser Ser Thr Pro Asp Asn
Val Ser Trp Arg His Pro Val Arg Gly 275 280 285Ser Leu Phe Ile Glu
Ser Leu Ile Lys His Met Lys Glu Tyr Ala Trp 290 295 300Ser Cys Asp
Leu Glu Asp Ile Phe Arg Lys Val Arg Phe Ser Phe Glu305 310 315
320Gln Pro Glu Phe Arg Leu Gln Met Pro Thr Ala Asp Arg Val Thr Leu
325 330 335Thr Lys Arg Phe Tyr Leu Phe Pro Gly His 340
345119346PRTMus musculusmisc_feature(1)..(346)DM_mmCASP1
(self-activating mouse Caspase 1); P2027 without epitope tag 119Met
Arg Met Lys Gln Leu Glu Asp Lys Ile Glu Glu Leu Leu Ser Lys1 5 10
15Ile Tyr His Leu Glu Asn Glu Ile Ala Arg Leu Lys Lys Leu Ile Gly
20 25 30Glu Arg Ser Ala Pro Ser Ala Glu Thr Phe Val Ala Thr Glu Asp
Ser 35 40 45Lys Gly Gly His Pro Ser Ser Ser Glu Thr Lys Glu Glu Gln
Asn Lys 50 55 60Glu Asp Gly Thr Phe Pro Gly Leu Thr Gly Thr Leu Lys
Phe Cys Pro65 70 75 80Leu Glu Lys Ala Gln Lys Leu Trp Lys Glu Asn
Pro Ser Glu Ile Tyr 85 90 95Pro Ile Met Asn Thr Thr Thr Arg Thr Arg
Leu Ala Leu Ile Ile Cys 100 105 110Asn Thr Glu Phe Gln His Leu Ser
Pro Arg Val Gly Ala Gln Val Asp 115 120 125Leu Arg Glu Met Lys Leu
Leu Leu Glu Asp Leu Gly Tyr Thr Val Lys 130 135 140Val Lys Glu Asn
Leu Thr Ala Leu Glu Met Val Lys Glu Val Lys Glu145 150 155 160Phe
Ala Ala Cys Pro Glu His Lys Thr Ser Asp Ser Thr Phe Leu Val 165 170
175Phe Met Ser His Gly Ile Gln Glu Gly Ile Cys Gly Thr Thr Tyr Ser
180 185 190Asn Glu Val Ser Asp Ile Leu Lys Val Asp Thr Ile Phe Gln
Met Met 195 200 205Asn Thr Leu Lys Cys Pro Ser Leu Lys Asp Lys Pro
Lys Val Ile Ile 210 215 220Ile Gln Ala Cys Arg Gly Glu Lys Gln Gly
Val Val Leu Leu Lys Asp225 230 235 240Ser Val Arg Asp Ser Glu Glu
Asp Phe Leu Thr Asp Ala Ile Phe Glu 245 250 255Asp Asp Gly Ile Lys
Lys Ala His Ile Glu Lys Asp Phe Ile Ala Phe 260 265 270Cys Ser Ser
Thr Pro Asp Asn Val Ser Trp Arg His Pro Val Arg Gly 275 280 285Ser
Leu Phe Ile Glu Ser Leu Ile Lys His Met Lys Glu Tyr Ala Trp 290 295
300Ser Cys Asp Leu Glu Asp Ile Phe Arg Lys Val Arg Phe Ser Phe
Glu305 310 315 320Gln Pro Glu Phe Arg Leu Gln Met Pro Thr Ala Asp
Arg Val Thr Leu 325 330 335Thr Lys Arg Phe Tyr Leu Phe Pro Gly His
340 345120106PRTArtificial SequenceSynthetic ADR concatemer with
HIS tag 120Met His His His His His His His His His His Gly Lys Pro
Ile Pro1 5 10 15Asn Pro Leu Leu Gly Leu Asp Ser Thr Gly Ile Pro Val
His Leu Glu 20 25 30Leu Ala Ser Met Thr Asn Met Glu Leu Met Ser Ser
Ile Val His Gln 35 40 45Gln Val Phe Pro Thr Glu Ala Gly Gln Ser Leu
Val Ile Ser Ala Ser 50 55 60Ile Ile Val Phe Asn Leu Leu Glu Leu Glu
Gly Asp Tyr Arg Gly Arg65 70 75 80Val Leu Glu Leu Phe Arg Ala Ala
Gln Leu Ala Asn Asp Val Val Leu 85 90 95Gln Ile Met Glu Leu Cys Gly
Ala Thr Arg 100 1051219PRTArtificial SequenceSynthetic KRAS G12D
9mer 121Val Val Gly Ala Asp Gly Val Gly Lys1 51229PRTArtificial
SequenceSynthetic KRAS G12V 9mer 122Val Val Gly Ala Val Gly Val Gly
Lys1 51239PRTArtificial SequenceSynthetic KRAS G13D 9mer 123Val Gly
Ala Gly Asp Val Gly Lys Ser1 51249PRTArtificial SequenceSynthetic
KRAS G12C 9mer 124Val Val Gly Ala Cys Gly Val Gly Lys1
512515PRTArtificial SequenceSynthetic KRAS G12C 15mer 125Met Lys
Leu Val Val Val Gly Ala Cys Gly Val Gly Lys Ser Ala1 5 10
1512675DNAArtificial SequenceSynthetic KRAS G12D 25mer nucleotide
sequence 126atgaccgagt acaagctggt ggtggtgggc gccgacggcg tgggcaagag
cgccctgacc 60atccagctga tccag 7512775DNAArtificial
SequenceSynthetic KRAS G12V 25mer nucleotide sequence 127atgaccgagt
acaagctggt ggtggtgggc gccgtgggcg tgggcaagag cgccctgacc 60atccagctga
tccag 7512875DNAArtificial SequenceSynthetic KRAS G13D 25mer
nucleotide sequence 128atgaccgagt acaagctggt ggtggtgggc gccggcgacg
tgggcaagag cgccctgacc 60atccagctga tccag 75129225DNAArtificial
SequenceSynthetic KRAS G12D 25mer^3 nucleotide sequence
129atgaccgagt acaagttagt ggttgtgggc gccgacggcg tgggcaagag
cgccctcacc 60atccagctta tccagatgac ggaatataag ttagtagtag tgggagccga
cggtgtcggc 120aagtccgctt tgaccattca acttattcag atgacagagt
ataagctggt cgttgtaggc 180gcagacggcg ttggaaagtc ggcactgacg
atccagttga tccag 225130225DNAArtificial SequenceSynthetic KRAS G12V
25mer^3 nucleotide sequence 130atgaccgagt acaagctcgt cgtggtgggc
gccgtgggcg tgggcaagag cgccctaacc 60atccagttga tccagatgac cgaatataag
ctcgtggtag tcggagcggt gggcgttggc 120aagtcagcgc taacaataca
actaatccaa atgaccgaat acaagctagt tgtagtcggt 180gccgtcggcg
ttggaaagtc agcccttaca attcagctca ttcag 225131225DNAArtificial
SequenceSynthetic KRAS G13D 25mer^3 nucleotide sequence
131atgaccgagt acaagctcgt agtggttggc gccggcgacg tgggcaagag
cgccctaacc 60atccagctca tccagatgac agaatataag cttgtggttg tgggagcagg
agacgtggga 120aagagtgcgt tgacgattca actcatacag atgaccgaat
acaagttggt ggtggtcggc 180gcaggtgacg ttggtaagtc tgcactaact
atacaactga tccag 22513275DNAArtificial SequenceSynthetic KRAS G12C
25mer nucleotide sequence 132atgaccgagt acaagctggt ggtggtgggc
gcctgcggcg tgggcaagag cgccctgacc 60atccagctga tccag
7513375DNAArtificial SequenceSynthetic KRAS WT 25mer nucleotide
sequence 133atgaccgagt acaagctggt ggtggtgggc gccggcggcg tgggcaagag
cgccctgacc 60atccagctga tccag 7513447DNAArtificial
SequenceSynthetic 5 UTR sequence; no promoter 134gggaaataag
agagaaaaga agagtaagaa gaaatataag agccacc 4713575PRTArtificial
SequenceSynthetic KRAS(G12D G12V G13D) 75mer 3MUT aa. seq 135Met
Thr Glu Tyr Lys Leu Val Val Val Gly Ala Asp Gly Val Gly Lys1 5 10
15Ser Ala Leu Thr Ile Gln Leu Ile Gln Met Thr Glu Tyr Lys Leu Val
20 25 30Val Val Gly Ala Val Gly Val Gly Lys Ser Ala Leu Thr Ile Gln
Leu 35 40 45Ile Gln Met Thr Glu Tyr Lys Leu Val Val Val Gly Ala Gly
Asp Val 50 55 60Gly Lys Ser Ala Leu Thr Ile Gln Leu Ile Gln65 70
75136225DNAArtificial SequenceSynthetic KRAS(G12D G12V G13D) 75mer
3MUT nt. seq 136atgaccgagt acaagctcgt tgtagtcggc gccgacggcg
tgggcaagag cgccttgacc 60atccagttga tccagatgac cgaatataag ttggtggtgg
taggcgcagt gggagttggc 120aagtcagcac tcacaattca gctcattcaa
atgacagaat acaagttagt cgttgtagga 180gcaggcgacg tcggcaagag
tgccttaacc attcaactaa tccag 225137100PRTArtificial
SequenceSynthetic KRAS(G12D G12V G13D G12C) 100mer 4MUT aa. seq
137Met Thr Glu Tyr Lys Leu Val Val Val Gly Ala Asp Gly Val Gly Lys1
5 10 15Ser Ala Leu Thr Ile Gln Leu Ile Gln Met Thr Glu Tyr Lys Leu
Val 20 25 30Val Val Gly Ala Val Gly Val Gly Lys Ser Ala Leu Thr Ile
Gln Leu 35 40 45Ile Gln Met Thr Glu Tyr Lys Leu Val Val Val Gly Ala
Gly Asp Val 50 55 60Gly Lys Ser Ala Leu Thr Ile Gln Leu Ile Gln Met
Thr Glu Tyr Lys65 70 75 80Leu Val Val Val Gly Ala Cys Gly Val Gly
Lys Ser Ala Leu Thr Ile 85 90 95Gln Leu Ile Gln
100138300DNAArtificial SequenceSynthetic KRAS(G12D G12V G13D G12C)
100mer 4MUT nt. seq 138atgaccgagt acaagctcgt ggtcgtcggc gccgacgggg
taggcaagtc cgctctgacc 60attcagctca tccagatgac ggagtacaaa ctcgtggtag
tgggagccgt gggtgtgggc 120aagagcgcgc tcaccatcca actcatccaa
atgaccgaat ataaactcgt cgtggtggga 180gccggcgacg tgggaaagag
cgcccttacc atccagttaa tccagatgac agaatacaag 240ctggtggtgg
tcggtgcctg cggcgtgggt aagtccgccc tgacaatcca gctgatccag
3001391137DNAArtificial SequenceSynthetic huSTING(V155M); no
epitope tag; nucleotide sequence 139atgccccaca gtagcctcca
ccccagcatc ccctgcccca gaggccacgg cgcacagaag 60gccgccctgg tgctgctgag
cgcctgtctg gtgaccctgt ggggtctggg cgagcccccc 120gagcacaccc
tgcggtacct cgtgctgcat ctggccagcc tgcagctggg cctgctgctg
180aacggcgtgt gcagcctggc cgaagagctg agacacatcc acagcagata
cagaggctcc 240tactggagaa ccgtcagagc ctgcctcggc tgtcccctga
gaagaggcgc cctgctgctc 300ctgagcatct acttctacta cagcctgccc
aacgccgtgg gccccccctt cacctggatg 360ctggccctgc tgggcctgag
ccaggccctg aacatcctgc tgggcctgaa gggcttggcc 420cccgccgaga
tctccgccgt gtgcgagaag ggcaacttca acatggccca tggccttgcc
480tggtcctact acatcggcta cctgagactg atcctgcccg agctgcaggc
cagaatcaga 540acctacaacc agcactacaa caacctgctg agaggcgccg
tgagccaaag actgtacatc 600ctgctgcccc tggactgcgg cgtgcccgac
aaccttagca tggccgaccc caacatcaga 660ttcctggaca agctgcccca
gcagaccggc gaccacgccg gcatcaagga cagagtgtac 720agcaacagca
tctacgagct gctggagaac ggccagagag ccggcacctg cgtgctggag
780tacgccaccc ccctgcagac cctgttcgcc atgagccagt acagccaggc
cggcttcagc 840agagaggaca gactggagca agccaagctg ttctgcagaa
ccctggagga catcctggcg 900gacgcccccg agagccaaaa caactgcaga
ctgatcgcct accaggagcc cgccgacgac 960agcagcttca gcctgagcca
ggaagtgctg agacacctga gacaggaaga gaaggaggag 1020gtgaccgtgg
gaagcctgaa gaccagcgcc gtgcccagca ccagcaccat gagccaggag
1080cccgagctgc tgatcagcgg catggagaag cccctgcccc tgagaaccga cttcagc
11371401137DNAArtificial SequenceSynthetic Hu STING(R284T); no
epitope tag; nucleotide sequence 140atgcctcaca gcagcctgca
ccctagcatc ccttgcccta gaggccacgg cgcccagaag 60gccgccctgg tgctgctgag
cgcctgcctg gtgaccctgt ggggcctggg cgagcctcct 120gagcacaccc
tgagatacct ggtgctgcac ctggccagcc tgcagctggg cctgctgctg
180aacggcgtgt gcagcctggc cgaggagctg agacacatcc acagcagata
cagaggcagc 240tactggagaa ccgtgagagc ctgcctgggc tgccctctga
gaagaggcgc cctgctgctg 300ctgagcatct acttctacta cagcctgcct
aacgccgtgg gccctccttt cacctggatg 360ctggccctgc tgggcctgag
ccaggccctg aacatcctgc tgggcctgaa gggcctggcc 420cctgccgaga
tcagcgccgt gtgcgagaag ggcaacttca acgtggccca cggcctggcc
480tggagctact acatcggcta cctgagactg atcctgcctg agctgcaggc
cagaatcaga 540acctacaacc agcactacaa caacctgctg agaggcgccg
tgagccagag actgtacatc 600ctgctgcctc tggactgcgg cgtgcctgac
aacctgagca tggccgaccc taacatcaga 660ttcctggaca agctgcctca
gcagaccggc gaccacgccg gcatcaagga cagagtgtac 720agcaacagca
tctacgagct gctggagaac ggccagagag ccggcacctg cgtgctggag
780tacgccaccc ctctgcagac cctgttcgcc atgagccagt acagccaggc
cggcttcagc 840agagaggaca ccctggagca ggccaagctg ttctgcagaa
ccctggagga catcctggcc 900gacgcccctg agagccagaa caactgcaga
ctgatcgcct accaggagcc tgccgacgac 960agcagcttca gcctgagcca
ggaggtgctg agacacctga gacaggagga gaaggaggag 1020gtgaccgtgg
gcagcctgaa gaccagcgcc gtgcctagca ccagcaccat gagccaggag
1080cctgagctgc tgatcagcgg catggagaag cctctgcctc tgagaaccga cttcagc
11371411137DNAArtificial SequenceSynthetic hu STING (R284M); no
epitope tag; nucleotide sequence 141atgccccaca gcagcctgca
cccctccatc ccctgtccca gaggccacgg cgcccagaag 60gccgccctgg tgctgctgag
cgcctgcctg gtgaccttat ggggcctggg cgagcccccc 120gagcacaccc
tgagatacct ggtcctgcac ctggccagcc tccagctggg cctgctgctc
180aacggcgtgt gtagcctggc cgaggagctg agacacatcc acagcagata
cagaggcagc 240tactggagaa ccgtgagagc ctgcctgggt tgcccactga
gaagaggagc tctgctgctg 300ctgagcatct acttctacta ctcgctgccc
aacgctgtgg gccccccctt cacctggatg 360ctggccctgc tgggtctgag
ccaggccctg aacatcctcc tgggcctgaa gggcctggcc 420cccgccgaga
taagcgccgt ttgcgagaag ggcaacttca acgtggccca tggcctggcc
480tggagctact acatcggcta cttacgcctg atcctgcccg agctgcaggc
cagaatcaga 540acctacaacc agcattacaa caacctgctg agaggcgccg
tgagccagag actgtatatc 600ctgctgcccc tggactgcgg cgtgcccgac
aacctgagca tggccgaccc caacatcaga 660ttcctggaca agctccccca
gcagaccggc gaccacgccg gaatcaaaga cagagtgtat 720agcaacagca
tctacgagct gctggagaac ggccagagag ccggcacctg cgtactggag
780tacgccaccc ccttgcagac cctgtttgcc atgagccagt acagccaggc
cggcttcagc 840agagaggaca tgctggagca ggccaagctg ttctgcagaa
ccctggagga catcctggcc 900gacgcccccg agagccagaa caactgcaga
ctgatcgcct accaagagcc cgccgacgac 960agcagcttca gcttaagcca
ggaggtgctg agacatctga gacaggagga gaaggaggag 1020gtgaccgtgg
gcagcctcaa gaccagcgct gtgccctcta ccagcaccat gagccaggag
1080cccgagctgc tgatcagcgg catggagaag cccctgcccc tgagaacaga cttcagc
11371421137DNAArtificial SequenceSynthetic Hu STING (R284K); no
epitope tag; nucleotide sequence 142atgccccata gcagcctgca
ccccagcatc ccctgcccca gaggccacgg cgcccagaag 60gccgccctgg
tcctgctgag
cgcatgcctg gtcaccctgt ggggcctggg cgagcccccc 120gagcacaccc
tgagatacct ggtgctgcac ctcgccagcc tgcagctggg cctgctgctg
180aacggcgtgt gcagcctggc cgaggagctg agacacatcc acagcagata
tagaggcagc 240tactggagaa ccgtgagagc ttgcctcggc tgccccctga
gaagaggcgc cctgctgctg 300ctgagcatct acttttacta cagcctgccc
aacgctgtgg gccccccttt cacgtggatg 360ctcgccctgc tgggactgag
ccaggccctg aacatcctgc tgggccttaa gggcctagcc 420cccgccgaga
tcagcgccgt gtgcgagaag ggcaacttca atgtggccca cggcctggcc
480tggagctact acatcggcta cctgagactg atcctgcccg agctgcaggc
cagaatcaga 540acctacaatc agcactacaa caacctgctg agaggcgccg
tgagccagag actgtacatc 600ctgctgcccc tggactgcgg cgtgcccgac
aacctcagca tggccgaccc caacatcaga 660ttcctggaca agctgcccca
gcagaccggc gaccacgccg gcatcaagga tcgcgtgtac 720agcaacagca
tctacgagct gctggaaaac ggccagagag ccggaacctg cgtgctggag
780tacgccacac ccctgcagac cctgttcgcc atgagccagt acagccaggc
cggcttcagc 840agagaggaca agctggagca ggccaagctg ttctgcagaa
ccctggagga tatcctcgcc 900gacgcccccg agagccagaa caactgcagg
ctgatcgcgt accaggagcc cgctgacgac 960agcagcttta gcctgagcca
ggaggtgctg agacatctgc gtcaagagga aaaggaggag 1020gtgaccgtgg
gctccctgaa gaccagcgcc gtgcccagca ccagcaccat gagccaggag
1080cccgagctgc tgatcagcgg catggagaag ccactgcccc tcagaaccga cttcagc
11371431137DNAArtificial SequenceSynthetic Hu STING(N154S); no
epitope tag; nucleotide sequence 143atgcctcaca gcagcctgca
ccctagcatc ccttgcccta gaggccacgg cgcccagaag 60gccgccctgg tgctgctgag
cgcctgcctg gtgaccctgt ggggcctggg cgagcctcct 120gagcacaccc
tgagatacct ggtgctgcac ctggccagcc tgcagctggg cctgctgctg
180aacggcgtgt gcagcctggc cgaggagctg agacacatcc acagcagata
cagaggcagc 240tactggagaa ccgtgagagc ctgcctgggc tgccctctga
gaagaggcgc cctgctgctg 300ctgagcatct acttctacta cagcctgcct
aacgccgtgg gccctccttt cacctggatg 360ctggccctgc tgggcctgag
ccaggccctg aacatcctgc tgggcctgaa gggcctggcc 420cctgccgaga
tcagcgccgt gtgcgagaag ggcaacttca gcgtggccca cggcctggcc
480tggagctact acatcggcta cctgagactg atcctgcctg agctgcaggc
cagaatcaga 540acctacaacc agcactacaa caacctgctg agaggcgccg
tgagccagag actgtacatc 600ctgctgcctc tggactgcgg cgtgcctgac
aacctgagca tggccgaccc taacatcaga 660ttcctggaca agctgcctca
gcagaccggc gaccacgccg gcatcaagga cagagtgtac 720agcaacagca
tctacgagct gctggagaac ggccagagag ccggcacctg cgtgctggag
780tacgccaccc ctctgcagac cctgttcgcc atgagccagt acagccaggc
cggcttcagc 840agagaggaca gactggagca ggccaagctg ttctgcagaa
ccctggagga catcctggcc 900gacgcccctg agagccagaa caactgcaga
ctgatcgcct accaggagcc tgccgacgac 960agcagcttca gcctgagcca
ggaggtgctg agacacctga gacaggagga gaaggaggag 1020gtgaccgtgg
gcagcctgaa gaccagcgcc gtgcctagca ccagcaccat gagccaggag
1080cctgagctgc tgatcagcgg catggagaag cctctgcctc tgagaaccga cttcagc
11371441137DNAArtificial SequenceSynthetic Hu STING(V147L); no
epitope tag; nucleotide sequence 144atgcctcaca gcagcctgca
ccctagcatc ccttgcccta gaggccacgg cgcccagaag 60gccgccctgg tgctgctgag
cgcctgcctg gtgaccctgt ggggcctggg cgagcctcct 120gagcacaccc
tgagatacct ggtgctgcac ctggccagcc tgcagctggg cctgctgctg
180aacggcgtgt gcagcctggc cgaggagctg agacacatcc acagcagata
cagaggcagc 240tactggagaa ccgtgagagc ctgcctgggc tgccctctga
gaagaggcgc cctgctgctg 300ctgagcatct acttctacta cagcctgcct
aacgccgtgg gccctccttt cacctggatg 360ctggccctgc tgggcctgag
ccaggccctg aacatcctgc tgggcctgaa gggcctggcc 420cctgccgaga
tcagcgccct gtgcgagaag ggcaacttca acgtggccca cggcctggcc
480tggagctact acatcggcta cctgagactg atcctgcctg agctgcaggc
cagaatcaga 540acctacaacc agcactacaa caacctgctg agaggcgccg
tgagccagag actgtacatc 600ctgctgcctc tggactgcgg cgtgcctgac
aacctgagca tggccgaccc taacatcaga 660ttcctggaca agctgcctca
gcagaccggc gaccacgccg gcatcaagga cagagtgtac 720agcaacagca
tctacgagct gctggagaac ggccagagag ccggcacctg cgtgctggag
780tacgccaccc ctctgcagac cctgttcgcc atgagccagt acagccaggc
cggcttcagc 840agagaggaca gactggagca ggccaagctg ttctgcagaa
ccctggagga catcctggcc 900gacgcccctg agagccagaa caactgcaga
ctgatcgcct accaggagcc tgccgacgac 960agcagcttca gcctgagcca
ggaggtgctg agacacctga gacaggagga gaaggaggag 1020gtgaccgtgg
gcagcctgaa gaccagcgcc gtgcctagca ccagcaccat gagccaggag
1080cctgagctgc tgatcagcgg catggagaag cctctgcctc tgagaaccga cttcagc
11371451137DNAArtificial SequenceSynthetic Hu STING (E315Q); no
epitope tag; nucleotide sequence 145atgcctcaca gcagcctgca
ccctagcatc ccttgcccta gaggccacgg cgcccagaag 60gccgccctgg tgctgctgag
cgcctgcctg gtgaccctgt ggggcctggg cgagcctcct 120gagcacaccc
tgagatacct ggtgctgcac ctggccagcc tgcagctggg cctgctgctg
180aacggcgtgt gcagcctggc cgaggagctg agacacatcc acagcagata
cagaggcagc 240tactggagaa ccgtgagagc ctgcctgggc tgccctctga
gaagaggcgc cctgctgctg 300ctgagcatct acttctacta cagcctgcct
aacgccgtgg gccctccttt cacctggatg 360ctggccctgc tgggcctgag
ccaggccctg aacatcctgc tgggcctgaa gggcctggcc 420cctgccgaga
tcagcgccgt gtgcgagaag ggcaacttca acgtggccca cggcctggcc
480tggagctact acatcggcta cctgagactg atcctgcctg agctgcaggc
cagaatcaga 540acctacaacc agcactacaa caacctgctg agaggcgccg
tgagccagag actgtacatc 600ctgctgcctc tggactgcgg cgtgcctgac
aacctgagca tggccgaccc taacatcaga 660ttcctggaca agctgcctca
gcagaccggc gaccacgccg gcatcaagga cagagtgtac 720agcaacagca
tctacgagct gctggagaac ggccagagag ccggcacctg cgtgctggag
780tacgccaccc ctctgcagac cctgttcgcc atgagccagt acagccaggc
cggcttcagc 840agagaggaca gactggagca ggccaagctg ttctgcagaa
ccctggagga catcctggcc 900gacgcccctg agagccagaa caactgcaga
ctgatcgcct accagcagcc tgccgacgac 960agcagcttca gcctgagcca
ggaggtgctg agacacctga gacaggagga gaaggaggag 1020gtgaccgtgg
gcagcctgaa gaccagcgcc gtgcctagca ccagcaccat gagccaggag
1080cctgagctgc tgatcagcgg catggagaag cctctgcctc tgagaaccga cttcagc
11371461137DNAArtificial SequenceSynthetic Hu STING (R375A); no
epitope tag; nucleotide sequence 146atgcctcaca gcagcctgca
ccctagcatc ccttgcccta gaggccacgg cgcccagaag 60gccgccctgg tgctgctgag
cgcctgcctg gtgaccctgt ggggcctggg cgagcctcct 120gagcacaccc
tgagatacct ggtgctgcac ctggccagcc tgcagctggg cctgctgctg
180aacggcgtgt gcagcctggc cgaggagctg agacacatcc acagcagata
cagaggcagc 240tactggagaa ccgtgagagc ctgcctgggc tgccctctga
gaagaggcgc cctgctgctg 300ctgagcatct acttctacta cagcctgcct
aacgccgtgg gccctccttt cacctggatg 360ctggccctgc tgggcctgag
ccaggccctg aacatcctgc tgggcctgaa gggcctggcc 420cctgccgaga
tcagcgccgt gtgcgagaag ggcaacttca acgtggccca cggcctggcc
480tggagctact acatcggcta cctgagactg atcctgcctg agctgcaggc
cagaatcaga 540acctacaacc agcactacaa caacctgctg agaggcgccg
tgagccagag actgtacatc 600ctgctgcctc tggactgcgg cgtgcctgac
aacctgagca tggccgaccc taacatcaga 660ttcctggaca agctgcctca
gcagaccggc gaccacgccg gcatcaagga cagagtgtac 720agcaacagca
tctacgagct gctggagaac ggccagagag ccggcacctg cgtgctggag
780tacgccaccc ctctgcagac cctgttcgcc atgagccagt acagccaggc
cggcttcagc 840agagaggaca gactggagca ggccaagctg ttctgcagaa
ccctggagga catcctggcc 900gacgcccctg agagccagaa caactgcaga
ctgatcgcct accaggagcc tgccgacgac 960agcagcttca gcctgagcca
ggaggtgctg agacacctga gacaggagga gaaggaggag 1020gtgaccgtgg
gcagcctgaa gaccagcgcc gtgcctagca ccagcaccat gagccaggag
1080cctgagctgc tgatcagcgg catggagaag cctctgcctc tggccaccga cttcagc
11371471137DNAArtificial SequenceSynthetic Hu
STING(V147L/N154S/V155M); no epitope tag; nucleotide sequence
147atgcctcaca gcagcctgca ccctagcatc ccttgcccta gaggccacgg
cgcccagaag 60gccgccctgg tgctgctgag cgcctgcctg gtgaccctgt ggggcctggg
cgagcctcct 120gagcacaccc tgagatacct ggtgctgcac ctggccagcc
tgcagctggg cctgctgctg 180aacggcgtgt gcagcctggc cgaggagctg
agacacatcc acagcagata cagaggcagc 240tactggagaa ccgtgagagc
ctgcctgggc tgccctctga gaagaggcgc cctgctgctg 300ctgagcatct
acttctacta cagcctgcct aacgccgtgg gccctccttt cacctggatg
360ctggccctgc tgggcctgag ccaggccctg aacatcctgc tgggcctgaa
gggcctggcc 420cctgccgaga tcagcgccct gtgcgagaag ggcaacttca
gcatggccca cggcctggcc 480tggagctact acatcggcta cctgagactg
atcctgcctg agctgcaggc cagaatcaga 540acctacaacc agcactacaa
caacctgctg agaggcgccg tgagccagag actgtacatc 600ctgctgcctc
tggactgcgg cgtgcctgac aacctgagca tggccgaccc taacatcaga
660ttcctggaca agctgcctca gcagaccggc gaccacgccg gcatcaagga
cagagtgtac 720agcaacagca tctacgagct gctggagaac ggccagagag
ccggcacctg cgtgctggag 780tacgccaccc ctctgcagac cctgttcgcc
atgagccagt acagccaggc cggcttcagc 840agagaggaca gactggagca
ggccaagctg ttctgcagaa ccctggagga catcctggcc 900gacgcccctg
agagccagaa caactgcaga ctgatcgcct accaggagcc tgccgacgac
960agcagcttca gcctgagcca ggaggtgctg agacacctga gacaggagga
gaaggaggag 1020gtgaccgtgg gcagcctgaa gaccagcgcc gtgcctagca
ccagcaccat gagccaggag 1080cctgagctgc tgatcagcgg catggagaag
cctctgcctc tgagaaccga cttcagc 11371481137DNAArtificial
SequenceSynthetic Hu STING(R284M/V147L/N154S/V155M); no epitope
tag; nucleotide sequence 148atgcctcaca gcagcctgca ccctagcatc
ccttgcccta gaggccacgg cgcccagaag 60gccgccctgg tgctgctgag cgcctgcctg
gtgaccctgt ggggcctggg cgagcctcct 120gagcacaccc tgagatacct
ggtgctgcac ctggccagcc tgcagctggg cctgctgctg 180aacggcgtgt
gcagcctggc cgaggagctg agacacatcc acagcagata cagaggcagc
240tactggagaa ccgtgagagc ctgcctgggc tgccctctga gaagaggcgc
cctgctgctg 300ctgagcatct acttctacta cagcctgcct aacgccgtgg
gccctccttt cacctggatg 360ctggccctgc tgggcctgag ccaggccctg
aacatcctgc tgggcctgaa gggcctggcc 420cctgccgaga tcagcgccct
gtgcgagaag ggcaacttca gcatggccca cggcctggcc 480tggagctact
acatcggcta cctgagactg atcctgcctg agctgcaggc cagaatcaga
540acctacaacc agcactacaa caacctgctg agaggcgccg tgagccagag
actgtacatc 600ctgctgcctc tggactgcgg cgtgcctgac aacctgagca
tggccgaccc taacatcaga 660ttcctggaca agctgcctca gcagaccggc
gaccacgccg gcatcaagga cagagtgtac 720agcaacagca tctacgagct
gctggagaac ggccagagag ccggcacctg cgtgctggag 780tacgccaccc
ctctgcagac cctgttcgcc atgagccagt acagccaggc cggcttcagc
840agagaggaca tgctggagca ggccaagctg ttctgcagaa ccctggagga
catcctggcc 900gacgcccctg agagccagaa caactgcaga ctgatcgcct
accaggagcc tgccgacgac 960agcagcttca gcctgagcca ggaggtgctg
agacacctga gacaggagga gaaggaggag 1020gtgaccgtgg gcagcctgaa
gaccagcgcc gtgcctagca ccagcaccat gagccaggag 1080cctgagctgc
tgatcagcgg catggagaag cctctgcctc tgagaaccga cttcagc
1137149141DNAArtificial SequenceSynthetic 3 UTR used in STING V155M
construct, containing miR122 binding site 149tgataatagg ctggagcctc
ggtggcctag cttcttgccc cttgggcctc cccccagccc 60ctcctcccct tcctgcaccc
gtacccccca aacaccattg tcacactcca gtggtctttg 120aataaagtct
gagtgggcgg c 1411501257DNAMus musculusmisc_feature(1)..(1257)super
mouse IRF3 S396D; no epitope tag 150atggagaccc ccaagcctag
aatcctgccc tggctggtga gccagctgga cctgggccag 60ctggagggcg tagcctggct
ggacgagagc agaaccagat tcagaatccc ctggaagcac 120ggcctgagac
aagacgccca gatggccgac ttcggcatct tccaggcctg ggccgaggcc
180agcggcgcct acacccctgg caaggataag cccgatgtga gcacctggaa
gagaaacttc 240agaagcgccc tgaacagaaa ggaggtgctg agactggccg
ccgacaatag caaggacccc 300tacgaccccc acaaggtgta cgagttcgtt
acccccggcg ccagggactt cgtgcacctg 360ggcgccagcc ccgacaccaa
cggcaagagc agcctgcccc acagccagga gaacctgccc 420aagctgttcg
atggcctgat cctgggcccc ctgaaggacg agggcagcag cgacctggcc
480atcgtgagcg accctagcca gcagctgccc tcccccaacg tgaacaactt
cctgaacccc 540gccccccagg agaaccccct gaagcaactg ctggccgagg
agcagtggga gttcgaggtg 600accgccttct acagaggcag acaggtgttc
cagcagaccc tgttctgccc cggcggcctg 660agactggtag gcagcaccgc
tgacatgacc ctgccctggc agcccgtgac cctgcccgac 720cccgaaggct
ttctgaccga caagctggtg aaggagtacg tcggccaagt gctgaagggc
780ctgggcaacg gcctggccct gtggcaggcc ggccagtgcc tgtgggccca
gagactcggc 840cacagccacg ccttctgggc cctgggcgag gaactcctgc
ccgatagcgg cagaggcccc 900gacggcgagg tgcacaagga caaggacggc
gccgtgttcg acctgcgccc cttcgtggcc 960gacctgatcg ccttcatgga
gggcagcggc cacagcccca gatataccct gtggttctgc 1020atgggcgaga
tgtggcccca ggaccagccc tgggtgaaga gactggtgat ggtgaaggtg
1080gtgcccacct gcctgaaaga gctgctggag atggccagag agggcggcgc
cagctccctg 1140aaaaccgtgg acctgcacat tgacaacagc cagcccatca
gcctgaccag cgaccagtac 1200aaggcctacc tgcaggacct ggtggaggac
atggacttcc aggccaccgg caacatc 12571511281DNAHomo
sapiensmisc_feature(1)..(1281)super human IRF3 S396D; no epitope
tag 151atgggcaccc ccaagcccag aatcctgccc tggctggtga gccagctgga
cctgggccag 60ctggagggag tggcctgggt gaacaagagc agaaccagat tcagaatccc
ctggaagcac 120ggcctcagac aggacgccca gcaggaggac ttcggcattt
ttcaggcttg ggccgaggcc 180accggcgcct acgtgcccgg cagagacaag
cccgacctgc ccacctggaa aagaaacttc 240agaagcgcct tgaatagaaa
ggagggcctg agactggccg aggacagaag caaggacccc 300cacgaccctc
acaagatcta cgagttcgtg aatagcggcg tgggcgactt tagccagccc
360gacaccagcc ccgacaccaa cggcggcggc agcaccagcg acacgcagga
ggacatcctg 420gatgaactgc tgggcaacat ggtgctggcc cccctgcccg
atcccggccc cccttcgctt 480gccgtggccc ccgagccctg cccccagccc
ctgagaagcc cctctctgga taaccccacc 540cccttcccca acctgggccc
cagcgagaat ccactgaaga gacttctggt ccccggcgag 600gagtgggagt
tcgaggtgac cgccttctac agaggcagac aggtgttcca gcagaccatc
660agctgccccg aaggcctgag attagtgggc agcgaagtgg gcgacaggac
cctgcccggg 720tggcccgtga ccctgcccga tcccggcatg agcctgaccg
acagaggtgt gatgagctac 780gtgagacacg tgctgagctg cctgggcggc
ggcctggcac tgtggagagc cggccagtgg 840ctgtgggccc agagactggg
ccactgccac acctactggg ccgtgagcga ggagctgctg 900cccaacagcg
gccacggccc cgacggcgag gtgcccaagg acaaggaagg gggcgtgttc
960gacctgggcc ccttcatcgt agacctgatc acctttaccg agggcagcgg
caggagcccc 1020agatacgccc tgtggttctg cgtgggcgaa agctggcccc
aggaccagcc ctggaccaag 1080agactggtga tggtgaaggt agtgcccacc
tgcctgagag ccttagtgga gatggccaga 1140gtgggcgggg ccagcagcct
ggagaacacc gtggatcttc acatcgacaa cagccacccc 1200ctgagcctga
ccagcgacca gtacaaggcc tacctgcagg acctggtgga gggcatggac
1260ttccagggcc ccggcgagac c 12811521509DNAArtificial
SequenceSynthetic Wild-type Hu IRF7 isoform A; P037 without epitope
tag 152atggcgctgg cccccgaaag agccgccccc agagtcctct tcggcgaatg
gctccttggc 60gaaatttcgt cgggctgcta cgagggctta caatggctgg atgaggcgag
aacctgtttc 120agggtgccct ggaaacactt cgccagaaag gatctaagcg
aagcagatgc tagaattttt 180aaggcttggg ccgtggccag gggaagatgg
cccccctcga gcagaggcgg cggccctccc 240cccgaggcag aaacggccga
gagagccgga tggaaaacca atttcagatg cgccctgaga 300tctacaagaa
gattcgtgat gcttagagac aacagcggag atcccgccga tccccataag
360gtgtatgccc tgtcccggga gctgtgctgg agggaagggc ctggcactga
ccagaccgaa 420gccgaagccc ccgcggccgt gccgccgccc caaggaggcc
caccaggccc tttcctcgct 480cacacccacg ccggtctgca agccccggga
cctctacctg cccctgccgg cgataaaggc 540gacctgttgc tgcaggccgt
ccaacagagc tgcctggccg atcatctgct cacagccagc 600tggggcgctg
accccgtccc aacaaaggcc cccggtgagg gccaagaagg cctgcctctg
660accggcgcct gtgccggcgg ccctggcctg cctgctggcg agctgtacgg
atgggctgtc 720gaaaccactc cctcccccgg cccccaacct gcggccctga
caaccggcga ggcagccgca 780cccgaaagcc cccaccaggc cgaaccctac
ctcagtccca gcccctccgc ctgcaccgct 840gtgcaggagc ccagccccgg
tgctctggac gtaacaatca tgtacaaagg cagaaccgtg 900cttcagaagg
tggttggaca cccctcctgt acttttctct acggcccccc cgaccctgcc
960gtgagagcta ccgacccgca acaggtggcc tttccctcgc ccgccgaact
gcccgatcaa 1020aaacagctga gatacaccga ggagctgctg agacacgtgg
cgccgggctt acacctagag 1080ttgagaggcc cccaactctg ggccagacgc
atgggcaagt gtaaggtgta ctgggaggtc 1140gggggccctc ccggctctgc
cagccccagc acccctgctt gtctcttgcc cagaaactgt 1200gataccccca
tcttcgactt ccgtgtattt ttccaggaac tggtcgagtt tagagccaga
1260cagagacgag gcagccccag atatacaatc tacctcggct tcggccagga
cctgagtgcc 1320ggcagaccta aggagaagtc gctggtccta gtgaagttag
agccctggct atgtagagtg 1380cacctggagg gcacccagag agaaggagtg
agcagcctgg acagcagcag cctgagtctg 1440tgcctgagct ccgccaactc
gctgtatgat gacatcgagt gtttcctcat ggagctggag 1500cagcccgcc
15091531509DNAArtificial SequenceSynthetic constitutively active Hu
IRF7 S477D/S479D; P033 without epitope tag 153atggcccttg cccctgagcg
ggccgccccc agagtgttat tcggcgagtg gctgctgggc 60gagatcagca gcggctgcta
cgagggactg cagtggctgg acgaggctag aacctgcttc 120agagtgccct
ggaagcattt cgccagaaaa gacctgagcg aggctgatgc tagaatcttc
180aaagcctggg ctgtggcccg aggaagatgg ccccccagca gcagaggagg
cggccctcct 240cccgaggccg aaaccgcaga gcgtgctggc tggaaaacca
actttaggtg tgccctgagg 300agcaccagaa gattcgttat gctcagagac
aacagcgggg accccgccga cccgcacaag 360gtgtacgcct taagtaggga
gctgtgctgg agagagggac cggggaccga ccaaaccgag 420gctgaggcgc
ccgccgccgt tccacctccc cagggtggtc ccccagggcc ctttctggca
480cacacccacg ccggattaca ggcgccaggg cccttacccg cccccgccgg
agacaaaggc 540gacctcctgc tgcaagccgt gcaacaaagc tgcctggccg
atcacttact aaccgctagc 600tggggcgccg atcctgttcc caccaaggcc
cccggtgaag ggcaagaagg actgccctta 660accggcgcct gtgccggagg
ccctggtctg ccagccggcg agctgtacgg ttgggctgtc 720gaaacaacac
ccagtccggg cccacagcct gccgctctga ccaccggcga agccgccgcc
780cccgagagcc cacaccaggc tgaaccctac ctgagcccca gccccagcgc
ctgcaccgct 840gtgcaggagc ctagccccgg cgctcttgat gtgacaataa
tgtacaaggg caggaccgtg 900ctgcaaaagg tcgtgggcca tccgtcgtgt
acctttctgt acggccctcc agaccccgcg 960gttagagcca ccgaccccca
gcaagtcgcc ttcccctccc ccgccgaact gcccgaccaa 1020aagcagctgc
ggtacacaga agaactactt agacacgtgg cccccggtct gcacttggag
1080ctgagaggcc cccagctctg ggccagaaga atgggcaagt gcaaagtgta
ctgggaggtg 1140ggcggcccac ccggctcagc ttcgccctcc acacccgcat
gcctgctgcc cagaaattgc 1200gacacgccca tcttcgattt tagagtgttc
tttcaggagt tggtggagtt cagagccaga 1260caaagacgcg gcagccccag
atacaccatt tacctcggct tcggccagga cctcagcgct 1320ggcagaccca
aggagaagag tctggtcctc gtgaagctgg agccctggct gtgcagagtg
1380cacctggagg gcacccagcg tgaaggcgtg agcagcctgg attcaagcga
cctggaccta 1440tgcctaagca gcgctaactc actgtacgac gatatcgaat
gcttcctgat ggaactggag 1500cagcctgcc 15091541509DNAArtificial
SequenceSynthetic constitutively active Hu IRF7 S475D/S477D/L480D;
P034 without epitope tag 154atggccctgg cacccgagag ggccgccccc
agggtgctct tcggcgagtg gttactaggc 60gaaattagca gcggctgcta tgaaggcctt
cagtggctgg acgaggccag aacctgcttt 120agagttccct ggaagcactt
cgcccggaaa gatctctctg aagccgacgc
cagaatattc 180aaggcctggg ctgtcgccag gggcaggtgg ccaccctcca
gccgaggtgg cggccctccc 240cctgaggctg agactgcgga aagggcgggc
tggaagacca atttcagatg cgctctgaga 300agcaccagac gttttgtgat
gctaagagac aatagcggcg atcccgccga cccccataag 360gtatacgcac
tgagccgaga gctctgttgg agagaaggcc ccggcaccga ccagaccgag
420gctgaagccc ctgcagccgt gcccccccct caaggcgggc cccccggccc
cttcctggcc 480catacccatg cagggttaca agcacccggg cccttgcccg
ccccagcggg agacaagggc 540gacctcttac tgcaggccgt gcaacaaagt
tgtctggcgg accacctgct gaccgcatca 600tggggcgcgg atcctgtgcc
caccaaggca cccggcgaag gccaggaggg cctgcccttg 660accggcgcct
gcgctggcgg acccggccta cctgctggcg aactgtatgg ctgggccgta
720gagacgactc ccagccctgg cccacaaccc gcggctttga ccaccggcga
agccgccgcc 780cccgagtctc cgcaccaggc cgagccttac ctcagcccaa
gccctagcgc ctgcaccgcc 840gtgcaagaac ctagccccgg agccctggat
gtgacaatca tgtacaaggg tagaaccgta 900ctgcaaaagg tggtgggtca
tcccagctgc acctttcttt acggcccacc cgaccctgcc 960gtgcgagcca
cagacccaca acaggtcgcc ttcccaagcc ccgccgaact gcccgatcag
1020aaacagctga gatatacaga ggagcttctg cggcacgtag ctcccggcct
acatctcgag 1080ctgaggggcc cacaactgtg ggccagacgc atgggcaaat
gcaaggtcta ctgggaagtg 1140ggaggccccc ccggcagcgc atctcccagc
acgcccgcgt gcctgctgcc tagaaattgc 1200gacaccccca tctttgactt
ccgggtattc tttcaggagc tggtagagtt cagagccagg 1260cagcggaggg
gctcccccag atacacaatc tacctgggct tcggacagga cctgtccgcc
1320ggccgcccca aggaaaagag cctggtgctg gtgaagctgg agccctggct
gtgtagggta 1380cacctcgaag gcacccagag agaaggagtg agctcgcttg
atgacagcga tctgtcggat 1440tgccttagca gcgccaacag cctgtatgat
gatatcgagt gcttccttat ggaactggag 1500cagcccgcc
15091551509DNAArtificial SequenceSynthetic constitutively active Hu
IRF7 S475D/S476D/S477D/S479D/S483D/S487D; P035 without epitope tag
155atggccctag cccccgaaag agcagctccc agagtgctgt tcggcgaatg
gctgcttggc 60gagatcagca gcggctgcta cgaaggcctg cagtggctgg acgaagcccg
cacctgtttc 120agagtgccct ggaagcactt cgctagaaag gatttgagcg
aggctgatgc tagaatcttt 180aaggcttggg ctgtggcaag aggcagatgg
ccgcctagta gcagaggggg cggacctccc 240cccgaggctg agaccgctga
gagagcaggg tggaaaacca acttcagatg cgcgctgaga 300agcacccgaa
gattcgtgat gctacgtgac aatagcggcg accccgccga cccccacaaa
360gtgtacgccc tgtcccgaga actttgctgg agagagggac ccggcaccga
tcaaacagag 420gctgaggccc cggccgctgt acccccgccc caaggaggcc
ccccaggccc ctttctggct 480catacacatg ccggcctgca ggcacccggg
cccctcccgg ctcctgccgg cgacaagggc 540gatctccttc tccaggccgt
gcagcagagc tgcctggccg atcacctgct gaccgcctcg 600tggggcgccg
accccgtgcc caccaaagcc ccgggtgaag gccaagaggg gctcccttta
660accggagcat gcgccggagg ccccggcctg ccagccggcg agttatatgg
ctgggctgtg 720gagaccacac cctcccccgg ccctcaaccc gctgccctga
ccaccggtga ggccgccgcc 780cccgagagcc cacaccaggc cgaaccctac
ctgagcccta gccctagcgc ctgcaccgcc 840gtgcaagaac ccagccccgg
agccctggat gtgaccatta tgtacaaggg ccggacagtg 900ctgcaaaagg
ttgtgggaca cccgagctgc acctttctgt acggtccgcc tgaccccgcc
960gtgagagcca cggacccgca gcaggtggcc ttcccctcac ccgcggagct
gcccgaccaa 1020aagcaactca gatacacaga agaactattg cgtcacgtcg
cgcccggcct gcatctggag 1080ctgagaggcc cccagctctg ggccagaagg
atgggcaaat gcaaggtgta ctgggaggtg 1140ggaggccccc ccggcagcgc
cagccccagc actcccgcgt gcctgctgcc cagaaattgc 1200gacactccca
tcttcgattt cagggtgttc ttccaggagc tggtggagtt cagagccagg
1260cagagaaggg gtagccccag atacacaatc tatctaggct ttggacaaga
tctgagcgcc 1320ggccggccta aggaaaaaag cctggtgctg gtaaagctgg
agccgtggct ttgtagagtg 1380cacctggagg ggacgcagcg agagggcgtg
agcagcttag acgacgatga cttggatctg 1440tgtctcgaca gcgccaacga
cttgtacgac gacatcgagt gcttcctgat ggaactggag 1500cagcccgcc
1509156846DNAArtificial SequenceSynthetic constitutively active
truncated Hu IRF7 1-246 + 468-503; P032 without epitope tag
156atggccctgg cccccgagag agccgccccc agagtgctct tcggcgagtg
gctgctgggc 60gagataagca gcggctgcta cgaaggtctg cagtggctag acgaggccag
aacctgcttt 120agagtgccct ggaagcactt cgctcgaaag gacctgtccg
aggccgatgc tagaattttt 180aaggcttggg ccgtcgctag gggaagatgg
ccccctagca gtagaggcgg cggcccccct 240cccgaagccg agacggccga
gagggccggc tggaaaacca atttcagatg cgccctgagg 300agcacccgca
ggttcgtaat gctgcgagac aatagcggcg atcctgcgga tcctcacaag
360gtttacgcct tgagtagaga actgtgctgg cgggagggcc ccggaaccga
ccagacggag 420gcagaggcac ccgctgccgt gcccccccct caaggaggac
cccctggacc ctttctggcc 480cacacccacg ctggtctgca ggccccaggc
ccactgcccg ccccagcggg cgataagggt 540gacctgctcc tacaggcggt
gcaacagagc tgtctggccg accacctgtt gaccgccagc 600tggggggccg
acccggtgcc caccaaagct cccggagagg gccaagaagg cctcccacta
660actggcgcct gcgccggggg cccgggatta cccgccggcg agctgtatgg
ctgggccgtg 720gagaccacgc ccagccccga gggcgtgtcg tccctggaca
gcagcagcct gagcctgtgc 780ctgagctccg ccaacagcct gtatgacgac
atcgagtgct tcctgatgga gctggaacaa 840cccgcc 846157846DNAArtificial
SequenceSynthetic constitutively active truncated Hu IRF7 1-246 +
468-503 plus S475D/S476D/S477D/S479D/S483D/S487D; P036 without
epitope tag 157atggcactgg cgcctgaaag agccgctccg cgtgtgctct
tcggcgagtg gctgctgggc 60gagatcagct ccggctgcta cgagggtcta cagtggctgg
acgaggccag aacctgtttt 120agagtgccct ggaagcactt cgcgagaaag
gacctgagcg aggccgacgc cagaatcttc 180aaagcctggg cagtggctag
gggcagatgg cctcccagca gccggggcgg cggcccaccc 240cccgaggccg
aaaccgccga aagagctggc tggaagacca acttcagatg cgccctgaga
300agcaccagaa gatttgtcat gctgagagat aattcaggag accccgccga
ccctcacaag 360gtgtacgccc tgtccagaga gctgtgttgg agagagggcc
ccggaaccga ccagaccgag 420gccgaggctc cagctgccgt gccacccccc
caaggcggac cacccggccc cttcttggca 480catacgcacg ccggcctcca
ggctcccggc cctctgcccg cccctgctgg tgacaaaggc 540gatctgctgc
tgcaagccgt ccagcaatcc tgcttggctg accacctgct gaccgctagc
600tggggagccg accccgttcc caccaaggct cccggagaag gacaggaggg
cctgcccctt 660accggcgctt gcgcgggggg ccctggcttg cctgccggcg
aactgtacgg ctgggccgtg 720gagaccacgc cttcccccga gggcgtgtcc
agcctggacg atgatgacct ggatctgtgc 780ctggacagcg ccaacgacct
gtacgatgac atcgagtgct ttttgatgga gctggagcag 840cccgcc
8461581224DNAArtificial SequenceSynthetic truncated Hu IRF7 1-151 +
247-503; P038 without epitope tag; null mutation 158atggccctgg
cccccgagag agccgcgccc agagtgctgt tcggcgaatg gctgctgggc 60gagatcagca
gcggctgcta tgagggcctg cagtggctcg acgaagccag gacgtgcttc
120agagtcccct ggaagcactt cgccagaaag gatctgagcg aggctgacgc
cagaatcttc 180aaggcctggg cagttgcgcg tgggagatgg ccccccagct
cgcggggcgg cggtcccccc 240cctgaggccg agaccgccga aagagccgga
tggaaaacca actttcgatg cgccctcaga 300agcaccagac ggtttgtgat
gctgagagat aacagcggcg accctgcaga cccccataaa 360gtgtatgccc
tgagcagaga gctgtgttgg cgagagggcc ccggaaccga ccaaaccgag
420gccgaggccc ccgccgccgt acccccccct caaggccccc agcctgctgc
tctgaccacg 480ggagaagccg ccgctcctga gagcccccac caagccgagc
cctatctgag ccctagcccc 540agcgcctgca ccgccgtgca ggagccctca
ccgggcgccc tagacgtgac catcatgtac 600aaggggcgca cggtgctgca
aaaggtggtg ggccacccca gctgcacctt cctgtacggc 660ccccccgacc
ctgccgtgag agccaccgac ccccagcaag tcgccttccc cagccccgcc
720gagctgcccg accagaagca gctgaggtac accgaggagt tgctgagaca
tgtggccccc 780ggcttgcacc tcgagctgag aggcccgcag ctctgggcca
gaagaatggg caagtgcaag 840gtgtactggg aggtgggcgg cccccccggc
agcgcgagcc caagcacccc ggcctgcctg 900ctgcctagaa actgcgacac
ccctatcttc gacttcagag tatttttcca ggagctggtc 960gagttcaggg
ccagacagcg tagaggcagc cccagataca ccatctacct tggattcggc
1020caggacctga gcgccggcag acccaaagag aagtccctgg tactggtgaa
gctagagccc 1080tggctgtgta gggtgcatct ggaaggcacc caaagagagg
gcgtaagctc gcttgacagc 1140agcagcctca gcctgtgcct gagcagcgct
aacagcttat acgacgacat cgagtgcttc 1200ctgatggagc tggaacaacc cgcc
12241591059DNAArtificial SequenceSynthetic truncated Hu IRF7
152-503; P039 without epitope tag; null mutation 159atgggcggcc
ctcccgggcc tttcctggcc catacacacg ccggcctaca ggctcctggc 60cctctgcccg
ccccggccgg cgacaagggc gacctcctgc tgcaggccgt gcagcagtcc
120tgtctggccg accacctgct gactgctagc tggggcgccg atcccgtgcc
caccaaggcc 180ccaggagagg ggcaagaggg cctgcctcta accggcgcat
gcgcaggtgg accaggcctc 240cccgccggcg agctgtatgg ttgggccgtg
gagacaaccc ccagccccgg cccgcagcct 300gctgcgctga ccacaggcga
ggccgctgcc cctgagagcc cccaccaagc tgaaccctac 360ctgagcccca
gcccctctgc ctgcacagcg gtgcaggagc ccagtcccgg cgccttggac
420gtgaccatca tgtataaggg caggactgtg ttacaaaagg tagtgggcca
cccaagttgt 480acctttctgt acgggccccc cgacccagcc gtgcgcgcca
ccgaccccca gcaggtggcc 540ttccccagcc ccgctgagtt gcccgatcag
aaacaactcc ggtacaccga ggaattactt 600agacatgtgg ctcccggcct
gcatctggag cttagaggtc cacagttgtg ggccagaaga 660atgggcaagt
gcaaggttta ttgggaggtc ggaggccccc cgggcagcgc cagccccagc
720acccccgcct gtcttctgcc cagaaactgc gacaccccaa tcttcgattt
cagagtgttt 780ttccaggaac tggtggagtt cagagcaagg caaagaagag
gcagccctag atacaccatc 840tacctgggct ttggccaaga cctgagcgcc
ggcagaccca aggaaaaatc cctggtcctg 900gtgaaactgg agccctggct
gtgcagagtc cacctggagg gcacccagag agagggcgtg 960agcagcctgg
actcgagcag cctgtccctg tgtctgagca gcgcgaattc gctatatgac
1020gacatcgaat gctttctgat ggagctggaa cagcccgcc
10591601269DNAArtificial SequenceSynthetic
KRAS(G12D)25mer_nt.STING(V155M) 160atgcctcaca gcagcctcca ccctagcatc
ccttgcccta gaggccacgg cgcccagaag 60gccgccctcg tgcttttaag cgcctgcttg
gtgacccttt ggggcttggg cgagcctcca 120gagcacacct tgagatattt
ggtgctccac ctggccagcc ttcagctggg cttgttactc 180aacggcgtgt
gcagcctggc cgaggagctg agacacatcc acagcagata cagaggcagc
240tactggagaa ccgtgagagc gtgtctgggc tgccctctga gaagaggcgc
cttgcttctt 300ctcagtatct acttctacta ctccctgcct aacgccgtgg
gccctccttt cacctggatg 360ctggcactgc tcggcctcag ccaggccctg
aacatcttgt tgggcttgaa gggcctggcc 420cctgccgaga tcagcgccgt
gtgcgagaag ggcaacttca acatggccca cggattggct 480tggagctact
acatcggcta cctgagactg atcctgcctg agctgcaggc cagaatcaga
540acctacaacc agcactacaa caacctgctg cgcggcgcag tgagccagag
actgtatatt 600ctgctgcctc tggactgcgg cgtgcctgac aacctgagca
tggccgaccc taacatcaga 660ttcctggaca agctgcctca gcagaccggc
gaccacgccg gcatcaagga cagagtgtac 720agcaacagca tctatgagct
gctcgagaat ggccagagag ccggcacctg cgtgctggag 780tacgccaccc
ctctgcagac cctgttcgcc atgagccagt atagtcaagc tggcttcagc
840agagaggaca gactggagca ggccaagctg ttctgcagaa ccctggagga
cattctggct 900gacgcccctg agagccagaa caactgccga ctgatcgcct
accaggaacc agccgacgac 960agcagcttca gtctttctca ggaggttctt
cgccacttgc gccaggagga gaaggaggag 1020gtgaccgtgg gcagcctgaa
gacctccgca gtccctagca ccagcaccat gagtcaggag 1080ccggagctat
taatcagcgg catggagaag cctcttccac tccgaaccga cttcagcgcc
1140accaacttca gcctgctgaa gcaggcaggt gacgttgagg agaatccggg
acctatgacc 1200gagtacaagc tggtggttgt gggcgccgac ggcgtgggca
agagcgccct gaccatccag 1260ctgatccag 12691611269DNAArtificial
SequenceSynthetic KRAS(G12D)25mer_ct.STING(V155M) 161atgaccgagt
acaagctagt agtcgtgggc gccgacggcg tgggcaagag cgccctcacc 60atccagctaa
tccaggccac caacttcagc ttgctcaagc aggccggcga cgtggaggag
120aacccaggcc ctatgcctca cagcagcctt caccctagca tcccttgccc
tagaggccac 180ggcgcccaga aggccgccct ggtgctgctg agcgcctgcc
tggtgaccct gtggggcctg 240ggcgagcctc ctgagcacac cctgagatat
ctggtgcttc acctggccag tttacagctg 300ggcctgcttc ttaacggcgt
gtgcagcctg gccgaggagc tgagacacat ccacagcaga 360tacagaggca
gctactggag aaccgtgaga gcctgcctag gctgccctct gagaagaggc
420gctctgttgc tactttccat ctacttctac tactccctgc ctaacgccgt
gggccctcct 480ttcacttgga tgctggcgtt gctgggtctg agccaggccc
tgaacatcct tctcggtctg 540aagggcctgg cccctgccga gatcagcgcc
gtgtgcgaga agggcaactt caacatggcc 600cacggactcg cctggagcta
ctacatcggc tacctgagac tgatcctgcc tgagctgcag 660gccagaatca
gaacctacaa ccagcactac aacaacctgc tgcggggcgc cgtgagccag
720agactgtata tacttcttcc tctggactgc ggcgtgcctg acaacctgag
catggccgac 780cctaacatca gattcctgga caagctgcct cagcagaccg
gcgaccacgc cggcatcaag 840gacagagtgt acagcaactc catttatgag
ctgctcgaga atggccagag agccggcacc 900tgcgtgctgg agtacgccac
ccctctgcag accctgttcg ccatgagcca gtacagtcag 960gctggattca
gcagagagga cagactggag caggccaagc tgttctgcag gacactggag
1020gacatactag cagacgcccc tgagagccag aacaactgca gactgattgc
ctaccaggag 1080cctgcggacg acagctcctt cagtctgagt caggaggtgt
tgcggcactt acgccaagaa 1140gagaaggagg aggtgaccgt gggcagcctg
aagactagcg ctgtgcctag caccagcaca 1200atgtcacagg agccggaatt
gctaatcagc ggcatggaga agcctctccc attacgtacc 1260gacttcagc
12691621419DNAArtificial SequenceSynthetic
KRAS(G12D)25mer^3_nt.STING(V155M) 162atgcctcaca gcagccttca
ccctagcatc ccttgcccta gaggccacgg cgcccagaag 60gccgccctag tgctccttag
cgcctgcctc gtgaccctat ggggcttagg cgagcctcca 120gagcacacct
tgagatacct cgtcctccac ctggctagtc tacagctggg ccttctcctc
180aacggcgtgt gcagcctggc cgaggagctg agacacatcc acagcagata
cagaggcagc 240tactggagaa ccgtgagagc gtgcctgggc tgccctctga
gaagaggcgc actgctgtta 300ctcagcatct acttctacta ctcactgcca
aacgccgtgg gccctccttt cacctggatg 360ctggccttgc tcggattgag
ccaggccctg aacattttac tgggattgaa gggcctggcc 420cctgccgaga
tcagcgccgt gtgcgagaag ggcaacttca acatggccca cggcctagct
480tggagctact acatcggcta cctgagactg atcctgcctg agctgcaggc
cagaatcaga 540acctacaacc agcactacaa caacctgctg cgtggagcgg
tgagccagag actgtatatc 600ctcctgcctc tggactgcgg agtgcctgac
aacctgagca tggccgaccc taacatcaga 660ttcctggaca agctgcctca
gcagaccggc gaccacgccg gcatcaagga cagagtgtac 720agcaactcaa
tctacgagct gttggagaat ggccagagag ccggcacctg cgtgctggag
780tacgccaccc ctctgcagac cctgttcgcc atgagccagt actctcaggc
aggcttcagc 840agagaggaca gactggagca ggccaagctg ttctgcagaa
ccctggagga catcctggcg 900gacgcccctg agagccagaa caactgccgg
cttatcgcct accaggagcc agcagacgac 960agcagcttct ctctctcaca
agaggtactg cgccatcttc gccaggagga gaaggaggag 1020gtgaccgtgg
gcagcctgaa gacatccgcc gtacctagca ccagcaccat gtctcaggaa
1080ccggaactgt tgatcagcgg catggagaag cctctgccac tgcgcaccga
cttcagcgcc 1140accaacttct ccctactgaa gcaagccggt gacgttgaag
agaaccctgg ccctatgacc 1200gagtacaagc tggtagtagt aggcgccgac
ggcgtgggca agagcgccct gaccatccag 1260ctgatccaga tgactgaata
taagcttgtc gtcgtgggcg cagatggcgt tggtaagagc 1320gcacttacaa
ttcaactcat tcagatgacg gagtataagc tggtggtggt cggagctgac
1380ggcgtaggca agagtgccct tactattcag ctaattcag
14191631419DNAArtificial SequenceSynthetic
KRAS(G12D)25mer^3_ct.STING(V155M) 163atgaccgagt acaagcttgt
ggtggttggc gccgacggcg tgggcaagag cgccttaacc 60atccagctta tccagatgac
agagtataag ctagtggtgg tcggcgcaga cggagtggga 120aagagtgcat
taactattca actcatccaa atgaccgaat acaagctagt agttgtgggt
180gcagatggcg tcggcaagtc tgcactgaca attcagctca tccaggccac
caacttcagc 240ctgctgaagc aggccggcga cgtggaggag aaccctggcc
ctatgcctca cagcagcctg 300caccctagca tcccttgccc tagaggccac
ggcgcccaga aggccgccct ggtgctgctg 360agcgcctgcc tggtgaccct
gtggggcctg ggcgagcctc ctgagcacac cctgagatac 420ctagttttgc
acctggcttc tctgcagctg ggcctactgc tcaacggcgt gtgcagcctg
480gccgaggagc tgagacacat ccacagcaga tacagaggca gctactggag
aaccgtgaga 540gcatgcttag gctgccctct gagaagaggc gctctgctcc
tcttgtccat ctacttctac 600tactcgctac ctaacgccgt gggccctcct
ttcacctgga tgctggccct cttgggatta 660agccaggccc tgaacatctt
gctgggactg aagggcctgg cccctgccga gatcagcgcc 720gtgtgcgaga
agggcaactt caacatggcc cacggactcg cttggagcta ctacatcggc
780tacctgagac tgatcctgcc tgagctgcag gccagaatca gaacctacaa
ccagcactac 840aacaacctgc tgcggggagc agtgagccag agactgtata
ttctgctccc tctggactgc 900ggcgtgcctg acaacctgag catggccgac
cctaacatca gattcctgga caagctgcct 960cagcagaccg gcgaccacgc
cggcatcaag gacagagtgt acagcaacag catttacgag 1020ctgctggaga
acggccagag agccggcacc tgcgtgctgg agtacgccac ccctctgcag
1080accctgttcg ccatgagcca gtactcccag gcaggattca gcagagagga
cagactggag 1140caggccaagc tgttctgccg tactcttgag gacatccttg
cagacgcccc tgagagccag 1200aacaactgcc ggttgattgc ctaccaggaa
ccggcagacg acagctcatt ctccttgtct 1260caggaggtcc ttagacacct
gcggcaggag gagaaggagg aggtgaccgt gggcagcctg 1320aagacatccg
ccgtgcctag cacgtctacc atgtcccagg agccggaact gctaatcagc
1380ggcatggaga agcctctgcc tctcaggacc gacttcagc
1419164380PRTArtificial SequenceSynthetic Hu STING (R284K) var; no
epitope tag 164Met Pro His Ser Ser Leu His Pro Ser Ile Pro Cys Pro
Arg Gly His1 5 10 15Gly Ala Gln Lys Ala Ala Leu Val Leu Leu Ser Ala
Cys Leu Val Thr 20 25 30Leu Trp Gly Leu Gly Glu Pro Pro Glu His Thr
Leu Arg Tyr Leu Val 35 40 45Leu His Leu Ala Ser Leu Gln Leu Gly Leu
Leu Leu Asn Gly Val Cys 50 55 60Ser Leu Ala Glu Glu Leu Arg His Ile
His Ser Arg Tyr Arg Gly Ser65 70 75 80Tyr Trp Arg Thr Val Arg Ala
Cys Leu Gly Cys Pro Leu Arg Arg Gly 85 90 95Ala Leu Leu Leu Leu Ser
Ile Tyr Phe Tyr Tyr Ser Leu Pro Asn Ala 100 105 110Val Gly Pro Pro
Phe Thr Trp Met Leu Ala Leu Leu Gly Leu Ser Gln 115 120 125Ala Leu
Asn Ile Leu Leu Gly Leu Lys Gly Leu Ala Pro Ala Glu Ile 130 135
140Ser Ala Val Cys Glu Lys Gly Asn Phe Asn Val Ala His Gly Leu
Ala145 150 155 160Trp Ser Tyr Tyr Ile Gly Tyr Leu Arg Leu Ile Leu
Pro Glu Leu Gln 165 170 175Ala Arg Ile Arg Thr Tyr Asn Gln His Tyr
Asn Asn Leu Leu Arg Gly 180 185 190Ala Val Ser Gln Arg Leu Tyr Ile
Leu Leu Pro Leu Asp Cys Gly Val 195 200 205Pro Asp Asn Leu Ser Met
Ala Asp Pro Asn Ile Arg Phe Leu Asp Lys 210 215 220Leu Pro Gln Gln
Thr Gly Asp His Ala Gly Ile Lys Asp Arg Val Tyr225 230
235 240Ser Asn Ser Ile Tyr Glu Leu Leu Glu Asn Gly Gln Arg Ala Gly
Thr 245 250 255Cys Val Leu Glu Tyr Ala Thr Pro Leu Gln Thr Leu Phe
Ala Met Ser 260 265 270Gln Tyr Ser Gln Ala Gly Phe Ser Arg Glu Asp
Lys Leu Glu Gln Ala 275 280 285Lys Leu Phe Cys Arg Thr Leu Glu Asp
Ile Leu Ala Asp Ala Pro Glu 290 295 300Ser Gln Asn Asn Cys Arg Leu
Ile Ala Tyr Gln Glu Pro Ala Asp Asp305 310 315 320Ser Ser Phe Ser
Leu Ser Gln Glu Val Leu Arg His Leu Arg Gln Glu 325 330 335Glu Lys
Glu Glu Val Thr Val Gly Ser Leu Lys Thr Ser Ala Val Pro 340 345
350Ser Thr Ser Thr Met Ser Gln Glu Pro Glu Leu Leu Ile Ser Gly Met
355 360 365Glu Lys Pro Leu Pro Leu Arg Thr Asp Phe Ser Thr 370 375
3801651140DNAArtificial SequenceSynthetic Hu STING (R284K) var; no
epitope tag 165atgccccata gcagcctgca ccccagcatc ccctgcccca
gaggccacgg cgcccagaag 60gccgccctgg tcctgctgag cgcatgcctg gtcaccctgt
ggggcctggg cgagcccccc 120gagcacaccc tgagatacct ggtgctgcac
ctcgccagcc tgcagctggg cctgctgctg 180aacggcgtgt gcagcctggc
cgaggagctg agacacatcc acagcagata tagaggcagc 240tactggagaa
ccgtgagagc ttgcctcggc tgccccctga gaagaggcgc cctgctgctg
300ctgagcatct acttttacta cagcctgccc aacgctgtgg gccccccttt
cacgtggatg 360ctcgccctgc tgggactgag ccaggccctg aacatcctgc
tgggccttaa gggcctagcc 420cccgccgaga tcagcgccgt gtgcgagaag
ggcaacttca atgtggccca cggcctggcc 480tggagctact acatcggcta
cctgagactg atcctgcccg agctgcaggc cagaatcaga 540acctacaatc
agcactacaa caacctgctg agaggcgccg tgagccagag actgtacatc
600ctgctgcccc tggactgcgg cgtgcccgac aacctcagca tggccgaccc
caacatcaga 660ttcctggaca agctgcccca gcagaccggc gaccacgccg
gcatcaagga tcgcgtgtac 720agcaacagca tctacgagct gctggaaaac
ggccagagag ccggaacctg cgtgctggag 780tacgccacac ccctgcagac
cctgttcgcc atgagccagt acagccaggc cggcttcagc 840agagaggaca
agctggagca ggccaagctg ttctgcagaa ccctggagga tatcctcgcc
900gacgcccccg agagccagaa caactgcagg ctgatcgcgt accaggagcc
cgctgacgac 960agcagcttta gcctgagcca ggaggtgctg agacatctgc
gtcaagagga aaaggaggag 1020gtgaccgtgg gctccctgaa gaccagcgcc
gtgcccagca ccagcaccat gagccaggag 1080cccgagctgc tgatcagcgg
catggagaag ccactgcccc tcagaaccga cttcagcacc 1140166186PRTHomo
sapiensmisc_feature(1)..(186)Human KRAS sp/P01116[1-186] 166Met Thr
Glu Tyr Lys Leu Val Val Val Gly Ala Gly Gly Val Gly Lys1 5 10 15Ser
Ala Leu Thr Ile Gln Leu Ile Gln Asn His Phe Val Asp Glu Tyr 20 25
30Asp Pro Thr Ile Glu Asp Ser Tyr Arg Lys Gln Val Val Ile Asp Gly
35 40 45Glu Thr Cys Leu Leu Asp Ile Leu Asp Thr Ala Gly Gln Glu Glu
Tyr 50 55 60Ser Ala Met Arg Asp Gln Tyr Met Arg Thr Gly Glu Gly Phe
Leu Cys65 70 75 80Val Phe Ala Ile Asn Asn Thr Lys Ser Phe Glu Asp
Ile His His Tyr 85 90 95Arg Glu Gln Ile Lys Arg Val Lys Asp Ser Glu
Asp Val Pro Met Val 100 105 110Leu Val Gly Asn Lys Cys Asp Leu Pro
Ser Arg Thr Val Asp Thr Lys 115 120 125Gln Ala Gln Asp Leu Ala Arg
Ser Tyr Gly Ile Pro Phe Ile Glu Thr 130 135 140Ser Ala Lys Thr Arg
Gln Arg Val Glu Asp Ala Phe Tyr Thr Leu Val145 150 155 160Arg Glu
Ile Arg Gln Tyr Arg Leu Lys Lys Ile Ser Lys Glu Glu Lys 165 170
175Thr Pro Gly Cys Val Lys Ile Lys Lys Cys 180
185167570RNAArtificial SequenceSyntheticmisc_feature5' 7 MeGpppG
2'Ome - OH 3'; Where A,C G & U = AMP, CMP, GMP &
N1-psi-UMP, respectively; Me = methyl; p = inorganic phosphate(KRAS
concatemer mRNA sequence; CX-012908) 167ggaaauaaga gagaaaagaa
gaguaagaag aaauauaaga gccaccauga ccgaguacaa 60gcucgugguc gucggcgccg
acgggguagg caaguccgcu cugaccauuc agcucaucca 120gaugacggag
uacaaacucg ugguaguggg agccgugggu gugggcaaga gcgcgcucac
180cauccaacuc auccaaauga ccgaauauaa acucgucgug gugggagccg
gcgacguggg 240aaagagcgcc cuuaccaucc aguuaaucca gaugacagaa
uacaagcugg ugguggucgg 300ugccugcggc guggguaagu ccgcccugac
aauccagcug auccagugau aauaggcugg 360agccucggug gccaugcuuc
uugccccuug ggccuccccc cagccccucc uccccuuccu 420gcacccguac
ccccgugguc uuugaauaaa gucugagugg gcggcaaaaa aaaaaaaaaa
480aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa
aaaaaaaaaa 540aaaaaaaaaa aaaaaaaaaa aaaaaucuag
5701681429RNAArtificial SequenceSyntheticmisc_feature5' 7 MeGpppG
2'Ome - OH 3'; Where A,C G & U = AMP, CMP, GMP &
N1-psi-UMP, respectively; Me = methyl; p = inorganic phosphate;
underline = miR-122 binding site(STING mRNA sequence; CX-012871)
168ggaaauaaga gagaaaagaa gaguaagaag aaauauaaga gccaccaugc
cccacaguag 60ccuccacccc agcauccccu gccccagagg ccacggcgca cagaaggccg
cccuggugcu 120gcugagcgcc ugucugguga cccugugggg ucugggcgag
ccccccgagc acacccugcg 180guaccucgug cugcaucugg ccagccugca
gcugggccug cugcugaacg gcgugugcag 240ccuggccgaa gagcugagac
acauccacag cagauacaga ggcuccuacu ggagaaccgu 300cagagccugc
cucggcuguc cccugagaag aggcgcccug cugcuccuga gcaucuacuu
360cuacuacagc cugcccaacg ccgugggccc ccccuucacc uggaugcugg
cccugcuggg 420ccugagccag gcccugaaca uccugcuggg ccugaagggc
uuggcccccg ccgagaucuc 480cgccgugugc gagaagggca acuucaacau
ggcccauggc cuugccuggu ccuacuacau 540cggcuaccug agacugaucc
ugcccgagcu gcaggccaga aucagaaccu acaaccagca 600cuacaacaac
cugcugagag gcgccgugag ccaaagacug uacauccugc ugccccugga
660cugcggcgug cccgacaacc uuagcauggc cgaccccaac aucagauucc
uggacaagcu 720gccccagcag accggcgacc acgccggcau caaggacaga
guguacagca acagcaucua 780cgagcugcug gagaacggcc agagagccgg
caccugcgug cuggaguacg ccaccccccu 840gcagacccug uucgccauga
gccaguacag ccaggccggc uucagcagag aggacagacu 900ggagcaagcc
aagcuguucu gcagaacccu ggaggacauc cuggcggacg cccccgagag
960ccaaaacaac ugcagacuga ucgccuacca ggagcccgcc gacgacagca
gcuucagccu 1020gagccaggaa gugcugagac accugagaca ggaagagaag
gaggagguga ccgugggaag 1080ccugaagacc agcgccgugc ccagcaccag
caccaugagc caggagcccg agcugcugau 1140cagcggcaug gagaagcccc
ugccccugag aaccgacuuc agcugauaau aggcuggagc 1200cucgguggcc
uagcuucuug ccccuugggc cuccccccag ccccuccucc ccuuccugca
1260cccguacccc ccaaacacca uugucacacu ccaguggucu uugaauaaag
ucugaguggg 1320cggcaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa
aaaaaaaaaa aaaaaaaaaa 1380aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa
aaaaaaaaaa aaaaucuag 1429169300RNAArtificial SequenceSynthetic
KRAS(G12D G12V G13D G12C) 100mer 4MUT nt. seq 169augaccgagu
acaagcucgu ggucgucggc gccgacgggg uaggcaaguc cgcucugacc 60auucagcuca
uccagaugac ggaguacaaa cucgugguag ugggagccgu gggugugggc
120aagagcgcgc ucaccaucca acucauccaa augaccgaau auaaacucgu
cgugguggga 180gccggcgacg ugggaaagag cgcccuuacc auccaguuaa
uccagaugac agaauacaag 240cugguggugg ucggugccug cggcgugggu
aaguccgccc ugacaaucca gcugauccag 3001701137RNAArtificial
SequenceSynthetic huSTING(V155M); no epitope tag; nucleotide
sequence 170augccccaca guagccucca ccccagcauc cccugcccca gaggccacgg
cgcacagaag 60gccgcccugg ugcugcugag cgccugucug gugacccugu ggggucuggg
cgagcccccc 120gagcacaccc ugcgguaccu cgugcugcau cuggccagcc
ugcagcuggg ccugcugcug 180aacggcgugu gcagccuggc cgaagagcug
agacacaucc acagcagaua cagaggcucc 240uacuggagaa ccgucagagc
cugccucggc uguccccuga gaagaggcgc ccugcugcuc 300cugagcaucu
acuucuacua cagccugccc aacgccgugg gcccccccuu caccuggaug
360cuggcccugc ugggccugag ccaggcccug aacauccugc ugggccugaa
gggcuuggcc 420cccgccgaga ucuccgccgu gugcgagaag ggcaacuuca
acauggccca uggccuugcc 480ugguccuacu acaucggcua ccugagacug
auccugcccg agcugcaggc cagaaucaga 540accuacaacc agcacuacaa
caaccugcug agaggcgccg ugagccaaag acuguacauc 600cugcugcccc
uggacugcgg cgugcccgac aaccuuagca uggccgaccc caacaucaga
660uuccuggaca agcugcccca gcagaccggc gaccacgccg gcaucaagga
cagaguguac 720agcaacagca ucuacgagcu gcuggagaac ggccagagag
ccggcaccug cgugcuggag 780uacgccaccc cccugcagac ccuguucgcc
augagccagu acagccaggc cggcuucagc 840agagaggaca gacuggagca
agccaagcug uucugcagaa cccuggagga cauccuggcg 900gacgcccccg
agagccaaaa caacugcaga cugaucgccu accaggagcc cgccgacgac
960agcagcuuca gccugagcca ggaagugcug agacaccuga gacaggaaga
gaaggaggag 1020gugaccgugg gaagccugaa gaccagcgcc gugcccagca
ccagcaccau gagccaggag 1080cccgagcugc ugaucagcgg cauggagaag
ccccugcccc ugagaaccga cuucagc 113717185RNAArtificial
SequenceSynthetic mir-122 171ccuuagcaga gcuguggagu gugacaaugg
uguuuguguc uaaacuauca aacgccauua 60ucacacuaaa uagcuacugc uaggc
8517222RNAArtificial SequenceSynthetic mir-122-3p_ 172aacgccauua
ucacacuaaa ua 2217322RNAArtificial SequenceSynthetic mir-122-3p
binding site 173uauuuagugu gauaauggcg uu 2217422RNAArtificial
SequenceSynthetic mir-122-5p 174uggaguguga caaugguguu ug
2217522RNAArtificial SequenceSynthetic mir-122-5p binding site
175caaacaccau ugucacacuc ca 2217646RNAArtificial SequenceSynthetic
5 UTR 176ggaaauaaga gagaaaagaa gaguaagaag aaauauaaga gccacc
4617712DNAArtificial SequenceSynthetic GC-Rich RNA Element
177ccgccgccgc cg 1217815DNAArtificial SequenceSynthetic GC-Rich RNA
Element 178ccgccgccgc cgccg 1517910DNAArtificial SequenceSynthetic
V1 - GC-Rich RNA Element 179ccccggcgcc 1018041DNAArtificial
SequenceSynthetic 5UTR 180gggaaataag agagaaaaga agagtaagaa
gaaatataag a 4118157DNAArtificial SequenceSynthetic V1-UTR
181gggaaataag agagaaaaga agagtaagaa gaaatataag accccggcgc cgccacc
5718254DNAArtificial SequenceSynthetic V2-UTR 182gggaaataag
agagaaaaga agagtaagaa gaaatataag accccggcgc cacc
5418345PRTArtificial SequenceSynthetic KRAS G12C 15mer^3 183Met Lys
Leu Val Val Val Gly Ala Cys Gly Val Gly Lys Ser Ala Met1 5 10 15Lys
Leu Val Val Val Gly Ala Cys Gly Val Gly Lys Ser Ala Met Lys 20 25
30Leu Val Val Val Gly Ala Cys Gly Val Gly Lys Ser Ala 35 40
45184225DNAArtificial SequenceSynthetic KRAS G12C 25mer^3
nucleotide sequence 184atgaccgagt acaagctcgt ggttgttggc gcctgcggcg
tgggcaagag cgccctcacc 60atccagctca tccagatgac agagtataag ttagtcgttg
tcggagcttg cggagttgga 120aagtcggcgc tcaccattca actcatacaa
atgacagaat ataagttagt ggtggtgggt 180gcgtgtggcg ttggcaagag
tgcgcttact atccagctca ttcag 22518592RNAArtificial SequenceSynthetic
5 UTR 185ucaagcuuuu ggacccucgu acagaagcua auacgacuca cuauagggaa
auaagagaga 60aaagaagagu aagaagaaau auaagagcca cc
92186119RNAArtificial SequenceSynthetic 3 UTR 186ugauaauagg
cuggagccuc gguggccaug cuucuugccc cuugggccuc cccccagccc 60cuccuccccu
uccugcaccc guacccccgu ggucuuugaa uaaagucuga gugggcggc
119187164RNAArtificial SequenceSynthetic 3 UTR with mi-122 and
mi-142.3p sites 187ugauaauagg cuggagccuc gguggccaug cuucuugccc
cuugggccca aacaccauug 60ucacacucca uccccccagc cccuccuccc cuuccuccau
aaaguaggaa acacuacaug 120cacccguacc cccguggucu uugaauaaag
ucugaguggg cggc 16418866RNAArtificial SequenceSynthetic Nucleotide
sequence encoding 2A peptide 188ggaagcggag cuacuaacuu cagccugcug
aagcaggcug gagacgugga ggagaacccu 60ggaccu 66189108RNAArtificial
SequenceSynthetic Nucleotide sequence encoding 2A peptide
189uccggacuca gauccgggga ucucaaaauu gucgcuccug ucaaacaaac
ucuuaacuuu 60gauuuacuca aacuggcugg ggauguagaa agcaauccag guccacuc
10819075RNAArtificial SequenceSynthetic KRAS G12D 25mer nucleotide
sequence 190augaccgagu acaagcuggu gguggugggc gccgacggcg ugggcaagag
cgcccugacc 60auccagcuga uccag 7519175RNAArtificial
SequenceSynthetic KRAS G12V 25mer nucleotide sequence 191augaccgagu
acaagcuggu gguggugggc gccgugggcg ugggcaagag cgcccugacc 60auccagcuga
uccag 7519275RNAArtificial SequenceSynthetic KRAS G13D 25mer
nucleotide sequence 192augaccgagu acaagcuggu gguggugggc gccggcgacg
ugggcaagag cgcccugacc 60auccagcuga uccag 75193225RNAArtificial
SequenceSynthetic KRAS G12D 25mer^3 nucleotide sequence
193augaccgagu acaaguuagu gguugugggc gccgacggcg ugggcaagag
cgcccucacc 60auccagcuua uccagaugac ggaauauaag uuaguaguag ugggagccga
cggugucggc 120aaguccgcuu ugaccauuca acuuauucag augacagagu
auaagcuggu cguuguaggc 180gcagacggcg uuggaaaguc ggcacugacg
auccaguuga uccag 225194225RNAArtificial SequenceSynthetic KRAS G12V
25mer^3 nucleotide sequence 194augaccgagu acaagcucgu cguggugggc
gccgugggcg ugggcaagag cgcccuaacc 60auccaguuga uccagaugac cgaauauaag
cucgugguag ucggagcggu gggcguuggc 120aagucagcgc uaacaauaca
acuaauccaa augaccgaau acaagcuagu uguagucggu 180gccgucggcg
uuggaaaguc agcccuuaca auucagcuca uucag 225195225RNAArtificial
SequenceSynthetic KRAS G13D 25mer^3 nucleotide sequence
195augaccgagu acaagcucgu agugguuggc gccggcgacg ugggcaagag
cgcccuaacc 60auccagcuca uccagaugac agaauauaag cuugugguug ugggagcagg
agacguggga 120aagagugcgu ugacgauuca acucauacag augaccgaau
acaaguuggu gguggucggc 180gcaggugacg uugguaaguc ugcacuaacu
auacaacuga uccag 22519675RNAArtificial SequenceSynthetic KRAS G12C
25mer nucleotide sequence 196augaccgagu acaagcuggu gguggugggc
gccugcggcg ugggcaagag cgcccugacc 60auccagcuga uccag
75197225RNAArtificial SequenceSynthetic KRAS G12C 25mer^3
nucleotide sequence 197augaccgagu acaagcucgu gguuguuggc gccugcggcg
ugggcaagag cgcccucacc 60auccagcuca uccagaugac agaguauaag uuagucguug
ucggagcuug cggaguugga 120aagucggcgc ucaccauuca acucauacaa
augacagaau auaaguuagu gguggugggu 180gcguguggcg uuggcaagag
ugcgcuuacu auccagcuca uucag 22519875RNAArtificial SequenceSynthetic
KRAS WT 25mer nucleotide sequence 198augaccgagu acaagcuggu
gguggugggc gccggcggcg ugggcaagag cgcccugacc 60auccagcuga uccag
7519947RNAArtificial SequenceSynthetic 5 UTR sequence; no promoter
199gggaaauaag agagaaaaga agaguaagaa gaaauauaag agccacc
47200225RNAArtificial SequenceSynthetic KRAS(G12D G12V G13D) 75mer
3MUT nt. seq 200augaccgagu acaagcucgu uguagucggc gccgacggcg
ugggcaagag cgccuugacc 60auccaguuga uccagaugac cgaauauaag uugguggugg
uaggcgcagu gggaguuggc 120aagucagcac ucacaauuca gcucauucaa
augacagaau acaaguuagu cguuguagga 180gcaggcgacg ucggcaagag
ugccuuaacc auucaacuaa uccag 2252011137RNAArtificial
SequenceSynthetic Hu STING(R284T); no epitope tag; nucleotide
sequence 201augccucaca gcagccugca cccuagcauc ccuugcccua gaggccacgg
cgcccagaag 60gccgcccugg ugcugcugag cgccugccug gugacccugu ggggccuggg
cgagccuccu 120gagcacaccc ugagauaccu ggugcugcac cuggccagcc
ugcagcuggg ccugcugcug 180aacggcgugu gcagccuggc cgaggagcug
agacacaucc acagcagaua cagaggcagc 240uacuggagaa ccgugagagc
cugccugggc ugcccucuga gaagaggcgc ccugcugcug 300cugagcaucu
acuucuacua cagccugccu aacgccgugg gcccuccuuu caccuggaug
360cuggcccugc ugggccugag ccaggcccug aacauccugc ugggccugaa
gggccuggcc 420ccugccgaga ucagcgccgu gugcgagaag ggcaacuuca
acguggccca cggccuggcc 480uggagcuacu acaucggcua ccugagacug
auccugccug agcugcaggc cagaaucaga 540accuacaacc agcacuacaa
caaccugcug agaggcgccg ugagccagag acuguacauc 600cugcugccuc
uggacugcgg cgugccugac aaccugagca uggccgaccc uaacaucaga
660uuccuggaca agcugccuca gcagaccggc gaccacgccg gcaucaagga
cagaguguac 720agcaacagca ucuacgagcu gcuggagaac ggccagagag
ccggcaccug cgugcuggag 780uacgccaccc cucugcagac ccuguucgcc
augagccagu acagccaggc cggcuucagc 840agagaggaca cccuggagca
ggccaagcug uucugcagaa cccuggagga cauccuggcc 900gacgccccug
agagccagaa caacugcaga cugaucgccu accaggagcc ugccgacgac
960agcagcuuca gccugagcca ggaggugcug agacaccuga gacaggagga
gaaggaggag 1020gugaccgugg gcagccugaa gaccagcgcc gugccuagca
ccagcaccau gagccaggag 1080ccugagcugc ugaucagcgg cauggagaag
ccucugccuc ugagaaccga cuucagc 11372021137RNAArtificial
SequenceSynthetic hu STING (R284M); no epitope tag; nucleotide
sequence 202augccccaca gcagccugca ccccuccauc cccuguccca gaggccacgg
cgcccagaag 60gccgcccugg ugcugcugag cgccugccug gugaccuuau ggggccuggg
cgagcccccc 120gagcacaccc ugagauaccu gguccugcac cuggccagcc
uccagcuggg ccugcugcuc 180aacggcgugu guagccuggc cgaggagcug
agacacaucc acagcagaua cagaggcagc 240uacuggagaa ccgugagagc
cugccugggu ugcccacuga gaagaggagc ucugcugcug 300cugagcaucu
acuucuacua cucgcugccc aacgcugugg gcccccccuu caccuggaug
360cuggcccugc ugggucugag ccaggcccug aacauccucc ugggccugaa
gggccuggcc 420cccgccgaga uaagcgccgu uugcgagaag ggcaacuuca
acguggccca uggccuggcc 480uggagcuacu acaucggcua cuuacgccug
auccugcccg agcugcaggc cagaaucaga 540accuacaacc agcauuacaa
caaccugcug agaggcgccg ugagccagag acuguauauc 600cugcugcccc
uggacugcgg cgugcccgac aaccugagca uggccgaccc caacaucaga
660uuccuggaca agcuccccca gcagaccggc gaccacgccg gaaucaaaga
cagaguguau 720agcaacagca ucuacgagcu gcuggagaac ggccagagag
ccggcaccug
cguacuggag 780uacgccaccc ccuugcagac ccuguuugcc augagccagu
acagccaggc cggcuucagc 840agagaggaca ugcuggagca ggccaagcug
uucugcagaa cccuggagga cauccuggcc 900gacgcccccg agagccagaa
caacugcaga cugaucgccu accaagagcc cgccgacgac 960agcagcuuca
gcuuaagcca ggaggugcug agacaucuga gacaggagga gaaggaggag
1020gugaccgugg gcagccucaa gaccagcgcu gugcccucua ccagcaccau
gagccaggag 1080cccgagcugc ugaucagcgg cauggagaag ccccugcccc
ugagaacaga cuucagc 11372031137RNAArtificial SequenceSynthetic Hu
STING (R284K); no epitope tag; nucleotide sequence 203augccccaua
gcagccugca ccccagcauc cccugcccca gaggccacgg cgcccagaag 60gccgcccugg
uccugcugag cgcaugccug gucacccugu ggggccuggg cgagcccccc
120gagcacaccc ugagauaccu ggugcugcac cucgccagcc ugcagcuggg
ccugcugcug 180aacggcgugu gcagccuggc cgaggagcug agacacaucc
acagcagaua uagaggcagc 240uacuggagaa ccgugagagc uugccucggc
ugcccccuga gaagaggcgc ccugcugcug 300cugagcaucu acuuuuacua
cagccugccc aacgcugugg gccccccuuu cacguggaug 360cucgcccugc
ugggacugag ccaggcccug aacauccugc ugggccuuaa gggccuagcc
420cccgccgaga ucagcgccgu gugcgagaag ggcaacuuca auguggccca
cggccuggcc 480uggagcuacu acaucggcua ccugagacug auccugcccg
agcugcaggc cagaaucaga 540accuacaauc agcacuacaa caaccugcug
agaggcgccg ugagccagag acuguacauc 600cugcugcccc uggacugcgg
cgugcccgac aaccucagca uggccgaccc caacaucaga 660uuccuggaca
agcugcccca gcagaccggc gaccacgccg gcaucaagga ucgcguguac
720agcaacagca ucuacgagcu gcuggaaaac ggccagagag ccggaaccug
cgugcuggag 780uacgccacac cccugcagac ccuguucgcc augagccagu
acagccaggc cggcuucagc 840agagaggaca agcuggagca ggccaagcug
uucugcagaa cccuggagga uauccucgcc 900gacgcccccg agagccagaa
caacugcagg cugaucgcgu accaggagcc cgcugacgac 960agcagcuuua
gccugagcca ggaggugcug agacaucugc gucaagagga aaaggaggag
1020gugaccgugg gcucccugaa gaccagcgcc gugcccagca ccagcaccau
gagccaggag 1080cccgagcugc ugaucagcgg cauggagaag ccacugcccc
ucagaaccga cuucagc 11372041137RNAArtificial SequenceSynthetic Hu
STING(N154S); no epitope tag; nucleotide sequence 204augccucaca
gcagccugca cccuagcauc ccuugcccua gaggccacgg cgcccagaag 60gccgcccugg
ugcugcugag cgccugccug gugacccugu ggggccuggg cgagccuccu
120gagcacaccc ugagauaccu ggugcugcac cuggccagcc ugcagcuggg
ccugcugcug 180aacggcgugu gcagccuggc cgaggagcug agacacaucc
acagcagaua cagaggcagc 240uacuggagaa ccgugagagc cugccugggc
ugcccucuga gaagaggcgc ccugcugcug 300cugagcaucu acuucuacua
cagccugccu aacgccgugg gcccuccuuu caccuggaug 360cuggcccugc
ugggccugag ccaggcccug aacauccugc ugggccugaa gggccuggcc
420ccugccgaga ucagcgccgu gugcgagaag ggcaacuuca gcguggccca
cggccuggcc 480uggagcuacu acaucggcua ccugagacug auccugccug
agcugcaggc cagaaucaga 540accuacaacc agcacuacaa caaccugcug
agaggcgccg ugagccagag acuguacauc 600cugcugccuc uggacugcgg
cgugccugac aaccugagca uggccgaccc uaacaucaga 660uuccuggaca
agcugccuca gcagaccggc gaccacgccg gcaucaagga cagaguguac
720agcaacagca ucuacgagcu gcuggagaac ggccagagag ccggcaccug
cgugcuggag 780uacgccaccc cucugcagac ccuguucgcc augagccagu
acagccaggc cggcuucagc 840agagaggaca gacuggagca ggccaagcug
uucugcagaa cccuggagga cauccuggcc 900gacgccccug agagccagaa
caacugcaga cugaucgccu accaggagcc ugccgacgac 960agcagcuuca
gccugagcca ggaggugcug agacaccuga gacaggagga gaaggaggag
1020gugaccgugg gcagccugaa gaccagcgcc gugccuagca ccagcaccau
gagccaggag 1080ccugagcugc ugaucagcgg cauggagaag ccucugccuc
ugagaaccga cuucagc 11372051137RNAArtificial SequenceSynthetic Hu
STING(V147L); no epitope tag; nucleotide sequence 205augccucaca
gcagccugca cccuagcauc ccuugcccua gaggccacgg cgcccagaag 60gccgcccugg
ugcugcugag cgccugccug gugacccugu ggggccuggg cgagccuccu
120gagcacaccc ugagauaccu ggugcugcac cuggccagcc ugcagcuggg
ccugcugcug 180aacggcgugu gcagccuggc cgaggagcug agacacaucc
acagcagaua cagaggcagc 240uacuggagaa ccgugagagc cugccugggc
ugcccucuga gaagaggcgc ccugcugcug 300cugagcaucu acuucuacua
cagccugccu aacgccgugg gcccuccuuu caccuggaug 360cuggcccugc
ugggccugag ccaggcccug aacauccugc ugggccugaa gggccuggcc
420ccugccgaga ucagcgcccu gugcgagaag ggcaacuuca acguggccca
cggccuggcc 480uggagcuacu acaucggcua ccugagacug auccugccug
agcugcaggc cagaaucaga 540accuacaacc agcacuacaa caaccugcug
agaggcgccg ugagccagag acuguacauc 600cugcugccuc uggacugcgg
cgugccugac aaccugagca uggccgaccc uaacaucaga 660uuccuggaca
agcugccuca gcagaccggc gaccacgccg gcaucaagga cagaguguac
720agcaacagca ucuacgagcu gcuggagaac ggccagagag ccggcaccug
cgugcuggag 780uacgccaccc cucugcagac ccuguucgcc augagccagu
acagccaggc cggcuucagc 840agagaggaca gacuggagca ggccaagcug
uucugcagaa cccuggagga cauccuggcc 900gacgccccug agagccagaa
caacugcaga cugaucgccu accaggagcc ugccgacgac 960agcagcuuca
gccugagcca ggaggugcug agacaccuga gacaggagga gaaggaggag
1020gugaccgugg gcagccugaa gaccagcgcc gugccuagca ccagcaccau
gagccaggag 1080ccugagcugc ugaucagcgg cauggagaag ccucugccuc
ugagaaccga cuucagc 11372061137RNAArtificial SequenceSynthetic Hu
STING (E315Q); no epitope tag; nucleotide sequence 206augccucaca
gcagccugca cccuagcauc ccuugcccua gaggccacgg cgcccagaag 60gccgcccugg
ugcugcugag cgccugccug gugacccugu ggggccuggg cgagccuccu
120gagcacaccc ugagauaccu ggugcugcac cuggccagcc ugcagcuggg
ccugcugcug 180aacggcgugu gcagccuggc cgaggagcug agacacaucc
acagcagaua cagaggcagc 240uacuggagaa ccgugagagc cugccugggc
ugcccucuga gaagaggcgc ccugcugcug 300cugagcaucu acuucuacua
cagccugccu aacgccgugg gcccuccuuu caccuggaug 360cuggcccugc
ugggccugag ccaggcccug aacauccugc ugggccugaa gggccuggcc
420ccugccgaga ucagcgccgu gugcgagaag ggcaacuuca acguggccca
cggccuggcc 480uggagcuacu acaucggcua ccugagacug auccugccug
agcugcaggc cagaaucaga 540accuacaacc agcacuacaa caaccugcug
agaggcgccg ugagccagag acuguacauc 600cugcugccuc uggacugcgg
cgugccugac aaccugagca uggccgaccc uaacaucaga 660uuccuggaca
agcugccuca gcagaccggc gaccacgccg gcaucaagga cagaguguac
720agcaacagca ucuacgagcu gcuggagaac ggccagagag ccggcaccug
cgugcuggag 780uacgccaccc cucugcagac ccuguucgcc augagccagu
acagccaggc cggcuucagc 840agagaggaca gacuggagca ggccaagcug
uucugcagaa cccuggagga cauccuggcc 900gacgccccug agagccagaa
caacugcaga cugaucgccu accagcagcc ugccgacgac 960agcagcuuca
gccugagcca ggaggugcug agacaccuga gacaggagga gaaggaggag
1020gugaccgugg gcagccugaa gaccagcgcc gugccuagca ccagcaccau
gagccaggag 1080ccugagcugc ugaucagcgg cauggagaag ccucugccuc
ugagaaccga cuucagc 11372071137RNAArtificial SequenceSynthetic Hu
STING (R375A); no epitope tag; nucleotide sequence 207augccucaca
gcagccugca cccuagcauc ccuugcccua gaggccacgg cgcccagaag 60gccgcccugg
ugcugcugag cgccugccug gugacccugu ggggccuggg cgagccuccu
120gagcacaccc ugagauaccu ggugcugcac cuggccagcc ugcagcuggg
ccugcugcug 180aacggcgugu gcagccuggc cgaggagcug agacacaucc
acagcagaua cagaggcagc 240uacuggagaa ccgugagagc cugccugggc
ugcccucuga gaagaggcgc ccugcugcug 300cugagcaucu acuucuacua
cagccugccu aacgccgugg gcccuccuuu caccuggaug 360cuggcccugc
ugggccugag ccaggcccug aacauccugc ugggccugaa gggccuggcc
420ccugccgaga ucagcgccgu gugcgagaag ggcaacuuca acguggccca
cggccuggcc 480uggagcuacu acaucggcua ccugagacug auccugccug
agcugcaggc cagaaucaga 540accuacaacc agcacuacaa caaccugcug
agaggcgccg ugagccagag acuguacauc 600cugcugccuc uggacugcgg
cgugccugac aaccugagca uggccgaccc uaacaucaga 660uuccuggaca
agcugccuca gcagaccggc gaccacgccg gcaucaagga cagaguguac
720agcaacagca ucuacgagcu gcuggagaac ggccagagag ccggcaccug
cgugcuggag 780uacgccaccc cucugcagac ccuguucgcc augagccagu
acagccaggc cggcuucagc 840agagaggaca gacuggagca ggccaagcug
uucugcagaa cccuggagga cauccuggcc 900gacgccccug agagccagaa
caacugcaga cugaucgccu accaggagcc ugccgacgac 960agcagcuuca
gccugagcca ggaggugcug agacaccuga gacaggagga gaaggaggag
1020gugaccgugg gcagccugaa gaccagcgcc gugccuagca ccagcaccau
gagccaggag 1080ccugagcugc ugaucagcgg cauggagaag ccucugccuc
uggccaccga cuucagc 11372081137RNAArtificial SequenceSynthetic Hu
STING(V147L/N154S/V155M); no epitope tag; nucleotide sequence
208augccucaca gcagccugca cccuagcauc ccuugcccua gaggccacgg
cgcccagaag 60gccgcccugg ugcugcugag cgccugccug gugacccugu ggggccuggg
cgagccuccu 120gagcacaccc ugagauaccu ggugcugcac cuggccagcc
ugcagcuggg ccugcugcug 180aacggcgugu gcagccuggc cgaggagcug
agacacaucc acagcagaua cagaggcagc 240uacuggagaa ccgugagagc
cugccugggc ugcccucuga gaagaggcgc ccugcugcug 300cugagcaucu
acuucuacua cagccugccu aacgccgugg gcccuccuuu caccuggaug
360cuggcccugc ugggccugag ccaggcccug aacauccugc ugggccugaa
gggccuggcc 420ccugccgaga ucagcgcccu gugcgagaag ggcaacuuca
gcauggccca cggccuggcc 480uggagcuacu acaucggcua ccugagacug
auccugccug agcugcaggc cagaaucaga 540accuacaacc agcacuacaa
caaccugcug agaggcgccg ugagccagag acuguacauc 600cugcugccuc
uggacugcgg cgugccugac aaccugagca uggccgaccc uaacaucaga
660uuccuggaca agcugccuca gcagaccggc gaccacgccg gcaucaagga
cagaguguac 720agcaacagca ucuacgagcu gcuggagaac ggccagagag
ccggcaccug cgugcuggag 780uacgccaccc cucugcagac ccuguucgcc
augagccagu acagccaggc cggcuucagc 840agagaggaca gacuggagca
ggccaagcug uucugcagaa cccuggagga cauccuggcc 900gacgccccug
agagccagaa caacugcaga cugaucgccu accaggagcc ugccgacgac
960agcagcuuca gccugagcca ggaggugcug agacaccuga gacaggagga
gaaggaggag 1020gugaccgugg gcagccugaa gaccagcgcc gugccuagca
ccagcaccau gagccaggag 1080ccugagcugc ugaucagcgg cauggagaag
ccucugccuc ugagaaccga cuucagc 11372091137RNAArtificial
SequenceSynthetic Hu STING(R284M/V147L/N154S/V155M); no epitope
tag; nucleotide sequence 209augccucaca gcagccugca cccuagcauc
ccuugcccua gaggccacgg cgcccagaag 60gccgcccugg ugcugcugag cgccugccug
gugacccugu ggggccuggg cgagccuccu 120gagcacaccc ugagauaccu
ggugcugcac cuggccagcc ugcagcuggg ccugcugcug 180aacggcgugu
gcagccuggc cgaggagcug agacacaucc acagcagaua cagaggcagc
240uacuggagaa ccgugagagc cugccugggc ugcccucuga gaagaggcgc
ccugcugcug 300cugagcaucu acuucuacua cagccugccu aacgccgugg
gcccuccuuu caccuggaug 360cuggcccugc ugggccugag ccaggcccug
aacauccugc ugggccugaa gggccuggcc 420ccugccgaga ucagcgcccu
gugcgagaag ggcaacuuca gcauggccca cggccuggcc 480uggagcuacu
acaucggcua ccugagacug auccugccug agcugcaggc cagaaucaga
540accuacaacc agcacuacaa caaccugcug agaggcgccg ugagccagag
acuguacauc 600cugcugccuc uggacugcgg cgugccugac aaccugagca
uggccgaccc uaacaucaga 660uuccuggaca agcugccuca gcagaccggc
gaccacgccg gcaucaagga cagaguguac 720agcaacagca ucuacgagcu
gcuggagaac ggccagagag ccggcaccug cgugcuggag 780uacgccaccc
cucugcagac ccuguucgcc augagccagu acagccaggc cggcuucagc
840agagaggaca ugcuggagca ggccaagcug uucugcagaa cccuggagga
cauccuggcc 900gacgccccug agagccagaa caacugcaga cugaucgccu
accaggagcc ugccgacgac 960agcagcuuca gccugagcca ggaggugcug
agacaccuga gacaggagga gaaggaggag 1020gugaccgugg gcagccugaa
gaccagcgcc gugccuagca ccagcaccau gagccaggag 1080ccugagcugc
ugaucagcgg cauggagaag ccucugccuc ugagaaccga cuucagc
1137210141RNAArtificial SequenceSynthetic 3 UTR used in STING V155M
construct, containing miR122 binding site 210ugauaauagg cuggagccuc
gguggccuag cuucuugccc cuugggccuc cccccagccc 60cuccuccccu uccugcaccc
guacccccca aacaccauug ucacacucca guggucuuug 120aauaaagucu
gagugggcgg c 1412111257RNAMus musculusmisc_feature(1)..(1257)super
mouse IRF3 S396D; no epitope tag 211auggagaccc ccaagccuag
aauccugccc uggcugguga gccagcugga ccugggccag 60cuggagggcg uagccuggcu
ggacgagagc agaaccagau ucagaauccc cuggaagcac 120ggccugagac
aagacgccca gauggccgac uucggcaucu uccaggccug ggccgaggcc
180agcggcgccu acaccccugg caaggauaag cccgauguga gcaccuggaa
gagaaacuuc 240agaagcgccc ugaacagaaa ggaggugcug agacuggccg
ccgacaauag caaggacccc 300uacgaccccc acaaggugua cgaguucguu
acccccggcg ccagggacuu cgugcaccug 360ggcgccagcc ccgacaccaa
cggcaagagc agccugcccc acagccagga gaaccugccc 420aagcuguucg
auggccugau ccugggcccc cugaaggacg agggcagcag cgaccuggcc
480aucgugagcg acccuagcca gcagcugccc ucccccaacg ugaacaacuu
ccugaacccc 540gccccccagg agaacccccu gaagcaacug cuggccgagg
agcaguggga guucgaggug 600accgccuucu acagaggcag acagguguuc
cagcagaccc uguucugccc cggcggccug 660agacugguag gcagcaccgc
ugacaugacc cugcccuggc agcccgugac ccugcccgac 720cccgaaggcu
uucugaccga caagcuggug aaggaguacg ucggccaagu gcugaagggc
780cugggcaacg gccuggcccu guggcaggcc ggccagugcc ugugggccca
gagacucggc 840cacagccacg ccuucugggc ccugggcgag gaacuccugc
ccgauagcgg cagaggcccc 900gacggcgagg ugcacaagga caaggacggc
gccguguucg accugcgccc cuucguggcc 960gaccugaucg ccuucaugga
gggcagcggc cacagcccca gauauacccu gugguucugc 1020augggcgaga
uguggcccca ggaccagccc ugggugaaga gacuggugau ggugaaggug
1080gugcccaccu gccugaaaga gcugcuggag auggccagag agggcggcgc
cagcucccug 1140aaaaccgugg accugcacau ugacaacagc cagcccauca
gccugaccag cgaccaguac 1200aaggccuacc ugcaggaccu gguggaggac
auggacuucc aggccaccgg caacauc 12572121281RNAHomo
sapiensmisc_feature(1)..(1281)super human IRF3 S396D; no epitope
tag 212augggcaccc ccaagcccag aauccugccc uggcugguga gccagcugga
ccugggccag 60cuggagggag uggccugggu gaacaagagc agaaccagau ucagaauccc
cuggaagcac 120ggccucagac aggacgccca gcaggaggac uucggcauuu
uucaggcuug ggccgaggcc 180accggcgccu acgugcccgg cagagacaag
cccgaccugc ccaccuggaa aagaaacuuc 240agaagcgccu ugaauagaaa
ggagggccug agacuggccg aggacagaag caaggacccc 300cacgacccuc
acaagaucua cgaguucgug aauagcggcg ugggcgacuu uagccagccc
360gacaccagcc ccgacaccaa cggcggcggc agcaccagcg acacgcagga
ggacauccug 420gaugaacugc ugggcaacau ggugcuggcc ccccugcccg
aucccggccc cccuucgcuu 480gccguggccc ccgagcccug cccccagccc
cugagaagcc ccucucugga uaaccccacc 540cccuucccca accugggccc
cagcgagaau ccacugaaga gacuucuggu ccccggcgag 600gagugggagu
ucgaggugac cgccuucuac agaggcagac agguguucca gcagaccauc
660agcugccccg aaggccugag auuagugggc agcgaagugg gcgacaggac
ccugcccggg 720uggcccguga cccugcccga ucccggcaug agccugaccg
acagaggugu gaugagcuac 780gugagacacg ugcugagcug ccugggcggc
ggccuggcac uguggagagc cggccagugg 840cugugggccc agagacuggg
ccacugccac accuacuggg ccgugagcga ggagcugcug 900cccaacagcg
gccacggccc cgacggcgag gugcccaagg acaaggaagg gggcguguuc
960gaccugggcc ccuucaucgu agaccugauc accuuuaccg agggcagcgg
caggagcccc 1020agauacgccc ugugguucug cgugggcgaa agcuggcccc
aggaccagcc cuggaccaag 1080agacugguga uggugaaggu agugcccacc
ugccugagag ccuuagugga gauggccaga 1140gugggcgggg ccagcagccu
ggagaacacc guggaucuuc acaucgacaa cagccacccc 1200cugagccuga
ccagcgacca guacaaggcc uaccugcagg accuggugga gggcauggac
1260uuccagggcc ccggcgagac c 12812131509RNAArtificial
SequenceSynthetic Wild-type Hu IRF7 isoform A; P037 without epitope
tag 213auggcgcugg cccccgaaag agccgccccc agaguccucu ucggcgaaug
gcuccuuggc 60gaaauuucgu cgggcugcua cgagggcuua caauggcugg augaggcgag
aaccuguuuc 120agggugcccu ggaaacacuu cgccagaaag gaucuaagcg
aagcagaugc uagaauuuuu 180aaggcuuggg ccguggccag gggaagaugg
ccccccucga gcagaggcgg cggcccuccc 240cccgaggcag aaacggccga
gagagccgga uggaaaacca auuucagaug cgcccugaga 300ucuacaagaa
gauucgugau gcuuagagac aacagcggag aucccgccga uccccauaag
360guguaugccc ugucccggga gcugugcugg agggaagggc cuggcacuga
ccagaccgaa 420gccgaagccc ccgcggccgu gccgccgccc caaggaggcc
caccaggccc uuuccucgcu 480cacacccacg ccggucugca agccccggga
ccucuaccug ccccugccgg cgauaaaggc 540gaccuguugc ugcaggccgu
ccaacagagc ugccuggccg aucaucugcu cacagccagc 600uggggcgcug
accccguccc aacaaaggcc cccggugagg gccaagaagg ccugccucug
660accggcgccu gugccggcgg cccuggccug ccugcuggcg agcuguacgg
augggcuguc 720gaaaccacuc ccucccccgg cccccaaccu gcggcccuga
caaccggcga ggcagccgca 780cccgaaagcc cccaccaggc cgaacccuac
cucaguccca gccccuccgc cugcaccgcu 840gugcaggagc ccagccccgg
ugcucuggac guaacaauca uguacaaagg cagaaccgug 900cuucagaagg
ugguuggaca ccccuccugu acuuuucucu acggcccccc cgacccugcc
960gugagagcua ccgacccgca acagguggcc uuucccucgc ccgccgaacu
gcccgaucaa 1020aaacagcuga gauacaccga ggagcugcug agacacgugg
cgccgggcuu acaccuagag 1080uugagaggcc cccaacucug ggccagacgc
augggcaagu guaaggugua cugggagguc 1140gggggcccuc ccggcucugc
cagccccagc accccugcuu gucucuugcc cagaaacugu 1200gauaccccca
ucuucgacuu ccguguauuu uuccaggaac uggucgaguu uagagccaga
1260cagagacgag gcagccccag auauacaauc uaccucggcu ucggccagga
ccugagugcc 1320ggcagaccua aggagaaguc gcugguccua gugaaguuag
agcccuggcu auguagagug 1380caccuggagg gcacccagag agaaggagug
agcagccugg acagcagcag ccugagucug 1440ugccugagcu ccgccaacuc
gcuguaugau gacaucgagu guuuccucau ggagcuggag 1500cagcccgcc
15092141509RNAArtificial SequenceSynthetic constitutively active Hu
IRF7 S477D/S479D; P033 without epitope tag 214auggcccuug ccccugagcg
ggccgccccc agaguguuau ucggcgagug gcugcugggc 60gagaucagca gcggcugcua
cgagggacug caguggcugg acgaggcuag aaccugcuuc 120agagugcccu
ggaagcauuu cgccagaaaa gaccugagcg aggcugaugc uagaaucuuc
180aaagccuggg cuguggcccg aggaagaugg ccccccagca gcagaggagg
cggcccuccu 240cccgaggccg aaaccgcaga gcgugcuggc uggaaaacca
acuuuaggug ugcccugagg 300agcaccagaa gauucguuau gcucagagac
aacagcgggg accccgccga cccgcacaag 360guguacgccu uaaguaggga
gcugugcugg agagagggac cggggaccga ccaaaccgag 420gcugaggcgc
ccgccgccgu uccaccuccc cagggugguc ccccagggcc cuuucuggca
480cacacccacg ccggauuaca ggcgccaggg cccuuacccg cccccgccgg
agacaaaggc 540gaccuccugc ugcaagccgu gcaacaaagc ugccuggccg
aucacuuacu aaccgcuagc 600uggggcgccg auccuguucc caccaaggcc
cccggugaag ggcaagaagg acugcccuua 660accggcgccu gugccggagg
cccuggucug ccagccggcg agcuguacgg uugggcuguc 720gaaacaacac
ccaguccggg cccacagccu gccgcucuga ccaccggcga agccgccgcc
780cccgagagcc cacaccaggc ugaacccuac cugagcccca gccccagcgc
cugcaccgcu 840gugcaggagc cuagccccgg cgcucuugau gugacaauaa
uguacaaggg caggaccgug 900cugcaaaagg ucgugggcca uccgucgugu
accuuucugu acggcccucc agaccccgcg 960guuagagcca ccgaccccca
gcaagucgcc uuccccuccc ccgccgaacu gcccgaccaa 1020aagcagcugc
gguacacaga agaacuacuu agacacgugg cccccggucu gcacuuggag
1080cugagaggcc cccagcucug ggccagaaga augggcaagu gcaaagugua
cugggaggug 1140ggcggcccac ccggcucagc uucgcccucc acacccgcau
gccugcugcc cagaaauugc 1200gacacgccca ucuucgauuu uagaguguuc
uuucaggagu ugguggaguu cagagccaga 1260caaagacgcg gcagccccag
auacaccauu uaccucggcu
ucggccagga ccucagcgcu 1320ggcagaccca aggagaagag ucugguccuc
gugaagcugg agcccuggcu gugcagagug 1380caccuggagg gcacccagcg
ugaaggcgug agcagccugg auucaagcga ccuggaccua 1440ugccuaagca
gcgcuaacuc acuguacgac gauaucgaau gcuuccugau ggaacuggag
1500cagccugcc 15092151509RNAArtificial SequenceSynthetic
constitutively active Hu IRF7 S475D/S477D/L480D; P034 without
epitope tag 215auggcccugg cacccgagag ggccgccccc agggugcucu
ucggcgagug guuacuaggc 60gaaauuagca gcggcugcua ugaaggccuu caguggcugg
acgaggccag aaccugcuuu 120agaguucccu ggaagcacuu cgcccggaaa
gaucucucug aagccgacgc cagaauauuc 180aaggccuggg cugucgccag
gggcaggugg ccacccucca gccgaggugg cggcccuccc 240ccugaggcug
agacugcgga aagggcgggc uggaagacca auuucagaug cgcucugaga
300agcaccagac guuuugugau gcuaagagac aauagcggcg aucccgccga
cccccauaag 360guauacgcac ugagccgaga gcucuguugg agagaaggcc
ccggcaccga ccagaccgag 420gcugaagccc cugcagccgu gccccccccu
caaggcgggc cccccggccc cuuccuggcc 480cauacccaug caggguuaca
agcacccggg cccuugcccg ccccagcggg agacaagggc 540gaccucuuac
ugcaggccgu gcaacaaagu ugucuggcgg accaccugcu gaccgcauca
600uggggcgcgg auccugugcc caccaaggca cccggcgaag gccaggaggg
ccugcccuug 660accggcgccu gcgcuggcgg acccggccua ccugcuggcg
aacuguaugg cugggccgua 720gagacgacuc ccagcccugg cccacaaccc
gcggcuuuga ccaccggcga agccgccgcc 780cccgagucuc cgcaccaggc
cgagccuuac cucagcccaa gcccuagcgc cugcaccgcc 840gugcaagaac
cuagccccgg agcccuggau gugacaauca uguacaaggg uagaaccgua
900cugcaaaagg ugguggguca ucccagcugc accuuucuuu acggcccacc
cgacccugcc 960gugcgagcca cagacccaca acaggucgcc uucccaagcc
ccgccgaacu gcccgaucag 1020aaacagcuga gauauacaga ggagcuucug
cggcacguag cucccggccu acaucucgag 1080cugaggggcc cacaacugug
ggccagacgc augggcaaau gcaaggucua cugggaagug 1140ggaggccccc
ccggcagcgc aucucccagc acgcccgcgu gccugcugcc uagaaauugc
1200gacaccccca ucuuugacuu ccggguauuc uuucaggagc ugguagaguu
cagagccagg 1260cagcggaggg gcucccccag auacacaauc uaccugggcu
ucggacagga ccuguccgcc 1320ggccgcccca aggaaaagag ccuggugcug
gugaagcugg agcccuggcu guguagggua 1380caccucgaag gcacccagag
agaaggagug agcucgcuug augacagcga ucugucggau 1440ugccuuagca
gcgccaacag ccuguaugau gauaucgagu gcuuccuuau ggaacuggag
1500cagcccgcc 15092161509RNAArtificial SequenceSynthetic
constitutively active Hu IRF7 S475D/S476D/S477D/S479D/S483D/S487D;
P035 without epitope tag 216auggcccuag cccccgaaag agcagcuccc
agagugcugu ucggcgaaug gcugcuuggc 60gagaucagca gcggcugcua cgaaggccug
caguggcugg acgaagcccg caccuguuuc 120agagugcccu ggaagcacuu
cgcuagaaag gauuugagcg aggcugaugc uagaaucuuu 180aaggcuuggg
cuguggcaag aggcagaugg ccgccuagua gcagaggggg cggaccuccc
240cccgaggcug agaccgcuga gagagcaggg uggaaaacca acuucagaug
cgcgcugaga 300agcacccgaa gauucgugau gcuacgugac aauagcggcg
accccgccga cccccacaaa 360guguacgccc ugucccgaga acuuugcugg
agagagggac ccggcaccga ucaaacagag 420gcugaggccc cggccgcugu
acccccgccc caaggaggcc ccccaggccc cuuucuggcu 480cauacacaug
ccggccugca ggcacccggg ccccucccgg cuccugccgg cgacaagggc
540gaucuccuuc uccaggccgu gcagcagagc ugccuggccg aucaccugcu
gaccgccucg 600uggggcgccg accccgugcc caccaaagcc ccgggugaag
gccaagaggg gcucccuuua 660accggagcau gcgccggagg ccccggccug
ccagccggcg aguuauaugg cugggcugug 720gagaccacac ccucccccgg
cccucaaccc gcugcccuga ccaccgguga ggccgccgcc 780cccgagagcc
cacaccaggc cgaacccuac cugagcccua gcccuagcgc cugcaccgcc
840gugcaagaac ccagccccgg agcccuggau gugaccauua uguacaaggg
ccggacagug 900cugcaaaagg uugugggaca cccgagcugc accuuucugu
acgguccgcc ugaccccgcc 960gugagagcca cggacccgca gcagguggcc
uuccccucac ccgcggagcu gcccgaccaa 1020aagcaacuca gauacacaga
agaacuauug cgucacgucg cgcccggccu gcaucuggag 1080cugagaggcc
cccagcucug ggccagaagg augggcaaau gcaaggugua cugggaggug
1140ggaggccccc ccggcagcgc cagccccagc acucccgcgu gccugcugcc
cagaaauugc 1200gacacuccca ucuucgauuu caggguguuc uuccaggagc
ugguggaguu cagagccagg 1260cagagaaggg guagccccag auacacaauc
uaucuaggcu uuggacaaga ucugagcgcc 1320ggccggccua aggaaaaaag
ccuggugcug guaaagcugg agccguggcu uuguagagug 1380caccuggagg
ggacgcagcg agagggcgug agcagcuuag acgacgauga cuuggaucug
1440ugucucgaca gcgccaacga cuuguacgac gacaucgagu gcuuccugau
ggaacuggag 1500cagcccgcc 1509217846RNAArtificial SequenceSynthetic
constitutively active truncated Hu IRF7 1-246 + 468-503; P032
without epitope tag 217auggcccugg cccccgagag agccgccccc agagugcucu
ucggcgagug gcugcugggc 60gagauaagca gcggcugcua cgaaggucug caguggcuag
acgaggccag aaccugcuuu 120agagugcccu ggaagcacuu cgcucgaaag
gaccuguccg aggccgaugc uagaauuuuu 180aaggcuuggg ccgucgcuag
gggaagaugg cccccuagca guagaggcgg cggccccccu 240cccgaagccg
agacggccga gagggccggc uggaaaacca auuucagaug cgcccugagg
300agcacccgca gguucguaau gcugcgagac aauagcggcg auccugcgga
uccucacaag 360guuuacgccu ugaguagaga acugugcugg cgggagggcc
ccggaaccga ccagacggag 420gcagaggcac ccgcugccgu gccccccccu
caaggaggac ccccuggacc cuuucuggcc 480cacacccacg cuggucugca
ggccccaggc ccacugcccg ccccagcggg cgauaagggu 540gaccugcucc
uacaggcggu gcaacagagc ugucuggccg accaccuguu gaccgccagc
600uggggggccg acccggugcc caccaaagcu cccggagagg gccaagaagg
ccucccacua 660acuggcgccu gcgccggggg cccgggauua cccgccggcg
agcuguaugg cugggccgug 720gagaccacgc ccagccccga gggcgugucg
ucccuggaca gcagcagccu gagccugugc 780cugagcuccg ccaacagccu
guaugacgac aucgagugcu uccugaugga gcuggaacaa 840cccgcc
846218846RNAArtificial SequenceSynthetic constitutively active
truncated Hu IRF7 1-246 + 468-503 plus
S475D/S476D/S477D/S479D/S483D/S487D; P036 without epitope tag
218auggcacugg cgccugaaag agccgcuccg cgugugcucu ucggcgagug
gcugcugggc 60gagaucagcu ccggcugcua cgagggucua caguggcugg acgaggccag
aaccuguuuu 120agagugcccu ggaagcacuu cgcgagaaag gaccugagcg
aggccgacgc cagaaucuuc 180aaagccuggg caguggcuag gggcagaugg
ccucccagca gccggggcgg cggcccaccc 240cccgaggccg aaaccgccga
aagagcuggc uggaagacca acuucagaug cgcccugaga 300agcaccagaa
gauuugucau gcugagagau aauucaggag accccgccga cccucacaag
360guguacgccc uguccagaga gcuguguugg agagagggcc ccggaaccga
ccagaccgag 420gccgaggcuc cagcugccgu gccacccccc caaggcggac
cacccggccc cuucuuggca 480cauacgcacg ccggccucca ggcucccggc
ccucugcccg ccccugcugg ugacaaaggc 540gaucugcugc ugcaagccgu
ccagcaaucc ugcuuggcug accaccugcu gaccgcuagc 600uggggagccg
accccguucc caccaaggcu cccggagaag gacaggaggg ccugccccuu
660accggcgcuu gcgcgggggg cccuggcuug ccugccggcg aacuguacgg
cugggccgug 720gagaccacgc cuucccccga gggcgugucc agccuggacg
augaugaccu ggaucugugc 780cuggacagcg ccaacgaccu guacgaugac
aucgagugcu uuuugaugga gcuggagcag 840cccgcc 8462191224RNAArtificial
SequenceSynthetic truncated Hu IRF7 1-151 + 247-503; P038 without
epitope tag; null mutation 219auggcccugg cccccgagag agccgcgccc
agagugcugu ucggcgaaug gcugcugggc 60gagaucagca gcggcugcua ugagggccug
caguggcucg acgaagccag gacgugcuuc 120agaguccccu ggaagcacuu
cgccagaaag gaucugagcg aggcugacgc cagaaucuuc 180aaggccuggg
caguugcgcg ugggagaugg ccccccagcu cgcggggcgg cggucccccc
240ccugaggccg agaccgccga aagagccgga uggaaaacca acuuucgaug
cgcccucaga 300agcaccagac gguuugugau gcugagagau aacagcggcg
acccugcaga cccccauaaa 360guguaugccc ugagcagaga gcuguguugg
cgagagggcc ccggaaccga ccaaaccgag 420gccgaggccc ccgccgccgu
accccccccu caaggccccc agccugcugc ucugaccacg 480ggagaagccg
ccgcuccuga gagcccccac caagccgagc ccuaucugag cccuagcccc
540agcgccugca ccgccgugca ggagcccuca ccgggcgccc uagacgugac
caucauguac 600aaggggcgca cggugcugca aaagguggug ggccacccca
gcugcaccuu ccuguacggc 660ccccccgacc cugccgugag agccaccgac
ccccagcaag ucgccuuccc cagccccgcc 720gagcugcccg accagaagca
gcugagguac accgaggagu ugcugagaca uguggccccc 780ggcuugcacc
ucgagcugag aggcccgcag cucugggcca gaagaauggg caagugcaag
840guguacuggg aggugggcgg cccccccggc agcgcgagcc caagcacccc
ggccugccug 900cugccuagaa acugcgacac cccuaucuuc gacuucagag
uauuuuucca ggagcugguc 960gaguucaggg ccagacagcg uagaggcagc
cccagauaca ccaucuaccu uggauucggc 1020caggaccuga gcgccggcag
acccaaagag aagucccugg uacuggugaa gcuagagccc 1080uggcugugua
gggugcaucu ggaaggcacc caaagagagg gcguaagcuc gcuugacagc
1140agcagccuca gccugugccu gagcagcgcu aacagcuuau acgacgacau
cgagugcuuc 1200cugauggagc uggaacaacc cgcc 12242201059RNAArtificial
SequenceSynthetic truncated Hu IRF7 152-503; P039 without epitope
tag; null mutation 220augggcggcc cucccgggcc uuuccuggcc cauacacacg
ccggccuaca ggcuccuggc 60ccucugcccg ccccggccgg cgacaagggc gaccuccugc
ugcaggccgu gcagcagucc 120ugucuggccg accaccugcu gacugcuagc
uggggcgccg aucccgugcc caccaaggcc 180ccaggagagg ggcaagaggg
ccugccucua accggcgcau gcgcaggugg accaggccuc 240cccgccggcg
agcuguaugg uugggccgug gagacaaccc ccagccccgg cccgcagccu
300gcugcgcuga ccacaggcga ggccgcugcc ccugagagcc cccaccaagc
ugaacccuac 360cugagcccca gccccucugc cugcacagcg gugcaggagc
ccagucccgg cgccuuggac 420gugaccauca uguauaaggg caggacugug
uuacaaaagg uagugggcca cccaaguugu 480accuuucugu acgggccccc
cgacccagcc gugcgcgcca ccgaccccca gcagguggcc 540uuccccagcc
ccgcugaguu gcccgaucag aaacaacucc gguacaccga ggaauuacuu
600agacaugugg cucccggccu gcaucuggag cuuagagguc cacaguugug
ggccagaaga 660augggcaagu gcaagguuua uugggagguc ggaggccccc
cgggcagcgc cagccccagc 720acccccgccu gucuucugcc cagaaacugc
gacaccccaa ucuucgauuu cagaguguuu 780uuccaggaac ugguggaguu
cagagcaagg caaagaagag gcagcccuag auacaccauc 840uaccugggcu
uuggccaaga ccugagcgcc ggcagaccca aggaaaaauc ccugguccug
900gugaaacugg agcccuggcu gugcagaguc caccuggagg gcacccagag
agagggcgug 960agcagccugg acucgagcag ccugucccug ugucugagca
gcgcgaauuc gcuauaugac 1020gacaucgaau gcuuucugau ggagcuggaa
cagcccgcc 10592211269RNAArtificial SequenceSynthetic
KRAS(G12D)25mer_nt.STING(V155M) 221augccucaca gcagccucca cccuagcauc
ccuugcccua gaggccacgg cgcccagaag 60gccgcccucg ugcuuuuaag cgccugcuug
gugacccuuu ggggcuuggg cgagccucca 120gagcacaccu ugagauauuu
ggugcuccac cuggccagcc uucagcuggg cuuguuacuc 180aacggcgugu
gcagccuggc cgaggagcug agacacaucc acagcagaua cagaggcagc
240uacuggagaa ccgugagagc gugucugggc ugcccucuga gaagaggcgc
cuugcuucuu 300cucaguaucu acuucuacua cucccugccu aacgccgugg
gcccuccuuu caccuggaug 360cuggcacugc ucggccucag ccaggcccug
aacaucuugu ugggcuugaa gggccuggcc 420ccugccgaga ucagcgccgu
gugcgagaag ggcaacuuca acauggccca cggauuggcu 480uggagcuacu
acaucggcua ccugagacug auccugccug agcugcaggc cagaaucaga
540accuacaacc agcacuacaa caaccugcug cgcggcgcag ugagccagag
acuguauauu 600cugcugccuc uggacugcgg cgugccugac aaccugagca
uggccgaccc uaacaucaga 660uuccuggaca agcugccuca gcagaccggc
gaccacgccg gcaucaagga cagaguguac 720agcaacagca ucuaugagcu
gcucgagaau ggccagagag ccggcaccug cgugcuggag 780uacgccaccc
cucugcagac ccuguucgcc augagccagu auagucaagc uggcuucagc
840agagaggaca gacuggagca ggccaagcug uucugcagaa cccuggagga
cauucuggcu 900gacgccccug agagccagaa caacugccga cugaucgccu
accaggaacc agccgacgac 960agcagcuuca gucuuucuca ggagguucuu
cgccacuugc gccaggagga gaaggaggag 1020gugaccgugg gcagccugaa
gaccuccgca gucccuagca ccagcaccau gagucaggag 1080ccggagcuau
uaaucagcgg cauggagaag ccucuuccac uccgaaccga cuucagcgcc
1140accaacuuca gccugcugaa gcaggcaggu gacguugagg agaauccggg
accuaugacc 1200gaguacaagc uggugguugu gggcgccgac ggcgugggca
agagcgcccu gaccauccag 1260cugauccag 12692221269RNAArtificial
SequenceSynthetic KRAS(G12D)25mer_ct.STING(V155M) 222augaccgagu
acaagcuagu agucgugggc gccgacggcg ugggcaagag cgcccucacc 60auccagcuaa
uccaggccac caacuucagc uugcucaagc aggccggcga cguggaggag
120aacccaggcc cuaugccuca cagcagccuu cacccuagca ucccuugccc
uagaggccac 180ggcgcccaga aggccgcccu ggugcugcug agcgccugcc
uggugacccu guggggccug 240ggcgagccuc cugagcacac ccugagauau
cuggugcuuc accuggccag uuuacagcug 300ggccugcuuc uuaacggcgu
gugcagccug gccgaggagc ugagacacau ccacagcaga 360uacagaggca
gcuacuggag aaccgugaga gccugccuag gcugcccucu gagaagaggc
420gcucuguugc uacuuuccau cuacuucuac uacucccugc cuaacgccgu
gggcccuccu 480uucacuugga ugcuggcguu gcugggucug agccaggccc
ugaacauccu ucucggucug 540aagggccugg ccccugccga gaucagcgcc
gugugcgaga agggcaacuu caacauggcc 600cacggacucg ccuggagcua
cuacaucggc uaccugagac ugauccugcc ugagcugcag 660gccagaauca
gaaccuacaa ccagcacuac aacaaccugc ugcggggcgc cgugagccag
720agacuguaua uacuucuucc ucuggacugc ggcgugccug acaaccugag
cauggccgac 780ccuaacauca gauuccugga caagcugccu cagcagaccg
gcgaccacgc cggcaucaag 840gacagagugu acagcaacuc cauuuaugag
cugcucgaga auggccagag agccggcacc 900ugcgugcugg aguacgccac
cccucugcag acccuguucg ccaugagcca guacagucag 960gcuggauuca
gcagagagga cagacuggag caggccaagc uguucugcag gacacuggag
1020gacauacuag cagacgcccc ugagagccag aacaacugca gacugauugc
cuaccaggag 1080ccugcggacg acagcuccuu cagucugagu caggaggugu
ugcggcacuu acgccaagaa 1140gagaaggagg aggugaccgu gggcagccug
aagacuagcg cugugccuag caccagcaca 1200augucacagg agccggaauu
gcuaaucagc ggcauggaga agccucuccc auuacguacc 1260gacuucagc
12692231419RNAArtificial SequenceSynthetic
KRAS(G12D)25mer^3_nt.STING(V155M) 223augccucaca gcagccuuca
cccuagcauc ccuugcccua gaggccacgg cgcccagaag 60gccgcccuag ugcuccuuag
cgccugccuc gugacccuau ggggcuuagg cgagccucca 120gagcacaccu
ugagauaccu cguccuccac cuggcuaguc uacagcuggg ccuucuccuc
180aacggcgugu gcagccuggc cgaggagcug agacacaucc acagcagaua
cagaggcagc 240uacuggagaa ccgugagagc gugccugggc ugcccucuga
gaagaggcgc acugcuguua 300cucagcaucu acuucuacua cucacugcca
aacgccgugg gcccuccuuu caccuggaug 360cuggccuugc ucggauugag
ccaggcccug aacauuuuac ugggauugaa gggccuggcc 420ccugccgaga
ucagcgccgu gugcgagaag ggcaacuuca acauggccca cggccuagcu
480uggagcuacu acaucggcua ccugagacug auccugccug agcugcaggc
cagaaucaga 540accuacaacc agcacuacaa caaccugcug cguggagcgg
ugagccagag acuguauauc 600cuccugccuc uggacugcgg agugccugac
aaccugagca uggccgaccc uaacaucaga 660uuccuggaca agcugccuca
gcagaccggc gaccacgccg gcaucaagga cagaguguac 720agcaacucaa
ucuacgagcu guuggagaau ggccagagag ccggcaccug cgugcuggag
780uacgccaccc cucugcagac ccuguucgcc augagccagu acucucaggc
aggcuucagc 840agagaggaca gacuggagca ggccaagcug uucugcagaa
cccuggagga cauccuggcg 900gacgccccug agagccagaa caacugccgg
cuuaucgccu accaggagcc agcagacgac 960agcagcuucu cucucucaca
agagguacug cgccaucuuc gccaggagga gaaggaggag 1020gugaccgugg
gcagccugaa gacauccgcc guaccuagca ccagcaccau gucucaggaa
1080ccggaacugu ugaucagcgg cauggagaag ccucugccac ugcgcaccga
cuucagcgcc 1140accaacuucu cccuacugaa gcaagccggu gacguugaag
agaacccugg cccuaugacc 1200gaguacaagc ugguaguagu aggcgccgac
ggcgugggca agagcgcccu gaccauccag 1260cugauccaga ugacugaaua
uaagcuuguc gucgugggcg cagauggcgu ugguaagagc 1320gcacuuacaa
uucaacucau ucagaugacg gaguauaagc uggugguggu cggagcugac
1380ggcguaggca agagugcccu uacuauucag cuaauucag
14192241419RNAArtificial SequenceSynthetic
KRAS(G12D)25mer^3_ct.STING(V155M) 224augaccgagu acaagcuugu
ggugguuggc gccgacggcg ugggcaagag cgccuuaacc 60auccagcuua uccagaugac
agaguauaag cuaguggugg ucggcgcaga cggaguggga 120aagagugcau
uaacuauuca acucauccaa augaccgaau acaagcuagu aguugugggu
180gcagauggcg ucggcaaguc ugcacugaca auucagcuca uccaggccac
caacuucagc 240cugcugaagc aggccggcga cguggaggag aacccuggcc
cuaugccuca cagcagccug 300cacccuagca ucccuugccc uagaggccac
ggcgcccaga aggccgcccu ggugcugcug 360agcgccugcc uggugacccu
guggggccug ggcgagccuc cugagcacac ccugagauac 420cuaguuuugc
accuggcuuc ucugcagcug ggccuacugc ucaacggcgu gugcagccug
480gccgaggagc ugagacacau ccacagcaga uacagaggca gcuacuggag
aaccgugaga 540gcaugcuuag gcugcccucu gagaagaggc gcucugcucc
ucuuguccau cuacuucuac 600uacucgcuac cuaacgccgu gggcccuccu
uucaccugga ugcuggcccu cuugggauua 660agccaggccc ugaacaucuu
gcugggacug aagggccugg ccccugccga gaucagcgcc 720gugugcgaga
agggcaacuu caacauggcc cacggacucg cuuggagcua cuacaucggc
780uaccugagac ugauccugcc ugagcugcag gccagaauca gaaccuacaa
ccagcacuac 840aacaaccugc ugcggggagc agugagccag agacuguaua
uucugcuccc ucuggacugc 900ggcgugccug acaaccugag cauggccgac
ccuaacauca gauuccugga caagcugccu 960cagcagaccg gcgaccacgc
cggcaucaag gacagagugu acagcaacag cauuuacgag 1020cugcuggaga
acggccagag agccggcacc ugcgugcugg aguacgccac cccucugcag
1080acccuguucg ccaugagcca guacucccag gcaggauuca gcagagagga
cagacuggag 1140caggccaagc uguucugccg uacucuugag gacauccuug
cagacgcccc ugagagccag 1200aacaacugcc gguugauugc cuaccaggaa
ccggcagacg acagcucauu cuccuugucu 1260caggaggucc uuagacaccu
gcggcaggag gagaaggagg aggugaccgu gggcagccug 1320aagacauccg
ccgugccuag cacgucuacc augucccagg agccggaacu gcuaaucagc
1380ggcauggaga agccucugcc ucucaggacc gacuucagc
14192251140RNAArtificial SequenceSynthetic Hu STING (R284K) var; no
epitope tag 225augccccaua gcagccugca ccccagcauc cccugcccca
gaggccacgg cgcccagaag 60gccgcccugg uccugcugag cgcaugccug gucacccugu
ggggccuggg cgagcccccc 120gagcacaccc ugagauaccu ggugcugcac
cucgccagcc ugcagcuggg ccugcugcug 180aacggcgugu gcagccuggc
cgaggagcug agacacaucc acagcagaua uagaggcagc 240uacuggagaa
ccgugagagc uugccucggc ugcccccuga gaagaggcgc ccugcugcug
300cugagcaucu acuuuuacua cagccugccc aacgcugugg gccccccuuu
cacguggaug 360cucgcccugc ugggacugag ccaggcccug aacauccugc
ugggccuuaa gggccuagcc 420cccgccgaga ucagcgccgu gugcgagaag
ggcaacuuca auguggccca cggccuggcc 480uggagcuacu acaucggcua
ccugagacug auccugcccg agcugcaggc cagaaucaga 540accuacaauc
agcacuacaa caaccugcug agaggcgccg ugagccagag acuguacauc
600cugcugcccc uggacugcgg cgugcccgac aaccucagca uggccgaccc
caacaucaga 660uuccuggaca agcugcccca gcagaccggc gaccacgccg
gcaucaagga ucgcguguac 720agcaacagca ucuacgagcu gcuggaaaac
ggccagagag ccggaaccug cgugcuggag 780uacgccacac cccugcagac
ccuguucgcc augagccagu acagccaggc cggcuucagc 840agagaggaca
agcuggagca ggccaagcug uucugcagaa cccuggagga
uauccucgcc 900gacgcccccg agagccagaa caacugcagg cugaucgcgu
accaggagcc cgcugacgac 960agcagcuuua gccugagcca ggaggugcug
agacaucugc gucaagagga aaaggaggag 1020gugaccgugg gcucccugaa
gaccagcgcc gugcccagca ccagcaccau gagccaggag 1080cccgagcugc
ugaucagcgg cauggagaag ccacugcccc ucagaaccga cuucagcacc
11402269PRTArtificial SequenceSynthetic EBV BRLF1 peptide 226Ala
Thr Ile Gly Thr Ala Met Tyr Lys1 52279PRTArtificial
SequenceSynthetic FLU peptide 227Ser Ile Ile Pro Ser Gly Pro Leu
Lys1 52289PRTArtificial SequenceSynthetic HIV NEF peptide 228Ala
Val Asp Leu Ser His Phe Leu Lys1 522910PRTArtificial
SequenceSynthetic EBV peptide 229Ala Val Phe Asp Arg Lys Ser Asp
Ala Lys1 5 102309PRTArtificial SequenceSynthetic HBV core antigen
peptide 230Tyr Val Asn Val Asn Met Gly Leu Lys1 52319PRTArtificial
SequenceSynthetic HC peptide 231Arg Val Cys Glu Lys Met Ala Leu
Tyr1 52329PRTArtificial SequenceSynthetic CMV peptide 232Lys Leu
Gly Gly Ala Leu Gln Ala Lys1 5
* * * * *
References